Annual Meeting Program

Transcription

Annual Meeting
Program
May 29-June 2, 2015
McCormick Place | Chicago, Illinois
am.asco.org
For the most up-to-date program information,
download the iPlanner mobile app at am.asco.org/arc.
51st Annual Meeting
May 29–June 2, 2015
Chicago, Illinois
ANNUAL MEETING PROGRAM
Copyright 2015 by the American Society of Clinical Oncology. All programs presented at
the 2015 Annual Meeting constitute copyrighted presentations owned by the American
Society of Clinical Oncology.
Copyright of the 2015 ASCO Annual Meeting Program is owned by the American
Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions
or presentations at this Annual Meeting and all ASCO educational and scientific
meetings. Attendees are encouraged to check the Annual Meeting program materials for
information about Annual Meeting-related publications for purchase and additional
ASCO online resources at am.asco.org, including the ASCO Virtual Meeting.
FOLLOW #ASCO15 ON TWITTER
1
CONTENTS
Scientific Sessions ............................................................................
Program Information .........................................................................
Continuing Medical Education and Program Evaluation .........................
Planning Committees ........................................................................
Onsite Details ...................................................................................
Featured Voices on Twitter and Tweetup ..............................................
Policies ...........................................................................................
Awards ............................................................................................
Supporters .......................................................................................
Ancillary Educational Events Directory ................................................
Program by Day ................................................................................
4
7
9
10
14
16
17
18
25
28
33
3
SCIENTIFIC SESSIONS
Breast Cancer
HER2/ER Oral Abstract Session ..............................................................
Triple-Negative/Cytotoxics/Local Therapy Oral Abstract Session .........................
Clinical Science Symposium: Predicting Response in Triple-Negative and HER2Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles ........................
HER2/ER Poster Discussion Session ........................................................
Triple-Negative/Cytotoxics/Local Therapy Poster Discussion Session ...................
HER2/ER Poster Session ......................................................................
Triple-Negative/Cytotoxics/Local Therapy Poster Session .................................
202
294
191
88
128
51
62
Cancer Prevention, Genetics, and Epidemiology
Oral Abstract Session ..........................................................................
92
Clinical Science Symposium: A Tale of Two Genomes: Interpreting Somatic and
Germ-Line Sequencing Results Together .................................................
Poster Discussion Session ....................................................................
Poster Session ..................................................................................
247
298
260
Central Nervous System Tumors
Oral Abstract Session .......................................................................... 304
Clinical Science Symposium: Immunotherapy for Central Nervous System Tumors:
Biomarkers and Novel Data ................................................................
Poster Session ..................................................................................
143
298
265
Developmental Therapeutics and Translational Research
Clinical Pharmacology and Experimental Therapeutics Oral Abstract Session ..........
Immunotherapy Oral Abstract Session .......................................................
Clinical Pharmacology and Experimental Therapeutics Poster Discussion Session ....
Immunotherapy Poster Discussion Session .................................................
Clinical Pharmacology and Experimental Therapeutics Poster Session ..................
Immunotherapy Poster Session ...............................................................
305
258
89
128
70
79
Gastrointestinal Cancer
Colorectal Cancer Oral Abstract Session ....................................................
Noncolorectal Cancer Oral Abstract Session ................................................
Clinical Science Symposium: To Lump or To Split: Molecular, Anatomic, and Etiologic
Subtyping of Noncolorectal Gastrointestinal Malignancies and Potential Therapeutic
Implications ...................................................................................
Colorectal Cancer Poster Discussion Session ...............................................
Noncolorectal Cancer Poster Discussion Session ..........................................
Colorectal Cancer Poster Session ............................................................
Noncolorectal Cancer Poster Session ........................................................
130
145
197
254
291
208
219
Genitourinary Cancer
Prostate Cancer Oral Abstract Session ......................................................
Nonprostate Cancer Oral Abstract Session ..................................................
Clinical Science Symposium: Molecular Drivers and Genomic Biomarkers in
Genitourinary Cancers ......................................................................
Prostate Cancer Poster Discussion Session .................................................
Nonprostate Cancer Poster Discussion Session ............................................
Prostate Poster Session .......................................................................
Nonprostate Poster Session ...................................................................
185
248
308
134
299
97
271
Gynecologic Cancer
Clinical Science Symposium: Intersection of the Mutanome and the Immunome .......
Poster Session ..................................................................................
204
293
135
103
Head and Neck Cancer
4
Clinical Science Symposium: New Evidence on the Role of Surgery and PET Scans
after Primary Chemoradiotherapy ..........................................................
Poster Session ..................................................................................
202
135
112
Health Services Research and Quality of Care
93
Clinical Science Symposium: Navigating Racial and Economic Disparities in Cancer
Care Delivery .................................................................................
Poster Session ..................................................................................
143
299
277
Leukemia, Myelodysplasia, and Transplantation
94
Poster Discussion Session .................................................................... 186
Poster Session .................................................................................. 147
Lung Cancer
Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Oral Abstract
Session .......................................................................................
Non-Small Cell Metastatic Oral Abstract Session ...........................................
Clinical Science Symposium: Immunotherapy in Lung Cancer: A Paradigm Shift .......
Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Discussion
Session .......................................................................................
Non-Small Cell Metastatic Poster Discussion Session .....................................
Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Session ....
Non-Small Cell Metastatic Poster Session ...................................................
131
146
196
255
291
231
237
Lymphoma and Plasma Cell Disorders
Lymphoma Oral Abstract Session ............................................................ 249
Myeloma Oral Abstract Session ............................................................... 309
Clinical Science Symposium: Chimeric Antigen Receptor T-Cell Therapy for B-Cell
Malignancies .................................................................................
Poster Session ..................................................................................
292
193
155
Melanoma/Skin Cancers
95
Poster Discussion Session .................................................................... 300
Poster Session .................................................................................. 284
Patient and Survivor Care
Clinical Science Symposium: Predicting and Improving Adverse Outcomes in Older
Patients with Cancer .........................................................................
Poster Session ..................................................................................
144
136
118
Pediatric Oncology
Pediatric Oncology I Oral Abstract Session ..................................................
Pediatric Oncology II Oral Abstract Session .................................................
Poster Session ..................................................................................
133
207
187
163
Sarcoma
Poster Session ..................................................................................
295
194
168
Tumor Biology
Poster Session ..................................................................................
296
187
174
5
SCIENTIFIC SESSIONS continued
Multidisciplinary Sessions
Clinical Science Symposium: Immunotherapy for Every Patient: Check Your
Enthusiasm ...................................................................................
Clinical Science Symposium: Targeted Therapies: Does the Disease Still Matter? .....
Clinical Science Symposium: New Diagnostics: When Actionable Is Objectionable ....
Global Oncology Symposium ..................................................................
Highlights of the Day Session I Including Clinical Trials Participation Awards ...........
Highlights of the Day Session II Including Partners in Progress Award ...................
Highlights of the Day Session III ..............................................................
Molecular Biology Tumor Board ...............................................................
Plenary Session Including the Science of Oncology Award and Lecture .................
6
50
184
247
38
140
199
302
35
191
PROGRAM INFORMATION
The Annual Meeting Program features the program organized by day. Dates and times are
subject to change. For the most up-to-date version of the program, consult the iPlanner,
available via the Attendee Resource Center (am.asco.org/arc).
Cross-Cutting Tracks
The topics of clinical trials, ethics, geriatric oncology, international, and value are important
for all oncology professionals and cut across disease- and topic-based tracks. These
cross-cutting themes have been incorporated into sessions of every track throughout the
meeting. For sessions that feature a cross-cutting track, visit am.asco.org or search by
track in the iPlanner.
eQ&A
Most Education and Scientific Sessions will offer multiple formats for question and answer
(Q&A) participation. In addition to asking a question via floor microphones, you can also submit
questions to session faculty using the following electronic (eQ&A) methods. Questions will be
answered as time permits during the scheduled session time.
Website (domestic/international attendees)
䡲 Go to pollev.com/roomname (insert the name of the room after the backslash; e.g.,
pollev.com/s101)
䡲 Type the speaker’s name, your question, and click submit
Text message (domestic attendees only)
䡲 Text the Room Name to 22333. You will receive a confirmation that you have joined
the room. To ask a question, type the speaker’s name, your question, and send.
Text questions are limited to 130 characters.
䡲 If you go to a different room, follow the instructions to join a new room; the system
will remove you from the previous room.
iPlanner App
䡲 Submit a question via the iPlanner mobile app by navigating to the session
information page and selecting “eQ&A: Ask a Question” at the bottom of the
page.
Room Names
Arie
E354b
E450
EHallD2
EHallD1
S100bc
S100a
S102
NHallB1
S103
S404
S406
S504
Scientific Sessions
Plenary Session
The Plenary Session includes abstracts selected by the Scientific Program Committee as
having practice-changing findings of the highest scientific merit.
Highlights of the Day Sessions
Highlights of the Day Sessions invite expert discussants to present key findings, put abstracts
into clinical context, and provide an overview of the previous day’s Oral Abstract Sessions.
Oral Abstract Sessions
Oral Abstract Sessions include didactic presentations of abstracts of the highest scientific merit,
as determined by the Scientific Program Committee. Experts in the field serve as discussants
and provide comprehensive themed discussions of the findings from the abstracts.
Clinical Science Symposia
Clinical Science Symposia provide a forum for science in oncology, combining didactic lectures
on a specific topic with the presentation of abstracts. Experts in the field serve as discussants to
place studies in the appropriate context and critically discuss the conclusions in terms of their
applicability to clinical practice. New this year, three special Clinical Science Symposia will be
designated around specific pathways that cut across cancer types.
7
PROGRAM INFORMATION continued
Poster Discussion Sessions
Select posters from the Poster Sessions will be discussed by expert discussants, with the
abstract authors participating as panel members. These sessions will be followed by networking
with the discussants and authors.
Poster Sessions
Poster Sessions include selected abstracts of clinical research in poster format. Trials in
Progress (TPS) abstracts are presented within a track’s Poster Session.
Educational Sessions
Special Sessions
Special Sessions are focused educational sessions that include award presentations and award
lectures by recipients of ASCO’s Special Awards; joint sessions planned collaboratively with
other societies; and sessions identified as being of particular interest, importance, and
relevance to oncology professionals.
Education Sessions
Education Sessions offer multidisciplinary explorations of focused topics in clinical oncology.
Extended Education Sessions
Extended Education Sessions are part of ASCO’s continuing effort to provide in-depth learning
experiences on topics that address educational needs in oncology.
Meet the Professor Sessions (Ticketed)
Meet the Professor Sessions provide open discussion between recognized experts and session
attendees, with an opportunity for attendees to obtain answers to specific questions.
Clinical Problems in Oncology Sessions (Ticketed)
Clinical Problems in Oncology Sessions combine the use of case-based panel discussion with
interactive audience-response technology.
8
Program Evaluation
Every participant is encouraged to submit feedback, provide session ratings, and access
certificates for the 2015 ASCO Annual Meeting through the iPlanner, the electronic
meeting companion. You can access the web version or download the mobile app via the
Attendee Resource Center (am.asco.org/arc). Your feedback is utilized by leadership to
enhance programs, develop new initiatives, gauge educational impact, and plan for
future meetings.
Credit requests and evaluations are due by Tuesday, July 7, 2015.
Access the following via the iPlanner mobile app or website:
● To provide feedback on a specific session
1. Select a session by searching by time or track
2. Select “Rate This Session” to submit feedback on each session you attend
● To access certificates and claim CME credit
1. Select a session by searching by time or track
2. Select “Claim CME Credit” to obtain a CME Certificate or Certificate of
Participation
● To provide feedback on your overall Meeting experience
1. Choose “Give Feedback” from the iPlanner mobile app home screen to
submit a Feedback Form
These tools can also be accessed through the “Evaluation, CME, and Certificates”
block in the Attendee Resource Center.
CME and Certificates
This live activity has been approved for 39.25 AMA PRA Category 1 Credit™. Physicians
should claim only the credit commensurate with the extent of their participation in the
activity. All nonphysician attendees are welcome to submit a request for a Certificate of
Participation, which may enable nonphysicians to apply their participation toward
re-licensure. Please note that all final decisions regarding the awarding of credits will be
made by the licensing organization to which the credits were submitted.
For questions or assistance, contact cme@asco.org.
Proof of Attendance
Certificates of Attendance are available for attendees who need a record of their
attendance at the Meeting but who do not require documentation for continuing
education purposes. Please note that this certificate does not award any AMA PRA
Category 1 Credit™. Certificates of Attendance are available for download through the
“Evaluation, CME, and Certificates” block in the Attendee Resource Center at
am.asco.org/arc.
9
PLANNING COMMITTEES
2014 –2015 ASCO Board of Directors
ASCO Officers
President
Peter Paul Yu, MD, FACP, FASCO
President-Elect
Julie M. Vose, MD, MBA, FASCO
Immediate Past President
Clifford A. Hudis, MD, FACP
Treasurer
Susan L. Cohn, MD
Chief Executive Officer
Allen S. Lichter, MD, FASCO
Directors
Smita Bhatia, MD, MPH
Charles David Blanke, MD, FACP, FASCO
Linda D. Bosserman, MD, FACP
Walter J. Curran Jr., MD
Stephen S. Grubbs, MD
Paulo M. G. Hoff, MD, PhD, FACP
Hagop M. Kantarjian, MD
David Khayat, MD, PhD, FASCO
Gary H. Lyman, MD, MPH, FACP, FRCP
(Edin), FASCO
Neal J. Meropol, MD, FASCO
Therese M. Mulvey, MD, FASCO
W. Charles Penley, MD, FASCO
Carolyn D. Runowicz, MD, FASCO
Lillian L. Siu, MD, FRCPC, FASCO
Eric P. Winer, MD, FASCO
2015 Conquer Cancer Foundation Board of Directors
Conquer Cancer Foundation Officers
Chair
W. Charles Penley, MD, FASCO
Treasurer
Gabriel N. Hortobagyi, MD, FASCO
Secretary
Thomas G. Roberts Jr., MD, MSocSc
Chief Executive Officer
Allen S. Lichter, MD, FASCO
Directors
Nancy R. Daly, MS, MPH
Lawrence H. Einhorn, MD, FASCO
John H. Glick, MD, FASCO
Michael L. Gordon, JD
Beth Y. Karlan, MD
Raj Mantena, RPh
Thomas A. Marsland, MD, FASCO
Robert J. Mayer, MD, FASCO
Martin J. Murphy, DMedSc, PhD, FASCO,
Chair Emeritus
Steven T. Rosen, MD, FACP
Aaron A. Sasson
Sandra M. Swain, MD, FACP, FASCO
Cancer Communications Committee News Planning Subcommittee
Chair
Gregory A. Masters, MD, FACP, FASCO
Chair-Elect
Don S. Dizon, MD
Immediate Past Chair
Jyoti D. Patel, MD
Subcommittee Liaisons
Hagop Kantarjian, MD, Board Liaison
Maria Teresa Bourlon, MD, Career
Development Subcommittee Liaison
Brian Michael Alexander, MD
Harold J. Burstein, MD, PhD, FASCO
Patricia A. Ganz, MD, FASCO
Stephen Hunger, MD
Smitha S. Krishnamurthi, MD
Merry Jennifer Markham, MD
Erica L. Mayer, MD, MPH
Sumanta Kumar Pal, MD
Joe B. Putnam, MD, FACS
Charles J. Ryan, MD
Lynn Mara Schuchter, MD, FASCO
Gary K. Schwartz, MD
10
Cancer Education Committee
John V. Cox, DO, MBA, FASCO, Chair
Apar Kishor Ganti, MD, MBBS, Chair-Elect
Gini F. Fleming, MD, Immediate Past Chair
Lillian L. Siu, MD, Board Liaison
Breast Cancer Track
Maxine S. Jochelson, MD, Track Leader
Jennifer A. Brown, MD
Angela DeMichele, MD
Charles E. Geyer Jr., MD, FACP
Raquel Nunes, MD
Debra A. Patt, MD, MPH, MBA
Hope S. Rugo, MD
Julia R. White, MD
Track
Joshua David Schiffman, MD, Track Leader
Monique A. De Bruin, MD
Jeri Kim, MD
P. Kelly Marcom, MD
Howard L. McLeod, PharmD
Electra D. Paskett, PhD
Ming Tai-Seale, PhD
Donald Lawrence Wickerham, MD
Care Delivery and Practice Management Track
David G. Pfister, MD, Track Leader
Aditya Bardia, MBBS, MPH
Kelly Bugos, RN
John Emmett Hennessy, MBA, CMPE
Thomas H. Openshaw, MD
Jeffery C. Ward, MD
Central Nervous System Tumors Track
Manmeet Singh Ahluwalia, MD, Track Leader
Jaishri O’Neill Blakeley, MD
Roger Stupp, MD
Clinical Trials Track
Janet Dancey, MD
Sumithra J. Mandrekar, PhD
Bhupinder Singh Mann, MBBS
Apostolia Maria Tsimberidou, MD, PhD
Developmental Therapeutics and Translational
Research Track
Roisin M. Connolly, MBBS, Track Leader
Howard A. Burris, MD
Francisco J. Esteva, MD, PhD
John Charles Morris, MD
Ethics Track
Jon C. Tilburt, MD
Beverly Moy, MD
Gastrointestinal (Colorectal) Cancer Track
Martin R.Weiser, MD, Track Leader
Chris R. Garrett, MD
Donald A. Richards, MD, PhD
Henry Q. Xiong, MD
Gastrointestinal (Noncolorectal) Cancer Track
Matthew H. G. Katz, MD, FACS, Track Leader
Tanios S. Bekaii-Saab, MD
Jimmy J. Hwang, MD
Se Hoon Park, MD
Vincent J. Picozzi, MD
Manish A. Shah, MD
Genitourinary Cancer Track
Andrea Borghese Apolo, MD, Track Leader
Thomas E. Hutson, DO, PharmD, FACP
Jose A. Karam, MD
John Ward McClean, MD
Stephen Boyd Riggs, MD
Nicholas J. Vogelzang, MD, FASCO
Geriatric Oncology Track
Andrew S. Artz, MD, MS
William P. Tew, MD
William W. Tse, MD
Gynecologic Cancer Track
Linda R. Duska, MD, Track Leader
Helen Mackay, MD
Matthew A. Powell, MD
Head and Neck Cancer Track
Anthony Cmelak, MD, Track Leader
Matthew G. Fury, MD
John Truelson, MD
Apar Kishor Ganti, MD, MBBS
Health Services Research and Quality of Care Track
Jennifer W. Mack, MD, Track Leader
Daniel J. Becker, MD
Nina A. Bickell, MD, MPH
Nicole Kuderer, MD
Dawn L. Hershman, MD
Bruce Lee Jacobs, MD
Track
David Leibowitz, MD, Track Leader
Jonathan Michael Gerber, MD
Jeffrey E. Lancet, MD
Lung Cancer Track
Laura Quan Man Chow, MD, Track Leader
Martin J. Edelman, MD
Craig H. Reynolds, MD
David R. Spigel, MD
Glen J. Weiss, MD
Mauro Zukin, MD
Lymphoma and Plasma Cell Disorders Track
Grzegorz S. Nowakowski, MD, Track Leader
Jeffrey Matous, MD
John M. Pagel, MD, PhD
Donna Ellen Reece, MD
Michael A. Thompson, MD, PhD
Melanoma/Skin Cancers Track
Suraj S. Venna, MD, Track Leader
Sanjiv S. Agarwala, MD
Jason John Luke, MD, FACP
Janice M. Mehnert, MD
Ahmad A. Tarhini, MD, PhD
Patient and Survivor Care Track
Karen L. Smith, MD, Track Leader
Deborah Mayer, PhD, AOCN, ANP-BC
Barbara J. Miller, MS, PA-C
11
PLANNING COMMITTEES continued
Maria Alma Rodriguez, MD
Nagendra Tirumali, MD
Pediatric Oncology Track
Gregory T. Armstrong, MD, MSCE, Track Leader
Najat C. Daw, MD
Stewart Goldman, MD
Joel A. Weinthal, MD
Professional Development Track
Anne S. Tsao, MD, Track Leader
Kristin Anderson, MD, MPH
Kelly J. Cooke, DO
Laura Williams Goff, MD
Lee M. Krug, MD
Jason Michael Samuelian, MD
Sarcoma Track
Gary K. Schwartz, MD, Track Leader
L. Johnetta Blakely, MD
Robert Mikael Henshaw, MD
Min S. Park, MD, MS
Tumor Biology Track
Elizabeth A. Maher, MD, PhD, Track Leader
Elise C. Kohn, MD
Kimryn Rathmell, MD, PhD
Eliezer Mendel Van Allen, MD
CEC Continuing Medical Education
Subcommittee
Antoinette J. Wozniak, MD, Chair
Michael P. Kosty, MD, FACP, FASCO,
Immediate Past Chair
Catherine H. Van Poznak, MD, Chair-Elect
Marlo A. Blazer, PharmD
Mary E. Cianfrocca, DO
Thomas W. Flaig, MD
Celestia S. Higano, MD, FACP
Wells A. Messersmith, MD
Michael O. Meyers, MD
R. Steven Paulson, MD
Maura Polansky, MS, PA-C
Bridgett Rossi, RN, MSN, CCRN, OCN
Jennifer E. Schwartz, MD, FRCPC
Thomas J. Semrad, MD
Eric D. Tetzlaff, PA-C
Ulka N. Vaishampayan, MD
Marie Wood, MD
Scientific Program Committee
Alan P. Venook, MD, Chair
Lynn Mara Schuchter, Chair-Elect
Jedd D. Wolchok, MD, PhD, Immediate Past
Chair
Biostatistics Track
Katherine Panageas, PhD, Track Leader
Urania Dafni, ScD
Susan G. Hilsenbeck, PhD
Wendy B. London, PhD
Ying Lu, PhD
Sumithra J. Mandrekar, PhD
Donna Niedzwiecki, PhD
Breast Cancer—HER2/ER Track
Priya Rastogi, MD, Track Leader
Carey K. Anders, MD
Tufia C. Haddad, MD
Cornelia Liedtke, MD
Shanu Modi, MD
Patrick Glyn Morris, MD
Alexandra Thomas, MD
Breast Cancer—Triple-Negative/Cytotoxics/Local
Therapy Track
Steven J. Isakoff, MD, PhD, Track Leader
Eleanor Elizabeth Harris, MD
Tari A. King, MD
Pamela N. Munster, MD
Deborah Toppmeyer, MD
Tiffany A. Traina, MD
Janice Maria Walshe, MD
Track
James M. Foran MD, FRCPC, Track Leader
Habibul Ahsan, MBBS, MSc
Eric Andrew Collisson, MD
Adam J. Olszewski, MD
Brian M. Wolpin, MD
Andrew B. Lassman, MD, Track Leader
Eric L. Chang, MD
Howard Alan Fine, MD
Daphne A. Haas-Kogan, MD
Developmental Therapeutics—Clinical
Pharmacology and Experimental Therapeutics
Track
Miguel Angel Villalona-Calero, MD, Track Leader
Emiliano Calvo, MD, PhD
Ryan Bruce Corcoran, MD, PhD
Gerald Steven Falchook, MD
Herbert Hurwitz, MD
Robin Kate Kelley, MD
Scott Kopetz, MD
Timothy Anthony Yap, PhD, MBBS, BSc, MRCP
Developmental Therapeutics—Immunotherapy
Track
Neil Howard Segal, MD, PhD, Track Leader
Charlotte Eielson Ariyan, MD, PhD
Gregory Lawrence Beatty, MD, PhD
Jonathan S. Cebon, MD, PhD
Lawrence Fong, MD
Zihai Li, MD, PhD
Andrew Parsa, MD, PhD
12
Edward Chu, MD, Track Leader
Chloe Evelyn Atreya, MD, PhD
Nancy N. Baxter, MD
Gong Chen, MD, PhD
Steven J. Cohen, MD
Gunnar Folprecht, MD
Kimmie Ng, MD, MPH
Bert H. O’Neil, MD
Thomas John Semrad, MD, FACP
Richard H. Wilson, MD
Zhen Zhang, MD, PhD
Andrew H. Ko, MD, Track Leader
Ghassan K. Abou-Alfa, MD
Waddah B. Al-Refaie, MD
Karyn A. Goodman, MD
Syma Iqbal, MD
Milind M. Javle, MD
Lisa A. Kachnic, MD
Geoffrey Yuyat Ku, MD, MBA
Emil Lou, MD, PhD
Nipun B. Merchant, MD
James Posey, MD
Michael J. Morris, MD, Track Leader
Peter Albers, MD
Kathleen A. Cooney, MD
Robert Dreicer, MD
Terence W. Friedlander, MD
Noah M. Hahn, MD
Jonathan E. Rosenberg, MD
Mark N. Stein, MD
Cora N. Sternberg, MD
Scott T. Tagawa, MD, MS
Neha Vapiwala, MD
David R. Spriggs, MD, Track Leader
John K. Chan, MD
Levi S. Downs Jr., MD
Paul Haluska, MD, PhD
Rebecca Sophie Kristeleit, MD, PhD
Kunle Odunsi, MD
Head and Neck Cancer Track
Quynh-Thu Le, MD, Track Leader
John F. Deeken, MD
Robert L. Ferris, MD, PhD, FACS
Robert I. Haddad, MD
Vassiliki Papadimitrakopoulou, MD
Track
Helen M. Parsons, PhD, Track Leader
George J. Chang, MD, MS
Shawn Dana Glisson, MD, FACP
Monika K. Krzyzanowska, MD, MPH
Rebecca A. Miksad, MD
Arden M. Morris, MD
Craig Evan Pollack, MD
Track
Michael Russell Bishop MD, FACP, Track Leader
Charalambos Andreadis, MD, MSCE
Ravi Bhatia, MD
Joseph G. Jurcic, MD
Celalettin Ustun, MD
Lung Cancer—Non–Small Cell
Local-Regional/Small Cell/Other Thoracic
Cancers Track
Gregory J. Riely, MD, PhD, Track Leader
Edward B. Garon, MD
Scott N. Gettinger, MD
Thomas A. Hensing, MD
Chuong D. Hoang, MD
Tom John, PhD, FRACP, MBBS
Feng Ming Kong, MD
Lung Cancer—Non–Small Cell Metastatic Track
Grace K. Dy, MD, Track Leader
Matthew A. Gubens, MD
Mark G. Kris, MD
Geoffrey R. Oxnard, MD
Luis Paz-Ares MD, PhD
Nathan A. Pennell, MD, PhD
Jonathan Riess, MD
Lecia V. Sequist, MD, MPH
Saad Zafar Usmani, MD, FACP, Track Leader
Ranjana H. Advani, MD
Alexander M. Lesokhin, MD
Sagar Lonial, MD
Thomas G. Martin III, MD
Owen A. O’Connor, MD, PhD
Svetomir Markovic, MD, PhD, Track Leader
Paul B. Chapman, MD
Adil Daud, MD
Georgina V. Long, PhD, BSc, FRACP, MBBS
Shari Beth Goldfarb, MD, Track Leader
Tessa Cigler, MD, MPH
Tara O. Henderson, MD, MPH
Monica Alexandra Iriso, MD
Arif Kamal, MD
Kavitha Ramchandran, MD
Charles L. Shapiro, MD
Katherine Van Loon, MD, MPH
Pediatric Oncology Track
Lisa Diller, MD, Track Leader
Steven G. DuBois, MD
Jeffrey Toretsky, MD
Sarcoma Track
Jonathan C. Trent II, MD, PhD, Track Leader
Venkata Ramesh Bulusu, MD, FRCR
Eric K. Nakakura, MD, PhD
Dennis A. Priebat, MD
Tumor Biology Track
Victoria Louise Seewaldt, MD, Track Leader
Michael J. Birrer, MD, PhD
Wolfgang Michael Korn, MD
Mark M. Moasser, MD
Andrew B. Nixon, PhD
David Potter, MD, PhD
Lawrence H. Schwartz, MD
13
ONSITE DETAILS
ASCO Annual Business Meeting
ASCO Members are encouraged to attend the 2015 ASCO Annual Business Meeting on Monday, June 1, from
12:00 PM to 1:00 PM in the South Building, Room S100a. The Annual Business Meeting includes the following:
● a report by the ASCO Treasurer on the financial state of the Society;
● a report by the Chief Executive Officer;
● the introduction of newly elected ASCO officers;
● passing of the presidential gavel; and
● an open forum for discussion of new initiatives and other Society matters of interest.
ASCO Headquarters Office
Need Assistance? Lost your badge? Head to ASCO Headquarters, located in the North Building, Room
N427a.
Emergency Response for Visitors
If an alarm sounds in McCormick Place:
● Visitors will be directed over the public announcement system to exit through the closest “Emergency Exit.”
● Doors marked as “Stairs” also serve as emergency exits.
● In the event of a power failure, all emergency systems will run on emergency power.
● Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to
McCormick Place.
Faculty Registration and Presenter Ready Room
During registration hours, all faculty will check in at the Faculty Registration and Presenter Ready Room,
located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty
and oral abstract presenters should report to this room to review and submit their presentations with
assistance from ASCO’s audiovisual personnel.
Oncology Professionals Hall
Located in the South Building, Level 3, Hall A, the Oncology Professionals Hall comprises Exhibits, Posters,
the Industry Expert Theater, a Food Court, and ASCO Bistro. Exhibits will highlight the most advanced
treatments, products, and services in oncology and provide attendees the opportunity to meet with
representatives from pharmaceutical companies, scientific publishers, and advocacy groups.
Exhibits are open during the following hours:
Saturday, May 30 .............................9:00 AM–5:00 PM
Sunday, May 31 ...............................9:00 AM–5:00 PM
Monday, June 1 ................................9:00 AM–5:00 PM
The Exhibitor Directory, which includes a list of all exhibitors, is available in multiple locations: Hall C
Registration, Materials Pickup, and the Grand Concourse entrance to the Oncology Professionals Hall.
Electronic versions of the Exhibitor Directory can be accessed through the iPlanner app and at kiosks outside
of the Grand Concourse entrance to the Hall.
General Posters are located on the far right side of the Oncology Professionals Hall and can be accessed
from the Grand Concourse entrance to the Oncology Professionals Hall.
Industry Expert Theater
The Industry Expert Theater is located in the back of the Oncology Professionals Hall by the Food Court and
will host hour-long presentations from industry leaders sharing the latest in oncology practices, products,
services, and technologies. Presentations are not certified for Continuing Medical Education credit. The
schedule will be available in the back of the Exhibitor Directory and online at am.asco.org.
Clinical Information Sharing That Works—REALLY! (An Interoperability Demonstration)
Make room in your schedule to attend interactive interoperability demonstrations. Presenters will highlight
seamless data sharing and electronic information exchange between clinical systems and applications.
Beginning at 9:00 AM on Monday, June 1, visit S405 at the top of each hour to see demonstrations of
improvements to the coordination and quality of care through real-time presentations in multiple electronic
health records and modular applications that use internationally recognized standards for electronic
information exchange between physicians and patients.
Services Available at McCormick Place
● Air Travel Assistance Desk: North Building, Level 3, Grand Concourse Lobby
● Annual Meeting Information Desks: Located throughout McCormick Place
● ASCO University Bookstore: North Building, Level 3, Grand Concourse Lobby; South Building, Level 3,
ASCO Central (Booth #7004)
● Charging Stations for Electronic Devices: Located on round tables throughout McCormick Place
● Chicago Information Desk: North Building, Level 3, Grand Concourse Lobby
● CME Help Desk: North Building 3, Level Grand Concourse Lobby
● ePoster /Virtual Meeting Station: Oncology Professionals Hall; South Building Level 3
● First Aid Stations: South Building, Level 2.5 near Business Center; East Building, Level 1 near Arie Crown Theater
● Hotel Assistance Desk: North Building, Level 3, Grand Concourse Lobby
● International Assistance Desk: North Building, Level 3, Grand Concourse Lobby
● Internet Stations with Printers: South Building, S101 Lobby; North Building, Level 2, by McDonalds;
North Building, Level 2.5; East Building, Hall D2 Lobby
14
● Laptop Station with Power Strips and Ethernet: North Building, Level 3, Grand Concourse Lobby
● Member Services Desk: North Building, Level 3, Grand Concourse Lobby; Oncology Professionals Hall,
South Building, ASCO Central (Booth #7004); North Building, Level 2, Hall C, Registration
● Networking Cafes with Power Outlets (featuring ASCO Live): North Building, Level 3, Grand
Concourse Lobby; South Building, S103 Lobby; East Building, Level 2, Arie Crown Lobby; East Building,
Level 3, D2 Lobby
● Nursing Lounge: North Building, Level 2, Room N227a
● Restaurant Reservations and ASCO Bistro Tickets Desk: North Building, Level 3, Grand Concourse
Lobby
● Share Your Meeting Feedback Desk: North Building 3, Level Grand Concourse Lobby; South Building,
Level 3, Oncology Professional Hall Entrance.
● Technology Assistance Desk: North Building, Level 3, Grand Concourse Lobby
Shuttle Bus Service
Complimentary shuttle service is provided between McCormick Place and all official ASCO hotels. The most
up-to-date shuttle schedule is available at am.asco.org/arc. Please be sure to check the ASCO Shuttle sign in
your hotel for any changes, additional information, frequency of service, and specific departure times for the
designated route.
Hours of Operation
Friday, May 29
Shuttle between hotels and McCormick Place
6:45 AM–7:00 PM*
Saturday, May 30
6:45 AM–7:00 PM*
Sunday, May 31
6:45 AM–7:00 PM*
Monday, June 1
6:45 AM–7:00 PM*
Tuesday, June 2
6:45 AM–1:30 PM*
* Last shuttle departs McCormick Place at this time.
Service will be approximately every 20 minutes. McCormick Place is the transfer point for all routes.
If you have any questions regarding the shuttle, or would like to make a reservation for a wheelchair
accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours
or call Kushner & Associates at 312-808-2000 during shuttle hours.
15
ONSITE DETAILS continued
Featured Voices on Twitter
If you use Twitter, we invite you to use and follow the official meeting hashtag #ASCO15 and to follow
ASCO’s Featured Voices for observations and insight. We thank our members who have agreed to lead this
social media conversation throughout the 2015 Annual Meeting. We invite all to join the conversation, too.
This year’s voices are as follows
Deanna Attai, MD
@DrAttai
Anees B. Chagpar, MD
@AneesChagpar
Matthew Katz, MD
@subatomicdoc
Gilberto Lopes, MD
@GlopesMd
Don S. Dizon, MD, FACP
@drdonsdizon
Michael J. Fisch, MD, MPH
@fischmd
Thomas George, MD
@TGeorgeMD
Merry J. Markham, MD
@DrMarkham
Robert S. Miller, MD
@rsm2800
Ryan Nipp, MD
@RyanNipp
David Graham, MD
@davidgrahammd
Arif Kamal, MD
@arifkamalmd
Naoto T. Ueno, MD, PhD
@teamoncology
Sumanta Pal, MD
@montypal
Nathan A. Pennell, MD, PhD
@n8pennell
Richard L. Schilsky, MD,
FASCO
@rschilsky
Michael Thompson, MD, PhD
@mtmdphd
Eric D. Whitman, MD
@Melanoma_doctor
Peter Paul Yu, MD, FACP,
FASCO
@YupOnc
Yousuf Zafar, MD, MHS
@yzafar
Please join us for the official #ASCO15 tweetup on Saturday, May 30 at 5:45 PM in McCormick
Place, Plate Room (South Building, Level 2.5 Food Court). Signs will be posted and staff will be
guiding attendees to the exact location.
16
POLICIES
For questions regarding these policies or attendee conduct, contact the ASCO Meetings Department at
meetings@asco.org or visit ASCO Headquarters (Room N427a).
Special Assistance
ASCO, all official ASCO hotels, and McCormick Place comply with the Americans with Disabilities Act. If you
require special assistance, please contact the 2015 ASCO Annual Customer Service Center at
ascohousing@jspargo.com or visit the Hotel Assistance Desk in the Grand Concourse Lobby onsite.
Age Requirement for Attendees
Because of the detailed nature of the programs and forums, no one under the age of 18 will be admitted to
any official Meeting function. This includes, but is not limited to, all Meeting sessions, the Oncology
Professionals Hall, and all ASCO-sponsored evening events.
Important Security and Attendee Conduct Information
For security reasons, the 2015 ASCO Annual Meeting badge will be required for admittance to all events.
Please wear your badge so that it can be easily seen at all times. Lost badges should be reported to the
Registration staff immediately. The following badge policies will be in effect throughout the Meeting:
● The 2015 ASCO Annual Meeting badge is the sole property of ASCO.
● The badge is nontransferable.
● False certification of individuals as paid Meeting attendees, misuse of badges, any method of assisting
unauthorized persons to gain access to any Meeting event, or any inappropriate or unauthorized conduct
will be just cause for repossessing badges of any individuals involved and expelling all parties involved
from the Meeting without obligation on the part of ASCO for refund of any fees.
In addition, individuals who are part of the 2015 ASCO Annual Meeting may not engage in any
demonstrations or other behavior that ASCO deems to be potentially disruptive to the conduct of the Meeting.
Violation of this rule is grounds for immediate dismissal from the Meeting and/or ineligibility for attendance at
future ASCO meetings or symposia. Any person who is dismissed from the Meeting may request that ASCO
review the matter, provided, however, that such dismissal will be effective immediately and will continue until
and unless ASCO issues a contrary decision.
Cancellation Statement
ASCO reserves the right to cancel the 2015 ASCO Annual Meeting because of unforeseen circumstances. In
the event of such cancellation, the full registration fee will be returned to each registrant.
Equal Opportunity Statement
The 2015 ASCO Annual Meeting is available without regard to race, color, sex, national origin, disability, age,
or veteran status as provided by law and in accordance with ASCO’s respect for personal dignity.
Authorization for Use of Image, Name, and Other Likeness
By attending the 2015 ASCO Annual Meeting or entering in the facility in which the 2015 ASCO Annual
Meeting takes place, you agree that ASCO or authorized third parties may photograph or record your
likeness, image, name, voice, and/or words, and may publish, display, reproduce, copy, and distribute your
likeness, image, name, voice, and/or words for promotional, educational, or membership activities worldwide
in all forms of media now known or later developed, including but not limited to advertising, training, websites,
presentations, and marketing materials. You further acknowledge that ASCO or authorized third parties shall
have the right, but not the obligation, to identify you in connection with such media by name and/or affiliation.
Recording (Audio, Video, and Still Photography)
Copyright of the 2015 ASCO Annual Meeting program is owned by ASCO. ASCO reserves the rights to all
recordings or reproductions of presentations at this Meeting and all ASCO meetings and symposia.
Any photography, filming, taping, recording, or reproduction in any medium, including via the use of tripodbased equipment, of any of the programs and/or posters presented at the 2015 ASCO Annual Meeting
without the express written consent of ASCO is strictly forbidden. Exception: Non-flash photography and
audio or video recording using hand-held equipment, for strictly personal and noncommercial use, are
permitted if not disruptive, as determined by ASCO.
No Soliciting in the Oncology Professionals Hall
The Oncology Professionals Hall gives 2015 ASCO Annual Meeting attendees the opportunity to meet with
representatives from the health care industry about their products and services in a professional atmosphere
that is consistent with the educational mission of ASCO. Meeting attendees are prohibited from soliciting
business from other attendees or exhibitors in the Oncology Professionals Hall, unless the solicitation occurs
within the specific exhibit space of the attendee.
No Smoking
Smoking is prohibited in all 2015 ASCO Annual Meeting facilities, including public areas and the Oncology
Professionals Hall. This policy will be enforced.
17
AWARDS
ASCO 2015 SPECIAL AWARDS
David A. Karnofsky Memorial Award and Lecture
Presented during the Annual Meeting Opening Session, Saturday, May 30, 9:30 AM, N Hall B1
Suzanne L. Topalian, MD, The Sidney Kimmel Comprehensive Cancer Center
Science of Oncology Award and Lecture
Presented during the Plenary Session, Sunday, May 31, 1:00 PM, N Hall B1
James P. Allison, PhD, The University of Texas MD Anderson Cancer Center
ASCO–American Cancer Society Award and Lecture
Presented on Monday, June 1, 11:30 AM, S102
Ernest Hawk, MD, MPH, The University of Texas MD Anderson Cancer Center
B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
Presented on Sunday, May 31, 9:45 AM, S102
Silvio Monfardini, MD, Istituto Palazzolo, Fondazione Don Gnocchi
Gianni Bonadonna Breast Cancer Award and Lecture
Presented at the 2015 Breast Cancer Symposium, September 25–27, San Francisco, California
Matthew Ellis, MD, PhD, Baylor College of Medicine
Pediatric Oncology Award and Lecture
Presented on Saturday, May 30, 1:15 PM, S504
Stephen E. Sallan, MD, Harvard Medical School/Dana-Farber Cancer Institute
Distinguished Achievement Award
Presented during the President’s Dinner, Friday, May 29
George Bosl, MD, FASCO, Memorial Sloan Kettering Cancer Center
Excellence in Teaching Award
Presented during the Special Session for Program Directors and Key Clinical Faculty, Friday,
May 29, E350
Dean F. Bajorin, MD, FACP, FASCO, Memorial Sloan Kettering Cancer Center
Humanitarian Award
Jose Angel Sanchez, MD, Hospital Escuela, University of Honduras
Partners in Progress Award
Presented during the Highlights of the Day II Session, Monday, June 1, 7:30 AM, E Hall D1
Mary Lou Smith, JD, MBA, Research Advocacy Network
Special Recognition Award
Archie Bleyer, MD, Knight Cancer Institute of the Oregon Health & Science University
Fellow of the American Society of Clinical Oncology (FASCO)
Kathy S. Albain, MD
Craig Earle, MD
Roscoe F. Morton, MD, FACP
Lori J. Pierce, MD
Lillian L. Siu, MD, FRCPC
Eric J. Small, MD
Sandra M. Swain, MD, FACP
18
Conquer Cancer Foundation Grants and Awards
2015 Merit Awards
Bradley Stuart Beller Special Merit Award
This special recognition is given to the fellow who submitted the overall highest-ranking abstract as
determined by the Scientific Program Committee.
María José de Miguel-Luken, MD, The Institute of Cancer Research and The Royal Marsden Hospital
Brigid Leventhal Special Merit Award
In honor of Brigid Leventhal, a physician-pioneer in pediatric research, the Brigid Leventhal Merit Award is
presented to the fellow who submitted the highest-ranking abstract in pediatrics as determined by the
Scientific Program Committee.
Mark A. Applebaum, MD, The University of Chicago
Pain and Symptom Management Special Merit Award
This special recognition is given to the fellow who submitted the highest-ranking abstract in pain and
symptom management research as determined by the Scientific Program Committee.
Ryan David Nipp, MD, Dana-Farber Cancer Institute/Harvard Cancer Center
James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology
Established in memory of James B. Nachman, MD, Professor of Pediatrics at the University of Chicago and
an internationally renowned pediatric cancer expert, this award is given to the junior faculty member who
submitted the highest-ranking abstract in pediatric oncology as determined by the Scientific Program
Committee.
Sébastien Héritier, MD, Versailles University & APHP, Trousseau Hospital
Merit Award Recipients*
Merit Awards are given annually in recognition of outstanding abstracts submitted to the Annual Meeting. The
Merit Award program was established to encourage more fellows and residents to attend the Annual Meeting
and to further promote clinical research in young scientists.
Tarek M. A. Abdel-Fatah, MBChB, PhD, MSc, Nottingham University City Hospital NHS Foundation Trust
Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center
Melissa Kate Accordino, MD, New York Presbyterian Columbia
Anosheh Afghahi, MD, MPH, Stanford University Medical Center
Arun Azad, MBBS, PhD, FRACP, BC Cancer Agency
Hatem Abdel Azim, MD, PhD, Institut Jules Bordet
Myron Best, BMed, VU University Medical Center
Pierre Camateros, MD, PhD, University of British Columbia
Wen Yee Chay, MBBS, MRCP, BC Cancer Agency
Yin Ting Cheung, PhD, BSc (Pharm), St. Jude Children’s Research Hospital
Dai Chihara, MD, PhD, The University of Texas MD Anderson Cancer Center
Victoria L. Chiou, MD, National Cancer Institute at the National Institutes of Health
Erin Frances Cobain, MD, University of Michigan Health System
Natalie Cook, MD, PhD, Princess Margaret Cancer Centre
Francesco Crea, MD, PhD, BC Cancer Agency
Jennifer A. Crozier, MD, Mayo Clinic
May Daher, MD, The University of Texas MD Anderson Cancer Center
Yasir Elamin, MD, Education Centre Beaumont Hospital
Lawson Eng, MD, Princess Margaret Cancer Centre
Zeynep Eroglu, MD, City of Hope
Bishoy Faltas, MD, Weill Cornell Medical College
Andre Poisl Fay, MD, Dana-Farber Cancer Institute
Pauline Funchain, MD, Cleveland Clinic
Daniel A. Goldstein, MD, Winship Cancer Institute of Emory University
Wilson I. Gonsalves, MD, Mayo Clinic
Emily Jean Guerard, MD, The University of North Carolina at Chapel Hill
Anasuya Gunturi, MD, PhD, Beth Israel Deaconess Medical Center
Jason W.D. Hearn, MD, Cleveland Clinic
Yanfeng Hu, MD, Nanfang Hospital, Southern Medical University
Kathryn Elizabeth Hudson, MD, Duke University Medical Center
Scott F. Huntington, MD, MPH, Abramson Cancer Center of the University of Pennsylvania
Haruka Itakura, MD, Stanford University Medical Center
Kevin Jao, MD, FRCPC, Princess Margaret Cancer Centre
John M. Kaczmar, MD, Temple University/Fox Chase Cancer Center
Reva Kakkar Basho, MD, The University of Texas MD Anderson Cancer Center
Shumei Kato, MD, The University of Texas MD Anderson Cancer Center
Yuki Katsuya, MD, National Cancer Center Hospital
19
AWARDS continued
Sharon Kim, BA, Mayo Clinic
Vadim S. Koshkin, MD, University of Michigan
Jeremy Howard Lewin, MBBS, FRACP, Peter MacCallum Cancer Centre
Stephanie Lheureux, MD, PhD, Princess Margaret Cancer Centre
Bob T. Li, MBBS, MPH, FRACP, Memorial Sloan Kettering Cancer Center
Xuewen Liu, MD, PhD, Columbia University Medical Center & Sun Yat-sen University Cancer Center
Kah Poh Loh, MBBCh, Baystate Medical Center
David Lorente, MD, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Arin L. Madenci, MD, MPH, Brigham and Women’s Hospital
Parag Mahale, MBBS, MPH, The University of Texas MD Anderson Cancer Center
Steven Brad Maron, MD, The University of Chicago
Jonathan Michael Marron, MD, Dana-Farber Cancer Institute, Boston Children’s Hospital
Deborah Catherine Marshall, MD, University of California, San Diego
Kara Noelle Maxwell, MD, PhD, University of Pennsylvania Perelman School of Medicine
Maria May, MD, IBYME-CONICET
Alvaro G. Menendez, MD, Roger Williams Medical Center/Boston University School of Medicine
Vasiliki Michalarea, MBBS, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Demytra Krista Lee Mitsis, MD, Roswell Park Cancer Institute
Amr Mohamed, MD, Morehouse School of Medicine
Jarushka Naidoo, MBBCh BAO, MRCPI, Memorial Sloan Kettering Cancer Center
Hiten Naik, BHSc (Hon), University of Toronto
Terence Ng, BSc (Pharm) Hons, National University of Singapore
David B. Page, MD, Memorial Sloan Kettering Cancer Center
Shalu Pahuja, MD, University of Pittsburgh Medical Center
Haeseong Park, MD, MPH, The University of Texas MD Anderson Cancer Center
YaoYao Guan Pollock, MD, Johns Hopkins University School of Medicine
Erqi L. Pollom, MD, Stanford University Medical Center
Sangeetha Prabhakaran, MD, Moffitt Cancer Center
Amanda J. Redig, MD, PhD, Dana-Farber Cancer Institute
Eleni Marie Rettig, MD, Johns Hopkins University School of Medicine
Adrian G. Sacher, MD, Dana-Farber Cancer Institute
Setareh Samimi, MD, Vancouver Centre: BC Cancer Agency
Koji Sasaki, MD, The University of Texas MD Anderson Cancer Center
Peter Stephen Savas, MBBS, Peter MacCallum Cancer Centre
Maria Clemence Schwaederle, PharmD, UC San Diego Moores Cancer Center
Nirav Niranjan Shah, MD, Abramson Cancer Center of the University of Pennsylvania
Payal Deepak Shah, MD, Memorial Sloan Kettering Cancer Center
Brandon S. Sheffield, MD, University of British Columbia
Julia Chia-Ying Shih, MD, Albert Einstein College of Medicine, Jacobi Medical Center
Shivani S. Shinde, MD, MPH, Mayo Clinic
Catherine A. Shu, MD, Memorial Sloan Kettering Cancer Center
Elizabeth Catherine Smyth, MB BCh, MSc, Royal Marsden Hospital
Lillian Mary Smyth, MD, Memorial Sloan Kettering Cancer Center
Anna Spreafico, MD, PhD, Princess Margaret Cancer Centre
Amirrtha Srikanthan, MD, Princess Margaret Hospital
Conor Ernst Steuer, MD, Emory University
Daniel G. Stover, MD, Dana-Farber Cancer Institute
Jaszianne A. Tolbert, MD, The Children’s Mercy Hospital
Meghna S. Trivedi, MD, Columbia University Medical Center
Neelima Vidula, MD, University of California, San Francisco
Judy Sing-Zan Wang, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ying Wang, MD, University of British Columbia
Stephanie B. Wheeler, PhD, The University of North Carolina at Chapel Hill
Michelle K. Wilson, MBChB, FRACP, Princess Margaret Cancer Centre
Dimitrios Zardavas, MD, Breast International Group
Nicholas Zdenkowski, BMed, ANZ Breast Cancer Trials Group
Tian Zhang, MD, Duke University Medical Center
Maria Zlobinsky Rubinstein, MD, Montefiore Medical Center
Merit Awards were generously supported by Amgen; AstraZeneca; the Bradley Stuart Beller Endowment
Fund; the Conquer Cancer Foundation Mission Endowment; Gilead Sciences, Inc.; Incyte Corporation; the
Kidney Cancer Association; Lilly; Novartis Oncology; Onyx Pharmaceuticals; Jackson G. Simpson; Takeda
Oncology; and TESARO. (This list reflects commitments as of April 22, 2015.)
*As of April 22, 2015.
20
2015 Comparative Effectiveness Research Professorship in Breast Cancer
Dawn Hershman, MD, MS, Columbia University Medical Center
This grant was generously supported by Breast Cancer Research Foundation®.
2015 Advanced Clinical Research Award in Breast Cancer
Priyanka Sharma, MD, University of Kansas Medical Center
This grant was generously supported by Breast Cancer Research Foundation®.
2015 Career Development Awards*
Sandra Pierina D’Angelo, MD, Memorial Sloan Kettering Cancer Center
Ayca Gucalp, MD, Memorial Sloan Kettering Cancer Center
Siwen Hu-Lieskovan, MD, PhD, David Geffen School of Medicine at UCLA
Douglas Buckner Johnson, MD, Vanderbilt University Medical Center
David Margel, MD, PhD, Rabin Medical Center
Sean Matthew McBride, MD, MPH, Memorial Sloan Kettering Cancer Center
Katherine Elizabeth Reeder-Hayes, MD, MBA, The University of North Carolina at Chapel Hill
Rizwan Romee, MD, Washington University
Florian Rudolf Schroeck, MD, MS, Dartmouth College
Vamsidhar Velcheti, MD, The Cleveland Clinic
Jason R. Westin, MD, The University of Texas MD Anderson Cancer Center
These grants were generously supported by Astellas; AstraZeneca; Breast Cancer Research
Foundation®; the Conquer Cancer Foundation Mission Endowment; Genentech
BioOncology™; Lilly; and Takeda Oncology. (This list reflects commitments as of April 22,
2015.)
*As of March 27, 2015.
2015 Clinical Trials Participation Awards
The purpose of the Clinical Trials Participation Awards is to increase the awareness of and
participation in clinical trials among physicians through the recognition of quality,
community-based clinical research sites. This award is generously supported by the Coalition of
Cancer Cooperative Groups.
Cancer Care Specialists of Central Illinois, Decatur, IL
Oncology and Hematology Associates of Southwest Virginia/Blue Ridge Cancer Care,
Roanoke, VA
Oncology Hematology Care, Inc., Cincinnati, OH
Scottsdale Healthcare, Scottsdale, AZ
St. Joseph’s Hospital and Medical Center, Phoenix, AZ
The Moses H. Cone Memorial Hospital/Cone Health Cancer Center, Greensboro, NC
2015 International Development and Education Awards*
The Conquer Cancer Foundation’s International Development and Education Award (IDEA)
provides support for early-career oncologists in developing countries to attend the ASCO
Annual Meeting and spend additional time at a cancer center in the United States or Canada.
Eligible recipients also receive three years of complimentary ASCO membership, which
includes a subscription to the Journal of Clinical Oncology. The awards are designed to provide
continuing medical education, assist in career development, and help establish strong
relationships between recipients and leading ASCO Members who serve as scientific mentors.
Shayan Kaka Salh Al-askary, MBBS (MBChB), Hiwa Cancer Center (Iraq)
Hamoud Hodeish Al-Hussaini, MD, MSc, National Oncology Center (Yemen)
Nisreen Yousef Amayiri, MBBS, MD, King Hussein Cancer Center (Jordan)
Nicoleta Zenovia Antone, MD, Ion Chiricuta Oncology Institute Cluj-Napoca (Romania)
Marjorie Rose Ferriols Bravo, MD, St. Luke’s Medical Center (Philippines)
Christianne Bourlon, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
(Mexico)
Claudia Maria Calderon, MD, Hospital General San Felipe (Honduras)
Jarin Chindaprasirt, MD, Chulalongkorn University (Thailand)
Rajeeb Kumar Shree Deo, MBBS, MD, Birendra Hospital (Nepal)
Nilufer Jasmine Selimah Fauzee, MBBS, MD, Central Health Laboratory, Victoria Hospital
(Mauritius)
21
AWARDS continued
Alvaro Henrique Ingles Garces, MD, Brazilian National Cancer Institute (INCA) (Brazil)
Khaoula Mazouzi, MD, CHU Constantine - Ibn Badis Hospital (Algeria)
Vivian Paintsil, MBBS (MBChB), Komfo Anokye Teaching Hospital (Ghana)
Herman Perroud, MD, PhD, Andres Hospital Italiano de Rosario (Argentina)
Chepsy Cherian Philip, MBBS, MD, DM, Christian Medical College & Hospital (India)
George Pupwe, MBBS (MBChB), Stellenbosh University-Medical School (South Africa)
Arathi Srinivasan, MBBS, MD, Kanchi Kamakoti Childs Trust Hospital (India)
Sule Unal, MD, Hacettepe University (Turkey)
Jule Franve Vasquez, MD, Instituto Nacional de Enfermedades Neoplasicas (Peru)
Qiongwen Zhang, MD, PhD, West China Hospital of Sichuan University (China)
These awards were generously supported by AstraZeneca; Roche; and Takeda Oncology.
2015 Long-term International Fellowships
Malek Baassiri, MD
“Late Outcomes of Adult Survivors of Childhood Acute Myeloblastic Leukemia (AML)
Diagnosed Between 1962-2002”
Home Institution: American University of Beirut Medical Center (Lebanon)
U.S. Sponsoring Institution: St. Jude Children’s Research Hospital
Mentor: Melissa Hudson, MD
Kimrom Hagos, MD
“Radiation and Chemoradiation side effect in patients with cervical cancer”
Home Institution: Black Lion Hospital, Addis Ababa University (Ethiopia)
U.S. Sponsoring Institution: Oregon Health & Science University
Mentor: Charles Thomas, MD
These awards were generously supported by the Conquer Cancer Foundation; Gilead
Sciences, Inc.; and Roche. (This list reflects commitments as of April 22, 2015.)
2015 Medical Student Rotation for Underrepresented Populations
Oladapo Adeniran, University of Illinois at Chicago
Cecil Benitez, Stanford University
Mario Martinez, University of Illinois at Chicago
Angel Moran, University of California, Davis
Dionisia Quiroga, Michigan State University
Elisa Quiroz, Ponce Health Sciences University
Jasmine Smith, University of South Carolina School of Medicine Greenville
These awards were generously supported by the Conquer Cancer Foundation Mission
Endowment; Eisai Inc.; Genentech BioOncology™; and Lilly. (This list reflects commitments as
of April 22, 2015.)
2015 Resident Travel Award for Underrepresented Populations
Olufunke Akinbobuyi, MD, Morehouse School of Medicine
Idoroenyi Amanam, MD, St. Mary Medical Center
Ebenezer Appah, MD, Meharry Medical College
Frederick Doamekpor, MD, Morehouse School of Medicine
Nancy Osuji-Oduh, MD, Morehouse School of Medicine
Linnea Perkins, MD, Ochsner Clinic
Sonya Reid-Lawrence, MD, Meharry Medical College
Oluchi Ukaegbu, MD, Vanderbilt University Medical Center
These awards were generously supported by Janssen Biotech, Inc. and Novartis Oncology.
(This list reflects commitments as of April 22, 2015.)
2015 Young Investigator Awards*
Daniel H. Ahn, DO, The Ohio State University
Ali Imran Amjad, MBBS, MD, University of Pittsburgh
Mark M. Awad, MD, PhD, Dana-Farber Cancer Institute
Pavan Bachireddy, MD, Dana-Farber Cancer Institute
Adam Richard Belanger, MD, The University of North Carolina at Chapel Hill
Melissa A. Burns, MD, Dana-Farber Cancer Institute
22
Matthew T. Campbell, MD, The University of Texas MD Anderson Cancer Center
Lan Gardner Coffman, MD, PhD, The University of Michigan
Natalie Bucheimer Collins, MD, PhD, Dana-Farber Cancer Institute
Cristina Cruz, MD, PhD, Vall d’Hebron Institute of Oncology
William Brian Dalton, MD, PhD, Johns Hopkins University
Helen Dinkelspiel, MD, Columbia University Medical Center
Lara Ann Dunn, MD, Memorial Sloan Kettering Cancer Center
Daniel Nathan Egan, MD, Fred Hutchinson Cancer Research Center
Yasir Y. Elamin, MBBS, The Royal College of Surgeons in Ireland
Bishoy Morris Faltas, MD, Joan & Sanford I. Weill Medical College of Cornell University
Christian Gocke, MD, PhD, Johns Hopkins University
Jennifer Brooke Goldstein, MD, The University of Texas MD Anderson Cancer Center
John Gordan, MD, PhD, University of California, San Francisco
Scott M. Haake, MD, H. Lee Moffitt Cancer Center and Research Institute at the University of
South Florida
Jonathan Matthew Hernandez, MD, Memorial Sloan Kettering Cancer Center
Valerie Malyvanh Jansen, MD, PhD, Vanderbilt University Medical Center
Matko Kalac, MD, PhD, Columbia University Medical Center
Michael Khodadoust, MD, PhD, Stanford University
Michael Sangmin Lee, MD, The University of Texas MD Anderson Cancer Center
Jonathan Merle Lehman, MD, PhD, Vanderbilt University Medical Center
Bob Li, MBBS, MPH, Memorial Sloan Kettering Cancer Center
Loretta Sze-Mun Li, MD, Dana-Farber Cancer Institute
Jyoti Malhotra, MD, MPH, Mount Sinai School of Medicine
Gulam Abbas Manji, MD, PhD, Columbia University Medical Center
Mark C. Markowski, MD, PhD, Johns Hopkins University
Benjamin Louis Maughan, MD, Johns Hopkins University
Kara N. Maxwell, MD, PhD, University of Pennsylvania
Shannon Rose McCurdy, MD, Johns Hopkins University
Jennifer Leigh McQuade, MD, The University of Texas MD Anderson Cancer Center
David Jesse Mulvihill, MD, Rutgers, The State University of New Jersey
Prabhjot S. Mundi, MD, Columbia University Medical Center
Mark Alan Murakami, MD, Dana-Farber Cancer Institute
David B. Page, MD, Memorial Sloan Kettering Cancer Center
Anthony Joseph Paravati, MD, MBA, University of California, San Diego
Robin Parihar, MD, PhD, Baylor College of Medicine
Eirini Pectasides, MD, Beth Israel Deaconess Medical Center
Jonathan Peled, MD, PhD, Memorial Sloan Kettering Cancer Center
Nitya Prabhakar Raj, MD, Memorial Sloan Kettering Cancer Center
David Ronan Raleigh, MD, PhD, University of California, San Francisco
Jorge Daniel Ramos, DO, University of Washington
Saleha Sajid, MBBS, MD, The University of Chicago
Eric L. Smith, MD, PhD, Memorial Sloan Kettering Cancer Center
Alexandra Snyder Charen, MD, Memorial Sloan Kettering Cancer Center
Enrique Soto Perez de Celis, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador
Zubiran
Elizabeth Harmon Stover, MD, PhD, Dana-Farber Cancer Institute
Benjamin Addison Teply, MD, MS, Johns Hopkins University
Zuzana Tothova, MD, PhD, Dana-Farber Cancer Institute
Michelle Treasure, MD, Case Western Reserve University
Kristina Marie Vander Wall, MD, University of California, Los Angeles
Aaron David Viny, MD, MS, Memorial Sloan Kettering Cancer Center
Kristina Hoot Young, MD, PhD, Providence Portland Medical Center
Jianjun Zhang, MD, PhD, The University of Texas MD Anderson Cancer Center
These grants were generously supported by AbbVie, Inc.; the American Association for Cancer
Research; Amgen; Anonymous; ASCO and Conquer Cancer Foundation Boards of Directors;
ASCO State Affiliate Council and ASCO Clinical Practice Committee; AstraZeneca; Boehringer
Ingelheim Pharmaceuticals, Inc.; Breast Cancer Research Foundation®; Celgene Corporation;
The Cholangiocarcinoma Foundation; Conquer Cancer Foundation; Conquer Cancer
Foundation Women Who Conquer Cancer; Eisai Inc.; Ethicon; Florida Society of Clinical
Oncology; Genentech BioOncology™; Gilead Sciences, Inc.; Incyte Corporation; Janssen
23
AWARDS continued
Biotech, Inc.; the John and Elizabeth Leonard Family Foundation; Journal of Clinical Oncology;
Kidney Cancer Association; Lilly; Merck Oncology; Novartis Oncology; Onyx Pharmaceuticals;
Susan K. Parsons, MD, and Walter Armstrong; Pfizer Oncology; The Reid R. Sacco Adolescent
and Young Adult Alliance; Roche; The Scopus Foundation; Young A. Sohn and Mark
Armenante; the Strike 3 Foundation; Takeda Oncology; and The WWWW Foundation Inc.
(QuadW) and The Sarcoma Fund of the QuadW Foundation of Communities Foundation of
Texas. (This list reflects commitments as of April 22, 2015.)
*As of April 23, 2015.
Past Grant Recipients
The Conquer Cancer Foundation congratulates the following grant recipients whose abstracts
were selected for the 2015 Annual Meeting. Their abstracts include the results of the research
funded by the Conquer Cancer Foundation. Visit conquercancerfoundation.org for more
information about the Conquer Cancer Foundation Grants and Awards Program.
Rahul Aggarwal, MD, 2012 Young Investigator Award (YIA)
Daniel Fontes Argolo, MD, 2014 Long-term International Fellowship (LIFe)
Karen Effinger, MD, MS, 2014 Young Investigator Award (YIA)
Alan Ho, MD, PhD, 2012 Career Development Award (CDA)
Neil Iyengar, MD, 2013 Young Investigator Award (YIA)
Meghan Karuturi, MD, 2014 Young Investigator Award (YIA)
Geoffrey Oxnard, MD, 2012 Career Development Award (CDA)
Ann Partridge, MD, MPH, 2010 Improving Cancer Care Grant (ICCG)
Melinda Telli, MD, 2010 Young Investigator Award (YIA)
Eliezer Van Allen, MD, 2013 Young Investigator Award (YIA)
24
2015 ANNUAL MEETING SUPPORTERS*
MISSION ENDOWMENT FOUNDING
DONORS
Bayer HealthCare Pharmaceuticals Inc.
Genentech BioOncology™
GlaxoSmithKline Oncology
Novartis Oncology
Sanofi Oncology
Boehringer Ingelheim Pharmaceuticals, Inc.
Lung Cancer Track
MISSION ENDOWMENT SUSTAINING
DONORS
AbbVie, Inc.
Amgen
Celgene Corporation
Eisai Inc.
HELSINN
Incyte Corporation
Lilly
Onyx Pharmaceuticals
Sanofi Oncology
Takeda Oncology
ENDOWED FUND DONORS
Bradley Stuart Beller Endowment Fund
Bradley Stuart Beller Special Merit Award
Evelyn H. Lauder YIA Endowment Fund
Breast Cancer Research Foundation®
James B. Nachman Pediatric Oncology Fund
James B. Nachman ASCO Junior Faculty Award in
Pediatric Oncology
John R. Durant, MD, YIA Endowment Fund
Celgene Corporation
The Sally Gordon YIA Endowment Fund
Anonymous
CANCERLINQ™ MAJOR SUPPORTERS
Amgen
Astellas
Cancer Treatment Centers of America®
Chan Soon-Shiong Family Foundation
HELSINN
Lilly
Raj Mantena, RPh
Novartis Oncology
Pfizer Oncology
Thomas G. Roberts, Jr., MD, and Susan M. DaSilva
Susan G. Komen®
Celgene Corporation
Breast Cancer Track
Leukemia, Myelodysplasia, and Transplantation Track
Lung Cancer Track
Annual Meeting Proceedings and Educational Book
Bundle
Breast Cancer Track
Genomic Health, Inc.
Breast Cancer Track
HELSINN
Health Services Research and Quality of Care Track
Incyte Corporation
Kidney Cancer Association
Lilly
Breast Cancer Track
Lung Cancer Track
Pre-Annual Meeting Seminar: New Drugs in Oncology
Ludwig Cancer Research
Cancer Prevention, Genetics, and Epidemiology Track
Merck Oncology
Annual Meeting Proceedings and Educational Book
Bundle
Breast Cancer Track
Lung Cancer Track
Myriad Genetics Laboratories, Inc.
Cancer Prevention, Genetics, and Epidemiology Track
EDUCATIONAL SUPPORT
Novartis Oncology
Best of ASCO Meetings Breast Cancer Track
Amgen
Astellas
Medivation
Pfizer Oncology
AstraZeneca
Breast Cancer Track
Lung Cancer Track
Pharmacyclics
25
2015 ANNUAL MEETING SUPPORTERS* continued
Society for Neuro-Oncology in honor of its 20th
Anniversary
Teva Oncology
Pre-Annual Meeting Seminar: Hematology for the
Oncologist
GENERAL SUPPORT
AbbVie, Inc.
Young Investigator Award
Alliance for Academic Internal Medicine and The
John A. Hartford Foundation
B.J. Kennedy Award and Lecture
Breast Cancer Research Foundation®
Advanced Clinical Research Award in Breast
Cancer
Career Development Award in Breast Cancer
Comparative Effectiveness Research Professorship
in Breast Cancer
Young Investigator Award in Breast Cancer (3)
Young Investigator Award in Breast Cancer, in honor
of Susan Hirschhorn and in memory of her
mother
Bristol-Myers Squibb
Annual Meeting Program Publications Bundle
ASCO iMeeting Mobile Application
Onsite Connectivity Resources Bundle
Brooks Brothers
Corporate Allies Conquering Cancer
American Association for Cancer Research
Conquer Cancer Foundation of ASCO/AACR Young
Investigator Translational Cancer Research Award
Celgene Corporation
ASCO Virtual Meeting
American Cancer Society
ASCO-American Cancer Society Award and Lecture
The Cholangiocarcinoma Foundation
Young Investigator Award in Cholangiocarcinoma
Amgen
Career Development Award
Merit Awards
Coalition of Cancer Cooperative Groups
Clinical Trials Participation Award
Anonymous
Young Investigator Award (2)
ASCO and Conquer Cancer Foundation Boards
of Directors
Jane C. Wright, MD, Young Investigator Award
ASCO International
International Innovation Grant
ASCO State Affiliate Council and ASCO Clinical
Practice Committee
Astellas
AstraZeneca
International Development and Education Award
Merit Awards
BABETTE
ASCO Live
Special Attendees Lounge Bundle
Bloomingdale’s
Boehringer Ingelheim Pharmaceuticals, Inc.
26
Conquer Cancer Foundation
Long-term International Fellowship
Conquer Cancer Foundation Mission
Endowment
Medical Student Rotation for Underrepresented
Populations
Merit Awards
Conquer Cancer Foundation Women Who
Conquer Cancer
David Yurman
Eisai Inc.
Populations
Ethicon
Fashion Outlets of Chicago
Florida Society of Clinical Oncology
Career Development Award (3)
Populations
Gilead Sciences, Inc.
Long-Term International Fellowship
Merit Awards
Palo Alto Medical Foundation
Leaders in Practice-Silver Supporter
GlaxoSmithKline Oncology
Gianni Bonadonna Breast Cancer Award and Lecture
Susan K. Parsons, MD, and Walter Armstrong
GO Airport Express
HELSINN
General Mission Support
iPlanner Mobile Application and Website Bundle
Incyte Corporation
Merit Awards
Infinity Pharmaceuticals Inc.
Ipsen Biopharmaceuticals Inc.
Janssen Biotech, Inc.
Resident Travel Award for Underrepresented
Populations
John and Elizabeth Leonard Family Foundation
Patient Access Network Foundation
Patient Advocate Scholarship Program
Pfizer Oncology
The Reid R. Sacco Adolescent and Young Adult
Alliance
Roche
Long-Term International Fellowship
The Scopus Foundation
Seattle Genetics
General Mission Support
Jackson G. Simpson
Merit Awards
Journal of Clinical Oncology
Young A. Sohn and Mark Armenante
Kidney Cancer Association
Merit Award in Kidney Cancer
Young Investigator Award in Kidney Cancer
Strike 3 Foundation
Young Investigator Award in Pediatric Oncology (2)
Lilly
Populations
Merit Awards
Patient Advocate Scholarship Program Bundle
Merck Oncology
Annual Meeting Program Publications Bundle
Michael’s Mission
Michael’s Mission/Conquer Cancer Foundation of
ASCO Career Development Award
Novartis Oncology
Merit Awards
Resident Travel Award for Underrepresented
Populations
Merit Awards
TAIHO Oncology, Inc.
Takeda Oncology
Abstracts on ASCO.org
ASCO Virtual Meeting
Merit Awards
Oncology Trainee Travel Awards
TESARO
Merit Awards
Teva Oncology
Tourneau, LLC
WWWW Foundation Inc. (QuadW) and The
Sarcoma Fund of the QuadW Foundation of
Communities Foundation of Texas
Young Investigator Award in Sarcoma, in Memory of
Willie Tichenor
*This list reflects commitments as of April 22, 2015.
27
ANCILLARY EDUCATIONAL EVENTS DIRECTORY
Below is a list of educational events hosted by other CME-accredited providers taking place in Chicago during
the 2015 ASCO Annual Meeting. For more information regarding these events, consult the contact
information in the listings below.
The events listed in this directory are independent, accredited educational activities held adjunct to the ASCO
Annual Meeting. These presentations are not sponsored or endorsed by ASCO.
Title: Questions from the Community: Investigators Provide Perspectives on Challenging Clinical Issues in
the Management of Non–Small Cell Lung Cancer
Date and Time: Friday, May 29 from 7:00 PM–9:00 PM
Location: Hilton Chicago, Grand Ballroom
CME Provider and Supporter(s): This event is sponsored by Research To Practice and supported by an
educational grant from Lilly.
Registration and Contact Information: Registration is encouraged as seating is limited. Register online at
researchtopractice.com/Meetings/NSCLC2015. For more information, please contact
meetings@researchtopractice.com or call (800) 233– 6153.
Event Summary
This CME symposium will focus on the discussion of actual cases and other challenging clinical situations
identified by a number of community-based oncologists to create a dynamic learning format designed to both
improve clinicians’ knowledge and assist them in becoming better and more effective caregivers. In the
months leading up to the event, Research To Practice, in collaboration with the invited faculty, will consult
with a small group of practicing medical oncologists who care for patients with non–small cell lung cancer to
identify clinical situations and/or ambiguous data sets for which they would like to receive expert perspective
and feedback. During each of the 5 modules at the live activity, one invited faculty member will deliver a brief
presentation reviewing recent data sets and ongoing clinical trials that inform decision making related to the
clinical scenarios identified during the premeeting planning sessions. Following each didactic presentation,
an extended panel discussion will be introduced to obtain the perspectives of the other faculty members on
these topics. To maintain audience interest and relevance, clinician attendees will have the opportunity to
participate in a premeeting survey utilizing networked iPads that will include general and case-based
questions related to the topics that will be discussed. The results will be displayed throughout the event to
foster additional conversation.
Faculty
Moderator
Neil Love, MD
Research To Practice
Speakers
Corey J. Langer, MD
Director of Thoracic Oncology, Abramson Cancer Center
Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Tony S. K. Mok, MD
Professor, Department of Clinical Oncology, The Chinese University of Hong Kong
Associate Professor of Medicine, Harvard Medical School, Center for Thoracic Cancers, Massachusetts
General Hospital Cancer Center
David R. Spigel, MD
Program Director, Lung Cancer Research, Sarah Cannon Research Institute
Heather Wakelee, MD
Associate Professor of Medicine
Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine
Title: Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and
Combinations
Date and Time: Friday, May 29 from 7:00 PM–9:00 PM (Registration and dinner begin at 6:00 PM.)
Location: Hilton Chicago, International South Ballroom
CME Provider and Supporter(s): This event is sponsored by Physicians’ Education Resource and
supported by an educational grant from AstraZeneca.
gotoper.com/go/ASC15Immuno. For more information, please contact info@gotoper.com or (609) 378-3701.
Event Summary
Immuno-Oncology is without a doubt one of the most exciting areas of cancer treatment development in
recent years. Novel immuno-oncology strategies are being evaluated in a number of solid tumors for which
there remains great unmet clinical needs, including lung cancer, squamous cell carcinoma of the head and
28
neck, and mesothelioma. These novel approaches to care for these tumors have the potential to redefine how
cancer is treated and managed. This symposium is structured in an interactive format that chronicles the
advances in medicine through a historical perspective, while employing an evidence-based roadmap to
forecast future therapeutic options with the potential to dramatically improve patient care. It includes
multimedia technology and interactive presentations from expert faculty that allow medical professionals to
enhance their understanding of the advances in immuno-oncology in order to translate and impact treatment
practices in the future.
There is no registration fee to participate in this live educational symposium. However, preregistration is
recommended, as seating is limited.
Faculty
Moderator
Roy S. Herbst, MD, PhD—Chair
Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, Chief of Medical Oncology,
Associate Director for Translational Research, Yale Cancer Center, Yale School of Medicine
Speakers
Julie Brahmer, MD
Interim Director, The Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus)
Interim Co-Director, Upper Aerodigestive Program, Associate Professor, Oncology, The Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins
Barbara Burtness, MD
Clinical Research Program Leader, Head and Neck Cancers Program, Co-Director, Developmental
Therapeutics Research Program, Professor of Medicine, Medical Oncology, Yale Cancer Center
Naiyer Rizvi, MD
Director, Thoracic Oncology, Director, Immunotherapeutics, Price Chair, Clinical Translational Research,
Columbia University Medical Center
Title: The Clinical Potential of Novel Poly ADP-Ribose Polymerase (PARP) Inhibitors for Improved
Management of Epithelial Ovarian Cancer
Date and Time: Saturday, May 30 from 6:30 PM– 8:45 PM
Location: Hilton Chicago, International North Ballroom
CME Provider and Supporter(s): This event is sponsored by Imedex and supported by an educational grant
from AstraZeneca.
imedex.com/ovarian-cancer-parp-inhibitors/index.asp. For more information, please contact
registration@imedex.com or call (800) 233 0957 (domestic) or ⫹1 (678) 242 0906 (outside the U.S.).
Event Summary
Care for patients with gynecologic cancers is becoming increasingly complex. PARP inhibitors (PARPis) have
been investigated in the maintenance and second-line setting in ovarian cancers with encouraging response
rates and improvement in progression-free survival, especially in patients with high-grade serous carcinoma.
Eight PARPis are currently being evaluated in more than 35 clinical trials. Increasingly, clinical trial design
and treatment of ovarian cancer are being based on histologic and molecular characteristics of the tumor, and
PARPis have the potential to be the first targeted agents that allow for patient selection to improve clinical
outcomes. Join us for this interactive symposium during which world-renowned experts engage in case and
panel discussions to evaluate the benefits and risks of emerging PARPis, identify ways to safely and
effectively incorporate these agents into practice, and provide tips for referring patient to appropriate trials.
Faculty
Bradley J. Monk, MD, FACOG, FACS—Chair
Creighton University School of Medicine, St. Joseph’s Hospital and Medical Center
Thomas J. Herzog, MD
University of Cincinnati
Ursula A. Matulonis, MD
Dana-Farber Cancer Institute/Harvard University School of Medicine
Title: Identification and Innovation of Novel EGFR TKIs for NSCLC
Date and Time: Saturday, May 30 from 7:00 PM–9:00 PM (Registration and dinner seating begins at 6:30
PM.)
CME Provider and Supporter(s): This event is sponsored by Letters & Sciences in joint providership with
the Postgraduate Institute for Medicine and supported by an educational grant from AstraZeneca.
NSCLCNovelTKIs.com. For more information, please email Jamie Miller at jmiller@letsci.org.
29
ANCILLARY EDUCATIONAL EVENTS DIRECTORY continued
Event Summary
With paradigm shifts in the approach to non–small cell lung cancer (NSCLC) treatment, customization of
treatment based on histology and molecular typing has become the standard of care. The identification of
treatment-resistant subsets and continuous development of targeted therapies in the NSCLC treatment
paradigm require education and expert guidance to support oncologists and other health-care providers in
their clinical decision making. To bridge clinical practice and knowledge gaps, leading experts, including a
distinguished faculty of principal investigators, clinicians, and researchers will identify the major mechanisms
of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs), and discuss the development of rationally
designed molecular targeted drugs used to help overcome treatment resistance. The faculty will also address
late-breaking evidence, discuss the role and sequencing of next-generation EGFR TKIs, as well as highlight
efforts to answer ongoing clinical challenges.
Faculty
Corey J. Langer, MD—Chair
Director of Thoracic Oncology, Abramson Cancer Center of the University of Pennsylvania
David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology, The Johns Hopkins University School of Medicine
Pasi A. Janne, MD, PhD
Professor of Medicine, Dana-Farber Cancer Institute
Heather Wakelee, MD
Associate Professor of Medicine (Oncology), Stanford University
Title: Best Practices and Emerging Treatment Strategies in the Management of Chemotherapy-Induced
Nausea and Vomiting
Date and Time: Sunday, May 31 from 6:30 PM–9:00 PM
Location: Hilton Chicago, International North Ballroom
CME Provider and Supporter(s): This event is sponsored by Imedex and supported by an educational grant
from TESARO, Inc.
imedex.com/cinv-management/index.asp. For more information, please contact registration@imedex.com or
call (800) 233 0957 (domestic) or ⫹1 (678) 242 0906 (outside the U.S.).
Event Summary
Chemotherapy-induced nausea and vomiting (CINV) is regarded by patients as one of the most distressing
and feared adverse effects of chemotherapy. Although it is estimated to afflict more than 70% of patients with
cancer undergoing both highly and moderately emetogenic treatment, the incidence and effects of CINV on
quality of life are often underestimated. Inadequate control of nausea and vomiting may necessitate reduced
treatment intensity and result in poor adherence to therapy. Delayed nausea and emesis, which may present
even in the absence of acute effects, remain targets for improved therapeutic intervention. Novel antiemetic
agents and strategies are being developed to improve CINV control, particularly of delayed nausea. Join us
for an interactive symposium during which world-renowned experts engage in case and panel discussions,
relating the pathophysiology of CINV to targets for therapeutic intervention and evaluating the implications of
recent guidelines and emerging safety and efficacy data for novel therapies and clinical approaches.
Faculty
Paul J. Hesketh, MD–Chair
Lahey Hospital and Medical Center
Matti S. Aapro, MD
Cinique de Genolier
Richard J. Gralla, MD
Albert Einstein College of Medicine
Title: The Biosimilar Matrix: The Impact of Biosimilars in Managing Neutropenia
Date and Time: Sunday, May 31 from 7:00 PM– 8:30 PM (Registration and dinner begin at 6:30 PM.)
Location: Sheraton Chicago Hotel & Towers, Chicago Ballroom 8 - Level 4
CME Provider and Supporter(s): This event is sponsored by Medscape Education and supported by an
independent educational grant from Sandoz, A Novartis Company.
Registration and Contact Information: Register online at medscape.org/sites/townhall/public/biosimilarmatrix. Registration is encouraged as seating is limited.
Event Summary
The recent introduction of biosimilars to the U.S. health-care scene has resulted in confusion among
clinicians regarding what they are, how they are made, how they differ from brand-name products, how they
are approved, and how they should be used in practice. A distinguished international team of multidisciplinary
30
experts will try to answer these questions by focusing on the efficacy, safety, and pharmacoeconomics of
granulocyte colony-stimulating factor (G-CSF) biosimilars in the context of managing neutropenia. Topics to
be covered include the development and regulatory pathway of these products, their clinical efficacy and
safety, and guidance on the role of G-CSF biosimilars as they may be applied in clinical practice. By the
conclusion of this session, attendees can expect to have achieved a greater sense of clarity around these
increasingly important biological products and their role in the care of patients with cancer.
Faculty
Moderator
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Speakers
Pere Gascón, MD, PhD
University of Barcelona
Edward Li, PharmD, MPH
University of New England College of Pharmacy
James G. Stevenson, PharmD
University of Michigan College of Pharmacy
Title: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming
Resistance
Date and Time: Sunday, May 31, from 7:00 PM–9:00 PM (Registration and dinner will begin at 6:00 PM.)
Location: Sheraton Chicago, Chicago Ballroom VI
CME Provider and Supporter(s): This event is sponsored by Physicians’ Education Resource and
supported by an educational grant from AstraZeneca.
Registration and Contact Information: Registration is encouraged as seating is limited. Register online
gotoper.com/go/ASC15Lung. For more information, please contact info@gotoper.com or call 609-378-3701.
Event Summary
“Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options. . . More Decisions. . .
Better Outcomes.” Lung cancer is the leading cause of cancer death in the United States. Despite progress in
early detection, lung cancer is often diagnosed at an advanced stage and patient prognosis in advanced
disease is poor. Non–small cell lung cancer (NSCLC) is the most common form of lung cancer, and accounts
for the vast majority of cases. EGFR-mutations have been established for quite some time as predictive
markers of response to certain EGFR-TKI therapies in the front-line setting. However, despite good initial
responses observed with front-line approaches in EGFR-mutated tumors, disease progression subsequent to
front-line EGFR-TKI treatment is inevitable. Second-generation irreversible EGFR-TKIs have been unable to
overcome T790M-mediated resistance as monotherapy, and there is a significant current unmet clinical need
for patients with acquired resistance in relapsed advanced NSCLC. This symposium will address these needs
in treating EGFR-mutant NSCLC through multiple lines of therapy.
There is no registration fee to participate in this live educational symposium. However, preregistration is
recommended, as seating is limited.
Faculty
Moderator
Mark G. Kris, MD
Attending, Thoracic Oncology Service, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan
Kettering Cancer Center
Speakers
David Gandara, MD
Professor of Medicine, Division of Hematology/Oncology, Director, Thoracic Oncology Program, Senior
Advisor to the Director, UC Davis Comprehensive Cancer Center
Geoffrey R. Oxnard, MD
Assistant Professor of Medicine, Dana Farber Cancer Institute
Helena A. Yu, MD
Assistant Attending, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Title: The Potential Therapeutic Benefits of Emerging Arginine Deprivation Agents
Date and Time: Sunday, May 31 from 7:00 PM–9:00 PM (Registration and dinner begins at 6:30 PM.)
CME Provider and Supporter(s): This event is sponsored by Med Learning Group and co-provided by
Ultimate Medical Academy/Complete Conference Management with support from an educational grant from
31
ANCILLARY EDUCATIONAL EVENTS DIRECTORY continued
Polaris Group.
medlearninggroup.com/cme-programming/asco-symposium. For more information, please contact Joe
Guerriero at (908) 358 – 6466.
Event Summary
This CME symposium is designed to meet the educational needs of oncology physicians and nurses as well
as other health-care providers involved in the treatment of patients with various cancers, including but not
limited to hepatocellular carcinoma, mesothelioma, acute myelogenous leukemia, acute lymphoblastic
leukemia, and non–small cell lung cancer. The faculty will explain the rationale for arginine deprivation
therapies, review the clinical experience with emerging ADI-PEG-20 compounds and their potential
therapeutic uses, and finally describe strategies to implement these new agents into multimodality drug
regimens.
Faculty
Ghassan Abou-Alfa, MD—Chair
Associate Professor, Memorial Sloan Kettering Cancer Center
Richard J. Bold, MD
Chief of Surgical Oncology, Professor, UC Davis Comprehensive Cancer Center
Eileen M. O’Reilly, MD
Associate Director, Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research,
Peter W. Szlosarek, MD, PhD
Physician Scientist, Barts Cancer Institute and St Bartholomew’s Hospital
Brian A. Van Tine, MD, PhD
Hematology/Oncology, Assistant Professor of Medicine, Sarcoma Program Director, Barnes-Jewish Hospital,
Washington University in St. Louis
32
American Society of Clinical Oncology
51st Annual Meeting
Meeting Program
Abstract Key
LBA: Late-Breaking Abstract
TPS: Trials in Progress Abstract
Friday, May 29, 2015
FRIDAY
1:00 PM - 2:15 PM Education Session
Acute Lymphoblastic Leukemia: A New Era of Targeted and Immunologic
Therapies
Location: E450
David I. Marks, MD, PhD
University Hospitals Bristol NHS Foundation Trust
Treatment of the Older Patient with Acute Lymphoblastic Leukemia: Balancing Risk and Benefit
Michel Sadelain, MD—Chair
Novel and Effective Immunotherapeutic Approaches in Acute Lymphoblastic Leukemia
Adele K. Fielding, MBBS, PhD
University College London
Management of Ph-Positive Acute Lymphoblastic Leukemia
Panel Question and Answer
Controversies in the Management of Germ Cell Tumors
Location: E354b
Alan Horwich, MD, PhD
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
The Role for Observation in Stage I Germ Cell Tumors, Outcomes, and Challenges
Lawrence H. Einhorn, MD
Indiana University School of Medicine
Salvage Approaches in Refractory Germ Cell Tumors
George J. Bosl, MD—Chair
Future Directions in Germ Cell Tumors
Early Detection of Cancer: Past, Present, and Future
Location: S404
Paul Graham Fisher, MD
Stanford University
Biomarkers for Early Cancer Detection
Joshua David Schiffman, MD—Chair
University of Utah
Imaging for Early Tumor Surveillance in High-Risk and General Populations
Peter Gibbs, MBBS, MD, FRACP
Royal Melbourne Hospital
Detection of Circulating Tumor Cells and Circulating Tumor DNA
34
FRIDAY
Molecular Oncology Tumor Board
Location: S100bc
S. Gail Eckhardt, MD—Chair
University of Colorado School of Medicine, Anschutz Medical Campus
Lillian L. Siu, MD, FRCPC
Princess Margaret Cancer Centre
Medical Oncology
Stanley R. Hamilton, MD
The University of Texas MD Anderson Cancer Center
Pathology
Nikolaus Schultz, PhD
Bioinformatics
Molly S. Daniels, MS, CGC
Genetic Counseling
1:00 PM - 2:15 PM Meet the Professor Session
Career Development in Pediatric Clinical Trials: Direction for Young
Investigators from NCI and Cooperative Group Leadership—Ticketed Session
Location: E451a
Nita Seibel, MD
National Cancer Institute
Lia Gore, MD
University of Colorado Cancer Center
1:00 PM - 3:15 PM Extended Education Session
Administrative Burdens in Oncology
Location: S504
1:00 PM
Robin Zon, MD, FACP, FASCO—Chair
Michiana Hematology Oncology PC
Growing Concern of Administrative Burdens in Practice
1:15 PM
Barbara L. McAneny, MD
New Mexico Oncology Hematology Consultants, LTD
Recognizing and Identifying Administrative Burdens in Practice
1:40 PM
Kimberly Woofter, RN
Michiana Hematology Oncology PC
Practice Administrator’s Perspective
2:05 PM
John Emmett Hennessy, CMPE
Sarah Cannon Cancer Services
Payers, Preauthorizations, and Payments: Transactional Burdens
35
2:30 PM
FRIDAY
Controversies in the Management of Premenopausal Breast Cancer: The Role
for Ovarian Suppression, Fertility Preservation, Bisphosphonates, and Local
Therapy
Location: E Hall D1
1:00 PM
Hope S. Rugo, MD—Chair
University of California, San Francisco
Hormonal Therapy for Early-Stage Breast Cancer in Premenopausal Women
1:24 PM
Halle C. F. Moore, MD
Cleveland Clinic
Should We Use GnRH Agonists for Fertility Preservation?
1:48 PM
Kutluk Oktay, MD
Institute for Fertility Preservation and New York Medical College
Fertility Options for Young Women with Breast Cancer
2:12 PM
Robert E. Coleman, MBBS, MD, FRCP
University of Sheffield, Weston Park Hospital
Use of Bisphosphonates in Premenopausal Women
2:36 PM
Barbara L. Smith, MD, PhD
Massachusetts General Hospital
Surgical Options for Young Women with Breast Cancer
3:00 PM
On the Shoulders of Giants: Chronic Lymphocytic Leukemia—Evolution of
Targeted and Immunotherapy
Location: S406
1:00 PM
Marcia S. Brose, MD, PhD—Chair
Abramson Cancer Center of the University of Pennsylvania
Welcome and Introductions
1:15 PM
Jesse A. Soodalter, MD
University of Chicago Medicine
Case Study Presentation and Discussion
1:45 PM
John C. Byrd, MD
Ohio State University Medical Center
History of Chronic Lymphocytic Leukemia and Molecular Targeted Therapy
2:15 PM
Michael Andrew Postow, MD
Case Study Presentation and Discussion
2:45 PM
Stephen J. Schuster, MD
Immunotherapy and Chronic Lymphocytic Leukemia
Personalizing Lung Cancer Therapy in the Adjuvant or Advanced Setting
Location: E Arie Crown Theater
36
1:00 PM
Thierry Le Chevalier, MD
Institut Gustave Roussy
Adjuvant Therapy for Elderly and Nonfit Patients in the Pan-Wildtype Setting
1:20 PM
Martin J. Edelman, MD—Chair
University of Maryland School of Medicine
Systemic Therapy of Pan-WT in Metastatic Setting
1:40 PM
Marc Ladanyi, MD
Next-Generation Sequencing and Other Platforms for Molecular Profiling
2:00 PM
Tony Mok, MD
Chinese University of Hong Kong
Molecularly Targeted Therapies: Their Trials and Roles in the Adjuvant and
Postchemoradiation Setting
2:20 PM
Grace K. Dy, MD
Roswell Park Cancer Institute
Clinical Trials and Treatment for Mutations Other Than EGFR/ALK/ROS1
2:40 PM
Laura Quan Man Chow
University of Washington
Considering Immunotherapy in the Adjuvant and Metastatic Setting
3:00 PM
FRIDAY
The ASCO Obesity Initiative: The Weight of the Evidence
Location: S102
1:00 PM
Pamela Jean Goodwin, MD, MSc, FRCPC
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of
Toronto
Obesity: Observational Evidence and Mechanisms
1:22 PM
Wendy Demark-Wahnefried, PhD, RD
University of Alabama at Birmingham Comprehensive Cancer Center
Weight Management and Nutrition: Interventions and Practical Considerations
1:44 PM
Lee Jones, PhD
Physical Activity: Observational Evidence and Mechanisms
2:06 PM
Kerry S. Courneya, PhD
University of Alberta
Physical Activity: Interventions and Practical Considerations
2:28 PM
Jennifer A. Ligibel, MD—Chair
Dana-Farber Cancer Institute
The ASCO Obesity Initiative: Current Status and Next Steps
2:50 PM
MOC and Lifelong Learning Workshop: ABIM Module 2014 —Ticketed Session
Location: E451b
Antoinette R. Tan, MD
Levine Cancer Institute, Carolinas HealthCare System
Bhoomi Mehrotra, MD
St. Francis Hospital
37
FRIDAY
Benjamin Philip Levy, MD
Mount Sinai Health Systems
Grant Writing Workshop
Location: S103
1:00 PM
Dean Frohlich
Conquer Cancer Foundation of the American Society of Clinical Oncology
Conquer Cancer Foundation Grants Program
1:15 PM
Ming Lei, PhD
National Cancer Institute at the National Institutes of Health
National Cancer Institute Training and Career Development Grants
1:30 PM
Susan Blaney, MD
Texas Children’s Cancer Center, Baylor College of Medicine
Choosing a Mentor and Obtaining Letters of Support
1:45 PM
Heather L. McArthur, MD
What to Do When Your First Grant Application Gets Rejected
2:00 PM
Karla V. Ballman, PhD
Mayo Clinic
Working with a Biostatistician
2:15 PM
Mary L. Disis, MD—Chair
Grant Writing Pearls
Kathleen A. Cooney, MD
University of Michigan Comprehensive Cancer Center
Small Group Discussion Table Leader
Suzanne Eleanor Dahlberg, PhD
Norah Lynn Henry, MD, PhD
Dawn L. Hershman, MD, MS
Bruno C. Medeiros, MD
Stanford University School of Medicine
Wells A. Messersmith, MD
1:00 PM - 5:45 PM Special Session
Global Oncology Symposium
Location: S100a
Gabriel N. Hortobagyi, MD, FACP—Co-Chair
38
FRIDAY
Yun Yen, MD, PhD—Co-Chair
Taipai Medical University
1:00 PM
David J. Kerr, MD, PhD
University of Oxford
Global Health Policy and the Accidental Tourist
1:30 PM
Sun Young Rha, MD, PhD
Yonsei University College of Medicine
Gastric Cancer: East versus West
1:45 PM
Adam Joel Bass, MD
Gastric Cancer Genetics and Implications of TCGA
2:05 PM
Kazuhiro Yoshida, MD, PhD
Gifu University School of Medicine
Genetic and Biological Characteristics of Gastric Cancer and Its Multidisciplinary
Treatment
2:25 PM
Randomized controlled trial of comaring gastrectomy (Gx) plus
chemotherapy (CTX) with CTX alone in advanced gastric cancer (AGC) with a
single non-curable factor: JCOG 0705/KGCA01 study (REGATTA) (Abstract
200) H. K. Yang, T. Tsujinaka, K. Nakamura, Y. W. Kim, M. Terashima, S. U. Han,
Y. Iwasaki, W. J. Hyung, A. Takagane, B. J. Park, K. Fujitani, S. Hahn, M. Sasako,
Y. J. Bang
2:35 PM
Manish A. Shah, MD
Weill Cornell Medical College
Gastric Cancer Discussion and Wrap-up
3:00 PM
3:15 PM
Break
3:30 PM
Anil D’Cruz, MBBS, MS, FRCS
Tata Memorial Hospital
Cancer Disparities and Access to Care
4:00 PM
Gilberto Lopes, MD, MBA, FAMS
Centro Paulista de Oncologia and HCor Onco
Minimal Essential Formularies
4:30 PM
Daniel F. Hayes, MD
Pathology Introduction
4:35 PM
Antonio C. Wolff, MD, FACP, FASCO
Johns Hopkins Kimmel Cancer Center
ASCO/College of American Pathologists Collaborations
4:50 PM
Matthew Zarka, MD
Mayo Clinic Arizona
Pathology Challenges in Limited Resource Settings
5:10 PM
Lawrence N. Shulman, MD
Improving Pathology in Limited Resource Settings: A Model from Rwanda
5:30 PM
Beyond Tyrosine Kinase Inhibitor Therapy: Incorporating Immunotherapy and
Metastasectomy into Renal Cell Carcinoma Management
Location: E354b
39
FRIDAY
James M. G. Larkin, MD, PhD—Chair
The Royal Marsden NHS Foundation Trust
New Pathways and Targets: Exploring New Agents for Advanced Renal Cell Carcinoma
Martin Henner Voss, MD
Integrating Immunotherapy and Other New Agents into the Current Treatment Paradigm in
Advanced Renal Cell Carcinoma
Axel Bex, MD, PhD
The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital
The Role of Metastasectomy in Patients with Renal Cell Carcinoma
Management of Hematologic Malignancies in Older Adults
Location: E450
H. Joachim Deeg, MD—Chair
Fred Hutchinson Cancer Research Center
Scientific Basis and Clinical Management of Myelodysplastic Syndrome for Older Adults
Maxwell Masters Krem, MD
Novel Targeted Therapy for Low-grade Lymphoid Malignancies in Older Adults
Paul A. Hamlin, MD
Management of Diffuse Large B-Cell Lymphoma in Older Adults
Achieving Precision Medicine through Therapeutic Drug Monitoring and
Pharmacogenomics—Ticketed Session
Location: E451a
Jan Hendrik Beumer, PharmD, PhD
University of Pittsburgh Cancer Institute
Federico Innocenti, MD, PhD
The University of North Carolina at Chapel Hill
Expediting the Learning Curve for Applied Cancer Genomics
Location: S100bc
3:45 PM
40
Howard L. McLeod, PharmD—Chair
Moffitt Cancer Center
Using Germ-Line and Somatic Genomic Data for Management of Patients with
Cancer
David N. Hayes, MD, MPH
Lineberger Comprehensive Cancer Center, The University of North Carolina at
Chapel Hill
Clinical-Grade Deep Sequencing for Cancer
4:25 PM
James M. Ford, MD
Incidental Germ-Line Findings and What to Do about Them
4:45 PM
Eliezer Mendel Van Allen, MD
Informatic Strategies to Turn Sequence Data into Cancer Patient Management
5:05 PM
Christine Marie Walko, PharmD, BCOP
Using Multidisciplinary Tumor Board to Augment the Value of Cancer Sequencing
5:25 PM
Robert R. McWilliams, MD
Mayo Clinic
Using the Multidisciplinary Tumor Board to Augment the Value of Cancer
Sequencing
5:45 PM
FRIDAY
4:05 PM
Practical Tips for Academic, Private, and Industry Career Tracks: Negotiating
Contracts and Education Debt Management
Location: S404
Ezra E. W. Cohen, MD—Chair
UC San Diego Moores Cancer Center
3:45 PM
David H. Johnson, MD
The University of Texas Southwestern Medical Center
Academia: Critical Items to Negotiate in Your Contract—Clinical Investigator and
Clinician Tracks
4:15 PM
Daniel F. Hoth, MD
Semafore
What I Wish I Knew Before Starting an Industry Career: The Good and the Bad
4:45 PM
Linda D. Bosserman, MD, FACP
City of Hope
Private Practice: Critical Factors to Negotiate in Contracts
5:15 PM
Jill Mattia, PhD
National Institutes of Health
Education Debt: National Institutes of Health Loan Repayment Program
5:45 PM
Special Session for Program Directors and Key Clinical Faculty: Milestones
201—Reviewing the Challenges and Addressing the Obstacles Including the
ASCO Excellence in Teaching Award Presentation
Location: E350
4:00 PM
Presentation of the 2015 Excellence in Teaching Award
41
FRIDAY
4:05 PM
Dean F. Bajorin, MD—Award Recipient
Excellence in Teaching Award
4:10 PM
Jill Gilbert, MD—Chair
Vanderbilt University
Welcome and Introductions
4:30 PM
Frances A. Collichio, MD
The University of North Carolina at Chapel Hill School of Medicine
Tricky Milestones and Tools for Addressing Them
4:50 PM
John C. Barrett, MD
VCU Massey Cancer Center
5:10 PM
Sandra Moutsios, MD
5:30 PM
Helen K. Chew, MD
UC Davis Medical Center
Debate on Chemotherapy and Radium 223 for the Optimal Treatment of
Advanced Prostate Cancer
Howard I. Scher, MD
Chemotherapy Should Be Given Late for Men with Metastatic Disease
Maha Hussain, MD, FACP, FASCO
Chemotherapy Should Be Given Early for Men with Metastatic Disease
Tanya B. Dorff, MD—Chair
USC Norris Comprehensive Cancer Center
Radium 223: Defining Timing, Patients, and Duration with Limited Data
Depression, Anxiety, Neuropathy, and Fatigue: An Update on the 2014 ASCO
Survivorship Guidelines and How to Incorporate Them into Practice
Location: S102
Ann H. Partridge, MD, MPH—Chair
ASCO Survivorship Guidelines: Challenges to Standardizing the Care for Adult Cancer
Survivors
Barbara L. Andersen, PhD
The Ohio State University
ASCO Guidelines: Anxiety and Depression in Cancer Survivors
42
FRIDAY
Guido Cavaletti, MD
University of Milan-Bicocca
ASCO Guidelines: Neuropathy in Cancer Survivors
Paul B. Jacobsen, PhD
ASCO Guidelines: Fatigue in Cancer Survivors
Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies
Location: E354b
Riccardo Lencioni, MD
Pisa University Hospital and School of Medicine
Interventional Radiologist Perspective
John Renz, MD, PhD
The University of Chicago Medicine
Hepatobiliary Surgeon and Transplant Perspective
Jorge A. Marrero, MS, MD
Hepatologist Perspective
Ghassan K. Abou-Alfa, MD—Chair
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
Medical Oncologist Perspective
Incorporating Novel Agents into Lymphoma Therapy: Value in Everyday
Practice
Location: E450
Gilles A. Salles, MD PhD
Hospices Civils de Lyon, Université Claude Bernard
Novel Agents in the Treatment of Follicular Lymphoma
Stephen Maxted Ansell, MD
Mayo Clinic
Novel Agents in Therapy of Hodgkin Lymphoma
Michelle A. Fanale, MD—Chair
Novel Agents in Therapy of T-Cell Lymphoma
43
FRIDAY
Individualizing the Approach to the Older Woman with Breast Cancer
Location: S406
Rinaa S. Punglia, MD, MPH
Can Radiation Be Avoided or Streamlined in Older Women with Breast Cancer?
Hyman B. Muss, MD—Chair
Chemotherapy for Older Patients with Breast Cancer: Should We Use More or Less?
Kevin S. Hughes, MD, FACS
Can We Do Less Surgery in the Breast and Axilla in Older Women with Breast Cancer?
Promises and Pitfalls of Lung Cancer Screening and Surveillance
Location: E Hall D1
Claudia I. Henschke, MD, PhD
Icahn School of Medicine at Mount Sinai
General Overview and Recommendations for Screening and Surveillance
Bernardo Haddock Lobo Goulart, MD, MS—Chair
Implementation Challenges in Lung Cancer Screening
ASCO Community Research Forum: Bringing Community-Based Researchers
Together to Advance Cancer Research—Ticketed Session
Location: E451a
Aurora Research Institute, Aurora Health Care
Howard A. Burris, MD
Sarah Cannon Research Institute, Tennessee Oncology
4:30 PM - 5:45 PM Clinical Problems in Oncology Session
Treating Newly Diagnosed Metastatic Colorectal Cancer: The Role of
Chemotherapy, Ablation, and Surgery—Ticketed Session
Location: E451b
44
FRIDAY
Stephen Barnett Solomon, MD
What Is the Role of Ablation/Embolization of Metastases?
Thomas Bachleitner-Hofmann, MD
Medical University of Vienna
Does the Primary Lesion Need Resection?
Cathy Eng, MD—Chair
What Is the Optimal Chemotherapy Sequence?
45
Saturday, May 30, 2015
7:30 AM - 8:00 AM Education Session
How to Navigate the Annual Meeting (Trainees and Early Career Oncologists
Only)
Location: S501
Jyoti D. Patel, MD—Chair
Feinberg School of Medicine, Northwestern University
Optimize Your Annual Meeting Experience
SATURDAY
Don S. Dizon, MD
Technology Tools and Resources to Help You Navigate the Meeting
Alternatives to ASP-Plus-Six: What Are the Options?
Location: S404
Jeffery C. Ward, MD—Chair
Swedish Cancer Institute Edmonds
The Realpolitik Perspective
Blase N. Polite, MD, MPP
The University of Chicago
The Oncologist’s Perspective
Rena M. Conti, PhD
The Economist’s Perspective
Brain Metastases: From Clinical Trials to Clinical Practice
Location: E354b
Frank Winkler, Dr. Med
University of Heidelberg
Molecular Biology of Brain Metastases: Implications for Therapy
Minesh P. Mehta, MD
University of Maryland Medical Systems
Whole-Brain Radiation and Stereotactic Radiosurgery in Brain Metastases: What Is the
Evidence?
Manmeet Singh Ahluwalia, MD—Chair
Cleveland Clinic
Immunotherapy and Targeted Therapy in Brain Metastases: A Tailor-Made Approach
46
Breast Cancer Chemoprevention: Proven but Publicly Ignored—An Update of
Benefit and Risk Data
Location: S100bc
Katherine D. Crew, MD, MS
Update on Risks and Benefits of Breast Cancer Chemoprevention Treatments When Applied as
Primary Prevention of Breast Cancer
SATURDAY
Powel Brown, MD, PhD—Chair
Provider Perceptions of Breast Cancer Chemoprevention Agents
Christine Holmberg, DPhil, MPH
Charité Universitätsmedizin Berlin, Berlin School of Public Health
Patient Perceptions of Breast Cancer Chemoprevention Agents
Challenges in Melanoma Clinical Trials: Will Our Success Hold Us Back?
Location: S406
Lynn Mara Schuchter, MD—Chair
A Good Problem to Have: Clinical Trials in the Era of Multiple Effective Agents
Marc Robert Theoret, MD
A Regulatory Perspective to Novel Therapeutics in Melanoma in 2015
Janice M. Mehnert, MD
Rutgers Cancer Institute of New Jersey
Should Comorbidities Be an Automatic Exclusion for Clinical Trials?
Diffuse Large B-Cell Lymphoma: Are We Ready for Molecular Subtype-Specific
Therapy?
Location: E450
David W. Scott, MBCHB, PhD
British Columbia Cancer Agency
Molecular Subtypes of Diffuse Large B-Cell Lymphoma: Ready for the Clinic?
Grzegorz S. Nowakowski, MD—Chair
Mayo Clinic
Molecular-Subtype-Specific Therapy of Diffuse Large B-Cell Lymphoma: Are We Ready to
Change Our Practice?
47
Myron Stefan Czuczman, MD
C-Myc Positive and Double Hit Diffuse Large B-Cell Lymphoma: Aggressive Subtype,
Aggressive Treatment?
Introduction to Methods in Comparative Effectiveness Research
Location: S102
SATURDAY
Sharon Hermes Giordano, MD, MPH—Chair
Overview of Comparative Effectiveness Research and Observational Study Design
Caprice Christian Greenberg, MD, MPH
University of Wisconsin School of Medicine and Public Health
Pragmatic Clinical Trials Including the Use of Patient-Centered Outcomes
Natasha K. Stout, MS, PhD
Harvard Medical School and Harvard Pilgrim Health Care Institute
Methods in Decision Analysis
Real-Time Molecular Genetic Profiling: The Future Is Now (Or Is It?)
Location: S504
Donald Williams Parsons, MD, PhD
Texas Children’s Cancer Center, Baylor College of Medicine
Clinical Tumor and Germ-Line Sequencing of Pediatric Malignancies
William L. Carroll, MD
NYU Langone Medical Center
State-of-the-Art Discovery with Tumor Profiling in Pediatric Oncology
Stephen J. Chanock, MD—Chair
Risks and Benefits of Real-Time Molecular Profiling
Sequence, Duration, and Cost of Treating Metastatic Unresectable Colorectal
Cancer
Location: E Hall D2
Marwan Fakih, MD
City of Hope Comprehensive Cancer Center
When to Add Biologics?
48
Cornelis J. A. Punt, MD, PhD
Academic Medical Center, University of Amsterdam
Systemic Treatment: Maintenance versus Holiday?
John Marshall, MD—Chair
Lombardi Comprehensive Cancer Center, Georgetown University
Is the Cost Justified?
SATURDAY
Treatment of the BRCA Mutation Carrier: Screening, Surveillance, and
Management
Judy Ellen Garber, MD, MPH
Update on Screening and Surveillance for BRCA Carriers: It’s Not Just Ovarian Cancer
Stanley B. Kaye, MBBS, MRCP, MD, FRCP, FRCPS, FRSE, FMedSci
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Chemotherapy for BRCA Mutation Carriers: Same but Different?
Elise C. Kohn, MD—Chair
PARP Inhibitors: The Holy Grail for BRCA Carriers?
When More Is Not Better: How to Integrate Goals of Care in Conversations
about Stopping Chemotherapy
Location: S100a
Jennifer S. Temel, MD—Chair
Massachusetts General Hospital Cancer Center
Challenges in Discussions about Stopping Chemotherapy in the Modern Era: What Do We
Know?
Lauris Kaldjian, MD
University of Iowa
An Ethical and Practical Framework Approach for Exploring Goals of Care
Thomas LeBlanc, MD, MA
Duke University School of Medicine
Evidence-Based Communication Strategies for Discussions at End of Life
8:00 AM - 9:15 AM Meet the Professor Session
Treatment of Multiple Myeloma in Elderly Patients—Ticketed Session
Location: E451a
49
Donna Ellen Reece, MD
Princess Margaret Hospital
8:00 AM - 9:15 AM Clinical Problems in Oncology Session
Optimal Lung Cancer Therapy for the Patient with Central Nervous System
Metastases and Leptomeningeal Disease—Ticketed Session
Location: E451b
SATURDAY
Mark G. Kris, MD—Chair
Systemic Chemotherapy, Immunotherapy, and Relevant Clinical Trials for Brain Metastases
and Leptomeningeal Disease in Lung Cancer
Christina S. Baik, MD, MPH
Molecularly Targeted Therapy for Brain Metastases and Leptomeningeal Disease
Michael Brada, DSc, FRCP, FRCR
University of Liverpool
Radiation and Localized Management of Brain Metastases and Leptomeningeal Disease
8:00 AM - 9:30 AM Clinical Science Symposium
Immunotherapy for Every Patient: Check Your Enthusiasm
Location: E Hall D1
Neil Howard Segal, MD, PhD—Chair
8:00 AM
Neil Howard Segal, MD, PhD
Introduction
8:05 AM
PD-1 blockade in tumors with mismatch repair deficiency. (Abstract LBA100)
D. T. Le, J. N. Uram, H. Wang, B. Bartlett, H. Kemberling, A. Eyring, A. Skora, N. S.
Azad, D. A. Laheru, R. C. Donehower, B. Luber, T. S. Crocenzi, G. A. Fisher, S. M.
Duffy, J. J. Lee, M. Koshiji, J. R. Eshleman, R. A. Anders, B. Vogelstein, L. A. Diaz Jr.
8:17 AM
Neil Howard Segal, MD, PhD (Discussion Abstract(s) LBA100)
Discussion
8:27 AM
Phase I/II safety and antitumor activity of nivolumab in patients with
advanced hepatocellular carcinoma (HCC): CA209 – 040. (Abstract LBA101)
A. B. El-Khoueiry, I. Melero, T. S. Crocenzi, T. H. Welling III, T. C. Yau, W. Yeo, A.
Chopra, J. Grosso, L. Lang, J. Anderson, C. M. Dela Cruz, B. Sangro
8:39 AM
Lawrence Fong, MD (Discussion of Abstract(s) LBA101)
UCSF Helen Diller Family Comprehensive Cancer Center
Discussion
8:51 AM
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus
docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell
lung cancer (NSCLC). (Abstract LBA109) L. Paz-Ares, L. Horn, H. Borghaei, D.
R. Spigel, M. Steins, N. Ready, L. Q. M. Chow, E. E. Vokes, E. Felip, E. Holgado,
F. Barlesi, M. Kohlhaeufl, O. Rodriguez, O. Arrieta, M. A. Burgio, J. Fayette, S. N.
Gettinger, C. Harbison, C. Dorange, F. G. Finckenstein, J. R. Brahmer
9:03 AM
Roy S. Herbst, MD, PhD (Discussion of Abstract(s) LBA109)
Yale School of Medicine
Discussion
9:15 AM
50
8:00 AM - 11:00 AM Extended Education Session
Geriatric Oncology: Research and Practice Updates for the Busy Clinician
8:00 AM
Siri Rostoft—Co-Chair
Oslo University Hospital
Best of Geriatric Conferences and Journals
8:20 AM
Andrew E. Chapman, DO
Thomas Jefferson University
Best of Oncology Conferences and Journals
8:40 AM
8:50 AM
Martine Extermann, MD, PhD—Co-Chair
Case 1: Using Risk-Assessment Tools for Chemotherapy Selection in Elderly
Patients
9:20 AM
Supriya Gupta Mohile, MD, MS
University of Rochester Medical Center
Case 2: Incorporating the New International Society of Geriatric Oncology
Guidelines into Prostate Cancer Management
9:50 AM
Nicole Doser Joz-Roland, MD
CUTR Sylvana
Case 3: Geriatrician Call-in—Getting Less Confused
SATURDAY
Location: S103
10:20 AM Hyman B. Muss, MD
Panel Moderator: Digital Geriatric Oncology in Research and Practice—How to Get
the Right Data in and Out
10:45 AM Panel Question and Answer
8:00 AM - 11:30 AM Poster Session
Breast Cancer—HER2/ER
Location: S Hall A
Abstracts 513–524 will be discussed during the Breast Cancer—HER2/ER Poster Discussion
Session. See page 88 for session information.
Board 1
Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in
subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of
node-positive (N1), hormone receptor–positive (HRⴙ), postmenopausal early
breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET).
(Abstract 513) B. Ejlertsen, M. Jensen, J. Eriksen, T. Kibøll, B. Bruun Rasmussen,
A. S. Knoop, S. Ferree, T. Haffner, C. Schaper, A. Lænkholm, Danish Breast
Cancer Cooperative Group (DBCG)
Board 2
Final analysis of a randomized comparison of letrozole (Let) vs observation
(Obs) as late reintroduction of adjuvant endocrine therapy (AET) for
postmenopausal women with hormone receptor positive (HRⴙ) breast
cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).
(Abstract 514) N. Zdenkowski, M. Green, F. M. Boyle, G. Kannourakis, P. G. Gill,
E. Bayliss, C. Saunders, S. Della-Fiorentina, N. Kling, I. Campbell, V. Gebski, A.
Veillard, L. C. Davies, R. Thornton, A. Fong, L. L. Reaby, J. F. Forbes, Australia
and New Zealand Breast Cancer Trials Group
Board 3
Ovarian function suppression, symptom burden, and quality of life in young
women with breast cancer: A prospective study. (Abstract 515) S. M.
Rosenberg, K. J. Ruddy, R. M. Tamimi, S. I. Gelber, L. Schapira, V. F. Borges,
S. E. Come, M. E. Meyer, E. P. Winer, A. H. Partridge
51
SATURDAY
Board 4
Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients
(pts) with early-stage breast cancer (BC). (Abstract 516) D. Zardavas, L. Te
Marvelde, R. Milne, H. Joensuu, M. Moynahan, B. Hennessy, I. Bieche, L. H. Saal,
O. Stal, B. Iacopetta, J. Dupont Jensen, S. O’Toole, M. Barbareschi, S. Noguchi, E.
Lerma, Q. Wang, M. J. Piccart-Gebhart, C. Sotiriou, S. Michiels Sr., S. Loi
Board 5
HER3 and paxillin signaling in ERⴙ HER2- metastatic breast cancer (MBC)
patients receiving letrozole (L) vs letrozole plus dasatinib (LⴙD) in a
randomized phase II trial. (Abstract 517) J. O’Shaughnessy, D. Paul, M. K.
Levin, Y. Wang, N. N. Hoke, C. Ramos
Board 6
DNA methylation in serum as an independent marker of outcome and
treatment response in TBCRC 005: A prospective study in metastatic breast
cancer (MBC) patients. (Abstract 518) K. Visvanathan, M. Fackler, Z. Zhang, Z.
Lopez-Bujanda, S. Jeter, L. J. Sokoll, L. Cope, C. Umbricht, D. Euhus, J. T.
Carpenter, A. M. Storniolo, R. Nanda, N. U. Lin, L. A. Carey, J. N. Ingle, S.
Sukumar, A. C. Wolff
Board 7
Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences
based on germline mutation status and potential implications for adjuvant
systemic therapy (AST). (Abstract 519) P. D. Shah, S. Patil, M. N. Dickler, K.
Offit, C. A. Hudis, M. E. Robson
Board 8
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with
carboplatin (carb) or as a single agent followed by post-progression therapy
in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)associated metastatic breast cancer (MBC). (Abstract 520) G. Somlo, P. H.
Frankel, T. H. Luu, C. X. Ma, B. Arun, A. A. Garcia, T. Cigler, L. Cream, H. A.
Harvey, J. A. Sparano, R. Nanda, H. K. Chew, T. J. Moynihan, L. T. Vahdat, M. P.
Goetz, A. Hurria, J. E. Mortimer, D. R. Gandara, A. P. Chen, J. N. Weitzel
Board 9
DNA repair deficiency biomarkers and identification of ER-positive breast
cancer patients who may benefit from veliparib/carboplatin: Results from the
I-SPY 2 trial. (Abstract 521) L. van’t Veer, L. Esserman, A. Sanil, A. Glas, T.
Severson, S. C. Linn, L. Brown Swigart, G. Hirst, I. Investigators, O. I. Olopade,
H. S. Rugo, D. Berry, D. M. Wolf, C. Yau
Board 10
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
(Abstract 522) S. M. Tolaney, M. Beeram, J. T. Beck, A. K. Conlin, E. C. Dees,
M. N. Dickler, T. L. Helsten, P. R. Conkling, W. J. Edenfield, D. A. Richards, P.
Turner, N. Cai, E. M. Chan, S. Pant, C. Becerra, K. Kalinsky, S. Puhalla, B. N.
Rexer, H. A. Burris III, M. P. Goetz
Board 11
Updated findings of a first-in-human, phase I study of margetuximab (M), an
Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with
HER2-positive advanced solid tumors. (Abstract 523) H. A. Burris, G.
Giaccone, S. Im, T. M. Bauer, D. Oh, S. F. Jones, J. L. Nordstrom, H. Li, D. A.
Carlin, J. E. Baughman, R. J. Lechleider, Y. Bang
Board 12
Adaptively randomized trial of neoadjuvant chemotherapy with or without the
Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. (Abstract
524) D. Tripathy, A. J. Chien, N. Hylton, M. B. Buxton, C. A. Ewing, A. M. Wallace,
A. Forero, H. G. Kaplan, R. Nanda, K. S. Albain, S. L. Moulder, B. B. Haley, A.
DeMichele, W. F. Symmans, L. van ’t Veer, M. Paoloni, L. Esserman, D. A. Berry,
D. Yee, I-SPY 2 TRIAL Consortium
Board 13
Molecular profiling of ER weakly-positive breast cancer. (Abstract 525) B. S.
Sheffield, Z. Kos, X. Wang, C. Chow, S. Lau, R. Wolber, C. B. Gilks, N. Myles, T. A.
Thomson, M. M. Hayes, R. Rachamadugu, I. J. Stijleman, P. B. Bernard, T. O.
Nielsen, S. K. Chia
Board 14
Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2
and prediction of relative endocrine benefit from tamoxifen and anastrozole
in HRⴙ breast cancer: A TransATAC study. (Abstract 526) Y. Zhang, I. Sestak,
J. M. Cuzick, M. Dowsett, C. A. Schnabel, D. Sgroi
Board 15
FES PET/CT analysis to evaluate the impact of localization of breast cancer
metastases on ER expression. (Abstract 527) H. H. Nienhuis, M. van Kruchten,
52
A. W. Glaudemans, A. H. Bongaerts, E. F. De Vries, C. P. Schroder, E. G. de Vries,
G. Hospers
Breast cancer recurrence in older patients with clinically node-negative
T1-T2 tumors managed without sentinel node biopsy (SNB) and without
adjuvant radiation therapy. (Abstract 528) M. N. Saleh, B. J. Sakr, S. M.
Witherby, A. J. Olszewski, W. M. Sikov
Board 17
Role of pazopanib (PZ) in modulating hormone resistance in advanced breast
cancer (ABC). (Abstract 529) M. C. Majure, M. E. Melisko, A. R. Karwat, A. J.
Chien, A. Goga, M. M. Moasser, J. W. Park, A. N. DeLuca, H. S. Rugo
Board 18
Evaluation of possible linkage between everolimus benefit in estrogen
receptor (ER)-positive breast cancer and genomic alterations of the
PI3K/AKT/mTOR pathway. (Abstract 530) E. P. Black, E. H. Romond,
J. Chmielecki, J. Sun, V. Kadamyan, M. D. Chambers, R. L. Stewart, E. V.
Dressler, M. Mehdi, C. Horbinski, S. A. Massarweh
Board 19
Efficacy and safety of neoadjuvant docetaxel, carboplatin,
trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2ⴙ breast cancer:
The Cleveland Clinic experience. (Abstract 531) S. R. Tiwari, B. Calhoun, J.
Abraham, G. T. Budd, H. C. Moore, A. Fanning, S. Valente, R. Stewart, S. W.
Andresen, S. B. LeGrand, J. P. Crowe, A. Dawson, J. Rowe, C. Booth, S. R.
Grobmyer, A. J. Montero
Board 20
Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway
on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast
cancer. (Abstract 532) S. A. Massarweh, J. Chmielecki, J. Sun, R. L. Stewart,
E. V. Dressler, V. Kadamyan, M. D. Chambers, C. Horbinski, M. Mehdi, E. P.
Black, E. H. Romond
Board 21
Recurrence score and clinicopathologic characteristics of TAILORx
participants by race and ethnicity. (Abstract 533) M. M. Zlobinsky Rubinstein,
R. J. Gray, J. A. Sparano, J. Zujewski, T. J. Whelan, K. S. Albain, D. F. Hayes,
C. E. Geyer Jr., E. C. Dees, E. A. Perez, M. M. Keane, C. Vallejos, T. F. Goggins,
I. A. Mayer, A. Brufsky, D. Toppmeyer, V. G. Kaklamani, J. N. Atkins, J. L.
Berenberg, G. W. Sledge
Board 22
The vitamin D receptor: A therapeutic target for the treatment of breast
cancer? (Abstract 534) A. M. Murray, N. C. Synnott, J. Crown, N. O’Donovan,
M. J. Duffy
Board 23
Significance of prospective multicenter decision impact WSG-BCIST Study in
postmenopausal ERⴙ HER2- N0 early breast cancer (EBC) for molecular
testing for intrinsic subtype definition. (Abstract 535) R. Wuerstlein, K. Sotlar,
O. Gluz, D. Hofmann, B. Otremba, R. Von Schumann, I. Witzel, C. Schindlbeck, W.
Janni, C. Schem, I. Bauerfeind, S. Hasmueller, H. Tesch, A. Paulenz, P. Morel, W.
Cowens, J. Hornberger, R. E. Kates, E. Pelz, N. Harbeck, West German Study
Group
Board 24
Incidence and survival for young women with operable breast cancer: SEER
1992–2011. (Abstract 536) M. C. Schroeder, S. Slycord, C. Lynch, A. Thomas
Board 25
An indirect evaluation of bone saturation with zoledronic acid after long-term
Q4 week dosing using plasma and urine pharmacokinetics. (Abstract 537)
G. N. Hortobagyi, W. Sallas, M. Zheng, R. W. Mohanlal
Board 26
Prospective study of the decision-making impact of the Breast Cancer Index
in the selection of patients with ERⴙ breast cancer for extended endocrine
therapy. (Abstract 538) T. B. Sanft, B. Aktas, B. Schroeder, V. Bossuyt, M.
DiGiovanna, M. M. Abu-Khalaf, G. G. Chung, A. Silber, E. W. Hofstatter, S. S.
Mougalian, L. Epstein, C. Hatzis, C. A. Schnabel, L. Pusztai
Board 27
Case-control study of hormone receptor expression in benign breast and
cancer risk. (Abstract 539) C. F. Healy, V. Parimi, S. A. Khan, J. Wang
Board 28
Relationship of germline polymorphisms to docetaxel toxicity in the
ROSE/TRIO-012 trial. (Abstract 540) S. Damaraju, V. Gorbunova, K. A. Gelmon,
J. Garcia Saenz, S. Morales, D. Y. Abigerges, J. Canon, I. Lifirenko, G. L. Cohen,
SATURDAY
Board 16
53
G. H. Jerusalem, F. Thireau, R. Fresco, V. Houé, M. F. Press, A. Narasimhan, J. R.
Mackey
SATURDAY
Board 29
Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer.
(Abstract 541) N. P. McAndrew, K. N. Maxwell, J. Stopfer, J. Powers, A. C. Brandt,
J. M. Long, K. L. Nathanson, S. M. Domchek
Board 30
There is more to the picture than meets the eye: Population-based study on
biopsy verification of suspected breast cancer recurrences. (Abstract 542) U.
Wilking, T. Hatschek, J. C. Bergh, L. S. Lindström
Board 31
21-gene recurrence score assay (RS) and impact on adjuvant chemotherapy
(CTx) use among lobular (L) and ductal (D) histology hormone receptor
positive (HRⴙ) early breast cancers (EBC). (Abstract 543) S. D. Baxter, L.
Gondara, C. Speers, A. Davidson, S. K. Chia, V. Bernstein, S. Ellard, S. Tyldesley,
C. A. Lohrisch
Board 32
Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in
a Danish Breast Cancer Cooperative Group (DBCG) cohort of
postmenopausal women diagnosed with hormone receptor-positive (HRⴙ)
early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).
(Abstract 544) A. Lænkholm, M. Jensen, J. Eriksen, T. Kibøll, B. Bruun
Rasmussen, A. S. Knoop, S. Ferree, T. Haffner, C. Schaper, B. Ejlertsen, Danish
Breast Cancer Cooperative Group (DBCG)
Board 33
Predictive testing for selection of patients for extended endocrine therapy:
Clinical utilization of Breast Cancer Index (BCI) in early-stage, ERⴙ, LNbreast cancer. (Abstract 545) S. C. Malamud, B. Schroeder, T. N. Operana, C. A.
Schnabel
Board 34
Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay
in a Danish Breast Cancer Cooperative Group (DBCG) cohort of
postmenopausal Danish women with hormone receptor-positive (HRⴙ) early
breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.
(Abstract 546) A. Lænkholm, M. Jensen, J. Eriksen, T. Kibøll, B. Bruun
Rasmussen, A. S. Knoop, S. Ferree, T. Haffner, C. Schaper, B. Ejlertsen, Danish
Breast Cancer Cooperative Group (DBCG)
Board 35
Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012
breast cancer trial. (Abstract 547) J. R. Mackey, O. N. Lipatov, M. Martin, M.
Webster, R. Hegg, S. Verma, M. Ramos Vazquez, R. Fresco, F. Thireau, V. Houé,
M. F. Press, A. Narasimhan, S. Damaraju
Board 36
Impact of combining PgR score and original preoperative endocrine
prognostic index (PEPI) score as a prognostic factor of neoadjuvant
endocrine therapy using exemestane in postmenopausal ER-positive/HER2negative breast cancer. (Abstract 548) S. Kurozumi, H. Matsumoto, K. Tozuka,
Y. Hayashi, K. Inoue, S. E. Nagai, H. Oba, J. Horiguchi, I. Takeyoshi, M. Kurosumi
Board 37
Bevacizumab maintenance (BM) in first line treatment for metastatic breast
cancer (MBC): A multicenter retrospective observational study. (Abstract
549) L. Mentuccia, A. Fabi, A. Cassano, P. Vici, A. Michelotti, I. Sperduti, M. G.
Sarobba, P. Marchetti, E. Rossi, V. Sini, M. Scognamiglio, D. Pellegrini, J.
Giampietro, A. Vaccaro, A. Pellegrino, L. Pizzuti, M. Palleschi, L. I. Moscetti, D.
Nicoletta, T. Gamucci
Board 38
Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be
safely treated without endocrine therapy? (Abstract 550) C. Perrin, J. Frenel, J.
Edeline, M. Robert, P. Tas, C. Lefeuvre-Plesse, C. Gourmelon, F. Le Du, M.
Campone, P. Kerbrat
Board 39
Influence of immunohistological detection of intratumoral urokinase-type
plasminogen activator (uPA) on disease outcome in endocrine-treated
postmenopausal patients with hormone receptor-positive early breast
cancer. (Abstract 551) C. F. Singer, M. Filipits, S. Jahn, L. Abete, R. Jakesz, R.
Greil, T. Bauernhofer, W. Kwasny, M. Seifert, F. Fitzal, M. Schmitt, F. Moinfar, M.
Gnant
54
Board 40
Prognostic significance of Focal Adhesion Kinase (FAK) in node-negative
breast cancer. (Abstract 552) M. Schmidt, L. van de Sandt, K. Almstedt, M. J.
Battista, A. Heimes, A. Lebrecht, G. Hoffmann, J. Rahnenfuehrer, J. G. Hengstler
Board 41
Medication use trajectories of postmenopausal breast cancer survivors and
matched cancer-free controls. (Abstract 553) K. Pan, R. T. Chlebowski, M. S.
Simon, R. Ray, J. Livaudais-Toman, S. D. Sullivan, M. L. Stefanick, R. B. Wallace,
M. LeBoff, E. C. Bluhm, E. D. Paskett
Board 42
Detection and functional analysis of estrogen receptor mutations (ESR1-mut)
in patients with metastatic breast cancer (MBC). (Abstract 554) S. Puhalla, P.
Wang, A. Bahreini, R. Gyanchandani, T. F. Ambros, R. J. Hartmaier, B. F. Kurland,
P. C. Lucas, H. E. Trejo Bittar, R. L. Hamilton, A. Mathew, J. P. Leone, N. E.
Davidson, K. R. Weiss, R. J. Watters, M. Nikiforova, A. M. Stern, A. Brufsky, A. V.
Lee, S. Oesterreich
Board 43
Adjuvant aromatase inhibitor adherence based on the Morisky Medication
Adherence Scale and identification of predictors to adherence. (Abstract 555)
P. Rosenblatt, O. G. Goloubeva, S. Kesmodel, E. C. Bellavance, S. Chumsri, T.
Bao, B. Heiss, E. M. Nichols, S. J. Feigenberg, N. Tait, K. H. Tkaczuk
Board 44
Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on
trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC).
(Abstract 556) J. Raphael, I. Y. Gong, S. Nofech-Mozes, J. M. Bartlett, H. Nafisi,
S. Verma
Board 45
Tamoxifen (TAM)-induced severe hot flashes (HF): Is dose reduction (DR) a
safe and effective strategy? (Abstract 557) C. I. Lee, P. Fox, B. Balakrishnar,
R. L. Balleine, B. Gao, P. Provan, S. Coulter, M. Tomlins, C. Liddle, R. Hui, M.
Wong, H. Gurney, N. Wilcken
Board 46
Molecular profiling to identify genetic heterogeneity in synchronous and
asynchronous breast cancers. (Abstract 558) W. M. Dean-Colomb, C. Yates,
S. K. Reddy, J. O’Shaughnessy, S. Z. Millis
Board 47
P95HER2 as a predictive marker in the phase III randomized HERNATA trial
of trastuzumab and chemotherapy as first-line therapy to metastatic or
locally advanced HER2-positive breast cancer. (Abstract 559) A. S. Knoop, M.
Andersson, K. D. Bjerre, Y. Zang, C. A. Schnabel, A. Laenkholm
Board 48
Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with
ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria
undergoing standard therapy. (Abstract 560) M. L. Pilewskie, C. Olcese, S.
Patil, K. J. Van Zee
Board 49
Variation in the use of granulocyte-colony stimulating factor (G-CSF) for
dose dense paclitaxel: A single institution retrospective study. (Abstract 561)
F. R. Paes, I. V. Luis, R. B. Costa, O. Metzger Filho, M. E. Hughes, K. Losk, K.
Camuso, C. A. Bunnell, M. Golshan, E. P. Winer, N. U. Lin
Board 50
Tumor infiltrating lymphocytes (TIL) and Ki67 suppression after neoadjuvant
therapy for HRⴙ/HER2- breast cancer (BC): Results from two prospective
trials. (Abstract 562) M. Dieci, G. Ficarra, P. F. Conte, V. Guarneri
Board 51
Hormonal treatment (HT) and late recurrence in early-stage breast cancer
(BC) patients. (Abstract 563) C. H. Barcenas, A. K. Sinha, G. N. Hortobagyi, V.
Valero, N. T. Ueno, S. H. Giordano, M. Chavez-Mac Gregor, A. M. Brewster, A.
Lucci Jr., D. Tripathy
Board 52
Oncotype-DX recurrence score distribution among breast cancer patients
harboring a germline mutation in the BRCA1/2 genes. (Abstract 564) R. Lewin,
S. Rizel, D. Hendler, V. Neiman, I. Ben-Aharon, N. Liebermann, D. Margel, D.
Zoref, A. Sulkes, R. Yerushalmi
Board 54
Steps in developing Watson for Oncology, a decision support system to
assist physicians choosing first-line metastatic breast cancer (MBC)
therapies: Improved performance with machine learning. (Abstract 566) J. Fu,
A. Gucalp, M. G. Zauderer, A. S. Epstein, M. G. Kris, J. Keesing, A. Caroline, M.
Megerian, T. Eggebraaten, R. DeLima, M. Setnes, P. Wildt, A. D. Seidman
55
SATURDAY
SATURDAY
Board 55
Variations in measured ER, PR, and HER2 status in synchronous and
asynchronous paired breast cancer (BC) tumors. (Abstract 567) C. Yates,
S. Z. Millis, S. K. Reddy, Z. Gatalica, J. O’Shaughnessy, W. M. Dean-Colomb
Board 56
Meta-analysis of clinical outcomes to second-line endocrine therapy for
visceral and non-visceral metastases. (Abstract 568) J. F. Robertson, C.
Campbell, A. Di Leo, S. R. Johnston, J. Bliss, I. Bradbury
Board 57
Blinded independent validation of the PAM50-based Chemo-Endocrine
Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2negative (HRⴙ/HER2-) breast cancer following neoadjuvant chemotherapy
(NAC). (Abstract 569) A. Prat, B. Jimenez Rodriguez, P. Sánchez Rovira, M.
Alvarez, L. Vicioso, V. de Luque, C. Fernandez-Sousa, M. C. Parrado, A. Santonja,
C. Ramirez Tortosa, A. Lavado Fernandez, E. Perez Ruiz, C. Gonzalez-Hermoso,
W. Buckingham, N. Dowidar, S. Ferree, A. Jeiranian, C. Schaper, N. Ribelles, E. Alba
Board 58
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as
first-line treatment for postmenopausal patients with ERⴙ and HER2advanced breast cancer (ABC) (PALOMA-1/TRIO-18). (Abstract 570) D. J.
Slamon, J. Crown, I. Lang, S. O. Kulyk, M. Schmidt, R. Patel, A. Thummala, N. L.
Voytko, S. Randolph, S. Kim, X. Huang, C. H. Bartlett, P. Schnell, R. S. Finn
Board 59
Efficacy and safety of first-line palbociclib plus letrozole compared with
letrozole alone in patients aged > 65 years with estrogen receptor-positive,
HER2-negative advanced breast cancer: A subgroup analysis by age of the
PALOMA-1/TRIO-18 trial. (Abstract 571) J. Crown, R. S. Finn, J. Ettl, K. Boer, R.
Patel, A. Thummala, S. Randolph, S. Kim, X. Huang, S. Nadanaciva, P. Schnell,
C. H. Bartlett, D. J. Slamon
Board 60
The effect of palbociclib (P) in combination with letrozole (L) on bone
metastases in women with ERⴙ/ HER2- metastatic breast cancer (MBC):
Subanalysis from a randomized phase II study. (Abstract 572) R. S. Finn, J.
Crown, I. Lang, S. O. Kulyk, M. Schmidt, R. Patel, A. Thummala, I. Bondarenko, S.
Randolph, S. Kim, X. Huang, E. Donnelly, C. H. Bartlett, D. J. Slamon
Board 61
Impact of locoregional therapy among women 70 years or older with early
stage hormone receptor positive breast cancer: A population based study.
(Abstract 573) S. S. Dawood, X. Lei, P. N. Mainwaring, S. Gupta, B. Sirohi, J.
Cortes, R. A. Dent
Board 62
A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and
Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk
(ORFR) in breast cancer (BC) patients treated with adjuvant aromatase
inhibitor (AI). (Abstract 574) D. B. Page, V. Mariotti, O. Davydov, S. Patil, D.
Hans, C. A. Hudis, A. Farooki, M. N. Fornier
Board 63
Clinical efficacy and safety profile of palbociclib (P) in combination with
letrozole (L) as first-line treatment in patients (pts) with ERⴙ and HER2advanced breast cancer (ABC) who have not received any systemic
treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. (Abstract 575)
R. S. Finn, J. Crown, J. Ettl, T. Pinter, A. Thummala, Y. V. Shparyk, R. Patel, S.
Randolph, S. Kim, X. Huang, Y. Jiang, C. H. Bartlett, D. J. Slamon
Board 64
GHRH-receptor as a new targetable biomarker in breast cancer and its
correlation with ER/PR/HER2 status. (Abstract 576) M. Nadji, N. L. Block, A. V.
Schally, J. F. Lara, R. A. Michaelson, R. Pulinthanathu, M. Tortora, S. M. Ali, K.
Leitzel, S. M. Rizvi, M. Y. Al-Marrawi, A. Lipton
Board 65
Activation of PI3K/AKT/mTOR pathway in ERⴙ breast cancer: Analysis of
paired primary and metastatic tumor samples. (Abstract 577) T. R. Pacheco,
A. C. Fernandes, S. M. Ali, M. Maia-Matos, A. L. Gaspar Gomes da Costa, C.
Abreu, A. T. Alves, L. Correia, J. F. Lara, R. A. Michaelson, A. R. Ferreira, M.
Matias, K. Leitzel, A. Lipton, L. Costa
Board 66
A prospective comparison of ER, PR, Ki67 and gene expression in paired
sequential core biopsies of primary, untreated breast cancer. (Abstract 578)
A. M. Thompson, S. M. Hadad, L. Jordan, P. Roy, C. Purdie, T. Iwamoto, L.
Pusztai, S. L. Moulder
56
Board 67
The pattern of somatic mutations and chromosomal copy number variations
(CNV) in young breast cancer (BC) patients (pts). (Abstract 579) H. A. Azim, B.
Nguyen, S. Brohee, M. J. Piccart-Gebhart, C. Sotiriou
Board 69
Impact on relapse free survival (RFS) of time to hormone therapy (HTx) after
diagnosis (Dx) of low risk hormone receptor positive (HRⴙ) early breast
cancer (BC). (Abstract 580) W. Chay, C. Speers, L. Gondara, S. Tyldesley, K. A.
Gelmon, C. A. Lohrisch
Board 70
Correlation between the DCIS Score and traditional clinicopathologic
features in the prospectively-designed Ontario population-based validation
study. (Abstract 581) E. Rakovitch, S. Nofech-Mozes, W. Hanna, F. L. Baehner,
R. Saskin, S. M. Butler, A. Tuck, S. Sengupta, L. Elavathil, P. A. Jani, M. Bonin, M.
Chang, S. Robertson, E. Slodkowska, C. H. Fong, J. M. Anderson, F. Jamshidian,
D. B. Cherbavaz, S. Shak, L. F. Paszat
Board 71
Cyclin D1 as a biomarker of response to fulvestrant (F) in hormone receptorpositive (HRⴙ) breast cancer (BC). (Abstract 582) K. P. Cascetta, D. Germain,
A. Tiersten
Board 72
Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant
chemotherapy in HER2-positive primary breast cancer. (Abstract 583) K.
Nakatsukasa, T. Taguchi, R. Sugimoto, K. Sakaguchi, T. Kotani, K. Hukuda, S.
Kawakami, I. Hujiwara
Board 73
Phase I study of HER3 targeted antibody patritumab in combination with
trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic
breast cancer (MBC). (Abstract 584) T. Saeki, H. Mukai, K. Aogi, T. Shigekawa,
S. Ueda, Y. Naito, N. Matsubara, S. Takashima, F. Hara, T. Yamashita, S.
Ohwada, Y. Sasaki
Board 74
Total pathologic complete response (tpCR) and event-free survival (EFS)
with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive
early breast cancer (EBC). (Abstract 585) C. Jackisch, R. Hegg, D.
Stroyakovskiy, J. Ahn, B. Melichar, S. Chen, A. Crepelle-Flechais, D. Heinzmann,
M. Shing, X. B. Pivot
Board 75
The co-administration of pertuzumab (P) and trastuzumab (T) as a single
infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2positive locally advanced or metastatic breast cancer (MBC) patients (pts):
VELVET study interim analysis. (Abstract 586) M. Andersson, J. López-Vega, T.
Petit, C. Zamagni, M. Donica, J. Kamber, E. A. Perez
Board 76
Associations of HER2-specific immunity with survival during treatment with
trastuzumab and chemotherapy in breast cancer. (Abstract 587) K. L.
Knutson, R. A. Clynes, P. Yeramian, K. P. Kemp, B. Shreeder, K. V. Ballman, K. S.
Tenner, C. L. Erskine, N. Norton, D. W. Northfelt, W. Tan, M. D. Pegram, C. J.
Calfa, E. A. Mittendorf, E. A. Perez
Board 77
Neoadjuvant chemotherapy in the real world: A study of 22,819 patients from
the Japanese National Clinical Database-Breast Cancer Registry. (Abstract
588) N. Niikura, A. Tomotaki, H. Miyata, T. Iwamoto, M. S. Kawai, K. Anan, T.
Kinoshita, S. Masuda, K. Tsugawa, Y. Tokuda
Board 78
Graded prognostic assessment (GPA) of HER2 positive breast cancer
patients with brain metastases. (Abstract 589) M. Chi, V. Alva Venur, A. M.
Mohammadi, S. T. Chao, G. T. Budd, A. J. Montero, H. C. Moore, P. Elson, J. H.
Suh, L. Angelov, G. H. Barnett, J. Abraham, M. S. Ahluwalia
Board 79
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with
HER2-amplified (HER2ⴙ) metastatic breast cancer (MBC). (Abstract 590)
P. D. Shah, S. Chandarlapaty, M. N. Dickler, G. Ulaner, S. J. Zamora, V. Sterlin, A.
Iasonos, C. M. Coughlin, A. Morozov, J. Ero, N. Rosen, T. Gilewski, M. N. Fornier,
N. T. Sklarin, M. F. Berger, M. Moynahan, C. A. Hudis, J. Baselga, S. Modi
Board 80
Effectiveness of targeting HER2 in heavily pretreated patients with occult
HER2-positive (tissue-negative, serum-positive and/or HER2-positive
circulating tumor cells) metastatic breast cancer in the clinical routine.
57
SATURDAY
(Abstract 591) C. M. Kurbacher, A. Quade, G. Kunstmann, S. Herz, J. A.
Kurbacher, M. A. Warm
SATURDAY
Board 81
Implications of high tumor infiltrating lymphocytes (TIL) in HER2-positive
and triple-negative breast cancer (TNBC). (Abstract 592) V. Kotoula, K.
Chatzopoulos, S. Lakis, Z. Alexopoulou, E. Timotheadou, F. Zagouri, G. E.
Pentheroudakis, H. Gogas, E. P. Galani, E. Tsolaki, S. Chrisafi, A. Koutras, G.
Aravantinos, P. Papakostas, P. A. Kosmidis, D. G. Pectasides, G. Fountzilas
Board 82
Correlation of trastuzumab treatment benefit with quantitative HER2
expression levels in HER2 positive metastatic breast cancer. (Abstract 593)
B. Bachmeier, J. Sperinde, J. M. Weidler, Y. Lie, A. Chenna, J. Winslow, J. Engel,
G. Schubert-Fritschle, C. Sommerhoff, C. J. Petropoulos, M. P. Bates, W. Huang,
A. Nerlich
Board 83
Prognostic impact of HER2 overexpression/amplification in women with
pT1a N0 M0 breast cancer with known screening status: First results from a
multicenter population-based cancer registry study. (Abstract 594) A.
Musolino, M. Michiara, D. Boggiani, A. Sikokis, A. Rimanti, B. Pellegrino, E.
Martella, F. Bozzani, P. Sgargi, M. Panebianco, G. Bisagni, F. Falcini, C. Pinto
Board 84
Evaluation of the Breast Cancer Index in patients with HER2ⴙ/HRⴙ breast
cancer for risk of late recurrence and potential extended endocrine benefit.
(Abstract 595) R. O’Regan, B. Schroeder, N. R. Blatner, C. A. Schnabel
Board 85
Determining whether functional subtyping with BluePrint 80-gene profile
could potentially identify two distinct triple positive subtypes with and
without trastuzumab/chemo-sensitivity. (Abstract 596) P. W. Whitworth, P. D.
Beitsch, M. C. Rotkis, J. V. Pellicane, M. Murray, P. Baron, C. L. Dul, A. M.
Mislowsky, C. H. Nash, P. D. Richards, L. A. Lee, L. Stork, F. De Snoo, S. Untch,
M. Gittleman, S. Akbari, J. Beatty
Board 86
Effect of ranolazine administered after trastuzumab treatment on
cardiotoxicity in mice. (Abstract 597) N. Maurea, C. Coppola, G. Piscopo, F.
Galletta, D. Rea, G. Riccio, G. Lombardi, A. Ottaiano, C. Arra, C. De Lorenzo, R. V.
Iaffaioli
Board 87
Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with
HER2-positive metastatic breast cancer (MBC) in the phase III trial
CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.
(Abstract 598) D. Miles, A. Lacasia, L. Lee, K. Dana, S. Heeson, A. Knott, C. C.
Portera, S. M. Swain
Board 88
Biologic characteristics of breast cancer in male compared to female: SEER
analysis. (Abstract 599) M. Shaik, D. Tamkus, A. Al-Janadi
Board 89
Effect of high MMP2 and low MMP9 baseline serum levels on outcome in
patients with HER2-positive inflammatory breast cancer (IBC) treated with
bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant
chemotherapy (NAC) in the BEVERLY 2 study. (Abstract 600) E. Tabouret, A.
Goncalves, F. Bertucci, J. Pierga, T. Petit, C. Levy, J. Ferrero, M. Campone, J.
Gligorov, F. Lerebours, H. H. Roche, T. D. Bachelot, Y. Toiron, J. Borg, O. L.
Chinot, P. Viens
Board 90
Expression levels of PARP1 and phospho-p65 protein in human HER2positive breast cancers. (Abstract 601) J. A. Stanley, L. C. Klepczyk, K. S.
Keene, S. Wei, Y. Li, A. Forero-Torres, W. E. Grizzle, M. Wielgos, J. D. Brazelton,
A. F. LoBuglio, E. S. Yang
Board 91
Phase 1b study of ONTⴚ380, an oral HER2-specific inhibitor, in combination
with capecitabine (C) and trastuzumab (T) in third line ⴙ treatment of HER2ⴙ
metastatic breast cancer (MBC). (Abstract 602) E. P. Hamilton, D. A. Yardley,
G. N. Hortobagyi, L. N. Walker, V. F. Borges, S. L. Moulder
Board 92
Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older
with HER2-positive advanced breast cancer: A subgroup analysis of the
Kamilla study. (Abstract 603) C. H. Barrios, A. Anton, S. Delaloge, F.
Montemurro, R. Wuerstlein, S. Robb, P. Button, P. A. Ellis
58
Board 93
The clinical utility of ERBB2 amplification detection in breast carcinoma
using a 341 gene hybrid capture-based next generation sequencing (NGS)
assay: Comparison with standard immunohistochemistry (IHC) and
Fluorescence In Situ Hybridization (FISH) assays. (Abstract 604) D. S. Ross,
A. Zehir, D. T. Cheng, K. Nafa, G. Jour, P. Razavi, D. M. Hyman, J. Baselga, M. F.
Berger, M. Ladanyi, M. E. Arcila
Board 94
HER2 quantification by mass spectrometry compared to IHC or ISH in
predicting clinical benefit from anti-HER2 therapy in HER2-positive breast
cancer (BC). (Abstract 605) P. Nuciforo, C. Aura, S. P. Thyparambil, M. Vilaro,
A. C. Garrido-Castro, V. Peg, J. Jimenez, W. A. Hoos, J. Burrows, T. A.
Hembrough, J. M. Perez-Garcia, J. Cortes, M. Scaltriti
Board 95
Crosstalk between PARP-1 and NF-␬B signaling pathways as a potential
determinant of PARPi sensitivity in trastuzumab resistant HER2ⴙ breast
cancer cell lines. (Abstract 606) M. Wielgos, T. Cooper, A. Forero-Torres, F. J.
Esteva, R. Schiff, C. K. Osborne, A. F. LoBuglio, E. S. Yang
Board 96
Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in
patients with HER2-overexpressing metastatic breast cancer (MBC): Updated
progression-free survival with overall survival result. (Abstract 607) L. M.
Smyth, N. M. Iyengar, S. Chandarlapaty, S. Sugarman, E. A. Comen, P. Drullinsky,
N. T. Sklarin, T. A. Traina, T. A. Troso-Sandoval, S. Patil, C. Wasserheit-Lieblich,
D. S. Argolo, J. Baselga, L. Norton, C. A. Hudis, C. T. Dang
Board 97
A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase
inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with
HER2ⴙ metastatic breast cancer (MBC). (Abstract 608) K. L. Jhaveri, E. P.
Hamilton, K. Miller, M. Roche, M. S. Berger, E. P. Winer, N. U. Lin
Board 98
Characterization of dominant T-cell clones by T-cell receptor (TCR) deep
sequencing as a potential predictive biomarker to neoadjuvant trastuzumab
(tras) in HER2-positive (HER2ⴙ) breast cancer. (Abstract 609) D. B. Page,
Y. H. Wen, E. Brogi, J. Yuan, R. O. Emerson, S. Patil, C. T. Dang, L. Norton, C. A.
Hudis, H. L. McArthur
Board 99
Efficacy and CNS progression analysis from the randomized phase 2 trial of
neratinib ⴙ paclitaxel vs trastuzumab ⴙ paclitaxel as first-line treatment for
HER2ⴙ metastatic breast cancer (NEfERTT). (Abstract 610) A. Awada, R.
Colomer, I. Bondarenko, K. Inoue, R. A. Badwe, G. Demetriou, X. Wang, V.
Smirnov, S. Lee, A. O. Mehta, S. Kim, Z. Shen, T. D. Bachelot, C. Goswami, S.
Deo, R. Bose, A. Wong, F. Xu, R. Bryce, L. A. Carey
Board 100
Whole exome sequencing (WES) in HER2ⴙ metastatic breast cancer (MBC)
patients (pts) with extraordinary responses to trastuzumab (T). (Abstract 611)
I. V. Luis, C. Oh, Z. Wang, P. Dipiro, E. M. Macrae, C. Painter, G. Kryukov, I. E.
Krop, E. P. Winer, N. U. Lin, N. Wagle
Board 101
ONT-380 in the treatment of HER2ⴙ breast cancer central nervous system
(CNS) metastases (mets). (Abstract 612) C. Ferrario, S. Welch, J. M. Chaves,
L. N. Walker, I. E. Krop, E. P. Hamilton, V. F. Borges, S. L. Moulder
Board 102
Lack of correlation of neoantigens arising from tumor somatic mutations
with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast
cancer (HER2ⴙ BC). (Abstract 613) P. S. Savas, R. Salgado, F. Caramia, C.
Denkert, S. Loibl, C. Sotiriou, F. Andre, T. P. Speed, S. Loi
Board 104
Neuromedin U to increase IL-6 levels and to expand cancer stem cells in
HER2-positive breast cancer cells. (Abstract 614) V. G. Martinez, S. Rani, C.
Corcoran, J. Crown, L. O’Driscoll
Board 105
Effect of somatic mutations in the four genes of the HER family on
occurrence in HER2-positive breast cancer, cell proliferation rates, and
resistance to HER2-targeted therapies in vitro. (Abstract 615) N. Elster, A. J.
Eustace, Y. Fan, J. Naidoo, J. Fay, E. Kay, A. Carr, O. S. Breathnach, P. G. Morris,
W. Grogan, A. D. Hill, C. Power, M. J. Allen, S. Kennedy, J. Crown, W. M.
Gallagher, S. Toomey, B. Hennessy
59
SATURDAY
SATURDAY
Board 106
Trastuzumab and pertuzumab-based versus other therapy as second-line
therapy in HER2-positive metastatic breast cancer: A retrospective study
from single center. (Abstract 616) D. S. Argolo, L. M. Smyth, N. M. Iyengar, S.
Patil, L. Norton, J. Baselga, C. A. Hudis, C. T. Dang
Board 107
HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during
lapatinib combination therapies in ALTTO. (Abstract 617) C. F. Spraggs, L. R.
Parham, L. Warren, L. S. Williams, L. P. Briley, D. Fraser, Z. Jiang, Z. Aziz, Z.
Tong, S. D. Moodley, A. O. Mehta, N. Jackson, J. Byrne, M. Andersson, M. Toi, L.
Harris, J. Gralow, R. Crescenzo, A. A. Armour
Board 108
Development of PF-05280014, a potential biosimilar to trastuzumab.
(Abstract 618) I. A. Jacobs, R. Ewesuedo, D. Yin, R. Li, S. Hurst, A. M. Ryan, C.
Ng, M. W. Leach, G. Finch, C. M. Zacharchuk
Board 109
Association of tumor infiltrating lymphocytes (TILs) with pathologic
response in baseline and post-brief exposure HER2ⴙ breast cancer biopsies
from BrUOG-211B. (Abstract 619) S. Avril, V. Varadan, K. Miskimen, J.
Gollamudi, M. M. Abu-Khalaf, G. Somlo, W. M. Sikov, L. Harris, S. Vinayak
Board 110
Mechanisms of acquired afatinib resistance in HER2-positive breast cancer
cells. (Abstract 620) A. Canonici, N. Conlon, C. Morgan, M. Cremona, A. J.
Eustace, B. Hennessy, J. Crown, N. O’Donovan
Board 111
HER3, PI3K, and JAK2 pathway activation on reverse phase protein
microarray (RPMA) in HER2-amplified residual disease (RD) refractory to
preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).
(Abstract 621) F. A. Holmes, C. Ramos, N. N. Hoke, M. K. Levin, V. A. Espina,
L. A. Liotta, K. Wang, N. A. Palma, J. O’Shaughnessy
Board 112
Final pre-specified analysis of the phase II trial of the AE37ⴙGM-CSF vaccine
in high risk breast cancer patients to prevent recurrence. (Abstract 622) J. M.
Greene, E. J. Schneble, J. Martin, M. Flores, J. S. Berry IV, A. F. Trappey III, T. J.
Vreeland, D. F. Hale, A. K. Sears, G. T. Clifton, E. von Hofe, J. T. Symanowski, A.
Ardavanis, N. M. Shumway, S. Ponniah, M. Papamichail, S. A. Perez, G. E.
Peoples, E. A. Mittendorf
Board 113a
MIRACLE study (CBCSG016): A randomized phase II study of letrozole
versus letrozole plus everolimus for hormone receptor positive
premenopausal women with recurrent or metastatic breast cancer on
goserelin treatment after progession on tamoxifen. (Abstract TPS623) B. Xu,
D. Liu, J. Lu, T. Ouyang, X. Li, Y. Fan
Board 113b
MONARCH 3: A randomized phase III study of anastrozole or letrozole plus
abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women
with HRⴙ, HER2-locoregionally recurrent or metastatic breast cancer (MBC).
(Abstract TPS624) M. P. Goetz, M. Toi, S. Klise, M. Frenzel, N. Bourayou, A. Di Leo
Board 114a
Phase III, randomized, double-blind, placebo-controlled study of ribociclib
(LEE011) in combination with either tamoxifen and goserelin or a nonsteroidal aromatase inhibitor (NSAI) and goserelin for the treatment of
premenopausal women with HRⴙ, HER2– advanced breast cancer (aBC):
MONALEESA-7. (Abstract TPS625) D. Tripathy, A. Bardia, S. A. Hurvitz, N.
Harbeck, M. Colleoni, F. A. Franke, L. W. Chow, S. Im, Z. Shao, J. R. Keyserlingk,
L. Mongay Soler, M. Horan, S. V. Dhuria, G. Hughes, Y. Lu
Board 114b
BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K)
inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women
with HRⴙ/HER2– locally advanced/metastatic breast cancer (BC) pretreated
with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)based treatment. (Abstract TPS626) A. Di Leo, E. Ciruelos, W. Janni, P. E.
Lonning, R. O’Regan, M. Hubalek, T. Csõszi, T. Decker, V. C. Tjan-Heijnen, D.
Weber, M. El-Hashimy, S. Goteti, C. Massacesi, T. D. Bachelot
Board 115a
LORELEI: A phase II randomized, double-blind study of neoadjuvant
letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2-negative, early-stage breast
cancer. (Abstract TPS627) E. De Azambuja, C. Saura, M. Oliveira, P. C. Dubsky,
60
Board 115b
A phase 2, randomized, open-label study of lucitanib in patients with FGF
aberrant metastatic breast cancer. (Abstract TPS628) M. M. Abu-Khalaf, I. A.
Mayer, C. Tankersley, J. Moy, A. R. Allen, C. L. Vogel, F. A. Holmes, R. Nanda, K.
Miller, R. Patel, L. Pusztai, C. L. Arteaga
Board 116a
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib
(GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)positive, HER2-negative locally advanced or metastatic breast cancer (BC)
enriched for pts with PIK3CA mutant tumors. (Abstract TPS629) J. Baselga, J.
Cortes, M. De Laurentiis, V. Diéras, N. Harbeck, Y. Im, W. Jacot, I. E. Krop, S.
Verma, T. R. Wilson, R. Lin, F. Schimmoller, J. Y. Hsu
Board 116b
A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR
inhibitor everolimus in postmenopausal women with hormone receptor
positive/HER2 negative breast cancer and a low/intermediate risk Oncotype
Dx Recurrence Score (’ 25). (Abstract TPS630) M. M. Abu-Khalaf, S. S.
Mougalian, T. B. Sanft, E. W. Hofstatter, G. G. Chung, K. B. Adelson, A. Silber,
D. S. Brandt, K. E. Bober-Sorcinelli, N. Fishbach, W. Zaheer Kidwai, K. D.
Sabbath, M. DiGiovanna, W. M. Sikov, L. Pusztai
Board 117a
Phase III study of Palbociclib in combination with Exemestane vs.
Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic
Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase
inhibitors (NSAI): PEARL study (GEICAM/2013– 02 CECOG/BC.1.3.006)
(Abstract TPS631) M. Martin, M. J. Inbar, E. M. Carrasco, I. Lang, M. Escudero, Z.
Kahan, C. H. Bartlett, B. Bermejo, E. Gal Yam, J. Chacon, Z. Zvirbule, J. Garcia
Saenz, J. de la Haba-Rodriguez, M. Koehler, M. J. Gil Gil, E. Ciruelos Gil, M.
Munoz-Mateu, S. Morales Murillo, J. Alonso, C. Zielinski, GEICAM Spanish Breast
Cancer Group and CECOG Central European Cooperative Oncology Group
Board 117b
A phase I trial assessing the maximum tolerated dose (MTD) and
pharmacokinetics of intrapleural bevacizumab after pleural puncture in
breast cancer patients with symptomatic recurrent metastatic pleural
effusion: The BEVAP trial. (Abstract TPS632) B. Rousseau, A. Hulin, X. Paoletti,
F. Coussy, F. Mefti, C. Dubot, A. Savignoni, C. Jayr, I. Turbiez, P. Mordant, E.
Brain, M. Gutierrez
Board 118a
A Phase II study of the safety and efficacy of alpelisib or buparlisib plus
letrozole in neoadjuvant treatment of postmenopausal women with
HRⴙ/HER2–, PIK3CA mutant or wild-type breast cancer. (Abstract TPS633)
I. A. Mayer, C. F. Singer, P. A. Fasching, F. A. Holmes, M. Gnant, L. G. Estevez,
M. Campone, M. Hubalek, A. C. Wolff, J. A. Perez-Fidalgo, E. P. Winer, G.
Atalla-Vidam, C. Kanwal, L. Blumenstein, N. Fretault, I. Diaz-Padilla, C. L. Arteaga
Board 118b
TARGIT-U.S.: A registry trial of targeted intraoperative radiation therapy
following breast-conserving surgery. (Abstract TPS634) M. Alvarado, E.
Gallant, J. S. Rice, S. R. Grobmyer, E. E. Harris, D. Holmes, D. Pavord, W. Small
Jr.
Board 119a
I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically
advanced, ERⴙ, HER2- breast cancer and molecular good-prognosis gene
signature. (Abstract TPS635) T. C. Haddad, M. D. Shah, W. F. Symmans, N.
Hylton, C. Yau, J. Lyandres, M. E. Melisko, A. Forero, K. S. Albain, H. G. Kaplan,
R. K. Viscusi, I. Investigators, D. A. Berry, L. Esserman, A. J. Chien
Board 119b
E2112: Randomized phase III trial of endocrine therapy plus
entinostat/placebo in patients with hormone receptor-positive advanced
breast cancer. (Abstract TPS636) R. M. Connolly, F. Zhao, K. Miller, A.
Tevaarwerk, L. I. Wagner, M. Lee, J. Murray, R. J. Gray, R. Piekarz, J. Zujewski,
J. A. Sparano
Board 120a
Phase III randomized, placebo-controlled clinical trial evaluating the use of
adjuvant endocrine therapy ⴙ/- one year of everolimus in patients with
high-risk, hormone receptor (HR) positive and HER2-negative breast cancer
(BC): SWOG/NRG/Alliance S1207 (NCT01674140). (Abstract TPS637) M.
61
SATURDAY
D. Zardavas, C. Fesl, A. Bardia, R. Lin, J. O. Fredrickson, H. Parmar, S. M. Singel,
J. Y. Hsu, M. J. Piccart-Gebhart, M. Gnant, J. Baselga
Chavez-Mac Gregor, W. E. Barlow, L. Pusztai, M. P. Goetz, P. Rastogi, P. A.
Ganz, E. P. Mamounas, S. Paik, H. Bandos, J. Gralow, D. L. Lew, G. N. Hortobagyi
SATURDAY
Board 120b
A phase I study of RAD1901, an oral selective estrogen receptor degrader, in
ER–positive, HER2–negative, postmenopausal advanced breast cancer
patients. (Abstract TPS638) W. A. Harb, F. Garner, M. Clarkin, K. A. Roberge,
A. G. Harris, G. Williams, G. Hattersley
Board 121a
Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79):
Multicentric, retro- and prospective collection of patient data and biomaterial
from patients with brain metastases. (Abstract TPS639) V. Mueller, E.
Laakmann, T. N. Fehm, V. Moebus, G. Von Minckwitz, S. Loibl, I. Witzel
Board 121b
A phase 2 single-arm study to assess clinical activity, efficacy and safety of
enzalutamide (ENZA) with trastuzumab in HER2ⴙ ARⴙ metastatic or locally
advanced breast cancer. (Abstract TPS640) M. E. Trudeau, E. P. Winer, J. L.
Steinberg, M. Liosatos, S. Poondru, M. N. Dydo, A. C. Peterson, W. J. Gradishar
Board 122a
HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus
trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in
anthracycline naive HER2-positive, locally advanced/metastatic breast
cancer patients previously treated with pertuzumab and ado-trastuzumab
emtansine (T-DM1). (Abstract TPS641) K. Miller, J. Cortes, S. A. Hurvitz, I. E.
Krop, D. Tripathy, S. Verma, K. Riahi, J. G. Reynolds, T. J. Wickham, I. Molnar,
D. A. Yardley
Board 122b
PATRICIA: A phase II study of palbociclib and trastuzumab with or without
letrozole in previously treated, postmenopausal patients with HER2-positive
metastatic breast cancer. (Abstract TPS642) P. Villagrasa, X. Gonzalez, M.
Oliveira, J. Vazquez, L. De La Pena, M. Llobet-Canela, A. Prat, E. Ciruelos
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Location: S Hall A
Abstracts 1009 –1020 will be discussed during the Breast Cancer—Triple-Negative/Cytotoxics/
Local Therapy Poster Discussion Session. See page 128 for session information.
Board 123
Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast
cancer. (Abstract 1009) S. S. Mougalian, J. B. Long, J. Hall, K. B. Adelson, M. M.
Abu-Khalaf, L. Pusztai, C. P. Gross
Board 124
Absence of disease-specific survival improvement over time among breast
cancer patients age 70 and older: 1990 –2007. (Abstract 1010) H. G. Kaplan,
J. A. Malmgren, M. K. Atwood
Board 125
Contralateral prophylactic mastectomy decision-making in the populationbased iCanCare study of early-stage breast cancer patients: Knowledge and
physician influence. (Abstract 1011) R. Jagsi, S. T. Hawley, K. A. Griffith, N. K.
Janz, A. W. Kurian, K. C. Ward, A. S. Hamilton, S. J. Katz, M. Morrow
Board 126
Can routine cavity shave margins (CSM) improve local control in breast
cancer? Initial results of the SHAVE trial, a prospective randomized
controlled trial of routine CSM vs. standard partial mastectomy (SPM).
(Abstract 1012) A. B. Chagpar, B. K. Killelea, T. N. Tsangaris, M. Butler, K.
Stavris, X. Yao, F. Li, V. Bossuyt, L. Pusztai, N. R. Horowitz
Board 127
Risk after local excision alone for DCIS patients. (Abstract 1013) E. Rakovitch,
S. Nofech-Mozes, W. Hanna, F. L. Baehner, R. Saskin, S. M. Butler, A. Tuck, S.
Sengupta, L. Elavathil, P. A. Jani, M. Bonin, M. Chang, S. Robertson, E.
Slodkowska, C. H. Fong, J. M. Anderson, F. Jamshidian, D. B. Cherbavaz, S.
Shak, L. F. Paszat
Board 128
A phase II, open-label, neoadjuvant, randomized study of LCL161 with
paclitaxel in patients with triple-negative breast cancer (TNBC). (Abstract
62
Board 129
A phase I study of veliparib (ABT-888) in combination with weekly
carboplatin and paclitaxel in advanced solid malignancies and enriched for
triple-negative breast cancer (TNBC). (Abstract 1015) S. Pahuja, J. H. Beumer,
L. J. Appleman, H. A. Tawbi, R. G. Stoller, J. J. Lee, Y. Lin, F. Ding, J. Yu, C. P.
Belani, A. P. Chen, V. L. Giranda, S. P. Shepherd, E. Chu, S. Puhalla
Board 130
Therapy of refractory/relapsed metastatic triple-negative breast cancer
(TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC),
sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (Abstract
1016) A. Bardia, L. T. Vahdat, J. R. Diamond, A. Starodub, R. L. Moroose, S. J.
Isakoff, A. J. Ocean, J. Berlin, W. A. Messersmith, S. S. Thomas, F. Wilhelm, W. A.
Wegener, P. P. Maliakal, R. M. Sharkey, D. M. Goldenberg, I. A. Mayer
Board 131
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with
triple negative early stage breast cancer (NCT01372579). (Abstract 1017)
V. G. Kaklamani, E. Hughes, K. P. Siziopikou, K. Timms, V. Abkevich, C.
Solimeno, A. Hartman, J. Jeruss, C. Meservey, B. Jovanovic, I. B. Helenowski, S.
Kahn, K. P. Bethke, N. Hansen, R. Uthe, S. Rosen, K. Hoskins, J. Von Roenn, S.
Jain, W. J. Gradishar
Board 132
Combined Homologous Recombination Deficiency (HRD) scores and
response to neoadjuvant platinum-based chemotherapy in triple-negative
and/or BRCA1/2 mutation-associated breast cancer. (Abstract 1018) M. L.
Telli, K. Timms, J. E. Reid, C. Neff, V. Abkevich, A. Gutin, Z. Sangale, D. Illiev, J. T.
Jones, B. Hennessy, J. S. Lanchbury, G. B. Mills, A. Hartman, J. M. Ford
Board 133
Concordance of intrinsic subtyping and risk of recurrence (ROR) scores
between matched primary and metastatic tissue from Triple Negative Breast
Cancer Trial (TNT). (Abstract 1019) M. C. Cheang, J. Bliss, M. Dowsett, L.
Kilburn, A. Grigoriadis, C. Gillett, S. Pinder, P. Gazinska, B. Haynes, S. Kernaghan,
H. Tovey, J. Owen, M. Harries, P. A. Ellis, A. N. Tutt, TNT Trial Management Group
and Investigators
Board 134
RespondR: A genomic score to predict the responsiveness of triple-negative
breast cancer patients to chemotherapy. (Abstract 1020) S. Buechler, Y.
Gokmen-Polar, S. S. Badve
Board 135
Role of ␤ blocker and angiotensin antagonist for the prophylaxis of early
onset anthracycline-induced ventricular dysfunction: A meta-analysis of five
randomized controlled trials. (Abstract 1021) N. Vincelette, S. Yun
Board 136
Standard chemotherapy versus capcitabine for older women with early stage
breast cancer: An update of CALGB/CTSU/Alliance 49907. (Abstract 1022)
H. B. Muss, D. A. Berry, C. T. Cirrincione, M. Theodoulou, A. Hurria, H. J. Cohen,
A. Partridge, L. Norton, C. A. Hudis, E. P. Winer
Board 137
Association of disregulated neuronal and peripheral BDNF with vulnerability
to paclitaxel-induced peripheral neuropathy. (Abstract 1023) D. Azoulay, A.
Leibovici, R. Sharoni, E. Shaoul, B. Gross, C. Suriu, L. Akria, A. Braester, H.
Goldberg
Board 138
Hippocampal memory impairment in breast cancer survivors after
chemotherapy measurement using covert testing. (Abstract 1024) A. J. Ryals,
A. C. Apple, J. X. Wang, D. Cella, F. J. Penedo, L. Wang, J. L. Voss
Board 139
Randomized study of tailored neoadjuvant chemotherapy according to the
expression of tau, topo II ␣, and ERCC1 versus standard chemotherapy in
HER2-negative breast cancer. (Abstract 1025) Y. Lu, D. Yeh, L. Tseng, S. Chen,
H. Lien, H. Chang, Y. Chang, S. Huang, C. Lin, A. Cheng, C. Huang
Board 140
The utility of bi-weekly eribulin therapy for metastatic breast cancer: A
Japanese multicenter phase II study (JUST-STUDY). (Abstract 1026) T.
Yoshinami, N. Masuda, T. Nakayama, F. Hara, Y. Sagara, H. Kawaguchi, K.
Watanabe, M. Sato, K. Aogi, K. Higaki, T. Morimoto, Y. Shigeoka, S. Tokunaga, H.
Morishima, Y. Yanagita, J. Tsurutani, S. Baba, K. Katayama, S. Morita, S. Ohtani
63
SATURDAY
1014) M. Parton, A. Bardia, S. Kummel, L. G. Estevez, C. Huang, J. C. Castan, M.
Ruiz Borrego, M. L. Telli, A. Lluch, R. Lopez, J. T. Beck, R. Ismail-Khan, S. Chen,
S. A. Hurvitz, I. A. Mayer, R. S. Atienza, S. Cameron, M. Krygowski, S. Kim
SATURDAY
Board 141
Utilization of neoadjuvant systemic therapy (NST) for breast cancer.
(Abstract 1027) J. J. Mohiuddin, A. M. Deal, L. A. Carey, J. L. Lund, B. R. Baker,
T. M. Zagar, E. Jones, L. B. Marks, R. C. Chen
Board 142
A comparison of toxicity profiles between standard and lower dose
capecitabine (CAP) in breast cancer (BC): a meta-analysis. (Abstract 1028) T.
Funakoshi, M. Suzuki, H. B. Muss
Board 143
Phase II randomized study of nab-paclitaxel versus conventional paclitaxel
as first-line therapy of metastatic HER2-negative breast cancer for
neurotoxicity characterization: An Oncosur Study Group study. (Abstract
1029) E. Ciruelos, N. Martinez, B. Cantos, M. Echarri, S. Enrech, C. Bueno, J. A.
Guerra, L. Manso, T. Pascual, C. Mendiola, C. Dominguez, J. F. Gonzalo, C.
Rodriguez de Antona, M. Apellaniz-Ruiz, J. L. Sanz, J. M. Sepúlveda
Board 145
A randomized phase III study of vinflunine versus an alkylating agent of
physician’s choice in metastatic breast cancer (MBC) previously treated with
or resistant to an anthracycline, a taxane, an antimetabolite and a vincaalkaloid. (Abstract 1031) J. Cortes, C. Levy, Y. Demidchik, L. Roman, H. P.
Bourgeois, C. Veyret, S. Spazzapan, J. Ferrero, T. Chao, Y. Karchmit, M. Espie,
J. A. Nabholtz, X. Gonzalez, V. Beliakouski, M. Campone
Board 146
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with
carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT
TN randomized phase II trial. (Abstract 1032) O. Gluz, U. Nitz, M. Christgen, E.
Grischke, H. Forstbauer, M. W. Braun, M. Warm, C. Uleer, B. Aktas, C.
Schumacher, J. Hackmann, N. Bangemann, P. Staib, C. Lindner, S. Kummel, C.
Liedtke, R. E. Kates, R. Wuerstlein, H. H. Kreipe, N. Harbeck, West German Study
Group ADAPT TN Investigators
Board 147
Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF)
prophylaxis in patients with breast cancer treated with dose dense epirubicin
(E), cyclophosphomide (C) ⴙ paclitaxel (T) Adjuvant chemotherapy:
Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). (Abstract
1033) R. Ramjeesingh, J. Kankesan, B. E. Chen, J. L. Pater, L. Han, P. O’Brien,
M. J. Burnell, L. E. Shepherd, W. R. Parulekar
Board 148
A nomogram to predict axillary response to neoadjuvant chemotherapy in
clinically node positive breast patients. (Abstract 1034) J. Vila, R. L. Bassett
Jr., E. A. Mittendorf, I. Bedrosian, S. F. Shaitelman, M. C. Stauder, M. Chavez-Mac
Gregor, J. K. Litton, W. T. Yang, L. Huo, H. M. Kuerer, K. Hunt, A. S. Caudle
Board 149
Direct effects on bone metabolism induced by perioperative anthracyclineand/or taxane-based chemotherapy depend on the menopausal status of
patients with primary breast cancer. (Abstract 1035) N. Rauschenbach, A. T.
Kurbacher, S. Herz, J. A. Kurbacher, K. Monreal, S. Sperling, C. M. Kurbacher
Board 150
Death during study treatment: An evaluation of events in 31 German clinical
trials. (Abstract 1036) J. Furlanetto, G. Von Minckwitz, B. Lederer, V. Möbus, H.
Lueck, C. Hanusch, C. Thomssen, M. Untch, S. Loibl
Board 151
Tumor infiltrating lymphocytes (TILs) in HER2 positive breast cancer:
Evaluation according to the new recommendations by the international TILs
working group 2014. (Abstract 1037) H. Nafisi, J. Raphael, I. Y. Gong, J. M.
Bartlett, S. Verma, S. Nofech-Mozes
Board 152
A phase I/II trial of olaparib in combination with eribulin in patients with
advanced or metastatic triple negative breast cancer (TNBC) previously
treated with anthracyclines and taxanes: First results from phase I. (Abstract
1038) H. Yasojima, H. Yamamoto, N. Masuda, K. Aogi, M. Takahashi, K.
Yonemori, M. Takeuchi, A. Hamada, K. Tamura, T. Sukigara, R. Nagasaka, R.
Nakano, Y. Tsujimoto, Y. Morioka, K. Higuchi, Y. Fujiwara
Board 153
Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with
low HER2 expression. (Abstract 1039) Q. J. Khan, A. O’Dea, C. J. Fabian, C. S.
Connor, M. McGinness, J. M. Mammen, J. L. Wagner, S. Baccaray, M. Springer, H.
Yeh, P. Sharma
64
Board 154
Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as
a novel prognostic, predictive, actionable gene in Breast Cancer (BC).
(Abstract 1040) T. M. Abdel-Fatah, D. Liu, D. Agarwal, R. Russell, O. M. Rueda,
P. M. Moseley, A. R. Green, A. Mukherjee, J. Reis-Filho, C. Caldas, I. O. Ellis, G.
Ball, S. Y. Chan
Board 155
A model-based approach to dose optimization of neurotoxic chemotherapy
for metastatic breast cancer (MBC). (Abstract 1041) M. Sharma, E. Gray, S.
Mehrotra, K. Wu, W. T. Barry, C. A. Hudis, E. P. Winer, A. P. Lyss, D. Toppmeyer,
A. Moreno-Aspitia, H. S. Rugo, M. J. Ratain, J. Gobburu
Board 156
Association of non-disruptive P53 mutations with poor progression-free
survival (PFS) in resected breast cancer treated with neoadjuvant
chemotherapy. (Abstract 1042) A. Martinez-Bueno, S. Baulies, M. A. Molina-Vila,
J. Bertran-Alamillo, M. Gonzalez Cao, X. Gonzalez, S. Viteri Ramirez, N.
Karachaliou, C. Teixido, M. Sanchez-Ronco, F. Tresserra, M. Cusido, R. Fabregas,
R. Rosell
Board 157
A single institution experience of salvage therapy for locally advanced breast
cancer: Treatments and trends. (Abstract 1043) J. Raphael, T. Paramsothy, J.
Lee, S. Gandhi
Board 158
Gene expression of metastatic biopsies for prediction of response to
palliative chemotherapy in breast cancer. (Abstract 1044) T. Foukakis, J.
Lorent, N. Tobin, L. S. Lindström, J. C. Bergh, T. Hatschek
Board 159
Proteomic analysis of primary and metastatic breast cancers and expression
of the folate receptor as a potential drug target. (Abstract 1045) T. A.
Hembrough, F. Cecchi, A. Blackler, S. P. Thyparambil, J. Burrows, J.
O’Shaughnessy
Board 160
Impact of systemic therapy on the outcomes of patients with metastatic
breast cancer to brain: MD Anderson Cancer Center (MDACC) experience
1999 –2012. (Abstract 1046) D. Bugano Diniz Gomes, R. E. Deeba, D. Suki, V.
Valero, S. L. Moulder, B. Arun, K. H. Koenig, E. A. Strom, L. Hsu, R. Sawaya, D.
Tripathy, N. K. Ibrahim
Board 161
Pre-treatment Near-Infrared Spectral Tomography (NIRST) to predict
pathologic complete response to neoadjuvant chemotherapy (NAC) in
women with locally advanced breast cancer (LABC). (Abstract 1047) P.
Kaufman, S. Jiang, R. diFlorio-Alexander, J. Gui, B. W. Pogue, K. D. Paulsen
Board 162
Impact of sequencing weekly paclitaxel (T) and dose-dense
doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose
intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant
chemotherapy (NAC). (Abstract 1048) N. M. LeCroy, I. Borrero, D. B. Dumercy,
E. Velis, A. T. Perez, M. Velez, A. Mani, A. B. Castrellon, C. Hawkins Locke, C.
Frankel, C. Sareli, C. J. Calfa
Board 163
Clinical evaluation of germline polymorphisms (SNPs) associated with
capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC). (Abstract
1049) P. H. O’Donnell, V. Trubetskoy, A. Nurhussein-Patterson, J. P. Hall, D. Huo,
G. F. Fleming, J. N. Ingle, I. A. Mayer, P. H. Morrow, A. M. Storniolo, A. ForeroTorres, C. H. Van Poznak, D. E. Merkel, G. L. Rosner, O. I. Olopade, M. J. Ratain,
N. Cox, M. Dolan, R. Nanda, Translational Breast Cancer Research Consortium
(TBCRC)
Board 164
The role of LHRH agonists in ovarian function preservation in
premenopausal women undergoing chemotherapy for early stage breast
cancer: A systematic review and meta-analysis. (Abstract 1050) R. R. Munhoz,
A. A. Pereira, A. D. Sasse, P. M. Hoff, T. A. Traina, C. A. Hudis, R. J. Marques
Board 165
FDG-PET/CT versus contrast enhanced CT for prediction of progression-free
and disease-specific survival in stage IV breast cancer patients. (Abstract
1051) C. Riedl, K. Pinker, L. Ong, M. S. Jochelson, G. Ulaner, H. L. McArthur,
M. N. Dickler, W. Weber
65
SATURDAY
SATURDAY
Board 166
The early effect of breast density legislation on mammogram reporting.
(Abstract 1052) E. J. Lee, K. Kam, S. S. Pairawan, K. Anderson, C. Cora, W. Bae,
K. Kazanjian, G. Nagaraj, S. S. Lum
Board 167
Breast cancer with extensive regional lymph node involvement: Toward
optimizing local management. (Abstract 1053) L. Z. Braunstein, S. Galland, S.
Goldberg, B. T. Sadek, M. Shenouda, R. Abi-Raad, S. M. MacDonald, A. G.
Taghian
Board 168
Risk of axillary node metastasis in Paget disease with invasive ductal
carcinoma. (Abstract 1054) S. M. Wong, R. A. Freedman, E. Stamell, Y. Sagara,
J. E. Brock, S. DeSantis, M. Golshan
Board 169
The efficacy and efficiency of half frozen section assessment of breast
cancer sentinel lymph nodes: A retrospective analysis of 1116 cases.
(Abstract 1055) H. Yang, S. Wang, J. Guo, Y. Cao
Board 170
Cosmetic outcome after breast conserving surgery and either external beam
or intraoperative radiotherapy for early breast cancer: Objective assessment
of patients from a randomized controlled trial in Lublin, Poland. (Abstract
1056) N. R. Williams, A. Kurylcio, M. Jankiewicz, J. Romanek, W. Polkowski, N.
Michalopoulos, M. R. Keshtgar
Board 171
Phase I dose escalation trial using stereotactic body radiation therapy
(SBRT) for partial breast irradiation (PBI). (Abstract 1057) A. S. Rahimi, A.
Spangler, D. P. Garwood, A. M. Leitch, R. Rao, S. Seiler, R. D. Wooldridge, A.
Rivers, S. Stevenson, S. Goudreau, B. B. Haley, Y. Dong, D. Euhus, K. V.
Albuquerque, M. Folkert, J. H. Heinzerling, C. Ding, C. Ahn, H. Choy, R. D.
Timmerman
Board 172
Evaluation of the new Commission on Cancer Quality measure for postmastectomy radiation treatment for breast cancer. (Abstract 1058) C. A.
Minami, N. Hansen, J. B. Strauss, J. Feinglass, J. P. Hayes, N. Rydzewski, D. J.
Bentrem, K. Y. Bilimoria
Board 173
Breast cancer brain metastases: Comprehensive review of tumor extent,
histology and treatment on survival. (Abstract 1059) J. A. Crozier, L. F. Cornell,
B. Rawal, E. A. Perez
Board 174
Effect of the use of immediate reconstruction on the rates of bilateral
mastectomy and adjuvant radiation therapy use in women with node-positive
breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071
(Alliance). (Abstract 1060) J. C. Boughey, L. M. McCall, B. G. Haffty, T. A.
Buchholz, E. A. Mittendorf, K. V. Ballman, K. Hunt
Board 175
Residual breast tissue after mastectomy in non high risk and BRCA mutated
patients. (Abstract 1061) G. Pfeiler, A. Farr, R. Woitek, T. Helbich, D.
Gschwantler-Kaulich, C. F. Singer, M. Bernathova
Board 176
Detrimental effect of blood-product transfusion on survival for patients with
breast cancer in Florida (1996 –2007). (Abstract 1062) H. Alghamdi, D.
Franceschi, F. Miao, M. M. Byrne, T. Koru-Sengul
Board 177
Impact of neoadjuvant chemotherapy to surgery interval on survival
outcomes in breast cancer patients. (Abstract 1063) R. A. Sanford, X. Lei, C. H.
Barcenas, E. A. Mittendorf, A. S. Caudle, V. Valero, D. Tripathy, S. H. Giordano, M.
Chavez-Mac Gregor
Board 178
Influence of marital status on tumor characteristics and survival in male
breast cancer. (Abstract 1064) S. Tadisina, U. Koduru, C. Chacko, O. Adekolujo,
R. Ehwarieme, J. Ramzy, M. L. Arora, J. Gernand, R. Kakarala, O. S. Adekolujo, S.
Smith
Board 179
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by
FEC neoadjuvant chemotherapy for patients with primary HER-2 negative
inflammatory breast cancer. (Abstract 1065) N. Matsuda, R. H. Alvarez, S.
Krishnamurthy, J. S. Willey, X. Wang, B. Lim, C. A. Parker, A. Marx, G. Babiera,
D. J. Booser, J. L. Murray, B. Arun, A. M. Brewster, J. M. Reuben, W. A.
Woodward, A. Lucci Jr., S. M. Gainer, D. Tripathy, V. Valero, N. T. Ueno
66
Board 180
MHC II antigen presentation pathway expression in triple-negative breast
cancer. (Abstract 1066) A. Forero-Torres, K. E. Varley, Y. Li, D. Chen, W. E.
Grizzle, E. Downs-Kelly, T. C. Burwell, D. J. Buchsbaum, R. M. Myers, A. F.
LoBuglio
Board 181
A study of triple-negative breast cancer patients tested with a 25-gene panel
of hereditary cancer genes. (Abstract 1067) J. F. Sandbach, G. Patel, E. King,
B. Evans, J. Kidd, L. R. Langer, K. Brown, R. J. Wenstrup, J. Saam
Board 182
Phase I dose-finding study of the gamma secretase inhibitor PF-03084014
(PF-4014) in combination with docetaxel in patients (pts) with advanced
triple-negative breast cancer (TNBC). (Abstract 1068) G. Curigliano, P. G.
Aftimos, E. C. Dees, P. LoRusso, M. D. Pegram, A. Awada, B. Huang, R. Cesari,
Y. Jiang, M. N. Shaik, K. A. Kern, M. A. Locatelli
Board 183
Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in
triple-negative breast cancer (TNBC). (Abstract 1069) A. Afghahi, M. Mathur, T.
Seto, M. Desai, P. Kenkare, K. C. Horst, A. K. Das, C. A. Thompson, H. S. Luft,
P. P. Yu, S. L. Gomez, Y. Low, N. H. Shah, A. W. Kurian, G. W. Sledge
Board 184
Masitinib plus carboplatin and gemcitabine for treatment of patients with
advanced triple negative breast cancer: An open label phase Ib/II trial.
(Abstract 1070) M. Campone, J. Ferrero, K. Gunzer, F. Priou, P. Dubreuil, C.
Mansfield, A. Moussy, O. Hermine
Board 185
Enzalutamide: A new hormonal treatment for triple-negative breast cancer?
(Abstract 1071) F. Caiazza, A. Murray, S. F. Madden, N. C. Synnott, N.
O’Donovan, J. Crown, M. J. Duffy
Board 186
Prognostic significance of tumor subtypes in male breast cancer: A
population-based study. (Abstract 1072) J. P. Leone, J. Leone, A. O. Zwenger,
J. Iturbe, C. T. Vallejo, B. A. Leone
Board 188
Neoadjuvant chemotherapy with dose-dense doxorubicin, cisplatin, and
paclitaxel in patients with early triple-negative breast cancer (TNBC).
(Abstract 1074) M. Frolova, E. Ignatova, E. Glazkova, A. Petrovsky, S. Tjulandin
Board 189
Rampant centrosome amplification and aggressive disease course of
triple-negative breast cancers. (Abstract 1075) V. Pannu, K. Mittal, G. H.
Cantuaria, M. D. Reid, X. Li, S. Donthamsetty, M. McBride, R. Osan, P. C. Rida, R.
Aneja
Board 190
Prognostic role of androgen receptor expression in triple-negative breast
cancer. (Abstract 1076) Y. Wang, F. Yang, F. Zhong, X. Guan
Board 191
Measurement of nucleotide excision repair activity and correlation with
cisplatin sensitivity. (Abstract 1077) A. Calkins, R. Szalat, M. Dreze, M.
Schnorenberg, R. Ceccaldi, J. D. Iglehart, J. Lazaro
Board 192
Nuclear HSET as a negative prognostic indicator and racial disparity
biomarker in breast cancer patients. (Abstract 1078) A. Ogden, P. C. Rida, S.
Klimov, V. Pannu, Y. Liu, M. D. Reid, X. Li, G. H. Cantuaria, R. Aneja
Board 193
DNA methylation signature to identify treatment response in triple negative
breast cancer. (Abstract 1079) B. Pineda, A. Diaz-Lagares, J. A. Perez-Fidalgo,
E. Alonso, J. Sandoval, I. Gonzalez, A. Crujeiras, O. Burgues, M. Esteller, A. Lluch,
P. Eroles
Board 194
A Phase II study of cabozantinib for metastatic triple-negative breast cancer
(TNBC). (Abstract 1080) S. M. Tolaney, D. R. Ziehr, H. Guo, W. T. Barry, M. J.
Higgins, S. J. Isakoff, J. E. Brock, E. Ivanova, C. Paweletz, M. Demeo, N. H.
Ramaiya, B. Overmoyer, R. K. Jain, D. G. Duda, E. P. Winer
Board 195
Contribution of immune system and tumor-related interferon signaling to
epirubicin response in triple-negative (TN) breast cancers. (Abstract 1081) G.
Bianchini, M. Callari, T. Iwamoto, M. Riba, L. Vigano’, A. Locatelli, M. Zambetti, T.
Karn, L. Pusztai, L. Gianni
Board 196
Cisplatin with or without rucaparib after preoperative chemotherapy in
patients with triple negative breast cancer: Final efficacy results of Hoosier
67
SATURDAY
Oncology Group BRE09 –146. (Abstract 1082) K. Miller, Y. Tong, D. R. Jones, T.
Walsh, M. A. Danso, C. X. Ma, P. Silverman, M. King, S. S. Badve, S. M. Perkins
SATURDAY
Board 197
A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC.
(Abstract 1083) J. S. Parker, A. C. Peterson, I. C. Tudor, J. Hoffman, H. Uppal
Board 198
Rac1 inhibition to sensitize triple negative breast cancer to EGFR inhibition.
(Abstract 1084) G. Azzi, E. Goka, D. Senderoff, M. E. Lippman
Board 199
Protein activation mapping and exploratory predictive markers for pCR in
triple-negative breast cancer patients treated with neratinib in the I-SPY 2
TRIAL. (Abstract 1085) J. D. Wulfkuhle, C. Yau, D. M. Wolf, R. I. Gallagher, J.
Deng, L. Brown Swigart, G. Hirst, M. C. Liu, J. W. Park, L. Esserman, D. A. Berry,
L. van’t Veer, E. Petricoin III, I-SPY 2 TRIAL Investigators
Board 200
Characterization of KCNK9 in The Cancer Genome Atlas breast cancer
dataset. (Abstract 1086) K. A. Dookeran, M. Argos, J. K. Kresovich, G. H.
Rauscher
Board 201
Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in
triple negative breast cancer. (Abstract 1087) M. Altan, K. A. Schalper, M.
Silver, D. L. Rimm
Board 202
Clinical utility of in depth RNA sequencing for non-metastatic triple negative
breast cancers. (Abstract 1088) B. Thouvenot, S. Verdun, J. Tomasina, B.
Hilselberger, M. Brulliard, L. Bonnard, M. Trarbach, V. Ogier, B. E. Bihain
Board 203
Prognostic markers in triple-negative breast cancer (TNBC): The role of
androgen receptor, e-cadherin, and Ki67. (Abstract 1089) G. R. Ricciardi, B.
Adamo, V. Barresi, A. Ieni, T. Franchina, M. Caruso, A. Zacchia, C. Fazzari, G.
Tuccari, V. Adamo
Board 204
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1
(PD-L1) expression in primary breast cancer (BC); correlations with clinical
characteristics and patient outcomes. (Abstract 1090) N. Vidula, C. Yau, A.
Goga, H. S. Rugo
Board 205
Reproducibility of homologous recombination deficiency (HRD) scores in
biopsies of triple negative breast cancer (TNBC) tumors. (Abstract 1091) K.
Timms, A. B. Chagpar, V. Wali, V. Bossuyt, J. E. Reid, A. Gutin, C. Neff, E. W.
Hofstatter, J. S. Lanchbury, L. Pusztai
Board 206
Outcomes with neoadjuvant versus adjuvant chemotherapy for T1–2 node
negative triple negative breast cancer. (Abstract 1092) P. Sharma, B. F. Kimler,
J. R. Klemp, C. Ward, C. S. Connor, M. McGinness, J. M. Mammen, J. L. Wagner,
A. L. Amin, C. J. Fabian, R. A. Jensen, A. K. Godwin, Q. J. Khan
Board 207
Transcriptomic and protein expression analysis of helicase antigen (HAGE)
in triple negative breast cancer (TNBC) as a novel prognostic and predictive
biomarker. (Abstract 1093) T. M. Abdel-Fatah, S. McArdle, D. Agarwal, P. M.
Moseley, A. R. Green, G. Ball, A. Pockley, I. O. Ellis, R. Rees, S. Y. Chan
Board 208
Association of tumor BRCA1 reversion mutation arising during neoadjuvant
platinum-based therapy in breast cancer (BC) with therapy resistance.
(Abstract 1094) A. Afghahi, K. Timms, S. Vinayak, K. C. Jensen, P. Chang, A.
Hartman, J. M. Ford, M. L. Telli
Board 209
Evaluation of local and distant recurrences pattern in patients with triple
negative breast cancer according to age. (Abstract 1095) J. C. Radosa, A.
Eaton, M. Stempel, A. Khander, C. Liedtke, E. Solomayer, M. Gunthner-Biller, M.
Morrow, T. A. King
Board 210
Effect of the anti-Warburg agent BPM 31510 on TAC therapy synergy and
survival in a xenograft model of triple-negative breast cancer (TNBC).
(Abstract 1096) N. R. Narain, A. R. Diers, A. Lee, R. Ouro-Djobo, M. Kiebish, V.
Vishnudas, J. J. Jimenez, R. Sarangarajan
Board 211
A 3-gene expression score as prognostic factor in triple negative and basal
breast tumors with residual disease. (Abstract 1097) J. A. Pinto, J. Araujo,
N. K. Cardenas, J. M. Balko, C. L. Arteaga, H. Gomez
68
Board 212
TOP2A-based prognostication in triple negative breast cancer and
correlation with basal phenotype. (Abstract 1098) B. C. Calhoun, C. Lanigan, B.
Rubin, K. C. Mrazeck, G. Rosa, M. Barnes, S. Dean, B. LaFleur
Board 213
Neratinib to inhibit the growth of triple-negative breast cancer cells. (Abstract
1099) M. Mullooly, D. Conklin, P. M. McGowan, N. A. O’Brien, N. O’Donovan, D. J.
Slamon, J. Crown, R. S. Finn, M. J. Duffy
Board 214a
Cardiac toxicity prevention in non-metastatic breast cancer patients treated
with anthracycline-based chemotherapy: A randomized, placebo controlled,
phase III trial—SAFE trial. (Abstract TPS1100) I. Meattini, R. Tarquini, C.
Saieva, A. Valoriani, P. Bonomo, I. Desideri, M. Loi, V. Scotti, C. De Luca Cardillo,
S. M. Magrini, G. Gensini, L. Livi
Board 214b
A randomized phase III trial comparing two dose-dense, dose-intensified
approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with
high-risk early breast cancer (GeparOcto). (Abstract TPS1101) A.
Schneeweiss, V. Moebus, J. Blohmer, S. D. Costa, C. Denkert, H. Eidtmann, C.
Hanusch, J. Hilfrich, J. B. Huober, C. Jackisch, S. Paepke, S. Kümmel, H. Tesch,
M. Untch, S. Loibl, G. Von Minckwitz
Board 215a
Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel
(P) with/without veliparib (ABT-888) in HER2–BRCA-associated locally
advanced or metastatic breast cancer (BC). (Abstract TPS1102) S. Puhalla,
H. S. Han, V. Diéras, M. Friedlander, G. Somlo, B. Arun, H. Wildiers, B. Kaufman,
J. M. Ayoub, M. Shan, D. Burmedi, Q. Qin, J. Qian, V. L. Giranda, S. P. Shepherd
Board 215b
POSNOC: Positive sentinel node—Adjuvant therapy alone versus adjuvant
therapy plus clearance or axillary radiotherapy: A randomised trial looking at
axillary treatment in early breast cancer (ISRCTN54765244). (Abstract
TPS1103) A. Goyal, R. E. Coleman, D. J. Dodwell, L. Fallowfield, V. A. Jenkins, B.
Mann, M. W. Reed, POSNOC Trialists Group
Board 216a
A phase 2 randomized, double-blind, placebo-controlled trial of hormone
therapy (HT) ⴞ radium-223 dichloride (Ra-223) in HER2- hormone receptorⴙ
breast cancer patients (pts) with bone metastases (mets). (Abstract TPS1104)
R. E. Coleman, L. Huang, O. Petrenciuc, P. Zaccarini
Board 216b
NRG BR002: A phase IIR/III trial of standard of care therapy with or without
stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly
oligometastatic breast cancer. (Abstract TPS1105) S. J. Chmura, K. A. Winter,
J. K. Salama, W. A. Woodward, V. F. Borges, H. A. Al-Hallaq, M. Matuszak, N. T.
Jaskowiak, M. T. Milano, H. Bandos, J. R. White
Board 217a
Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo)
vs gem/carbo as first-line treatment for metastatic triple-negative breast
cancer (mTNBC) in a phase 2/3 trial (tnAcity). (Abstract TPS1106) D. A.
Yardley, J. Cortes, R. E. Coleman, P. F. Conte, A. Brufsky, J. O’Shaughnessy,
G. L. Wright, J. F. Eakle, S. Wilks, M. Shtivelband, R. R. Young, C. Bengala, H. Li,
J. Miller, D. Barton, N. Harbeck
Board 217b
A phase 3, open-label, randomized, parallel, 2-arm international study of the
oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with
locally advanced and/or metastatic breast cancer (EMBRACA). (Abstract
TPS1107) J. K. Litton, J. L. Blum, Y. Im, M. Martin, L. A. Mina, H. H. Roche, H. S.
Rugo, F. Visco, C. Zhang, N. A. Lokker, D. L. Lounsbury, W. Eiermann
Board 218a
A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib
(BMN 673) in patients with germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO). (Abstract TPS1108) N. C. Turner,
J. Balmaña, P. A. Fasching, S. A. Hurvitz, M. L. Telli, F. Visco, A. M. Wardley, C.
Zhang, N. A. Lokker, D. L. Lounsbury, M. E. Robson
Board 218b
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in
patients with high-risk HER2-negative breast cancer (BC) and a germline
BRCA1/2 mutation (gBRCAm). (Abstract TPS1109) A. N. Tutt, B. Kaufman,
R. D. Gelber, E. Mc Fadden, C. D. Goessl, G. Viale, A. Arahmani, D. Fumagalli,
69
SATURDAY
H. A. Azim Jr., W. Wu, A. Grocholewicz, J. P. Costantino, P. Rastogi, J. E. Garber,
C. E. Geyer Jr.
SATURDAY
Board 219a
METRIC: A randomized international study of the antibody-drug conjugate
glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic
gpNMB-overexpressing triple-negative breast cancer (TNBC). (Abstract
TPS1110) D. A. Yardley, M. E. Melisko, A. Forero, B. R. Daniel, A. J. Montero,
T. H. Guthrie, V. A. Canfield, C. A. Oakman, H. K. Chew, C. Ferrario, G. H.
Volas-Redd, R. R. Young, N. L. Henry, L. Aneiro, Y. He, C. D. Turner, T. A. Davis,
L. T. Vahdat, The METRIC Study Group
Board 219b
LOTUS: A randomized, phase II, multicenter, placebo-controlled study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with
paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC). (Abstract TPS1111) S. Kim, A. R. Tan, S.
Im, R. Villanueva, V. Valero, C. Saura, M. Oliveira, S. J. Isakoff, S. M. Singel, R. A.
Dent
Board 220a
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor
ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as
neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).
(Abstract TPS1112) M. Oliveira, C. Saura, A. Gonzalez-Martin, J. C. Andersen,
J. G. Fisher, I. Calvo, E. Ciruelos, M. Gil, L. De La Pena, M. Llobet-Canela, Y. Choi,
S. Jia, S. Yalamanchili, S. M. Singel, P. H. Patel, J. Baselga, S. J. Isakoff
Board 220b
Women’s triple-negative, first-line treatment: Improving outcomes in triplenegative breast cancer (TNBC) using molecular triaging and diagnostic
imaging to guide neoadjuvant therapy (NACT). (Abstract TPS1113) S. L.
Moulder, N. T. Ueno, W. T. Yang, J. Ensor Jr., V. Valero, J. K. Litton, R. K. Murthy,
N. K. Ibrahim, B. Arun, E. A. Mittendorf, K. Hunt, F. Meric-Bernstam, A. M.
Thompson, H. Piwnica-Worms, D. Tripathy, W. F. Symmans
Developmental Therapeutics—Clinical Pharmacology and Experimental
Therapeutics
Location: S Hall A
Abstracts 2509 –2520 will be discussed during the Developmental Therapeutics—Clinical
Pharmacology and Experimental Therapeutics Poster Discussion Session. See page 89 for
session information.
Board 225
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291
combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung
cancer. (Abstract 2509) G. R. Oxnard, S. S. Ramalingam, M. Ahn, S. Kim, H. A.
Yu, H. Saka, L. Horn, K. Goto, Y. Ohe, M. Cantarini, P. Frewer, M. Lahn, J. C.
Yang
Board 226
ABT-414 in patients with advanced solid tumors likely to overexpress the
epidermal growth factor receptor (EGFR). (Abstract 2510) G. D. Goss, E. E.
Vokes, M. S. Gordon, L. Gandhi, K. P. Papadopoulos, D. W. Rasco, M. Pedersen,
J. S. Fischer, K. Chu, W. Ames, H. Xiong, H. Lee, J. Zeng, L. Roberts-Rapp, P.
Ansell, E. Reilly, K. D. Holen, A. W. Tolcher
Board 227
Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in
advanced solid tumors, including patients with brain metastases. (Abstract
2511) S. Deva, R. D. Baird, N. Cresti, J. Garcia-Corbacho, L. Hogarth, E. P.
Frenkel, K. Kawaguchi, A. Arimura, K. Donaldson, J. Posner, D. Sarker, D. I.
Jodrell, R. Plummer, J. F. Spicer
Board 228
Safety and tolerability of increasing doses of CB-839, a first-in-class, orally
administered small molecule inhibitor of glutaminase, in solid tumors.
(Abstract 2512) J. J. Harding, M. L. Telli, P. N. Munster, M. H. Le, C. Molineaux,
70
Board 229
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK),
and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult
patients (pt) with advanced solid tumors including grade III/IV glioblastoma
multiforme (GBM). (Abstract 2513) D. Roda, Y. Drew, A. Azaro, A. D. Smith, A.
Greystoke, E. Sicart, P. V. Escriba, X. Busquets, V. LLado, V. Tur, E. Klumper, J.
Rodon Ahnert, L. R. Molife, R. Plummer
Board 230
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in
patients with solid malignancies. (Abstract 2514) S. P. Blagden, I. Rizzuto, C.
Stavraka, D. O’Shea, P. Suppiah, M. Patel, A. Sukumaran, N. Loyse, N. Bharwani,
A. Rockall, H. Gabra, M. El-Bahrawy, H. Wasan, R. C. Leonard, N. A. Habib, J. G.
Gribben, E. A. Ghazaly, C. McGuigan
Board 231
TP53 mutations emerge in circulating cell-free DNA obtained from patients
undergoing treatment with the HDM2 antagonist SAR405838. (Abstract 2515)
J. W. Watters, M. A. Dickson, G. K. Schwartz, A. Le Cesne, R. Bahleda, A. J.
Wagner, E. Choy, M. J. De Jonge, M. Light, J. Jung, J. Lee, S. Mace
Board 232
Genomic mutation profiling (GMP) and clinical outcome of patients treated
with buparlisib (PI3K inhibitor) in the “Signature” program. (Abstract 2516)
S. A. Piha-Paul, J. A. Knost, F. S. Braiteh, J. T. Beck, D. L. Spitz, S. W. Papish,
B. A. Hellerstedt, P. Nikolinakos, M. H. Taylor, S. P. Chawla, L. S. Schwartzberg,
D. A. Smith, S. Szpakowski, L. Zhang, T. White, C. Lebedinsky
Board 233
Alka-372– 001: First-in-human, phase I study of entrectinib – an oral pan-trk,
ROS1, and ALK inhibitor – in patients with advanced solid tumors with
relevant molecular alterations. (Abstract 2517) F. G. De Braud, M. Niger, S.
Damian, B. Bardazza, A. Martinetti, G. Pelosi, G. Marrapese, L. Palmeri, G. Cerea,
E. Valtorta, S. Veronese, A. Sartore-Bianchi, E. Ardini, A. Isachi, M. Martignoni, A.
Galvani, D. Luo, L. Yeh, A. M. Senderowicz, S. Siena
Board 234
First-in-human, phase I study assessing imalumab (Bax69), a first-in-class
anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in
advanced solid tumors. (Abstract 2518) D. Mahalingam, M. R. Patel, J. C.
Sachdev, L. L. Hart, N. Halama, R. K. Ramanathan, J. Sarantopoulos, X. Liu, S.
Yazji, D. Jaeger, D. R. Adib, R. Kerschbaumer, A. M. Tsimberidou
Board 235
First-in-human phase I administration of YS110, a monoclonal antibody
directed against the CD26 immunostimulatory molecule in advanced cancer
patients. (Abstract 2519) E. Angevin, N. Isambert, V. N. Trillet-Lenoir, B. You, J.
Alexandre, G. Zalcman, P. Viehl, F. Farace, F. Valleix, T. Podoll, Y. Kuramochi, I.
Miyashita, O. Hosono, N. H. Dang, K. Ohnuma, T. Yamada, Y. Kaneko, C.
Morimoto
Board 236
First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC
in patients with advanced solid tumors. (Abstract 2520) D. S. Hong, I. GarridoLaguna, I. E. Krop, V. Subbiah, T. L. Werner, C. M. Cotter, E. P. Hamilton, K.
Velastegui, D. Xuan, R. Bugarini, A. Gollerkeri, H. A. Burris III
Board 237
Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb)
recognizing endosialin in Japanese patients (pts) with hepatocellular
carcinoma (HCC). (Abstract 2521) M. Ikeda, T. Aramaki, Y. Inaba, K. Nakai, T.
Doi, T. Okusaka
Board 238
Phase I trial and pharmacokinetic study of Tanibirumab, a fully human
monoclonal antibody to the vascular endothelial growth factor receptor 2 in
patients with refractory solid tumors. (Abstract 2522) S. Lee, J. Ham, H. Kim,
S. Byeon, W. Lee, J. Yoo, J. M. Sun, J. Lee, S. Park, J. Park, M. Ahn, H. Lim, W.
Kang, Y. Park
Board 239
Molecular characteristics in breast cancer tumors treated with neoadjuvant
chemotherapy with and without bevacizumab: Results from NeoAva—
Randomized phase II study. (Abstract 2523) O. Engebraaten, L. Silwal-Pandit,
E. K. Moller, S. Nord, M. Krohn, H. M. Vollan, H. v. Gythfeldt, E. Borgen, O. Garred,
71
SATURDAY
M. K. Bennett, E. Mittra, H. A. Burris III, A. S. Clark, M. Dunphy, F. Meric-Bernstam,
M. R. Patel, A. DeMichele, J. R. Infante
A. Fangberget, M. M. Holmen, S. Lundgren, E. A. Wist, O. C. Lingjaerde, B.
Naume, A. Borresen-Dale
SATURDAY
Board 240
Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension
for finding biomarkers of efficacy. (Abstract 2524) J. de la Haba-Rodriguez, S.
Morales, A. Guerrero, N. Martinez, A. Martinez Peinado, A. Anton, M. MunozMateu, J. Garcia Saenz, M. Ramos Vazquez, M. J. Gil Gil, M. Margeli, S. Servitja,
B. Bermejo, J. C. Jurado, E. Aranda, M. Casas, C. Rodrı́guez-Martı́n, E. M.
Carrasco, R. Caballero, M. Martin, GEICAM Spanish Breast Cancer Group
Board 241
A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in
patients with advanced solid tumors. (Abstract 2525) S. Sharma, Y. Kang, J. R.
Weis, G. W. Gilcrease, C. Davidson, R. Kingsford, J. Collett, N. Orgain, M. Ryu, B.
Ryoo, S. Park, H. Yoo, S. Kim
Board 242
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in
advanced solid tumors. (Abstract 2526) E. J. Kim, T. J. Semrad, D. R. Gandara,
J. Riess, T. Li, A. Yu, K. Matsukuma, P. C. Mack, K. Kelly
Board 243
First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor
G1T28. (Abstract 2527) R. G. Tiessen, P. J. Roberts, J. A. Sorrentino, H. S. White,
K. M. Makhuli, J. E. Bisi, J. C. Strum, E. Hoogdalem, R. K. Malik
Board 244
Overcoming the proliferation rate paradox: Clinical evaluation of a
continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205. (Abstract
2528) K. B. Mross, D. Scharr, H. Richly, S. Bauer, B. Krauss, R. Krauss, B. Hauns,
T. Prenzel, H. Kohlhof, R. Baumgartner, M. E. Scheulen
Board 245
Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in
clinical development to reduce chemotherapy-induced myelosuppression.
(Abstract 2529) P. J. Roberts, H. S. White, J. A. Sorrentino, H. Tadema, M. Sale,
R. G. Tiessen, J. E. Bisi, K. M. Makhuli, E. Hoogdalem, R. K. Malik, J. C. Strum
Board 246
SLC1A5 to predict outcome with chemotherapy in early triple-negative breast
cancer. (Abstract 2530) A. Affan, V. Varadan, H. L. Gilmore, K. Miskimen, Y.
Jeon, S. Parsai, Z. Ronai, L. Harris
Board 247
Phase I dose-escalation study with extended daily administration of
Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with
solid tumors. (Abstract 2531) H. C. Pitot, H. Hurwitz, C. Zanna, J. M. Brill, G.
Vuagniaux, E. Rouits, J. M. Sorensen, D. C. Smith
Board 248
First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in
patients with advanced solid tumors. (Abstract 2532) N. Matsubara, K. Shitara,
Y. Naito, Y. Kuboki, I. Ohno, H. Takahashi, H. Bando, T. Kojima, N. Fuse, T.
Yamazaki, N. Hirayama, H. Fujita, T. Nishida, T. Doi
Board 249
First-in-human study of LY3039478, a Notch signaling inhibitor in advanced
or metastatic cancer. (Abstract 2533) C. Massard, A. Azaro, C. Le Tourneau, J.
Soria, M. Alt, C. Smith, U. Ohnmacht, G. Oakeley III, B. Patel, E. Yuen, K. A.
Benhadji, J. Rodon Ahnert
Board 250
Trends in the characteristics, dose-limiting toxicities and efficacy of phase I
oncology trials: The Cancer Research UK experience. (Abstract 2534) H. H.
Wong, C. Barton, G. Acton, R. McLeod, R. Darby-Dowman, J. McQuillan, H.
Turner, S. Wan, Z. Backholer, J. Peters, S. E. Halford
Board 251
A phase I study of intravenous artesunate (IV AS) in patients with solid
tumors. (Abstract 2535) J. F. Deeken, H. Wang, B. G. Smaglo, J. J. Hwang, A. R.
He, L. M. Weiner, J. Marshall, G. Giaccone, S. V. Liu, J. Luecht, C. Urso, J. Y.
Spiegel, A. Cheema, M. J. Pishvaian
Board 252
Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts)
with advanced solid tumors. (Abstract 2536) A. Gazzah, V. Boni, J. Soria, E.
Holgado, C. Even, M. Ould Kaci, S. Nazabadioko, W. Xue, E. Calvo
Board 253
Phase I trial of the HSP-90 inhibitor PU-H71. (Abstract 2537) J. F. Gerecitano,
S. Modi, R. Rampal, A. E. Drilon, M. G. Fury, M. M. Gounder, J. J. Harding, D. M.
Hyman, A. M. Varghese, M. H. Voss, F. O. France, T. Taldone, E. Gomes
72
Board 254
Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with
hepatic impairment (HI). (Abstract 2538) J. Sarantopoulos, A. C. Mita, A. R. He,
J. L. Wade III, C. Hsueh, J. C. Morris, A. C. Lockhart, D. Quinn, J. J. Hwang, J. W.
Mier, W. Zhang, C. Wack, J. Yin, P. Clot, O. Rixe
Board 255
Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid
tumors (ST): Use of multiomics platform to evaluate reversal of Warburg
effect. (Abstract 2539) R. Zinner, P. P. Yu, N. R. Narain, R. Sarangarajan, M.
Kiebish, V. Vishnudas, Y. Sun, L. Rodrigues, V. R. Akmaev, S. Brouwer, J.
Stevens, E. Benaim, M. A. Shah
Board 256
Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347
(CH5183284), a novel FGFR inhibitor. (Abstract 2540) C. Zanna, A. Vaslin,
M. H. Voss, R. S. Heist, C. Hierro, J. G. Supko, K. Nakai, N. Ishii, A. Menetrey, M.
Roubaudi-Fraschini, J. Cordier, J. Douchain, V. Nicolas-Metral
Board 257
A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in
patients with advanced or metastatic solid tumors. (Abstract 2541) A. Zer, R.
Verheijen, F. Y. De Vos, S. Hotte, F. Eskens, L. Pronk, L. L. Siu, D. Schnell, N.
Steeghs, M. H. Langenberg, H. Hirte, M. J. De Jonge
Board 258
Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor
Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
(Abstract 2542) D. S. Tan, M. Pang, W. Yong, R. A. Soo, C. E. Chee, Y. Thian, A.
Gopinathan, A. L. Wong, P. Koe, R. Sundar, J. Ho, S. Friedlander, Y. Landesman,
T. Rashal, D. McCauley, S. Shacham, S. Lee, B. C. Goh
Board 259
Predicting outcomes in patients with advanced malignancies treated on
Phase 1 clinical trials. (Abstract 2543) K. Wong, D. Gao, H. McCoy, A. Brock,
R. W. Powell, C. L. O’Bryant, D. R. Camidge, L. Gore, A. Jimeno, J. R. Diamond,
W. A. Messersmith, S. G. Eckhardt, S. Leong
Board 260
First-in-man combination phase I study of TAS-114 and S-1 in patients (pts)
with advanced solid tumors. (Abstract 2544) T. Doi, K. Yoh, K. Shitara, H.
Takahashi, M. Ueno, S. Kobayashi, M. Morimoto, S. Ohkawa, T. Okusaka, H.
Ueno, C. Morizane, S. Shiba, N. Okano, D. Naruge, F. Nagashima, J. Furuse, K.
Koba, K. Noguchi
Board 261
Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth
Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid
tumors. (Abstract 2545) K. P. Papadopoulos, A. W. Tolcher, A. Patnaik, D. W.
Rasco, G. Chambers, M. Beeram, R. Savage, T. Hall, B. E. Schwartz, J. Kazakin,
P. LoRusso
Board 262
Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials
of the National Institutes of Health Cancer Therapy Evaluation Program
(CTEP). (Abstract 2546) A. E. Drilon, A. Eaton, K. Schindler, M. M. Gounder, G. L.
Smith, D. Vulih, P. J. Harris, D. R. Spriggs, P. Ivy, A. Iasonos, M. E. Lacouture,
D. M. Hyman
Board 263
A first in human Phase I/II study of NUC-1031 in patients with advanced
gynecological cancers. (Abstract 2547) S. P. Blagden, I. Rizzuto, C. Stavraka,
D. O’Shea, P. Suppiah, M. Patel, N. Loyse, A. Sukumaran, N. Bharwani, A.
Rockall, H. Gabra, M. El-Bahrawy, H. S. Wasan, R. C. Leonard, N. A. Habib, C.
McGuigan, J. G. Gribben, E. A. Ghazaly
Board 264
Biomarker analysis from a Phase I study of copanlisib with expansion
cohorts in solid tumors with and without PIK3CA mutations and NHL.
(Abstract 2548) C. E. Pena, M. Jeffers, I. Genvresse, L. J. Appleman, R. K.
Ramanathan, A. Patnaik
Board 265
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as
first-line treatment in patients with advanced nonsquamous non small cell
lung cancer or malignant pleural mesothelioma. (Abstract 2549) P. A. Zucali,
M. Simonelli, F. De Vincenzo, G. Fatuzzo, M. Bertossi, M. Perrino, C. Miggiano, L.
Giordano, C. Bonifacio, F. Mrakic Sposta, A. Santoro
73
SATURDAY
DaGama, M. Uddin, G. Chiosis, J. S. Lewis, S. K. Lyashchenko, S. M. Larson, C.
Pressl, M. Dunphy
SATURDAY
Board 266
SORAVE: A phase I trial to evaluate safety and efficacy of combination
therapy with everolimus and sorafenib. (Abstract 2550) C. Mattonet, L.
Nogova, M. Scheffler, S. Y. Michels, D. Kahraman, C. Kobe, U. Fuhr, A. A.
Suleiman, Y. Tian, F. Soergel, K. Toepelt, R. Schnell, M. Schlaak, K. Rhiem, R.
Buettner, J. Wolf
Board 267
Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small
molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced
cancers (CA). (Abstract 2551) D. Matei, M. J. Edelman, J. C. Sachdev, P. Klein,
S. Rao, S. Burgess, R. Clark, R. K. Ramanathan, E. A. Morris, W. A. Harb
Board 268
ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as
complementary approaches to response assessment. (Abstract 2552) S. E.
Bates, M. L. Lindenberg, C. Bryla, M. E. Burotto Pichun, N. Patronas, L. AmiriKordestani, E. M. Gonzalez, T. Fojo, S. Balasubramaniam, P. L. Choyke
Board 269
Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in
patients with advanced malignancies primarily confined to the peritoneal
cavity. (Abstract 2553) M. C. Cristea, T. W. Synold, P. H. Frankel, S. E. Rivkin, D.
Lim, V. M. Chung, J. Chao, M. T. Wakabayashi, I. B. Paz, E. S. Han, P. Lin, L. A.
Leong, A. Hakim, M. I. Carroll, H. Openshaw, N. Prakash, T. H. Dellinger, M. S.
Park, R. Morgan
Board 270
A phase I study of ARQ 197 in combination with temsirolimus in advanced
solid tumors. (Abstract 2554) C. Kyriakopoulos, J. Kolesar, J. C. Eickhoff,
J. Heideman, G. Liu, K. B. Wisinski
Board 271
First-in-human phase I study of the DNA repair inhibitor DT01 in combination
with radiotherapy in patients with in transit melanoma. (Abstract 2555) C. Le
Tourneau, B. Dreno, Y. Kirova, J. Grob, T. Jouary, C. Dutriaux, L. Thomas, C.
Lebbe, L. Mortier, P. Saiag, M. Avril, E. Maubec, P. Bey, J. Cosset, J. Sun, B.
Asselain, F. Devun, M. E. Marty, M. Dutreix
Board 272
Rationale for the combination of veliparib with platinum-based
chemotherapy. (Abstract 2556) D. Maag, L. Solomon, T. Hopkins, G. Bukhofzer,
Y. Shi, C. Donawho, G. Zhu, L. E. Rodriguez, T. Penning, E. DiGiammarino, S. C.
Panchal, E. F. Johnson
Board 273
Genomic landscape of DNA repair genes in cancer: Mutation and copy
number variation (CNV) frequencies. (Abstract 2557) J. Anker, Y. Chae
Board 274
Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in
patients with advanced solid tumors. (Abstract 2558) J. R. Eads, S. S.
Krishnamurthi, J. N. Saltzman, N. J. Meropol, J. A. Bokar, J. Gibbons, H. B. Koon,
N. Sharma, P. Savvides, J. Pink, Y. Xu, J. H. Beumer, P. Fu, K. Beatty, D. Kane, M.
Rodal, J. Czalkiewicz, J. Riendeau, S. L. Gerson, A. Dowlati
Board 275
Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA
damage induced by chemotherapeutic agents and irradiation exposure.
(Abstract 2559) J. J. Ji, Y. Zhang, C. E. Redon, A. Chen, S. Holbeck, M. G.
Hollingshead, R. E. Parchment, Y. Pommier, J. E. Tomaszewski, J. H. Doroshow,
W. Bonner
Board 276
A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in
patients (pts) with metastatic solid tumors. (Abstract 2560) R. R. Aggarwal,
J. A. Grabowsky, A. Reinert, S. Thomas, T. Truong, C. Chun, P. N. Munster
Board 277
Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients
with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
(Abstract 2561) M. Zhu, A. Kratzer, J. Johnson, C. Holland, C. Brandl, I. Singh, A.
Wolf, S. Doshi
Board 278
Pharmacogenetic variants associated with differential sirolimus clearance in
pediatric patients. (Abstract 2562) J. Wright, R. Karns, T. Mizuno, M. Basu, B. D.
Weiss, D. Adams, A. Vinks, B. Aronow, J. P. Perentesis
Board 279
Mass balance study of TAS-102 using 14C labeling analyzed by accelerator
mass spectrometry. (Abstract 2563) J. J. Lee, J. Seraj, K. Yoshida, M. Narurkar,
74
Board 280
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in
patients with advanced solid tumors (NCT01673737). (Abstract 2564) P. L.
Bedard, M. A. Davies, S. Kopetz, K. T. Flaherty, G. Shapiro, J. J. Luke, A.
Spreafico, B. Wu, C. Gomez, S. Cartot-Cotton, F. Mazuir, S. Micallef, B. Demers,
D. Juric
Board 281
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet
formulation in patients with advanced solid tumours: Phase I open-label
studies. (Abstract 2565) E. R. Plummer, H. M. Verheul, S. Rottey, K. Leunen,
G. H. Jerusalem, C. D. Rolfo, D. L. Nielsen, L. R. Molife, R. Kristeleit, J. d. VosGeelen, M. Mau-Sørensen, P. M. Soetekouw, C. van Herpen, H. Swaisland, A.
Fielding, K. So, W. Bannister, L. Dirix
Board 282
A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients
with advanced cancers. (Abstract 2566) D. Papadatos-Pastos, R. Kumar, T. A.
Yap, R. Ruddle, S. Decordova, P. Jones, G. Halbert, M. D. Garrett, R. McLeod, Z.
Backholer, K. E. Swales, F. I. Raynaud, J. S. De Bono, U. Banerji
Board 283
Patterns of hepatic impairment in phase I clinical trials. (Abstract 2567) A. S.
Mansfield, D. Vulih, G. L. Smith, P. J. Harris, S. P. Ivy
Board 284
Predictive PK/PD models for hematological toxicities to inform MTD
determination and regimen selection for ADCs. (Abstract 2568) S. Palani, J. C.
Masters, X. Meng, D. Xuan
Board 285
Regulatory considerations for clinical pharmacology during development of
antibody-drug conjugates. (Abstract 2569) S. S. Shord, S. J. Schrieber, H.
Zhao, B. Booth, N. A. Rahman
Board 286
A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics
and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients
with solid tumors. (Abstract 2570) U. N. Lassen, D. S. Hong, N. Diamantis, V.
Subbiah, R. Kumar, M. Sorensen, S. Lisby, R. L. Coleman, J. S. De Bono
Board 287
Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome
in breast cancer patients (pts) receiving capecitabine. (Abstract 2571) M.
Etienne-Grimaldi, J. Boyer, L. Llorca, G. Romieu, T. D. Bachelot, V. Dieras, J.
Merlin, F. Pinguet, F. Thomas, C. Ferrand, C. Bobin-Dubigeon, X. B. Pivot, R.
Largillier, M. Mousseau, A. Goncalves, H. H. Roche, J. Ciccolini, J. Ferrero, G. A.
Milano, GPCO-Unicancer group
Board 288
Identification of candidates for sorafenib dose-escalation using sorafenib
plasmatic concentration monitoring: Proof of concept. (Abstract 2572) J.
Arrondeau, B. Blanchet, A. Thomas-Schoemann, O. Huillard, P.
Boudou-Rouquette, J. Giroux, A. Cessot, C. Tlemsani, R. Coriat, J. Alexandre, M.
Vidal, F. Goldwasser
Board 289
Population pharmacokinetics and dosing implications for cobimetinib in
patients with solid tumors. (Abstract 2573) K. Han, J. Jin, M. Marchand, S.
Eppler, N. W. Choong, S. P. Hack, M. A. Sovak, N. Tikoo, R. Bruno, M. J. Dresser,
L. Musib, N. R. Budha
Board 290
Recommendations in a new drug application review for dose optimization to
potentially improve gastrointestinal tolerability of a tyrosine kinase inhibitor.
(Abstract 2574) R. Leong, P. Song, Q. Liu, H. Zhao, G. M. Blumenthal, S. Khozin,
Y. Pan, P. Zhao, P. Keegan, B. Booth, N. A. Rahman
Board 291
When investigating predictive biomarkers, beware of the qualitative
interaction. (Abstract 2575) H. M. Mackey, T. Bengtsson
Board 292
Carboplatin dosing based on estimated Glomerular Filtration Rate (GFR)
using IDMS creatinine: A comparison of estimated GFR based on IDMS
creatinine in the Cockroft-Gault (CG) formula (IDMS-GFR), with measured
GFR using 51Cr-EDTA (51Cr-GFR). (Abstract 2576) J. R. Whittle, J. W. Graham,
H. Ismail, M. Lichtenstein, R. J. Hicks, O. McNally, L. R. Mileshkin, D. Zannino, M.
Rosenthal, D. Rischin, A. L. Hamilton
75
SATURDAY
H. Mizuguchi, S. Strychor, J. Fiejdasz, T. Faulkner, L. Pollice, S. Mason, W. Sun,
E. Chu, M. Croft, J. Nguteren, C. Tedder, J. H. Beumer
SATURDAY
Board 293
Results of OAK: A phase 1, open-label, multicentre study to compare two
dosage forms of AZD5363 and to explore the effect of food on the
pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in
patients with advanced solid malignancies. (Abstract 2577) E. J. Dean, U.
Banerji, J. H. Schellens, M. Krebs, B. Jimenez, R. van der Noll, A. Foxley, J. W.
Yates, N. Taylor, S. Evans, T. Guy, E. Casson, P. Rugman, S. Salim, J. P.
Lindemann, P. Lawrence
Board 294
Exposure-response (E-R) and case-control analyses of ramucirumab leading
to recommendation for dosing optimization in patients with gastric cancer.
(Abstract 2578) R. Jin, H. Li, L. H. Zhang, H. Zhao, L. Fashoyin-Aje, S. Lemery, P.
Keegan, B. Booth, N. A. Rahman, Y. Wang, V. Sinha, L. Zhao
Board 295
Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with
metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the
phase 3 RECOURSE trial. (Abstract 2579) J. M. Cleary, R. J. Mayer, E. Van
Cutsem, F. Yamashita, K. Yoshisue, I. Ieiri, A. Ohtsu, H. Lenz
Board 296
A phase I, first-in-human study of argx-111, a monoclonal antibody targeting
c-met in patients with solid tumors. (Abstract 2580) P. G. Aftimos, P.
Barthelemy, C. D. Rolfo, V. Hanssens, N. De Jonge, K. Silence, T. Dreier, H. de
Haard, M. Peeters, A. Thibault, A. Awada
Board 297
Comparison of adult oncology phase 1 trials to pediatric oncology phase 1
trials of targeted therapies. (Abstract 2581) V. Subbiah, J. D. Kawedia, A.
Christensen, K. R. Hess, K. Patel, E. Wood, R. D. Bitar, N. C. Daw
Board 298
The association of relative survival benefit and approval of oncological
drugs: An analysis of oncology drug advisory committee reviews. (Abstract
2582) I. U. Amanam, A. B. Gardner, S. L. James, D. S. Kapp, J. K. Chan
Board 299
A phase I dose escalation study of the tolerability of the oral VEGFR and
EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor
selumetinib (S) in solid tumors. (Abstract 2583) W. O. Saka, S. Pacey, F. H.
Blackhall, J. Garcia-Corbacho, A. Fusi, I. Karydis, M. Hategan, G. Laviste, S. E.
Halford, C. Foxton, R. McLeod, S. Wan, D. C. Talbot
Board 300
Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor
vorinostat in patients with advanced malignancies. (Abstract 2584) H. Park, I.
Garrido-Laguna, A. Naing, S. Fu, G. S. Falchook, S. A. Piha-Paul, J. J. Wheler,
D. S. Hong, V. Subbiah, A. M. Tsimberidou, A. O. Kaseb, Y. Oki, R. Zinner, S.
Patel, V. M. Velez Bravo, M. A. Fanale, F. Meric-Bernstam, R. Kurzrock, F. Janku
Board 301
Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel
antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced
solid tumors. (Abstract 2585) L. Vidal Boixader, L. Gaba, I. Victoria, M. Brunet, P.
Paredes, E. Buxo, T. Vilella, G. Riu, M. Cortal, M. Gomez-Ferreria, J. Alfon, C.
Domenech, P. Gascon
Board 302
Phase I study of pemetrexed and sorafenib in advanced solid tumors.
(Abstract 2586) A. S. Poklepovic, D. A. Shafer, J. D. Roberts, C. E. Geyer Jr., P.
Dent, R. Moran, M. Tombes, E. Shrader, K. Strickler, W. Wan
Board 303
Phase I study of INC280 plus erlotinib in patients with MET expressing
adenocarcinoma of the lung. (Abstract 2587) C. E. McCoach, A. Yu, D. R.
Gandara, J. Riess, T. Li, P. Lara Jr., P. C. Mack, L. Beckett, E. D. Slosberg, K.
Kelly
Board 304
Phase I combination of pazopanib and everolimus in PIK3CA mutation
positive/PTEN loss patients with advanced solid tumors refractory to
standard therapy. (Abstract 2588) H. V. Rodrigues, J. Lim, B. Stephen, F. Janku,
A. M. Tsimberidou, S. A. Piha-Paul, S. Fu, A. Naing, V. Subbiah, G. S. Falchook,
R. Kurzrock, J. J. Wheler
Board 305
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in
patients (pts) with advanced solid tumors. (Abstract 2589) C. K.
Kollmannsberger, S. Sharma, G. Shapiro, K. N. Chi, J. Christensen, V. R. Tassell,
R. C. Chao, D. Faltaos, H. Hurwitz
76
Board 306
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with
other antitumor agents. (Abstract 2590) Z. A. Wainberg, G. Shapiro, G.
Curigliano, S. Leong, R. S. Kristeleit, M. Alsina Maqueda, C. D. Britten, M. Milella,
M. R. Middleton, A. J. Olszanski, U. N. Vaishampayan, J. A. Lopez-Martin, K. A.
Gelmon, N. Brega, K. J. Pierce, R. Perea, B. E. Houk, N. Pathan, A. Gollerkeri,
A. R. Razak
Board 307
Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of
the oral selective c-Met inhibitor tepotinib (MSC2156119J). (Abstract 2591)
G. S. Falchook, R. Kurzrock, H. M. Amin, S. Fu, S. A. Piha-Paul, F. Janku, H.
Zheng, B. Sarholz, A. Johne, D. S. Hong
Board 308
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual
PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors:
Final DE results. (Abstract 2592) R. S. Kristeleit, N. F. Brown, D. Hess, M.
Joerger, R. Von Moos, J. Rodón, C. Hierro, A. Childs, A. Stathis, S. Dimitrijevic, M.
Stumm, R. Herrmann, C. Sessa, V. Bize, V. Hess, A. Wicki
Board 309
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib
(MEKi) in patients with selected advanced solid tumors. (Abstract 2593) H.
Arkenau, A. Gazzah, R. Plummer, S. P. Blagden, G. Mak, J. Soria, A. Greystoke, I.
Rizzuto, D. Rogan, J. Mazumdar, K. Laubscher, K. R. Auger, L. S. Swartz, M. L.
Mattern, N. Nebot, R. P. Singh, R. A. Fleming, L. Yan
Board 310
NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus
(T) in advanced rare cancers. (Abstract 2594) J. Dancey, M. K. Krzyzanowska,
D. M. Provencher, W. Y. Cheung, R. J. Macfarlane, T. Alcindor, P. Ghatage, A. A.
Gupta, S. A. Laurie, M. B. Sawyer, S. Welch, M. Salim, S. Ellard, D. A. Wall, M. S.
Tsao, J. Sederias, H. Xu, T. O. Nielsen, S. L. Asa, H. W. Hirte
Board 311
Activity of crizotinib in relapsed MET amplified malignancies: Results of the
French AcSé Program. (Abstract 2595) G. Vassal, M. Ledeley, C. Tournigand, T.
Aparicio, I. Ray-Coquard, L. Taillandier, B. Escudier, B. You, A. Goncalves, C.
Lombard Bohas, J. Seitz, T. Andre, J. Merlio, L. Arnould, G. Ferretti, Y. Menu, T.
Mortier, E. Lonchamp, C. Mahier - Ait Oukhatar, D. Moro-Sibilot
Board 312
STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK
inhibitor, in patients with advanced solid tumors with relevant molecular
alterations. (Abstract 2596) M. R. Patel, T. M. Bauer, S. V. Liu, A. E. Drilon, J. J.
Wheler, A. T. Shaw, A. F. Farago, S. I. Ou, D. Luo, L. Yeh, Z. Hornby, A. M.
Senderowicz, J. Lim
Board 313
Phase I study of combination of crizotinib (C) and dasatinib (D) in patients
(pts) with advanced cancer. (Abstract 2597) S. Kato, D. L. Fontes Jardim, F. M.
Johnson, V. Subbiah, S. A. Piha-Paul, A. M. Tsimberidou, G. S. Falchook, D. D.
Karp, J. J. Wheler, R. Zinner, F. Janku, S. Fu, L. Dandu, E. Browne, F. MericBernstam, D. S. Hong
Board 314
A phase 1, open-label study to evaluate the safety and pharmacokinetics of
the anti ErbB3 antibody, KTN3379, alone or in combination with targeted
therapies in patients with advanced tumors. (Abstract 2598) T. M. Bauer, J. R.
Infante, J. P. Eder, P. LoRusso, T. LaVallee, R. Gedrich, C. Sidor, G. S. Falchook
Board 315
Phase I study of temsirolimus in combination with cetuximab in patients with
advanced solid tumors. (Abstract 2599) A. Hollebecque, R. Bahleda, J. Thery, L.
Faivre, M. Le Deley, A. Paci, A. Varga, A. Gazzah, C. Massard, V. Poinsignon, K.
Malekzadeh, V. Ribrag, E. Angevin, S. Postel-Vinay, C. A. Gomez-Roca, M.
Gharib, F. Dufour, J. Soria, J. Spano
Board 316
A phase I study of temsirolimus plus erlotinib in patients with refractory solid
tumors. (Abstract 2600) A. Wang-Gillam, B. R. Tan Jr., S. N. Waqar, R. Suresh,
D. Morgensztern, B. A. Van Tine, R. Nieman, R. Govindan, A. C. Lockhart
Board 317a
Pharmacodynamic study using FLT PET/CT in advanced solid malignancies
treated with a sequential combination of X-82 and docetaxel. (Abstract
TPS2601) M. M. Rampurwala, L. Carmichael, J. C. Eickhoff, J. Kolesar, K. Binger,
J. Heideman, S. Perlman, C. Liang, R. Jeraj, G. Liu, J. Y. Bruce
77
SATURDAY
SATURDAY
Board 317b
A phase I study of a novel inhibitor of protein phosphatase 2A alone and with
docetaxel. (Abstract TPS2602) A. S. Mansfield, V. M. Chung, J. S. Kovach
Board 318a
First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in
patients with advanced solid tumors. (Abstract TPS2603) G. Shapiro, P.
LoRusso, U. N. Vaishampayan, M. Kittaneh, J. F. Hilton, J. M. Cleary, K.
Velastegui, D. Xuan, S. Hua, R. L. Shazer, H. Borghaei
Board 318b
A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in
selected advanced solid tumors. (Abstract TPS2604) M. Provencio Pulla, J.
Tabernero, V. Moreno, J. Trigo Perez, R. Lopez, R. Kristeleit, A. Awada, A. Leary,
J. Alexandre, J. Delord, S. Ferrari, A. Santoro, E. Bajetta, V. Subbiah, S. Weitman,
V. M. Villalobos, E. Raymond, A. Sundlov, P. Lardelli, S. P. Chawla
Board 319a
A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase
2, to treat subjects with advanced solid tumors. (Abstract TPS2605) D. W.
Rasco, A. Patnaik, A. W. Tolcher, K. P. Papadopoulos, C. Peterson, E. Benaim
Board 319b
A phase I, dose-escalation, multi-center study of PFK-158 in patients with
advanced solid malignancies explores a first-in-man inhbibitor of glycolysis.
(Abstract TPS2606) R. A. Redman, P. R. Pohlmann, M. R. Kurman, G. Tapolsky,
J. A. Chesney
Board 320a
Phase I study of procaspase activating compound-1 (PAC-1) in the treatment
of advanced malignancies. (Abstract TPS2607) O. C. Danciu, M. K. Nicholas, R.
Emmadi, H. Xie, P. J. Hergenrother, T. M. Tarasow, A. Z. Dudek
Board 320b
A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to
treat subjects with advanced solid tumors. (Abstract TPS2608) S. G. Eckhardt,
W. L. Gluck, M. Gutierrez, C. Peterson, E. Benaim
Board 321a
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus
investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase
inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced
solid tumors. (Abstract TPS2609) A. J. Olszanski, M. R. Middleton, R. Bahleda,
R. S. Heist, L. Rangachari, X. Zhou, V. Bozón, M. Kneissl, T. Macarulla
Board 321b
STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib
(MLN8237) given in combination with selective VEGFR inhibitor pazopanib
for therapy of solid tumors. (Abstract TPS2610) A. Z. Dudek, I. Unal, H. Xie,
L. E. Feldman, N. K. Venepalli, O. C. Danciu
Board 322a
A randomized Phase 2a study to assess pharmacodynamics, antitumor
activity and safety of intravenous BAL101553, a novel microtubule inhibitor,
at two dose levels in adult patients with selected advanced solid tumors.
(Abstract TPS2611) R. S. Kristeleit, A. D. Smith, N. R. Haris, I. H. Zubairi, J. W.
King, M. de Miguel Luken, M. D’Arcangelo, J. MacDonald, N. F. Brown, A. H.
Calvert, A. L. Hannah, S. Anderson, F. Bachmann, M. Maurer, A.
Schmitt-Hoffmann, H. A. Lane, M. F. Engelhardt, T. Evans, R. Plummer, L. R.
Molife
Board 322b
Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin
(TRAP) in patients with ASS1-deficient mesothelioma and non-squamous
lung cancer. (Abstract TPS2612) P. W. Szlosarek, J. F. Spicer, T. Szyszko, G. J.
Cook, P. Chan, M. Hategan, D. Repana, J. P. Steele, P. Schmid, M. Diaz, A.
Johnston, M. Sheaff, R. Khadeir, J. S. Bomalaski, S. Pacey
Board 323a
A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic
study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients
with advanced solid tumors. (Abstract TPS2613) G. Shapiro, J. W. Mier, J. F.
Hilton, L. Gandhi, N. G. Chau, A. J. Bullock, J. G. Supko, S. J. Verselis, K. Murgo,
C. Sze, S. Gotthardt, A. Wolanski, W. J. Alexander, A. Kumar, S. A. Holden, K.
Chafai-Fadela, S. Ram, K. E. Menon
Board 323b
Phase I trial of the combination of bortezomib and clofarabine in adults with
refractory solid tumors. (Abstract TPS2614) G. H. O’Sullivan Coyne, S.
Kummar, K. T. Do, S. Holbeck, M. G. Hollingshead, Y. Horneffer, L. Juwara, A. K.
Srivastava, L. Rubinstein, R. Piekarz, E. Sharon, H. Streicher, B. A. Conley, R.
Antony, J. M. Collins, A. Chen, J. H. Doroshow
78
Board 324a
First-in-human investigation of the oral first-in-class fatty acid synthase
(FASN) inhibitor, TVB-2640. (Abstract TPS2615) A. J. Brenner, D. D. Von Hoff,
J. R. Infante, M. R. Patel, S. F. Jones, H. A. Burris III, C. Rubino, W. McCulloch, V.
Zhukova-Harrill, G. Kemble
Board 324b
Phase 1 dose-escalation study of EBC-46 given by intratumoral injection to
patients with refractory cutaneous and subcutaneous tumors. (Abstract
TPS2616) J. D. Lickliter, B. Panizza, C. S. Karapetis, V. A. Gordon, P. W. Reddell,
K. T. Lingard, R. M. Cusack, P. De Souza
Board 325a
Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced
cancer patients with somatic alterations in BRCA1/2, mutations/deletions in
PTEN or PTEN loss, a homologous recombination defect,
mutations/deletions in other BRCA pathway genes and germline mutation S
in BRCA1/2 (not breast or ovarian cancer). (Abstract TPS2617) S. A. PihaPaul, J. B. Goldstein, K. R. Hess, S. Fu, D. S. Hong, F. Janku, D. D. Karp, A.
Naing, V. Subbiah, A. M. Tsimberidou, J. J. Wheler, R. Zinner, G. B. Mills, F.
Meric-Bernstam
Board 325b
A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase
(PARP), and topotecan (TPT) in patients with solid tumors. (Abstract
TPS2618) A. E. Wahner Hendrickson, M. E. Menefee, L. C. Hartmann, H. J. Long
III, D. W. Northfelt, J. M. Reid, F. Boakye-Agyeman, K. S. Flatten, G. G. Poirier, J.
Lensing, C. Erlichman, S. H. Kaufmann, P. Haluska
Board 326a
A phase I trial of oral 5-azacitidine in combination with romidepsin in
advanced solid tumors with an expansion cohort in virally mediated cancers
and liposarcoma. (Abstract TPS2619) K. A. Reiss, M. A. Rudek, S. SartoriusMergenthaler, M. Downs, D. Cosgrove, S. Gaillard, S. Baylin, N. Ahuja, N. S. Azad
Board 326b
Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in
patients with advanced non-small-cell lung cancer harboring specific
molecular alterations. (Abstract TPS2620) T. M. Bauer, A. T. Shaw, B. Solomon,
B. Besse, L. P. James, J. S. Clancy, G. Mugundu, J. Martini, A. Abbattista, E. Felip
Board 327a
A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor,
MGCD516, in patients with advanced solid tumors. (Abstract TPS2621) G. K.
Schwartz, D. Adkins, R. S. Heist, M. Abbott, S. L. Barber, R. C. Chao, S. T.
Neuteboom, I. Chen, J. Christensen, T. M. Bauer
Board 327b
A randomized, open-label, Phase II trial evaluating the clinical benefit of a
maintenance treatment targeting tumor molecular alterations in patients with
advanced solid tumors. (Abstract TPS2622) M. Toulmonde, C. Le Tourneau, A.
Italiano, C. Seigne, I. L. Ray-Coquard, C. Cropet, A. Flechon, F. Desseigne, M. Alt,
C. De La Fouchardiere, J. Fayette, E. Borcoman, P. Heudel, L. Jaouen, M.
Bernardin, D. Pérol, J. Blay
Board 328a
First-in-human dose escalation study of oral ONC201 in advanced solid
tumors. (Abstract TPS2623) M. N. Stein, T. M. Mayer, R. A. Moss, A. W. Silk, N.
Chan, B. G. Haffty, R. S. DiPaola, Y. Beckett, E. Bentlyewski, L. Zheng, B. Fang, J.
Allen, J. M. Mehnert
Board 328b
A first-in-human study of LOXO-101, a highly selective inhibitor of the
tropomyosin receptor kinase (TRK) family. (Abstract TPS2624) H. A. Burris,
M. S. Brose, A. T. Shaw, T. M. Bauer, A. F. Farago, R. C. Doebele, S. Smith, M.
Fernandes, S. Cruickshank, J. A. Low
Location: S Hall A
Abstracts 3009 –3020 will be discussed during the Developmental Therapeutics—Immunotherapy Poster Discussion Session. See page 128 for session information.
79
SATURDAY
SATURDAY
Board 335
Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts)
with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the
KEYNOTE-029 phase 1 study. (Abstract 3009) M. B. Atkins, T. K. Choueiri, F. S.
Hodi, J. A. Thompson, W. Hwu, D. F. McDermott, M. Brookes, A. Tosolini, S.
Ebbinghaus, Z. Yang, C. K. Gause, R. F. Perini, A. Ribas
Board 336
Preliminary safety and activity of nivolumab and its combination with
ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. (Abstract
3010) J. H. Sampson, G. Vlahovic, S. Sahebjam, A. M. Omuro, J. M. Baehring,
D. A. Hafler, A. D. Voloschin, P. Paliwal, J. Grosso, V. Coric, T. F. Cloughesy, M.
Lim, D. A. Reardon
Board 337
Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a
squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.
(Abstract 3011) N. H. Segal, S. I. Ou, A. S. Balmanoukian, M. G. Fury, E.
Massarelli, J. R. Brahmer, J. Weiss, P. Schoffski, S. J. Antonia, C. Massard, D. P.
Zandberg, S. Khleif, X. Li, M. Rebelatto, K. Steele, P. B. Robbins, J. A. BlakeHaskins, M. O. Butler
Board 338
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized
comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in
patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
(Abstract 3012) I. Puzanov, R. Dummer, J. Schachter, A. C. Pavlick, R. Gonzalez,
P. A. Ascierto, K. A. Margolin, O. Hamid, S. S. Agarwala, M. S. Carlino, J. Utikal, M.
Lotem, A. Ribas, P. Mohr, C. M. Roach, M. Dolled-Filhart, X. Li, S. Ebbinghaus,
S. P. Kang, A. Daud
Board 339
An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with
advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed
after receiving 1 or more prior systemic regimens. (Abstract 3013) T. M.
Bauer, M. McCleod, J. C. Chandler, G. R. Blumenschein Jr., L. S. Schwartzberg,
H. Burris, D. Waterhouse, R. M. Jotte, M. Hussein, D. R. Spigel, D. S. Thompson,
X. Li, C. H. Reynolds
Board 340
Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1)
antibody, in combination with tremelimumab, a cytotoxic T-lymphocyteassociated protein-4 (CTLA-4) antibody, in patients (pts) with advanced
NSCLC. (Abstract 3014) S. J. Antonia, S. B. Goldberg, A. S. Balmanoukian, R. E.
Sanborn, K. Steele, R. Narwal, P. B. Robbins, Y. Gu, J. J. Karakunnel, N. A. Rizvi
Board 341
Molecular, immune and histopathological characterization of NSCLC based
on PDL1 expression on tumor and immune cells and association with
response to the anti-PDL1 antibody MPDL3280A. (Abstract 3015) S. N.
Gettinger, M. Kowanetz, H. Koeppen, I. I. Wistuba, M. Kockx, E. E. Kadel III, N. A.
Rizvi, A. I. Spira, F. R. Hirsch, Z. Boyd, M. Denker, A. Minn, D. S. Shames, A.
Sandler, D. S. Chen, P. S. Hegde, D. R. Spigel
Board 342
CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and
evidence of intra-tumoral immune activation. (Abstract 3016) J. H. Schellens,
J. Tabernero, U. N. Lassen, I. Melero, K. Homicsko, G. Argilés, J. Perez Gracia, M.
Sorensen, G. Coukos, E. ANGEVIN, H. Joensuu, E. V. Brummelen, C. W. Menke,
T. K. Nayak, S. Romagnoli, B. Reis, S. Soehrman Brossard, S. Evers, J. M. Saro
Suarez, H. M. Verheul
Board 343
A first-in-human dose escalation study of PEGylated recombinant human
IL-10 (AM0010) in advanced solid tumors. (Abstract 3017) J. R. Infante, A.
Naing, K. P. Papadopoulos, K. A. Autio, P. A. Ott, D. J. Wong, G. S. Falchook,
M. R. Patel, S. Pant, M. Whiteside, J. C. Bendell, T. M. Bauer, F. Janku, M. M.
Javle, D. S. Hong, M. Oft
Board 344
A phase I study of intratumoral injection of ipilimumab and interleukin-2 in
patients with unresectable stage III-IV melanoma. (Abstract 3018) R. C.
Bowen, S. Meek, M. Williams, K. F. Grossmann, R. I. Andtbacka, T. L. Bowles,
J. R. Hyngstrom, S. A. Leachman, D. Grossman, S. L. Holmen, M. W. VanBrocklin,
H. T. Khong
Board 345
Immunogenomics-based development of personalized immunotherapy for
lung cancers. (Abstract 3019) Y. Daigo, A. Takano, K. Teramoto, Y. Nakamura
80
Board 346
Vaccination of MSI-H colorectal cancer patients with frameshift peptide
antigens: A phase I/IIa clinical trial. (Abstract 3020) M. Kloor, M.
Reuschenbach, J. Karbach, M. Rafiyan, S. Al-Batran, C. Pauligk, E. Jaeger, M. von
Knebel Doeberitz
Board 347
Phase I, first-in-human trial of LV305 in patients with advanced or metastatic
cancer expressing NY-ESO-1. (Abstract 3021) N. Somaiah, M. S. Block, J. W.
Kim, G. Shapiro, P. Hwu, J. P. Eder, R. L. Jones, S. Gnjatic, H. Lu, F. J. Hsu, S.
Pollack
Board 348
Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with
autologous CTL019 T-cells. (Abstract 3022) N. N. Shah, D. A. Torigian, M.
Farwell, W. Hwang, N. V. Frey, S. Nasta, D. J. Landsburg, A. R. Mato, C. H. June,
S. J. Schuster, D. L. Porter, J. Svoboda
Board 349
Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C),
an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced
solid tumors. (Abstract 3023) K. Shitara, Y. Yamada, K. Yoh, Y. Naito, S. Iwasa,
N. Yamamoto, A. von Heydebreck, H. Achiwa, T. Doi
Board 350
Phase I study of MEDI0639 in patients with advanced solid tumors. (Abstract
3024) G. S. Falchook, A. Dowlati, A. Naing, M. J. Gribbin, D. W. Jenkins, L. L.
Chang, D. W. Lai, D. C. Smith
Board 351
Baseline serum predictors of clinical response to CTLA4 inhibitor therapy in
melanoma patients. (Abstract 3025) K. Homicsko, N. Bordry, D. Gfeller, D. E.
Speiser, O. Michielin
Board 352
Correlation of gene expression signatures and clinical outcomes in patients
with advanced gastric cancer treated with pembrolizumab (MK-3475).
(Abstract 3026) V. Shankaran, K. Muro, Y. Bang, R. Geva, D. V. Catenacci, S.
Gupta, J. P. Eder, R. Berger, A. Loboda, A. Albright, R. Cristescu, E. Murphy, T.
McClanahan, M. Ayers, M. Nebozhyn, J. K. Lunceford, M. Koshiji, K. Heath, J. D.
Cheng, H. Chung
Board 353
TCR use and cytokine response in PD-1 blockade. (Abstract 3027) J. M.
Zaretsky, S. M. Blum, L. Robert Faja, R. O. Emerson, A. Ribas
Board 354
Biomarker analysis of patients treated with anti-CD19 chimeric antigen
receptor (CAR) T cells. (Abstract 3028) A. Bot, J. Kochenderfer, A. Mardiros, A.
Perez, L. Navale, R. Chang, Y. Wei-Shen, S. Yoder, J. Xiao-Chi, S. A. Rosenberg,
W. Y. Go, J. S. Wiezorek, M. Roberts, D. D. Chang
Board 355
Immunological long-term follow-up of neuroblastoma stage IV patients after
anti-GD2 CH14.18 antibody treatment. (Abstract 3029) S. Kayser, V. Icheva, S.
Stevanovic, N. Siebert, J. Feucht, H. N. Lode, R. Handgretinger, T. Feuchtinger
Board 356
Association of epithelial-mesenchymal transition with an
immunosuppressive, inflammatory tumor microenvironment with elevated
levels of checkpoint inhibitors in lung adenocarcinoma. (Abstract 3030) Y.
Lou, L. Diao, E. R. Parra Cuentas, W. Denning, L. Chen, Y. H. Fan, J. Rodriguez,
L. A. Byers, J. Wang, V. Papadimitrakopoulou, C. Behrens, I. I. Wistuba, P. Hwu,
J. Heymach, D. L. Gibbons
Board 357
Exploratory analysis of clinical and translational factors associated with the
inflamed phenotype in HNSCC. (Abstract 3031) N. Rajasekaran, H. E. Kohrt, Z.
Zuo, M. K. Keck, A. Khattri, M. W. Lingen, J. P. Kline, T. Gajewski, E. E. Vokes,
T. Y. Seiwert
Board 358
A phase I dose-escalation clinical trial of a peptide-based human
papillomavirus therapeutic vaccine with candida skin test reagent as a novel
vaccine adjuvant for treating women with biopsy-proven cervical
intraepithelial neoplasia 2/3. (Abstract 3032) M. Nakagawa, S. L. Stratton, R.
Myrick, R. Vaughn, L. M. Donnalley, H. Coleman, M. Mercado, A. MoermanHerzog, H. J. Spencer, W. C. Hitt, G. Low, N. Manning, S. McKelvey, D. Smith, M.
Smith, A. Phillips, C. M. Quick, S. K. Jeffus, L. F. Hutchins, W. Greenfield
Board 359
Immunotoxin therapy in animal model of HuD antigen positive small cell lung
cancer. (Abstract 3033) B. Wang, W. Lu, P. Dowling
81
SATURDAY
SATURDAY
Board 360
Results of the phase IIb part of TIME study evaluating TG4010
immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients
receiving first line chemotherapy. (Abstract 3034) E. A. Quoix, F. Forget, Z.
Papai-Szekely, C. H. Ottensmeier, J. J. Nemunaitis, E. Felip, L. Crino, A.
Szczesna, A. Tavernaro, G. Lacoste, B. Bastien, J. Limacher
Board 361
Comprehensive analysis of variation of tumor infiltrating lymphocytes during
neoadjuvant chemotherapy in triple-negative breast cancer. (Abstract 3035)
C. Castaneda Altamirano, E. A. Mittendorf, P. Arboleda Ezcurra, S. Casavilca
Zambrano, M. T. Nunez Butron, Y. Wu, M. Castillo Garcia, K. I. Rojas, V. Villegas
Bernaola, C. Belmar Lopez, K. Dolores Cerna, H. L. Gomez, J. E. Abugattas Saba,
J. M. Cotrina, A. M. Gonzalez-Angulo, T. Vidaurre
Board 362
Phase I/II study of tecemotide cancer immunotherapy for Japanese patients
with unresectable stage III non-small cell lung cancer (NSCLC). (Abstract
3036) H. Nokihara, N. Katakami, T. Hida, F. Imamura, H. Sakai, S. Atagi, M.
Nishio, C. Helwig, H. Achiwa, T. Tamura
Board 363
Pharmacokinetics and myeloid effector cell engagement of an engineered
IgA antibody against the epidermal growth factor receptor. (Abstract 3037) T.
Valerius, S. Lohse, S. Meyer, M. J. Jansen, L. A. Meulenbroek, M. Nederend, U.
Möginger, A. Kretschmer, K. Klausz, S. Derer, P. Sondermann, D. Kolarich, M.
Peipp, J. H. Leusen, M. Gramatzki
Board 364
Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1
antibody, avelumab (MSB0010718C), on human tumor cells. (Abstract 3038)
K. Tsang, B. Boyerinas, C. Jochems, M. Fantini, C. R. Heery, R. A. Madan, J. L.
Gulley, J. Schlom
Board 365
Phase I study to evaluate the safety and tolerability of MEDI4736, an antiprogrammed cell death ligand-1 (PD-L1) antibody, in Japanese patients with
advanced solid tumors. (Abstract 3039) H. Iguchi, N. Nogami, T. Kozuki, T.
Matsumoto, K. Tamura, N. Yamamoto, A. Shimomura, Y. Hoshino, Y. Michibata,
M. Nii, Y. Fujiwara
Board 366
Strategies for clinical development of monoclonal antibodies beyond
first-in-man trials: Tested doses and rationale for dose selection. (Abstract
3040) M. Vinches, A. Cuenant, M. Alexandre, A. Durigova, N. Hayaoui, C. Mollevi,
L. Gianni, D. Tosi
Board 367
Adoptive immunotherapy of acute myeloid leukemia (AML) with allogenic
CAR t-cells targeting CD123. (Abstract 3041) R. Galetto, C. Lebuhotel, P.
Francon, A. Gouble, J. Smith
Board 368
Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal
dosing regimen for patients with unresectable malignant mesothelioma
(MM). (Abstract 3042) R. Narwal, A. DiPietro, R. Ibrahim, L. Calabrò, M. Maio,
P. B. Robbins, L. Roskos
Board 369
T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells
after infusion and activity in vivo. (Abstract 3043) C. Regan, J. Clark, T. Moore,
K. Moxley, G. Scurti, A. Lau Clark, B. Dropulic, H. Embree, K. Shirai, E. GarrettMayer, M. Li, K. Tobin Vealey, J. M. Eby, C. Le Poole, M. Nishimura
Board 370
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with
metastatic or locally advanced solid tumors: assessment of safety and
tolerability in a phase I, open-label expansion study. (Abstract 3044) K. Kelly,
M. R. Patel, J. R. Infante, N. Iannotti, P. Nikolinakos, J. Leach, D. Wang, J. C.
Chandler, G. H. Jerusalem, J. S. Gurtler, H. Arkenau, I. Speit, A. von Heydebreck,
K. M. Chin, C. R. Heery, J. L. Gulley
Board 371
A phase II study of novel three peptides combination with gemcitabine as a
first-line therapy for advanced pancreatic cancer (VENUS-PC study).
(Abstract 3045) H. Tanaka, N. Suzuki, H. Iguchi, K. Uesugi, K. Hirakawa, R.
Amano, A. Aruga, T. Hatori, I. Hidenobu, Y. Umeda, M. Shimada, K. Yoshimatsu,
R. Shimizu, H. Ozasa, H. Hayashi, K. Sakata, T. Ueno, H. Furukawa, S. Hazama,
M. Oka
82
Board 372
Effect of denileukin diftitox (DD) on vaccine-induced T-cell responses and
depletion of Tregs in melanoma. (Abstract 3046) J. J. Luke, Y. Zha, K.
Matijevich, T. Gajewski
Board 373
Safety and tolerability results from a phase I study of MEDI4736, a human
IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with
gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). (Abstract
3047) B. C. Creelan, L. Q. Chow, D. Kim, S. Kim, T. Yeh, J. J. Karakunnel, D. L.
Gibbons
Board 374
Phase II randomized trial of autologous tumor lysate dendritic cell vaccine
(ADC) plus best supportive care (BSC) compared with BSC, in pre-treated
advanced colorectal cancer patients. (Abstract 3048) J. Maurel, M. CaballeroBaños, J. Mila, J. Tabera, S. Varea, R. Vilana, L. Bianchi, P. Arguis, E. Pineda, G.
Carrera, M. Cuatrecasas, D. Páez, M. Martin-Richard, M. Pagés, J. Ayuso, J. Cid,
M. Lozano, X. Garcia-Albeniz, A. Castells, R. Vilella
Board 375
A subgroup with improved overall survival from the phase 2 IMPACT study:
Maintenance therapy of metastatic colorectal cancer patients with the TLR-9
agonist MGN1703. (Abstract 3049) J. Riera-Knorrenschild, D. Arnold, H. Kopp, F.
Mayer, H. Kroening, D. Nitsche, J. Kuhlmann, R. Ziebermayr, J. Andel, A. Zurlo, B.
Wittig, W. Scheithauer, H. Schmoll
Board 376
CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target
cell lysis by CD30/CD16A TandAb AFM13. (Abstract 3050) X. Zhao, N.
Rajasekaran, U. Reusch, J. Marschner, M. Treder, H. E. Kohrt
Board 377
Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine
Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine
with and without IMMⴚ101 in advanced pancreatic cancer. (Abstract 3051)
A. G. Dalgleish, The IMAGE 1 Trial Investigators
Board 378
Effect of human OX40 ligand fusion protein (MEDI6383) on immune cells of
the humoral and cell-mediated immune response in a non-human primate
model. (Abstract 3052) M. D. Oberst, S. Eck, N. Buss, A. Pierce, H. Park, H. Kim,
A. Sylwester, M. Axhelm, L. Picker, A. Weinberg, L. De Haan, S. A. Hammond
Board 379
A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune
checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal
cell carcinoma (mRCC). (Abstract 3053) A. Gunturi, S. Aung, D. F. McDermott,
E. I. Buchbinder
Board 380
Targeting the Wnt5a-␤-catenin pathway in the melanoma microenvironment
to augment checkpoint inhibitor immunotherapy. (Abstract 3054) B. A. Hanks,
F. Zhao, K. Evans, A. Holtzhausen, M. Tsutsui, D. Tyler
Board 381
Pharmacokinetic profile and receptor occupancy of avelumab
(MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label,
dose escalation trial in patients with advanced solid tumors. (Abstract 3055)
C. R. Heery, G. H. O’Sullivan Coyne, J. L. Marte, H. Singh, L. M. Cordes, R. A.
Madan, R. N. Donahue, I. Grenga, L. Lepone, B. Neuteboom, I. Speit, K. M. Chin,
J. Schlom, J. L. Gulley
Board 382
Human OX40 ligand fusion protein (MEDI6383) as a potent OX40 agonist and
immuno-modulator in vitro and in vivo. (Abstract 3056) S. A. Hammond, C.
Morris, C. Auge, Q. Du, K. Mulgrew, K. McGlinchey, S. Eck, N. Buss, J. Hair, C.
Stracener, L. De Haan, M. Damschroder, A. Weinberg, M. D. Oberst
Board 383
In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3
TandAbs. (Abstract 3057) L. G. Eissenberg, J. K. RItchey, J. A. Fox, U. Reusch,
S. Knackmuss, J. Guenot, J. F. DiPersio
Board 384
Population pharmacokinetic (popPK) model of pembrolizumab (pembro;
MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.
(Abstract 3058) T. C. Gangadhar, J. Mehnert, A. Patnaik, O. Hamid, M. S. Carlino,
F. S. Hodi, C. U. Blank, A. Ribas, C. Robert, A. Kondic, M. Ahamadi, T.
Freshwater, R. de Greef, M. van Vugt, G. Lubiniecki, S. Ebbinghaus, S. P. Kang, A.
Daud
83
SATURDAY
SATURDAY
Board 385
Phosphatidylserine targeting antibody in combination with anti-PD-1
antibody treatment activates infiltrating T lymphocytes of the spleen and
tumor microenvironment in pre-clinical models of melanoma and breast
cancer. (Abstract 3059) X. Huang, J. Gong, V. Nguyen, S. Yin, C. Baldwin, R. A.
Brekken, S. King, J. Hutchins, B. Freimark
Board 386
Activation of CD8ⴙ tumor infiltrating lymphocytes by bavituximab in a 3D ex
vivo system of lung cancer patients. (Abstract 3060) S. Altiok, M. Mediavilla
Valera, J. Kreahling, D. Noyes, T. N. Razabdouski, N. L. Kallinteris, J. Shan, S. J.
Antonia
Board 387
A phase I/II study of ipilimumab in women with metastatic or recurrent
cervical carcinoma: A study of the Princess Margaret and Chicago N01
Consortia. (Abstract 3061) S. Lheureux, M. O. Butler, B. Clarke, M. C. Cristea,
L. P. Martin, K. S. Tonkin, G. F. Fleming, A. Tinker, H. W. Hirte, D. Tsoref, H.
Mackay, N. C. Dhani, P. Ghatage, N. Pham, V. Motta, L. Wang, K. Karakasis, S.
Udagani, H. Streicher, A. M. Oza
Board 388
Second generation antihistamines after breast cancer diagnosis to improve
prognosis both in patients with ERⴙ and ER- breast cancer. (Abstract 3062)
H. L. Olsson, R. Einefors, P. Broberg
Board 389
A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in
patients (pts) with advanced cancers. (Abstract 3063) H. Bakhribah, G. K. Dy,
W. Ma, Y. Zhao, M. Opyrchal, A. Purmal, S. Gollnick, W. E. Brady, G. J. Fetterly, N.
Ngamphaiboon, T. Reungwetwattana, S. M. Jacob, C. O’Hara, F. Siedlecki, A.
Adjei, L. Burdelya, I. Bespalov, L. L. Miller, A. Gudkov, A. A. Adjei
Board 390
MyD88/CD40-based costimulation to enhance survival and proliferation of
chimeric antigen receptor (CAR)-modified T cells. (Abstract 3064) A. E.
Foster, P. Chang, P. Lin, J. Crisostomo, A. Mahendravada, A. Lu, M. Khalil, K. M.
Slawin, D. Spencer
Board 391
A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a
fully human anti KIR monoclonal antibody (mAb) in patients (pts) with
various hematologic (HEM) or solid malignancies (SOL). (Abstract 3065) N.
Vey, A. Goncalves, L. Karlin, S. Lebouvier-Sadot, F. Broussais, D. Marie, D.
Berton-Rigaud, P. Andre, R. A. Zerbib, R. Buffet, T. Prébet, A. Charbonnier, J. Rey,
A. Pigneux, J. Bennouna, N. Boissel, G. A. Salles
Board 392
Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug
conjugate targeting Axl-expressing solid cancers. (Abstract 3066) E. C. Breij,
S. Verploegen, A. Lingnau, E. N. van den Brink, M. Janmaat, M. Houtkamp, W.
Bleeker, D. Satijn, P. Parren
Board 393
Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. (Abstract
3067) K. A. Schalper, D. E. Carvajal-Hausdorf, J. F. McLaughlin, M. Altan, K. N.
Syrigos, R. S. Herbst, D. L. Rimm
Board 394
Model-based analysis of the relationship between pembrolizumab (MK-3475)
exposure and efficacy in patients with advanced or metastatic melanoma.
(Abstract 3068) R. W. Joseph, T. C. Gangadhar, I. Puzanov, C. Robert, O. Hamid,
R. Dummer, A. Ribas, J. M. Mehnert, A. Daud, K. A. Celentano, J. A. Lindia, M. S.
Chatterjee, D. C. Turner, K. Mayawala, J. Elassaiss-Schaap, D. P. de Alwis, X. Li,
S. Ebbinghaus, S. P. Kang, R. Kefford
Board 395
UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy
against CD19ⴙ B-cell leukemias. (Abstract 3069) J. Smith, L. Poirot, B. Philip, C.
Schiffer-Mannoui, S. Derniame, H. Zhan, S. Stafford, S. Reynier, S. Arnould, A.
Gouble, W. Qasim, K. Peggs, M. Pule, D. Sourdive
Board 396
Durability and characteristics of objective tumor responses with the innate
immune cell modulator Imprime PGG in combination with standard of care
frontline treatment for patients (Pts) with metastatic non-squamous NSCLC.
(Abstract 3070) W. Engel-Riedel, F. Schneller, M. Wolf, W. Schuette, M. Ma, P.
Mattson, J. R. Lowe, A. H. Braun
Board 397
Safety of Imprime PGG, a novel innate immune cell modulator, in adults with
stage IV non-small cell lung cancer: an integrated analysis of two
84
Board 398
Safety, immunogenicity, and clinical activity of the immunotherapeutic
vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian
tube, or peritoneal cancer. (Abstract 3072) J. A. Villella, M. K. Wilson, N. L.
Berinstein, J. Brown, S. Lheureux, M. O. Butler, J. Ramsahai, K. Odunsi, M.
Karkada, J. J. Nemunaitis, M. Morse, T. Pejovic, J. Bentley, G. Weir, L.
MacDonald, M. Stanford, T. Burzykowski, R. Nigam, M. Mansour, A. M. Oza
Board 399
A first-in-human phase 1 dose-escalating trial of G305 in patients with solid
tumors expressing NY-ESO-1. (Abstract 3073) A. Mahipal, K. Odunsi, S.
Gnjatic, S. Kim-Schulze, R. T. Kenney, S. Ejadi
Board 400
A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with
enhanced immune stimulatory activity alone and in combination with
immune checkpoint inhibitors. (Abstract 3074) S. J. Gardai, A. Epp, G. Linares,
L. Westendorf, M. K. Sutherland, H. Neff-LaFord, J. G. Drachman, S. Peng, C. Law
Board 401
Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK
cell-mediated cytotoxicity. (Abstract 3075) N. Rajasekaran, S. Dutt, A.
Marabelle, R. Houot, M. Sadaram, J. Hebb, I. Sagiv-Barfi, S. Ambulkar, A. S.
Rajapaksa, C. Chester, E. Waller, H. E. Kohrt
Board 402
Transfer of anti-breast cancer immunity induced by infusions of bispecific
antibody armed T cells and boosted with ex vivo primed T cells after stem
cell transplant in metastatic breast cancer patients. (Abstract 3076) A. Thakur,
L. G. Lum, R. Rathore, Z. Al-Kadhimi, E. Tomaszewski, D. Schalk, Q. Liu, J. P.
Uberti, V. Ratanatharathorn
Board 403
First interim exploratory analysis of immune response in patients with
advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in
combination with low-dose cyclophosphamide in an ongoing phase II trial.
(Abstract 3077) R. B. Cohen, D. Morgensztern, W. V. Walsh, L. Bazhenova, A. M.
Melnyk, J. T. Beck, J. J. Nemunaitis, T. H. Schreiber, M. L. Price
Board 404
An analysis of phase II and III therapeutic cancer vaccine trials and review of
the successes and failures behind 10 different vaccine modalities. (Abstract
3078) H. E. Kohrt, A. C. Tan, A. Goubier
Board 405
Anti-tumor efficacy and PD-L1 expression in the tumor microenvironment
after poxvirus-based active immunotherapy and PD-1 blockade. (Abstract
3079) S. J. Mandl, S. P. Foy, B. Sennino, T. dela Cruz, E. Gordon, F. Kemp, V.
Xavier, R. B. Rountree, A. Franzusoff
Board 407
Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2
therapies on induction of oligoclonal T cell and antibody responses against
HER2. (Abstract 3081) W. R. Gwin, A. Hobeika, T. Osada, Z. Hartman, Q. Cheng,
G. Broadwater, G. G. Kimmick, K. L. Blackwell, M. Morse, K. Lyerly
Board 408
Allogeneic myeloma GVAX with lenalidomide in near complete remission to
enhance progression free survival. (Abstract 3082) I. Borrello, K. Noonan, A. K.
Ferguson, A. Sidorski, L. Rudrarajuraraju, A. Casildo, C. A. Huff
Board 409
Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy
in patients with Merkel cell carcinoma (MCC). (Abstract 3083) S. Bhatia, D.
Ibrani, N. Vandeven, N. Miller, M. Shinohara, D. Byrd, U. Parvathaneni, E.
Shantha, O. K. Afanasiev, M. Donahue, D. M. Koelle, F. J. Hsu, P. Nghiem
Board 410
First-in-human dose-escalating trial of E.coli purine nucleoside
phosphorylase and fludarabine gene therapy for advanced solid tumors.
(Abstract 3084) T. K. Chung, E. Rosenthal, W. B. Parker, P. Allan, L. Clemons, D.
Lowman, J. Hong, F. R. Hunt, J. Richman, R. M. Conry, K. Mannion, W. Carroll, L.
Nabell, E. J. Sorscher
Board 411
An evaluation of local and systemic immune markers following intratumoral
administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory
cancer patients with solid tumors. (Abstract 3085) S. A. Pesonen, T. Ranki, E.
85
SATURDAY
randomized phase 2 studies. (Abstract 3071) F. Schneller, W. Engel-Riedel, M.
Thomas, J. Kollmeier, P. Sadjadian, M. Wolf, W. Schuette, C. C. Taitt, R. D. Huhn,
M. Ma, P. Mattson, J. R. Lowe, A. H. Braun
Jäger, J. Karbach, C. Wahle, T. K. Joensuu, T. Alanko, K. Partanen, K. Kairemo, R.
Turkki, N. Linder, J. Lundin, A. Ristimäki, M. Majumder, A. Kumar, C. Heckman, M.
Kankainen, A. Hemminki, M. Von Euler, M. E. Jaderberg
SATURDAY
Board 412
Immunomodulatory effects of OX40 agonists in a defined antigen challenge
in cynomolgus macaques. (Abstract 3086) S. L. Lambert, D. Heeke, K. Patton,
R. Lin, C. Shambaugh, S. Aslam, L. Yu, F. Zuo, A. Pierce, X. Paliard
Board 413a
Phase I, open-label study of MEDI0680, an anti-programmed cell death-1
(PD-1) antibody, in combination with MEDI4736, an anti-programmed cell
death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
(Abstract TPS3087) O. Hamid, L. Q. Chow, F. Tavakkoli, S. Marshall, M. J.
Gribbin, J. J. Karakunnel, J. E. Gray
Board 413b
A phase I, multicenter, open-label, first-in-human study to evaluate
MEDI0680, an anti-programmed cell death-1 antibody, in patients with
advanced malignancies. (Abstract TPS3088) J. R. Infante, S. Goel, F. Tavakkoli,
S. Marshall, P. B. Robbins, G. D’Angelo, M. J. Gribbin, J. J. Karakunnel, A. Naing
Board 414a
First-in-human study assessing safety and tolerability of REGN1979, a novel
CD20xCD3 bispecific antibody, in patients with CD20ⴙ B-cell malignancies
previously treated with anti-CD20 therapy. (Abstract TPS3089) C. M.
Brownstein, L. Adriaens, R. Bannerji, J. C. Chavez, R. Levy, S. M. Ansell, R. H.
Advani, S. Patel, A. Kostic, P. Trail, I. Lowy, H. E. Kohrt
Board 414b
Phase I study to evaluate the safety and efficacy of MEDI4736 in combination
with tremelimumab in patients with recurrent or metastatic (R/M) squamous
cell carcinoma of the head and neck (SCCHN). (Abstract TPS3090) L. L. Siu,
K. P. Papadopoulos, F. Y. Tsai, A. R. Hansen, P. B. Robbins, X. Li, D. W. Lai, J. A.
Blake-Haskins, M. G. Fury
Board 415a
A phase 1b/2, open-label study to evaluate the safety and tolerability of
MEDI6469 in combination with immune therapeutic agents or therapeutic
mAbs in patients with selected advanced solid tumors or aggressive B-cell
lymphomas. (Abstract TPS3091) J. D. Powderly, M. Gutierrez, D. Wang, Y.
Chae, D. Mahadevan, F. S. Braiteh, B. S. Glisson, D. Fu, M. Jordan, J. T. McDevitt,
M. C. Lanasa, B. D. Curti
Board 415b
A phase Ib study of neoadjuvant immune biomarker modulation with
cetuximab and motolimod in head and neck cancer (HNC). (Abstract
TPS3092) B. A. Kansy, S. P. Gibson, R. M. Srivastava, J. K. Bryan, R. M.
Hershberg, R. L. Ferris
Board 416a
A phase I study of MEDI6383, an OX40 agonist, in adult patients with select
advanced solid tumors. (Abstract TPS3093) T. M. Bauer, Y. Chae, S. Patel,
S. P. D’Angelo, G. R. Blumenschein Jr., J. Norton, C. Pound, M. C. Lanasa, B. D.
Curti
Board 416b
KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients
(pts) with recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC) who have failed platinum and cetuximab. (Abstract TPS3094) S. F.
Powell, S. V. Liu, A. Sukari, C. H. Chung, J. Bauml, R. I. Haddad, C. K. Gause, M.
Niewood, L. L. Gammage, H. Brown, A. Meister, J. D. Cheng, M. M. Gitau
Board 417a
A Phase II multicenter trial to evaluate combination ipilimumab and highdose IL-2 in patients with unresectable stage III and IV melanoma. (Abstract
TPS3095) H. Kaufman, J. Wang, B. D. Curti, J. Clark, M. S. Ernstoff, A. Silk, J. M.
Mehnert, A. Zloza, J. Shih, D. F. McDermott
Board 417b
Phase I study evaluating high dose ADXS11– 001 treatment in women with
carcinoma of the cervix. (Abstract TPS3096) S. A. Ghamande, R. Dobbins, L.
Marshall, D. Wheatley, C. Prince, D. J. Mauro, J. E. Janik, S. Khleif
Board 418a
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous
infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
(Abstract TPS3097) E. De Vries, V. Heinemann, W. M. Fiedler, T. Seufferlein,
H. M. Verheul, D. De Groot, J. C. von Einem, S. Ren, K. Cheung, E. Rasmussen, J.
Volkland, G. D. Means, A. Kratzer, A. Wolf, S. Stienen
86
Board 418b
A randomized multicenter phase Ib/II study to assess the safety and the
immunological effect of chemoradiation therapy (CRT) in combination with
pembrolizumab (anti-PD1) to CRT alone in patients with resectable or
borderline resectable pancreatic cancer. (Abstract TPS3098) M. H. Katz, T. W.
Bauer, G. R. Varadhachary, G. R. Petroni, T. Bullock, C. L. Slingluff Jr., O. E.
Rahma
Board 419a
A phase I study to evaluate the safety and tolerability of MEDI4736, an antiprogrammed cell death-ligand-1 (PD-L1) antibody, in combination with
tremelimumab in patients with advanced solid tumors. (Abstract TPS3099)
P. A. Ott, M. K. Callahan, K. Odunsi, A. J. Park, L. S. Pan, R. R. Venhaus, J. J.
Karakunnel, F. S. Hodi, J. D. Wolchok
Board 419b
“ARMY”: First-in-human study of the humanized, defucosylated monoclonal
antibody (mAb) MEN1112/OBT357 targeting CD157 antigen, in relapsed or
refractory (R/R) acute myeloid leukemia (AML). (Abstract TPS3100) A.
Venditti, D. Breems, V. Havelange, G. Martinelli, S. Baldini, M. Binaschi, A. Crea,
E. Leo, C. A. Maggi, S. Manzini, M. Matera, P. Mazzei, C. Rossi, S. Scartoni, A.
Scordari, G. Tonini, K. Wilson, A. Capriati, C. Simonelli
Board 420a
Phase I expansion cohort trial to investigate the safety and clinical activity of
avelumab (MSB0010718C) in patients with metastatic or locally advanced
solid tumors. (Abstract TPS3101) C. R. Heery, J. R. Infante, N. Iannotti, K. Kelly,
P. Nikolinakos, A. von Heydebreck, K. M. Chin, J. L. Gulley
Board 420b
Genetically engineered NY-ESO-1 specific T cells in HLA-A201ⴙ patients
with advanced cancers. (Abstract TPS3102) M. S. Merchant, M. C. Cristea, E. A.
Stadtmauer, W. D. Tap, S. P. D’Angelo, S. A. Grupp, T. Holdich, G. Binder-Scholl,
B. K. Jakobsen, K. Odunsi, A. Rapoport, C. Mackall
Board 421a
Phase I/II study of stereotactic body radiation therapy (SBRT) to metastatic
lesions in the liver or lung in combination with monoclonal antibody to OX40
in patients with progressive metastatic breast cancer (mBC) after systemic
therapy. (Abstract TPS3103) M. Crittenden, A. K. Conlin, N. Moxon, B. D. Curti
Board 421b
Study of hTERT and IL-12 DNA immunotherapy using electroporation in
patients with solid tumors after definitive surgery and adjuvant therapy.
(Abstract TPS3104) R. H. Vonderheide, C. Aggarwal, D. L. Bajor, J. Goldenberg,
C. Loch, J. C. Lee, J. Yan, M. P. Morrow, A. DeMichele, C. J. Langer, P. J.
O’Dwyer, D. B. Weiner, Z. Yang, M. L. Bagarazzi
Board 422a
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L
and Poly-ICLC With Low-Dose Radiotherapy. (Abstract TPS3105) T. U.
Marron, A. Binder, N. Bhardwaj, S. Kim-Schulze, T. Keler, T. Davis, E. Crowley,
A. M. Salazar, J. Brody
Board 422b
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated
Listeria monocytogenes vaccine (⌬AactA/⌬AinlB) expressing EGFRvIII and
NY-ESO-1, in patients with WHO grade III/IV astrocytomas. (Abstract
TPS3106) M. Crittenden, K. S. Bahjat, R. Li, P. A. Gore, C. Fountain, B. Hanson, J.
Skoble, P. Lauer, A. Murphy, T. W. Dubensky Jr., D. G. Brockstedt, W. J. Urba
9:30 AM - 12:00 PM Special Session
Opening Session with Conquer Cancer Foundation Top Donors Recognition,
Guest Speaker’s Address, Presidential Address, and David A. Karnofsky
Memorial Award and Lecture
Location: N Hall B1
9:30 AM
William Charles Penley, MD
Tennessee Oncology
Conquer Cancer Foundation: Welcome Remarks and Top Donor Recognition
Awards
87
SATURDAY
9:45 AM
Michael E. Porter, PhD
Harvard Business School
Guest Speaker’s Address: Value-Based Health Care Delivery
10:30 AM Allen S. Lichter, MD, FASCO
Introduction of Peter Paul Yu, MD, FACP, FASCO
Peter Paul Yu, MD, FACP, FASCO
Presidential Address: Illumination & Innovation—Transforming Data into Learning
11:15 AM Clifford A. Hudis, MD, FACP
Introduction of Suzanne Louise Topalian, MD
SATURDAY
Suzanne Louise Topalian, MD—Award Lecturer
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
David A. Karnofsky Memorial Award and Lecture: PD-1 Pathway Blockade—A
Common Denominator for Cancer Therapy
MOC and Lifelong Learning Workshop: ABIM Module 2013—Ticketed Session
Location: E451b
Jeffrey M. Peppercorn, MD, MPH
Thomas W. Flaig, MD
1:15 PM - 2:30 PM Poster Discussion Session
Location: N Hall B1
Ian E. Krop, MD, PhD—Co-Chair
Patrick G. Morris, MD, MSC—Co-Chair
Beaumont Hospital
1:15 PM
William John Gradishar, MD (Discussion of Abstract(s) 513-515)
Lurie Comprehensive Cancer Center of Northwestern University
Adjuvant Endocrine Therapy: For Whom, How Long, and at What Cost?
1:27 PM
1:33 PM
Jorge Reis-Filho, MD, PhD (Discussion of Abstract(s) 516 –518)
The Next Chapter in Biomarker Research
1:45 PM
1:51 PM
Rebecca Alexandra Dent, MD (Discussion of Abstract(s) 519 –521)
National Cancer Center Singapore
Individualizing Treatment in DNA Repair-Deficient Breast Cancer
2:03 PM
88
2:09 PM
Javier Cortes, MD, PhD (Discussion of Abstract(s) 522–524)
Vall D’Hebron University Hospital
Early-Phase Research on Novel Agents
2:21 PM
Posters discussed in this session are on display in the Breast Cancer—HER2/ER Poster Session. See page 51 for poster information. Networking with presenters and discussants will take
place right outside of the session room after the discussion.
SATURDAY
Therapeutics
Location: S406
Gerald Steven Falchook, MD, MS—Co-Chair
Sarah Cannon Research Institute At HealthONE
Robin Kate Kelley, MD—Co-Chair
1:15 PM
David Paul Carbone, MD, PhD (Discussion of Abstract(s) 2509-2511)
The Ohio State Univeristy Comprehensive Cancer Center
Novel Strategies for Attacking Epidermal Growth Factor Receptor
1:27 PM
1:33 PM
Robert Wesolowski, MD (Discussion of Abstract(s) 2512–2514)
Exploiting Metabolic Processes as Therapeutic Targets
1:45 PM
1:51 PM
James F. Spicer, MD (Discussion of Abstract(s) 2515–2517)
King’s College London
Signals in Subpopulations: Molecularly Enriched Clinical Trials
2:03 PM
2:09 PM
Boon C. Goh, MD (Discussion of Abstract(s) 2518 –2520)
National University Hospital
Targeting the Interface of the Microenvironment and Immune System
2:21 PM
Posters discussed in this session are on display in the Developmental Therapeutics—Clinical
Pharmacology and Experimental Therapeutics Poster Session. See page 70 for poster information. Networking with presenters and discussants will take place right outside of the session
room after the discussion.
Pediatric Oncology Award and Lecture
Location: S504
Presentation of the 2015 Pediatric Oncology Award
Stephen E. Sallan, MD
Dana-Farber Cancer Institute/Harvard Medical School
An Autobiography of “We”
89
Adjuvant Therapy for Stage II and III Colon Cancer: Patient Selection, Optimal
Agents, and Chemoprevention
Location: E Hall D2
Zsofia Kinga Stadler, MD
Chemotherapy for Stage II Colon Cancer
SATURDAY
Hanna Kelly Sanoff, MD, MPH
Chemotherapy for Stage III
Jeffrey A. Meyerhardt, MD, MPH—Chair
Chemoprevention Strategies
Challenges in Managing and Coordinating Care in Different Settings for
Geriatric Patients with Cancer
Location: S100a
Arti Hurria, MD—Chair
City of Hope
Incorporating Geriatric Assessment in Decision Making for Elderly Patients with Cancer
Miriam B. Rodin, MD, PhD
St. Louis University Medical School
Optimizing Communication between Geriatric Care Providers and Oncologists
Heidi D. Klepin, MD, MS
Wake Forest University, School of Medicine
Hands-on Management: Chemotherapy Dosing, Polypharmacy, and Toxicity Assessment in
Elderly Patients with Cancer
How to Translate the Wealth of Information in The Cancer Genome Atlas into
Improved Outcomes: Data Mining and Biologic Validation
Location: E450
Charles M. Perou, PhD—Chair
What Can I Learn about My Tumor by Looking at Yours? The PAN-CAN Project
William C. Hahn, MD, PhD
From TCGA to Signaling Networks: Moving Along the Translational Road
90
Lynda Chin, MD
Biological Validation of Potentially Druggable Targets from The Cancer Genome Atlas
Positive Trials in Lung Cancer: Statistical versus Real Clinical Significance
Location: E Hall D1
SATURDAY
Rogerio Lilenbaum, MD
Yale University School of Medicine
Recent Positive Clinical Trials and Data in Context of Study Results, Design, and Endpoints
Natasha B. Leighl, MD, MMSc, FRCPC—Chair
Clinically Meaningful Positive Trials in Lung Cancer Incorporating ASCO Benchmarks,
Disparate Populations, the Real-Life Setting, and Community
Marcus A. Neubauer, MD
The US Oncology Network, McKesson Specialty Health
Value in Lung Cancer Care: The Use of Standardized Pathways and Cost-Effectiveness
The Challenge to Stay Current: Incorporating Technology into Practice
Location: S404
Jeremy Warner, MD, MS—Chair
Vanderbilt-Ingram Cancer Center
Advances in Website Information Resources to Aid in Clinical Practice
Aurora Research Institute, Aurora Health Care
Using Social Media to Learn and Communicate
Laura E. Strong, PhD
Quintessence Biosciences, Inc.
Electronic Tools for Patient-Reported Outcomes
The Older Patient with Glioblastoma—Ticketed Session
Location: E451a
Wolfgang Wick, MD
University of Heidelberg Medical Center
Fabio Massaiti Iwamoto, MD
91
1:15 PM - 4:15 PM Oral Abstract Session
Location: S100bc
Habibul Ahsan, MD, MMedSc—Co-Chair
Adam J. Olszewski, MD—Co-Chair
Memorial Hospital of Rhode Island
SATURDAY
1:15 PM
Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of
Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (Abstract
1500) D. L. Wickerham, R. S. Cecchini, V. G. Vogel, J. P. Costantino, W. M.
Cronin, T. B. Bevers, L. Fehrenbacher, E. R. Pajon, J. L. Wade III, A. Robidoux,
R. G. Margolese, J. M. James, C. D. Runowicz, P. A. Ganz, S. E. Reis, W. J.
McCaskill-Stevens, L. G. Ford, V. C. Jordan, N. Wolmark
1:27 PM
Vasomotor symptoms, BMI, and adherence to tamoxifen in the National
Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer
Prevention Trial (P-1). (Abstract 1501) F. L. Walcott, S. R. Land, J. P.
Costantino, D. Midthune, B. K. Dunn
1:39 PM
Estrogen alone and health outcomes in black women by African ancestry.
(Abstract 1502) R. T. Chlebowski, W. Barrington, A. K. Aragaki, J. E. Manson, G.
Sarto, M. O’Sullivan, J. A. Cauley, L. Qi, R. B. Wallace, R. L. Prentice
1:51 PM
Powel Brown, MD, PhD (Discussion of Abstract(s) 1500 –1502)
Chemoprevention in Breast Cancer: Large-Trial Results
2:03 PM
2:15 PM
Predisposing germline mutations in high grade ERⴙHER2- breast cancer
(BC) patients diagnosed (Dx). (Abstract 1503) J. E. Garber, N. M. Tung, E. P.
Elkin, B. Allen, A. Hartman, N. Singh, R. J. Wenstrup, E. P. Winer, N. U. Lin
2:27 PM
Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy
(RRSO) in women with BRCA mutations (BRCAⴙ): A multicenter,
prospective study. (Abstract 1504) C. A. Shu, M. C. Pike, A. R. Jotwani, T. M.
Friebel, R. A. Soslow, D. A. Levine, M. E. Robson, J. A. Konner, J. L. Blum, S. L.
Neuhausen, J. E. Garber, M. B. Daly, C. Isaacs, R. A. Eeles, P. A. Ganz, C.
Aghajanian, K. Offit, S. M. Domchek, T. R. Rebbeck, N. D. Kauff
2:39 PM
Initial results of a prospective, multicenter trial to study inherited lung cancer
risk associated with germline EGFR T790M: INHERIT EGFR. (Abstract 1505)
G. R. Oxnard, J. C. Heng, E. J. Root, I. R. Rainville, A. L. Sable-Hunt, K. P.
Shane-Carson, D. P. Carbone, G. L. Wiesner, J. E. Garber
2:51 PM
James M. Ford, MD (Discussion of Abstract(s) 1503–1505)
New Familial Syndromes: Building New Cohorts and Interventions
3:03 PM
3:15 PM
Statin use and all-cancer mortality: Prospective results from the Women’s
Health Initiative. (Abstract 1506) A. Wang, A. K. Aragaki, J. Y. Tang, A. W.
Kurian, J. E. Manson, R. T. Chlebowski, M. S. Simon, P. M. Desai, S. WassertheilSmoller, S. Liu, S. Kritchevsky, H. A. Wakelee, M. L. Stefanick
3:27 PM
Post-diagnosis BMI and physical activity in association with triple-negative
breast cancer prognosis: Results from 5 prospective cohorts. (Abstract
1507) S. J. Nechuta, B. J. Caan, W. Y. Chen, M. Dwek, M. Gao, S. Flatt, E. Poole,
R. E. Patterson, J. P. Pierce, C. Robertson, R. Swann, W. Zheng, X. Shu
92
3:39 PM
Alcohol consumption and prognosis in patients with stage III colon cancer: A
correlative analysis of phase III trial NCCTG N0147 (Alliance). (Abstract 1508)
A. I. Phipps, Q. Shi, P. J. Limburg, G. D. Nelson, D. J. Sargent, F. A. Sinicrope, E.
Chan, S. Gill, R. M. Goldberg, M. S. Kahlenberg, S. Nair, A. F. Shields, P. A.
Newcomb, S. R. Alberts
3:51 PM
John A. Baron, MD (Discussion of Abstract(s) 1506 –1508)
The Association among Lifestyle, Cancer Risk, and Outcomes
4:03 PM
SATURDAY
Location: S102
Helen M. Parsons, PhD, MPH—Co-Chair
The University of Texas Health Science Center at San Antonio
Ann Partridge, MD, MPH—Co-Chair
1:15 PM
The Technology Enhanced Navigation (TEN) Trial among low-income
patients with breast cancer. (Abstract 6500) K. J. Helzlsouer, S. Appling, S.
Scarvalone, S. Manocheh, L. Gallicchio, R. MacDonald, D. Henninger, A. Varanasi
1:27 PM
Financial burden of cancer clinical trials: Impact of an equity program
intervention. (Abstract 6501) R. D. Nipp, D. Finkelstein, E. Powell, L. Vittorio, N.
Birrer, B. A. Chabner, H. Lee, B. Moy
1:39 PM
Trends in resource utilization and costs during implementation of a lay
navigation program. (Abstract 6502) G. B. Rocque, M. Pisu, B. E. Jackson, E. A.
Kvale, A. Acemgil, R. A. Taylor, W. Demark-Wahnefried, K. Kenzik, Y. Li, M.
Martin, N. Lisovicz, K. Meneses, M. Fouad, E. E. Partridge
1:51 PM
Ann H. Partridge, MD, MPH (Discussion of Abstract(s) 6500-6502)
Interventions to Improve Equity in Cancer Care Delivery
2:03 PM
2:15 PM
How should we estimate costs of care attributable to cancer? (Abstract 6503)
A. B. Chen, L. Li, A. Cronin, G. Brooks, B. D. Kavanagh, D. Schrag
2:27 PM
Cost of chemotherapy for metastatic colorectal cancer with either
bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.
(Abstract 6504) D. Schrag, A. C. Dueck, M. J. Naughton, D. Niedzwiecki, C. Earle,
J. E. Shaw, A. Grothey, H. S. Hochster, C. D. Blanke, A. P. Venook
2:39 PM
Necitumumab in metastatic squamous non-small cell lung cancer
(mSqNSCLC): Establishing a value-based cost. (Abstract 6505) D. A.
Goldstein, Q. Chen, T. Ayer, D. H. Howard, J. Lipscomb, S. S. Ramalingam, F. R.
Khuri, C. Flowers
2:51 PM
Peter Bach, MD (Discussion of Abstract(s) 6503– 6505)
Cost and Value in Cancer Treatment Choice
3:03 PM
3:15 PM
Value of information analyses for real-time prioritization decisions within a
cancer clinical trials cooperative group. (Abstract 6506) C. S. Bennette, S. D.
Ramsey, D. L. Veenstra, A. Basu, J. J. Carlson
3:27 PM
Physician-driven variation in non-recommended imaging for women with
early stage breast cancer. (Abstract 6507) A. N. Lipitz Snyderman, C. S. Sima,
E. B. Elkin, C. L. Atoria, C. Anderson, V. S. Blinder, P. Bach
93
3:39 PM
Prevalence and consequences of second opinions from medical oncologists
for early-stage breast cancer: Results from the iCanCare study. (Abstract
6508) A. W. Kurian, C. R. Friese, I. Bondarenko, R. Jagsi, S. J. Katz
3:51 PM
Caprice Christian Greenberg, MD, MPH (Discussion of Abstract(s)
6506 – 6508)
University of Wisconsin School of Medicine and Public Health
Decision Making in Settings of Uncertainty
4:03 PM
SATURDAY
Joseph G. Jurcic, MD—Co-Chair
To Be Determined—Co-Chair
1:15 PM
Correlation of acute myeloid leukemia (AML) stem cell phenotype with
cytogenetic/molecular features and prognosis. (Abstract 7000) J. M. Gerber,
J. F. Zeidner, S. Morse, A. Blackford, B. Perkins, B. Yanagisawa, H. Zhang, L.
Morsberger, J. E. Karp, Y. Ning, C. D. Gocke, G. L. Rosner, B. Smith, R. J. Jones
1:25 PM
Association between KIR genes and risk of MDS. (Abstract 7001) M. Daher, C.
Sobieski, D. Marin, T. Sekine, E. J. Shpall, R. E. Champlin, H. M. Kantarjian, G.
Garcia-Manero, K. Rezvani
1:35 PM
The international Prognostic Index for patients with CLL (CLL-IPI): An
international meta-analysis. (Abstract 7002) N. Kutsch, J. Bahlo, J. C. Byrd, H.
Dohner, B. Eichhorst, M. Else, C. Geisler, M. R. Grever, S. Leprêtre, M. Bergman,
D. S. Neuberg, D. Oscier, R. Rosenquist, T. Robak, T. D. Shanafelt, S.
Stilgenbauer, M. J. Hallek, International CLL-IPI working group
1:45 PM
Wendy Stock, MD (Discussion of Abstract(s) 7000 –7002)
The University of Chicago Medical Center
New Biomarkers and Prognostic Indicators in Leukemia and Myelodysplastic
Syndrome
1:57 PM
2:07 PM
Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent
inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute
myeloid leukemia (AML). (Abstract 7003) M. J. Levis, A. E. Perl, J. K. Altman,
J. E. Cortes, E. K. Ritchie, R. A. Larson, C. C. Smith, E. S. Wang, S. A. Strickland,
M. R. Baer, M. R. Litzow, D. Claxton, G. J. Schiller, C. Ustun, C. Liu, S. Gill, B.
Sargent, E. Bahceci
2:17 PM
Clinical activity of ERY001 (erythrocyte encapsulated l-asparaginase) and
native l-asparaginase (L-ASP) in combination with COOPRALL regimen in
phase III randomized trial in patients with relapsed acute lymphoblastic
leukemia (ALL). (Abstract 7004) Y. Bertrand, A. Baruchel, X. G. Thomas, N. Blin,
E. Tavernier Tardy, Y. Perel, N. Vey, V. Gandemer, V. Cacheux, F. Mazingue, E.
Raffoux, G. Plat, M. Poiree, J. Stephan, A. Auvrignon, D. Plantaz, I. Pellier, C.
Bonin, I. El-Hariry, A. Ferster
2:27 PM
Ibrutinib combined with bendamustine and rituximab (BR) in previously
treated chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL): First results from a randomized, double-blind, placebo-controlled,
phase III study. (Abstract LBA7005) A. A. Chanan-Khan, P. Cramer, F.
Demirkan, G. Fraser, R. S. Silva, H. Pylypenko, S. Grosicki, A. Janssens, A.
Pristupa, J. Mayer, M. Dilhuydy, J. Loscertales, N. L. Bartlett, A. Avigdor, S. Rule,
S. Sun, M. Mahler, M. Salman, A. J. Howes, M. J. Hallek
94
2:37 PM
Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best
available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia
vera myelofibrosis (PPV-MF), or post-essential
thrombocythemia-myelofibrosis (PET-MF). (Abstract LBA7006) R. A. Mesa, M.
Egyed, A. Szoke, A. Suvorov, A. Perkins, J. Mayer, P. Ganly, E. Jourdan, H. C.
Schouten, P. Tosi, C. M. Farber, P. Zachee, C. Scheid, J. P. Dean, P. Cernohous,
J. Nangalia, J. Kiladjian, A. M. Vannucchi, A. Mead, C. N. Harrison
2:47 PM
Lloyd Earl Damon, MD (Discussion of Abstract(s) 7003-LBA7006)
Advancements in the Therapy of Hematologic Malignancies
2:59 PM
3:09 PM
Long-term follow-up of patients with acute myelogenous leukemia receiving
an autologous telomerase-based dendritic cell vaccine. (Abstract 7007) H. J.
Khoury, R. Collins, W. G. Blum, P. J. Stiff, J. Lebkowski, E. Wirth III, K. Nishimoto,
J. F. DiPersio
3:19 PM
Allogeneic transplantation for myelofibrosis: Final analysis of a prospective
study after a median follow up of 5 years. (Abstract 7008) U. R. Popat, R. L.
Bassett Jr., J. Chen, A. M. Alousi, P. Anderlini, S. O. Ciurea, C. Hosing, R. B.
Jones, P. Kebriaei, I. F. Khouri, S. Konoplev, M. J. De Lima, Y. Nieto, B. Oran,
M. H. Qazilbash, G. Rondon, E. J. Shpall, S. Verstovsek, B. Andersson, R. E.
Champlin
3:29 PM
Association of reduced intensity conditioning (RIC) allograft (alloHCT) as
first transplant approach in relapsed/refractory grade 3(G-3) follicular
lymphoma (FL) with improved outcomes in long-term survivors. (Abstract
7009) E. Klyuchnikov, U. Bacher, N. Kröger, P. Hari, K. W. Ahn, D. G. Maloney,
S. M. Smith, A. M. Sureda, J. Carreras, M. Hamadani
3:39 PM
Efficacy and safety of CD19-targeted 19 –28z CAR modified T cells in adult
patients with relapsed or refractory B-ALL. (Abstract 7010) J. H. Park, I.
Riviere, X. Wang, Y. Bernal, T. Purdon, E. Halton, K. J. Curran, C. S. Sauter, M.
Sadelain, R. J. Brentjens
3:49 PM
Michael R. Bishop, MD, FACP (Discussion of Abstract(s) 7007-7010)
Cellular Therapies Including Hematopoietic Cell Transplantation and Chimeric
Antigen Receptor T cells for Hematologic Malignancies
4:01 PM
Location: E354b
Axel Hauschild, MD—Co-Chair
University of Kiel
Sekwon Jang, MD—Co-Chair
Inova Comprehensive Cancer and Research Institute
1:15 PM
Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind
randomized controlled trial. (Abstract 9000) A. J. Martin, A. Chen, B. Choy,
P. F. Penas, G. Halliday, R. Dalziell, C. McKenzie, R. A. Scolyer, H. M. Dhillon,
J. L. Vardy, G. St George, N. Chinniah, D. Damian
1:27 PM
Long term follow up of survival in a randomised trial of wide or narrow
excision margins in high risk primary melanoma. (Abstract 9001) A. J. Hayes,
L. Maynard, R. A’Hern, G. Coombes, J. Newton-Bishop, M. Timmons, M. Cook, J.
Theaker, J. Bliss, J. M. Thomas
95
SATURDAY
SATURDAY
1:39 PM
Survival of SLNB-positive melanoma patients with and without complete
lymph node dissection: A multicenter, randomized DECOG trial. (Abstract
LBA9002) U. Leiter, R. Stadler, C. Mauch, W. Hohenberger, N. Brockmeyer, C.
Berking, C. Sunderkötter, M. Kaatz, K. Schulte, P. Lehmann, T. Vogt, J. Ulrich, R.
Herbst, W. Gehring, J. Simon, U. Keim, C. Garbe
1:51 PM
Surveillance imaging with FDG-PET in the follow-up of melanoma patients at
high risk of relapse. (Abstract 9003) J. H. Lewin, A. Sanelli, I. Walpole, D. Kee,
M. A. Henderson, D. Speakman, J. Spillane, D. E. Gyorki, V. Estall, L. Te
Marvelde, K. Pope, M. Chua, G. A. McArthur, R. J. Hicks, M. J. Shackleton
2:03 PM
Daniel G. Coit, MD (Discussion of Abstract(s) 9000 –9003)
Primary Prevention and Surgical Management of Early-Stage Skin Cancer
2:15 PM
2:27 PM
Clinical response, progression-free survival (PFS), and safety in patients
(pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined
with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (Abstract
9004) F. S. Hodi, M. A. Postow, J. A. Chesney, A. C. Pavlick, C. Robert, K. F.
Grossmann, D. F. McDermott, G. P. Linette, N. Meyer, J. K. Giguere, S. S.
Agarwala, M. F. Shaheen, M. S. Ernstoff, D. R. Minor, A. Salama, M. H. Taylor,
P. A. Ott, C. E. Horak, P. Gagnier, J. D. Wolchok
2:39 PM
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled
analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in
KEYNOTE-001. (Abstract 9005) A. Daud, A. Ribas, C. Robert, F. S. Hodi, J. D.
Wolchok, A. M. Joshua, W. Hwu, J. S. Weber, T. C. Gangadhar, R. W. Joseph,
R. S. Dronca, A. Patnaik, H. M. Zarour, R. Kefford, J. A. Lindia, X. Li, S.
Ebbinghaus, S. P. Kang, O. Hamid
2:51 PM
Svetomir Markovic, MD, PhD (Discussion of Abstract(s) 9004 –9005)
Mayo Clinic
PD-1 Inhibition in Advanced Melanoma
3:03 PM
3:15 PM
Update of progression-free survival (PFS) and correlative biomarker analysis
from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in
advanced BRAF-mutated melanoma. (Abstract 9006) J. M. Larkin, Y. Yan, G. A.
McArthur, P. A. Ascierto, G. Liszkay, M. Maio, M. Mandalà, L. V. Demidov, D.
Stroyakovskiy, L. Thomas, L. De La Cruz-Merino, V. Atkinson, C. Dutriaux, C.
Garbe, M. Wongchenko, I. A. Rooney, I. Chang, S. P. Hack, B. Dréno, A. Ribas
3:27 PM
A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK
inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to
BRAFi treatment. (Abstract 9007) R. J. Sullivan, J. S. Weber, S. P. Patel, R.
Dummer, W. H. Miller Jr., D. Cosgrove, M. S. Carlino, D. S. Tan, C. Lebbe, T.
Cipani, E. Élez, H. Maacke, P. Nikolopoulos, M. Aout, L. A. De Parseval, P. A.
Ascierto
3:39 PM
BRAF inhibitor acquired resistance: A multicenter meta-analysis of the
spectrum and clinical implications of resistance mechanisms. (Abstract
9008) D. B. Johnson, A. M. Menzies, L. Zimmer, Z. Eroglu, F. Ye, S. Zhao, A.
Sucker, H. Rizos, W. Hugo, R. Gutzmer, R. Kefford, H. Gogas, X. Kong, R. A.
Scolyer, L. A. Garraway, J. A. Sosman, A. Ribas, R. Lo, G. V. Long, D.
Schadendorf
3:51 PM
Michael A. Davies, MD, PhD (Discussion of Abstract(s) 9006 –9008)
Response and Resistance with BRAF/MEK Inhibition
4:03 PM
96
1:15 PM - 4:45 PM Poster Session
Genitourinary (Prostate) Cancer
Location: S Hall A
Board 1
Phase III SYNERGY trial: Docetaxel ⴙ/- custirsen and overall survival in
patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
and poor prognosis. (Abstract 5009) K. N. Chi, C. S. Higano, B. A. Blumenstein,
J. A. Reeves, S. Feyerabend, G. Gravis, J. Ferrero, C. Jacobs, J. S. De Bono,
SYNERGY Investigators
Board 2
A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel
(CAB) plus or minus carboplatin (CARB) in men with metastatic castrationresistant prostate cancer (mCRPC). (Abstract 5010) P. G. Corn, S. Tu, A. J.
Zurita, S. K. Subudhi, J. C. Araujo, J. Kim, E. Jonasch, L. C. Pagliaro, A. O.
Siefker-Radtke, J. Wang, X. Wang, E. I. Heath, C. Logothetis, A. Aparicio
Board 3
Efficacy analysis of a phase III study of androgen deprivation therapy (ADT)
ⴙ/- docetaxel (D) for men with biochemical relapse (BCR) after
prostatectomy. (Abstract 5011) M. J. Morris, P. Hilden, M. E. Gleave, A. J.
Armstrong, M. A. Carducci, F. Saad, E. S. Dayan, J. Filipenko, I. Acosta, G. Heller,
H. I. Scher
Board 4
Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostatespecific antigen (PSA) and bone alkaline phosphatase (bALP) in patients
(pts) with castration-resistant prostate cancer (CRPC) and bone metastases
(mets): A phase 1/2a clinical trial. (Abstract 5012) M. J. Morris, C. S. Higano,
H. I. Scher, C. Sweeney, E. S. Antonarakis, D. H. Shevrin, C. J. Ryan, Y. Loriot, K.
Fizazi, N. Pandit-Taskar, J. E. Garcia-Vargas, K. Lyseng, M. Bloma, J. A.
Carrasquillo
Board 5
Association of SLCO transport genes with intraprostatic abiraterone (ABI)
levels and pathologic outcomes in men with high-risk localized prostate
cancer (PCa). (Abstract 5013) E. A. Mostaghel, E. Cho, J. L. Wright, M. Loda, B.
Marck, A. M. Matsumoto, D. Tamae, T. M. Penning, S. P. Balk, P. W. Kantoff, P.
Nelson, M. Taplin, R. B. Montgomery
Board 6
EARLY CTC decline as a biomarker of response to treatment in castrationresistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38
trials. (Abstract 5014) D. Lorente, D. Olmos, J. Mateo, D. Bianchini, G. Seed, P.
Flohr, M. Crespo, I. Figueiredo, S. Miranda, K. Baeten, T. Pitfield, A. Molina, T.
Kheoh, R. T. Mccormack, H. I. Scher, J. S. De Bono
Board 7
Genomic analysis of circulating cell-free DNA (cfDNA) to investigate
mechanisms of primary and acquired resistance to enzalutamide (ENZ) in
metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5015) A.
Azad, A. Wyatt, S. Volik, A. Haegert, F. Mo, S. Le Bihan, R. H. Bell, S. A.
Anderson, B. McConeghy, R. Shukin, M. E. Gleave, C. Collins, K. N. Chi
Board 8
Validation of a genomic classifier for prediction of metastasis following
postoperative salvage radiation therapy. (Abstract 5016) R. Den, E. Davicioni,
V. Choeurng, L. Howard, A. de Hoedt, M. Du Plessis, K. Yousefi, L. L. Lam, C.
Buerki, E. J. Trabulsi, A. Dicker, J. Karnes, S. J. Freedland
Board 9
Progression of low- to high-grade prostate cancer: Molecular profiling of
tissue obtained by serial targeted biopsy. (Abstract 5017) G. S. Palapattu,
A. K. Cani, J. Huang, D. H. Hovelson, D. Lu, D. Margolis, S. Natarajan, R. Mehra,
J. S. Montgomery, T. M. Morgan, S. A. Tomlins, L. S. Marks
Board 10
Combination statin/metformin and prostate cancer specific mortality: A
population-based study. (Abstract 5018) G. L. Lu-Yao, Y. Lin, D. Moore, J.
Graff, A. Stroup, K. McGuigan, S. Crystal, S. Amin, K. Demissie, R. S. DiPaola
97
SATURDAY
Abstracts 5009 –5020 will be discussed during the Genitourinary (Prostate) Cancer Poster Discussion Session. See page 134 for session information.
SATURDAY
Board 11
A phase III trial of short-term androgen deprivation therapy in intermediaterisk prostate cancer treated with radiotherapy. (Abstract 5019) A. Nabid, N.
Carrier, E. Vigneault, L. Souhami, C. Lemaire, M. Brassard, B. Bahoric, R.
Archambault, F. Vincent, T. Nguyen-Huynh
Board 12
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
(Abstract 5020) J. W. Hearn, G. AbuAli, C. Magi-Galluzzi, C. A. Reddy, K. Chang,
E. A. Klein, N. Sharifi
Board 13
Association of the prostate cancer risk mutation G84E in HOXB13 with the
subtype of ETS fusion negative adenocarcinoma with early age of diagnosis.
(Abstract 5021) T. J. Schnoeller, M. Luedeke, A. Rinckleb, J. L. Stanford, L.
Fitzgerald, J. Schleutker, T. Wahlfors, R. A. Eeles, Z. Kote-Jarai, S. Weikert, H.
Krause, K. Herkommer, J. Hoegel, C. Maier
Board 14
Project Data Sphere: A first look at prostate cancer including concomitant
medication use, prognosis, and toxicity. (Abstract 5022) A. M. Joshua, B. Gill,
L. Khoja, M. Pintilie, K. Abdallah
Board 15
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane
antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate
cancer after radical prostatectomy. (Abstract 5023) T. Maurer, J. Gschwend, H.
Wester, M. Souvatzoglou, A. Beer, K. Holzapfel, G. Weirich, B. Haller, H. Kübler,
M. Schwaiger, M. Eiber
Board 16
Statin use at the time of initiation of androgen deprivation therapy and time
to progression in patients with hormone-sensitive prostate cancer. (Abstract
5024) L. C. Harshman, X. Wang, M. Nakabayashi, W. Xie, L. B. Valenca, L.
Werner, Y. Yu, A. Kantoff, C. Sweeney, L. A. Mucci, M. Pomerantz, G. M. Lee,
P. W. Kantoff
Board 17
Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide
in men with metastatic castration resistant prostate cancer (mCRPC).
(Abstract 5025) A. J. Armstrong, S. Halabi, P. Healy, J. J. Alumkal, E. Y. Yu, C.
Winters, C. Hobbs, C. Soleau, R. Slottke, K. Mundy, D. J. George
Board 18
National prostate cancer screening rates following the 2012 United States
Preventive Services Task Force recommendation discouraging prostatespecific antigen (PSA)-based screening. (Abstract 5026) M. W. Drazer, D. Huo,
S. E. Eggener
Board 19
The combination of DNA ploidy status and PTEN/6q15 deletions to provide
strong and independent prognostic information in prostate cancer. (Abstract
5027) M. Lennartz, S. Minner, M. Kluth, S. Brasch, H. Wittmann, L. Paterna, H.
Heinzer, R. Simon, G. Sauter, T. Schlomm
Board 20
Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P)
in patients (pts) with metastatic castration-resistant prostate cancer
(mCRPC). (Abstract 5028) E. M. Posadas, K. N. Chi, R. De Wit, M. J. De Jonge,
G. Attard, T. W. Friedlander, M. K. Yu, P. Hellemans, C. Chien, C. C. Abrams, M.
Gonzalez, G. C. Trudel, V. Chauhan, J. Jiao, F. Saad
Board 21
STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity
in metastatic castration resistant prostate cancer (mCRPC). (Abstract 5029)
D. C. Danila, M. Fleisher, J. A. Carrasquillo, H. Gilbert, M. J. Morris, L. P. Bellomo,
P. J. Hendrikx, E. Szafer-Glusman, A. Herkal, C. Patel, N. A. Schreiber, K. R.
Curtis, D. J. Maslyar, V. Lemahieu, B. M. Fine, M. J. Mamounas, A. J. Ungewickell,
M. R. Lackner, H. I. Scher, O. Kabbarah
Board 22
Immune responses and clinical outcomes in STAND, a randomized phase 2
study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen
deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC)
after local therapy failure. (Abstract 5030) E. S. Antonarakis, A. S. Kibel, G. W.
Adams, L. I. Karsh, A. Elfiky, N. D. Shore, N. J. Vogelzang, J. M. Corman, J. C.
Maher, T. DeVries, C. McCoy, N. A. Sheikh, C. G. Drake
Board 23
Baseline analysis of circulating tumor cell (CTC) enumeration and androgen
receptor (AR) localization in men with metastatic castration-resistant
prostate cancer (mCRPC) in TAXYNERGY. (Abstract 5031) S. T. Tagawa, G.
98
Board 25
Performance of CCP assay in an updated series of biopsy samples obtained
from commercial testing. (Abstract 5033) J. W. Davis, E. Crawford, N. Shore,
P. T. Scardino, J. D. Tward, L. Harrison, B. Evans, L. FitzGerald, S. Stone, M. K.
Brawer
Board 26
Radium-223 in an international early access program (EAP): Effects of
concomitant medication on overall survival in metastatic castration-resistant
prostate cancer (mCRCP) patients. (Abstract 5034) F. Saad, J. Carles, S.
Gillessen, D. Heinrich, J. Gratt, K. Miller, S. Nilsson, J. O’Sullivan, M. Tucci, M.
Wirth, A. Heidenreich
Board 27
Circulating tumor cell (CTC) enumeration in men with metastatic castrationresistant prostate cancer (mCRPC) treated with enzalutamide
post-chemotherapy (phase 3 AFFIRM study). (Abstract 5035) M. Fleisher, D. C.
Danila, K. Fizazi, M. Hirmand, B. Selby, D. Phung, J. S. De Bono, H. I. Scher
Board 28
Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castrationresistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL
study. (Abstract 5036) T. M. Beer, A. J. Armstrong, C. N. Sternberg, C. S. Higano,
D. E. Rathkopf, Y. Loriot, F. Saad, A. M. Joshua, J. S. De Bono, P. M. Venner,
J. Carles, P. N. Mainwaring, C. P. Evans, T. Parli, H. H. Mansbach, S.
Bhattacharya, S. Van Os, D. Phung, B. F. Tombal
Board 29
Phase 1 study with expansion cohorts of cabozantinib (C) ⴙ abiraterone (A)
in metastatic castration resistant prostate cancer (mCRPC): Investigatorsponsored study. (Abstract 5037) C. Sweeney, K. P. Gray, L. C. Harshman, M.
Taplin, A. F. Pace, K. Dumas, J. G. Supko, K. A. Zukotynski, B. D. Bernard, M.
Pomerantz, A. Elfiky, P. W. Kantoff
Board 30
Acute toxicity and early quality of life after dose intensified salvage
radiotherapy for biochemically recurrent prostate cancer after
prostatectomy. First results of the randomized trial SAKK 09/10. (Abstract
5038) P. Ghadjar, T. Hoelscher, P. Gut, M. Guckenberger, G. Hildebrandt, A.
Mueller, L. Plasswilm, A. Papachristofilou, S. Hayoz, M. Sumila, H. Kranzbuehler,
Y. Najafi, P. Ost, N. C. Azinwi, D. R. Zwahlen, C. Reuter, S. Bodis, P. Wust, J.
Bernhard, D. M. Aebersold
Board 31
Testosterone-guided schedule of androgen deprivation therapy (ADT) as an
alternative to a fixed schedule in management of prostate cancer. (Abstract
5039) S. Niraula, F. E. Vera Badillo, A. J. Templeton, A. Dodd, Z. Nugent, I.
Tannock
Board 32
Immune response from STRIDE, a randomized, phase 2, open label study of
sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz)
administration in metastatic castration-resistant prostate cancer (mCRPC).
(Abstract 5040) D. I. Quinn, C. G. Drake, R. Dreicer, E. S. Antonarakis, N. D.
Shore, J. M. Corman, R. S. Concepcion, C. M. Pieczonka, N. N. Chang, T.
DeVries, N. A. Sheikh, D. P. Petrylak
Board 33
Relationship between abiraterone plasma concentration and PSA response
in metastatic castration resistant prostate cancer patients. (Abstract 5041) E.
Carton, G. Noe, O. Huillard, J. Giroux, A. Cessot, M. Peyromaure, M. Zerbib, C.
Narjoz, A. Thomas-Schoemann, M. Vidal, F. Goldwasser, B. Blanchet, J.
Alexandre
Board 34
Genomic analysis of circulating tumor cells (CTCs) from men with metastatic
castration resistant prostate cancer (mCRPC) in the context of enzalutamide
therapy. (Abstract 5042) J. Li, J. Beaver, R. L. Bitting, S. Gregory, A. J. Armstrong
Board 35
Nine-year follow-up for a study of diffusion-weighted MRI in a prospective
active surveillance cohort for prostate cancer. (Abstract 5043) D. R.
Henderson, N. M. DeSouza, K. Thomas, V. A. Morgan, S. F. Riches, S. A. Sohaib,
D. P. Dearnaley, C. Parker, N. J. Van As
99
SATURDAY
Galletti, E. S. Antonarakis, S. Tasaki, A. Gjyrezi, D. Worroll, L. Portella, B. J. Kirby,
J. Stewart, A. Zaher, F. Saad, M. Vanhuyse, S. Suri, T. B. Lannin, C. Gruber, E.
Pratt, G. Sonpavde, M. A. Eisenberger, D. M. Nanus, P. Giannakakou
SATURDAY
Board 36
Computer automated bone scan index (BSI) as an analytically validated
imaging biomarker to quantitate change in bone scan of patients with
metastatic prostate cancer. (Abstract 5044) A. Anand, D. Minarik, R. Kaboteh,
S. Lindgren Belal, M. Reza, A. Joseffson, L. Edenbrandt, A. Bjartell
Board 37
Identification of germline mutations in men with early onset prostate cancer.
(Abstract 5045) P. Pilie, A. M. Johnson, K. A. Zuhlke, L. A. Okoth, S. Tomlins,
K. A. Cooney
Board 38
Influence of prostate cancer disease state and therapeutic selection on
peripheral whole-blood RNA signature. (Abstract 5046) B. C. Liaw, U.
Chippada-Venkata, Y. Gong, L. Wang, J. Zhu, M. M. Heck, C. Tsao, M. D. Galsky,
W. K. Oh
Board 40
Prognostic index model (PIM) for overall survival (OS) in metastatic
castration-resistant prostate cancer (mCRPC) patients (pts) without prior
chemotherapy treated with abiraterone acetate (AA). (Abstract 5047) C. J.
Ryan, T. Kheoh, J. Li, A. Molina, P. De Porre, J. Carles, E. Efstathiou, P. W.
Kantoff, P. F. Mulders, F. Saad, T. W. Griffin, K. N. Chi
Board 41
Association of single nucleotide polymorphisms (SNPs) in ESR1 and PRMT8
and response to treatment with abiraterone acetate (AA) in men with
metastatic castration refractory prostate cancer (mCRPC). (Abstract 5048) N.
Agarwal, A. Alex, J. M. Farnham, S. B. Patel, S. K. Tantravahi, C. Teerlink, F. S.
Albright, R. A. Stephenson, L. A. Cannon-Albright
Board 42
TERRAIN. (Abstract 5049) S. Chowdhury, A. Heidenreich, A. Villers, L. Klotz,
D. R. Siemens, D. Phung, F. Wang, D. Forer, S. Van Os, N. D. Shore
Board 43
LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer
(CRPC) patients (pts) progressing on second line anti-androgen (AA):
NYU-08479/PCCTC. (Abstract 5050) A. C. Ferrari, J. J. Alumkal, M. N. Stein,
T. M. Mayer, S. Torneten, J. Babb, M. Taplin, R. S. DiPaola, T. M. Beer
Board 44
Phase 1–2 study of progesterone receptor (PR) inhibition with extendedrelease (ER) onapristone (ONA) in patients (pts) with castration-resistant
prostate cancer (CRPC): PK, safety and PR testing results from the dose
escalation cohort. (Abstract 5051) A. Jayaram, K. Nowakowska, J. Mateo, D.
Nava Rodrigues, R. Riisnaes, A. Zukiwski, S. Proniuk, A. S. Bexon, J. Bisaha, D.
Bianchini, Z. Zafeiriou, R. Perez Lopez, N. Tunariu, J. S. De Bono, G. Attard
Board 45
Disease burden and outcome in metastatic hormone sensitive prostate
cancer (mHSPC). (Abstract 5052) L. Albiges, W. Xie, Y. Chen, J. Boher, L. B.
Valenca, B. D. Bernard, S. Culine, M. Habibian, M. A. Carducci, R. S. DiPaola, G.
Liu, M. Pomerantz, M. Nakabayashi, P. W. Kantoff, K. Fizazi, G. Gravis, C.
Sweeney
Board 46
IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone
on PSA and radiographic disease progression in patients with
non-metastatic castration-resistant prostate cancer. (Abstract 5053) C. J.
Ryan, E. D. Crawford, N. D. Shore, W. Underwood III, A. Londhe, S. C. Black, T.
McGowan, P. W. Kantoff
Board 47
Tumor-directed PET imaging of metastases in metastatic castration-resistant
prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific
membrane antigen (PSMA) antibody J591. (Abstract 5054) J. L. Feldman, M. J.
Morris, D. F. Martinez, S. T. Tagawa, D. M. Nanus, S. B. Solomon, J. A.
Carrasquillo, V. E. Reuter, J. S. Lewis, J. A. O’ Donoghue, S. F. Slovin, D. E.
Rathkopf, M. Gonen, V. Beylergil, J. C. Durack, S. M. Cheal, N. H. Bander, H. I.
Scher, S. M. Larson, N. Pandit-Taskar
Board 49
Molecular characterization of clinically defined aggressive variant prostate
cancer (AVPCa) in prospectively collected tissues and corresponding patient
derived xenografts (PDX). (Abstract 5055) A. Aparicio, L. Shen, E. L. Tapia, J.
Lu, H. Chen, J. Zhang, G. Wu, X. Wang, P. Troncoso, P. G. Corn, T. C. Thompson,
B. M. Broom, K. A. Baggerly, C. Logothetis, S. N. Maity
Board 50
A molecular and clinico-pathological model for predicting abiraterone
acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate
100
Board 51
Validation of correlation of RECIST changes with survival in metastatic
castration-resistant prostate cancer (mCRPC). (Abstract 5057) G. R. Pond,
A. J. Templeton, D. P. Petrylak, A. Fandi, B. F. Tombal, M. Rosenthal, G.
Sonpavde
Board 52
Development of an imaging approach to detect splice variants of androgen
receptor in prostate cancer. (Abstract 5058) Y. Imamura, A. H. Tien, J.
Kunzhong, J. Pan, K. Lin, R. J. Andersen, M. Sadar
Board 53
Tissue-based genomics to augment post-prostatectomy risk stratification in
a natural history cohort. (Abstract 5059) A. Ross, M. H. Johnson, K. Yousefi, E.
Davicioni, H. L. Fedor, S. Glavaris, V. Choeurng, C. Buerki, L. L. Lam, N. Erho,
E. B. Humphreys, G. J. Netto, M. Han, A. W. Partin, B. J. Trock, E. M. Schaeffer
Board 54
Evaluation of the contribution of individual gene groups to a 17-gene
prognostic prostate cancer signature. (Abstract 5060) D. Knezevic, R. Lu, E.
Burke, M. Rothney, N. Zhang, H. Lawrence, P. G. Febbo
Board 55
Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and
leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk
prostate cancer (LHRPC). (Abstract 5061) E. Efstathiou, P. Troncoso, E. L.
Tapia, J. W. Davis, M. A. Titus, A. Hoang, I. N. Prokhorova, S. Wen, C. Logothetis
Board 56
Genomic characterization of primary and metastatic prostate cancer (PC)
using a targeted next-generation sequencing assay. (Abstract 5062) W.
Abida, K. R. Curtis, B. S. Taylor, M. E. Arcila, R. Brennan, D. C. Danila, D. E.
Rathkopf, M. J. Morris, S. F. Slovin, D. B. Solit, D. M. Hyman, A. Gopalan, M. F.
Berger, N. Schultz, H. I. Scher
Board 57
Ra-223 experience in pretreated patients: EAP setting. (Abstract 5063) A. O.
Sartor, D. C. Fernandez, M. J. Morris, A. Iagaru, A. Brown Jr., F. Almeida, C.
Sweeney, M. R. Smith, A. Dicker, Y. Wong, N. D. Shore, J. Gratt, O. Petrenciuc, J.
Germino, N. J. Vogelzang
Board 58
Interim performance of a non-DRE urine exosome gene signature to predict
Gleason >7 prostate cancer on initial prostate needle biopsy from patients
enrolled in a prospective observational trial. (Abstract 5064) M. J. Donovan,
M. Noerholm, S. Bentink, S. Belzer, J. Skog, G. A. Brown, J. S. Cochran, V. O’Neill
Board 59
Contemporary national trends of prostate cancer screening among privately
insured patients in the United States. (Abstract 5065) S. P. Kim, J. Karnes,
C. P. Gross, N. J. Meropol, H. K. Van Houten, R. Abouassaly, N. D. Shah
Board 60
Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for
castration resistant prostate cancer (CRPC). (Abstract 5066) M. E. Gross, T. B.
Dorff, D. I. Quinn, K. Massopust, P. M. Diaz, O. O. Castellanos, D. B. Agus
Board 61
Detecting predictive androgen receptor modifications in circulating prostate
cancer cells. (Abstract 5067) J. Steinestel, M. Luedeke, A. Arndt, T. Schnoeller,
J. K. Lennerz, C. Maier, M. Cronauer, K. Steinestel, M. Boegemann, A. J. Schrader
Board 62
Androgen receptor (AR) amplification in patients (pts) with metastatic
castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi)
and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West
Coast Prostate Cancer Dream Team (WCDT). (Abstract 5068) R. R. Aggarwal,
G. Thomas, J. Youngren, A. Foye, S. Olson, P. Paris, T. M. Beer, C. J. Ryan, O.
Witte, C. P. Evans, M. E. Gleave, J. Stuart, J. J. Alumkal, A. Toschi, N. Zona, R. E.
Reiter, P. Lara Jr., K. N. Chi, E. J. Small
Board 63a
Androgen receptor modulation optimized for response: Splice variant
(ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of
galeterone vs enzalutamide in men with metastatic castration-resistant
prostate cancer (mCRPC) expressing AR-V7 splice variant. (Abstract
101
SATURDAY
cancer (mCRPC). (Abstract 5056) M. Kohli, R. Qin, L. Wang, H. Sicotte, R.
Carlson, W. Tan, R. E. Jimenez, J. Eckel-Passow, B. A. Costello, H. C. Pitot, F.
Quevedo, R. S. Dronca, K. Wu, T. J. Moynihan, T. H. Ho, A. H. Bryce, T. D. Atwell,
B. P. McMenomy, S. Dehm
TPS5069) M. Taplin, E. S. Antonarakis, D. T. Dransfield, K. J. Ferrante, J. S. De
Bono
SATURDAY
Board 63b
Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel
chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men
with advanced (mCRPC) prostate cancer. (Abstract TPS5070) N. J. Vogelzang,
T. M. Beer, J. Bartunkova, R. Kuklı́k, K. Miller, W. K. Oh, S. Oudard, H. S. Pandha,
A. O. Sartor, R. Spisek, N. G. Borgstein, W. R. Gerritsen
Board 64a
A phase 3 randomized, placebo-controlled double-blind study of ARN-509
plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC). (Abstract TPS5071) D. E. Rathkopf, G.
Attard, E. Efstathiou, M. K. Yu, T. W. Griffin, M. B. Todd, D. Wu, T. Kheoh, X. Zhao,
F. Saad
Board 64b
A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a
novel AR N-terminal domain inhibitor, in men with metastatic castrationresistant prostate cancer (mCRPC) with progression after enzalutamide or
abiraterone. (Abstract TPS5072) R. B. Montgomery, E. S. Antonarakis, M.
Hussain, K. Fizazi, A. M. Joshua, G. Attard, M. Sadar, F. Perabo, K. N. Chi
Board 65a
Phase II multicenter study to analyze the predictive value of fusion gene
TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of
response to enzalutamide in patients with metastatic castration resistant
prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial.
(Abstract TPS5073) E. Grande, E. Gonzalez-Billalabeitia, I. Duran, C. Santander,
E. Gallardo Diaz, A. Gonzalez del Alba, J. Puente, A. Rodriguez Sanchez, A. Font,
M. Climent, L. Leon Mateos, M. Sáez, B. Mellado, M. J. Méndez-Vidal, S. VazquezEstevez, O. Fernandez Calvo, M. P. Fernandez Perez, T. Alonso, D. E. Castellano
Board 65b
A randomized phase II study of androgen deprivation therapy with or without
PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.
(Abstract TPS5074) P. L. Palmbos, F. Y. Feng, S. A. Tomlins, W. K. Kelly, A. K.
Morgans, M. Taplin, N. Agarwal, E. S. Antonarakis, P. Twardowski, J. Jacobson,
M. S. Davenport, S. Daignault, K. E. Knudsen, M. Hussain
Board 66a
A prospective, multicenter, randomized phase II trial of best systemic
therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the
primary tumor in metastatic prostate cancer. (Abstract TPS5075) B. F. Chapin,
S. E. Mcguire, X. Wang, P. Troncoso, J. W. Davis, N. Navai, S. K. Subudhi, A. J.
Zurita, J. C. Araujo, C. A. Pettaway, S. F. Matin, L. L. Pisters, J. F. Ward, S. Tu, J.
Wang, O. Le, C. Logothetis, A. Aparicio
Board 66b
Randomized phase-2 study of sipuleucel-T with or without radium-223 in men
with asymptomatic/minimally symptomatic bone-metastatic castrateresistant prostate cancer (CRPC). (Abstract TPS5076) J. Park, A. O. Sartor, R.
Sullivan, S. King, E. S. Antonarakis
Board 67a
Randomised phase 3 trial of enzalutamide in first line androgen deprivation
therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP
1304). (Abstract TPS5077) I. D. Davis, M. R. Stockler, A. J. Martin, V. Marchesin,
O. Deignan, R. McDermott, W. R. Parulekar, S. A. North, B. Graham, A. P. Long,
F. T. Roncolato, S. Yip, W. Hague, C. Dazo, X. Coskinas, C. Sweeney
Board 67b
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy
with radiation therapy for high risk, clinically localised prostate cancer: The
ANZUP ENZARAD Trial (ANZUP 1303). (Abstract TPS5078) S. G. Williams, I. D.
Davis, C. Sweeney, M. R. Stockler, A. J. Martin, V. Marchesin, O. Deignan, R.
McDermott, A. P. Long, F. T. Roncolato, S. Yip, W. Hague, E. Tu, X. Coskinas,
P. L. Nguyen
Board 68a
A randomized phase II study comparing bipolar androgen therapy vs.
enzalutamide in asymptomatic men with castration resistant metastatic
prostate cancer: The TRANSFORMER trial. (Abstract TPS5079) B. A. Teply,
E. S. Antonarakis, M. A. Carducci, C. J. Paller, H. Wang, H. Cao, A. N. Spitz, J.
Luo, M. A. Eisenberger, S. R. Denmeade
102
Board 68b
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with
high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
(Abstract TPS5080) K. Fizazi, N. D. Shore, T. L. Tammela, T. Sarapohja, A.
Vuorela, I. Kuss, A. Snapir, M. R. Smith, ARAMIS Investigators
Board 69a
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVACVF immunotherapy in men with asymptomatic/minimally symptomatic
metastatic castration-resistant prostate cancer. (Abstract TPS5081) J. L.
Gulley, J. L. Giacchino, J. B. Breitmeyer, A. J. Franzusoff, D. Panicali, J. Schlom,
P. W. Kantoff
Board 69b
ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination
with abiraterone acetate (abiraterone) and prednisone in the treatment of
asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with
bone predominant metastatic castration-resistant prostate cancer (mCRPC).
(Abstract TPS5082) M. R. Smith, C. Parker, B. F. Tombal, K. Miller, F. Saad, F.
Fang, A. Zhang, M. Kornacker, C. S. Higano
Board 70a
The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III
efficacy and safety study of continued enzalutamide plus docetaxel after
disease progression on enzalutamide alone in patients with metastatic
castration-resistant prostate cancer. (Abstract TPS5083) S. Chowdhury, R.
Davidson, A. Coppell, H. Mobasheri, A. Stari, R. Snijder, C. Treadwell, A. S.
Merseburger
Board 70b
The role of highly selective androgen receptor (AR) targeted therapy in men
with biochemically relapsed hormone sensitive prostate cancer. (Abstract
TPS5084) R. R. Aggarwal, J. J. Alumkal, R. Z. Szmulewitz, C. S. Higano, A. H.
Bryce, M. K. Yu, C. De Boer, G. Choque-Gonzales, E. J. Small
Gynecologic Cancer
Location: S Hall A
Abstracts 5513–5524 will be discussed during the Gynecologic Cancer Poster Discussion Session. See page 135 for session information.
Board 71
A phase II open-label, multicenter study of single-agent rucaparib in the
treatment of patients with relapsed ovarian cancer and a deleterious BRCA
mutation. (Abstract 5513) R. Shapira-Frommer, A. M. Oza, S. M. Domchek, J.
Balmaña, M. R. Patel, L. Chen, Y. Drew, H. A. Burris III, J. Korach, M. Flynn, V. L.
Bowering, M. A. Morgan, S. P. Watkins, D. Simpson, S. Goble, L. Maloney, R. S.
Kristeleit
Board 72
Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin
(C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low
genetic risk (NCT01445418). (Abstract 5514) V. L. Chiou, E. C. Kohn, C. M.
Annunziata, L. M. Minasian, S. Lipkowitz, M. Yu, N. Gordon, N. D. Houston, J. Lee
Board 73
Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B)
and carboplatin (C) in patients with persistent or recurrent ovarian cancer
(OC): An NRG/Gynecologic Oncology Group study. (Abstract 5515) D. S.
Dizon, W. E. Brady, H. A. Lankes, D. A. Jandial, S. B. Howell, R. J. Schilder, J. H.
Beumer, S. M. Christner, S. Strychor, M. A. Powell, A. R. Hagemann, K. N. Moore,
J. L. Walker, P. DiSilvestro, P. M. Fracasso, NRG Oncology
Board 74
A phase Ib dose-escalation study of binimetinib (MEK162) in combination
with weekly paclitaxel in patients with platinum-resistant epithelial ovarian,
fallopian tube or primary peritoneal cancer. (Abstract 5516) R. N. Grisham,
M. S. Gordon, W. A. Harb, C. Aghajanian, D. S. McMeekin, K. McKinley, L. R.
Anderson, R. Chavira, J. Christy-Bittel, E. Barrett, K. N. Moore
103
SATURDAY
SATURDAY
Board 75
Randomized phase III study comparing paclical-carboplatin with paclitaxelcarboplatin in patients with recurrent platinum-sensitive epithelial ovarian
cancer. (Abstract 5517) I. Vergote, A. Brize, A. S. Lisyanskaya, M. Lichinitser
Board 76
Preliminary single agent activity of IMGN853, a folate receptor alpha (FR␣)targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial
ovarian cancer (EOC) patients (pts): Phase I trial. (Abstract 5518) K. N. Moore,
L. P. Martin, S. M. Seward, T. M. Bauer, D. M. O’Malley, R. P. Perez, A. M. Oza, W.
Jeong, M. W. Kirby, Y. Zhou, M. F. Michenzie, J. Ponte, R. Ruiz-Soto, M. J. Birrer
Board 77
Autologous oxidized whole-tumor antigen vaccine in combination with
angiogenesis blockade to elicit antitumor immune response in ovarian
cancer. (Abstract 5519) J. L. Tanyi, L. Kandalaft, E. Ophir, S. Bobisse, R.
Genolet, E. Zsiros, D. A. Torigian, R. Mick, A. Harari, G. Coukos
Board 78
MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial—A
randomized phase II study of carboplatin and paclitaxel ⴙ/- cetuximab, in
advanced and/or recurrent cervical cancer. (Abstract 5520) S. Pignata, G.
Scambia, D. Lorusso, U. De Giorgi, M. Nicoletto, R. Lauria, A. Mosconi, C. Sacco,
C. Omarini, P. Tagliaferri, G. Ferrandina, S. Cinieri, C. Pisano, S. C. Cecere, M. Di
Napoli, V. Salutari, M. Piccirillo, G. Daniele, C. Gallo, F. Perrone
Board 79
Effect of sentinel lymph-node biopsy alone on the morbidity of the surgical
treatment of early cervical cancer: Results from the prospective randomized
study Senticol2. (Abstract 5521) P. Mathevet, F. Lecuru, SENTICOL2 Group
Board 80
CT perfusion as an early biomarker of treatment efficacy in advanced ovarian
cancer: An ECOG-ACRIN and NRG GOG study. (Abstract 5522) T. Lee, C. S.
Ng, Z. Zhang, S. Lee, H. Marques, K. Burgers, F. Su, J. Bauza, R. S. Mannel, J. L.
Walker, W. K. Huh, S. C. Rubin, P. DiSilvestro, L. P. Martin, J. K. Chan, M. A.
Bookman, R. L. Coleman
Board 81
The role of PET-CT in treatment decision making for women with locally
advanced cervical cancer. (Abstract 5523) L. M. Elit, A. W. Fyles, C. Gu, G. R.
Pond, D. D’Souza, R. Samant, M. Anthes, G. Thomas, M. Fillion, J. Arsenault, I.
Dayes, T. J. Whelan, K. Y. Gulenchyn, M. N. Levine
Board 82
Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in high
risk endometrial cancer. (Abstract 5524) M. Atri, Z. Zhang, F. Dehdashti, W.
Koh, S. Ali, R. S. Mannel, K. Moxley, P. DiSilvestro, M. Pearl, S. D. King, M. Plante,
x. Zhou, M. Gold
Board 83
Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in
combination with bevacizumab followed by bevacizumab (CPB) and
secondary cytoreduction surgery in platinum-sensitive recurrent ovarian
cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient
reported outcomes (PRO) on chemotherapy randomization. (Abstract 5525)
K. Basen-Engquist, H. Q. Huang, T. J. Herzog, D. K. Armstrong, P. Sabbatini, J. L.
Walker, B. G. Kim, K. Fujiwara, K. S. Tewari, D. M. O’Malley, R. L. Coleman
Board 84
Clinical characteristics and survival outcomes in BRCA1-methylated
epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278
patients across five studies. (Abstract 5526) R. D. Kalachand, I. Ruscito, D.
Dimitrova, P. Benedetti Panici, J. Sehouli, S. Olek, E. I. Braicu, L. Lu, D. Katsaros,
H. Yu, M. S. Carey, R. Broaddus, K. H. Lu, G. B. Mills, M. I. Harrell, K. J. Agnew,
E. M. Swisher, W. Grogan, B. Stordal, B. Hennessy
Board 85
Efficacy and safety comparison between belotecan and topotecan in patients
with recurrent or refractory ovarian cancer: A multi-center, randomized,
open-labelled, parallel-group phase IIb trial. (Abstract 5527) H. Kim, S. Park,
C. Park, Y. Kim, B. Kim, Y. Song, B. G. Kim, C. Cho, J. Kim
Board 86
Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine,
each with/without bevacizumab, as first line chemotherapy for patients with
mucinous epithelial ovarian cancer (mEOC). (Abstract 5528) M. E. Gore, A.
Hackshaw, W. E. Brady, R. T. Penson, R. J. Zaino, W. G. McCluggage, R.
Ganesan, N. Wilkinson, T. Perren, A. Montes, J. Summers, R. Lord, G. G. Dark,
104
Board 87
Efficacy and safety of olaparib monotherapy in a subgroup of patients with a
germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II
open-label study. (Abstract 5529) S. M. Domchek, R. Shapira-Frommer, R. K.
Schmutzler, M. W. Audeh, M. Friedlander, J. Balmaña, G. Mitchell, G. Fried, S. M.
Stemmer, A. Hubert, O. Rosengarten, N. Loman, J. D. Robertson, H. Mann, B.
Kaufman
Board 88
A GINECO phase I study evaluating lenalidomide (Le) combined with
pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6
months) recurrent ovarian cancer (LROC) patients (pts). (Abstract 5530) F.
Selle, A. Lesoin, M. Kaminsky, P. Follana, I. Ray-Coquard, D. Berton-Rigaud, A.
Floquet, A. Hardy-Bessard, F. Joly, E. Pujade-Lauraine, GINECO
Board 89
Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or
without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)
(GEICO 1205/NOVA TRIAL). (Abstract 5531) Y. Garcı́a, A. De Juan, C. Mendiola,
P. Barretina-Ginesta, L. Vidal, A. Santaballa, I. Bover, M. Gil-Martin, A. Manzano,
M. Rubio, M. Romeo, A. Gomez de Liaño, E. Garcı́a-Martı́nez, A. Gonzalez-Martin
Board 90
Use of homologous recombination deficiency (HRD) score to enrich for
niraparib sensitive high grade ovarian tumors. (Abstract 5532) K. M. Wilcoxen,
M. Becker, C. Neff, V. Abkevich, J. T. Jones, X. Hou, Y. Wang, A. Hartman, M. M.
AlHilli, A. Gutin, S. Agarwal, K. Timms, P. Haluska
Board 91
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation
of chemotherapy and survival in recurrent ovarian cancer patients: An
individual participant data meta-analysis of the North-Eastern German
Society of Gynecological Oncology (NOGGO) of 1,213 patients. (Abstract
5533) H. Woopen, R. Richter, R. Chekerov, T. Siepmann, J. Sehouli
Board 92
Characteristics of homologous recombination deficiency (HRD) in paired
primary and recurrent high-grade serous ovarian cancer (HGSOC). (Abstract
5534) J. N. Patel, J. Sehouli, K. Timms, C. Solimeno, J. E. Reid, J. S. Lanchbury, I.
Braicu, S. Darb-Esfahani, M. Ganapathi, R. N. Ganapathi
Board 93
Role of HE4, CA125, and ultrasound in risk assessment in pelvic mass
patients: Results from a prospective, multicentric study. (Abstract 5535) E. I.
Braicu, U. Torsten, H. Mecke, R. Richter, K. Ames, L. Hellmeyer, K. Hasenbein, G.
Nohe, F. Chen, C. R. Beteta, R. Isermann, R. Chekerov, M. Bustamante, A.
Dueckelmann, M. Christophi, M. Bodo, N. Monetaer, M. Zimmermann, J. BonnessZaloum, J. Sehouli, Charité Vivantes Ovarian Cancer Network
Board 94
Is it time to change the primary endpoint in clinical trials in recurrent ovarian
cancer (ROC)?: Symptom burden and outcomes in patients with platinum
resistant/refractory (PRR) and potentially platinum sensitive ROC
receiving > 3 lines of chemotherapy (PPS > 3)—The Gynecologic Cancer
Intergroup (GCIG) Symptom Benefit Study (SBS). (Abstract 5536) M.
Friedlander, M. R. Stockler, R. O’Connell, F. Joly, A. Lanceley, F. Hilpert, A.
Okamoto, E. Aotani, S. Pignata, P. P. Donnellan, A. M. Oza, E. Avall-Lundqvist,
J. S. Berek, K. M. Sjoquist, K. Gillies, P. Butow, M. T. King
Board 95
First-in-human phase I/II dose-escalation study of IMAB027 in patients with
recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
(Abstract 5537) U. Sahin, D. Jaeger, F. Marme, A. Mavratzas, J. Krauss, J. De
Greve, I. Vergote, O. Tureci
Board 96
Correlation of baseline clinical characteristics and laparoscopic extent of
carcinomatosis of women with initially unresectable ovarian, tubal or
peritoneal adenocarcinoma, in ANTHALYA study: A randomized, open-label,
phase II study assessing the efficacy and the safety of bevacizumab in
neoadjuvant. (Abstract 5538) R. Rouzier, S. Gouy, F. Selle, E. Lambaudie, F.
Guyon, V. Fourchotte, C. Pomel, P. E. Colombo, E. Kalbacher, S. Martin, R.
Fauvet, P. Follana, A. Lesoin, F. Lecuru, V. Menguy, Y. Ghazi, E. Chereau, S.
Zohar, P. H. Cottu, F. Joly
105
SATURDAY
G. J. Rustin, M. J. Mackean, N. Reed, S. Kehoe, H. Christensen, J. A. Ledermann,
D. M. Gershenson
SATURDAY
Board 97
Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges
for biomarker-directed therapy. (Abstract 5539) M. K. Wilson, K. Lin, I. A.
McNeish, E. M. Swisher, H. Giordano, E. Mann, M. Raponi, L. Maloney, S.
Yerganian, M. Mehdi, R. Yelensky, L. Rolfe, A. R. Allen, A. M. Oza
Board 98
Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC):
Opportunities for clinical trials. (Abstract 5540) M. Friedlander, K. Russell, S. Z.
Millis, Z. Gatalica, A. Voss
Board 99
Phase I study of intraperitoneal IL-12 plasmid formulated with PEG-PEIcholesterol lipopolymer administered in combination with pegylated
liposomal doxorubicin in recurrent or persistent epithelial ovarian, Fallopian
tube, or primary peritoneal cancer patients: An NRG/GOG study. (Abstract
5541) P. H. Thaker, W. E. Brady, W. H. Bradley, K. Anwer, R. D. Alvarez
Board 100
A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent
platinum-resistant Müllerian cancer. (Abstract 5542) R. T. Penson, S. T. Berlin,
P. Konstantinopoulos, C. N. Krasner, U. Matulonis, A. Ambrosio, D. Suzin, S. A.
Collins, M. J. Birrer, Y. C. Cohen
Board 101
Urinary acetylated polyamines in ovarian cancer. (Abstract 5543) J. U.
Maenpaa, R. Niemi, A. Roine, M. Hakkinen, P. Kumpulainen, T. Keinanen, J.
Vepsalainen, T. Lehtimaki, N. Oksala
Board 102
A phase I trial and pharmacokinetic study of non-pegylated liposomeencapsulated doxorubicin citrate (NPLD) plus carboplatin in patients with
recurrent gynecological and primary peritoneal tumors. (Abstract 5544) A.
Poveda, A. Oaknin, I. Romero, A. Guerrero, L. Calabuig, J. Del Campo
Board 103
Comparison of metachronous epithelial ovarian carcinomas. (Abstract 5545)
D. Arguello, C. D. Ackerman, S. K. Reddy, Z. Gatalica, S. D. Richard
Board 104
What clinical factors influence advanced BRCA1/2 mutant ovarian cancer
patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor
(PARPi) treatment? (Abstract 5546) S. Rafii, C. Gourley, J. Ang, R. Kumar, E.
Geuna, T. Rye, L. Ashcroft, B. Powell, R. Shapira-Frommer, M. Friedlander, L.
Chen, U. Matulonis, B. Kaufman, J. De Greve, A. M. Oza, S. N. Banerjee, M. E.
Gore, L. R. Molife, S. B. Kaye, T. A. Yap
Board 105
Development and validation of a prognostic nomogram to predict overall
survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA
substudy. (Abstract 5547) C. Lee, E. Gibbs, F. T. Roncolato, L. C. Davies, C. Le
Maignan, W. Meier, M. Arcusa Lanza, P. Rosenberg, C. Marchetti, I. Vergote, P.
Witteveen, A. Bamias, S. Serra, J. Provencal, G. De Rauglaudre, V. Gebski, M.
Friedlander, E. Pujade-Lauraine
Board 106
Exploratory outcome analyses according to stage and residual disease in the
ICON7 trial of front-line carboplatin/paclitaxel (CP) ⴞ bevacizumab (BEV) for
ovarian cancer (OC). (Abstract 5548) A. Gonzalez-Martin, A. M. Oza, A. C.
Embleton, J. Pfisterer, J. A. Ledermann, E. Pujade-Lauraine, G. Kristensen, M. A.
Bertrand, P. J. Beale, A. Cervantes-Ruiperez, E. Kent, R. S. Kaplan, M. M. Parmar,
N. Scotto, L. Mitchell, T. Perren
Board 107
Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent
ovarian cancer (OC): Results from a single arm extension phase of the phase
I FIH study. (Abstract 5549) A. Oaknin, A. Floquet, C. Le Tourneau, I. L. RayCoquard, F. Joly, M. Hidalgo, A. Leary, O. Krieter, A. Lahr, S. Rossomanno, K.
Lechner, T. Nayak, C. Boetsch, G. Rasuo, A. Morel, I. Vergote
Board 108
Frequency, severity and timing of common adverse events (AEs) with
maintenance olaparib in patients (pts) with platinum-sensitive relapsed
serous ovarian cancer (PSR SOC). (Abstract 5550) U. Matulonis, M.
Friedlander, A. Du Bois, C. Gourley, I. Vergote, G. J. Rustin, C. L. Scott, W. Meier,
R. Shapira-Frommer, T. Safra, D. Matei, A. Fielding, E. McMurtry, S. Spencer, H.
Mann, D. Parry, J. A. Ledermann
Board 109
Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant
recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.
(Abstract 5551) A. Bamias, M. A. Dimopoulos, F. Zagouri, A. Veillard, J. Kosse, A.
106
Board 110
Prognostic and predictive value of primary vs secondary platinum resistance
for bevacizumab treatment in platinum-resistant ovarian cancer in the
AURELIA trial. (Abstract 5552) F. Trillsch, S. Mahner, F. Hilpert, L. C. Davies, E.
Garcı́a-Martı́nez, G. Kristensen, A. Savarese, P. Vuylsteke, M. Los, F. Zagouri, L.
Gladieff, J. Sehouli, C. Lee, V. Gebski, E. Pujade-Lauraine
Board 111
Single agent trabectedin in heavily pretreated patients with recurrent ovarian
cancer (ROC). (Abstract 5553) F. Boumedien, J. Adam, K. Akkour, N. LeTarte,
D. M. Provencher
Board 112
Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging
changes with a focus on IC subtype: data from prospective GEICO registry.
(Abstract 5554) I. Romero, C. M. Churruca, A. Redondo, A. Santaballa, E. Calvo,
B. Ojeda, J. Del Campo, N. Laı́nez, E. Garcı́a-Martı́nez, M. Romeo, I. Bover, C.
Mendiola, C. Caballero, J. Martinez Sr., A. Herrero, A. Sánchez, A. De Juan, S.
Hernando Polo, J. A. Lopez-Guerrero, A. Poveda, GEICO
Board 113
Epigenome and genome alterations in platinum resistant ovarian cancer.
(Abstract 5555) D. Matei, F. Fang, H. Cardenas, D. F. Miller, A. Buechlein, Q. Yu,
S. M. Perkins, Y. Liu, G. Jiang, P. Taverna, H. N. Keer, D. B. Rusch, K. P. Nephew
Board 114
Validation of a second-generation mia (MIA2G) for triage of adnexal masses.
(Abstract 5556) J. Wolf, T. Pappas, Z. Zhang, A. Smith, T. Hudson, B. Carpenter,
D. G. Munroe, L. J. Sokoll
Board 115
The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and
metronomic cyclophosphamide in patients with recurrent platinum-resistant
ovarian cancer. (Abstract 5557) M. H. Eichbaum, M. Schmidt, E. Grischke, G.
Gebauer, H. Fricke, F. Lenz, E. Bischofs, M. Wallwiener, F. Marme, A.
Schneeweiss, C. Sohn, J. Rom, C. Mayer
Board 116
Phase 1 study of IMGN853, a folate receptor alpha (FR␣)-targeting antibodydrug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC)
and other FRA-positive solid tumors. (Abstract 5558) H. Borghaei, D. M.
O’Malley, S. M. Seward, T. M. Bauer, R. P. Perez, A. M. Oza, W. Jeong, M. F.
Michenzie, M. W. Kirby, G. Chandorkar, R. Ruiz-Soto, M. J. Birrer, K. N. Moore
Board 117
A phase 1 study optimizing the dosing of olaparib tablet formulation
combined with cediranib in recurrent ovarian cancer. (Abstract 5559) J. Liu, J.
Lee, W. Luo, M. J. Birrer, C. Whalen, N. D. Houston, E. Obermayer, T. Spagnoletti,
W. T. Barry, E. C. Kohn, S. P. Ivy, U. Matulonis
Board 118
Ovarian carcinosarcoma share similar molecular profile as ovarian serous
carcinoma but not endometrial carcinosarcoma. (Abstract 5560) H. Mahdi, J.
Xiu, S. K. Reddy, R. Debernardo
Board 119
Derivation of a second generation multivariate index assay to improve
specificity in pre-surgical evaluation of adnexal masses for risk of ovarian
malignancy. (Abstract 5561) Z. Zhang, T. Pappas, L. J. Sokoll, A. Smith, L. Chen,
D. W. Chan, D. G. Munroe
Board 120
Early drug development in advanced gynecologic cancer based on genetic
tumor profiling. (Abstract 5562) A. C. Garrido-Castro, G. Argilés, D. Moreno, M.
Vilaro, V. Rodriguez-Freixinos, T. Macarulla, C. Cruz, A. Azaro, E. Élez, M. Alsina,
J. M. Perez-Garcia, J. Jimenez, P. Nuciforo, A. Vivancos, J. Seoane, J. Del
Campo, J. Rodón, J. Tabernero, A. Oaknin
Board 121
Use of neoadjuvant chemotherapy in advanced ovarian cancer. (Abstract
5563) L. Meyer, A. Cronin, C. C. Sun, M. A. Bookman, R. A. Burger, M. C. Cristea,
J. J. Griggs, C. F. Levenback, G. Mantia-Smaldone, U. Matulonis, J. C. Niland,
D. M. O’Malley, A. A. Wright
Board 122
Baseline predictors of early treatment failure in patients with platinum
resistant/refractory (PRR) and potentially platinum sensitive (PPS > 3)
recurrent ovarian cancer (ROC) receiving > 3 lines of chemotherapy: The
Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).
107
SATURDAY
Santaballa, M. R. Mirza, G. Tabaro, I. Vergote, H. Bloemendal, M. Lykka, A.
Floquet, C. Lee, V. Gebski, E. Pujade-Lauraine
(Abstract 5564) F. T. Roncolato, R. O’Connell, F. Joly, A. Lanceley, F. Hilpert, A.
Okamoto, E. Aotani, S. Pignata, P. P. Donnellan, A. M. Oza, E. Avall-Lundqvist,
J. S. Berek, K. M. Sjoquist, K. Gillies, P. Butow, M. R. Stockler, M. T. King, M.
Friedlander
SATURDAY
Board 123
Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear
export in patients with heavily pretreated gynecological cancers. (Abstract
5565) I. Vergote, B. Lund, H. Havsteen, Z. Ujmajuridze, K. Leunen, C. Aaquist
Haslund, T. Juhler-Noettrup, H. Roed, T. Rashal, A. L. Kranich, Y. Landesman, J.
Saint-Martin, R. Carlson, S. Shacham, M. Kauffman, M. R. Mirza
Board 124
Genomic characterization of long-term responders to olaparib. (Abstract
5566) S. Lheureux, J. A. Ledermann, S. Runswick, D. R. Hodgson, K. Timms, J. S.
Lanchbury, S. B. Kaye, C. Gourley, D. Bowtell, E. C. Kohn, C. L. Scott, U.
Matulonis, T. Panzarella, B. A. Dougherty, J. C. Barrett, Z. Lai, M. o’Connor, J. D.
Robertson, T. W. Ho, A. M. Oza
Board 125
Phase 2 studies of multiple peptides cocktail vaccine for treatment-resistant
cervical and ovarian cancer. (Abstract 5567) S. Takeuchi, T. Shoji, M. Kagabu,
T. Honda, A. Kojima, Y. Nitta, T. Sugiyama, Y. Nakamura
Board 126
Propensity-score analysis of neoadjuvant chemotherapy vs. primary surgery
in advanced ovarian cancer: Does surgical quality matter? (Abstract 5568) H.
Bae, S. Kang, S. Seong, J. W. Kim, S. Y. Ryu, B. Kim, J. Nam
Board 127
Feasibility and outcome of interval debulking surgery (IDS) after carboplatinpaclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the
MITO-16A-MANGO OV2A phase 4 trial. (Abstract 5569) G. Daniele, D. Lorusso,
G. Scambia, M. Di Napoli, M. Nicoletto, E. Breda, N. Colombo, G. Artioli, B.
Daniele, G. Lo Re, F. Raspagliesi, V. Chiappa, V. Salutari, G. Ferrandina, S.
Greggi, A. Baldoni, M. Piccirillo, R. Fossati, F. Perrone, S. Pignata
Board 128
Durable tumor remission in patients with platinum-resistant ovarian cancer
receiving nivolumab. (Abstract 5570) J. Hamanishi, M. Mandai, T. Ikeda, M.
Minami, A. Kawaguchi, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda,
Y. Hosoe, S. Morita, A. Shimizu, T. Honjo, I. Konishi
Board 129
A phase 1b, open-label, non-randomized multicenter study of birinapant in
combination with conatumumab in subjects with relapsed epithelial ovarian
cancer, primary peritoneal cancer, or fallopian tube cancer. (Abstract 5571)
E. P. Hamilton, M. J. Birrer, B. A. DiCarlo, S. Gaillard, L. P. Martin, J. J.
Nemunaitis, R. P. Perez, R. J. Schilder, C. M. Annunziata, C. G. Begley, S. J.
Hager
Board 130
Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for
recurrent ovarian cancer. (Abstract 5572) R. E. O’Cearbhaill, D. M. Hyman,
W. P. Tew, A. Iasonos, N. A. Cangemi, C. Aghajanian, K. M. Bell-McGuinn, V.
Makker, M. L. Hensley, J. A. Konner, R. N. Grisham, K. Diaz-Macinnis, P.
Sabbatini, D. R. Spriggs
Board 131
A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus
weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer
patients. (Abstract 5573) S. E. Rivkin, D. Iriarte, H. Sloan, C. Wiseman, J. Moon,
G. E. Goodman, A. Bondurant, D. Veljovich, P. Y. Jiang, T. A. Wahl, C. Shah, C.
Drescher, H. G. Kaplan, W. A. Peters, E. Ellis, M. F. Fer, M. S. Park, E. Johnston
Board 132
BL1 gene expression subtype to predict outcome in serous ovarian cancers.
(Abstract 5574) R. Seitz, D. R. Hout, S. W. Morris, B. Z. Ring
Board 133
Genomic profile and immune infiltrate in paired ovarian cancer (OC) samples
pre- and post-neoadjuvant chemotherapy (NC). (Abstract 5575) A. Leary, C.
Genestie, J. Adam, A. Le Formal, P. Pautier, C. Lhomme, R. chen-Min-Tao, A.
Auguste
Board 134
Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations
(tmBRCA) and association with response and outcome following platinum
monotherapy in high grade serous ovarian cancer (HGSOC). (Abstract 5576)
R. Brown, K. Timms, J. Paul, E. Hughes, M. El-Bahrawy, J. H. Steel, S. Kalva, X.
108
Board 135
Delayed recurrences and survival after relapse in patients initially treated
with intraperitoneal chemotherapy for advanced ovarian cancer: A
Gynecologic Oncology Group study. (Abstract 5577) D. S. Kapp, J. Java, T. J.
Herzog, M. Markman, D. K. Armstrong, B. J. Monk, J. K. Chan
Board 136
Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor
ganetespib (G) combined with weekly paclitaxel (P) in women with highgrade serous, high-grade endometrioid, or undifferentiated, platinumresistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
(Abstract 5578) I. Ray-Coquard, I. Braicu, R. Berger, S. Mahner, J. Sehouli, A. G.
Zeimet, E. Pujade Lauraine, P. A. Cassier, U. Moll, H. Ulmer, K. Leunen, C. Marth,
I. Vergote, N. Concin
Board 137
The use of patient-derived xenograft models for prioritizing therapeutic
targets. (Abstract 5579) C. L. Scott, M. Topp, A. M. Hadley, V. Heong, M. I.
Harrell, O. McNally, S. B. Fox, K. Lodhia, P. Haluska, D. Bowtell, E. M. Swisher, M.
Wakefield, Australian Ovarian Cancer Study
Board 138
Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator
in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal
cancer: Clinical and immune responses. (Abstract 5580) J. B. Liao, R. E.
Swensen, J. Reichow, K. J. Ovenell, J. Childs, D. Higgins, B. Buening, B. A. Goff,
C. Morishima, M. L. Disis
Board 139
Modifiable risk factors for ovarian cancer: A multinational case-control
study. (Abstract 5581) M. Shaik, T. Lehman, O. A. Alkharabsheh, R. Modali, B.
Hrinczenko
Board 140
EP-100 ⴙ paclitaxel to overcome taxane resistance in patients with recurrent
LHRH-receptor expressing ovarian cancer. (Abstract 5582) A. M. Nick, R.
Urban, M. E. Gordinier, C. Leuschner, T. Rado, L. M. Bavisotto, J. Whisnant, R. L.
Coleman
Board 141
Combination therapy with temsirolimus and trabectedin for recurrent clear
cell carcinoma of the ovary: A phase II study with biomarker analysis.
(Abstract 5583) M. Takano, H. Kouta, K. Kudoh, T. Kita, R. Kikuchi, M. Miyamoto,
T. Yoshikawa, T. Goto, K. Furuya, Y. Tamada, A. Suga, Y. Kikuchi
Board 142
Omentin as a biomarker associated with improved overall survival in serous
ovarian cancer. (Abstract 5584) M. Onstad, L. L. Holman, C. Au Yeung, R.
Schmandt, S. C. Mok, M. F. Munsell, K. H. Lu
Board 143
Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node
metastasis in advanced cervical cancer. (Abstract 5585) M. Atri, Z. Zhang, F.
Dehdashti, S. Lee, S. Ali, W. Koh, K. N. Moore, L. M. Landrum, J. Kim, P.
DiSilvestro, E. L. Eisenhauer, F. M. Schnell, M. Gold
Board 144
Identifying actionable mutations in uterine leiomyosarcoma. (Abstract 5586)
T. Soumerai, D. M. Hyman, R. Murali, A. Zehir, R. E. O’Cearbhaill, M. E. Arcila, C.
Aghajanian, R. A. Soslow, D. B. Solit, M. L. Hensley
Board 145
Phase II study of concurrent chemoradiotherapy with weekly CDDP/PTX in
patients with locally advanced uterine cervical cancer: JACCRO-GY-01 trial.
(Abstract 5587) M. Takekuma, Y. Hirashima, K. Umayahara, S. Noda, T. Ohno, E.
Miyagi, F. Hirahara, E. Hirata, E. Kondo, T. Tabata, Y. Nagai, Y. Aoki, M.
Wakatsuki, M. Takeuchi, T. Toita, N. Takeshima, K. Takizawa
Board 146
Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with
advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.
(Abstract 5588) P. Heudel, M. Fabbro, C. Roemer-Becuwe, I. Treilleux, M.
Kaminsky, A. Arnaud, F. Joly, S. Roche Forestier, R. Herve, I. Ray-Coquard
Board 147
Molecular profiling and targeted therapy in advanced endometrial cancer.
(Abstract 5589) M. K. Wilson, P. L. Bedard, A. M. Joshua, H. Mackay, M. O.
Butler, N. C. Dhani, S. Lheureux, C. Martin-Lorente, V. Rodriguez-Freixinos, B.
109
SATURDAY
Liu, Y. Wang, N. R. Rama, C. Wilhelm-Benartzi, A. Gutin, L. Lewsley, N. Siddiqui,
N. Patel, J. S. Lanchbury, H. Gabra, E. A. Stronach
Clarke, P. Shaw, A. Milea, L. Wang, S. Kamel-Reid, T. Stockley, J. Bruce, T. J.
Pugh, A. M. Oza
SATURDAY
Board 148
Synergistic effects of cabozantinib to temozolomide and bevacizumab in
patients with heavily pretreated relapsed uterine leiomyosarcoma. (Abstract
5590) S. Ikeda, K. Kudoh, N. Sasaki, M. Takano, T. Goto, R. Kikuchi, M.
Sakamoto, T. Kita, N. Susumu, D. Aoki, H. Kouta, Y. Kikuchi
Board 149
Optimal debulking surgery in patients with advanced uterine
carcinosarcoma: A multi-institutional retrospective study from the Japanese
Gynecologic Oncology Group. (Abstract 5591) K. Harano, A. Hirakawa, M.
Yunokawa, T. Nakamura, T. Satoh, T. Nishikawa, D. Aoki, K. Ito, T. Nakanishi, N.
Susumu, K. Takehara, Y. Watanabe, H. Watari, T. Saito
Board 150
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or
temsirolimus and alternating megestrol acetate and tamoxifen for advanced
endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group
study. (Abstract 5592) A. P. Myers, V. L. Filiaci, Y. Zhang, M. Pearl, K. Behbakht,
V. Makker, P. Hanjani, S. Zweizig, J. J. Burke II, G. Downey, K. K. Leslie, M. J.
Birrer, G. F. Fleming
Board 151
Onapristone (ONA) in progesterone receptor (PR)-expressing tumors:
Efficacy and biomarker results of a dose-escalation phase 1 study. (Abstract
5593) P. H. Cottu, A. Italiano, A. Varga, M. Campone, A. Leary, A. Floquet, D.
Berton-Rigaud, M. Sablin, A. Lesoin, C. Lhomme, A. S. Bexon, E. M. Gilles, D.
Jackson, J. Bisaha, A. Zukiwski, J. Bosq, J. Bonneterre
Board 152
Does metformin use affect transporter, hormone receptor and mTOR
pathway target expression in endometrial cancers of women with Type II
diabetes mellitus? (Abstract 5594) D. R. Roque, A. M. Dizon, B. S. Rambally, S.
O’Connor, P. A. Gehrig, S. Denslow, V. L. Bae-Jump
Board 153
Molecular profile comparison of endometrial, renal and ovarian clear cell
carcinoma: Is it the same disease at different sites? (Abstract 5595) R.
Debernardo, H. Mahdi, K. Russell, J. Xiu, S. Z. Millis, S. K. Reddy, M. Friedlander
Board 154
Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer
(EC) patients (pts) treated in phase I trials of novel molecularly targeted
agents (MTAs). (Abstract 5596) A. George, V. Michalarea, S. Rafii, C. O. Michie,
M. Wong, R. Bowen, L. Y. Han, T. van Hagen, G. Rallis, U. Banerji, R. S. Kristeleit,
J. S. De Bono, S. N. Banerjee, L. R. Molife, M. E. Gore, S. B. Kaye, T. A. Yap
Board 155
PET/MRI in cervical cancer: Insights into tumor biology. (Abstract 5597) K.
Pinker-Domenig, P. Baltzer, H. Magometschnigg, S. Polanec, P. Andrezejewski,
A. E. Sturdza, D. Georg, S. Polterauer, V. Seebacher, A. Reinthaller, T. Helbich, R.
Poetter, P. Georg
Board 156
Feasibility of a physical activity intervention for ethnically diverse
endometrial cancer survivors. (Abstract 5598) A. Rossi, C. Garber, M. Ortiz, A.
Moadel-Robblee, G. Kaur, S. Viswanathan, M. H. Einstein, G. L. Goldberg, N.
Nevadunsky
Board 157
The use of adjuvant treatment in stage I endometrioid endometrial cancer in
the National Cancer Database (NCDB). (Abstract 5599) A. Jain, E. Handorf, G.
Mantia-Smaldone
Board 158
A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the
treatment of advanced, persistent, or recurrent carcinoma of the cervix: An
NRG/GOG study. (Abstract 5600) P. H. Thaker, W. E. Brady, H. A. Lankes, D. E.
Cohn, C. Aghajanian, D. G. Mutch, R. S. Mannel, K. M. Bell-McGuinn, P.
DiSilvestro, D. Jelovac, J. S. Carter, R. Salani
Board 159
Evaluation of biomarker alterations in small cell cervical cancer identifies
therapeutic options. (Abstract 5601) J. K. Burzawa, S. Z. Millis, S. K. Reddy, I. A.
Astsaturov, R. L. Coleman, J. Brown, M. M. Frumovitz
Board 160
Comprehensive genomic profiling (CGP) of cervical squamous cell
carcinoma (cSCC) to identifiy targeted therapy options. (Abstract 5602) J. A.
Elvin, M. Bailey, B. A. Carneiro, S. M. Ali, J. Vergilio, N. A. Palma, J. Chmielecki,
110
Board 161
Weekly administration of bevacizumab, eribulin, and oxalilplatin in patients
with platinum-resistant ovarian carcinomas: A phase II study with biomarker
analysis. (Abstract 5603) Y. Ikeda, M. Takano, H. Kouta, K. Kudoh, T. Kita, R.
Kikuchi, M. Miyamoto, T. Yoshikawa, T. Goto, K. Furuya, Y. Tamada, A. Suga, Y.
Kikuchi
Board 162
Impact of older age on chemotherapy toxicity and quality of life in women
with advanced or recurrent cervical cancer: A NRG Oncology—GOG
Ancillary Study. (Abstract 5604) E. M. Ko, J. Java, K. Schmitz, M. Randall, J.
Bloss, G. F. Fleming, D. H. Moore, B. J. Monk, H. B. Muss, L. Van Le
Board 163a
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard
chemotherapy in platinum sensitive relapsed high grade serous ovarian
carcinoma (HGSOC). (Abstract TPS5605) C. Gourley, H. Gabra, I. Vergote, B.
Basu, J. Brenton, M. Von Euler, U. Björklund, A. M. Smith, J. Green
Board 163b
A phase III study of trabectedin (T) plus pegylated liposomal doxorubicin
(PLD) versus PLD for treatment of advanced-relapsed epithelial ovarian,
primary peritoneal, or fallopian tube cancer. (Abstract TPS5606) R. L.
Coleman, B. J. Monk, R. E. Knoblauch, T. V. Parekh, S. Triantos, R. S. Maul, Y. C.
Park, T. J. Herzog
Board 164a
ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib
combination versus bevacizumab and niraparib as sequential therapy in
women with platinum-sensitive epithelial ovarian, fallopian tube, or
peritoneal cancer. (Abstract TPS5607) M. R. Mirza, C. E. Mortensen, E. AvallLundqvist, L. Bjorge, J. S. Berek, J. Herrstedt, A. Juul Holm, T. Kirkegaard, J.
Maenpaa
Board 164b
Multicenter randomized Phase II study of AZD1775 plus chemotherapy
versus chemotherapy alone in patients with platinum-resistant TP53-mutated
epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Abstract
TPS5608) K. N. Moore, D. S. McMeekin, E. P. Hamilton, D. K. Strickland, S. F.
Jones, D. M. Stults, N. Laing, D. R. Spigel, H. A. Burris III
Board 165a
A phase 2, open-label study of niraparib in women with advanced, relapsed,
high-grade serous epithelial ovarian, fallopian tube or primary peritoneal
cancer after >3 previous chemotherapy regimens. (Abstract TPS5609) K. N.
Moore, B. Rimel, S. Agarwal, J. Balser, R. E. Martell, B. J. Monk
Board 165b
The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11
study: A multinational, randomized, open-label phase 3 study of binimetinib
(MEK162) versus physician’s choice chemotherapy in patients with recurrent
or persistent low-grade serous carcinomas of the ovary, fallopian tube, or
primary peritoneum. (Abstract TPS5610) B. J. Monk, R. N. Grisham, C. Marth,
S. N. Banerjee, F. Hilpert, R. L. Coleman, E. Pujade-Lauraine, S. Pignata, M. R.
Mirza, A. M. Oza, J. M. del Campo, M. K. Oehler, A. James, J. Christy-Bittel, E.
Barrett, A. P. Boyd, I. Vergote
Board 166a
A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group
B adenovirus, administered intraperitoneally (IP): Dose finding and proof of
concept in platinum-resistant epithelial ovarian cancer. (Abstract TPS5611)
I. A. McNeish, A. Michael, C. Twelves, R. Glasspool, M. A. Ajaz, R. Morrison, O.
Xeniou, R. Brown, K. Fisher, C. Blanc
Board 166b
Open label phase II clinical trial of orteronel (TAK-700) in metastatic or
advanced non-resectable granulosa cell ovarian tumors: The Greko II
study—GETHI 2013– 01. (Abstract TPS5612) J. Rodriguez-Moreno, J. Garcı́aDonas, L. Garrigos, N. Laı́nez, A. Santaballa, A. Redondo, J. F. Cueva, M. Rubio,
S. Hernando Polo, I. Bover, I. Palacio, Z. Garcia-Casado, E. Grande, A. Hurtado
Board 167a
A randomized, placebo-controlled phase II trial comparing gemcitabine
monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in
women with recurrent, platinum-resistant epithelial ovarian, primary
peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo,
111
SATURDAY
G. M. Frampton, D. Lipson, P. Stephens, V. A. Miller, M. L. Johnson, F. J. Giles,
J. S. Ross, O. Dorigo
Chicago, and California consortia. (Abstract TPS5613) S. Lheureux, J. I.
Weberpals, A. E. Wahner Hendrickson, G. F. Fleming, A. Olawaiye, I. Brana, H.
Mackay, N. C. Dhani, M. K. Wilson, V. Rodriguez-Freixinos, C. Martin-Lorente, J.
Ward, K. Chang, L. Wang, V. Speers, K. Karakasis, V. L. Bowering, A. Chen, J.
Brenton, A. M. Oza
SATURDAY
Board 167b
Targeting VEGFRi resistance through HIF-1á suppression: Phase II clinical
trial evaluating CRLX101 as monotherapy and in combination with
bevacizumab in recurrent platinum resistant ovarian cancer. (Abstract
TPS5614) C. N. Krasner, M. J. Birrer, S. T. Berlin, M. K. Buss, S. Eliasof, E. G.
Garmey, M. Hennessey, N. S. Horowitz, P. Konstantinopoulos, U. A. Matulonis
Board 168a
A phase I dose-escalation and pharmacokinetic study of hyperthermic
intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin at the time
of primary cytoreductive surgery for advanced ovarian, fallopian tube, and
peritoneal carcinomas. (Abstract TPS5615) L. M. Randall, D. Gillen, F. W. Liu,
K. S. Tewari, R. H. Eskander, K. R. Penner, R. Bristow
Board 168b
Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine
endometrioid adenocarcinoma (EC) expressing the activated progesterone
receptor (APRpos). (Abstract TPS5616) J. Bonneterre, A. Leary, M. Campone, A.
Italiano, M. Sablin, A. Floquet, D. Berton-Rigaud, C. Lhommé, A. Lesoin, D.
Chocteau-Bouju, M. Fabbro, L. Favier, L. Gladieff, I. Ray-Coquard, A. S. Bexon,
E. M. Gilles, J. Bisaha, A. Zukiwski, P. H. Cottu
Board 169a
Phase II clinical trial of eribulin in advanced or recurrent cervical cancer (CC).
(Abstract TPS5617) J. Garcia, Y. G. Lin, S. Louie, E. Yoo, D. D. Tsao-Wei, K. E.
Tierney, L. L. Brunette, K. Matsuo, H. Q. Pham, A. A. Yessaian, S. G. Groshen, G.
Facio, K. Watkins, L. D. Roman, L. I. Muderspach, A. A. Garcia
Board 169b
A single arm, single stage phase II trial of trametinib (GSK1120212) and
GSK2141795 in persistent or recurrent cervical cancer. (Abstract TPS5618) U.
Matulonis, A. A. Wright, S. A. Collins, S. M. Campos, P. Konstantinopoulos, K.
MacNeill, S. Morrissey, V. Patterson, C. Whalen, J. Liu
Board 170a
Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent
pelvic radiation for locally advanced cervical cancer. (Abstract TPS5619)
A. E. Garcia-Soto, N. D. McKenzie, L. Portelance, R. P. Castillo, J. M. Pearson,
J. J. Hu, J. A. Lucci, L. L. Lin, F. Simpkins
Location: S Hall A
Abstracts 6012– 6023 will be discussed during the Head and Neck Cancer Poster Discussion
Board 335
Final overall survival analysis of EXAM, an international, double-blind,
randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in
medullary thyroid carcinoma (MTC) patients with documented RECIST
progression at baseline. (Abstract 6012) M. Schlumberger, R. Elisei, S. Müller,
P. Schöffski, M. S. Brose, M. H. Shah, L. F. Licitra, B. Jarzab, V. Medvedev, M.
Kreissl, E. E. Cohen, L. J. Wirth, H. Y. Ali, C. Hessel, Y. Yaron, D. W. Ball, B.
Nelkin, S. I. Sherman
Board 336
Efficacy and safety of lenvatinib for the treatment of patients with 131Irefractory differentiated thyroid cancer with and without prior VEGF-targeted
therapy. (Abstract 6013) K. Newbold, R. Elisei, M. H. Taylor, M. K.
Krzyzanowska, M. H. Shah, A. O. Hoff, B. Robinson, C. Dutcus, J. Song, M. A.
Habra
Board 337
Pharmacodynamic biomarkers of outcomes in the phase III study of
lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). (Abstract
6014) M. Tahara, M. Schlumberger, R. Elisei, M. A. Habra, N. Kiyota, C. Dutcus, J.
112
Board 338
Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated
thyroid cancer patients receiving placebo and/or sorafenib in the phase III
DECISION study. (Abstract 6015) C. Kappeler, D. P. Healy, C. Baumer, G.
Meinhardt, R. Elisei, M. Schlumberger, M. S. Brose
Board 339
Enriched expression of PD-L1 and other immune targets after epithelialmesenchymal transition (EMT) in squamous head and neck and lung
cancers. (Abstract 6016) M. P. Mak, L. Diao, P. Tong, J. Wang, P. Ng, R.
Cardnell, D. N. Hayes, G. Robertson, J. Myers, A. K. El-Naggar, W. N. William Jr.,
K. R. Coombes, J. N. Weinstein, G. B. Mills, J. Heymach, D. L. Gibbons, L. A.
Byers
Board 340
Inflamed-phenotype gene expression signatures to predict benefit from the
anti-PD-1 antibody pembrolizumab in PD-L1ⴙ head and neck cancer
patients. (Abstract 6017) T. Y. Seiwert, B. Burtness, J. Weiss, J. P. Eder, J.
Yearley, E. Murphy, M. Nebozhyn, T. McClanahan, M. Ayers, J. K. Lunceford, R.
Mehra, K. Heath, J. D. Cheng, L. Q. Chow
Board 341
PDL1-expressing circulating tumor cells (CTCs) in head and neck squamous
cell carcinoma (HNSCC). (Abstract 6018) G. Koutsodontis, A. Strati, M. Avgeris,
E. Maratou, V. Ramfidis, G. Konstantinidis, P. Economopoulou, G. Kotsantis, K.
Tsigaridas, E. M. Vagia, N. Haralambakis, C. Sasaki, A. Scorilas, C. Perisanidis, M.
Vasilakopoulou, A. Strimpakos, E. Lianidou, A. Psyrri
Board 342
Utilization and outcomes of low dose versus high dose cisplatin in head and
neck cancer patients receiving concurrent radiation. (Abstract 6019) S. J.
Wong, L. Li, L. M. Hess, A. Y. Chen, W. J. Curran Jr., P. M. Harari, R. J. Kimple,
B. A. Murphy, L. L. Opincar, A. S. Garden
Board 343
Differential impact of cisplatin dose intensity on human papillomavirus
(HPV)-related (ⴙ) and HPV-unrelated (ⴚ) locoregionally advanced head and
neck squamous cell carcinoma (LAHNSCC). (Abstract 6020) A. Spreafico, S.
Huang, W. Xu, R. Granata, C. Liu, J. N. Waldron, E. Chen, J. Ringash, A. Bayley,
K. K. Chan, A. J. Hope, A. R. Razak, B. Perez-Ordonez, I. Weinreb, P. Bossi, E.
Orlandi, L. F. Licitra, B. O’Sullivan, L. L. Siu, J. J. Kim
Board 344
Symptom reduction from IMRT dose deintensification: Results from ECOG
1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS
V2). (Abstract 6021) A. Cmelak, S. Li, S. Marur, W. Zhao, W. H. Westra, C. H.
Chung, M. L. Gillison, J. Gilbert, J. E. Bauman, L. I. Wagner, R. L. Ferris, D. R.
Trevarthen, B. A. Murphy, T. Galloway, B. Burtness
Board 345
Safety analysis of a phase III randomized trial of chemotherapy with or
without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma
of the head and neck (R/M SCCHN). (Abstract 6022) A. Argiris, S. Li, P.
Savvides, A. A. Forastiere, B. Burtness
Board 346
Biomarker analysis in recurrent and/or metastatic head and neck squamous
cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib
versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). (Abstract 6023)
E. E. Cohen, L. F. Licitra, J. Fayette, T. C. Gauler, P. M. Clement, J. J. Grau, J. Del
Campo, A. Mailliez, R. I. Haddad, J. B. Vermorken, M. Tahara, J. Guigay, L.
Geoffrois, M. C. Merlano, N. F. Dupuis, B. Burtness, N. Gibson, F. Solca, E.
Ehrnrooth, J. H. Machiels
Board 347
Ultra-deep targeted sequencing to identify HRAS, TP53, and CDKN2A
somatic mutations as molecular prognostic markers in patients with
advanced oral squamous cell carcinoma. (Abstract 6024) T. Yen, C. Peng, S.
Peng, C. Liao, W. Hsieh
Board 348
New aspects regarding the induction chemotherapy with TPF and radio
chemotherapy in head and neck cancer. (Abstract 6025) E. Boelke, C.
Matuschek, S. Gripp, K. Kammers, W. Budach
Board 349
Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with
concurrent chemoradiotherapy (CRT) for locoregionally advanced head and
113
SATURDAY
Xu, J. Zhu, T. Hihara, S. McGrath, M. Matijevic, T. Kadowaki, Y. Funahashi, S. I.
Sherman
neck carcinoma. (Abstract 6026) L. K. Mell, Y. A. Yu, K. T. Brumund, G. A.
Daniels, S. J. Advani, R. A. Weisman, P. R. Sanghvi, P. J. Martin, M. E. Wright, S.
Onyeama, Q. Zhang, A. Pold, T. Chamberlin, A. Frentzen, A. A. Szalay
SATURDAY
Board 350
Can somatic copy number alterations detected by ultradeep targeted
sequencing predict prognosis in oral squamous cell carcinoma? (Abstract
6027) T. Yen, S. Chen, C. Liao, H. Chen, H. Liu
Board 351
Adjuvant chemo-radiotherapy (CRT) versus radiotherapy (RT) alone for
locally advanced salivary gland carcinoma among older population: SEERMedicare analysis. (Abstract 6028) T. Tanvetyanon, K. Fisher, T. Padhya, K. J.
Otto, J. J. Caudell, A. Trotti
Board 352
Application of a robust and novel ex vivo platform mimicking patient
heterogenous tumor microenvironment for personalized cancer treatment.
(Abstract 6029) K. Govind Babu, B. Majumder, S. Thiyagarajan, B. Ulaganathan,
R. Surindran, A. Shenoy, M. A. Kuriakose, M. Loda, R. Beroukhim, P. Horowitz, S.
Agarwal, P. Radhakrishnan, M. Sundaram, S. Sengupta, P. K. Majumder
Board 353
Response rates, toxicity, and quality of life for locally regionally advanced
head and neck squamous cell carcinoma after induction chemotherapy with
weekly nab-paclitaxel, carboplatin, and cetuximab. (Abstract 6030) J. Weiss,
J. Gilbert, J. E. Grilley-Olson, A. M. Deal, B. S. Chera, J. J. Liao, B. A. Murphy,
M. C. Weissler, D. N. Hayes
Board 354
A phase II study of axitinib in patients with recurrent or metastatic
nasopharyngeal carcinoma (NPC). (Abstract 6031) E. P. Hui, B. Ma, F. Mo,
M. K. Kam, S. L. Chan, H. H. Loong, R. Ho, S. Leung, A. D. King, K. Wang, A. T.
Ahuja, C. Chan, C. W. Hui, C. Wong, A. T. Chan
Board 355
A gene expression profile to predict recurrence of advanced tongue
squamous cell carcinoma (TSCC): Discovery and external validation.
(Abstract 6032) T. Enokida, T. Wakasugi, T. Yamazaki, M. Takahashi, Y. Higuchi,
R. Hayashi, S. Fujii, M. Tahara
Board 356
Genomic landscape of anaplastic thyroid cancer. (Abstract 6033) J.
Capdevila, A. Vivancos, X. Matias-Guiu, C. Iglesias, F. Salva, X. Serres, O.
Gonzalez, E. Caubet, J. Jimenez, C. Zafon, F. M. Mancuso, G. Caratu, C. Alvarez,
R. Mayor, J. Tabernero, J. Seoane
Board 357
The SMART strategy: Subdividing M1 stage and aiming remission for target
nasopharyngeal carcinoma patients with metachronous metastasis.
(Abstract 6034) L. Shen, P. Wu, Y. Xia, W. Li, C. Chen
Board 358
A meta-analysis of weekly cisplatin versus three weekly cisplatin
chemotherapy plus current radiotherapy for advanced head and neck cancer.
(Abstract 6035) Y. Zhang, J. Guan, Q. Li, N. Xiao, L. Li, M. Chen, M. Yang, Y. Dai,
C. Zhang, L. Chen
Board 359
A meta-analysis comparing cisplatin-based to carboplatin-based
chemotherapy in moderate to advanced squamous cell carcinoma of head
and neck (SCCHN). (Abstract 6036) Q. Li, J. Guan, Y. Zhang, M. Chen, L. Li, N.
Xiao, M. Yang, Y. Dai, C. Zhang, L. Chen
Board 360
Phase II study with conventional radiotherapy (RT) ⴙ cetuximab in patients
with advanced larynx cancer who responded to induction chemotherapy (IC):
An organ preservation TTCC study. (Abstract 6037) R. Mesia, J. Garcia Saenz,
A. Lozano, M. Pastor Sr., J. J. Grau, J. Martinez Trufero, J. J. Lambea- Sorrosal, J.
Martinez Galan, J. Mel, B. Gonzalez, S. Vazquez, M. Manos Pujol, M. Taberna, B.
Cirauqui, E. del Barco, E. Casado, J. Rubió, A. Rodriguez Jaraiz, J. J. Cruz,
Spanish Head and Neck Cancer Cooperative Group
Board 361
Bioradiotherapy for head and neck cutaneous squamous cell carcinoma.
(Abstract 6038) J. D. Palmer, J. Strasser, A. Hanlon, E. A. Mauer, M. Dzeda, N.
Hockstein, R. Witt, C. Schneider, A. Raben
Board 362
Alliance A091104: A phase II trial of MK-2206 in patients (pts) with
progressive, recurrent/metastatic adenoid cystic carcinoma. (Abstract 6039)
114
Board 363
Comprehensive genomic profiling of salivary gland adenocarcinomas to
reveal frequency of druggable targets. (Abstract 6040) M. J. Hawryluk, K.
Wang, D. Khaira, J. Chmielecki, S. M. Ali, J. A. Elvin, J. Vergilio, R. Yelensky, D.
Lipson, V. A. Miller, P. J. Stephens, J. S. Ross
Board 364
Hepatitis C virus seropositivity and head and neck cancers: A new trio.
(Abstract 6041) P. Mahale, E. M. Sturgis, H. A. Torres
Board 365
The role of cetuximab in induction chemotherapy: Comparison of APF-C
(nab-paclitaxel, cisplatin, 5-FU ⴙ cetuximab) with APF, both followed by
chemoradiation therapy (CRT), in patients with locally advanced head and
neck squamous cell carcinoma (HNSCC). (Abstract 6042) D. Adkins, J. C. Ley,
T. M. Wildes, L. S. Michel, J. Rich, R. Paniello, R. Uppaluri, W. L. Thorstad, H. A.
Gay, K. Trinkaus, T. Rachocki, B. Nussenbaum
Board 366
A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to
cetuximab in patients with incurable head and neck squamous cell
carcinoma (HNSCC). (Abstract 6043) L. S. Michel, J. C. Ley, T. M. Wildes, K.
Trinkaus, D. Adkins
Board 367
Augmenting pre-operative risk of recurrence stratification in differentiated
thyroid carcinoma using machine learning and high dimensional
transcriptional data from thyroid FNA. (Abstract 6044) S. I. Sherman, M.
Pagan, J. Huang, B. Lin, J. Diggans, E. Tom, B. Haugen, R. M. Tuttle, G. Kennedy
Board 368
Prognostic value of HPV detection with three primer sets in 255 Head-Neck
cancers. (Abstract 6045) C. Lo Nigro, D. Vivenza, M. Monteverde, M. Fortunato,
N. Denaro, L. Lattanzio, F. Tonissi, V. Astesana, E. Russi, M. C. Merlano
Board 369
Head and neck cancer (HNSCC) subgroups defined by HPV RNA status, gene
expression patterns, and TP53 mutations are associated with lymph node
metastasis and survival. (Abstract 6046) A. Dietz, G. Wichmann, M. Rosolowski,
K. Krohn, M. Kreuz, A. Boehm, D. Halama, D. Holzinger, M. Pawlita, J. Hess, C.
Engel, D. Hasenclever, M. Scholz, P. Ahnert, H. Kirsten, A. Hemprich, C. Wittekind,
O. Herbarth, M. Loeffler
Board 370
Prognostic value of mid-treatment total lesion glycolysis in p16ⴙ
oropharyngeal cancer. (Abstract 6047) E. L. Pollom, J. Song, B. Y. Durkee, S.
Aggarwal, T. Bui, R. Li, Q. Le, B. W. Loo, W. Hara
Board 371
Effect of age and lenvatinib treatment on overall survival for patients with
I-refractory differentiated thyroid cancer in SELECT. (Abstract 6048) M. S.
Brose, M. Schlumberger, M. Tahara, L. J. Wirth, B. Robinson, R. Elisei, K.
Newbold, N. Kiyota, A. O. Hoff, C. Dutcus, J. Song, S. I. Sherman, M. H. Taylor
131
Board 372
Clinical trials outcomes of combined BKM120 and cetuximab compared to
BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and
neck (R/M-SCCHN). (Abstract 6049) H. Kim, H. Kang, M. Yun, S. Lim, C. Kim, M.
Ahn, J. Sun, J. Kim, S. Paik, B. Cho
Board 373
Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using
induction chemotherapy (IC) in locally advanced head and neck squamous
cell cancer (LA-HNSCC). (Abstract 6050) V. M. Villaflor, E. E. Cohen, J. M.
Melotek, R. J. Brisson, T. Karrison, E. A. Blair, L. Portugal, K. Stenson, J. A. De
Souza, A. Langerman, T. Y. Seiwert, E. E. Vokes, D. J. Haraf
Board 374
Randomized phase II study of cabazitaxel versus methotrexate in patients
with recurrent or metastatic squamous cell carcinoma of the head and neck
(SCCHN) previously treated with platinum-based therapy. (Abstract 6051) S.
Rottey, A. Van Maanen, J. Vandenbulcke, B. Filleul, E. Seront, S. Henry, L. A.
D’Hondt, C. Lonchay, S. Holbrechts, P. Boegner, D. J. Brohee, D. Dequanter, I.
Louviaux, B. Sautois, N. Whenham, G. J. Berchem, B. Vanderschueren, C.
Fontaine, S. Schmitz, J. H. Machiels
Board 375
Predictive and prognostic values of post chemoradiotherapy PET/CT and the
effect of salvage surgery on survival in head and neck squamous cell
115
SATURDAY
A. L. Ho, N. R. Foster, J. P. Meyers, S. Deraje Vasudeva, N. Katabi, C. R.
Antonescu, D. G. Pfister, L. E. Horvath, C. Erlichman, G. K. Schwartz
carcinoma (HNSCC). (Abstract 6052) R. Kim, C. Ock, B. Keam, T. Kim, J. Kim, J.
Paeng, S. Lee, T. Kwon, D. Kim, H. Wu, M. Sung, D. S. Heo, J. Hah, S. Kwon
SATURDAY
Board 376
Quality of life (QOL) in a phase III randomized trial of standard fractionation
radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated
fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts)
with locoregionally advanced squamous cell carcinoma of the head and neck
(LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). (Abstract
6053) J. Ringash, J. N. Waldron, L. L. Siu, R. Martino, E. Winquist, J. R. Wright, A.
Nabid, J. H. Hay, A. Hammond, K. Sultanem, S. Hotte, C. Leong, A. A. El-Gayed,
F. Naz, K. Ramchandar, T. E. Owen, A. Montenegro, B. O’Sullivan, B. E. Chen,
W. R. Parulekar
Board 377
Long-term outcomes for radiotherapy alone verse combined
chemoradiotherapy for patients with stage II nasopharyngeal carcinoma in
the era of intensity-modulated radiotherapy. (Abstract 6054) M. Hu, F.
Pingping, F. Bingjie, Z. Guoli, L. Xijun, Y. Jinming
Board 378
Concurrent chemoradiation using weekly versus tri-weekly cisplatin in
locally advanced squamous cell carcinoma of the head and neck (SCCHN): A
comparative analysis. (Abstract 6055) A. Mohamed, K. Schrapp, T. K.
Owonikoko, C. E. Steuer, Z. Chen, S. Pakkala, R. N. Pillai, J. Wadsworth, K. A.
Higgins, S. S. Ramalingam, J. J. Beitler, D. M. Shin, F. R. Khuri, M. Behera, N. F.
Saba
Board 379
Genomic landscape of salivary gland tumors. (Abstract 6056) S. K. Elkin, S.
Kato, M. C. Schwaederle, B. N. Tomson, T. L. Helsten, J. Carter, R. Kurzrock
Board 380
The phase III clinical study about the effect of Kangfuxin Solution (Chinese
herbal medicine compound preparation) on the radiation induced oral and
upper gastrointestinal mucositis in nasopharyngeal carcinoma patients.
(Abstract 6057) J. Lang, M. Feng, Y. Luo, Z. Fan Sr., Q. Jiang, H. Bai Sr., Y.
Huang
Board 381
Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe
radiomucositis in head and neck cancer patients: A phase II randomized trial.
(Abstract 6058) J. Giralt, Y. Tao, R. Bensadoun, R. V. Lalla, E. M. Ozsahin, G.
Pajkos, R. Kortmann, J. Contreras-Martinez, P. Ceruse, X. Zasadny, F. Arias de la
Vega, P. Attali, B. Vasseur, M. Henke
Board 383
Molecular profiling of tumour budding to implicate TGF-␤ mediated
epithelial-mesenchymal transition as a therapeutic target. (Abstract 6059)
D. H. Jensen, E. Dabelsteen, L. Specht, a. K. Fiehn, M. H. Therkildsen, F. C.
Nielsen, L. Joenson, J. Vikesaa, C. von Buchwald
Board 384
A randomized phase II trial of the MET inhibitor tivantinib ⴙ cetuximab
versus cetuximab alone in patients with recurrent/metastatic head and neck
cancer. (Abstract 6060) E. E. Vokes, F. P. Worden, D. Adkins, J. E. Bauman, D.
Lim, A. Sukari, K. A. Rao, S. A. Wagner, K. K. Curtis, B. J. Gitlitz, K. A. Price, J. L.
Wade III, V. M. Villaflor, J. A. De Souza, T. Karrison, W. M. Stadler, T. Y. Seiwert
Board 385
Evaluation of the impact of tumor HPV status on outcome in patients with
locally advanced unresectable head and neck squamous cell carcinoma
(HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel:
retrospective analysis of EORTC24971 study. (Abstract 6061) A. Psyrri, C.
Fortpied, G. Koutsodontis, M. Avgeris, J. Menis, L. Herman, L. Giurgea, E.
Remenar, J. A. Langendijk, A. Awada, P. H. De Mulder, H. R. Kienzer, M.
Degardin, A. Kotsinas, S. Oosting, V. Gregoire, L. F. Licitra, J. B. Vermorken
Board 386
Treatment-associated mortality in head and neck cancer receiving
chemotherapy and radiation: Meta-analysis of published trials. (Abstract
6062) P. Bossi, C. Resteghini, M. Cinquini, C. Bergamini, E. Orlandi, L. D. Locati,
R. Granata, S. Alfieri, N. Iacovelli, C. Fallai, L. F. Licitra
Board 387
MLH1, MSH2, MSH3 and EXO1 polymorphisms and head and neck squamous
cell carcinoma risk and prognosis. (Abstract 6063) G. J. Lourenco, G. A.
Nogueira, C. B. Oliveira, F. A. Marson, L. Lopes-Aguiar, E. F. Costa, T. R. Lima,
V. T. Liutti, F. Leal, V. A. Santos, J. A. Rinck Jr., C. S. Lima
116
Board 388
Outcomes of head and neck squamous cell carcinomas (HNSCC) treated with
reirradiation (RRT) at Mayo Clinic. (Abstract 6064) K. K. Curtis, H. J. Ross, A. L.
Garrett, T. A. Jizba, H. Kosiorek, S. H. Patel, W. Wong, M. Y. Halyard, R. L. Foote
Board 389
Use of chemotherapy with IMRT reirradiation: MDACC experience. (Abstract
6065) M. A. Edson, A. S. Garden, V. Takiar, G. B. Gunn, C. D. Fuller, D. I.
Rosenthal, M. S. Kies, J. Phan
Board 390
Double blind multicenter phase III GORTEC trial evaluating the efficacy of
oral immune modulating formulae therapy during adjuvant
radiochemotherapy in head and neck squamous cell carcinoma (HNSCC).
(Abstract 6066) P. Boisselier, P. Graff-Cailleaud, C. Sire, O. Gallocher, S.
Lavau-Denes, M. Garcia-Ramirez, M. Alfonsi, D. Cupissol, M. Kaminsky, S. Fiore,
N. Flori, H. de Forges, R. Garrel, C. Janiszewski, S. Thezenas, P. Senesse
Board 392
Is there a role for induction chemotherapy in the setting of concomitant
chemoradiation in locally advanced head and neck cancer: A systematic
review and meta-analysis of randomized controlled trials. (Abstract 6068) A.
Popovtzer, I. Ben-Aharon, E. E. Cohen, L. Vidal
Board 393
Combination of everolimus and sorafenib in the treatment of thyroid cancer:
Update on phase II study. (Abstract 6069) E. J. Sherman, A. L. Ho, M. G. Fury,
S. S. Baxi, L. Dunn, J. S. Lee, B. L. Lipson, D. G. Pfister
Board 394
Characteristics of PD-L1, PD-1 expressions and CD8ⴙ tumor infiltrating
lymphocyte in EBV-associated nasopharyngeal carcinoma. (Abstract 6070)
K. -. Mahaprom, N. Larbcharoensub, E. Sirachainan, C. Jiarpinitnun, N. Trachu, J.
Leopairut, P. Karnsombut, N. Tubthong, D. Pangpunyakulchai, N. Ngamphaiboon
Board 395
A pilot, single arm, prospective trial using neoadjuvant rapamycin prior to
definitive therapy in head and neck squamous cell carcinoma. (Abstract
6071) K. Shirai, T. A. Day, E. Szabo, C. Van Waes, P. E. O’Brien, M. G. Matheus,
K. Godwin, A. J. Sood, J. A. Vick, D. Martin, L. Vitale-Cross, A. Molinolo, J. S.
Gutkind
Board 396
A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with
metastatic differentiated thyroid cancer who have progressed on sorafenib
alone. (Abstract 6072) M. S. Brose, A. B. Troxel, M. Yarchoan, A. B. Cohen, K.
Harlacker, N. A. Dyanick, Z. A. Posey, R. Makani, P. Prajapati, L. M. Zifchak, C.
Grande, C. M. Squillante
Board 397
Landscape of genetic alterations in non-smoking patients with oral tongue
carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck
squamous cell carcinoma data. (Abstract 6073) N. F. Saba, S. Newman, M. R.
Rossi, C. E. Steuer, H. Zhang, M. Patel, J. Wadsworth, M. El-Deiry, K. R.
Magliocca, T. K. Owonikoko, F. R. Khuri, D. M. Shin, Z. G. Chen
Board 398
Phase I study of cetuximab, intensity-modulated radiotherapy (C-IMRT), and
intratumoral EGFR antisense (AS) DNA in patients with locally advanced
head and neck cancer (HNC). (Abstract 6074) J. E. Bauman, U. Duvvuri, W. E.
Gooding, D. A. Clump, B. J. Karlovits, A. M. Wehbe, F. R. Miller, J. T. Johnson,
R. L. Ferris, S. Kim, D. E. Heron, J. Ohr, J. R. Grandis, A. Argiris
Board 399
Effect of the extent of lymph node dissection on overall survival in patients
treated for oral cavity squamous cell carcinoma. (Abstract 6075) J. L. Shah,
M. Kaplan, V. Divi, Q. Le, W. Hara
Board 400
Outcomes of elderly patients treated for oral cavity squamous cell
carcinoma. (Abstract 6076) J. L. Shah, M. Kaplan, A. D. Colevas, Q. Le, W. Hara
Board 401
Low pre-operative absolute monocyte count to predict overall survival
benefit for oral cavity squamous cell carcinoma. (Abstract 6077) T. Bui, J. L.
Shah, M. Kaplan, A. D. Colevas, Q. Le, W. Hara
Board 402
Patterns of CD8ⴙ T-cell infiltration and immune escape mechanisms in head
and neck cancer. (Abstract 6078) V. Saloura, Z. Zuo, A. Khattri, H. E. Kohrt,
M. W. Lingen, T. Gajewski, M. Kowanetz, E. E. Vokes, T. Y. Seiwert
Board 403
Correlation of specific genetic aberrations and signaling pathways with
T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel
117
SATURDAY
candidate biomarkers for checkpoint blockade therapy. (Abstract 6079) Z.
Zuo, V. Saloura, H. E. Kohrt, M. K. Keck, A. Khattri, M. W. Lingen, J. P. Kline, T.
Gajewski, E. E. Vokes, T. Y. Seiwert
SATURDAY
Board 404
Comparison of two large, genetically and clinically annotated head and neck
cancer (HNC) cohorts (TCGA, CHGC) and differential treatment effects on
TP53 mutated, as well as oral cavity cancers. (Abstract 6080) J. Bragelmann,
Z. Zuo, A. Khattri, M. K. Keck, V. M. Villaflor, J. DeSouza, D. J. Haraf, M. W.
Lingen, E. E. Vokes, T. Y. Seiwert
Board 405
Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC):
Tumor stage, propensity to bone and liver metastasis, risk of relapse, and
overall survival. (Abstract 6081) R. Ferrarotto, Y. Mitani, Y. Cai, L. Diao, J.
Wang, M. B. Nilsson, B. S. Glisson, M. S. Kies, W. N. William Jr., M. E. Kupferman,
P. A. Zweidler-McKay, A. Futreal, A. K. El-Naggar, J. Heymach
Board 406
Systematic review and meta-analysis of the safety and efficacy of minimally
invasive compared to open thymectomy for thymic malignancies. (Abstract
6082) A. J. Friedant, E. Handorf, S. Su, W. J. Scott
Board 407a
A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics,
and preliminary clinical activity of MEDI0562 in patients with recurrent or
metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
(Abstract TPS6083) R. S. Leidner, S. P. Patel, M. G. Fury, R. L. Ferris, J. T.
McDevitt, M. C. Lanasa, B. S. Glisson
Board 407b
KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475)
versus standard treatment in patients with recurrent or metastatic head and
neck cancer. (Abstract TPS6084) E. E. Cohen, J. H. Machiels, K. J. Harrington,
B. Burtness, S. W. Shin, C. K. Gause, A. M. Swift, H. Brown, A. M. Perrone, J. D.
Cheng, R. F. Swaby, C. Le Tourneau
Board 408a
Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities.
(Abstract TPS6085) S. A. Khan, J. E. Bauman, B. Burtness, A. E. Frankel, J.
Harper, R. S. Hughes, P. Kurian, L. L. Myers, L. A. Nedzi, D. L. Schwartz, B. D.
Sumer, J. Truelson, H. Zhu
Board 408b
A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in
patients with recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN): HAWK (NCT02207530). (Abstract TPS6086) D. P.
Zandberg, A. Jarkowski III, U. A. Emeribe, T. Goswami, G. Melillo
Board 409a
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line
recurrent/metastatic head and neck squamous cell carcinoma. (Abstract
TPS6087) J. Guigay, U. Keilholz, R. Mesia Sr., N. Vintonenko, J. Bourhis, A.
Auperin
Board 409b
Window of opportunity trial of HPV E7 antigen-expressing Listeria-based
therapeutic vaccination prior to robotic surgery for HPV-positive
oropharyngeal cancer. (Abstract TPS6088) B. Miles, S. Gnjatic, M. Donovan,
E. M. Genden, K. Misiukiewicz, R. Krupar, Y. M. Saenger, E. G. Demicco, M. R.
Posner, A. G. Sikora
Location: S Hall A
Abstracts 9512–9523 will be discussed during the Patient and Survivor Care Poster Discussion
Board 171
118
Pilot study of family caregiver burden in home hospice: Stress-induced
immune changes. (Abstract 9512) A. Ladha, J. S. Kaur, S. Lee, R. A. Vierkant,
W. K. Nevala
Board 172
Quality of life and satisfaction with care in caregivers of patients with
advanced cancer: Results from a trial of early palliative care. (Abstract 9513)
J. C. McDonald, N. Swami, B. Hannon, A. Pope, L. W. Le, A. M. Oza, N. B. Leighl,
I. Tannock, M. K. Kryzanowska, G. Rodin, C. Zimmermann
Board 173
Depression and anxiety among family caregivers of patients with advanced
cancer. (Abstract 9514) J. N. Fishbein, R. D. Nipp, A. El-Jawahri, W. F. Pirl, S.
Moran, C. McCarty, J. Eusebio, E. R. Gallagher, E. R. Park, V. A. Jackson, J. A.
Greer, J. S. Temel
Board 174
Intended and unintended consequences: Ethics, communication, and
prognostic disclosure in pediatric oncology. (Abstract 9515) J. M. Marron, A.
Cronin, T. I. Kang, J. W. Mack
Board 175
A randomized, controlled trial of a cardiopulmonary resuscitation (CPR)
video decision support tool for seriously ill hospitalized patients with
advanced cancer. (Abstract 9516) A. El-Jawahri, J. S. Temel, K. Ramchandran,
V. A. Jackson, Y. Chang, E. Walker-Corkery, E. Mann, A. E. Volandes
Board 176
Quality of life and mood in patients with advanced cancer: Associations with
prognostic understanding and coping style. (Abstract 9517) R. D. Nipp, A.
El-Jawahri, W. F. Pirl, J. N. Fishbein, S. Moran, C. McCarty, J. Eusebio, E. R.
Gallagher, E. R. Park, V. A. Jackson, J. A. Greer, J. S. Temel
Board 177
Clinical performance of the DigniCap system, a scalp hypothermia system, in
preventing chemotherapy-induced alopecia. (Abstract 9518) H. S. Rugo, P.
Klein, S. A. Melin, S. A. Hurvitz, M. E. Melisko, A. Moore, G. D. Park, E. Bageman,
R. D’Agostino Jr., E. S. Ver Hoeve , T. Cigler
Board 178
Chronic health conditions (CHCs) following cisplatin-based chemotherapy
(CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS).
(Abstract 9519) M. I. Abu Zaid, H. D. Sesso, C. Fung, D. R. Feldman, R. J.
Hamilton, D. J. Vaughn, C. Beard, M. J. Moore, D. M. Sahasrabudhe, E. Johnson,
S. Fossa, L. H. Einhorn, L. B. Travis, The Platinum Study Group
Board 179
Comparison between clinician- and patient-reporting of baseline (BL) and
post-BL symptomatic toxicities in cancer cooperative group clinical trials
(NCCTG N0591 [Alliance]). (Abstract 9520) T. M. Atkinson, D. V. Satele, J. A.
Sloan, D. Mehedint, J. M. Lafky, E. M. Basch, A. C. Dueck
Board 180
Long-term safety of fertility preservation by ovarian stimulation and
concurrent aromatase inhibitor treatment in women with breast cancer.
(Abstract 9521) K. Oktay, V. Turan, J. Kim
Board 181
The impact of adjuvant breast cancer (BC) chemotherapy on ovarian reserve
and menses. (Abstract 9522) S. B. Goldfarb, G. Bedoschi, E. Grunblatt, S.
Goswami, T. Cigler, J. Quistorff, F. Pacheco, R. Stobezki, M. E. Robson, F. Moy,
C. A. Hudis, S. Patil, M. N. Dickler, K. Oktay
Board 182
Treatment-related amenorrhea among young women one year following
diagnosis of early-stage breast cancer. (Abstract 9523) P. D. Poorvu, S. I.
Gelber, S. M. Rosenberg, R. M. Tamimi, K. J. Ruddy, S. L. Bober, V. F. Borges,
S. E. Come, L. Schapira, A. H. Partridge
Board 183
Differences in attitudes and beliefs toward end-of-life treatments between
hematologic (Heme) and solid tumor (ST) oncology specialists. (Abstract
9524) D. Hui, S. Bansal, M. Park, A. S. Reddy, J. E. Cortes, F. V. Fossella, E.
Bruera
Board 184
Quality of life, depression, and end-of-life outcomes in hospitalized patients
with advanced cancer. (Abstract 9525) K. E. Hudson, S. P. Wolf, A. P.
Abernethy, T. W. LeBlanc
Board 185
Trends and regional variation of end-of-life cancer care in the Medicare
program. (Abstract 9526) S. Wang, J. Hall, J. B. Long, C. E. Pollack, E. Bradley,
K. B. Adelson, C. P. Gross
Board 186
Burden of inpatient care and treatments in terminally-ill cancer patients:
results from a population-based, retrospective study from administrative
119
SATURDAY
data in France. (Abstract 9527) L. Morin, R. Aubry, Y. Beaussant, P. Rochigneux,
F. Goldwasser, C. Tournigand
SATURDAY
Board 187
Exploring the preferences for place of death among cancer patients and their
caregivers. (Abstract 9528) M. Vidal, A. Rodriguez Nunez, D. Hui, J. Allo, J. L.
Williams, M. Park, S. Frisbee-Hume, E. Bruera
Board 188
Practice pattern treating older women with early stage breast cancer at
Johns Hopkins. (Abstract 9529) Y. G. Pollock, A. Blackford, S. Jeter, A. CiminoMathews, M. Camp, S. Harvey, F. Asrari, J. Wright, V. Stearns
Board 189
Frailty and outcomes in older adults undergoing pancreaticoduodenectomy.
(Abstract 9530) T. M. Le, G. Nielsen, M. Smolkin, W. Dale, E. E. Ramsdale
Board 190
Evaluation of two different doses of weekly nab-paclitaxel (NP) in older
breast cancer (BC) patients (pts). (Abstract 9531) L. Biganzoli, L. Orlando, A.
Minisini, M. Pistelli, S. Spazzapan, E. Simoncini, E. R. Caremoli, S. Leo, D. Baldari,
E. Zafarana, P. Fedele, E. Magnolfi, L. Pavesi, A. Brunello, A. Molino, S. De
Placido, D. Tomcikova, A. Di Leo, F. Puglisi
Board 191
Novel method to stratify elderly patients with prostate cancer. (Abstract
9532) R. Carmona, K. Zakeri, G. B. Green, D. P. Triplett, J. D. Murphy, L. K. Mell
Board 192
Health related quality of life (HRQOL) in older adults with cancer: The
potential of a single-item screen. (Abstract 9533) M. Pergolotti, A. M. Deal,
G. R. Williams, J. T. Bensen, A. L. Bryant, B. B. Reeve, H. B. Muss
Board 193
Novel method to stratify elderly patients with head and neck cancer.
(Abstract 9534) R. Carmona, G. B. Green, K. Zakeri, S. Gulaya, B. Xu, R. Verma,
C. Williamson, B. S. Rose, J. D. Murphy, F. Vaida, L. K. Mell
Board 194
Construction of a frailty index for older adults with cancer using a geriatric
assessment. (Abstract 9535) E. J. Guerard, A. M. Deal, G. R. Williams, T. A.
Jolly, W. A. Wood, H. B. Muss
Board 195
Feasibility of administering a geriatric assessment to older adults with
cancer using web-based and touchscreen platforms. (Abstract 9536) J. G.
Kim, C. Akiba, D. Mitani, D. D. Smith, M. J. Loscalzo, S. J. Forman, M. Koczywas,
S. K. Pal, V. M. Chung, N. Nathwani, M. Fakih, L. Popplewell, B. R. Ferrell, V.
Katheria, A. Hurria
Board 196
Is standard dose appropriate in elderly non-small cell lung carcinoma
(NSCLC) patients treated with erlotinib? (Abstract 9537) F. Bigot, J. Arrondeau,
P. Boudou-Rouquette, J. Chapron, A. Thomas-Shoemann, A. Cessot, O. Huillard,
C. Tlemsani, A. Le Bel, M. Vidal, J. Alexandre, A. Chahwakilian, D. Dusser, B.
Blanchet, F. Goldwasser
Board 197
Functional decline during first-line chemotherapy in elderly patients can be
predicted by abnormal G8 score and performance status. (Abstract 9538) C.
Chakiba, C. A. Bellera, M. Fonck, J. Blanc, J. Ceccaldi, Y. Imbert, L. Cany, J.
Dauba, H. Caillou, S. Mathoulin-Pélissier, M. Rainfray, P. Soubeyran
Board 198
Association of baseline pro-inflammatory (IL-6, CRP) and coagulation
(D-dimer) markers with relative dose intensity (RDI) in women with breast
cancer (BC) undergoing (neo) adjuvant chemotherapy (chemo). (Abstract
9539) Y. Yuan, N. L. Vora, D. D. Smith, T. W. Synold, J. E. Mortimer, T. H. Luu, G.
Somlo, J. R. Waisman, J. Chao, A. Levi, J. Choi, V. Katheria, V. Tran, S. Mi, L.
Zavala, A. Hurria
Board 199
Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast
cancer (MBC): Update of a new option suitable in older elderly. (Abstract
9540) I. U. Carreca, G. Bronte, A. Carreca, V. Bazan, D. Cova, A. Russo
Board 200
Safety of biosimilar filgrastim in elderly patients undergoing neutropeniainducing chemotherapy: a subanalysis of the NEXT study. (Abstract 9541) D.
Kamioner, F. Maloisel, S. Leprêtre, C. Berthou, H. Albrand
Board 201
Association of geriatric assessment factors with falls in older adults
initiating chemotherapy. (Abstract 9542) T. M. Wildes, W. P. Tew, R. J.
Maggiore, B. J. Edwards, H. J. Cohen, D. D. Smith, S. G. Mohile, C. Owusu, H. D.
120
Board 202
Feasibility of a home-based walking program in female breast cancer
patients age 60ⴙ during chemotherapy. (Abstract 9543) K. A. Nyrop, A. M.
Deal, S. M. Alston, S. A. Dixon, H. Muss
Board 203
Do quality of life, physical function, or the Wheatley Index at diagnosis
predict 1-year survival with intensive chemotherapy in older and younger
acute myeloid leukemia patients? (Abstract 9544) N. Timilshina, H. Breunis,
G. A. Tomlinson, J. M. Brandwein, S. M. Alibhai
Board 204
Differences between patient and caregiver assessments and their
association with caregiver burden in caregivers of older adults with cancer.
(Abstract 9545) T. Hsu, M. Loscalzo, R. Ramani, S. J. Forman, L. Popplewell,
K. L. Clark, V. Katheria, R. Strowbridge, R. Rinehart, K. Matthews, J. Dillehunt, T.
Feng, D. D. Smith, A. Hurria
Board 205
Advanced cancer patients’ reported priorities regarding wishes at the end of
life: A randomized controlled study. (Abstract 9546) M. O. Delgado-Guay, V. J.
De la Cruz, S. Frisbee-Hume, J. L. Williams, J. Wu, D. D. Liu, M. Fisch, E. Bruera
Board 206
Evaluation of the MPM2 score versus clinical predictions of mortality in a
tertiary cancer center. (Abstract 9547) A. Wiesenthal, V. Dave, H. T. Thaler,
P. A. Glare
Board 207
Distress in older adult cancer patients approaching end of life. (Abstract
9548) E. A. Kvale, G. B. Rocque, K. S. Bevis, A. Acemgil, R. A. Taylor, W. DemarkWahnefried, K. Kenzik, Y. Li, K. Meneses, M. Martin, M. Fouad, E. E. Partridge, M.
Pisu
Board 208
“Months, Not Years”: Impact of Clinical Discussions of Advanced Cancer
Life-Expectancy on Patient Illness Understanding. (Abstract 9549) A. S.
Epstein, H. G. Prigerson, L. Saltz, E. M. O’Reilly, M. A. Shah, P. K. Maciejewski
Board 209
Standardizing measurement of tobacco use in cancer clinical trials. (Abstract
9550) S. R. Land, G. W. Warren, C. Moinpour, J. S. Ostroff, J. Crafts, J. Folz, J. L.
Gulley, E. Szabo, V. Chollette, T. H. Brandon, S. Duffy, D. K. Hatsukami, C. M.
Dresler, E. R. Gritz, R. Schnoll, L. Sarna, N. Rigotti, J. C. Buckner, S. A. Mitchell, B.
Toll
Board 210
Dissonance reduction as prominent coping strategy in phase I study
participants. (Abstract 9551) D. A. van der Biessen, D. Klein, P. G. van der Helm,
M. P. Lolkema, R. H. Mathijssen, M. J. De Jonge
Board 211
Twelve-month prevalence of mental disorders in cancer patients across
major tumor entities. (Abstract 9552) A. Mehnert, S. Kuhnt, E. Brähler, H. Faller,
M. Härter, M. Keller, H. Schulz, K. Wegscheider, J. Weis, H. Wittchen, U. Koch
Board 212
Psychosocial distress and its effects on the health-related quality of life of
primary brain tumor patients. (Abstract 9553) D. M. Randazzo, F. McSherry,
J. E. Herndon II, M. L. Affronti, E. S. Lipp, C. Flahiff, E. Miller, S. Woodring, M.
Freeman, P. Healy, J. Minchew, S. Boulton, A. Desjardins, G. Vlahovic, H. S.
Friedman, S. T. Keir, K. B. Peters
Board 213
Patient-reported outcomes following choice for contralateral prophylactic
mastectomy. (Abstract 9554) E. S. Hwang, C. Rushing, T. D. Locklear, G.
Samsa, A. P. Abernethy, D. M. Atisha
Board 214
Relationship between physician-adjudicated adverse events (AE) and
patient-reported health-related quality of life (HRQoL) in a phase II clinical
trial of patients (pts) with metastatic uveal melanoma (UM). (Abstract 9555)
T. M. Atkinson, J. L. Hay, L. A. Doyle, D. Paucar, S. C. Smith, Y. Li, R. D. Carvajal
Board 215
Change in second-hand smoke exposure after a lung and head and neck
cancer diagnosis and subsequent patient smoking cessation. (Abstract 9556)
L. Eng, D. Alton, T. Yoannidis, Y. Song, R. Milne, S. Sarabia, Z. Merali, S.
Habbous, M. Brown, A. Vennettilli, F. A. Shepherd, N. Leighl, A. J. Hope, D.
Howell, J. M. Jones, P. Selby, W. Xu, D. P. Goldstein, M. E. Giuliani, G. Liu
121
SATURDAY
Klepin, C. P. Gross, S. M. Lichtman, A. Gajra, V. Katheria, C. Akiba, A. Hurria, The
Cancer and Aging Research Group
SATURDAY
Board 216
Psychological distress during hospitalization for hematopoietic stem cell
transplantation to predict lower quality of life and high post-traumatic stress
disorder symptoms at 6 months post-transplant. (Abstract 9557) H.
VanDusen, L. Traeger, J. N. Fishbein, T. Keenan, J. A. Greer, W. F. Pirl, V. A.
Jackson, J. Eusebio, E. R. Gallagher, T. A. Graubert, J. M. Peppercorn, T. R.
Spitzer, K. K. Ballen, S. L. McAfee, B. Dey, Y. A. Chen, J. S. Temel, A. El-Jawahri
Board 217
Treatment-adherence beliefs and behaviors in patients with chronic myeloid
leukemia (CML). (Abstract 9558) J. S. Buzaglo, C. Karten, M. F. Miller, J. A.
Greer, E. S. Weiss, M. J. Mauro
Board 218
Association between oncologists’ dispositional affect and depressive
symptoms in their patients with metastatic cancer. (Abstract 9559) W. F. Pirl,
J. Lerner, J. Eusebio, L. Traeger, L. Fields, A. El-Jawahri, J. A. Greer, J. S. Temel
Board 219
Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer
survivors. (Abstract 9560) A. Gifford, J. Lawrence, D. Case, S. Rapp, L. Baker, S.
Craft, D. L. Groteluschen, H. Klepin, G. Lesser, M. J. Naughton, B. Sachs, T. A.
Samuel, K. Sink, J. Williamson, E. G. Shaw
Board 220
The price of survival: Breast cancer patient preferences about fertility.
(Abstract 9561) A. Srikanthan, E. Amir, A. A. Gupta, N. N. Baxter, E. D. Kennedy
Board 221
Young adult cancer survivors’ expectations of physicians for reproductive
and sexual health care. (Abstract 9562) Y. Wang, P. Camateros, W. Y. Cheung
Board 222
Second primary malignancies in hepatocellular carcinoma: A populationbased study. (Abstract 9563) B. K. Shah, P. Kandel, A. Khanal
Board 223
A comparison of the natural history of oxaliplatin- and paclitaxel-induced
neuropathy (NCCTG N08C1, N08CB/Alliance). (Abstract 9564) K. J. Ruddy, D.
Pachman, R. Qin, D. K. Seisler, E. M. Smith, S. Puttabasavaiah, P. J. Novotny,
L. E. Ta, A. S. Beutler, N. D. Wagner-Johnston, N. Staff, A. Grothey, S. R. Dakhil,
C. L. Loprinzi
Board 224
Effects of strength training intervention in breast cancer survivors. (Abstract
9565) J. Monterroso, K. Dittus, A. Crocker, N. Kokinda, P. O’Brien
Board 225
A randomized controlled trial (RCT) of a supportive care package
(SurvivorCare, SC) for survivors of colorectal cancer (CRC). (Abstract 9566)
M. Jefford, K. Gough, A. Drosdowsky, L. Russell, S. Aranda, P. N. Butow, J.
Phipps-Nelson, J. Young, M. Krishnasamy, A. Ugalde, D. King, A. Strickland, M. E.
Franco, R. h. Blum, C. Johnson, V. Ganju, J. D. Shapiro, G. Chong, J. Charlton, P.
Schofield
Board 226
Results of the ASCO survey of cancer survivorship research: Summary and
implications. (Abstract 9567) P. B. Jacobsen, J. H. Rowland, E. D. Paskett, F.
Van Leeuwen, C. S. Moskowitz, S. Katta, D. Wollins, L. L. Robison
Board 227
Household secondhand smoke exposure among community-dwelling cancer
survivors in the United States. (Abstract 9568) O. Akinboro, O. Olorunfemi, I. R.
Hantman, P. Basak, E. Phillips, D. Pomerantz, B. Bernhardt, R. A. Gucalp, S.
Jesmajian
Board 228
Racial differences in upper extremity function for breast cancer survivors.
(Abstract 9569) L. T. Dean, A. DeMichele, S. Q. Li, C. Colameco, A. J. StephensShields, M. Coursey, J. J. Mao
Board 229
Comprehensive characterization of cisplatin-related hearing loss in U.S. and
Canadian Testicular Cancer Survivors (TCS). (Abstract 9570) H. E. Wheeler,
L. B. Travis, A. Budnick, D. R. Feldman, L. H. Einhorn, R. J. Hamilton, D. J.
Vaughn, C. Beard, C. Fung, E. Johnson, M. J. Moore, D. M. Sahasrabudhe, S. D.
Fossa, H. D. Sesso, M. Dolan, R. D. Frisina, The Platinum Study Group
Board 230
TOPS: A randomised controlled trial of a multidisciplinary intervention for
post-cancer fatigue. (Abstract 9571) C. Sandler, D. Goldstein, S. Horsfield, B. K.
Bennett, M. Friedlander, P. A. Bastick, C. R. Lewis, E. Segelov, F. M. Boyle, M. T.
Chin, B. K. Barry, K. Webber, A. R. Lloyd, TOPS Investigators
122
Board 231
Phase II feasibility study of a physical activity and dietary change weight loss
intervention in a subset analysis of breast cancer survivors (SWOG S1008).
(Abstract 9572) H. Greenlee, D. Lew, D. L. Hershman, J. P. Pierce, L. K. Hansen,
V. A. Newman, J. Korner, A. Sayegh, L. Fehrenbacher, S. S. Lo, J. R. Klemp, K.
Rinn, J. M. Robertson, J. M. Unger, J. Gralow, K. S. Albain, R. S. Krouse, C. J.
Fabian
Board 232
Survival outcome of cancer patients with pericardial effusions. (Abstract
9573) D. El Haddad, C. Iliescu, W. N. William Jr., E. Mouhayar
Board 233
Cancer survivors’ experiences with insurance, employment and personal
finances: Results from a multi-site study. (Abstract 9574) L. Nekhlyudov, R.
Walker, R. Ziebell, B. Rabin, S. Nutt, J. Chubak
Board 234
Distress in cancer survivors attending a multidisciplinary survivorship clinic.
(Abstract 9575) T. B. Sanft, L. Epstein, S. Capozza, M. Harrigan, M. A. Jauk, A.
Khairallah, J. Jorge, L. Sokoloff, S. Chen, A. B. Chagpar, M. L. Irwin
Board 235
Prevalence of hypogonadism in patients with previously treated germ cell
tumors. (Abstract 9576) T. J. Miller, L. H. Einhorn, N. H. Hanna, V. Champion, P.
Monahan, T. E. Stump, M. J. Brames, S. Case-Eads
Board 236
Self-efficacy through survivorship: Results from the LIVESTRONG Cancer
Navigation Study. (Abstract 9577) B. Hemingway, S. R. Arvey, R. Rechis, L.
Squiers, E. Eargle, K. Treiman
Board 237
Cardiac care after myocardial infarction in cancer survivors: A populationbased study. (Abstract 9578) K. K. Chan, A. Yan, W. Y. Cheung, C. Earle, D. Ko
Board 238
Healthcare plan and provider ratings among cancer survivors. (Abstract
9579) M. T. Halpern, M. Urato, M. Schwartz, E. E. Kent
Board 239
Using survivorship care plans (SCP) to improve cancer communication and
care coordination. (Abstract 9580) D. Mayer, A. M. Deal, J. M. Crane, R. C.
Chen, G. Asher, L. Hanson, S. B. Wheeler, A. Gerstel, M. Green, D. L. Rosenstein
Board 240
Cancer patients’ attitudes, knowledge, and preferences for smoking
cessation (SC). (Abstract 9581) L. Eng, D. Alton, T. Yoannidis, Q. Kong, R. Milne,
S. Sarabia, Z. Merali, L. Murphy, M. Brown, J. N. Waldron, A. Pierre, A. Bezjak,
A. J. Hope, D. Howell, J. M. Jones, P. Selby, W. Xu, D. P. Goldstein, M. E. Giuliani,
G. Liu
Board 241
Degradation of extracellular matrix measured in serum for predicting
mortality risk in women diagnosed with cancer: The Prospective
Epidemiologic Risk Factor (PERF I) study. (Abstract 9582) N. Willumsen, S. N.
Kehlet, C. L. Bager, K. Dragsbaek, J. Neergaard, H. B. Hansen, A. Bay-Jensen,
D. J. Leeming, C. Christiansen, M. A. Karsdal
Board 242
Outcomes and predictors of hospital mortality in metastatic cancer patients
receiving life sustaining treatments (LSTs). (Abstract 9583) K. Loh, M. Shieh,
A. J. Kansagra, P. Lindenauer, P. Pekow, M. Stefan, T. Lagu
Board 243
Treatment-specific risks of second malignancy and cardiovascular disease
in Hodgkin lymphoma survivors. (Abstract 9584) S. de Vries, F. A. van
Nimwegen, M. Schaapveld, P. J. Lugtenburg, A. D. Krol, J. M. Roesink, J. M.
Raemaekers, B. M. Aleman, F. Van Leeuwen
Board 244
Sexual morbidity and unmet needs among members of a metastatic breast
cancer registry. (Abstract 9585) J. S. Buzaglo, M. F. Miller, B. L. Andersen, M.
Longacre, P. A. Robinson
Board 245
QOL at 3 years after diagnosis in aggressive lymphoma survivors. (Abstract
9586) C. A. Thompson, M. J. Maurer, C. Allmer, S. M. Ansell, R. M. Ferzoco, T. M.
Habermann, D. J. Inwards, P. B. Johnston, R. Klebig, W. R. Macon, I. N. Micallef,
K. J. Yost, U. Farooq, B. K. Link, J. R. Cerhan
Board 246
Employment and quality of life (QOL) in human papillomavirus-related
(HPVⴙ) oropharynx cancer treated with definitive chemoradiation (CTRT).
(Abstract 9587) S. S. Baxi, H. Xiao, M. G. Fury, C. L. Atoria, L. Dunn, T. Salz, E. J.
Sherman, A. L. Ho, N. Y. Lee, D. G. Pfister
123
SATURDAY
SATURDAY
Board 247
Young and strong: A randomized study to improve care for young women
with breast cancer. (Abstract 9588) A. H. Partridge, K. J. Ruddy, W. T. Barry, M.
Greaney, J. A. Ligibel, K. Sprunck-Harrild, S. M. Rosenberg, E. Baker, J. R.
Hoverman, K. Emmons
Board 248
A feasibility study of an electronic interface between Internet-based
survivorship care plans and electronic medical records (EMR)/tumor
registries. (Abstract 9589) C. Hill-Kayser, L. A. Jacobs, S. C. Palmer, M. K.
Hampshire, C. Vachani, S. B. Edge, E. J. McNamara, J. M. Metz
Board 249
Failure to follow directions for prescription medications to save money
among cancer survivors. (Abstract 9590) A. Jemal, Z. Zheng, T. Wang, X. Han
Board 250
Prediction models of smoking cessation in lung and head and neck cancer
patients: Role of second-hand smoke (SHS) exposure. (Abstract 9591) G. Liu,
Y. Song, D. Alton, T. Yoannidis, R. Milne, S. Sarabia, Z. Merali, S. Habbous, M.
Brown, A. Vennettilli, A. J. Hope, D. Howell, J. M. Jones, P. Selby, D. P. Goldstein,
M. E. Giuliani, W. Xu, L. Eng
Board 251
Sexual and marital dysfunction in women with gynecologic cancer: A
multi-institutional, cross-sectional trial. (Abstract 9592) S. Guntupalli, D. Flink,
J. Sheeder, J. Leifermann, A. I. Tergas, Y. Ioffe, J. D. Wright, K. Behbakht
Board 252
National data on sorafenib therapy adherence for veterans with
hepatocellular carcinoma. (Abstract 9593) S. Malhotra, D. P. Wu, Y. A. Park
Board 253
A phase II randomized, double-blind, placebo-controlled study to evaluate
naldemedine for the treatment of opioid-induced constipation (OIC) in
patients with cancer pain. (Abstract 9594) N. Boku, N. Katakami, S. Fujita, K.
Oda, K. Tauchi, K. Nakata, K. Shinozaki, M. Okuno, Y. Kawai, H. Kikukawa, R.
Suzuki, H. Nakazawa, H. Kojima, M. Mizutani, T. Hara, T. Yokota, Y. Suzuki, M.
Narabayashi
Board 254
Can pregabalin prevent paclitaxel-associated neuropathy?: A pilot trial.
(Abstract 9595) S. S. Shinde, D. K. Seisler, G. S. Soori, P. J. Atherton, D. R.
Pachman, J. M. Lafky, K. J. Ruddy, C. L. Loprinzi
Board 255
Predictors of hand-foot syndrome (HFS) in randomised double-blind,
placebo-controlled trial of pyridoxine for prevention of capecitabine induced
HFS. (Abstract 9596) Y. Yap, L. Kwok, R. C. Ng, N. Wong, S. Lo, W. Chay, J. W.
Chia, C. Tham, S. Tan, V. Z. Mok, J. K. Koh, M. Loh, H. Toh, W. Koo, R. C. Soong,
S. Choo
Board 256
Should all antiemetic guidelines recommend adding a NK1 receptor
antagonist (NK1RA) in patients (pts) receiving carboplatin (carbo)? Efficacy
evaluation of NEPA, a fixed combination of the NK1RA, netupitant, and
palonosetron. (Abstract 9597) K. Jordan, R. J. Gralla, G. Rizzi
Board 257
Palonosetron or granisetron for prevention of CINV in patients with breast
cancer receiving dexamethasone and fosaprepitant following anthracycline
plus cyclophosphamide (AC) regimen. (Abstract 9598) K. Matsumoto, M.
Takahashi, K. Sato, T. Takano, Y. Ryushima, M. Doi, K. Aogi, K. Fujiwara, K.
Tamura, M. Hosoda, S. Tokunaga, A. Makiyama, K. Miyamoto, Y. Hozumi, K.
Yanagihara, C. K. Imamura, Y. Chiba, S. Nakamura, T. Saeki, WJOG: West Japan
Oncology Group
Board 258
Use of mobile device technology to collect patient-reported symptoms
during radiotherapy for head and neck cancer: A prospective feasibility
study. (Abstract 9599) A. D. Falchook, G. Tracton, L. Stravers, M. Fleming, B. B.
Reeve, E. M. Basch, B. S. Chera
Board 259
Association of severe pain with poor response to opioids, psychological
distress, and aberrant drug taking behaviors in a large cohort of cancer
patients. (Abstract 9600) V. Dave, R. Roberts, Y. Griffo, N. Moryl, R. Tickoo, K.
Cubert, A. Gulati, J. Hung, V. Puttanniah, S. Horn, P. Brown, V. Malhotra, P. A.
Glare, C. Inturrisi
Board 260
Minimal clinically important differences in the Edmonton Symptom
Assessment Scale in cancer patients: A prospective study. (Abstract 9601) D.
124
Board 261
Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of
chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with
solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.
(Abstract 9602) E. S. Winer, H. Safran, F. Forget, B. Karaszewska, S. Bauer, D.
Khan, B. M. Johnson, P. M. Burgess, D. C. Althouse, G. Chan, Y. Mostafa Kamel
Board 262
Febrile neutropenia risk factors: A subanalysis of the NEXT study. (Abstract
9603) N. Jovenin, F. Maloisel, S. Leprêtre, D. Kamioner, C. Berthou, H. Albrand
Board 263
Pilot trial assessing the efficacy and safety of a supplemental B vitamin
complex to reduce the onset and severity of chemotherapy-induced
peripheral neuropathy. (Abstract 9604) J. M. Schloss, M. Colosimo, C. Airey,
A. W. Linanne, P. Masci, L. Vitetta
Board 264
Prospective multicenter study evaluating adrenal suppression after
dexamethasone therapy as an antiemetic in cancer patients: a KSWOG
(Korean South West Oncology Group) study. (Abstract 9605) H. Han, J. Park,
S. Park, K. Lee, S. Bae, H. Kim, S. Kim, H. Yun, W. Bae, H. Shim, J. Hwang, S.
Cho, M. Park
Board 265
Patient self-evaluation of side-effects related to adjuvant chemotherapy in
breast cancer: A prospective study. (Abstract 9606) F. Montemurro, G. Mittica,
C. Cagnazzo, M. Foresto, V. Longo, P. Berchialla, G. Solinas, P. Culotta, R.
Martinello, A. Calori, B. Grasso, C. Volpone, G. Bertola, G. Parola, M. Del Torre, P.
Giuliano, M. Aglietta, A. Ballari
Board 266
Identifying predictors of taxane-induced peripheral neuropathy using
shotgun proteomics technology. (Abstract 9607) M. S. Trivedi, E. I. Chen, D.
Awad, A. Koller, P. Patel, K. Kalinsky, M. A. Maurer, K. D. Crew, D. L. Hershman
Board 267
A randomized trial of vitamin D3 in aromatase inhibitor-associated
musculoskeletal symptoms. (Abstract 9608) A. C. Shapiro, S. A. Adlis, S. Liang,
K. Robien, M. N. Kirstein, E. Anderson, R. E. Lerner
Board 268
Usefulness of denosumab to nonsquamous non-small cell lung cancer
patients with bone metastases. (Abstract 9609) H. Udagawa, S. Niho, K. Kirita,
S. Umemura, S. Matsumoto, K. Yoh, H. Ohmatsu, K. Goto
Board 269
Phase II study of preventive effect of topical menthol for chemotherapyinduced peripheral neurotoxicity. (Abstract 9610) K. Nakamura, M. Nakamura,
T. Onikubo, K. Uchibori, K. Tauchi
Board 270
Longitudinal study of pneumonitis and esophagitis-related symptoms in
patients receiving concurrent chemoradiation for NSCLC. (Abstract 9611)
X. S. Wang, Q. Shi, C. S. Cleeland, M. O’Reilly, T. Xu, R. H. Bokhari, D. R. Gomez,
Q. Nguyen, R. Komaki, R. Mohan, J. D. Cox, Z. X. Liao
Board 271
The conversion ratio (CR) for opioid rotation (OR) from strong opioids to
transdermal fentanyl (TDF) in cancer patients. (Abstract 9612) A. S. Reddy, A.
Haider, S. Tayjasanant, J. Wu, D. D. Liu, S. Yennu, M. De la Cruz, M. Vidal, S. K.
Reddy, E. Bruera
Board 272
Association of high symptom burden with oral oncolytic agents. (Abstract
9613) J. A. Severson, E. R. Mackler, B. Marini, D. W. Blayney
Board 273
Randomized pilot study comparing high-dose (HD) influenza vaccine to
standard-dose (SD) influenza vaccine in adult oncology patients younger
than 65 receiving chemotherapy. (Abstract 9614) S. Jamshed, A. R. Falsey,
L. J. Dimitroff, J. S. Santelli, E. E. Walsh
Board 274
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly
emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy
(MEC). (Abstract 9615) M. Chasen, L. Urban, I. Schnadig, B. L. Rapoport, A.
Poma, S. Arora, R. M. Navari, L. S. Schwartzberg, C. Gridelli
Board 275
Evaluation of brain-derived neurotrophic factor (BDNF) genetic
polymorphism (rs6265) on chemotherapy-associated cognitive impairment in
125
SATURDAY
Hui, O. M. Shamieh, C. E. Paiva, P. Perez-Cruz, J. Kwon, M. Muckaden, M. Park,
S. Yennu, J. Kang, E. Bruera
early-stage breast cancer (ESBC) patients. (Abstract 9616) T. NG, S. Teo, H.
Yeo, M. Shwe, Y. Gan, Y. Cheung, Y. Tan, W. Yong, P. Madhukumar, K. Loh, S. Koo,
A. Jain, G. Lee, M. Wong, R. A. Dent, Y. Yap, R. C. Ng, C. Khor, H. Ho, A. Chan
SATURDAY
Board 276
Development and validation of a Clinical Index of Severe Febrile
Neutropenia: A prospective multicenter study. (Abstract 9617) J. V. Echaburu,
A. Blasco, J. Martinez Sr., C. Font, M. Antonio Rebollo, M. Biosca, A.
Ramchandani, J. Hernando-Cubero, E. Martinez de Castro, J. Espinosa Sr., C.
Beato, I. Aragon Manrique, F. J. Garcı́a Navalón, I. Ghanem Canete Sr., E.
Sevillano, A. Manzano, M. Garrido Sr., E. Castanon, P. Jiménez-Fonseca, A.
Carmona Bayonas, Supportive Care Working Group of the Spanish Society of
Medical Oncology (SEOM)
Board 277
Efficacy and safety of rolapitant for prevention of chemotherapy-induced
nausea and vomiting (CINV) in patients (pts) receiving
anthracycline-cyclophosphamide (AC)-based chemotherapy. (Abstract 9618)
I. D. Schnadig, M. R. Modiano, A. Poma, S. Arora, L. S. Schwartzberg
Board 278
Evaluating the effect of neutropenic diet on infection and mortality rate in
cancer patients: A meta-analysis. (Abstract 9619) M. B. Sonbol, B. Firwana, M.
Diab, T. E. Witzig
Board 279
Risk assessment of anticancer treatments beyond performance status: A
prospective study in 277 cancer patients. (Abstract 9620) A. Jouinot, C.
Vazeille, J. Durand, N. Neveux, A. Cessot, P. Boudou-Rouquette, J. Giroux, I.
Gataa, S. Bellanger, J. Alexandre, L. Cynober, F. Goldwasser
Board 280
Clinical predictors of recurrent venous thromboembolism (VTE) in cancer
patients from a randomized trial of long-term tinzaparin versus warfarin for
treatment: The CATCH study. (Abstract 9621) A. A. Khorana, R. Bauersachs,
P. W. Kamphuisen, G. Meyer, M. S. Janas, M. F. Jarner, A. Lee, CATCH
Investigators
Board 281
Efficacy and safety of rolapitant for prevention of chemotherapy-induced
nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
(Abstract 9622) P. J. Hesketh, L. S. Schwartzberg, M. R. Modiano, S. Arora, A.
Poma, I. D. Schnadig
Board 282
Establishing a new quality of life (QL) / patient reported outcome (PRO) /
symptom scale in advanced cancer: Content validity for the “CSS” based on
input from 3860 patients. (Abstract 9623) J. C. Shih, P. Chourasia, R. J. Gralla,
P. Msaouel, R. Sidlow, P. J. Hollen
Board 283
Sleep quality and its association with fatigue, symptom burden, and mood in
patients with advanced cancer in a phase 1 clinic. (Abstract 9624) G. George,
E. C. Iwuanyanwu, K. O. Anderson, S. A. Piha-Paul, J. J. Wheler, R. Zinner, A.
Naing, A. M. Tsimberidou, F. Janku, V. Subbiah, C. S. Cleeland, T. R. Mendoza,
D. S. Hong
Board 284
Patient-reported experience combining complementary and alternative
medicine (CAM) with conventional oncology treatment (COT). (Abstract 9625)
A. G. Menendez, A. Saied, N. J. Espat
Board 285
Interpreting the febrile neutropenia rates from randomized controlled trials
for consideration of primary prophylaxis in the real world: A systematic
review and meta-analysis. (Abstract 9626) J. Truong, E. Lee, M. E. Trudeau,
K. K. Chan
Board 286
Can a homeopathic medicine complex reduce hot flashes induced by
adjuvant endocrine therapy in localized breast cancer patients? Results of a
randomized placebo-controlled phase III trial. (Abstract 9627) P. Heudel, I.
Van Praagh, B. Duvert, I. Cauvin, A. Hardy-Bessard, J. Jacquin, L. Stefani, A. Belliere,
L. Vincent, D. Dramais, J. Guastalla, E. Blanc, A. Belleville, E. Lavergne, D. Pérol
Board 287
A randomised, open-label trial of a Multimodal Intervention (Exercise,
Nutrition and Anti-inflammatory Medication) plus standard care versus
standard care alone to prevent / attenuate cachexia in advanced cancer
patients undergoing chemotherapy. (Abstract 9628) S. Kaasa, T. Solheim, B. J.
Laird, T. Balstad, G. B. Stene, A. Bye, M. T. Fallon, P. Fayers, K. Fearon
126
Board 288
A phase III, randomized, double-blind study of single-dose intravenous
fosaprepitant in preventing chemotherapy-induced nausea and vomiting
associated with moderately emetogenic chemotherapy. (Abstract 9629) B. L.
Rapoport, C. Weinstein, E. S. Camacho, S. A. Khanani, E. Beckford-Brathwaite, L.
Kevill, W. Vallejos, L. W. Liang, S. J. Noga
Board 289
Effective complementary ASCO policy and day to day decision support
strategies optimize anti-emetic choices. (Abstract 9630) A. Baranwal, D. Q.
Huff, K. B. Knopf, C. L. Bennett, W. S. Shimp, M. L. Fishman, W. J. Hrushesky
Board 290
Do cancer patients present with subclinical peripheral neuropathy prior to
initiating neurotoxic chemotherapy? (Abstract 9631) S. Ramnarine, L. J.
Williams, M. T. Fallon
Board 291
Cost communication preferences, financial burden, and health-related
quality-of-life (HRQoL). (Abstract 9632) J. A. De Souza, J. O’Connor, B. J. Yap,
K. Wroblewski, C. Daugherty
Board 292
Randomized trial of a home-based exercise intervention for patients with
advanced colorectal cancer: Effects on physical functioning and activity
levels. (Abstract 9633) K. Basen-Engquist, P. A. Parker, C. Eng, Y. Li, D. B.
Johnson, B. K. Kee, S. S. Thomas, L. Wong, T. S. Crocenzi, J. Song, M. Fisch
Board 293a
A feasibility trial of geriatric assessment and integrated care plan for older
cancer patients. (Abstract TPS9634) M. Puts, S. Sattar, K. McWatters, K. Lee, E.
Amir, M. K. Krzyzanowska, A. M. Joshua, J. Monette, D. Wan-Chow-Wah, R. W.
Jang, S. M. Alibhai
Board 293b
VOTRAGE study pazopanib in vulnerable elderly patients after geriatric
assessment—A phase I study with geriatric criteria. (Abstract TPS9635) L.
Mourey, A. Ravaud, L. Digue, C. Terret, E. Sevin, T. Filleron, L. Balardy
Board 294a
Cancer-related cognitive dysfunction (CRCD) and psychosocial development
in young adult cancer survivors. (Abstract TPS9636) K. Edelstein, N. M.
D’Agostino, G. R. Pond, S. Aubin, A. Matthew, K. Wahl, A. A. Gupta, P. Kavan, M.
Crump, P. L. Bedard, A. C. Schuh, D. C. Hodgson, T. Vuong, T. Muanza, G. Batist,
L. J. Bernstein
Board 294b
Rehabilitation of cognitive dysfunction in brain tumor patients. (Abstract
TPS9637) N. M. Richard, L. J. Bernstein, W. P. Mason, N. Laperriere, C. Chung, B.
Millar, C. Maurice, K. Edelstein
Board 295a
A phase III randomized double-blind study of prophylactic topical dapsone
5% versus moisturizer for cetuximab-induced papulopustular (acneiform)
rash. (Abstract TPS9638) M. E. Lacouture, V. Belum, D. Kehn, A. Cercek, N. E.
Kemeny
Board 295b
Efficacy and safety of olanzapine combined with aprepitant, palonosetron,
and dexamethasone for the prevention of cisplatin-based chemotherapyinduced nausea and vomiting for gynecological cancer: KCOG G-1301 phase
II trial. (Abstract TPS9639) M. Abe, Y. Kasamatsu, K. Nobuhiro, S. Kuji, A.
Tanaka, N. Takahashi, M. Takekuma, Y. Hirashima, S. Nishio, Y. Itani, Y. Ichikawa,
Y. Itonaga, T. Hirakawa, K. Nasu, K. Miyagi, J. Murakami, K. Ito
Board 296a
TabPRO trial: Tablet-based real-time detection of patient-reported outcomes
during adjuvant outpatient chemotherapy for breast cancer. (Abstract
TPS9640) M. R. Mallmann, C. M. Domroese, C. Fuhrmann, F. Thangarajah, L.
Leitzen, A. Ulhaas, F. Bach, D. Engelhardt, E. D. Beier, M. Keyver-Paik, C. Coch,
C. Kaiser, A. Abramian, B. Nuding, W. Malter, S. Kraemer, M. Wirtz, C. Rudlowski,
O. Zivanovic, W. C. Kuhn
Board 296b
Three-arm randomized trial of sodium alginate, orally administered
mucoprotective agent, for preventing radiation esophagitis in pts with locally
advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent
chemoradiotherapy (CRT): Okayama Lung Cancer Study Group 1401.
(Abstract TPS9641) K. Hotta, K. Ninomiya, I. Oze, A. Bessho, T. Murakami, N.
Sone, S. Harita, N. Nogami, S. Kuyama, M. Tanimoto, K. Kiura
127
SATURDAY
Board 297a
Anticoagulation therapy in selected cancer patients at risk of recurrence of
venous thromboembolism. (Abstract TPS9642) A. Young, J. Phillips, H.
Hancocks, A. Marshall, J. Grumett, J. Dunn, O. Chapman
Board 297b
Phase 3 randomized double blind placebo controlled trial evaluating Omega3 in the prevention of Taxane or Platinum Induced Peripheral Sensory
Neuropathy. (Abstract TPS9643) R. Maroun, R. Saleh, J. Asselah, M. Haziza,
S. H. Meterissian, N. Bouganim
SATURDAY
Location: N Hall B1
Tiffany A. Traina, MD—Co-Chair
Janice Maria Walshe, MD—Co-Chair
St Vincent’s University Hospital
3:00 PM
Lodovico Balducci, MD (Discussion of Abstract(s) 1009-1010)
Determining the Tipping Point in Geriatric Oncology
3:12 PM
3:18 PM
Tari A. King, MD (Discussion of Abstract(s) 1011–1013)
Drivers of Decision Making in Local Therapy: Choosing Wisely
3:30 PM
3:36 PM
Kathy Miller, MD (Discussion of Abstract(s) 1014 –1016)
Indiana University Melvin and Bren Simon Cancer Center
Novel Agents in Triple-Negative Breast Cancer
3:48 PM
3:54 PM
Shridar Ganesan, MD, PhD (Discussion of Abstract(s) 1017–1020)
Rutgers Cancer Institute of New Jersey
Triple-Negative Breast Cancer: Divide and Conquer
4:06 PM
Posters discussed in this session are on display in the Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Poster Session. See page 62 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion.
Location: S406
Charlotte Eielson Ariyan, MD, PhD—Co-Chair
Gregory Lawrence Beatty, MD, PhD—Co-Chair
Hospital of the University of Pennsylvania
3:00 PM
Harriet M. Kluger, MD (Discussion of Abstract(s) 3009 –3012)
Expanding Indications of Checkpoint Blockade
3:12 PM
128
3:18 PM
Matthew David Hellmann, MD (Discussion of Abstract(s) 3013–3015)
Optimizing Immunotherapy in Non-Small Cell Lung Cancer
3:30 PM
3:36 PM
Michael T. Lotze, MD (Discussion of Abstract(s) 3016 –3018)
Hillman Cancer Center
Getting More Out of Your Cytokines
3:48 PM
3:54 PM
Lillian L. Siu, MD, FRCPC (Discussion of Abstract(s) 3019 –3021)
Getting Specific: Antigens and Vaccines
4:06 PM
Posters discussed in this session are on display in the Developmental Therapeutics—Immunotherapy Poster Session. See page 79 for poster information. Networking with presenters and
discussants will take place right outside of the session room after the discussion.
ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global
Perspective on Value
Location: S100a
Rolf A. Stahel, MD—Co-Chair
University Hospital Zurich
Peter Paul Yu, MD, FACP, FASCO—Co-Chair
Lowell E. Schnipper, MD
Beth Israel Deaconess Medical Center
ASCO’s Value-Based Framework
Elisabeth De Vries, MD, PhD
University Medical Center Groningen
ESMO’s Magnitude of Clinical Benefit Scale
Alexandru E. Eniu, MD, PhD
Cancer Institute Ion Chiricuta Cluj-Napoca
Disparity of Cancer Medicine Access in Europe
Gilberto Lopes, MD, MBA, FAMS
Centro Paulista de Oncologia and HCor Onco
Essential Drug Compendium
Implications of Intratumor Heterogeneity for Personalized Therapy
Location: E450
Michalina Janiszewska, PhD
Molecular Evolution of Human Breast Tumors
129
SATURDAY
Charles Swanton, PhD, FRCP—Chair
The Francis Crick Institute—Lincoln’s Inn Fields Laboratory
Role of Intratumoral Heterogeneity in Understanding Drug Resistance
Liran Shlush, MD, PhD
Clonal Evolution Models of Tumor Heterogeneity
SATURDAY
Enhancing Communications Skills: The Comskil Training Program—Ticketed
Session
Location: E451a
Philip A. Bialer, MD
Coping with Chaos and Other Challenges in Medicine
Location: S404
Linda H. Clever, MD, MACP—Chair
RENEW
Gastrointestinal (Colorectal) Cancer
Location: E Hall D2
Edward Chu, MD—Co-Chair
University of Pittsburgh
Richard H. Wilson, MD—Co-Chair
Queen’s University Belfast
3:00 PM
A multi-center randomized controlled trial of mFOLFOX6 with or without
radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC
study): Preliminary results. (Abstract 3500) Y. Deng, P. Chi, P. Lan, L. Wang, L.
Cui, D. Chen, J. Cao, H. Wei, X. Peng, Z. Huang, G. Cai, R. Zhao, Y. Luo, Y.
Zhang, Y. Cai, J. Wang
3:12 PM
Radiofrequency ablation (RFA) combined with chemotherapy for
unresectable colorectal liver metastases (CRC LM): Long-term survival
results of a randomized phase II study of the EORTC-NCRI CCSG-ALM
Intergroup 40004 (CLOCC). (Abstract 3501) T. Ruers, C. J. Punt, F. van
Coevorden, J. Pierie, I. Borel Rinkes, J. A. Ledermann, G. J. Poston, W. O.
Bechstein, M. Lentz, M. E. Mauer, E. Van Cutsem, M. P. Lutz, B. Nordlinger
3:24 PM
SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ⴞ
bevacizumab (bev) versus mFOLFOX6 ⴙ selective internal radiation therapy
(SIRT) ⴞ bev in patients (pts) with metastatic colorectal cancer (mCRC).
(Abstract 3502) P. Gibbs, V. Heinemann, N. K. Sharma, M. P. Findlay, J. Ricke, V.
Gebski, M. Van Buskirk, G. A. Van Hazel, SIRFLOX Study Group
130
3:36 PM
Ricky A. Sharma, MA, MB, Bchir, FRCP, FRCR, PhD (Discussion of
Abstract(s) 3500 –3502)
Gray Institute for Radiation Oncology and Biology, University of Oxford
How Many Modalities Are Enough?
3:48 PM
4:00 PM
Vitamin D status and survival of metastatic colorectal cancer patients: Results
from CALGB/SWOG 80405 (Alliance). (Abstract 3503) K. Ng, A. P. Venook, K.
Sato, C. Yuan, B. W. Hollis, D. Niedzwiecki, C. Ye, I. Chang, B. H. O’Neil, F. Innocenti,
H. Lenz, C. D. Blanke, R. J. Mayer, C. S. Fuchs, J. A. Meyerhardt
4:12 PM
Impact of aspirin as secondary prevention in an unselected cohort of 25,644
patients with colorectal cancer: A population-based study. (Abstract 3504) S.
Bains, M. Mahic, M. Cvancarova, S. Yaqub, L. Dørum, B. Bjørnbeth, B. Møller,
K. W. Brudvik, K. Tasken
4:24 PM
Andrew T. Chan, MD, MPH (Discussion of Abstract(s) 3503–3504)
Over-the-Counter Therapies for Colon Cancer
4:36 PM
4:48 PM
Comprehensive molecular characterization of colorectal cancer reveals
genomic predictors of immune cell infiltrates. (Abstract 3505) M. Giannakis, S.
Shukla, J. X. Mu, R. Nishihara, M. Yamauchi, Y. Sukawa, Z. Qian, K. Nosho, K.
Inamura, S. Bahl, K. Ng, A. T. Chan, J. A. Meyerhardt, S. B. Gabriel, E. Lander, C.
Wu, G. Getz, C. S. Fuchs, S. Ogino, L. A. Garraway
5:00 PM
Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III
colon cancers from patients (pts) treated with adjuvant FOLFOX ⴙ/cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. (Abstract 3506)
A. Zaanan, Q. Shi, J. Taieb, S. R. Alberts, T. C. Smyrk, C. Julie, A. Zawadi, J.
Tabernero, E. Mini, R. M. Goldberg, G. Folprecht, J. L. Van Laethem, K. Le Malicot,
D. J. Sargent, P. Laurent-Puig, F. A. Sinicrope
5:12 PM
Prognostic value of BRAF V600E and KRAS exon 2 mutations in
microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts)
treated with adjuvant FOLFOXⴙ/- cetuximab: A pooled analysis of 3934 pts
from the PETACC8 and N0147 trials. (Abstract 3507) J. Taieb, K. Le Malicot,
F. M. Penault-Llorca, O. Bouche Sr., Q. Shi, S. N. Thibodeau, J. Tabernero, E.
Mini, R. M. Goldberg, G. Folprecht, J. Van Laethem, D. J. Sargent, S. R. Alberts, P.
Laurent-Puig, F. A. Sinicrope
5:24 PM
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer
patients (mCRC): The HERACLES trial. (Abstract 3508) S. Siena, A. SartoreBianchi, S. Lonardi, L. Trusolino, C. Martino, K. Bencardino, F. Leone, V. Zagonel,
E. Valtorta, V. Torri, G. Siravegna, A. Amatu, E. F. Bonazzina, F. Rusconi, S.
Ghezzi, F. Ciardiello, S. Veronese, P. M. Comoglio, A. Bardelli, S. Marsoni
5:36 PM
Sabine Tejpar, MD, PhD (Discussion of Abstract(s) 3505–3508)
University of Leuven, KUL
Molecular Profiling to Inform Prognosis and Treatment
5:48 PM
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Location: E Hall D1
Scott N. Gettinger, MD—Co-Chair
Charles M. Rudin, MD, PhD—Co-Chair
131
SATURDAY
SATURDAY
3:00 PM
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP
doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC0701 MAPS randomized phase 3 trial. (Abstract 7500) G. Zalcman, J. Mazières,
J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I.
Monnet, V. Gounant, H. Janicot, R. Gervais, C. Locher, B. Milleron, Q. Tran, M.
Lebitasy, F. Morin, C. Creveuil, J. Parienti, A. Scherpereel, French Cooperative
Thoracic Intergroup (IFCT)
3:12 PM
Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC)
versus placebo plus BIC in previously treated patients with advanced
malignant pleural mesothelioma (MPM). (Abstract 7501) R. M. Gaafar, A. G.
Favaretto, V. Gregorc, F. Grossi, J. Jassem, A. Polychronis, P. Bidoli, M. Tiseo,
M. E. O’Brien, R. Shah, P. Taylor, S. Novello, A. Muzio, A. Bearz, P. Badurak, L.
Greillier, A. Lambiase, C. Bordignon
3:24 PM
Anna K. Nowak, MBBS, FRACP, PhD (Discussion of Abstract(s) 7500 –7501)
Sir Charles Gairdner Hospital
New (and Old) Directions in Mesothelioma
3:36 PM
3:48 PM
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell
lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE028. (Abstract 7502) P. A. Ott, M. E. Fernandez, S. Hiret, D. Kim, R. A. Moss, T.
Winser, S. Yuan, J. D. Cheng, B. Piperdi, J. M. Mehnert
4:00 PM
Phase I/II study of nivolumab with or without ipilimumab for treatment of
recurrent small cell lung cancer (SCLC): CA209 – 032. (Abstract 7503) S. J.
Antonia, J. C. Bendell, M. H. Taylor, E. Calvo, D. Jaeger, F. G. De Braud, P. A. Ott,
M. C. Pietanza, L. Horn, D. T. Le, M. Morse, J. A. Lopez-Martin, P. A. Ascierto, O.
Christensen, J. Grosso, J. S. Simon, C. Lin, J. P. Eder
4:12 PM
Results from a randomized study of carboplatin and etoposide (CE) with or
without palifosfamide (Pa) in extensive stage small cell lung cancer (ESSCLC): The MATISSE study. (Abstract 7504) S. I. Jalal, L. H. Einhorn, G. Lo, P.
Lavin, F. M. Lebel
4:24 PM
A multicenter, randomised, phase III trial comparing fixed dose versus
toxicity-adjusted dose of cisplatin ⴙ etoposide in advanced SCLC patients.
The STAD-1 trial. (Abstract 7505) A. Morabito, G. Daniele, A. G. Favaretto, V.
Filipazzi, A. Rossi, V. Gebbia, F. Castiglione, L. Cavanna, E. Maiello, G. Valmadre,
R. Costanzo, A. Manzo, L. Bonanno, E. Piazza, P. Maione, G. Mancuso, M. Di
Maio, M. Piccirillo, C. Gallo, C. Gridelli
4:36 PM
Roy S. Herbst, MD, PhD (Discussion of Abstract(s) 7502–7505)
Small Cell Lung Cancer: A Glimpse of Light
4:48 PM
5:00 PM
Final overall survival (OS) results of the phase III PROCLAIM trial:
Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic
radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy
(CTX) in locally advanced nonsquamous non-small cell lung cancer
(nsNSCLC). (Abstract 7506) S. Senan, A. M. Brade, L. Wang, J. F.
Vansteenkiste, S. R. Dakhil, B. Biesma, M. Martinez Aguillo, J. Aerts, R. Govindan,
B. Rubio-Viqueira, C. R. Lewanski, D. R. Gandara, H. Choy, T. Mok, A. Hossain,
N. A. Iscoe, J. Treat, A. G. Koustenis, N. Chouaki, E. E. Vokes
5:12 PM
Randomized phase III trial of customized adjuvant chemotherapy (CT)
according BRCA-1 expression levels in patients with node positive resected
non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group
trial (Eudract:2007– 000067-15; NCTgov: 00478699). (Abstract 7507) B.
Massuti, M. Cobo, J. Rodriguez-Paniagua, A. Ballesteros, T. Moran, R. Arrabal, J.
Gonzalez Larriba, I. Barneto, Y. W. Pun, J. De Castro, S. Ponce Aix, C. Baamonde,
M. Munoz, G. Lopez-Vivanco, J. Rivas, D. Isla, R. Lopez, J. Sanchez, J. SanchezPaya, R. Rosell, Spanish Lung Cancer Group (GECP/SLCG)
132
5:24 PM
Mark A. Socinski, MD (Discussion of Abstract(s) 7506 –7507)
Improving the Cure Rate in Early-Stage Lung Cancer
5:36 PM
Pediatric Oncology I
Gregory T. Armstrong, MD, MSCE—Co-Chair
St. Jude Children’s Research Hospital
Maureen Megan O’Brien, MD—Co-Chair
Cincinnati Children’s Hospital Medical Center
3:00 PM
Morbidity and mortality associated with subsequent meningiomas among
childhood cancer survivors exposed to cranial radiotherapy: A report from
the Childhood Cancer Survivor Study (CCSS). (Abstract 10000) D. C. Bowers,
C. S. Moskowitz, J. F. Chou, C. M. Mazewski, J. P. Neglia, G. T. Armstrong, W. M.
Leisenring, L. L. Robison, K. C. Oeffinger
3:12 PM
Chemotherapy and brain function in long-term survivors of childhood acute
lymphoblastic leukemia (ALL). (Abstract 10001) Y. Cheung, S. Fellah, W. Liu,
R. J. Ogg, D. Srivastava, C. I. Kimberg, T. M. Brinkman, C. Pui, L. L. Robison,
M. M. Hudson, K. R. Krull
3:24 PM
Neurocognitive function of children treated for high-risk B-acute
lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus
high-dose methotrexate (HDMTX): A report from the Children’s Oncology
Group (COG). (Abstract 10002) N. J. Winick, L. M. Embry, K. K. Hardy, J. A.
Kairalla, M. Devidas, D. Armstrong, S. Hunger, W. L. Carroll, E. Larsen, E. A.
Raetz, M. L. Loh, R. Noll
3:36 PM
Sabine Mueller, MD, PhD (Discussion of Abstract(s) 10000 –10002)
Central Nervous System-Directed Therapies: Outcomes from a Pediatric
Neurologist’s Perspective
3:48 PM
4:00 PM
Langerhans cell histiocytosis in children: Correlation of BRAF status with
clinical characteristic. (Abstract 10003) S. Héritier, J. Emile, M. Barkaoui, A.
Moreau, V. Rigau, F. Dijoud, C. Chassagne, F. Charlotte, K. Mokhtari, S.
Boudjemaa, A. Coulomb, M. Peuchmaur, M. Copin, S. Fraitag, T. Molina, E.
Jeziorski, C. Thomas, M. de Menthon, J. Haroche, J. Donadieu
4:12 PM
Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or
refractory BRAF V600E high- and low-grade gliomas (HGG, LGG),
Langerhans cell histiocytosis (LCH), and other solid tumors (OST). (Abstract
10004) M. W. Kieran, D. R. Hargrave, K. J. Cohen, I. Aerts, I. J. Dunkel, T. R.
Hummel, I. Jimenez, A. D. Pearson, C. A. Pratilas, J. Whitlock, E. Bouffet, W. V.
Shen, A. Broniscer, A. Bertozzi, J. L. Sandberg, A. M. Florance, B. B. Suttle, P.
Haney, M. W. Russo, B. Geoerger
4:24 PM
Phase I study of ceritinib in pediatric patients (Pts) with malignancies
harboring a genetic alteration in ALK (ALKⴙ): Safety, pharmacokinetic (PK),
and efficacy results. (Abstract 10005) B. Geoerger, J. Schulte, C. M. Zwaan, M.
Casanova, M. Fischer, L. Moreno, T. Trahair, I. Jimenez, H. Kang, A. S. Pappo, E.
Schafer, B. D. Weiss, M. Healy, K. Li, T. Lin, A. Boral, A. D. Pearson
4:36 PM
Lia Gore, MD (Discussion of Abstract(s) 10003–10005)
BRAF and ALK: Emerging Targets in Pediatric Cancer Therapy Across Disease Silos
133
SATURDAY
Location: S504
SATURDAY
4:48 PM
5:00 PM
Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant
(SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia
(Phⴙ ALL) on Children’s Oncology Group AALL0622. (Abstract 10006) W. B.
Slayton, J. A. Kairalla, K. R. Schultz, M. Devidas, S. Helian, M. Pulsipher, B. H.
Chang, W. L. Carroll, M. J. Borowitz, V. I. Brown, N. J. Winick, A. J. Carroll, N. A.
Heerema, J. M. Gastier-Foster, B. L. Wood, S. L. Mizrahy, S. Hunger
5:12 PM
Feasibility of intensive post-Induction therapy incorporating clofarabine
(CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed
high risk B-lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group
AALL1131. (Abstract 10007) M. Burke, M. Devidas, S. Chen, L. Gore, E. Larsen,
J. M. Hilden, M. L. Loh, N. J. Winick, W. L. Carroll, E. A. Raetz, S. Hunger, W. L. Salzer
5:24 PM
Gemtuzumab ozogamycin (GO) and toxic mortality (TM) in children and
adolescents with acute myeloid leukemia (AML) enrolled on Children’s
Oncology Group (COG) trial AAML0531. (Abstract 10008) J. A. Tolbert, L.
Sung, R. Aplenc, T. A. Alonzo, Y. J. Wang, R. B. Gerbing, S. Meshinchi, A. S.
Gamis
5:36 PM
Lewis B. Silverman, MD (Discussion of Abstract(s) 10006 –10008)
New Developments in Pediatric Leukemia
5:48 PM
Jorge A. Garcia, MD—Co-Chair
Cleveland Clinic
Neha Vapiwala, MD—Co-Chair
University of Pennsylvania
4:45 PM
David M. Nanus (Discussion of Abstract(s) 5009 –5012)
Weill Medical College of Cornell University
Taxanes: Novel Combinations and Clinical States
4:57 PM
5:03 PM
Karen E. Knudsen, PhD (Discussion of Abstract(s) 5013–5015)
The Kimmel Cancer Center, Thomas Jefferson University
Molecular and Genomic Predictors of Response and Resistance to Androgen
Receptor-Directed Therapy
5:15 PM
5:21 PM
To Be Determined (Discussion of Abstract(s) 5016 –5017)
Prognostic Profiling in Prostate Cancer
5:33 PM
5:39 PM
Noel W. Clarke, MBBS, FRCS, ChM (Discussion of Abstract(s) 5018 –5020)
The Christie at Salford Royal Hospitals
Cholesterol and Testosterone in Prostate Cancer
5:51 PM
Posters discussed in this session are on display in the Genitourinary (Prostate) Cancer Poster
Session. See page 97 for poster information. Networking with presenters and discussants will
take place right outside of the session room after the discussion.
134
Gynecologic Cancer
Location: E354b
Linda R. Duska, MD—Co-Chair
University of Virginia Health System
4:45 PM
Jonathan A. Ledermann, MD, FRCP (Discussion of Abstract(s) 5513–5514)
University College London Cancer Institute
Embarassment of Riches: PARP Inhibitors versus Antiangiogenics
4:57 PM
5:03 PM
Alexandra Leary, MD (Discussion of Abstract(s) 5515–5519)
The Royal Marsden Hospital
New Agents in Ovarian Cancer for Platinum-Resistant and/or Platinum-Sensitive
Disease
5:15 PM
5:21 PM
Sang Young Ryu, MD, PhD (Discussion of Abstract(s) 5520 –5521)
Korea Cancer Center Hospital
Advancing Cervix Cancer Therapy
5:33 PM
5:39 PM
Lawrence H. Schwartz, MD (Discussion of Abstract(s) 5022–5024)
Columbia University Medical Center/New York Presbyterian Hospital
Through the Glass: PET and CT Imaging in Gynecologic Cancers
5:51 PM
Posters discussed in this session are on display in the Gynecologic Cancer Poster Session. See
page 103 for poster information. Networking with presenters and discussants will take place
right outside of the session room after the discussion.
Location: S406
Anthony Cmelak, MD—Chair
4:45 PM
Robert I. Haddad, MD (Discussion of Abstract(s) 6012– 6015)
The Changing Treatment Landscape for Advanced Thyroid Cancers
4:57 PM
5:03 PM
Peter S. Hammerman, MD, PhD (Discussion of Abstract(s) 6016 – 6018)
The Role of the Immune Microenvironment in Head and Neck Cancer
5:15 PM
5:21 PM
Kevin J. Cullen, MD (Discussion of Abstract(s) 6019 – 6021)
University of Maryland Greenebaum Cancer Center
Dose Intensity: New Answers to an Old Question
5:33 PM
135
SATURDAY
Paul Haluska, MD, PhD—Co-Chair
Mayo Clinic
5:39 PM
John F. Deeken, MD (Discussion of Abstract(s) 6022– 6023)
Inova Comprehensive Cancer and Research Institute
Progress in the Management of Recurrent and/or Metastatic Head and Neck Cancer
5:51 PM
Posters discussed in this session are on display in the Head and Neck Cancer Poster Session.
See page 112 for poster information. Networking with presenters and discussants will take place
SATURDAY
Location: S404
Tessa Cigler, MD, MPH—Co-Chair
Weill Cornell Breast Center
Katherine Van Loon, MD, MPH—Co-Chair
4:45 PM
Kavitha Ramchandran, MD (Discussion of Abstract(s) 9512–9514)
Stanford Cancer Institute/Stanford University School of Medicine
Caregivers: The Forgotten Patient
4:57 PM
5:03 PM
Arif Kamal, MD (Discussion of Abstract(s) 9515–9517)
Duke University Medical Center
Speak Now: Discussing Difficult Topics with Patients
5:15 PM
5:21 PM
Charles L. Shapiro, MD (Discussion of Abstract(s) 9518 –9520)
Reporting and Managing Toxicities: Putting Patients First
5:33 PM
5:39 PM
Karen L. Smith, MD (Discussion of Abstract(s) 9521–9523)
Washington Cancer Institute, MedStar Washington Hospital Center
Oh Baby! Fertility after Cancer
5:51 PM
Posters discussed in this session are on display in the Patient and Survivor Care Poster Session. See page 118 for poster information. Networking with presenters and discussants will take
place right outside of the session room after the discussion.
Payment Reform in Oncology: The Way Forward
Location: S100a
Jeffery C. Ward, MD—Chair
Swedish Cancer Institute Edmonds
Moderator
The Push for Value-Based Payment for Oncology: Understanding the Current Payer
Environment
136
Harold D. Miller
Center for Healthcare Quality and Payment Reform
Better Ways to Pay for Cancer Care: Creating Win-Win-Win Approaches for Oncologists,
Cancer Patients, and Payers
Fee-for-Service and Alternative Models: Perspective of AMA and Personal Experiences
SATURDAY
Evolution, Medicine, and Cancer
Location: S100bc
Athena Aktipis, PhD
Evolutionary Context of Cancer: Why Do People Get Cancer?
Carlo Maley, PhD—Chair
Clonal Evolution in Metastasis: How Can Darwin Improve Cancer Outcome?
Matthew Breen, PhD
North Carolina State University
Comparative Oncology: What Can Dogs and Sea Lions Teach Us about Cancer?
New Strategies to Understand and Target Initiation of Aggressive Cancers
Location: E450
Victoria Louise Seewaldt, MD—Chair
Lessons from Cancer Initiation Studies in Black Women
Virginia F. Borges, MD
Role of Collagen Cross-Linking in Breast Cancer Initiation
Deborah W. Knapp, DVM, DACVIM
Purdue University
Alternative Models of Gene-Environment Interaction during Cancer Initiation
Tackling Endocrine Resistance: Transforming Biology into Innovative Drugs
Location: N Hall B1
137
Mitchell Dowsett, PhD—Chair
Illuminating the Biology of Endocrine Resistance
Myles Brown, MD
Androgen Receptor-Positive Disease: Biology and Clinical Implications
Richard S. Finn, MD
University of California, Los Angeles Medical Center
New Drug Development for Endocrine-Resistant Breast Cancers
SATURDAY
The Learning Health Care System: Using Big Data to Inform Clinical Decision
Making
Location: S102
Lynne Penberthy, MD, MPH—Chair
Security and Privacy in the Era of Big Data: Overcoming Challenges
Richard L. Schilsky, MD, FASCO
CancerLinQ Nuts and Bolts of Computer Learning Systems
Anne-Marie Meyer, PhD
Big Data in Practice: Practical Tips for Using Big Data in Cancer Care
Ductal Carcinoma In Situ in 2015—Ticketed Session
Location: E451a
Eun-Sil Shelley Hwang, MD, MPH
Gary M. Freedman, MD
Perelman School of Medicine of the University of Pennsylvania
Immunotherapy for Melanoma: Sequencing, Combinations, and Side
Effects—Ticketed Session
Location: E451b
Frances A. Collichio, MD
Immune-Related Adverse Events Associated with CTLA4 and PD1/PDL1 Blockade
138
Antoni Ribas, MD, PhD
David Geffen School of Medicine at the University of California, Los Angeles
Immunotherapy-Based Combinations
SATURDAY
Michael B. Atkins, MD—Chair
Lombardi Comprehensive Cancer Center
Sequencing of Immunotherapy and Targeted Therapy
139
Sunday, May 31, 2015
7:30 AM - 9:15 AM Highlights of the Day Session
Highlights of the Day Session I Including Clinical Trial Participation Awards
Location: E Hall D1
Lynn Mara Schuchter, MD—Chair
7:30 AM
Clinical Trial Participation Awards
7:45 AM
8:00 AM
Steven J. Cohen, MD
Fox Chase Cancer Center
8:15 AM
Richard A. Larson, MD
8:30 AM
Natasha B. Leighl, MD, MMSc, FRCPC
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
8:45 AM
Svetomir Markovic, MD, PhD
Mayo Clinic
SUNDAY
Training Program Directors’ Breakfast (Training Program Directors and
Associate Training Program Directors Only)
Location: S404
Helen K. Chew, MD
UC Davis Medical Center
ASCO Updates
Catherine H. Van Poznak, MD
Quality Initiatives in Your Training Program
Jamie H. Von Roenn, MD
Palliative Care Grant Update
Jill Gilbert, MD—Chair
Opportunities for Faculty Development
Lisa Johnson, MHS, MT(ASCP)SC
ASCO University Updates
Improving Clinical Trial Efficiency: Thinking outside the Box
140
Richard Simon, DSc
National Institutes of Health
Enrichment Design Strategies: Excitement, Caution, and Usefulness
Sumithra J. Mandrekar, PhD—Chair
Mayo Clinic
The Rationale and Logistics of Umbrella Trial Designs
Suzanne Eleanor Dahlberg, PhD
Basket Trial Designs: Identifying the Exceptional Responders
Locoregional Therapies in the Setting of Systemic Treatment Advances:
What’s Next?
Location: S406
Sanjiv S. Agarwala, MD—Chair
St. Luke’s Medical Center
A Changing Topography: The Role of Intralesional Therapy in Melanoma
SUNDAY
Ahmad A. Tarhini, MD, PhD
Neoadjuvant Approaches to Melanoma: Alternatives to Immediate Resection
Cornelis Verhoef, MD, PhD
Erasmus MC Cancer Institute
Perfusion or Infusion in the Era of Effective Systemic Therapy
Managing Ovarian Cancer in the Older Woman: How to Best Select and
Sequence Surgery and Chemotherapy for Optimal Outcome
Location: E354b
Linda R. Duska, MD—Chair
University of Virginia Health System
Ovarian Cancer Surgery in the Elderly Patient: Keep It Short and Sweet
Kathleen N. Moore, MD
University of Oklahoma Health Sciences Center
Ovarian Cancer Chemotherapy in the Elderly Patient: Less Is More
William P. Tew, MD
Clinical Trials in the Older Patient: Who, When, and Why?
141
PI3-Kinase: Genomics to Clinical Practice
Location: S100bc
Christine H. Chung, MD—Chair
The Johns Hopkins University School of Medicine
PIK3CA: The Most Common “Targetable” Genetic Alteration in Head and Neck Cancer—Who
Might Benefit?
Matthew G. Fury, MD
Regeneron Pharmaceuticals
Optimal Integration of PI3K Targeting into Standard Clinical Regimens
J. Silvio Gutkind, PhD
National Institute of Dental and Craniofacial Research at the National Institutes of Health
Overcoming Resistance to Cetuximab with PIK3CA Mutations
SUNDAY
Managing the Toxicity of Androgen Deprivation Therapy in Prostate Cancer
and Anti-VEGF/mTOR Therapy in Renal Cell Carcinoma—Ticketed Session
Location: E451a
Thomas Hutson, DO, PharmD
Texas Oncology–Baylor Charles A. Sammons Cancer Center
Matthew Raymond Smith, MD, PhD
Using Molecular Profiling to Inform Decision Making in Non-GIST Sarcomas:
Case-Based Approaches—Ticketed Session
Location: E451b
William D. Tap, MD—Chair
FMS/Kit and Pigmented Villonodular Synovitis
Robin Lewis Jones, MD
The Royal Marsden Hospital
Targeting Platelet-Derived Growth Factor Receptors in Dermatofibrosarcoma
David Morgan Thomas, MBBS, PhD
Peter MacCallum Cancer Centre
Targeting Rank Ligand in Giant Cell Tumor of Bone
142
Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel
Data
Location: E450
Eric L. Chang, MD—Co-Chair
USC Norris Comprehensive Cancer Center and Keck School of Medicine
8:00 AM
ReACT: Overall survival from a randomized phase II study of rindopepimut
(CDX-110) plus bevacizumab in relapsed glioblastoma. (Abstract 2009) D. A.
Reardon, J. Schuster, D. D. Tran, K. L. Fink, L. B. Nabors, G. Li, D. A. Bota, R. V.
Lukas, A. Desjardins, L. S. Ashby, J. P. Duic, M. M. Mrugala, A. Werner, T.
Hawthorne, Y. He, J. A. Green, M. J. Yellin, C. D. Turner, T. A. Davis, J. H.
Sampson, The ReACT Study Group
8:12 AM
Fabio Massaiti Iwamoto, MD (Discussion of Abstract(s) 2009)
EGFRvIII Vaccines in Glioblastoma
8:24 AM
Phase II multicenter study of gene mediated cytotoxic immunotherapy as
adjuvant to surgical resection for newly diagnosed malignant glioma.
(Abstract 2010) L. K. Aguilar, L. A. Wheeler, A. G. Manzanera, S. D. Bell, R.
Cavaliere, J. M. McGregor, S. Lo, J. C. Grecula, H. B. Newton, B. Badie, T. W.
Trask, D. S. Baskin, J. Portnow, P. Z. New, E. Aguilar-Cordova, E. Chiocca
8:36 AM
John H. Sampson, MD, PhD (Discussion of Abstract(s) 2010)
Viral Therapies for Brain Tumors
8:48 AM
Newly diagnosed glioblastoma patients treated with an autologous heat
shock protein peptide vaccine: PD-L1 expression and response to therapy.
(Abstract 2011) O. Bloch, J. J. Raizer, M. Lim, M. Sughrue, R. Komotar, J.
Abrahams, D. O’Rourke, A. D’Ambrosio, J. N. Bruce, A. Parsa
9:00 AM
Amy B. Heimberger, MD (Discussion of Abstract(s) 2011)
Biomarkers for Immune-Based Therapies in Glioblastoma
9:12 AM
Navigating Racial and Economic Disparities in Cancer Care Delivery
Location: S504
Jennifer W. Mack, MD—Co-Chair
Dana-Farber/Boston Children’s Blood Disorders Center
Craig Evan Pollack, MD—Co-Chair
The Johns Hopkins University
8:00 AM
Financial insolvency as a risk factor for mortality among patients with
cancer. (Abstract 6509) A. Bansal, S. D. Ramsey, C. R. Fedorenko, D. K. Blough,
K. A. Overstreet, V. Shankaran, P. A. Newcomb
8:12 AM
Yousuf Zafar, MD, MHS (Discussion of Abstract(s) 6509)
Going for Broke: Cancer and Personal Finances
143
SUNDAY
Albert Lai, MD, PhD—Co-Chair
UCLA Neuro-Oncology Program
8:24 AM
The impact of patient navigation on racial and ethnic disparities: Results
from the patient navigation research program. (Abstract 6510) N. Ko, F.
Snyder, P. C. Raich, E. D. Paskett, D. Dudley, J. Lee, P. H. Levine, K. M. Freund
8:36 AM
Kim Felder Rhoads, MD, MS, MPH (Discussion of Abstract(s) 6510)
Stanford University
Navigating Toward Health
8:48 AM
Effect of organizational approaches on safety-net hospitals’ cancer care
quality. (Abstract 6511) N. A. Bickell, A. Moss, M. Castaldi, A. Shah, A. Sickles,
P. J. Pappas, T. Lewis, M. Kemeny, S. Arora, L. Schleicher, A. Srinivasan, L. L.
Montgomery, K. Fei, B. Bellacera, R. Franco, A. S. McAlearney
9:00 AM
Dawn L. Hershman, MD, MS (Discussion of Abstract(s) 6511)
Improving Quality through Patient-Centered Organizational Structures
9:12 AM
Predicting and Improving Adverse Outcomes in Older Patients with Cancer
Location: S102
Monica Alexandra Iriso, MD—Co-Chair
Hospital Español
SUNDAY
Arif Kamal, MD—Co-Chair
8:00 AM
Association between renal function and chemotherapy-related toxicity in
older adults with cancer. (Abstract 9509) L. L. Peterson, A. Hurria, T. Feng,
S. G. Mohile, C. Owusu, H. D. Klepin, C. P. Gross, S. M. Lichtman, A. Gajra, I. G.
Glezerman, V. Katheria, L. Zavala, D. D. Smith, W. P. Tew
8:12 AM
William W. Tse, MD (Discussion of Abstract(s) 9509)
West Virginia University
Clinical Trials in the Older Patient: Who, When, and Why?
8:24 AM
Evaluation of a web-based cognitive rehabilitation programme (CRP) in
cancer survivors reporting cognitive symptoms following chemotherapy.
(Abstract 9510) V. J. Bray, H. M. Dhillon, M. Bell, M. Kabourakis, H. Rice, D. Yip,
F. M. Boyle, M. Price, J. L. Vardy
8:36 AM
Rachel A. Freedman, MD, MPH (Discussion of Abstract(s) 9510)
Exercise for the Brain
8:48 AM
A clinical score to predict early death at 100 days after a comprehensive
geriatric assessment (CGA) in elderly cancer patients: A prospective study
with 815 patients. (Abstract 9511) R. Boulahssass, S. Gonfrier, J. Ferrero, F.
Auben, C. Rambaud, V. Mari, J. Turpin, T. Piche, B. Isabelle, J. Bereder, J.
Hannoun Levi, J. Delotte, R. Largillier, L. Evesque, P. Follana, D. Borchiellini, D.
Benchimol, J. Guigay, E. Francois, O. Guerin
9:00 AM
To Be Determined (Discussion of Abstract(s) 9511)
Prediction of Death in Older Patients: Close to the End?
9:12 AM
144
8:00 AM - 11:00 AM Oral Abstract Session
Gastrointestinal (Noncolorectal) Cancer
Location: E Hall D2
Emil Lou, MD—Co-Chair
University of Minnesota
8:00 AM
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial
of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as
first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or
gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. (Abstract
4000) D. Cunningham, N. C. Tebbutt, I. Davidenko, A. M. Murad, S. Al-Batran,
D. H. Ilson, S. Tjulandin, E. Gotovkin, B. Karaszewska, I. Bondarenko, M. A.
Tejani, A. A. Udrea, M. A. Tehfe, N. Baker, K. S. Oliner, Y. Zhang, T. Hoang, R.
Sidhu, D. V. Catenacci
8:12 AM
Relationship between PD-L1 expression and clinical outcomes in patients
with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody
pembrolizumab (MK-3475) in KEYNOTE-012. (Abstract 4001) Y. Bang, H.
Chung, V. Shankaran, R. Geva, D. V. Catenacci, S. Gupta, J. P. Eder, R. Berger,
E. J. Gonzalez, A. Ray, M. Dolled-Filhart, K. Emancipator, K. Pathiraja, J. K.
Lunceford, J. D. Cheng, M. Koshiji, K. Muro
8:24 AM
Neoadjuvant chemotherapy for resectable oesophageal and junctional
adenocarcinoma: Results from the UK Medical Research Council
randomised OEO5 trial (ISRCTN 01852072). (Abstract 4002) D. Alderson, R. E.
Langley, M. G. Nankivell, J. M. Blazeby, M. Griffin, A. Crellin, H. I. Grabsch, A. F.
Okines, C. Goldstein, S. Falk, J. Thompson, R. Krysztopik, F. Y. Coxon, S.
Pritchard, R. Langer, S. P. Stenning, D. Cunningham
8:36 AM
INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study
of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A
study by the Australasian Gastrointestinal Trials Group (AGITG)—Final
overall and subgroup results. (Abstract 4003) N. Pavlakis, K. M. Sjoquist, E.
Tsobanis, A. J. Martin, Y. Kang, Y. Bang, C. J. O’Callaghan, N. C. Tebbutt, S. Y.
Rha, J. Lee, J. Cho, L. R. Lipton, M. J. Burnell, T. Alcindor, A. Strickland, J. Kim, S.
Yip, J. Simes, J. R. Zalcberg, D. Goldstein
8:48 AM
Geoffrey Yuyat Ku, MD, MBA (Discussion of Abstract(s) 4000 – 4003)
Searching for Positive Signals in Gastroesophageal Cancer
9:00 AM
9:12 AM
SWOG S0518: Phase III prospective randomized comparison of depot
octreotide plus interferon alpha-2b versus depot octreotide plus
bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients
(NCT00569127). (Abstract 4004) J. C. Yao, K. Guthrie, C. Moran, J. R. Strosberg,
M. H. Kulke, J. A. Chan, N. K. LoConte, R. R. McWilliams, E. M. Wolin, B. I. Mattar,
S. McDonough, H. X. Chen, C. D. Blanke, H. S. Hochster
9:24 AM
Randomized phase II study of everolimus (E) versus everolimus plus
bevacizumab (EⴙB) in patients (Pts) with locally advanced or metastatic
pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
(Abstract 4005) M. H. Kulke, D. Niedzwiecki, N. R. Foster, B. Fruth, P. L. Kunz,
H. F. Kennecke, E. M. Wolin, A. P. Venook
9:36 AM
Diane Lauren Reidy, MD (Discussion of Abstract(s) 4004 – 4005)
Targeting Angiogenic and Other Molecular Pathways in Neuroendocrine Tumors
9:48 AM
145
SUNDAY
James Posey, MD—Co-Chair
10:00 AM
High response rate and PFS with PEGPH20 added to
nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic
cancer patients with high-HA tumors: Interim results of a randomized phase
II study. (Abstract 4006) S. R. Hingorani, W. P. Harris, A. E. Hendifar, A. J.
Bullock, X. W. Wu, Y. Huang, P. Jiang
10:12 AM
CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients
with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A
prospective randomized phase III study. (Abstract 4007) M. Sinn, T. Liersch, K.
Gellert, H. Messmann, W. O. Bechstein, D. Waldschmidt, L. Jacobasch, M.
Wilhelm, B. M. Rau, R. Grützmann, A. Weinmann, G. Maschmeyer, U. Pelzer, J.
Stieler, J. K. Striefler, B. M. Ghadimi, M. Bahra, H. Oettle, B. Dörken, H. Riess
10:24 AM
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by
chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer
(PDAC): Initial results from Alliance Trial A021101. (Abstract 4008) M. H. Katz,
Q. Shi, S. A. Ahmad, J. M. Herman, R. d. Marsh, E. A. Collisson, L. H. Schwartz,
R. C. Martin II, W. C. Conway, M. Truty, H. L. Kindler, A. M. Lowy, P. A. Philip, T. S.
Bekaii-Saab, D. B. Cardin, N. K. LoConte, A. P. Venook
10:36 AM
Kenneth H. Yu, MD (Discussion of Abstract(s) 4006 – 4008)
Pancreatic Cancer: The Current State and Future of Research
10:48 AM
SUNDAY
Lung Cancer—Non-Small Cell Metastatic
Location: N Hall B1
Luis Paz-Ares, MD, PhD—Co-Chair
Hospital Universitario Doce de Octubre
Nithya Ramnath, MD—Co-Chair
8:00 AM
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR
mutation-positive advanced non-small cell lung cancer (NSCLC): Results
from a phase 1 expansion cohort. (Abstract 8000) S. S. Ramalingam, J. C.
Yang, C. K. Lee, T. Kurata, D. Kim, T. John, N. Nogami, Y. Ohe, Y. Rukazenkov, P.
Frewer, M. Cantarini, S. Ghiorghiu, P. A. Janne
8:12 AM
Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive
non-small cell lung cancer (NSCLC) patients (pts). (Abstract 8001) L. V.
Sequist, J. W. Goldman, H. A. Wakelee, D. R. Camidge, H. A. Yu, A. Varga, B.
Solomon, G. R. Oxnard, S. I. Ou, V. Papadimitrakopoulou, B. H. Chao, S. V. Liu,
K. L. Reckamp, A. I. Spira, Z. Piotrowska, D. Despain, C. A. Karlovich, S. Yurasov,
J. Soria
8:24 AM
Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with
advanced squamous cell carcinoma (SCC) of the lung following platinumbased chemotherapy: Overall survival (OS) analysis from the global phase III
trial LUX-Lung 8 (LL8). (Abstract 8002) J. Soria, E. Felip, M. Cobo, S. Lu, K. N.
Syrigos, K. Lee, E. Goker, V. Georgoulias, W. Li, D. Isla, S. Z. Guclu, A. Morabito,
Y. Min, A. Ardizzoni, S. M. Gadgeel, B. Wang, V. K. Chand, G. D. Goss, LUX-Lung
8 Investigators
8:36 AM
Cabozantinib (C), erlotinib (E) or the combination (EⴙC) as second- or
third-line therapy in patients with EGFR wild-type (wt) non-small cell lung
cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer
Research Group (E1512). (Abstract 8003) J. W. Neal, S. E. Dahlberg, H. A.
Wakelee, S. C. Aisner, M. Bowden, D. P. Carbone, S. S. Ramalingam
146
8:48 AM
Gregory J. Riely, MD, PhD (Discussion of Abstract(s) 8000 – 8003)
Targeting the Target in Non–Small Cell Lung Cancer and Squamous Cell
Carcinoma
9:00 AM
9:12 AM
Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus
cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the
lung (SqLC): WJOG5208L. (Abstract 8004) T. Shukuya, T. Yamanaka, T. Seto,
H. Daga, K. Goto, H. Saka, S. Sugawara, T. Takahashi, S. Yokota, H. Kaneda, T.
Kawaguchi, S. Nagase, T. Oguri, Y. Iwamoto, T. Nishimura, Y. Hattori, K.
Nakagawa, Y. Nakanishi, N. Yamamoto
9:24 AM
Whole brain radiotherapy for brain metastases from non-small lung cancer:
Quality of life (QoL) and overall survival (OS) results from the UK Medical
Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).
(Abstract 8005) P. M. Mulvenna, M. G. Nankivell, R. Barton, C. Faivre-Finn, P.
Wilson, B. Moore, E. McColl, I. Brisbane, D. Ardron, B. Sydes, C. Pugh, T. Holt, N.
Bayman, S. Morgan, C. Lee, K. Waite, R. Stephens, M. M. Parmar, R. E. Langley
9:36 AM
David R. Gandara, MD (Discussion of Abstract(s) 8004 – 8005)
UC Davis Comprehensive Cancer Center
Managing Advanced or Relapsed Disease: Challenging the Convention
9:48 AM
10:00 AM
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib
(D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with
BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
(Abstract 8006) D. Planchard, H. J. Groen, T. Kim, J. R. Rigas, P. J. Souquet,
C. S. Baik, F. Barlesi, J. Mazières, E. A. Quoix, C. M. Curtis Jr., B. Mookerjee, A. N.
Bartlett-Pandite, C. Tucker, A. D’Amelio Jr., B. E. Johnson
10:12 AM
Phase II study of cabozantinib for patients with advanced RET-rearranged
lung cancers. (Abstract 8007) A. E. Drilon, C. S. Sima, R. Somwar, R. Smith,
M. S. Ginsberg, G. J. Riely, C. M. Rudin, M. Ladanyi, M. G. Kris, N. A. Rizvi
10:24 AM
Efficacy and safety of the ALK inhibitor alectinib in ALKⴙ non-small-cell lung
cancer (NSCLC) patients who have failed prior crizotinib: An open-label,
single-arm, global phase 2 study (NP28673). (Abstract 8008) S. I. Ou, J. Ahn, L.
De Petris, R. Govindan, J. Yang, B. G. Hughes, H. Lena, D. Moro-Sibilot, A. Bearz,
S. V. Ramirez, T. Mekhail, A. I. Spira, A. H. Zeaiter, W. Bordogna, B. Balas, S.
Golding, P. N. Morcos, D. Kim
10:36 AM
Alex A. Adjei, MD, PhD (Discussion of Abstracts(s) 8006-8008)
Prognostic Profiling in Lung Cancer
10:48 AM
Location: S Hall A
Abstracts 7011–7022 will be discussed during the Leukemia, Myelodysplasia, and Transplantation Poster Discussion Session. See page 186 for session information.
Board 1
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination
with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory
(R/R) CLL including pts with del17p/TP53 mutation. (Abstract 7011) J. C.
Barrientos, S. Coutre, S. De Vos, I. Flinn, N. D. Wagner-Johnston, M. T.
Schreeder, J. P. Sharman, T. E. Boyd, K. R. Rai, J. Leonard, B. Sorensen, A.
Viggiano, T. M. Jahn, R. R. Furman
147
SUNDAY
SUNDAY
Board 2
Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose
administered to patients with previously treated chronic lymphocytic
leukemia (CLL). (Abstract 7012) P. M. Barr, J. R. Brown, P. Hillmen, S. O’Brien,
J. C. Barrientos, N. M. Reddy, S. Coutre, S. P. Mulligan, U. Jäger, R. R. Furman, F.
Cymbalista, M. Montillo, C. Dearden, T. Robak, C. Moreno, J. Pagel, J. A. Burger,
S. Suzuki, D. F. James, J. C. Byrd
Board 3
Prognostic testing patterns in CLL pts treated in U.S. practices from the
Connect CLL registry. (Abstract 7013) A. Mato, C. Flowers, C. M. Farber, M. A.
Weiss, T. J. Kipps, M. Kozloff, C. Nabhan, I. Flinn, D. L. Grinblatt, N. Lamanna,
K. A. Sullivan, P. Kiselev, E. Flick, K. A. Foon, A. S. Swern, J. P. Sharman
Board 4
Association of relapse of FLT3-ITD AML with normal karyotype with internal
tandem duplication allelic burden, base-pair insertion length, and NPM1
status. (Abstract 7014) S. L. Sammons, S. Bentzen, R. Faramand, V. Duong, M.
Tidwell, E. A. Sausville, M. R. Baer, A. Emadi
Board 5
Activity of the mitochondrial metabolism inhibitor cpi-613 in combination
with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or
refractory acute myeloid leukemia (AML). (Abstract 7015) T. S. Pardee, K.
Stadelman, S. Isom, L. R. Ellis, D. Berenzon, D. D. Hurd, D. S. Howard, R.
Harrelson, M. Manuel, S. Dralle, S. Lyerly, B. L. Powell
Board 6
Safety and tolerability of the combination of ATRA ⴙ arsenic trioxide (ATO) ⴙ
gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia
(APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. (Abstract 7016)
J. E. Lancet, M. Othus, D. J. DeAngelo, S. Coutre, R. S. Komrokji, M. S. Tallman,
M. R. Litzow, F. R. Appelbaum
Board 7
Correlation of overall survival (OS) with bone marrow blast (BMBL) response
in patients (pts) with myelodysplastic syndrome. (Abstract 7017) L. R.
Silverman, P. Fenaux, P. Greenberg, E. P. Demakos, V. Santini, J. F. Seymour,
S. C. Navada, M. E. Petrone, B. R. Snyder, N. Azarnia, G. Garcia-Manero
Board 8
Effect of long noncoding RNA RUNXOR on the epigenetic regulation of
RUNX1 in acute myelocytic leukemia. (Abstract 7018) H. Wang, R. Guo, A. R.
Hoffman, J. Hu, W. Li
Board 9
NFAT2 to regulate anergy induction in CLL through Lck. (Abstract 7019) M.
Maerklin, J. S. Heitmann, F. Truckenmueller, M. Ganser, H. Kopp, S. Wirths, L.
Kanz, A. Rao, M. R. Mueller
Board 10
GATA-1, FOG-1, and FLI-1 regulation in essential thrombocythemia
independently from JAK2 and CALR mutations. (Abstract 7020) C. R. Rinaldi,
J. Lally, L. BROWN, C. Graham
Board 11
A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic
leukemia (CMML). (Abstract 7021) E. Padron, A. E. Dezern, K. Vaddi, P. A.
Scherle, Q. Zhang, Y. Ma, M. Balasis, S. Tinsley, H. Ramadan, C. Zimmerman,
D. P. Steensma, G. J. Roboz, J. E. Lancet, A. F. List, M. A. Sekeres, R. S. Komrokji
Board 12
Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs.
2nd generation tyrosine kinase inhibitors in patients with chronic myeloid
leukemia in chronic phase. (Abstract 7022) K. Sasaki, H. M. Kantarjian, E.
Jabbour, F. Ravandi, K. Takahashi, M. Konopleva, G. Borthakur, G. GarciaManero, W. G. Wierda, N. G. Daver, P. Jain, S. Pierce, M. B. Rios, J. E. Cortes
Board 13
A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent
or refractory chronic graft versus host disease (cGVHD). (Abstract 7024)
D. B. Miklos, M. Arora, C. S. Cutler, R. Nakamura, M. Juretic, Y. Li, L. A. Styles,
D. F. James, S. M. Jaglowski
Board 14
Symptomatic BK virus as a significant independent predictor of immune
suppression and poor overall survival in allogeneic hematopoietic stem cell
recipients. (Abstract 7025) A. Abudayyeh, A. Hamdi, H. Y. Lin, M. Abdelrahim, G.
Rondon, D. P. Kontoyiannis, A. L. Olson, B. Andersson, R. E. Champlin, E. J.
Shpall, K. Rezvani
148
Board 15
The relationship between HIF family gene expression in allogeneic T-cell
products and acute graft-versus-host disease. (Abstract 7026) J. Rimando, S.
Larrick, N. Fowler, L. Castiello, S. A. Ali, M. Sabatino, D. Stroncek, T. Felizardo,
D. H. Fowler
Board 16
Physical activity as a predictor of outcomes in hematopoietic stem cell
transplantation (HSCT) recipients. (Abstract 7027) A. Mishra, B. Yue, J. Kim, C.
Anasetti, J. A. Pidala, M. L. Riches, H. S. Jim
Board 17
Association of higher total nucleated cell dose with improved survival in
patients receiving donor lymphocyte infusion after allogeneic stem cell
transplantation. (Abstract 7028) N. Singh, A. J. Kumar, A. Gao, M. R. Luskin,
N. V. Frey, E. O. Hexner, A. W. Loren, S. M. Luger, E. A. Stadtmauer, D. L. Porter,
R. Reshef
Board 18
A randomized controlled trial of ibandronate for the prevention of bone loss
following allogeneic stem cell transplantation. (Abstract 7029) X. Pundole,
R. E. Champlin, U. R. Popat, C. P. Escalante, W. A. Murphy Jr., R. F. Gagel, H. Lu
Board 19
Outcomes of hematopoietic stem cell transplant (HSCT) in HIV patients in
HAART era. (Abstract 7030) K. Mehta, A. P. Im, H. Wang, P. Veldkamp
Board 20
Post-transplantation long-term events in a cohort of HIV-positive patients
affected by relapsed/refractory lymphoma. (Abstract 7031) E. Zanet, C.
Durante, M. Rupolo, M. Mazzucato, S. Zanussi, P. De Paoli, A. Lleshi, M. Taborelli,
D. Serraino, U. Tirelli, M. Spina, M. Michieli
Board 21
Ratio of total leucocyte count to C-reactive protein: Does it help differentiate
engraftment fever from infective fever in patients undergoing autologous
stem cell transplant? (Abstract 7032) S. Punatar, A. Gokarn, D. Rajamanickam
K., A. Gupta, L. Mathew, S. Kannan, N. Khattry
Board 21B
Results of a phase III randomized, controlled study evaluating the efficacy
and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for
previously treated chronic lymphocytic leukemia (CLL). (Abstract 7023) J. A.
Jones, M. Wach, T. Robak, J. R. Brown, A. R. Menter, E. Vandenberghe, L.
Ysebaert, N. D. Wagner-Johnston, J. Polikoff, H. S. Salman, K. M. Taylor, S.
Coutre, S. E. Spurgeon, S. D. Kendall, I. Flinn, L. Dreiling, R. Dubowy, Y. Cho, S.
Peterman, C. Owen
Board 22
Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin,
etoposide) compared to G-CSF and plerixafor (GⴙP) mobilization in
lymphoid malignancies. (Abstract 7033) L. W. Veltri, B. Dhakal, A. K. Singavi, S.
Wen, J. Luo, M. D. Craig, A. Cumpston, A. Shillingburg, K. Watkins, J. Esselman,
M. C. Pasquini, T. S. Fenske, P. Hari, M. Hamadani, A. S. Kanate
Board 23
The impact of HBO on early ALC recovery following high-dose therapy and
autologous transplantation. (Abstract 7034) O. S. Aljitawi, M. Markiewicz, A.
Seng, T. L. Lin, S. Ganguly, J. Mahnken, A. Singh, L. Shune, S. H. Abhyankar, B.
Lipe, D. Allin, J. McGuirk, T. Yankee
Board 24
Outcomes of ASCT for cardiac AL-amyloidosis and cardiac light chain
deposition disease. (Abstract 7035) A. A. Abdallah, S. Atrash, A. Bakhous, D.
Alapat, M. Zangari
Board 25
Long-term outcomes of rituximab use prior to autologous stem cell
transplant (ASCT) in low-grade follicular lymphoma (FL) at the time of first
progression. (Abstract 7036) R. A. Ferro, V. R. Bhatt, L. Smith, M. A. Lunning,
P. J. Bierman, J. O. Armitage, G. Bociek, J. Vose
Board 26
Overall survival and treatment response in patients with myelodysplastic
syndrome and acute myeloid leukemia treated with DNA methyl-transferase
inhibitors vs. conventional care regimens: A meta-analysis of 5 randomized
trials. (Abstract 7037) S. Yun, N. Vincelette, J. Segar
Board 27
Exosome transcriptome analysis provides novel tools for CLL patient
stratification. (Abstract 7038) R. Calogero, M. Arigoni, F. Riccardo, A. RodriguezVicente, J. M. Hernandez, F. Zolezzi
149
SUNDAY
SUNDAY
Board 28
Cellular immunotherapy for refractory hematological malignancies. (Abstract
7039) J. L. Reagan, L. D. Fast, K. Mantripragada, M. Nevola, K. Rosati, A.
Schumacher, H. Safran, M. I. Quesenberry, E. S. Winer, J. N. Butera, P. J.
Quesenberry
Board 29
A meta-analysis of randomized clinical trials in acute promyelocytic leukemia
(APL). (Abstract 7040) F. Lo-Coco, M. S. Tallman, G. Barnes, I. Guerra, V.
Damera, M. Martin, U. W. Mueller
Board 30
Impact of unbalanced karyotypes at diagnosis on prognosis of CML.
(Abstract 7041) R. Hehlmann, L. Kalmanti, C. Dietz, M. Lauseker, C. Haferlach, B.
Schlegelberger, M. Jotterand, M. C. Müller, M. Haenel, C. Köhne, M. Goebeler, M.
Pfreundschuh, L. Balleisen, A. Burchert, S. W. Krause, M. Pfirrmann, J. Hasford, A.
Hochhaus, S. Saussele, A. Fabarius
Board 31
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline
therapy for chronic lymphocytic leukemia. (Abstract 7042) N. J. Short, M. J.
Keating, W. G. Wierda, S. Faderl, A. Ferrajoli, Z. Estrov, S. C. Smith, S. M. O’Brien
Board 32
Safety and activity of blinatumomab for older patients (pts) with
relapsed/refractory (R/R) B–precursor acute lymphoblastic leukemia (ALL) in
two phase 2 studies. (Abstract 7043) H. M. Kantarjian, A. S. Stein, R. C. Bargou,
C. Grande, R. A. Larson, M. Stelljes, J. E. Benjamin, C. Jia, M. S. Topp
Board 33
Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia
(AML) and myelodysplastic syndrome (MDS). (Abstract 7044) J. E. Cortes, S.
Faderl, J. Pagel, C. Jung, S. Yoon, Y. Koh, A. D. Pardanani, R. S. Hauptschein, K.
Lee, J. Lee
Board 34
Impact of nilotinib treatment on subclinical cardiovascular biomakers.
(Abstract 7045) M. Gardembas, S. Henni, A. Corby, L. Omarjee, N. Ifrah, G.
Leftheriotis
Board 35
Survival of de novo and secondary acute promyelocytic leukemia: A
propensity matched analysis of the Surveillance, Epidemiology and End
Results database. (Abstract 7046) R. Pathak, S. Giri, M. G. Martin, V. R. Bhatt
Board 36
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase
chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
(Abstract 7047) M. Talpaz, J. E. Cortes, H. M. Kantarjian, N. P. Shah, D. L. Bixby,
I. Flinn, T. J. O’Hare, S. Hu, V. M. Rivera, T. P. Clackson, M. G. Conlan, F. G.
Haluska, B. J. Druker, M. W. Deininger, M. J. Mauro
Board 37
Safety and feasibility of anticoagulation prophylaxis with enoxaparin in acute
lymphoblastic leukemia during asparaginase-based intensification therapy.
(Abstract 7048) H. A. Sibai, J. T. Seki, N. Sakurai, A. C. Schuh, K. W. Yee, M. D.
Minden, A. D. Schimmer, V. Gupta, J. M. Brandwein
Board 38
Elevated blood pressure (BP) and adverse events (AEs) of hypertension
(HTN) in ponatinib (PON) leukemia trials. (Abstract 7049) H. J. Khoury, M.
Baccarani, F. Guilhot, A. Hochhaus, T. P. Hughes, J. H. Lipton, S. Lustgarten, K.
Yanase, M. G. Conlan, J. E. Cortes, M. W. Deininger, H. M. Kantarjian, N. P. Shah,
M. Talpaz, M. J. Mauro
Board 39
Phase I trial of ␣-particle therapy with actinium-225 (225Ac)-lintuzumab
(anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated
acute myeloid leukemia (AML). (Abstract 7050) J. G. Jurcic, F. Ravandi, J. M.
Pagel, J. H. Park, B. Smith, D. Douer, M. Y. Levy, E. Estey, H. M. Kantarjian, D.
Earle, D. Cicic, D. A. Scheinberg
Board 40
Re-exposure to blinatumomab after CD19-positive relapse: Experience from
three trials in patients (pts) with relapsed/refractory B-precursor acute
lymphoblastic leukemia (R/R ALL). (Abstract 7051) M. S. Topp, M. Stelljes, G.
Zugmaier, P. Barnette, L. T. Heffner, T. M. Trippett, R. C. Bargou, C. Holland, J.
Benjamin, M. R. Litzow
Board 41
RAS mutation acquisition at transformation from myelodysplastic syndrome
to acute myeloid leukemia to predict outcome. (Abstract 7052) T. Badar, J. E.
150
Board 42
O-desulfated heparin and chemotherapy for the treatment of AML. (Abstract
7053) T. Kovacsovics, A. S. Mims, M. E. Salama, N. Rao, J. Pantin, M. W. Deininger,
T. P. Kennedy, L. M. Bavisotto, K. M. Boucher, S. G. Marcus, P. J. Shami
Board 43
A multidrug resistant engineered CAR T cell for allogeneic combination
immunotherapy. (Abstract 7054) J. Valton
Board 44
Allogeneic hematopoietic cell transplant (HCT) in patients (pts) > 60 years of
age with first relapsed or refractory acute myeloid leukemia (R/R AML) after
treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus
cytarabine (pla/cyt): Results from VALOR. (Abstract 7055)
G. J. Schiller, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, S. A.
Strickland, H. P. Erba, A. Pigneux, H. Horst, C. Recher, V. M. Klimek, O. Odenike,
A. R. Craig, R. Ward, J. Smith, H. M. Kantarjian, R. K. Stuart, F. Ravandi, VALOR
Investigators Group
Board 45
Cardiovascular events in patients with chronic myelogenous leukemia
treated with tyrosine kinase inhibitors: A systematic review and metaanalysis. (Abstract 7056) C. Chai-Adisaksopha, C. M. Hillis, W. Lam
Board 46
Factors influencing outcomes in patients (Pts) with relapsed/refractory
b-precursor acute lymphoblastic leukemia (r/r ALL) treated with
blinatumomab in a phase 2 study. (Abstract 7057) H. Kantarjian, N. Gökbuget,
S. M. O’Brien, A. S. Stein, C. Jia, S. J. Forman, R. C. Bargou, A. K. Fielding, L. T.
Heffner, R. A. Larson, S. Neumann, T. Maniar, D. Nagorsen, M. S. Topp
Board 47
Performance status and comorbidities on outcome of hypomethylating
therapy in older adults (>60 years old) with acute myeloid leukemia.
(Abstract 7058) A. Chana, L. A. Ford, E. A. Griffiths, J. E. Thompson, M. Wetzler,
E. S. Wang
Board 48
Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with
relapsed acute myeloid leukemia. (Abstract 7059) D. Sanford, W. G. Blum, F.
Ravandi, R. B. Klisovic, G. Borthakur, A. R. Walker, G. Garcia-Manero, G.
Marcucci, W. G. Wierda, S. P. Whitman, H. M. Kantarjian, J. E. Cortes
Board 49
Association between early promoter methylation changes and outcome in
older acute myeloid leukemia patients treated on SWOG S0703
(NCT0065884). (Abstract 7060) S. Nand, N. Achille, M. Othus, K. W. Phelan, S.
Zhang, K. A. Cooper, J. E. Godwin, F. R. Appelbaum, J. P. Radich, H. P. Erba, N.
Zeleznik-Le
Board 50
Azacitidine in older patients with acute myeloid leukemia (AML): Results
from the ALMA study according to the MRC risk index score. (Abstract 7061)
J. F. Falantes, V. Martinez Robles, J. Bargay, G. Deben, A. Garrido, J. Casano, O.
Salamero, J. M. Bergua, E. Colado, R. Garcia, C. Pedro, S. Redondo, M. Tormo, S.
Bonanad, M. Diez-Campelo, M. Perez-Encinas, A. de la Fuente, B. Xicoy, P.
Montesinos, F. Ramos
Board 51
An alvocidib-containing regimen is highly effective in AML patients through a
mechanism dependent on MCL1 expression and function. (Abstract 7062)
B. D. Smith, S. L. Warner, C. Whatcott, A. Siddiqui-Jain, B. Bahr, E. Dettman, C.
Doykan, M. H. Cardone, S. D. Weitman, D. Bearss
Board 52
Ethnic differences in survival of elderly chronic myeloid leukemia patients in
pre- and post-imatinib era in the United States. (Abstract 7063) D. Uprety,
B. K. Shah
Board 53
The prognostic impact of combined NPM1ⴙ/FLT3- mutational status in newly
diagnosed acute myeloid leukemia (AML) patients with intermediate risk
cytogenetics according to age and treatment modality. (Abstract 7064) M.
Hefazi, M. A. Siddiqui, M. M. Patnaik, A. P. Wolanskyj, H. Alkhateeb, D. Zblewski,
M. A. Elliott, W. J. Hogan, M. R. Litzow, A. Al-Kali
Board 54
Infectious complications in AML patients treated with induction vs.
hypomethylating therapy. (Abstract 7065) M. M. Jalbut, A. M. Brunner, P. C.
151
SUNDAY
Cortes, E. Jabbour, G. Borthakur, M. Konopleva, T. M. Kadia, Z. Bohannan, S.
Pierce, F. Ravandi, K. Patel, R. Luthra, H. M. Kantarjian, G. Garcia-Manero
Amrein, E. C. Attar, K. K. Ballen, G. Hobbs, A. M. Perry, C. P. Joseph, D. S.
Neuberg, A. T. Fathi
SUNDAY
Board 55
Digital Fusion-Gene expression profiling in acute leukemia (AL): Clinical
validation of throughput molecular technology in laboratory medicine.
(Abstract 7066) A. Akhter, F. Rashid-Kolvear, F. Farooq, A. Qureshi, M. ShabaniRad, G. Sinclair, D. A. Stewart, A. Mansoor
Board 56
Construction and characterization of novel CD33/CD3 tandem diabodies
(TandAbs) for the treatment of acute myeloid leukemia (AML). (Abstract 7067)
U. Reusch, K. H. Harrington, C. J. Gudgeon, I. Fucek, K. Ellwanger, M. Weichel, S.
Knackmuss, E. Zhukovsky, J. A. Fox, J. Guenot, R. B. Walter
Board 57
Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Phⴙ)
advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase
inhibitor (TKI) failure. (Abstract 7068) C. Gambacorti-Passerini, H. M.
Kantarjian, D. Kim, H. J. Khoury, J. H. Lipton, T. H. Brümmendorf, K. Noonan, E.
Matczak, E. Leip, J. E. Cortes
Board 58
Clinical activity, safety profile, and hepatotoxicity of TGR-1202, a novel once
daily PI3K␦ inhibitor, in patients with CLL and B-cell lymphoma. (Abstract
7069) H. A. Burris, M. R. Patel, T. S. Fenske, O. A. O’Connor, C. Deng, D. M.
Brander, M. Gutierrez, S. F. Jones, J. G. Kuhn, H. P. Miskin, P. Sportelli, S. V.
Vakkalanka, I. Flinn
Board 59
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients
with refractory/recurrent acute myelogenous leukemia (AML). (Abstract 7070)
F. Ravandi, I. Gojo, M. M. Patnaik, M. D. Minden, H. M. Kantarjian, A. Levonas, C.
Fancourt, R. Lam, A. Meister, M. Jones, R. K. Kemp, C. Knox, S. Rose, P. Shah
Patel, R. Tibes
Board 60
Development of a bispecific tetravalent CD33/CD3 TandAb for the treatment
of AML. (Abstract 7071) U. Reusch, K. Ellwanger, M. Weichel, V. Molkenthin,
J. A. Fox, S. Knackmuss, I. Fucek, E. Rajkovic, E. Zhukovsky, J. Guenot, M. Treder
Board 61
Serum chemokines and cytokines in CLL patients treated with duvelisib, a
PI3K-␦,␥ inhibitor. (Abstract 7072) M. Douglas, K. Allen, J. Sweeney, S. M.
O’Brien, I. Flinn, S. M. Horwitz, J. C. Byrd, M. R. Patel, B. S. Kahl, F. M. Foss, P.
Porcu, V. Kelly, H. Stern
Board 62
The dual SRC-ABL inhibitors in Phⴙ acute lymphoblastic leukemia to
enhance synergy between targeted BCR-ABL and BCL-2 inhibitors. (Abstract
7073) J. T. Leonard, S. E. Spurgeon, E. A. Traer, B. M. Hayes-Lattin, M. Loriaux, J.
Tyner, B. J. Druker, B. H. Chang
Board 63
Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-␦,␥
inhibitor, in patients with treatment-naïve CLL. (Abstract 7074) M. R. Patel,
S. M. O’Brien, K. Faia, K. White, M. Douglas, K. Allen, J. L. Kutok, J. Sweeney, V.
Kelly, I. Flinn, J. C. Byrd, H. Stern
Board 64
CDA status as predictive marker of aplasia duration and clinical outcome in
AML patients receiving cytarabine based chemotherapy. (Abstract 7075) C.
Mercier, R. Fanciullino, J. Colle, G. Venton, V. Ivanov, G. Sebahoun, J. Ciccolini,
R. Costello
Board 65
Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic
myeloid leukemia (CML) after prior imatinib (IM) failure. (Abstract 7076) J. H.
Lipton, J. E. Cortes, H. J. Khoury, H. M. Kantarjian, D. Kim, P. Schafhausen, M.
Zeremski, N. Bardy-Bouxin, M. Shapiro, E. Leip, C. Gambacorti-Passerini, T. H.
Brümmendorf
Board 66
First report of a phase I/II study of DFP-10917, a nucleoside analog, given by
continuous infusion (CI) in patients (pts) with relapsed or refractory acute
leukemia. (Abstract 7077) H. M. Kantarjian, E. Jabbour, G. Garcia-Manero, T. M.
Kadia, C. D. Dinardo, N. G. Daver, G. Borthakur, N. Jain, J. Waukau, M. Kwari,
B. D. Anderson, K. Iizuka, C. Jin, W. Plunkett
Board 67
A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab
(AL) in the early treatment of patients (Pts) with high risk chronic
152
Board 68
Moxetumomab pasudotox and minimal residual disease in hairy cell
leukemia. (Abstract 7079) R. J. Kreitman, E. Arons, K. Still, M. S. Tallman, M.
Stetler-Stevenson, C. Yuan, D. J. FitzGerald, I. Pastan
Board 69
Correlation of genomic analysis by MyAML with chemotherapy drug
sensitivity. (Abstract 7080) P. S. Becker, M. W. Schmitt, L. A. Loeb, W. Gu, Q.
Wei, Z. Xie, A. R. Carson, T. Martins, C. A. Blau, V. Oehler, K. Y. Yeung
Board 70
Phase II trial of the combination of subcutaneous bortezomib (Bortez) and
pegylated liposomal doxorubicin (PLD) for the treatment of patients with
acute myelogenous leukemia (AML). (Abstract 7081) B. K. Tomlinson, J. M.
Tuscano, M. Abedi, J. Welborn, R. O’Donnell, M. Arora, R. Verman, K. Jones, B. A.
Jonas
Board 71
Lenalidomide added to bendamustine-rituximab for untreated chronic
lymphocytic leukemia (CLL): A phase 1 study. (Abstract 7082) J. S. Abramson,
M. S. Davids, L. Werner, D. C. Fisher, P. Armand, P. C. Amrein, D. S. Neuberg,
E. P. Hochberg, J. R. Brown
Board 72
Clinical outcome of adult acute lymphoblastic leukemia based on
Philadelphia chromosome status and socioeconomic status. (Abstract 7083)
B. D. Dao, J. Y. Law, P. Le, A. Gao, C. Ahn, K. Kumar, L. D. Anderson, R. Collins,
H. C. Li, P. A. Patel, N. Sadeghi, M. Vusirikala, H. V. Naina, P. P. Scaglioni
Board 73
Prognostic impact of renal insufficiency (RI) at diagnosis in patients with
chronic lymphocytic leukemia (CLL). (Abstract 7084) P. Strati, K. G. Chaffee,
S. J. Achenbach, S. L. Slager, S. M. Schwager, T. Call, N. Leung, T. D. Shanafelt
Board 74
Effect of grade (G) 3 fibrosis on clinical outcome of patients (Pts) with
myelodysplastic syndromes (MDS): Mayo Clinic Experience. (Abstract 7085)
N. Cheema, F. Baidoun, D. Zblewski, S. Hashmi, N. Gangat, A. P. Wolanskyj, W. J.
Hogan, M. R. Litzow, D. Chen, A. Al-Kali
Board 75
Up-regulation of CALR in patients with essential thrombocythemia
independent from CALR mutations. (Abstract 7086) C. R. Rinaldi, L. Brown, C.
Graham, R. Simpson, J. Lally
Board 76
Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial.
(Abstract 7087) S. Verstovsek, A. M. Vannucchi, M. Griesshammer, T. Masszi, S.
Durrant, F. Passamonti, C. N. Harrison, F. Pane, P. Zachee, M. Hino, B. Moiraghi,
C. B. Miller, V. Rosti, R. A. Mesa, M. M. Jones, H. Zhen, J. Li, N. Francillard, D.
Habr, J. Kiladjian
Board 77
Case series of hypomethylating agents (HMA) effect on
myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPN-U):
Mayo Clinic experience. (Abstract 7088) A. K. Abou Hussein, M. M. Patnaik, D.
Zblewski, N. Gangat, S. Hashmi, M. A. Elliott, W. J. Hogan, M. R. Litzow, A. Al-Kali
Board 78
Outpatient allogeneic hematopoietic cell transplant following alemtuzumab
based reduced intensity conditioning in patients with advanced mycosis
fungoides/Sezary syndrome. (Abstract 7089) E. Purev, R. Srinivasan, G. Aue,
D. Stroncek, H. Khuu, C. Ramos, L. Cook, E. Cho, M. Schmitt, R. W. Childs
Board 79
Hepatitis C virus infection in patients undergoing hematopoietic cell
transplantation in the era of direct-acting antiviral agents. (Abstract 7090) A.
Kyvernitakis, P. Mahale, U. R. Popat, Y. Jiang, R. E. Champlin, H. A. Torres
Board 80
Influence of variant allele frequency (VAF) on the phenotypic penetrance of
TP53 mutations in myeloid malignancies. (Abstract 7091) D. A. Sallman, R. S.
Komrokji, C. Vaupel, N. Al Ali, J. E. Lancet, A. F. List, J. Hall, E. Padron
Board 81
Prognostic and predictive value of IPSS-R in assessing overall survival (OS)
in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
(Abstract 7092) L. R. Silverman, P. Fenaux, A. Al-Kali, M. R. Baer, M. A. Sekeres,
G. J. Roboz, G. Gaidano, B. L. Scott, P. Greenberg, U. Platzbecker, D. P.
Steensma, K. A. Kreuzer, L. A. Godley, R. Collins, E. L. Atallah, N. Azarnia, G.
Garcia-Manero
153
SUNDAY
lymphocytic leukemia (CLL). (Abstract 7078) N. Bose, C. Zent, G. J. Weiner, B.
LaPlant, N. Ottoson, S. Leonardo, A. Jonas, R. D. Huhn, A. H. Braun, S. M. Ansell
SUNDAY
Board 82
Use of dual donor T-cell chimerism to predict prognosis after double cord
blood allogeneic transplantation. (Abstract 7093) M. Baljevic, K. Cao, R. E.
Champlin, C. Hosing, N. Shah, S. Parmar, K. Rezvani, A. L. Olson, E. J. Shpall, B.
Oran
Board 83a
A phase II, randomized trial of standard of care with or without midostaurin
to prevent relapse following allogeneic stem cell transplantation in patients
with FLT3-ITD mutated acute myeloid leukemia. (Abstract TPS7094) R. T.
Maziarz, B. L. Scott, S. R. Mohan, A. Deol, M. M. Patnaik, K. Haines, B. Elliott,
C. S. Paley, H. F. Fernandez
Board 83b
Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor
ibrutinib in combination with obinutuzumab vs. chlorambucil in combination
with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130):
iLLUMINATE. (Abstract TPS7095) I. Flinn, C. Moreno, D. S. Gill, T. J. Kipps, Y.
Shaw, Y. Li, L. A. Styles, D. F. James, J. G. Gribben
Board 84a
A multicenter, open-label phase 2a study of ibrutinib with or without
cytarabine in patients with acute myeloid leukemia (PCYC-1131). (Abstract
TPS7096) J. E. Cortes, E. Estey, A. S. Stein, T. Graef, N. Cavazos, T. Kinoshita, Y.
Luan, A. Tawashi
Board 84b
An international phase 3 randomized, placebo-controlled study of CC-486
(oral azacitidine) maintenance therapy in patients with acute myeloid
leukemia (AML) in complete remission (CR): The Quazar AML maintenance
trial. (Abstract TPS7097) G. J. Roboz, F. Ravandi, D. Selleslag, P. Montesinos, A.
Wei, K. Porkka, A. Almeida, M. R. Savona, S. R. Mohan, J. F. Falantes, M. Voso,
K. Kumar, F. Camus, I. La Torre, H. Kantarjian, B. Skikne
Board 85a
First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6
inhibitor, in subjects with relapsed or refractory acute myeloid leukemia
(AML). (Abstract TPS7098) N. G. Daver, M. Konopleva, H. E. Kohrt, J. S.
Fridman, D. Johnson, J. C. Jaen, H. M. Kantarjian, J. E. Cortes
Board 85b
GRASPA-AML 2012– 01 study (NCT01810705): A multicenter, open,
randomized phase 2b trial evaluating ERY001 (L-asparaginase encapsulated
in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in
treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients,
unfit for intensive chemotherapy. (Abstract TPS7099) X. G. Thomas, E.
Tavernier Tardy, R. Guieze, P. Chevallier, J. Marolleau, F. Orsini, I. Hitchcock, I.
El-Hariry
Board 86a
A phase 1b trial of duvelisib, a PI3K-␦,␥ inhibitor, in combination with
obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s
tyrosine kinase inhibitor (BTKi). (Abstract TPS7100) J. S. Blachly, J. R. Brown,
J. C. Barrientos, N. Jain, V. Kelly, S. Garnick, J. Rodstrom, J. Sweeney, S. Tang,
J. C. Byrd
Board 86b
Phase III randomized, double-blind, active-controlled study of momelotinib
versus ruxolitinib in patients with myelofibrosis. (Abstract TPS7101) E. F.
Winton, T. Devos, S. T. Oh, U. Platzbecker, M. Wadleigh, S. Jun, P. Lee, W. Deng,
V. Gupta
Board 87a
Phase III randomized, open-label, active-controlled study of momelotinib
versus best available therapy in ruxolitinib-treated patients with
myelofibrosis. (Abstract TPS7102) V. Gupta, M. R. Baer, S. T. Oh, C. B. Miller,
S. Jun, P. Lee, H. Dong, A. Reiter
Board 87b
Phase 1 study to evaluate the safety and tolerability of MEDI4736, an antiprogrammed cell death ligand-1 (PD-L1) antibody, in myelodysplastic
syndrome (MDS) after treatment with hypomethylating agents. (Abstract
TPS7103) G. Garcia-Manero, C. A. Schiffer, L. A. Godley, R. Paquette, U.
Platzbecker, P. B. Robbins, J. Norton, J. J. Karakunnel, R. C. Lindsley
154
Location: S Hall A
Board 335
Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy
for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study
(NCCTG N1085 [Alliance]). (Abstract 8518) P. B. Johnston, B. LaPlant, G. S.
Nowakowski, I. N. Micallef, S. M. Ansell, T. M. Habermann, J. Colgan, T. E. Witzig
Board 336
Multivariate analysis of PFS from the AETHERA trial: A phase III study of
brentuximab vedotin consolidation after autologous stem cell transplant for
HL. (Abstract 8519) J. A. Walewski, A. Nademanee, T. Masszi, J. Holowiecki, M.
Abidi, A. I. Chen, P. J. Stiff, S. Viviani, V. Bachanova, J. W. Sweetenham, S. Lee,
D. Huebner, E. K. Larsen, N. N. Hunder, C. H. Moskowitz
Board 337
Interim analysis of a phase I study of INCB040093, a PI3K␦ inhibitor, alone or
in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts)
with relapsed or refractory (r/r) B-cell malignancies. (Abstract 8520) T. J.
Phillips, A. Forero-Torres, T. Sher, C. S. Magid Diefenbach, M. Talpaz, P. A.
Scherle, R. Schaub, L. Zhou, J. Pulini, L. Leopold, M. A. Spear, P. M. Barr
Board 338
A phase I/II trial of the combination of romidepsin and lenalidomide in
patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell
lymphoma. (Abstract 8521) N. Mehta-Shah, M. A. Lunning, A. M. Boruchov, J.
Ruan, S. Nair, P. Lynch, R. Byrne, A. J. Moskowitz, M. J. Matasar, J. F.
Gerecitano, P. A. Hamlin, J. Leonard, C. H. Moskowitz, P. L. Myskowski, C.
Querfeld, P. Nolan, M. Palomba, D. J. Straus, A. D. Zelenetz, S. M. Horwitz
Board 339
Prognostic index for chronic and smoldering types adult T-cell
leukemia/lymphoma. (Abstract 8522) H. Katsuya, M. Shimokawa, K. Ishitsuka,
K. Kawai, M. Amano, A. Utsunomiya, R. Hino, S. Hanada, T. Jo, K. Tsukasaki, Y.
Moriuchi, E. Sueoka, S. Yoshida, H. Suzushima, M. Miyahara, K. Yamashita, T.
Eto, T. Yamanaka, J. Suzumiya, K. Tamura
Board 340
Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs.
placebo (PBO) maintenance therapy after single autologous stem cell
transplant (ASCT) for multiple myeloma (MM). (Abstract 8523) S. A. Holstein,
K. Owzar, P. G. Richardson, C. Jiang, C. C. Hofmeister, H. Hassoun, D. D. Hurd,
E. A. Stadtmauer, S. Giralt, S. M. Devine, V. Hars, J. R. Postiglione, D. J. Weisdorf,
R. Vij, J. S. Moreb, N. S. Callander, T. G. Martin, T. C. Shea, K. C. Anderson, P. L.
McCarthy
Board 341
FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated
with continuous lenalidomide plus low-dose dexamethasone (Rd) vs
melphalan, prednisone, and thalidomide (MPT). (Abstract 8524) T. Facon, C.
Hulin, M. A. Dimopoulos, A. Belch, D. E. Reece, J. V. Catalano, A. Pinto, H.
Ludwig, N. J. Bahlis, M. Cavo, P. Moreau, L. Qiu, R. LeBlanc, R. Schots, S. V.
Rajkumar, J. Marek, G. Chen, A. L. Ervin-Haynes
Board 342
Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs
lenalidomide and dexamethasone (Rd) in patients with relapsed multiple
myeloma (RMM) by line of therapy: Secondary analysis from an interim
analysis of the phase III study ASPIRE (NCT01080391). (Abstract 8525) M. A.
Dimopoulos, A. K. Stewart, S. V. Rajkumar, T. Masszi, A. Oriol, R. Hajek, L.
Rosinol, D. S. Siegel, G. Mihaylov, V. Goranova-Marinova, P. Rajnics, A. Suvorov,
R. Niesvizky, A. J. Jakubowiak, J. F. San Miguel, H. Ludwig, N. J. Zojwalla, P.
Moreau, A. Palumbo
Board 343
Panobinostat plus bortezomib and dexamethasone in patients with relapsed
or relapsed and refractory multiple myeloma who received prior bortezomib
and IMiDs: A predefined subgroup analysis of PANORAMA 1. (Abstract 8526)
155
SUNDAY
Abstracts 8518 – 8529 will be discussed during the Lymphoma and Plasma Cell Disorders
Poster Discussion Session. See page 193 for session information.
J. F. San Miguel, V. T. Hungria, S. Yoon, M. Beksac, M. A. Dimopoulos, A.
Elghandour, W. W. Jedrzejczak, A. Guenther, T. Na Nakorn, N. Siritanaratkul, R. L.
Schlossman, J. Hou, P. Moreau, S. Lonial, J. Lee, H. Einsele, M. Sopala, B.
Bengoudifa, C. Corrado, P. G. Richardson
SUNDAY
Board 344
Updated results from CHAMPION-1, a phase I/II study investigating weekly
carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory
multiple myeloma (RRMM). (Abstract 8527) J. R. Berenson, A. Cartmell, A.
Bessudo, R. M. Lyons, W. A. Harb, D. Tzachanis, M. Coleman, R. V. Boccia, R. M.
Rifkin, P. Patel, S. Dixon, J. G. Berdeja
Board 345
A phase II study of panobinostat with lenalidomide and weekly
dexamethasone in myeloma. (Abstract 8528) A. Chari, H. J. Cho, S. S. Parekh,
A. Dhadwal, K. Garcia, G. Morgan, N. Belostotsky, C. Carter, D. Catamero, J.
Escalon, D. Verina, M. Yum, L. La, E. Chan, J. Gullie, S. Jagannath
Board 346
Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2
study. (Abstract 8529) G. A. Salles, S. J. Schuster, S. De Vos, N. D. WagnerJohnston, A. Viardot, C. Flowers, M. Will, M. Breuleux, W. R. Godfrey, B.
Sorensen, A. Gopal
Board 347
Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus
autologous stem cell transplant (ASCT) in newly diagnosed multiple
myeloma (NDMM): Results of a randomized, phase III trial. (Abstract 8530) S.
Lentzsch, S. Miao, J. M. Schecter, K. A. Griffith, D. P. Normolle, M. Y. Mapara,
R. L. Redner, N. Villanueva
Board 348
Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor
cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell
malignancies: Safety profile and clinical activity. (Abstract 8531) I. Flinn, P. A.
Hamlin, D. K. Strickland, A. Pandey, M. Birrell, G. Coffey, J. Leeds, J. T. Curnutte,
J. A. Burger, N. D. Wagner-Johnston, M. R. Patel
Board 349
Idelalisib monotherapy and durable responses in patients with relapsed or
refractory Waldenstroms Macroglobulinemia (WM). (Abstract 8532) S. Coutre,
J. Leonard, C. Flowers, A. J. Davies, W. Jurczak, J. C. Byrd, S. E. Spurgeon, S.
Peterman, L. Holes, Y. Cho, B. Sorenson, W. R. Godfrey, A. K. Gopal
Board 350
A phase I study combining bendamustine with rituximab, etoposide and
carboplatin (TREC) in patients with aggressive relapsed or refractory
lymphoma. (Abstract 8533) L. Budde, D. B. Martin, M. Philip, A. R. Shustov, T.
Gooley, T. L. Chen, E. N. Libby, E. Y. Chen, K. Kojouri, A. Langerak, J. E. Roden,
B. E. Kammerer, N. L. Knudsen, S. D. Smith, O. W. Press, A. K. Gopal
Board 351
A phase I study of gemcitabine and bendamustine in relapsed/refractory
Hodgkin’s lymphoma. (Abstract 8534) J. B. Cohen, L. Wei, K. J. Maddocks, L. T.
Heffner, A. A. Langston, C. Flowers, S. M. Devine, K. A. Blum
Board 352
Interim results from a dose-escalation study of the BCL-2 inhibitor
venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in
patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma
(NHL). (Abstract 8535) S. De Vos, C. Flowers, D. Wang, L. J. Swinnen, N. H.
Fowler, E. G. Reid, J. Cordero, M. Gifford, D. D’Amico, M. Dunbar, M. Zhu, A. H.
Salem, S. H. Enschede, J. L. Ricker, D. Chien, R. Humerickhouse, M. Kozloff
Board 353
Development of the molecular diagnostic (MDx) DLBCL Lymphoma
Subtyping Test (LST) on the nCounter Analysis System. (Abstract 8536) B.
Wallden, S. Ferree, H. Ravi, N. Dowidar, T. Hood, P. Danaher, A. MashadiHossein, G. Wright, C. Schaper, J. J. Storhoff
Board 354
Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and
HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma.
(Abstract 8537) J. G. Berdeja, Y. Oki, M. R. Patel, A. Copeland, I. Flinn, S. S.
Neelapu, J. Viner, J. Wang, J. F. Gerecitano, A. Younes
Board 355
Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin
alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with
newly diagnosed T- and NK-cell lymphoma (T/NKCL). (Abstract 8538) D.
Chihara, B. Pro, S. Loghavi, R. N. Miranda, L. Medeiros, M. A. Fanale, F. B.
156
Board 356
Pre-treatment circulating tumor DNA as a biomarker for disease burden in
diffuse large B cell lymphoma (DLBCL). (Abstract 8539) F. Scherer, D. M.
Kurtz, M. R. Green, A. M. Newman, D. M. Klass, L. Zhou, R. Krishnan, C. Liu, C.
Glover, R. S. Ohgami, R. J. Hicks, C. Keane, K. A. Kong, M. Faham, M. S.
Hertzberg, M. K. Gandhi, R. H. Advani, R. Levy, M. Diehn, A. A. Alizadeh
Board 357
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of
relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final
results of phase 1 study NCCTG N1088/ALLIANCE. (Abstract 8540) G. S.
Nowakowski, B. LaPlant, W. R. Macon, M. A. Gertz, T. M. Habermann, D. J.
Inwards, I. N. Micallef, D. B. Wender, J. Leonard, T. E. Witzig
Board 358
Telomere profile of Reed-Sternberg and Hodgkin cells in diagnostic biopsy in
Hodgkin lymphoma as a predictor of clinical response. (Abstract 8541) J. B.
Tompkins, C. Taylor-Kashton, C. Li, M. Klassen, H. Stewart, M. Cheang, P. J.
Lambert, M. R. Nasr, C. Morales, H. Knecht, D. A. Wall, S. Mai
Board 359
Lenalidome in combination with rituximab for relapsed or refractory mantel
cell lymphoma: Updated analysis of a phase 2 trial. (Abstract 8542) Y. Wang,
M. Dela Rosa, S. Zhou, M. Badillo, A. Addison, L. Zhang, H. J. Lee, J. E.
Romaguera, M. Wang
Board 360
Analysis of “double-hit” lymphoma cases by genetic subtype. (Abstract
8543) D. J. Landsburg, A. M. Petrich, J. S. Abramson, A. Sohani, O. W. Press,
R. D. Cassaday, J. C. Chavez, K. W. Song, A. D. Zelenetz, M. Gandhi, N. M. Shah,
T. Fenske, J. Jasso, L. Medeiros, D. T. Yang, C. Nabhan
Board 361
Phase 1 trial of brentuximab vedotin in combination with gemcitabine for
pediatric and young adult patients with relapsed or refractory Hodgkin
lymphoma, a Children’s Oncology Group report. (Abstract 8544) P. D. Cole,
M. Metzger, R. A. Drachtman, T. M. Horton, X. Liu, C. H. Ahern, C. Minard, E. Fox,
S. Blaney, B. Weigel, K. M. Kelly
Board 362
Survival of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and
peripheral T-cell lymphoma (PTCL): A propensity matched analysis of the
Surveillance, Epidemiology and End Results (SEER) database. (Abstract
8545) S. Manandhar, S. Giri, V. R. Bhatt, R. Pathak, G. Bociek, J. O. Armitage, J.
Vose
Board 363
Treatment of refractory/relapse vitreoretinal lymphoma: Result of a
multicenter retrospective study from the LOC network on temozolomide in
monotherapy. (Abstract 8546) S. Choquet, M. Baron, C. Soussain, C. Houillier,
E. Gyan, N. Cassoux, V. Touitou, C. Fardeau, V. Leblond, K. Hoang-Xuan
Board 364
Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of
lenalidomide vs investigator’s choice in relapsed/refractory mantle cell
lymphoma. (Abstract 8547) M. Trneny, T. Lamy, J. A. Walewski, D. Belada, J.
Mayer, J. A. Radford, W. Jurczak, F. Morschhauser, J. Alexeeva, S. Rule, T. N.
Biyukov, M. Patturajan, M. C. Bravo, J. Cabecadas, L. Arcaini, SPRINT Trial
Investigators
Board 366
Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory
B-cell NHL and high-risk CLL. (Abstract 8548) M. A. Lunning, J. Vose, N. H.
Fowler, L. J. Nastoupil, M. T. Schreeder, T. Siddiqi, C. Flowers, J. B. Cohen, S.
Blumel, M. Miguel, W. H. Tse, E. K. Pauli, K. Cutter, P. Sportelli, H. P. Miskin, M. S.
Weiss, S. V. Vakkalanka, S. Viswanadha, S. M. O’Brien
Board 367
Clinical significance of radiotherapy in the treatment of limited stage NK/T
cell lymphoma. (Abstract 8549) S. Lee, Y. Chae, B. Kang, S. Yoon, J. Kim, J.
Moon, B. Lee, Y. Do, Y. Park, H. Yhim, D. Yang, J. Chung, M. Song, J. Lee, J.
Kwak, S. Jeong
Board 368
Breast implant-associated anaplastic large cell lymphoma: Proposal for
optimal management. (Abstract 8550) M. W. Clemens, C. E. Butler, K. Hunt,
157
SUNDAY
Hagemeister, L. Fayad, J. E. Romaguera, F. Samaniego, S. S. Neelapu, A.
Younes, N. H. Fowler, M. A. Rodriguez, M. Wang, L. W. Kwak, P. McLaughlin,
N. H. Dang, Y. Oki
M. A. Fanale, S. M. Horwitz, H. Liu, C. McCarthy, L. J. Nastoupil, J. Liu, L.
Medeiros, R. N. Miranda
SUNDAY
Board 369
Rituximab maintenance therapy in B-cell lymphoma: A meta-analysis.
(Abstract 8551) Y. Wang, Y. Shen, F. Yang, L. J. Sanchez, X. Guan, V. T. Chang,
M. Wang
Board 370
CD30ⴙ expression in peripheral T-cell lymphomas (PTCLs): A subset
analysis from the international, prospective T-Cell Project. (Abstract 8552) M.
Federico, M. Bellei, S. Luminari, S. M. Horwitz, S. Montoto, E. Zucca, S. A. Pileri,
Y. Ko, P. L. Zinzani, J. M. Connors, F. M. Foss, A. Polliack, M. Cabrera, W. Kim, M.
Spina, C. A. De Souza, S. Bobillo Varela, I. Dlouhy, R. H. Advani, J. Vose, T-Cell
Project
Board 371
A phase I trial of lenalidomide maintenance after autologous stem cell
transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.
(Abstract 8553) J. Svoboda, L. Strelec, N. N. Shah, E. A. Chong, K. Montrey, K.
Walsh, S. F. Huntington, A. Mato, D. J. Landsburg, S. Nasta, S. J. Schuster
Board 372
Outcomes and prognostic factors in marginal zone lymphoma: Case
comprehensive cancer center cumulative experience of 358 cases. (Abstract
8554) A. Starr, P. Fu, P. F. Caimi, E. L. Campagnaro, B. W. Cooper, M. J. De Lima,
H. M. Lazarus, S. L. Gerson, H. Meyerson, D. Jagadeesh, M. R. Smith, R. M.
Dean, B. L. Pohlman, B. T. Hill, B. M. William
Board 373
Exercise patterns and quality of life among survivors of aggressive
lymphoma. (Abstract 8555) R. M. Ferzoco, J. R. Cerhan, M. J. Maurer, C. Allmer,
K. J. Yost, T. M. Habermann, S. M. Ansell, D. J. Inwards, T. E. Witzig, L. F. Porrata,
G. S. Nowakowski, W. R. Macon, J. N. Towns, U. Farooq, B. K. Link, C. A.
Thompson
Board 374
A new class of anti-cancer drugs targeting the tyrosine kinase receptor
ROR1 in CLL. (Abstract 8556) H. Mellstedt, S. Khan, M. Hojjat-Farsangi, A. H.
Daneshmanesh, J. Vagberg, S. Bystrom, J. Schultz, M. Norin, E. Olsson, C.
Lofberg, C. Norstrom, T. Olin, A. Österborg, A. Moshfegh
Board 375
BRD4 degraders produce long-lasting loss of BRD4 protein and robust
efficacy in Burkitt’s lymphoma cells. (Abstract 8557) K. Coleman, J. Lu, Y.
Qian, M. Altieri, K. Raina, H. Dong, J. Wang, J. Hines, A. P. Crew, C. M. Crews
Board 376
A phase 1 study of INCB040093, a PI3K␦ inhibitor, alone or in combination
with INCB039110, a selective JAK1 inhibitor: Interim results from patients
(pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
(Abstract 8558) A. Forero-Torres, P. M. Barr, C. S. Magid Diefenbach, T. Sher, R.
Schaub, L. Zhou, J. Pulini, L. Leopold, M. A. Spear, M. Talpaz, T. J. Phillips
Board 377
High throughput in vitro combination sensitivity screen in hematologic
malignancies with the phosphoinositide-3 kinase (PI3K)-␦,␥ inhibitor,
duvelisib. (Abstract 8559) K. Faia, K. White, J. Proctor, P. Andrade, M. Pink, R.
Rickles, J. Grenier, E. Boghaert, A. J. Souers, J. Leverson, V. J. Palombella, K.
McGovern, J. L. Kutok
Board 378
Early high-dose therapy and autologous stem-cell transplantation in
angioimmunoblastic T-cell lymphoma: Outcome study using the National
Cancer Data Base. (Abstract 8560) P. K. Karanam, B. M. Parsons, M. AlHamadani, R. S. Go
Board 379
Association of hemophagocytic lymphohistiocytosis (HLH) with poor
outcomes in adults with NK- and T-cell lymphoma (NKTCL). (Abstract 8561)
M. V. Shah, T. E. Witzig, M. O’Byrne, P. Kapoor, A. P. Wolanskyj, A. L. Feldman,
B. K. Link, J. R. Cerhan, M. J. Maurer, S. A. Parikh
Board 380
Role of radiation (RT) in primary mediastinal large B-cell lymphoma
(PMBCL): An analysis of the Surveillance, Epidemiology, and End Results
(SEER) database. (Abstract 8562) S. Giri, V. R. Bhatt, R. Pathak, G. Bociek, J.
Vose, J. O. Armitage
Board 381
Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with
chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma
158
Board 382
The outcome of ALK positive and ALK negative anaplastic large cell
lymphoma (ALCL) following DA-EPOCH. (Abstract 8564) C. Lai, S. Pittaluga,
M. Shovlin, S. M. Steinberg, M. J. Roschewski, E. S. Jaffe, W. H. Wilson, K.
Dunleavy
Board 383
Phase II study of rituximab plus high-dose ara-C (HDAC)-containing
chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma
(MCL): Japan Clinical Oncology Group study (JCOG0406). (Abstract 8565) M.
Ogura, K. Tobinai, T. Shibata, K. Ando, M. Kurosawa, H. Gomyo, N. Uike, N.
Tsukamoto, N. Fukuhara, T. Shimoyama, M. Taniwaki, K. Nosaka, Y. Matsuno, T.
Hotta, K. Tsukasaki, Y. Morishima, K. Yamamoto, Japan Clinical Oncology
Group-Lymphoma Study Group (JCOG-LSG)
Board 384
Outcome comparison of allogeneic vs. autologous stem cell transplantation
in transformed low grade lymphoid malignancies: A meta-analysis of
comparative studies. (Abstract 8566) S. Yun, N. Vincelette, J. Segar
Board 385
Is rituximab sub-optimally dosed in indolent B cell lymphoma? (Abstract
8567) Y. Sawalha, B. Rouphail, X. Jia, R. M. Dean, B. T. Hill, D. Jagadeesh, B. L.
Pohlman, P. Elson, M. R. Smith
Board 386
Relationship of distinct B-cell receptor (BCR) isotype in diffuse large b-cell
lymphoma (DLBCL) with ABC and GCB genetic signatures and association
with signaling molecules of clinical significance. (Abstract 8568) A. Qureshi,
A. Akhter, F. Farooq, J. Luider, D. A. Stewart, A. Mansoor
Board 387
Overall survival in patients with Hodgkin lymphoma: Disparities by insurance
status. (Abstract 8569) R. Parikh, M. L. Grossbard, L. B. Harrison, J. Yahalom
Board 388
Distinct early response dynamics of circulating tumor DNA and circulating
tumor cells during therapy of B-cell NHL. (Abstract 8570) D. M. Kurtz, F.
Scherer, M. R. Green, M. S. Khodadoust, D. M. Klass, L. Zhou, R. Krishnan, C.
Glover, C. Liu, K. A. Kong, M. Faham, R. Levy, M. Diehn, A. A. Alizadeh
Board 389
Effect of prednisone and rituximab prephase on early toxicity in older DLBCL
patients (pts) receiving RCHOP within a NHL specific comprehensive
geriatric assessment (CGA) trial. (Abstract 8571) C. N. Owens, A. Iannotta, J. F.
Gerecitano, M. J. Matasar, A. Noy, C. H. Moskowitz, P. Drullinsky, M. Palomba,
D. J. Straus, S. M. Horwitz, A. D. Zelenetz, C. S. Portlock, A. Kumar, P. A. Hamlin
Board 390
Prognostic value of interim 18F-FDG PET/CT in patients with diffuse large
B-cell lymphoma treatment with R-CHOP: SUVmax reduction-based
assessment at two cycles of chemotherapy. (Abstract 8572) X. Zhang, W. Fan
Board 391
A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with
or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple
myeloma (RRMM). (Abstract 8573) A. J. Jakubowiak, M. Offidani, B. Pegourie, J.
De La Rubia, L. Garderet, K. Laribi, A. Bosi, R. Marasca, J. Laubach, A.
Mohrbacher, A. M. Carella, A. K. Singhal, C. Tsao, M. J. Lynch, E. W. Bleickardt, Y.
Jou, A. Palumbo
Board 392
A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in
relapsed or refractory multiple myeloma (rrMM). (Abstract 8574) M. S. Raab,
H. Goldschmidt, H. Agis, I. Blau, H. Einsele, M. M. Engelhardt, B. Ferstl, M.
Gramatzki, C. Röllig, K. Weisel, P. Kloepfer, D. Weinelt, S. Härtle, C. Peschel
Board 393
Analysis of outcomes based on response for patients with relapsed or
relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1
study. (Abstract 8575) V. T. Hungria, J. F. San Miguel, S. Yoon, M. Beksac, M. A.
Dimopoulos, A. Elghandour, W. W. Jedrzejczak, A. Guenther, T. Na Nakorn, N.
Siritanaratkul, R. L. Schlossman, J. Hou, P. Moreau, S. Lonial, J. Lee, H. Einsele,
M. Sopala, B. Bengoudifa, C. Corrado, P. G. Richardson
Board 394
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199)
monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). (Abstract
159
SUNDAY
(iNHL) in idelalisib (IDELA) trials. (Abstract 8563) J. C. Barrientos, P. Ghia, J.
Pagel, G. A. Salles, J. P. Sharman, S. Stilgenbauer, O. Gurtovaya, Y. Kim, B.
Philip, A. D. Zelenetz
8576) S. Kumar, R. Vij, J. L. Kaufman, J. Mikhael, T. Facon, P. Moreau, M. Amiot,
S. Alzate, L. J. Morris, J. A. Ross, M. Dunbar, M. Zhu, S. K. Agarwal, J. Leverson,
S. H. Enschede, R. Humerickhouse, C. Touzeau
SUNDAY
Board 395
The prognostic significance of CD45 expression by clonal bone marrow
plasma cells in multiple myeloma. (Abstract 8577) W. I. Gonsalves, V.
Rajkumar, W. Morice, M. Timm, A. Dispenzieri, F. Buadi, M. Lacy, Y. Lin, D. Dingli,
S. R. Hayman, S. R. Zeldenrust, S. J. Russell, N. Leung, P. Kapoor, M. A. Gertz, S.
Kumar
Board 396
Outcome at first relapse after frontline RVD regimen plus lenalidomide
maintenance in transplant eligible MM patients. (Abstract 8578) M. Roussel, B.
Hebraud, D. Caillot, X. Leleu, M. Macro, C. Hulin, C. Chaleteix, M. Escoffre Barbe,
L. Karlin, G. Marit, L. Garderet, B. Pegourie, A. Stoppa, P. Lenain, B. Royer, H.
Avet-Loiseau, M. Attal
Board 397
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational
hypoxia-activated prodrug, combined with bortezomib and dexamethasone
in patients with relapsed/refractory multiple myeloma (RR MM). (Abstract
8579) J. Laubach, N. S. Raje, A. J. Yee, P. Armand, R. L. Schlossman, J.
Rosenblatt, J. A. Hedlund, M. G. Martin, C. H. Reynolds, K. H. Shain, I. Zackon, L.
Stampleman, E. Boswell, S. Chuma, R. Liguori, D. Handisides, S. Kroll, K. C.
Anderson, P. G. Richardson, I. M. Ghobrial
Board 398
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination
with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R)
multiple myeloma (MM). (Abstract 8580) C. Touzeau, A. A. Chanan-Khan, A. W.
Roberts, A. Agarwal, T. Facon, D. Lebovic, P. Moreau, D. E. Darden, L. J. Morris,
J. A. Ross, A. H. Salem, W. Munasinghe, M. Zhu, J. Leverson, S. H. Enschede, R.
Humerickhouse, S. J. Harrison
Board 399
Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood
progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and
PBPC as part of tandem autologous transplant (TAT) for patients with
multiple myeloma. (Abstract 8581) G. Somlo, A. Liu, T. E. Schultheiss, P. H.
Frankel, R. T. Spielberger, L. Popplewell, K. Zhou, D. Hawkins, A. Y. Krishnan, F.
Sahebi, P. M. Parker, S. J. Forman, J. Y. Wong
Board 400
Overall survival in newly diagnosed MM patients with del(17p): A report from
the Connect MM Registry. (Abstract 8582) J. J. Shah, R. Abonour, B. G. Durie,
J. Mehta, M. Narang, H. R. Terebelo, C. Gasparetto, K. Toomey, J. W. Hardin, S.
Srinivasan, G. Larkins, R. J. Ricafort, Y. M. Nagarwala, R. M. Rifkin
Board 401
Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma
following early high dose therapy and autologous hematopoietic cell
transplantation (SCT). (Abstract 8583) G. P. Kaufman, M. A. Gertz, A.
Dispenzieri, M. Lacy, F. Buadi, D. Dingli, S. R. Hayman, P. Kapoor, S. V.
Rajkumar, S. Kumar
Board 402
A phase I/II trial of very low to low-dose continuous azacitidine in
combination with standard doses of lenalidomide and low-dose
dexamethasone in patients with relapsed or refractory multiple myeloma.
(Abstract 8584) F. J. Reu, D. Grabowski, R. Z. Mahfouz, H. M. Lazarus, R. M.
Dean, B. Faiman, J. Reed, M. Karam, K. Hamilton, S. Fada, M. E. Kalaycio, J. N.
Valent, C. J. Samaras, R. M. Sobecks, L. McCowen, J. Elberson, H. Liu, Y.
Saunthararajah, Y. Chew, M. R. Smith
Board 403
The therapeutic benefit and toxicity from multiple myeloma phase I trials,
2004 through 2014. (Abstract 8585) E. Malek, J. J. Driscoll, J. Welge
Board 404
Impact of total therapies on clinical outcome of myeloma stratified by risk
and molecular subgroups. (Abstract 8586) C. J. Heuck, N. Weinhold, S.
Thanendrarajan, C. K. Stein, F. Van Rhee, A. Rosenthal, Y. Jethava, R. Khan, A.
Hoering, F. E. Davies, B. Barlogie, G. J. Morgan
Board 405
Pre-clinical translational studies of daratumumab in patients with myeloma
or AL amyloidosis undergoing autologous hematopoietic stem cell
160
Board 406
Effect of IMiD compounds on CD38 expression on multiple myeloma cells:
MOR202, a human CD38 antibody in combination with pomalidomide.
(Abstract 8588) R. Boxhammer, S. Steidl, J. Endell
Board 407
Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS,
smoldering multiple myeloma, and multiple myeloma. (Abstract 8589) J. T.
Larsen, V. Ramakrishnan, L. Wellik, T. K. Kimlinger, S. V. Rajkumar, S. Kumar
Board 408
Assessing clinical response in multiple myeloma (MM) patients treated with
monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex
assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.
(Abstract 8590) C. McCudden, A. Axel, D. Slaets, S. Frans, J. Bald, J. M.
Schecter, T. Ahmadi, T. Plesner, K. Sasser
Board 409
Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and
pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory
multiple myeloma (RRMM). (Abstract 8591) J. R. Berenson, L. Stampleman, A.
Bessudo, P. Rosen, L. M. Klein, T. B. Woliver, M. S. Flam, S. Eshaghian, Y. Nassir,
R. A. Swift, R. A. Vescio
Board 410
Clinical outcomes in t(11;14) multiple myeloma. (Abstract 8592) M. Alhaj
Moustafa, S. V. Rajkumar, A. Dispenzieri, M. Lacy, M. A. Gertz, F. Buadi, D. Dingli,
S. R. Hayman, P. Kapoor, Y. L. Hwa, J. A. Lust, R. S. Go, R. A. Kyle, S. Kumar
Board 411
Analyzing the relationship of response and survival in patients with
refractory or relapsed and refractory multiple myeloma (RRMM) treated with
pomalidomide plus low-dose dexamethasone (POM ⴙ LoDEX) in the MM-003
trial. (Abstract 8593) K. Weisel, P. Moreau, C. J. Gibson, K. W. Song, O.
Saunders, L. A. Sternas, K. Hong, M. H. Zaki, M. A. Dimopoulos
Board 413
Outcomes and treatment of patients with POEMS syndrome experiencing
progression or relapse after first line treatment. (Abstract 8594) T. Kourelis,
R. A. Kyle, S. Kumar, M. A. Gertz, M. Lacy, P. Kapoor, F. Buadi, R. S. Go, J. A.
Lust, S. R. Hayman, V. Rajkumar, S. R. Zeldenrust, S. J. Russell, D. Dingli, Y. Lin,
N. Leung, A. Dispenzieri
Board 414
Phase III trial of stem cell transplantation compared to melphalan and
dexamethasone in the treatment of immunoglobulin light chain amyloidosis
(AL). (Abstract 8595) M. A. Gertz, M. Lacy, A. Dispenzieri, F. Buadi, D. Dingli,
S. R. Hayman, S. Kumar, N. Leung, J. A. Lust, S. V. Rajkumar, S. J. Russell, V.
Suman, W. J. Hogan
Board 415
Survival trends in young patients with Waldenstrom macroglobulinemia
(WM). (Abstract 8596) N. Vallumsetla, J. Paludo, M. Gertz, S. M. Ansell, R. S. Go,
V. Rajkumar, R. A. Kyle, F. Buadi, A. Dispenzieri, M. Lacy, D. Dingli, S. R.
Hayman, N. Leung, S. Kumar, P. Kapoor
Board 416
Outcomes of primary plasmacytoma (PP) in United States (US). (Abstract
8597) G. Guru Murthy, R. Venkitachalam, V. R. Bhatt, I. Dhakal, J. Y. Lee, Y.
Jethava, P. D. Emanuel, P. Mehta
Board 417
A national study on conditional survival and excess mortality after high dose
therapy with autologous stem cell transplantation for non-Hodgkin
lymphoma. (Abstract 8598) K. B. Smeland, C. E. Kiserud, G. F. Lauritzsen, A. K.
Blystad, U. Fagerli, R. S. Falk, O. Fluge, A. Fossa, A. Kolstad, J. H. Loge, M.
Maisenholder, S. Kvaløy, H. Holte
Board 418a
A randomized, double-blind, placebo-controlled, phase 3 study of rituximab
with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127CA). (Abstract TPS8599) M. A. Dimopoulos, X. Leleu, J. Matous, D. MacDonald,
J. Trotman, A. Oriol, C. Shustik, A. Tedeschi, R. Garcia-Sanz, L. T. Heffner, S. Ma,
B. Mahe, C. Tam, O. Tournilhac, J. Li, P. Singh, E. Bilotti, T. Graef, S. P. Treon, C.
Buske
Board 418b
Randomized, phase III trial of the efficacy and safety of lenalidomide plus
R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell
161
SUNDAY
transplantation (SCT). (Abstract 8587) C. P. Chaulagain, X. Ma, P. Doshi, S. W.
Wong, A. K. Klein, K. A. Sprague, P. Zhou, R. Comenzo
lymphoma. (Abstract TPS8600) G. S. Nowakowski, A. Chiappella, T. E. Witzig,
M. Spina, L. Zhang, J. Flament, J. Repici, U. Vitolo
SUNDAY
Board 419a
A phase III study of ibrutinib in combination with either bendamustine and
rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone (R-CHOP) in patients with previously treated follicular
lymphoma or marginal zone lymphoma. (Abstract TPS8601) N. H. Fowler, W.
Hiddemann, J. Leonard, J. S. Larsen, E. Rose, S. H. Zhuang, J. Vermeulen, S.
Sun, L. Mentzer, T. Yeh, G. A. Salles
Board 419b
A phase I study with an expansion cohort of the combination of ipilimumab
and brentuximab vedotin in patients with relapsed/refractory Hodgkin
lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).
(Abstract TPS8602) C. S. Magid Diefenbach, H. Li, B. S. Kahl, M. J. Robertson, J.
Cohen, R. H. Advani, R. Ambinder, T. S. Fenske, S. M. Ansell
Board 420a
AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory
(R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety
of lenalidomide plus rituximab (R2) versus placebo plus rituximab. (Abstract
TPS8603) J. Leonard, J. G. Gribben, M. Trnı̀ný, P. Scheinberg, K. Tobinai, N. H.
Fowler, N. Kilavuz, P. Fustier, B. Amoroso, AUGMENT Trial Investigators
Board 420b
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory
CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal
antibody, in combination with local radiation in low-grade B-cell lymphomas.
(Abstract TPS8604) M. S. Khodadoust, M. P. Chu, D. Czerwinski, K. McDonald, S.
Long, H. E. Kohrt, R. T. Hoppe, R. H. Advani, R. Lowsky, R. Levy
Board 421a
Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline
treatment of patients (pts) with CD30ⴙ mature T-cell lymphomas (MTCL).
(Abstract TPS8605) O. A. O’Connor, B. Pro, T. Illidge, L. H. Trumper, E. K.
Larsen, T. J. Manley
Board 421b
MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory
(R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus
rituximab (R2) induction followed by maintenance R2 followed by
lenalidomide versus R2 induction followed by rituximab (R) maintenance.
(Abstract TPS8606) D. J. Andorsky, P. J. Franson, J. L. Mouro, J. Li, K. A. Foon,
J. P. Sharman, MAGNIFY Trial Investigators
Board 422a
A phase 2 trial of INCB040093 alone or in combination with INCB039110 in
patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma
(cHL). (Abstract TPS8607) P. M. Barr, T. Sher, T. J. Phillips, D. Lebovic, L. Zhou,
J. Pulini, M. A. Spear, A. Forero-Torres
Board 422b
A randomized open-label study of bortezomib, melphalan, and prednisone
(VMP) versus daratumumab (DARA) plus VMP in patients with previously
untreated multiple myeloma (MM) who are ineligible for high-dose therapy:
54767414MMY3007 (Alcyone). (Abstract TPS8608) M. Mateos, M. Cavo, A. J.
Jakubowiak, R. L. Carson, M. Qi, R. Bandekar, W. Crist, T. Ahmadi, J. F. San
Miguel
Board 423a
Twin randomized studies of daratumumab (DARA; D) plus standard of care
(lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd])
versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM):
54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor). (Abstract
TPS8609) A. Palumbo, M. A. Dimopoulos, D. E. Reece, P. Sonneveld, A. Spencer,
A. A. Chanan-Khan, H. Goldschmidt, H. Yeh, J. M. Schecter, X. Qin, H. Amin, M. E.
Guckert, T. Ahmadi, R. Z. Orlowski
Board 423b
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide
(POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD])
versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple
myeloma (RRMM). (Abstract TPS8610) P. G. Richardson, A. Bensmaine, T.
Doerr, J. Wang, M. H. Zaki, MM-007 Study Investigators
Board 424a
Denosumab compared with zoledronic acid for the treatment of bone disease
in adults with newly diagnosed multiple myeloma: An international,
162
randomized, double-blind trial. (Abstract TPS8611) N. S. Raje, E. Terpos, B. G.
Durie, R. Garcia-Sanz, K. Shimizu, W. Willenbacher, L. Zhu, D. J. Warner, A.
Palumbo
Board 424b
A multicenter, randomized, open-label, phase 2 study of carfilzomib with or
without ARRY-520 (filanesib) in patients with advanced multiple myeloma.
(Abstract TPS8612) J. A. Zonder, N. S. Raje, E. C. Scott, C. C. Hofmeister, N.
Lendvai, L. D. Anderson, P. Hari, G. J. Orloff, J. G. Berdeja, S. Singhal, M. Craig,
J. N. Valent, M. Ptaszynski, J. Schreiber, R. Aitchison, S. Z. Usmani
Board 425a
The AFFIRM Study: A multicenter phase 2 study of single-agent filanesib
(ARRY-520) in patients with advanced multiple myeloma. (Abstract TPS8613)
S. Lonial, M. Delforge, H. Einsele, P. Moreau, M. Kaiser, M. A. Dimopoulos, A.
Oriol, M. Gyger, B. Hilder, A. M. Ptaszynski, R. Aitchison, R. Z. Orlowski
Board 425b
The VITAL study: A randomized, double-blind, placebo-controlled, global,
phase III study of NEOD001 in patients with AL amyloidosis and cardiac
dysfunction. (Abstract TPS8614) M. Liedtke, G. Merlini, H. J. Landau, R.
Comenzo, D. C. Seldin, B. M. Weiss, J. A. Zonder, J. Walling, G. Kinney, M. Koller,
M. A. Gertz
Pediatric Oncology
Abstracts 10018 –10029 will be discussed during the Pediatric Oncology Poster Discussion Session. See page 187 for session information.
Board 88
Pulmonary function in adult survivors of childhood cancer: A report from the
St. Jude Lifetime Cohort Study (SJLIFE). (Abstract 10018) D. M. Green, L. Zhu,
M. J. Krasin, S. Srinivasan, D. C. Stokes, D. K. Srivastava, K. K. Ness, B.
McCarville, D. A. Mulrooney, G. T. Armstrong, C. Pui, S. L. Spunt, M. Metzger, F.
Navid, A. M. Davidoff, B. N. Rao, L. L. Robison, M. M. Hudson
Board 89
Second malignancies in neuroblastoma patients: A report from the
International Neuroblastoma Risk Group. (Abstract 10019) M. A. Applebaum,
T. O. Henderson, W. B. London, N. R. Pinto, S. L. Volchenboum, J. R. Park, A.
Naranjo, A. D. Pearson, B. Hero, S. Diskin, S. L. Cohn
Board 90
Temporal trends in health status among adults in the Childhood Cancer
Survivor Study (CCSS). (Abstract 10020) K. K. Ness, M. M. Hudson, K. E.
Jones, W. M. Leisenring, M. Stovall, D. M. Green, J. P. Neglia, T. O. Henderson,
J. N. Casillas, J. Ford, K. E. Effinger, K. C. Oeffinger, G. T. Armstrong, L. L.
Robison, P. C. Nathan
Board 91
Survival and late effects in the risk-stratified hepatoblastoma patients treated
by JPLT-2 protocol. (Abstract 10021) E. Hiyama, S. Kurihara, Y. Ueda, T.
Hishiki, K. Ida, T. Iehara, T. Oue, M. Yano, K. Watanabe, K. Hoshino, K. Ko, Y.
Tanaka
Board 92
The DICER1 syndrome: Genotype-phenotype correlation in PPB patients.
(Abstract 10022) L. A. Doros, J. Turner, G. M. Williams, C. Rossi, K. P. Schultz, D.
Stewart, L. P. Dehner, Y. H. Messinger, D. A. Hill
Board 93
Clinical outcome and biological predictors of relapse following nephrectomy
only for very low risk Wilms tumor (VLR WT): A report from Children’s
Oncology Group AREN0532. (Abstract 10023) C. V. Fernandez, E. Perlman,
E. A. Mullen, Y. Chi, T. E. Hamilton, K. W. Gow, F. A. Ferrer, D. C. Barnhart, P. F.
Ehrlich, G. Khanna, J. A. Kalapurakal, T. Bocking, V. Huff, Q. An, J. I. Geller, P. E.
Grundy, J. R. Anderson, J. S. Dome, R. C. Shamberger, AREN0532 Renal Study
Committee
Board 94
Loss of STAG2 expression and prognosis in Ewing sarcoma family of
tumors. (Abstract 10024) A. Bahrami, J. Wu, M. A. Dyer, O. Delattre, A. S. Pappo
163
SUNDAY
Location: S Hall A
SUNDAY
Board 95
Activity of Hsp90-inhibitor drug conjugate (HDC) STA-12– 8666 in preclinical
models of pediatric sarcoma. (Abstract 10025) C. Heske, A. Mendoza, C.
Yeung, D. A. Proia, L. Neckers, L. J. Helman
Board 96
RNA helicase DDX3 is a novel therapeutic target for Ewing sarcoma.
(Abstract 10026) D. M. Loeb, B. A. Wilky, C. Kim, G. McCarty, L. R. DeVine, R. N.
Cole, V. Raman
Board 97
The methylome of pediatric acute myeloid leukemia. (Abstract 10027) S.
Pounds, X. Cao, S. Raimondi, J. Downing, R. C. Ribeiro, J. E. Rubnitz, J. K. Lamba
Board 98
Accuracy of adverse event reporting on a phase III clinical trial for pediatric
acute myeloid leukemia: A report from the Children’s Oncology Group.
(Abstract 10028) T. P. Miller, Y. Li, M. Kavcic, T. A. Alonzo, M. Hall, Y. Huang,
R. B. Gerbing, B. Fisher, S. M. Luger, D. Rubin, A. B. Troxel, L. Sung, A. S. Gamis,
R. Aplenc
Board 99
Temsirolimus and intensive re-induction chemotherapy for 2nd or greater
relapse of acute lymphoblastic leukemia (ALL): A Children’s Oncology Group
study. (Abstract 10029) S. R. Rheingold, J. Whitlock, S. K. Tasian, D. T. Teachey,
M. J. Borowitz, X. Liu, C. H. Ahern, C. Minard, E. Fox, B. Weigel, S. Blaney
Board 100
Association of higher lung dose received during total body irradiation for
allogeneic hematopoetic stem cell transplantation in children with acute
lymphoblastic leukemia with inferior progression-free and overall survival: A
report from the Children’s Oncology Group. (Abstract 10030) N. Esiashvili, X.
Lu, S. Hunger, T. E. Merchant, P. A. Brown, D. A. Wall, S. A. Grupp, M. Pulsipher
Board 101
Intramuscular (IM) or intravenous (IV): Impact of Erwinia asparaginase route
of administration on asparaginase activity. (Abstract 10031) O. O. Okusanya,
P. A. Dinndorf, J. Bullock, B. A. Habtemariam, N. Mehrotra, A. B. Deisseroth, G. H.
Reaman, N. A. Rahman, A. T. Farrell
Board 102
Long-term outcome of six months maintenance chemotherapy for ALL in
children: TCCSG L92–13E study. (Abstract 10032) M. Kato, A. Manabe, S.
Ishimaru, M. Seki, K. Yoshida, D. Tomizawa, D. Hasegawa, T. Inukai, Y. Arakawa,
T. Aoki, M. Okuya, K. Kaizu, K. Kato, Y. Taneyama, S. Ogawa, K. Koh, M.
Tsuchida, A. Ohara
Board 103
Identification of patients with post-induction CNS 2 status and outcomes in
acute lymphoblastic leukemia. (Abstract 10033) A. Gurunathan, A. V. Desai,
L. C. Bailey, Y. Li, J. Choi, S. R. Rheingold
Board 104
Kidney Injury Molecule-1 and its association with delayed clearance and drug
exposure in pediatric oncology patients treated with high dose methotrexate.
(Abstract 10034) A. J. Bukowinski, T. Mizuno, T. Fukuda, A. Vinks, S. Goldstein,
A. Lane, J. P. Perentesis, M. M. O’Brien
Board 105
Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG)
administration with rate of adverse events (AE) in standard risk (SR) Acute
Lymphoblastic Leukemia (ALL) Children’s Oncology Group (COG) trials.
(Abstract 10035) K. W. Maloney, A. L. Angiolillo, R. J. Schore, M. Devidas, X. Lu,
C. Wang, A. M. Friedmann, L. A. Mattano Jr., M. L. Loh, E. A. Raetz, L. C. Stork,
N. J. Winick, S. Hunger, W. L. Carroll
Board 106
Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or
refractory solid tumors: A Children’s Oncology Group Study. (Abstract
10036) R. E. Norris, E. Fox, J. M. Reid, A. T. Ralya, X. Liu, C. H. Ahern, C. Minard,
J. Dahl, R. Eubank, B. Weigel
Board 107
Exploring Tenascin-C as a novel therapeutic target in pediatric brainstem
glioma. (Abstract 10037) A. M. Saratsis
Board 108
Diagnostic and prognostic role of circulating miR-206 in rhabdomyosarcoma
patients. (Abstract 10038) M. Miyachi, K. Tsuchiya, Y. Nitta, K. Ouchi, H.
Yoshida, K. Kikuchi, Y. Kuwahara, T. Iehara, H. Hosoi
Board 109
Anti-tumor efficacy in SIOPEL 6: A multi-centre open label randomised phase
III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in
patients receiving cisplatin (Cis) monotherapy for standard risk
164
Board 110
Proton versus conventional radiotherapy for pediatric salivary gland tumors:
Acute toxicity and dosimetric characteristics. (Abstract 10040) S. R. Grant, D.
Grosshans, A. Mahajan
Board 111
Molecular mechanisms for telomere maintenance in neuroblastoma.
(Abstract 10041) A. Bahrami, S. Lee, Y. Fan, J. Morris, A. S. Pappo, W. L. Furman
Board 112
Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials
through CCG, POG, and COG: Learning from the past to move forward.
(Abstract 10042) J. P. Lagmay, M. D. Krailo, H. Dang, A. Kim, D. S. Hawkins, O.
Beaty, B. C. Widemann, T. Zwerdling, L. Bomgaars, A. Langevin, H. E. Grier, B.
Weigel, S. Blaney, R. G. Gorlick, K. A. Janeway
Board 113
Vesicular monoamine transporter protein expression in neuroblastoma: A
report from the Children’s Oncology Group. (Abstract 10043) S. G. DuBois, W.
Temple, L. Mendelsohn, G. E. Kim, E. Nekritz, C. Gustafson, L. Lin, K. Giacomini,
A. Naranjo, C. Van Ryn, G. A. Yanik, S. G. Kreissman, M. D. Hogarty, K. K.
Matthay
Board 114
Meta-analysis of effects of demographic and treatment variables on outcome
for localized paratesticular rhabdomyosarcoma (PT RMS) in North America
and Europe. (Abstract 10044) D. Walterhouse, D. A. Barkauskas, A. Ferrari, E.
Koscielniak, M. Stevens, H. Martelli, G. Seitz, D. A. Rodeberg, M. Shnorhavorian,
R. Dasgupta, J. C. Breneman, J. R. Anderson, D. S. Hawkins, V. Minard-Colin
Board 115
Treatment outcomes of pediatric and young adult sporadic desmoid tumors.
(Abstract 10045) S. Helmig, J. G. Pressey, J. Sorger
Board 116
The prognostic significance of MIBG uptake in left supraclavicular lymph
nodes in high risk neuroblastoma patients. (Abstract 10046) S. Ash, I. Yaniv,
A. Steinmetz, Z. Bar-Sever
Board 117
Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of
osseous metastases in newly diagnosed and recurrent osteosarcoma.
(Abstract 10047) C. Hurley, B. McCarville, B. L. Shulkin, S. Mao, J. Wu, F. Navid,
N. C. Daw, A. S. Pappo, M. W. Bishop
Board 118
ImmunoPET compared with conventional imaging modalities for the
detection of Ewing sarcoma metastases in a preclinical model. (Abstract
10048) A. F. O’Neill, J. L. Dearling, T. Tupper, R. Modiste, G. Dai, Q. Nguyen, A. L.
Kung, A. Packard
Board 119
Analysis of prognostic factors of clinical outcome in children and
adolescents enrolled in phase I trials: A multicentre European collaborative
study. (Abstract 10049) F. Carceller Lechon, F. Bautista, I. Jimenez, R. HladunAlvaro, C. Giraud, L. Bergamaschi, M. Dandapani, I. Aerts, F. Doz, D. Frappaz, M.
Casanova, B. Morland, D. R. Hargrave, L. V. Marshall, G. Vassal, A. D. Pearson,
B. Geoerger, L. Moreno
Board 120
Efficacy in six courses of nonmethotrexate three-drug chemotherapy and
surgery in osteosarcoma: 25-year experience. (Abstract 10050) R. Kebudi, I.
Ayan, H. Ozger, F. B. Cakir, O. Gorgun, S. Buyukkapu Bay, B. Bilgic
Board 121
Comparison of clinical features and outcomes in patients with extraskeletal
versus skeletal localized Ewing sarcoma: A report from the Children’s
Oncology Group. (Abstract 10051) T. Cash, E. McIlvaine, M. D. Krailo, S. L.
Lessnick, E. R. Lawlor, N. N. Laack, J. Sorger, N. Marina, H. E. Grier, L.
Granowetter, R. B. Womer, S. G. DuBois
Board 122
A phase I study of sirolimus in combination with metronomic therapy in
children with recurrent and refractory solid/CNS tumors. (Abstract 10052) M.
Qayed, T. Cash, M. Tighiouart, T. MacDonald, K. C. Goldsmith, L. S. Kean, P.
Church, H. M. Katzenstein
165
SUNDAY
hepatoblastoma (SR-HB). (Abstract 10039) P. R. Brock, R. Maibach, M. Childs,
K. Rajput, E. A. Neuwelt, D. Roebuck, M. J. Sullivan, V. Laithier, M. Ronghe, L.
Lockwood, P. dall’Igna, E. Hiyama, B. Brichard, J. Skeen, M. E. Mateos, M. Fabre,
A. A. Rangaswami, M. Capra, P. Czauderna, B. Morland
SUNDAY
Board 123
A phase I/II clinical trial of veliparib (ABT-888) and radiation followed by
maintenance therapy with veliparib and temozolomide in patients with newly
diagnosed diffuse intrinsic pontine glioma (DIPG): A Pediatric Brain Tumor
Consortium Interim Report of Phase I Study. (Abstract 10053) P. A. Baxter,
J. M. Su, X. Li, A. Onar-Thomas, C. A. Billups, P. A. Thompson, S. Goldman, S.
Gururangan, T. Young-Poussaint, E. M. McKeegan, X. Wan, V. L. Giranda, A.
Paulino, E. Smith, S. Blaney, J. M. Boyett, M. Fouladi
Board 124
Pharmacogenetic markers for efficacy and toxicity of chemotherapy in
osteosarcoma patients. (Abstract 10054) H. I. Vos, M. J. Coenen, H.
Gelderblom, T. van der Straaten, E. S. de Bont, W. T. van der Graaf, H. Schreuder,
F. N. van Leeuwen, H. Guchelaar, D. M. Te Loo
Board 125
Developmental pharmacokinetics of topotecan (TPT), a renally excreted
drug, in infants and young children with brain tumors. (Abstract 10055) V. M.
Daryani, K. E. Harstead, J. F. Scott, D. A. Ward, S. L. Throm, D. C. Bowers, A. E.
Bendel, P. G. Fisher, K. D. Wright, A. Broniscer, G. W. Robinson, A. J. Gajjar, C. F.
Stewart
Board 126
Haploidentical stem cell transplantation and subsequent immunotherapy
with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.
(Abstract 10056) P. Lang, T. Illhardt, M. Ebinger, P. Schlegel, H. Teltschik, T.
Feuchtinger, C. Schwarze, R. L. Ladenstein, H. N. Lode, H. Loibner, W. Schwinger,
C. Urban, R. Handgretinger
Board 127
Association of pharmacogenetic variants with progressive disease in
osteosarcoma patients. (Abstract 10057) H. I. Vos, M. J. Coenen, H.
Gelderblom, E. S. de Bont, W. Van Der Graaf, L. C. Kremer, H. Guchelaar, D. M.
Te Loo
Board 128
Safety and tolerability of crizotinib in combination with chemotherapy for
relapsed or refractory solid tumors or anaplastic large cell lymphoma: a
Children’s Oncology Group phase I consortium study. (Abstract 10058) E. G.
Greengard, Y. P. Mosse, X. Liu, C. H. Ahern, C. Minard, S. Blaney, E. Fox, B.
Weigel
Board 129
Phase 1 trial of p28 (NSC745104), a non-HDM2 mediated peptide inhibitor of
p53 ubiquitination in children with recurrent or progressive CNS tumors: A
final report from the Pediatric Brain Tumor Consortium. (Abstract 10059)
R. R. Lulla, S. Goldman, C. Beattie, T. Yamada, I. Pollack, P. G. Fisher, S. Wu,
J. M. Boyett, M. Fouladi
Board 130
Transcriptome based individualized therapy of refractory pediatric cancer in
adolescents and young adults. (Abstract 10060) B. Weidenbusch, G. H.
Richter, U. Dirksen, T. G. Grunewald, L. Lindner, I. Teichert von Luettichau, U. R.
Mansmann, S. Burdach
Board 131
Phase II study of nimotuzumab and radiotherapy in children and adolescents
with newly diagnosed diffuse intrinsic pontine gliomas (DIPG). (Abstract
10061) S. Epelman, V. Odone, E. Gorender, R. S. Medeiros, L. Martins
Board 132
The genomic landscape of anaplastic Wilms tumors with diffuse versus focal
anaplasia. (Abstract 10062) G. G. Malouf, L. Dainese, X. Su, A. Verschuur, C.
Bergeron, R. Mouawad, A. Blaise, Y. Le Bouc, D. Khayat, A. Coulomb
Board 133
Localized vagina/uterus rhabdomyosarcoma (VU RMS): Results of a pooled
analysis from four international cooperative groups. (Abstract 10063) V.
Minard-Colin, J. R. Anderson, G. Bisogno, D. Schwob, D. A. Rodeberg, M.
Stevens, A. Ferrari, H. Martelli, D. Walterhouse, G. De Salvo, C. A. Arndt, A. Rey,
O. Oberlin, C. Haie Meder, D. S. Hawkins
Board 134
Late outcomes among adult survivors of childhood non-Hodgkin lymphoma
(NHL): A report from the St. Jude Lifetime Cohort Study. (Abstract 10064)
M. J. Ehrhardt, J. T. Sandlund, N. Zhang, K. K. Ness, W. Chemaitilly, K. R. Krull,
T. M. Brinkman, D. B. Crom, L. E. Kun, S. C. Kaste, G. T. Armstrong, D. M. Green,
D. K. Srivastava, L. L. Robison, M. M. Hudson, D. A. Mulrooney
Board 135
Patterns and predictors of psychological distress in adult survivors of
childhood cancer: A Childhood Cancer Survivor Study (CCSS). (Abstract
166
10065) N. M. D’Agostino, K. Edelstein, N. Zhang, C. J. Recklitis, T. M. Brinkman,
D. Srivastava, W. M. Leisenring, L. L. Robison, G. T. Armstrong, K. R. Krull
CELF4 variant and anthracycline-related cardiomyopathy (anth-card): A COG
Study (ALTE03N1). (Abstract 10066) X. Wang, C. Sun, A. Quinones Lombrana,
P. Singh, W. Landier, L. Hageman, M. Mather, L. Chen, S. Armenian, N. J. Winick,
J. P. Ginsberg, J. P. Neglia, K. C. Oeffinger, S. M. Castellino, Z. E. Dreyer, M. M.
Hudson, L. L. Robison, J. G. Blanco, S. Bhatia
Board 137
Longitudinal evaluation of health status and chronic conditions in aging
pediatric astrocytoma survivors: A Childhood Cancer Survivor Study (CCSS)
report. (Abstract 10067) K. E. Effinger, P. G. Fisher, K. K. Ness, K. R. Krull, N.
Marina, M. Stovall, K. C. Oeffinger, G. T. Armstrong, L. L. Robison, P. C. Nathan,
W. M. Leisenring, M. M. Hudson
Board 138
Quality of life assessment in retinoblastoma: A cross-sectional study of 122
survivors. (Abstract 10068) A. Batra, M. Kumari, R. Paul, D. Dhawan, S. Bakhshi
Board 139
Risk stratification to guide long-term follow up of teenage and young adult
survivors of childhood cancer. (Abstract 10069) S. J. Stanway, R. Windsor, S.
Depani, E. Potter, K. Khabra, M. Taj
Board 140
Long-term outcomes by race/ethnicity in the Childhood Cancer Survivor
Study (CCSS) cohort. (Abstract 10070) S. Bhatia, Q. Liu, W. M. Leisenring, K. K.
Ness, T. M. Gibson, L. L. Robison, G. T. Armstrong, Y. Yasui
Board 141
Intestinal obstruction in survivors of childhood cancer: A report from the
Childhood Cancer Survivor Study (CCSS). (Abstract 10071) A. L. Madenci, S.
Fisher, L. Diller, R. E. Goldsby, W. M. Leisenring, K. C. Oeffinger, L. L. Robison,
C. A. Sklar, M. Stovall, R. Weathers, G. T. Armstrong, Y. Yasui, C. B. Weldon
Board 142
Neurocognitive, emotional, and quality of life outcomes in long-term
survivors of rhabdomyosarcoma: A report from the Childhood Cancer
Survivor Study (CCSS). (Abstract 10072) M. Schapiro, R. J. Hayashi, W. Liu,
D. K. Srivastava, D. Jeffe, S. M. Perkins, G. T. Armstrong, L. L. Robison, M.
Stovall, W. M. Leisenring, K. R. Krull
Board 143
Adverse fat depots, marrow adiposity, and skeletal deficits in long-term
survivors of pediatric hematopoietic stem cell transplantation. (Abstract
10073) S. Mostoufi-Moab, J. Magland, E. Isaacoff, W. Sun, C. S. Rajapakse, B.
Zemel, F. Wehrli, K. Shekdar, J. Baker, J. Long, M. B. Leonard
Board 144
Temporal changes in treatment exposures in the Childhood Cancer Survivor
Study (CCSS). (Abstract 10074) A. Mertens, J. Whitton, J. P. Neglia, D. M.
Green, T. M. Gibson, M. Stovall, M. M. Hudson, L. L. Robison, G. T. Armstrong, Y.
Yasui, W. M. Leisenring
Board 145
Longitudinal smoking patterns in survivors of childhood cancer: A
Childhood Cancer Survivor Study (CCSS) update. (Abstract 10075) T. M.
Gibson, W. Liu, G. T. Armstrong, D. K. Srivastava, M. M. Hudson, W. M.
Leisenring, A. Mertens, R. Klesges, K. C. Oeffinger, P. C. Nathan, L. L. Robison
Board 146
The effect of sociodemographic factors and therapy on survival in pediatric
liver cancers: A SEER population study. (Abstract 10076) M. Xing, H. S. Kim
Board 147
Palonosetron vs ondansetron: Prevention of chemotherapy-induced nausea
and vomiting in pediatric patients in a multicycle study. (Abstract 10077) E.
Kabickova, A. Wachtel, E. Basharova, T. Spinelli, P. Nicolas, G. Kovacs
Board 148
Risk assessment in children presenting with fever and chemotherapyinduced neutropenia. (Abstract 10078) K. Schratz, M. Beauchemin, Z. Jin, A.
Lee, M. L. Sulis
Board 149a
A multicentric study of interval compressed multiagent chemotherapy and
metronomic chemotherapy for patients with Ewing sarcoma family of
tumors: The Latin American Pediatric Oncology Group trial. (Abstract
TPS10079) L. J. Gregianin, M. Scopinaro, A. Rose, E. Boldrini, S. Ferman, A. S.
Petrilli Sr., C. M. Costa, D. Kirst, G. Dufort, M. Villarroel, C. Salgado, M. A.
Almeida, M. Valero, M. Rizzatti, L. A. Castillo, L. Siqueira, D. Lustosa, M. Pizza, G.
Rey, A. Brunetto
SUNDAY
Board 136
167
Board 149b
Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with
interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory
neuroblastoma patients. (Abstract TPS10080) H. N. Lode, D. Valteau-Couanet,
A. Garaventa Sr., J. Gray, V. Castel, I. Yaniv, N. Siebert, C. Jensen, S. Endres, L.
Pill, C. Eger, D. Seidel, M. Juettner, S. Kietz, K. Ehlert, E. Janzek, H. Loibner, I.
Mueller, R. L. Ladenstein
Board 150a
A phase II study of pazopanib in children, adolescents, and young adults
with refractory solid tumors. (Abstract TPS10081) A. Lee, J. Glade Bender, B.
Weigel, E. Fox, A. C. Huff, H. Tada, S. M. Blaney, P. Langmuir
Board 150b
A randomised phase IIb trial of bevacizumab added to temozolomide ⴞ
irinotecan for children with refractory/relapsed neuroblastoma - BEACONNeuroblastoma, a European Innovative Therapies for Children with Cancer
(ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma
Group (SIOPEN) trial. (Abstract TPS10082) L. Moreno, J. Laidler, V. Moroz, C.
Owens, H. Rubie, P. Berlanga, A. Castellano, K. Nysom, R. L. Ladenstein, J.
Rossler, C. M. Zwaan, M. Elliott, G. Makin, D. Murphy, S. A. Burchill, N. Jerome,
R. F. Rousseau, P. Kearns, K. Wheatley, A. D. Pearson
Board 151a
Early detection of transformation of plexiform neurofibromas to malignant
peripheral nerve sheath tumors in neurofibromatosis type 1. (Abstract
TPS10083) S. Bhaumik, D. Stewart, A. Pemov, P. L. Choyke, E. Dombi, J. Glod, M.
Miettinen, J. Khan, S. M. Steinberg, A. Goodwin, A. Baldwin, B. C. Widemann
SUNDAY
Sarcoma
Location: S Hall A
Abstracts 10508 –10519 will be discussed during the Sarcoma Poster Discussion Session. See
page 194 for session information.
Board 152
The somatic mutational landscape in soft tissue sarcoma: Early results from
TCGA data. (Abstract 10508) A. S. Brohl, H. R. Shah, Y. Wang, A. Kasarskis,
R. G. Maki
Board 153
Next generation sequencing of synovial sarcomas. (Abstract 10509) M.
Vlenterie, M. H. Hillebrandt-Roeffen, U. E. Flucke, P. J. Groenen, B. B. Tops, W.
Van Der Graaf, Y. M. Versleijen-Jonkers
Board 154
Clinical application of prognostic gene expression signature in fusion
gene-negative rhabdomyosarcoma: A report from the Children’s Oncology
Group. (Abstract 10510) P. Hingorani, E. Missiaglia, J. Shipley, J. R. Anderson,
T. J. Triche, M. Delorenzi, J. M. Gastier-Foster, M. Wing, D. S. Hawkins, S. Skapek
Board 155
The who and what of imaging in sarcoma and correlation with survival.
(Abstract 10511) V. S. Koshkin, V. Bolejack, L. H. Schwartz, B. Zhao, R. Chugh,
R. L. Wahl, D. K. Reinke, L. J. Helman, S. Patel, S. Schuetze, L. H. Baker
Board 156
Event-free survival and overall survival in 2,253 patients with osteosarcoma
registered to EURAMOS-1. (Abstract 10512) S. Smeland, J. Whelan, S. S.
Bielack, N. Marina, G. Jovic, T. Butterfass-Bahloul, G. Calaminus, M. Eriksson, H.
Gelderblom, R. G. Gorlick, P. C. Hogendoorn, J. Hook, L. Kager, M. D. Krailo, T.
Kühne, R. Randall, K. Sundby Hall, L. A. Teot, M. R. Sydes, M. L. Bernstein,
EURAMOS Investigators
Board 157
Forty years of randomized trials in advanced/metastatic soft tissue sarcoma
(STS): Endpoint selection, surrogacy and quality of reporting. (Abstract
10513) A. Zer, R. M. Prince, E. Amir, A. R. Razak
Board 158
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in
combination with pazopanib in patients with advanced soft tissue sarcoma
(STS). (Abstract 10514) S. Attia, R. F. Riedel, S. I. Robinson, R. M. Conry, K.
Sankhala, B. K. Seon, D. Alvarez, B. J. Adams, C. P. Theuer, R. G. Maki
168
Board 159
A phase II study of tivozanib in patients with metastatic and non-resectable
soft tissue sarcomas. (Abstract 10515) M. Agulnik, M. M. Milhem, A.
Rademaker, C. Humphreys, S. E. Abbinanti, L. E. Nye, R. Cehic, A. Polish, C. R.
Vintilescu, T. McFarland, K. M. Skubitz, S. I. Robinson, S. H. Okuno, B. A. Van
Tine
Board 160
A phase I/II clinical trial of belinostat (PXD101) in combination with
doxorubicin in patients with soft tissue sarcomas (STS). (Abstract 10516) J.
Vitfell-Rasmussen, M. Lind-Hansen, A. Safwat, P. Rossen, P. Knoblauch, R. L.
Jones, I. R. Judson, A. Krarup-Hansen
Board 161
Detection of KIT mutants in circulating tumor DNA (ctDNA) and their
association with ponatinib anti-tumor activity in patients (pts) with advanced
gastrointestinal stromal tumors (GIST). (Abstract 10517) M. C. Heinrich, J.
Hodgson, M. von Mehren, G. D. Demetri, J. A. Fletcher, J. G. Sun, J. R. Pritchard,
S. Zhang, V. M. Rivera, S. George
Board 162
Plasma sequencing to detect a multitude of secondary KIT resistance
mutations in metastatic gastrointestinal stromal tumors (GIST). (Abstract
10518) S. Bauer, T. Herold, T. Mühlenberg, A. Reis, J. Falkenhorst, M. Backs, J.
Ketzer, F. Breitenbuecher, M. H. Schuler, S. Grunewald
Board 163
An NGS assay strategy with FFPE and cfDNA to determine primary and
secondary mutations across the initial diagnosis and subsequent
recurrence/progression of patients with localized, recurrent and metastatic
GIST. (Abstract 10519) N. Somasundaram, R. Lim, J. Chng, D. Ho, A. Gan, C. W.
Chua, M. Farid, S. B. Ng, I. B. Tan, R. H. Quek
Board 164
A phase II trial of sorafenib (SO) in advanced chordoma patients (pt).
(Abstract 10520) E. Amela, E. Bompas, A. Le Cesne, E. Tresch, A. Italiano, S.
Piperno-Neumann, O. Collard, D. Vansteene, J. Domont, E. Saada, N. Isambert, S.
Salas, C. Chevreau, F. Bertucci, S. C. Delaine, J. Blay, N. Penel
Board 165
Patient-reported outcome instruments meaningful and relevant for
tenosynovial giant cell tumor (TGCT): A qualitative study. (Abstract 10521) H.
Gelhorn, S. Tong, G. Maclaine, J. H. Healey, S. V. Bukata, V. L. Keedy, S. P.
Anthony, A. J. Wagner, D. D. Von Hoff, A. S. Singh, C. Becerra, J. Hanlon, W.
Lenderking, L. Murray, H. H. Hsu, P. S. Lin, W. D. Tap
Board 166
Pilot trial of vigil immunotherapy in Ewing’s sarcoma. (Abstract 10522) M.
Ghisoli, M. A. Barve, R. Schneider, R. G. Mennel, C. Lenarsky, G. Wallraven, P.
Kumar, D. Nemunaitis, A. Roth, N. N. Senzer, F. A. Fletcher, J. J. Nemunaitis
Board 167
Perioperative chemotherapy with cisplatin (CP) and doxorubicin (DOX) with
and without high-dose methotrexate (HDM) in adult osteosarcoma (AOT): Is
methotrexate warranted? (Abstract 10523) L. S. Rocha, M. V. Negrao, D. d.
Girardi, V. P. Camargo, L. B. Alban, P. M. Hoff, O. Feher
Board 168
Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish
Group for Research on Sarcoma (GEIS) Study. (Abstract 10524) J. Martin
Broto, A. Fernandez-Serra, J. Duran, S. Calabuig-Fariñas, A. Gutierrez, I. FelipeAbrio, D. Sanchez-Izquierdo, J. Martinez-Trufero, A. Casado Herraez, A. Poveda,
L. Rubio Martinez Sr., C. Balana, F. Losa, C. M. Valverde, J. Rubió, J. Cruz, L.
Gonzalez de Sande, C. Tous, R. Cubedo, J. A. Lopez-Guerrero
Board 169
Stem cell rescue from irradiation of multiple tumor sites combined with
high-dose chemotherapy, followed by reduced intensity conditioning and
allogeneic stem cell transplantation in patients with advanced pediatric
sarcomas: Preliminary results of the MetaEICESS 2007 protocol. (Abstract
10525) S. Burdach, U. Thiel, A. Wawer, I. Teichert von Luettichau, F. Blaeschke,
T. G. Grunewald, M. Steinborn, B. Roeper, M. Molls, C. Salat, T. Klingebiel, P.
Bader, E. Koscielniak, P. Lang, U. Dirksen, H. Jurgens, H. Kolb
Board 170
Prognostic factors analysis of extraskeletal osteosarcoma: Updated results
of an EMSOS study. (Abstract 10526) A. Longhi, A. Leithner, S. S. Bielack, D.
Biau, A. Krieg, F. M. Klenke, J. Casanova, C. Gerrand, S. Hecker-Nolting, G.
Bisogno, C. Ferrari, A. Righi, S. Ferrari
169
SUNDAY
SUNDAY
Board 171
High dose ifosfamide in metastatic high-grade osteosarcoma, after failure of
standard multimodal chemotherapy. (Abstract 10527) E. Palmerini, P. Picci, E.
Marchesi, E. L. Staals, M. Cesari, A. Longhi, A. Paioli, D. Vanel, A. Comandone,
D. M. Donati, S. Ferrari
Board 172
Sustained response of complex giant cell tumors with denosumab: Single
center 8-year experience. (Abstract 10528) N. S. Chawla, S. V. Bukata, K. K.
Sankhala, W. E. Mendanha, V. Narasimhan, L. Menendez, N. Bernthal, E. W.
Brien, V. S. Chua, S. P. Chawla
Board 173
Functional and clinical long-term outcome of Ewing sarcoma treatment.
(Abstract 10529) A. Ranft, C. Hoffmann, C. Winter, A. Warby, D. Rosenbaum, U.
Dirksen, H. Juergens
Board 174
Phase II trial of gemcitabine plus rapamycin as second line in advanced
osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.
(Abstract 10530) J. Martin Broto, A. Redondo, C. M. Valverde, M. Á. Vaz Salgado,
J. Mora, X. Garcia del Muro, M. Sancho Marquez, J. Martinez-Trufero, R. Diaz
Beveridge, A. Gutierrez, P. Blay, C. Tous, P. Luna Fra, A. Lopez-Pousa
Board 175
Clinical characteristics and treatment outcomes of clear cell
chondrosarcomas: MD Anderson Cancer Center Series. (Abstract 10531)
A. P. Conley, R. L. Satcher, W. Wang, A. J. Lazar, P. S. Fox, P. P. Lin, B. Moon,
J. E. Bird, D. M. Araujo, V. Ravi, N. Somaiah, S. Patel, R. S. Benjamin, V. O. Lewis
Board 176
Anti-tumor effects of dovitinib in patient-derived gastrointestinal stromal
tumor (GIST) xenograft models. (Abstract 10532) Y. K. Gebreyohannes, T. Van
Looy, A. Wozniak, J. Wellens, H. Li, J. Cornillie, U. Vanleeuw, L. Vreys, M. Squires,
A. Rodriguez, M. Debiec-Rychter, R. Sciot, P. Schoffski
Board 177
ReGISTry study of high risk GIST patients after complete resection: The
adjuvant therapy and pathological diagnosis in Japan. (Abstract 10533) T.
Nishida, Y. Kitagawa, Y. Kurokawa, Y. Komatsu, C. Ishioka, T. Doi, Y. Yamada, M.
Ozaka, H. Cho, T. Kanda, T. Sugiyama, A. Sawaki, Y. Kakeji, T. Hirai, S. Hato, H.
Baba, K. Shirao, S. Hirota, T. Kagimura
Board 178
Selective indications of surgery in esophageal gastrointestinal stromal
tumors: A retrospective study of the French Sarcoma Group (FSG). (Abstract
10534) F. Duffaud, P. Meeus, F. Bertucci, j. Delhorme, E. Stoeckle, N. Isambert, E.
Bompas, J. Gagniere, O. Bouche Sr., M. Toulmonde, S. Salas, J. Blay, S.
Bonvalot, French Sarcoma Group
Board 179
Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal
stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results
from a phase 2 study. (Abstract 10535) M. C. Heinrich, M. von Mehren, G. D.
Demetri, J. A. Fletcher, J. G. Sun, D. Kerstein, M. G. Conlan, S. George
Board 180
Clinicopathological impact of protein phosphatase 2, regulatory subunit A,
alpha mutations in gastrointestinal stromal tumors. (Abstract 10536) M. Ishii,
Y. Suehara, K. Akaike, K. Mukaihara, D. Kubota, T. Okubo, T. Takagi, T. Yao, K.
Kaneko, T. Saito
Board 181
Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal
tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year
interim analysis. (Abstract 10537) C. P. Raut, N. J. Espat, R. G. Maki, D. M.
Araujo, C. H. Keir, T. F. Williams, R. P. DeMatteo
Board 182
Treatment of advanced gastrointestinal stromal tumors (GIST): Are results of
second-line sunitinib therapy related to duration of response of first-line
imatinib? (Abstract 10538) D. Katz, S. Greenberg-Dotan, I. Feldhamer, H.
Bitterman, A. Hammerman
Board 183
Identification of therapy options for rare and resistant gastrointestinal
stromal tumors (GIST). (Abstract 10539) R. Feldman, S. K. Reddy, Z. Gatalica,
M. J. Pishvaian
Board 184
Does aggressive local treatment have an impact on survival in children with
metastatic rhabdomyosarcoma? (Abstract 10540) M. W. Ben Arush, V.
Minard-Colin, V. Mosseri, A. Desfachelles, C. Bergeron, N. Algret, S. Fassola, N.
170
Board 185
Combined sunitinib and IMRT for preoperative treatment of locally advanced
soft tissue sarcoma: Results of a phase I trial of the German Interdisciplinary
Sarcoma Group GISG 03. (Abstract 10541) J. Jakob, A. Simeonova, B. Kasper,
U. Ronellenfitsch, G. Rauch, F. K. Wenz, P. Hohenberger
Board 186
Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in
EORTC phase II trial 90101 “CREATE”. (Abstract 10542) P. Schoffski, A.
Wozniak, S. Stacchiotti, P. Rutkowski, M. Debiec-Rychter, R. Sciot, J. Blay, L.
Lindner, S. J. Strauss, D. A. Anthoney, M. G. Leahy, P. Reichardt, S. Marreaud, S.
Collette, J. Steuve, T. Raveloarivahy, S. Bauer
Board 187
High-risk soft tissue sarcoma of extremity and trunk wall: A retrospective
comparison of local control in patients treated with or without radiation
therapy at a single reference center. (Abstract 10543) M. Fiore, C. Sangalli, E.
Palassini, S. Radaelli, C. Colombo, C. Morosi, D. Callegaro, A. P. Fontana, P. G.
Casali, A. Gronchi
Board 188
Association of hematological toxicity (tox) and outcome to doxorubicin
(DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the
EORTC-Soft Tissue and Bone Sarcoma Group database. (Abstract 10544) S.
Sleijfer, E. Rizzo, S. Litière, R. H. Mathijssen, I. R. Judson, H. Gelderblom, A.
Italiano, W. Van Der Graaf, A. Gronchi
Board 189
Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact
on survival. (Abstract 10545) S. J. Harris, M. Maruzzo, K. Thway, O. Al-Muderis,
R. L. Jones, A. Miah, C. Benson, I. R. Judson
Board 190
Longer term cardiac safety of aldoxorubicin. (Abstract 10546) S. P. Chawla, K.
Sankhala, S. Wieland, D. J. Levitt
Board 191
Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma:
A meta-analysis. (Abstract 10547) M. Savina, S. Litière, N. Penel, V. Rondeau
Sr., T. Burzykowski, M. Toulmonde, A. Italiano, S. Mathoulin-Pélissier, C. A.
Bellera
Board 192
Cost-effectiveness analysis of preoperative versus postoperative
radiotherapy in resectable extremity soft tissue sarcoma. (Abstract 10548) M.
Qu, A. V. Louie, N. Wasif
Board 193
Epidemiology, treatment (tx) patterns and outcomes in Asian soft tissue
sarcoma (STS) patients: Results from the Soft Tissue Sarcoma in the Asia
Pacific Region (STAR) study. (Abstract 10549) R. H. Quek, M. Farid, E. Wang,
A. Asavamongkolkul, A. Leung, N. Prayogo, T. Punyaratabandhu, E. Yeoh, S.
Shantakumar, S. Manson, R. K. Ngan
Board 194
Targeted next generation sequencing in well-differentated/dedifferentiated
liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations.
(Abstract 10550) N. Somaiah, H. Beird, K. R. Shaw, W. Wang, A. P. Conley, V.
Ravi, K. E. Torres, D. Ingram, C. L. Roland, V. Subbiah, B. W. Feig, A. J. Lazar,
R. S. Benjamin, S. Patel, P. Hwu, A. Futreal, F. Meric-Bernstam, D. S. Hong
Board 195
A retrospective analysis of patients with soft tissue sarcoma treated longterm with trabectedin. (Abstract 10551) E. J. Davis, R. Chugh, S. Patel, S.
Schuetze
Board 196
Multimodal treatment of pulmonary artery sarcoma: A single center
experience. (Abstract 10552) S. Secondino, V. Grazioli, R. Dore, F. Valentino, M.
Pin, G. C. Callegari, M. Paulli, P. Pedrazzoli, A. D’Armini
Board 197
Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous
DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile.
(Abstract 10553) S. Stacchiotti, M. A. Pantaleo, T. Negri, A. Astolfi, E. Conca, G.
Dagrada, V. Indio, M. Urbini, P. Collini, C. Morosi, M. Fiore, C. Colombo, E.
Palassini, A. P. Dei Tos, B. Vincenzi, F. Grosso, U. Pastorino, A. Gronchi, S. Pilotti,
P. G. Casali
171
SUNDAY
Andre, E. Thebaud, N. Corradini, V. Bernier, H. Martelli, D. Ranchere-Vince, D.
Orbach
SUNDAY
Board 198
Natural history and outcome in a large series of primary
dermatofibrosarcoma protuberans (DFSP) treated at a reference institution.
(Abstract 10554) A. P. Fontana, C. Colombo, M. Fiore, S. Radaelli, S. Stacchiotti,
V. Colia, P. Collini, M. Barisella, G. Dagrada, S. Pilotti, P. G. Casali, A. Gronchi
Board 199
The lipogenic phenotype reprograms the epigenome in sarcomas. (Abstract
10555) W. A. Chow, M. Guan
Board 200
Primary high-grade myxofibrosarcoma/pleomorphic malignant fibrous
histiocytoma: Percent myxoid component to improve outcome prediction.
(Abstract 10556) A. Y. Lee, N. P. Agaram, L. Qin, M. F. Brennan, S. Singer
Board 201
Postoperative morbidity and mortality in a large series of primary
retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the
Transatlantic RPS Working Group. (Abstract 10557) D. C. Strauss, D.
Callegaro, S. Bonvalot, R. Miceli, C. J. Swallow, P. Hohenberger, F. van
Coevorden, R. L. Haas, P. Rutkowski, R. E. Pollock, M. Fiore, A. J. Hayes, M.
Fairweather, C. P. Raut, A. Gronchi
Board 202
Validation of the Royal Marsden Hospital (RMH) prognostic score in 100
patients with advanced sarcoma enrolled in early phase clinical trials at a
major cancer center. (Abstract 10558) M. Wagner, K. R. Hess, D. S. Hong, C.
Tang, A. Naing, S. Fu, F. Janku, S. A. Piha-Paul, R. Zinner, J. J. Wheler, A. M.
Tsimberidou, S. Patel, N. Somaiah, V. Ravi, R. S. Benjamin, F. Meric-Bernstam, V.
Subbiah
Board 203
The benefit of adjuvant radiotherapy in high-grade retroperitoneal sarcoma:
A SEER analysis. (Abstract 10559) J. E. Bates, A. Mazloom, S. Dhakal, L. S.
Constine
Board 204
A phase II study of temsirolimus and liposomal doxorubicin for patients with
recurrent and refractory bone and soft tissue sarcomas. (Abstract 10560)
C. F. Meyer, K. A. Thornton, M. M. Trucco, B. A. Wilky, U. Shafique, M. CarreraHaro, P. Shah, A. R. Chen, J. Powell, D. M. Loeb
Board 205
Imatinib mesylate (IM) activity in patients (pts) with locally advanced
tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).
(Abstract 10561) P. A. Cassier, R. G. Maki, A. J. Wagner, E. Bompas, H.
Gelderblom, J. R. Kroep, D. M. Thomas, A. Italiano, B. M. Seddon, W. Van Der
Graaf, J. Domont, J. Blay, S. Stacchiotti
Board 206
Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final
update after the closure of the named use program. (Abstract 10562) N. Hindi,
S. Pilotti, R. Maestro, A. P. Dei Tos, E. Palassini, C. Morosi, A. Messina, S.
Provenzano, T. Negri, M. Fiore, A. Gronchi, M. Brenca, P. G. Casali, S. Stacchiotti
Board 207
Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive
fibromatosis. (Abstract 10563) S. Kummar, K. T. Do, G. H. O’Sullivan Coyne, B.
Turkbey, P. S. Meltzer, E. Polley, Y. Horneffer, L. Juwara, R. Antony, P. L. Choyke,
S. A. Mitchell, L. J. Helman, A. Chen, J. H. Doroshow
Board 208
A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in
patients (pts) with advanced solid tumors. (Abstract 10564) A. J. Wagner, U.
Banerji, A. Mahipal, N. Somaiah, H. A. Hirsch, C. Fancourt, A. Levonas, R. Lam, A.
Meister, R. K. Kemp, C. Knox, S. Rose, D. S. Hong
Board 209
Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.
(Abstract 10565) C. Kim, E. Kim, J. Han, H. Chon, S. Heo, Y. Lee, Y. Cho, J. Suh,
K. Shin, J. Ahn, H. Chung, S. Y. Rha, S. Kim, H. Kim
Board 210
Time to secondary resistance (TTSR) after rechallenge with trabectedin (T) in
myxoid round cell liposarcoma (MRCLPS) patients. (Abstract 10566) R.
Sanfilippo, V. Colia, E. Fumagalli, R. Bertulli, C. Morosi, A. Messina, S. Pilotti, A. P.
Dei Tos, A. Gronchi, P. G. Casali
Board 211
Pazopanib for soft tissue sarcoma (STS) in the first- line setting with
denosumab. (Abstract 10567) H. Narahara, K. Yasuda, K. Morita, H. Matsumoto,
Y. Yasunaga, Y. Inui, S. Kawata, K. Takahashi, S. Teraoka
172
Board 212
A new simple low-cost multiplexed targeted sequencing assay to detect
recurrent fusion genes in sarcomas. (Abstract 10568) E. Angot, P. Ruminy, V.
Marchand, F. Blanchard, E. Colas, j. Picquenot, M. Cornic, C. Bastard, J. Sabourin,
F. Jardin
Board 213
A phase 1b study with selinexor, a first in class selective inhibitor of nuclear
export (SINE) in patients with advanced sarcomas: An efficacy analysis.
(Abstract 10569) M. M. Gounder, A. Zer, W. D. Tap, A. A. Gupta, M. Keohan,
M. A. Dickson, S. P. D’Angelo, P. Chi, L. R. Tanner, T. Konen, T. Rashal, D.
McCauley, J. Saint-Martin, R. Carlson, T. Marshall, S. Shacham, M. R. Mirza, M.
Kauffman, G. Schwartz, A. R. Razak
Board 214
Pattern of relapse in limb/girdle low-grade liposarcoma/atypical lipomatous
tumor (ALT) during guidelines-suggested follow up (FU). (Abstract 10570) R.
Piana, L. D’Ambrosio, E. Maldi, A. Boglione, D. Galizia, M. Boffano, E. Bellato, U.
Albertini, P. Bergnolo, P. Boccone, E. Palesandro, A. Linari, A. Comandone
Board 215
Primary chest wall soft tissue sarcomas: Predictors of survival following
surgical resection in a large population cohort. (Abstract 10571) S. Rehmani,
A. M. Al-Ayoubi, R. M. Flores, F. Y. Bhora
Board 216
Local control following resection of primary retroperitoneal sarcoma with
and without preoperative radiotherapy. (Abstract 10572) C. J. Swallow, A.
Cannell, B. Dickson, S. Burtenshaw, P. W. Chung, R. A. Gladdy, B. O’Sullivan,
C. N. Catton
Board 217
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with
advanced, unresectable, and/or metastatic sarcoma who have failed prior
therapies. (Abstract 10573) A. E. Hendifar, N. S. Chawla, K. K. Sankhala, X.
Zhang, D. V. Quon, V. S. Chua, L. Fernandez, W. E. Mendanha, S. P. Chawla
Board 218
Metastatic non-uterine leiomyosarcoma: Prognostic factors, overall survival,
and chemotherapy outcomes. (Abstract 10574) S. P. D’Angelo, A. N.
Shoushtari, J. Landa, D. Kuk, A. J. Sanchez, B. Lala, M. A. Dickson, M. M.
Gounder, M. Keohan, W. D. Tap
Board 219a
A randomized phase II/III study, comparing perioperative adriamycin plus
ifosfamide versus gemcitabine plus docetaxel for operable high grade soft
tissue sarcomas in extremity or trunk: JCOG1306. (Abstract TPS10575) K.
Tanaka, K. Kataoka, J. Mizusawa, T. Yonemoto, H. Morioka, H. Hiraga, H.
Chuuman, T. Ohno, A. Matsumine, S. Abe, K. Matuso, M. Takahashi, K. Hiraoka,
H. Fukuda, Y. Iwamoto
Board 219b
EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as
first line treatment in elderly patients with metastatic or advanced soft tissue
sarcoma of the Working Group Medical Oncology (AIO) and German
Interdisciplinary Sarcoma Group (GISG). (Abstract TPS10576) V. Gruenwald,
A. Kunitz, M. K. Schuler, H. Kopp, B. Kasper, L. Lindner, J. Chemnitz, A. Stein, P.
Schöffski, B. Steffen, S. Bauer, G. Egerer, M. Kneba, M. Crysandt, A. Koch
Board 220a
A study of the safety and efficacy of the combination of gemcitabine and
docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.
(Abstract TPS10577) S. P. Chawla, P. Schoffski, J. Blay, R. L. Jones, H.
Gelderblom, S. Attia, B. Chmielowski, B. A. Van Tine, J. C. Trent II, S. Patel, A. J.
Wagner, J. K. Viele, R. Chugh, A. Le Cesne, G. Tinoco, K. K. Sankhala, J. Falcone,
C. Schweizer, S. Weil, R. G. Maki
Board 220b
SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in
patients (Pts) with advanced sarcomas. (Abstract TPS10578) M. A. Burgess, J.
Crowley, D. K. Reinke, R. F. Riedel, S. George, S. Movva, B. A. Van Tine, L. E.
Davis, S. Schuetze, J. Hu, S. Attia, D. A. Priebat, D. R. Reed, S. P. D’Angelo, S. H.
Okuno, R. G. Maki, S. Patel, L. H. Baker, H. A. Tawbi
173
SUNDAY
Tumor Biology
Location: S Hall A
Abstracts 11010 –11021 will be discussed during the Tumor Biology Poster Discussion Session.
See page 187 for session information.
SUNDAY
Board 222
Next-generation sequencing to reveal somatic mutations that confer
sensitivity to everolimus. (Abstract 11010) S. Lim, H. Park, S. Kim, N. Kwon, J.
Lee, M. Ryu, J. Ahn, H. Kim, H. Chung, J. Kim, Y. Kang, B. Cho
Board 223
Next generation sequencing (NGS) to identify targetable recurring mutations
and exceptional responders in relapsed and high-risk childhood and
adolescent/young adult (AYA) malignancies. (Abstract 11011) B. Turpin, R.
Karns, M. Sarangdhar, B. D. Weiss, J. I. Geller, M. Absalon, M. M. O’Brien, R.
Nagarajan, C. L. Phillips, L. M. Chow, M. D. DeWire, D. Adams, K. C. Burns, T. R.
Hummel, M. Fouladi, A. M. Hammill, J. Mangino, J. G. Pressey, B. Aronow, J. P.
Perentesis
Board 224
Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone
marrow failure after radium-223. (Abstract 11012) E. Etchebehere, J. C. Araujo,
D. Milton, P. S. Fox, N. Swanston, H. A. Macapinlac, E. Rohren
Board 225
Imaging peritoneal metastasis of gastric cancer with PET/CT and the
radiotracer 18F-fluorothymidine (18F-FLT): Proof-of-concept study. (Abstract
11013) Y. Honma, T. Terauchi, U. Tateishi, D. Kano, K. Nagashima, N. T. Okita, A.
Takashima, S. Iwasa, K. Kato, T. Hamaguchi, Y. Shimada, N. Boku, Y. Yamada
Board 226
Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer
versus tumor mutational status. (Abstract 11014) M. Dunphy, J. J. Harding,
J. S. Lewis, I. K. Mellinghoff, A. M. Omuro, J. Hsieh, H. Zhang, P. Zanzonico, S.
Venneti, S. Carlin, A. Younes, J. F. Gerecitano, S. K. Lyashchenko, L. Harris, A.
Lashley, H. Kung, C. B. Thompson, D. P. Kelsen
Board 227
Subjects’ views on compensation for donating biospecimens. (Abstract
11015) R. D. Pentz, T. R. Deal, T. White, M. Dixon, K. A. Hendershot
Board 228
Progesterone receptor isoform ratio to define the molecular signature of
luminal breast cancers and their antiprogestin responsiveness. (Abstract
11016) M. May, P. Rojas, G. Sequeira, A. Elia, P. Martinez Vazquez, P. Gonzalez,
M. C. Abba, A. Molinolo, S. M. Hewitt, C. M. Perou, H. Gass, C. Lanari
Board 229
A head-to-head comparison of Mammaprint and Oncotype Dx: A McGill
University Health Center Experience. (Abstract 11017) R. Maroun, R. Saleh, J.
Asselah, A. Omeroglu, A. Gulbeyaz, S. H. Meterissian, N. Bouganim
Board 230
Circulating tumor cell (CTC) EMT and stem cell biomarker expression predict
overall survival (OS) in mCRC by a combined immunomagnetic qRT-PCR
approach. (Abstract 11018) Y. Ning, W. Zhang, D. L. Hanna, A. Mendez, D.
Yang, Y. Sunakawa, S. Stremitzer, S. Matsusaka, S. Okazaki, A. Parekh, R. E.
El-Khoueiry, B. Flores, S. Hauch, A. Barzi, A. B. El-Khoueiry, H. Lenz
Board 231
Prospective study comparing outcomes in patients with advanced
malignancies on molecular alteration-matched versus non-matched therapy.
(Abstract 11019) J. J. Wheler, R. Yelensky, B. Stephen, D. S. Hong, R. Zinner, V.
Subbiah, S. Fu, D. D. Karp, G. S. Falchook, A. Naing, A. M. Tsimberidou, S. A.
Piha-Paul, F. Janku, Y. Li, J. Lee, V. A. Miller, F. Meric-Bernstam, R. Kurzrock
Board 232
Comprehensive genomic profiling of sarcomas from 267 adolescents and
young adults to reveal a spectrum of targetable genomic alterations.
(Abstract 11020) D. Morosini, J. Chmielecki, M. Goldberg, J. S. Ross, P. J.
Stephens, V. A. Miller, L. E. Davis
Board 233
Comparison of tumor-infiltrating lymphocytes between primary and
metastatic tumors in breast cancer patients. (Abstract 11021) R. Ogiya, N.
Kumaki, G. Bianchini, T. Iwamoto, N. Hayashi, T. Tanaka, N. Niikura, Y. Tokuda
174
Board 234
Complications following immediate breast reconstruction and influence on
breast cancer recurrence rates. (Abstract 11022) S. M. Beecher, D. P. O’leary,
C. Malone, R. McLaughlin, K. Sweeney, A. Hussey, M. J. Kerin
Board 235
Inhibition of AKT3 to increase migration and metastasis by upregulation of
S100A4 protein expression. (Abstract 11023) F. Ewald, A. Grottke, T. Lange, U.
Schumacher, B. Nashan, M. Juecker
Board 236
Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in
patients with gastrointestinal (GI) and genitourinary (GU) malignancies.
(Abstract 11024) T. Zhang, R. Boominathan, B. Foulk, M. C. Connelly, C. Rao, G.
Kemeny, J. H. Strickler, J. L. Abbruzzese, M. R. Harrison, D. J. George, H. Hurwitz,
M. A. Garcia-Blanco, A. J. Armstrong
Board 237
Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in
resected pancreas cancer. (Abstract 11025) J. S. Wang, M. Sausen, S. ParpartLi, D. M. Murphy, V. E. Velculescu, L. D. Wood, S. Solt-Linville, E. Sugar, B.
Bartlett, C. Blair, T. Dauses, E. M. Jaffee, R. H. Hruban, D. Laheru, L. A. Diaz Jr.
Board 238
Emergence of KRAS mutation in detection of circulating tumor DNA during
treatments for metastatic gastrointestinal cancer patients. (Abstract 11026)
Y. Takayama, K. Suzuki, T. Daito, K. Ichida, T. Fukui, Y. Muto, N. Kakizawa, H.
Imoto, Y. Taniyama, Y. Kaneda, H. Tanaka, F. Watanabe, T. Kato, F. Hasegawa,
M. Saito, S. Tsujinaka, Y. Miyakura, H. Noda, F. Konishi, T. Rikiyama
Board 239
Subclassification of prostate cancer circulating tumor cells (CTCs) by
nuclear size reveals very-small nuclear CTCs in patients with visceral
metastases. (Abstract 11027) Y. Lu, J. Chen, H. Ho, J. Lichterman, L. W. Chung,
K. Li, Z. Ke, H. Tseng, E. M. Posadas
Board 240
Molecular profiling of circulating tumor cells in non-metastatic breast cancer.
(Abstract 11028) V. Forte, W. Zhu, D. Barrak, A. Ring, V. Punj, D. Tripathy, M. Yu,
A. Raghavendra, G. Yang, J. E. Lang
Board 241
Applying a mitotic index to circulating tumor cells and its prognostic
significance: A cytological approach to patient stratification. (Abstract
11029) D. L. Adams, S. S. Martin, S. Chumsri, M. Charpentier, R. K. Alpaugh, M.
Cristofanilli, C. Tang, C. C. Haudenschild
Board 242
Exploring the intra-patient PIK3CA mutational heterogeneity of circulating
tumour cells by massive parallel sequencing in patients with metastatic
hormone receptor-positive breast cancer. (Abstract 11030) B. De Laere, D. J.
Peeters, R. Salgado, P. B. Vermeulen, P. A. van Dam, S. J. Van Laere, L. Y. Dirix
Board 243
Vemurafenib to eliminate BRAF-mutated circulating epithelial tumor cells
(CETCs) from blood of patients with malignant melanoma. (Abstract 11031)
D. Zimon, M. Pizon, E. Stein, U. A. Pachmann, K. Pachmann
Board 244
Folate receptor-positive circulating tumor cell detected by LT-PCR based
method as a diagnostic biomarker for non-small cell lung cancer. (Abstract
11032) X. Chen, F. Zhou, X. Li, G. Yang, L. Zhang, S. Ren, C. Zhao, Q. Deng, W.
Li, G. Gao, A. Li, C. Zhou
Board 245
ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational
status in colorectal cancer patient: Preliminary data from liquid biopsy.
(Abstract 11033) M. Di Salvatore, C. Paolillo, A. Orlandi, M. Rodriquenz, E. Rossi,
M. Basso, A. Strippoli, F. Aroldi, C. Bagalà, E. D. Capoluongo, C. Pozzo, A.
Cassano, C. Barone
Board 246
EpCAM-independent isolation of EMT- circulating tumor cells in patients with
primary breast cancer who receive primary systemic therapy. (Abstract
11034) F. Le Du, T. Fujii, D. W. Davis, W. Wu, S. Jackson, M. Chavez-Mac Gregor,
C. H. Barcenas, J. L. Murray, V. Valero, D. Tripathy, J. M. Reuben, N. T. Ueno
Board 247
Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs)
associated to phenotypic CTC heterogeneity in metastatic castrate resistant
prostate cancer (mCRPC). (Abstract 11035) M. Landers, S. Greene, N. A.
Schreiber, A. Rodriguez, R. M. Bambury, D. C. Danila, D. E. Rathkopf, M. Fleisher,
J. Louw, A. Jendrisak, D. Marrinucci, R. V. Dittamore, H. I. Scher
175
SUNDAY
SUNDAY
Board 248
Centrosome amplification and prognosis in breast cancer. (Abstract 11036)
R. A. Denu, M. E. Burkard
Board 249
SOD2 rs4880 CT/CC genotype to predict poor survival for Chinese gastric
cancer patients received platinum and fluorouracil based adjuvant
chemotherapy. (Abstract 11037) Z. Xu, Y. Chen, N. Lee, M. Wang, J. Chen
Board 250
Clinical impact of expanded BRAF mutational status on the outcome for
metastatic colorectal cancer patients with anti-EGFR antibody: An analysis
of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal
Antibodies by Comprehensive Cancer Genomics). (Abstract 11038) S. Yuki, T.
Yoshino, K. Tsuchihara, E. Shinozaki, K. Muro, T. Nishina, K. Yamaguchi, K.
Akagi, K. Yamazaki, T. Yamanaka, S. Nomura, S. Fujii, H. Esumi, Y. Abe, A. Ohtsu
Board 251
TLR6 polymorphism associated with overall survival in metastatic colorectal
cancer (mCRC) patients treated with FOLFIRI/bevacizumab enrolled in FIRE3.
(Abstract 11039) S. Okazaki, S. Stintzing, V. Heinemann, S. Cao, W. Zhang, D.
Yang, Y. Ning, Y. Sunakawa, S. Stremitzer, S. Matsusaka, R. Elkhoueiry, A.
Mendez, A. Parekh, H. Lenz
Board 253
Stratification markers for the risk of recurrence after curative resection of
stage II or III gastric cancer and potential clinical applications. (Abstract
11040) T. Oshima, K. Sakamaki, Y. Miyagi, T. Yoshikawa, M. Shiozawa, H. Cho, Y.
Rino, C. Kunisaki, A. Tsuburaya, T. Imada, M. Masuda
Board 254
Effect of mutant TP53 genotypes on the outcome of breast cancer (BC)
patients in different clinical tumor subtypes. (Abstract 11041) G. Fountzilas,
M. A. Dimopoulos, G. Kouvatseas, E. Timotheadou, G. E. Pentheroudakis, H.
Gogas, D. G. Pectasides, C. Christodoulou, E. Charalambous, A. Lyberopoulou, H.
Linardou, C. Papandreou, A. Psyrri, G. Aravantinos, C. Markopoulos, V. Venizelos,
I. Efstratiou, K. T. Kalogeras, S. Lakis, V. Kotoula
Board 255
PI3K/PTEN/Akt/mTOR pathway aberrations and co-incidence of hormone
receptors and HER2 in 19,784 diverse solid tumors. (Abstract 11042) S. Z.
Millis, S. Ikeda, D. Arguello, R. Feldman, R. T. Maney, J. Xiu, S. K. Reddy, R.
Kurzrock
Board 256
piRNA-651 as a prognostic marker in surgically resected non-small-cell lung
cancer. (Abstract 11043) N. Vinolas, F. Aya, A. Navarro, R. M. Marrades, A.
Cordeiro, A. Fernandez, N. Chic, J. M. Gimferrer, J. Ramirez, L. Molins, M. Monzo
Board 257
Does age influence the intrinsic biology of breast cancer? (Abstract 11044) T.
Osako, S. McKinney, D. Yap, G. Turashvili, S. Aparicio
Board 258
Identification of novel prognostic markers of glioblastoma using
computational strategies on four genomic datasets. (Abstract 11045) H.
Itakura, O. Gevaert
Board 259
Assessment of circulating free DNA concentration as a prognostic and
predictive biomarker in a large cohort of non-small cell lung cancer treated
by platinum-based chemotherapy. (Abstract 11046) C. Tissot, A. Toffart, S.
Villar, P. J. Souquet, P. Merle, D. Moro-Sibilot, M. Pérol, J. Zavadil, C. Brambilla,
M. Olivier, S. Couraud
Board 260
APC mutations in myeloid malignancies: Incidence and impact on
leukemogenesis. (Abstract 11047) A. Nazha, B. Przychodzen, H. Makishima, M.
Narkhede, M. E. Kalaycio, D. J. Seastone, H. Carraway, A. T. Gerds, S.
Mukherjee, A. S. Advani, J. Carew, M. A. Sekeres, J. P. Maciejewski
Board 261
Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from
patients with BRAF V600E-mutant advanced cancers. (Abstract 11048) F.
Janku, C. T. Vibat, G. S. Falchook, H. J. Huang, D. S. Hong, S. A. Piha-Paul, V.
Subbiah, N. M. Ramzanali, S. Hancock, A. Naing, D. D. Karp, G. Nitti, G. Cabrilo,
R. Luthra, S. P. Patel, M. J. Overman, S. Kopetz, M. G. Erlander, V. Melnikova, F.
Meric-Bernstam
Board 262
Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC)
in HRⴙ/HER2- early breast cancer (EBC) patients. (Abstract 11049) B.
Jimenez Rodriguez, A. Lavado Fernandez, N. Ribelles, P. Sanchez-Rovira, L.
176
Board 263
Evaluation of invasive breast cancer using a 12-chemokine gene expression
score (CS): Correlation with clinical outcomes. (Abstract 11050) S.
Prabhakaran, V. T. Rizk, W. J. Fulp, A. E. Berglund, J. J. Mule’, H. H. Soliman
Board 264
Prognostic significance of stromal versus intratumoral infiltrating CD8ⴙ
lymphocytes in resected non-small cell lung cancer. (Abstract 11051) M.
Ameratunga, K. Asadi, M. Walkiewicz, C. Murone, P. Mitchell, T. John
Board 265
Analysis of the prognostic value of the tumor immunologic profile in
resectable NSCLC. (Abstract 11052) M. Usó, E. Jantus-Lewintre, R. Sirera, S.
Calabuig-Fariñas, A. Blasco, R. Guijarro, E. Pastor, C. Camps
Board 266
Wild type VHL clear cell renal cell carcinomas: A distinct morphological and
clinical entity with PD-L1 expression. (Abstract 11053) L. Crouzet, A. Brunot, J.
Dagher, A. Pladys, J. Edeline, B. Laguerre, P. Kerbrat, G. Verhoest, K. Bensalah,
P. Bellaud, R. Viel, F. Jouan, N. Rioux-Leclercq, S. Kammerer-Jacquet
Board 267
Immune response triggered by a novel molecular crosstalk of major
hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways.
(Abstract 11054) S. Graver, S. Stremitzer, Y. Sunakawa, W. Edelmann, M. Kockx,
M. Schartl, S. J. Scherer, H. Lenz, M. Mazzone
Board 268
Detection of rare somatic mutational profiles in metastatic colorectal cancer
(mCRC) during routine RAS sequencing using next generation sequencing
(NGS). (Abstract 11055) J. Merlin, M. Husson, M. Rouyer, A. Leroux, A. Harle
Board 269
[18F]FMAU for PET imaging in breast cancer patients. (Abstract 11056) P.
Conti, K. Chen, D. Tripathy, H. Jadvar
Board 270
Clinical impact of high-throughput sequencing in patients with advanced
cancer: Lessons learned from the Michigan Oncology Sequencing Center.
(Abstract 11057) E. F. Cobain, D. R. Robinson, Y. Wu, F. P. Worden, D. C. Smith,
S. Schuetze, R. Chugh, N. Ramnath, A. F. Schott, D. F. Hayes, A. M. Chinnaiyan,
M. Talpaz
Board 271
Allowance of tumor-educated platelets for multiclass liquid biopsy-based
diagnosis of cancer. (Abstract 11058) M. Best, N. Sol, I. Kooi, J. Nilsson, B.
Westerman, B. Ylstra, J. Dorsman, E. F. Smit, H. M. Verheul, J. C. Reijneveld,
B. A. Tannous, P. Wesseling, T. Wurdinger
Board 272
Improvement in imaging of metastatic breast cancer (BC) with a novel
pretargeted immuno-PET targeting CEA: First clinical results. (Abstract
11059) C. Rousseau, A. Rauscher, A. Faivre-Chauvet, T. Carlier, L. Ferrer, D. M.
Goldenberg, R. M. Sharkey, J. Barbet, F. Kraeber-Bodere, M. Campone
Board 273
Predictive value of coexisting KRAS and TP53 mutations on response to
chemotherapy in non-small cell lung cancer (NSCLC). (Abstract 11060) P.
Tomasini, K. Jao, S. Kamel-Reid, T. Stockley, M. S. Tsao, G. Liu, N. B. Leighl, R.
Feld, P. A. Bradbury, M. Pintilie, C. Mascaux, F. A. Shepherd
Board 274
Detection of low abundant somatic mutations in circulating exosomal RNA
and cfDNA with next-generation sequencing. (Abstract 11061) V. J. O’Neill, D.
Enderle, J. J. Wheler, T. Koestler, C. Berking, J. Skog, M. Noerholm, K. Flaherty, F.
Janku
Board 275
Assessing HER2 testing quality in breast cancer (BC): Variables that
influence HER2-positivity from a large, multicenter, observational study in
Germany. (Abstract 11062) J. Ruschoff, A. Lebeau, H. H. Kreipe, H. Sinn, C. D.
Gerharz, W. Koch, J. Ammann, M. Untch
Board 276
Towards rapid and cost-effective point-of-care detection of TMPRSS2:ERG
fusion transcripts in urine via a novel methodology. (Abstract 11063) E. J.
Wee, K. M. Koo, P. N. Mainwaring, M. Trau
Board 277
Preliminary direct evidence of a dose-response relationship for [Y-90]microsphere selective internal radionuclide therapy (SIRT) in hepatic
177
SUNDAY
Vicioso, M. Alvarez, V. de Luque, C. Ramirez Tortosa, W. Buckingham, C.
Schaper, A. Jeiranian, N. Dowidar, S. Ferree, E. Villar, I. Zarcos, A. SanchezMuñoz, C. Gonzalez-Hermoso, C. Llacer Perez, A. Prat, E. Alba
malignancy. (Abstract 11064) D. L. Bailey, K. P. Willowson, E. J. Bernard, D.
Chan, N. Pavlakis, S. J. Clarke
SUNDAY
Board 278
Development of a PD-L1 immunohistochemistry (IHC) assay for use as a
companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung
cancer (NSCLC). (Abstract 11065) M. Dolled-Filhart, C. M. Roach, G. Toland,
J. Musser, G. M. Lubiniecki, G. Ponto, K. Emancipator
Board 279
[18F]AA-7: PET imaging in patients with suspected glioma. (Abstract 11066)
S. Nozaki, T. Oshita, Y. Nakatani, Y. Sasano, K. Yamamoto, W. Hume, Y. Wada,
A. Ishii, M. Tanaka, S. Shiomi, N. Tsuyuguchi, K. Kodama, Y. Watanabe
Board 281
Non-invasive determination of HER2-expression in metastatic breast cancer
by using 68Ga-ABY025 PET/CT. (Abstract 11067) H. Lindman, A. Wennborg, I.
Velikyan, J. Feldwisch, V. Tolmachev, D. Sandberg, H. Olofsson, M. Sandstrom,
M. Lubberink, J. Carlsson, J. Sorensen
Board 282
A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating
tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with
erlotinib. (Abstract 11068) M. Yanagita, C. Paweletz, A. O’Connell, D. M.
Jackman, Y. Kuang, G. R. Oxnard, P. A. Janne
Board 283
Contrast-enhanced spectral mammography (CESM) compared with breast
MRI for breast cancer detection. (Abstract 11069) L. Liao, L. Li, P. Germaine, E.
Tinney
Board 285
Identification of novel and potentially targetable receptor tyrosine kinase
alterations in colorectal carcinoma using a 341 gene hybrid capture-based
next-generation sequencing assay. (Abstract 11071) J. F. Hechtman, M. E.
Arcila, D. T. Cheng, D. B. Solit, R. D. Yaeger, D. M. Hyman, M. F. Berger, J. Shia,
E. Vakiani, A. Zehir, M. Ladanyi
Board 286
Analysis of cell-free circulating tumor DNA in patients with glioblastoma and
other primary brain tumors. (Abstract 11072) D. E. Piccioni, R. B. Lanman, R. J.
Nagy, A. Talasaz, S. C. Pingle, S. Kesari
Board 287
Raise and decline of KRAS mutant clones in colorectal cancers (CRCs)
treated with multiple rounds of anti-EGFR antibodies. (Abstract 11073) G.
Siravegna, B. Mussolin, M. Buscarino, G. Corti, G. Crisafulli, A. Ponzetti, C.
Cremolini, S. Lamba, A. Avallone, G. Rospo, S. Veronese, A. Budillon, C.
Montagut, P. Racca, R. B. Corcoran, F. Di Nicolantonio, F. Loupakis, S. Siena, A.
Sartore-Bianchi, A. Bardelli
Board 288
The Prospective Epidemiologic Risk Factor (PERF I) Study: A serum
biomarker reflecting collagen type I degradation as an early detection tool for
cancer. (Abstract 11074) C. L. Bager, S. N. Kehlet, N. Willumsen, A. Bay-Jensen,
J. Neergaard, K. Dragsbaek, D. J. Leeming, H. B. Hansen, C. Christiansen, M. A.
Karsdal
Board 289
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor
LY3023414 (LY) in patients (pts) with advanced cancer. (Abstract 11075) K. N.
Moore, A. M. Varghese, D. M. Hyman, S. Callies, J. Lin, V. Wacheck, S. Pant, T. M.
Bauer, J. C. Bendell
Board 290
Lung cancer patients with HER2 mutations treated with chemotherapy and
HER2 targeted drugs: Results form the EUHER2 cohort study. (Abstract
11076) J. Mazières, F. Barlesi, T. Filleron, B. Besse, I. Monnet, M. Beau-Faller, S.
Peters, E. Dansin, M. Frueh, M. Pless, N. Karachaliou, M. Wislez, P. Fournel, V.
Westeel, F. Cappuzzo, A. B. Cortot, D. Moro-Sibilot, J. Milia, O. Gautschi
Board 291
Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver
oncogene and a novel therapeutic target in non-small cell lung cancer
(NSCLC). (Abstract 11077) Y. Elamin, S. Toomey, A. Carr, K. Gately, S. Rafee,
W. Grogan, P. G. Morris, O. S. Breathnach, J. Crown, K. O’Byrne, B. Hennessy
Board 292
Identifying driver mutations in squamous cell lung cancer (SCC): The Lung
Cancer Genomics Ireland (LCGI) study. (Abstract 11078) S. Rafee, S. Toomey,
Y. Elamin, A. Carr, K. Gately, S. Finn, S. Nicholson, S. Cuffe, J. Crown, P. G.
178
Board 293
The anti-proliferative effects of RF EMF amplitude-modulated at tumor
specific frequencies and mediation by calcium. (Abstract 11079) H. Jimenez,
J. W. Zimmerman, R. D’Agostino Jr., X. Yi, I. Brezovich, M. Wang, M. J. Pennison,
D. Chen, N. Kuster, F. Costa, A. Barbault, C. F. Blackman, B. Pasche
Board 294
TBCRC-010: Phase I/II study of dasatinib in combination with zoledronic acid
(ZA) for the treatment of breast cancer bone metastasis (MBC-bone).
(Abstract 11080) Z. I. Mitri, R. Nanda, K. L. Blackwell, C. Costelloe, I. Hood, A. M.
Brewster, N. K. Ibrahim, K. H. Koenig, G. N. Hortobagyi, C. H. Van Poznak, M. F.
Rimawi, S. L. Moulder
Board 295
Prognostic significance of ␤2 adrenergic receptor expression in the patients
with non-small cell lung cancer. (Abstract 11081) T. Yazawa, K. Kaira, A.
Shimizu, T. Nagashima, Y. Ohtaki, K. Obayashi, T. Asao, T. Oyama, I. Takeyoshi,
K. Shimizu
Board 296
Mutant HRAS as novel target for MEK and mTOR inhibitors. (Abstract 11082)
M. Kiessling, A. Curioni Fontecedro, P. Samaras, M. Scharl, G. Rogler
Board 297
Stereotactic ablative radiotherapy (SABR) as re-irradiation for an isolated
infield lymph node recurrence. (Abstract 11083) N. Bhatt, N. E. Dunlap, X. Wu,
S. Rai, A. E. Dragun
Board 298
Germline variants in cancer risk genes detected by NGS-based
comprehensive tumor genomic profiling (CGP). (Abstract 11084) M. J. Hall,
M. B. Daly, E. A. Ross, J. Boyd, E. M. Sanford, J. Sun, P. Stephens, D. Liss, S.
Chen, V. A. Miller, R. Yelensky, V. N. Giri
Board 299
Higher CD3 cell counts in apheresis collection in relation to superior survival
in patients with multiple myeloma. (Abstract 11085) S. Kim, M. Gertz, A.
Dispenzieri, M. Lacy, F. Buadi, S. R. Hayman, D. Dingli, P. Kapoor, J. Winters,
D. A. Gastineau, W. J. Hogan, L. F. Porrata, S. Kumar
Board 300
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with
advanced solid tumors. (Abstract 11086) K. R. Spencer, J. M. Mehnert, A. R.
Tan, R. A. Moss, K. Levinson, M. N. Stein, L. Huzzy, M. P. Kane, D. Gibbon, J. J.
Wright, J. Aisner, R. S. DiPaola, S. Chen, Y. Wen, J. Goydos
Board 301
Identification and functional characterization of a long non-coding RNA
driving hormone-independent prostate cancer progression. (Abstract 11087)
F. Crea, A. Parolia, H. Xue, P. Frumento, Y. Wang, A. Haegert, K. N. Chi, A.
Zoubeidi, C. Collins
Board 302
Characterization of LASEP3 as a serological and prognostic biomarker and a
therapeutic target for lung cancer. (Abstract 11088) A. Takano, Y. Nakamura,
Y. Daigo
Board 303
A prospective validation of plasma ddPCR for rapid EGFR and KRAS
genotyping of advanced NSCLC patients (pts). (Abstract 11089) A. G. Sacher,
C. Paweletz, R. Alden, A. O’Connell, S. L. Mach, P. A. Janne, G. R. Oxnard
Board 304
Ocular toxicity with MEK inhibitors in phase I trials: A single centre
experience across six clinical trials. (Abstract 11090) V. Michalarea, M. de
Miguel Luken, N. Diamantis, A. Garg, L. Maubon, T. A. Yap, L. R. Molife, J. S. De
Bono, P. Ursell, U. Banerji
Board 305
Investigation of non-V600 BRAF mutations commonly found in NSCLC for
their sensitivity to dabrafenib or trametinib. (Abstract 11091) A. Noeparast, G.
Verschelden, I. Umelo, S. De Brakeleer, L. Decoster, E. Teugels, J. De Greve
Board 306
A functional kinome screen to identify pathways of anthracycline resistance
in patient-derived breast cancer cells. (Abstract 11092) H. Richards, O.
Nikolova, K. Gurley, C. Grandori, K. Christopher, V. K. Gadi
Board 307
Genomics, transcriptomics, and proteomics in the clinical setting:
Integrating whole genome and RNA sequencing with quantitative proteomics
to better inform clinical treatment selection. (Abstract 11093) S. Rabizadeh,
179
SUNDAY
Morris, W. Grogan, O. S. Breathnach, E. Kay, A. O’Grady, B. Hennessy, K.
O’Byrne
S. C. Benz, J. Burrows, T. A. Hembrough, J. Z. Sanborn, C. J. Vaske, P. SoonShiong
SUNDAY
Board 308
Measurement of soluble programmed death-ligand 1 (soluble PD-L1) to
predict survival in biliary tract cancer patients treated with chemotherapy.
(Abstract 11094) H. Ha, A. Nam, J. Bang, Y. Choi, D. Oh, T. Kim, K. Lee, S. Han,
S. Im, Y. Bang
Board 309
Correlation of cancer-associated macrophage-like cells with systemic
therapy and pathological stage in numerous malignancies. (Abstract 11095)
D. L. Adams, R. C. Bergan, S. S. Martin, S. Chumsri, M. Charpentier, R. G.
Lapidus, R. K. Alpaugh, M. Cristofanilli, S. Tsai, C. Tang, M. J. Edelman
Board 310
Effect of the timing of sunitinib administration on the predictive value of
biomarkers in renal cell cancer (mRCC). (Abstract 11096) J. M. Ebos, M.
Mastri, J. M. Hudson, C. R. Lee, A. Tracz, K. Attwood, P. N. Burns, R. S. Kerbel,
G. A. Bjarnason
Board 311
Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in
phase II clinical trials. (Abstract 11097) M. C. Schwaederle, M. M. Zhao, J. Lee,
A. Eggermont, R. L. Schilsky, J. Mendelsohn, V. Lazar, R. Kurzrock
Board 312
Identification of subtypes of triple negative breast cancer (TNBC) that are
sensitive to CDK4/6 inhibition. (Abstract 11098) U. Asghar, M. T. HerreraAbreu, R. Cutts, I. Babina, A. Pearson, N. C. Turner
Board 313
Squamousness: Next-generation sequencing to reveal shared molecular
features across squamous tumor types. (Abstract 11099) M. C. Schwaederle,
S. K. Elkin, B. N. Tomson, J. Carter, R. Kurzrock
Board 314
Association of paclitaxel-induced sensory peripheral neuropathy with the
ABCB1 genetic variant and age. (Abstract 11100) C. Shimizu, Y. Tanabe, A.
Hamada, M. Yunokawa, T. Takano, S. Koganemaru, O. Yukinori, N. Tamura, Y.
Fujiwara, K. Tamura
Board 315
Exosomes isolation and characterization in non small cell lung carcinoma
patients: Proof of concept study. (Abstract 11101) C. D. Rolfo, M.
Giallombardo, M. Castiglia, J. Jorge Chacartegui, M. Provencio, R. Alessandro, A.
Carreca, P. Roca, J. Oliver, I. Bover, J. P. Van Meerbeeck, A. Russo, M. Peeters,
P. Pauwels
Board 316
Impact of BMI on survival and toxicity in early breast cancer: An exploratory
analysis of prospective randomized phase III study N-SAS BC02 and 03.
(Abstract 11102) Y. Naito, Y. Ohashi, I. Yokota, T. Watanabe, H. Iwata, S.
Ohsumi, S. Ohno, Y. Hozumi, S. Yamamoto, M. Takahashi, T. Aihara, H. Mukai
Board 317
Precision oncology: the UC San Diego Moores Cancer Center PREDICT
experience. (Abstract 11103) B. A. Parker, M. C. Schwaederle, R. B. Schwab,
G. A. Daniels, D. E. Piccioni, T. L. Helsten, L. Bazhenova, P. T. Fanta, S. M.
Lippman, R. Kurzrock
Board 319
Pharmacodynamic (PD) assessment using FLT-PET/CT imaging in patients
treated with an interrupted high-dose axitinib schedule. (Abstract 11105) L.
Cavalcante, M. Scarpelli, L. Carmichael, J. Heideman, S. Perlman, R. Jeraj, G. Liu,
J. Y. Bruce
Board 320
The long term outcome of clinical trial-based treatment comparing standard
treatment for metastatic breast cancer. (Abstract 11106) G. Kim, J. Sohn, S.
Park, H. Park, S. Kim
Board 321
Theranostic biomarkers involved in immunomodulation and the PI3KCA
signal transduction pathway in HPV-induced cervical, oropharyngeal, and
anal carcinoma. (Abstract 11107) N. Hashemi Sadraei, R. Feldman, Z. Gatalica,
S. K. Reddy, P. M. Boland, K. S. Tewari
Board 322
Drug efflux pump expression in 50,000 molecularly-profiled cancer patients.
(Abstract 11108) R. Feldman, B. L. Abbott, S. K. Reddy, M. Castro
Board 323
Randomized phase II trial comparing molecularly targeted therapy based on
tumor molecular profiling versus conventional therapy in patients with
180
refractory cancer: Results of the SHIVA trial. (Abstract 11113) C. Le Tourneau,
J. Delord, A. Goncalves, C. Gavoille, C. Dubot, N. Isambert, M. Campone, O.
Tredan, C. Mauborgne, S. Armanet, N. Servant, I. Bieche, V. Bernard, D. Gentien,
P. Jézéquel, V. Attignon, S. Boyault, A. Vincent-Salomon, M. Kamal, X. Paoletti
The DETECT Study Program: Personalized treatment in advanced breast
cancer based on circulating tumor cells (CTCs). (Abstract TPS11109) A.
Schramm, T. W. Friedl, S. Albrecht, J. B. Huober, B. K. Rack, E. K. Trapp, P. A.
Fasching, F. Taran, A. D. Hartkopf, A. Schneeweiss, V. Mueller, B. Aktas, K.
Pantel, F. Meier-Stiegen, W. Janni, T. N. Fehm
Board 324b
The genomics of Young Lung Cancer Study. (Abstract TPS11110) B. J. Gitlitz,
D. Morosini, A. L. Sable-Hunt, B. J. Addario, M. B. Jennings, S. L. Mach, G. R.
Oxnard
Board 325a
MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab,
erlotinib, vemurafenib, and vismodegib in patients who have advanced solid
tumors with mutations or gene expression abnormalities targeted by these
agents. (Abstract TPS11111) H. A. Burris, H. Hurwitz, E. A. Perez, D. Spigel, C.
Swanton, J. D. Hainsworth, L. Leon, M. Beattie, M. Brammer, C. Sweeney
Board 325b
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest
wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the
addition of RNRT to breast RT post breast-conserving surgery (BCS) will
reduce invasive cancer events in patients (pts) with positive axillary (Ax)
nodes who are ypN0 after neoadjuvant chemotherapy (NC). (Abstract
TPS11112) E. P. Mamounas, H. Bandos, J. R. White, T. B. Julian, A. J. Khan, S. F.
Shaitelman, M. A. Torres, S. A. McCloskey, F. A. Vicini, P. A. Ganz, S. Paik, N.
Gupta, J. P. Costantino, W. J. Curran Jr., N. Wolmark
SUNDAY
Board 324a
9:45 AM - 11:00 AM Special Session
ASCO/American Association for Cancer Research (AACR) Joint Session:
Translating Biology into Therapeutics
Location: E354b
Carlos L. Arteaga, MD—Co-Chair
Andrew H. Ko, MD
Hedgehog Pathway in Pancreatic Cancer
Maha Hussain, MD, FACP, FASCO
Angiogenesis and Prostate Cancer
Alan Ashworth, PhD, FRS
PARP Inhibitors in BRCA-Deficient Cancers
181
B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric
Oncology
Location: S102
Memorial Solan Kettering Cancer Center
Presentation of the 2015 B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology
Silvio Monfardini, MD
Istituto Palazzolo Fondazione Don Gnocchi
Transforming Data into Activities Designed for Older Cancer Patients
Best of the Rest: Top Head and Neck Abstracts from 2014–2015 Oncology Meetings
Location: S100bc
Quynh-Thu Le, MD—Chair
Stanford University Medical Center
Best of the American Society for Radiation Oncology
SUNDAY
Amanda Psyrri, MD, PhD
Attikon Hospital and National Kapodistrian University of Athens
Best of ESTRO/ECCO
Tanguy Y. Seiwert, MD
Best of the American Association for Cancer Research
Cutaneous Squamous, Basal, and Merkel Cell Cancers
Location: S406
Danny Rischin, MBBS, MD, FRACP—Chair
Current Approaches and Future Directions in the Management of Merkel Cell Carcinoma
Sandro V. Porceddu, MD
Princess Alexandra Hospital
Adjuvant Radiation Based on Histology and Other Risk Factors: What Is Currently Known?
Jean Y. Tang, MD, PhD
Hedgehog Inhibitors and Other Management of Basal Cell Carcinoma
Epidemiology: From Genetics to Practice
Location: S100a
182
James M. Foran, MD—Chair
Mayo Clinic
Epidemiology in Practice: From Risk Factor to Clinical Outcome
Karen H. Lu, MD
Value of Family History in Common Cancers
Thomas A. Sellers, PhD
Risk and Relevance: Why Does Epidemiology Matter?
Let the Sunshine In: Industry’s Impact on Oncology Research and Practice
Location: S504
Richard Gaynor, MD
Eli Lilly and Company
Industry Perspectives: Toward Fair and Fruitful Interactions
SUNDAY
Beverly Moy, MD, MPH—Chair
Massachusetts General Hospital Cancer Center and Harvard Medical School
Increasing Prominence of Financial Relationships with Industry in Oncology
Reshma Jagsi, MD, DPhil
University of Michigan Health System
Pitfalls of Direct-to-Consumer Advertising in Oncology for Clinical Practice
Mark J. Ratain, MD
Implications of the Sunshine Act for Oncologists and Researchers
Value Concepts in the Management of Ovarian Cancer
Location: E450
Usha Menon, MD
University College London, Institute for Women’s Health
Early Ovarian Cancer: Can We Find It, Can We Stop It, Can We Afford It?
Douglas A. Levine, MD
Personalized Treatment in Ovarian Cancer: Fancy Science or Expensive Hype?
David R. Spriggs, MD—Chair
Crossroads in Treatment: Primary Treatment Choices, Consolidation, and the Postplatinum
Endgame
183
Understanding Inherited High-Risk Cancer Genes and When to Refer Families
for Genetic Testing—Ticketed Session
Location: E451a
Acute Myeloid Leukemia: State-of-the-Art Management in 2015—Ticketed
Session
Location: E451b
Charles Alan Schiffer, MD—Chair
Wayne State University
Consideration in the Management of Acute Myeloid Leukemia in Elderly Patients
Jessica K. Altman, MD
Northwestern University
Choosing the Best Frontline Regimen in Acute Myeloid Leukemia: Integrating Clinical and
Genomic Features
SUNDAY
John F. DiPersio, MD, PhD
Washington University School of Medicine in St. Louis
Postremission Therapy for Acute Myeloid Leukemia: Transplant and Beyond
Targeted Therapies: Does the Disease Still Matter?
Location: E Hall D1
Richard M. Goldberg, MD—Chair
The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute
9:45 AM
Overall survival in COMBI-d, a randomized, double-blinded, phase III study
comparing the combination of dabrafenib and trametinib with dabrafenib and
placebo as first-line therapy in patients (pts) with unresectable or metastatic
BRAF V600E/K mutation-positive cutaneous melanoma. (Abstract 102) G. V.
Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. G. De Braud, J. M. Larkin, C.
Garbe, T. Jouary, A. Hauschild, J. Grob, V. Chiarion-Sileni, C. Lebbe, M. Mandalà,
M. Millward, D. J. DeMarini, J. G. Irani, F. Jin, R. S. Swann, B. Mookerjee, K.
Flaherty
9:57 AM
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor
dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts)
with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).
(Abstract 103) C. E. Atreya, E. Van Cutsem, J. C. Bendell, T. Andre, J. H.
Schellens, M. S. Gordon, A. J. McRee, P. J. O’Dwyer, K. Muro, J. Tabernero, R.
van Geel, R. Sidhu, J. G. Greger, F. A. Rangwala, M. Motwani, Y. Wu, K. W.
Orford, R. B. Corcoran
10:09 AM
Scott Kopetz, MD, PhD, FACP (Discussion of Abstract(s) 102–103)
184
10:21 AM
A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase
I study of intermittent, low dose intensity schedules of the dual MEK/RAF
inhibitor, RO5126766 (RO) in patients (pts) with advanced solid tumors.
(Abstract 104) M. de Miguel Luken, D. Roda, R. Perez Lopez, B. Jimenez, H.
Hassam, N. Sathiyayogan, M. Parmar, A. J. Turner, E. Hall, N. Tunariu, L. R.
Molife, T. A. Yap, J. S. De Bono, U. Banerji
10:33 AM
Phase I study of combination vemurafenib, carboplatin, and paclitaxel in
patients (pts) with BRAF-mutant advanced cancer. (Abstract 105) S. Kato, F.
Janku, S. A. Piha-Paul, A. Naing, D. D. Karp, A. M. Tsimberidou, V. Subbiah, R.
Zinner, W. Hwu, M. M. Javle, K. L. Parkhurst, N. M. Ramzanali, R. Kurzrock, F.
Meric-Bernstam, Y. Chae, K. Kim, G. S. Falchook
10:45 AM
David B. Solit, MD (Discussion of Abstract(s) 104 –105)
10:57 AM
9:45 AM - 12:45 PM Oral Abstract Session
Channing Judith Paller, MD—Co-Chair
9:45 AM
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in
castration-resistant prostate cancer (CRPC). (Abstract 5000) H. I. Scher, M. J.
Morris, W. M. Stadler, C. S. Higano, S. Halabi, M. R. Smith, E. M. Basch, K. Fizazi,
C. J. Ryan, E. S. Antonarakis, P. G. Corn, G. Liu, J. S. De Bono, L. H. Schwartz,
T. M. Beer, W. K. Kelly, M. Hussain, A. O. Sartor, P. W. Kantoff, A. J. Armstrong
9:57 AM
Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First
overall survival results from STAMPEDE (NCT00268476). (Abstract 5001)
N. D. James, M. R. Sydes, M. D. Mason, N. W. Clarke, D. P. Dearnaley, M. R.
Spears, R. Millman, C. Parker, A. W. Ritchie, J. M. Russell, J. Staffurth, R. J.
Jones, S. P. Tolan, J. Wagstaff, A. Protheroe, R. Srinivasan, A. J. Birtle, J. M.
O’Sullivan, R. Cathomas, M. M. Parmar, STAMPEDE Investigators
10:09 AM
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus
AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and
prednisone for localized, high-risk prostate cancer (RTOG 0521). (Abstract
LBA5002) H. M. Sandler, C. Hu, S. A. Rosenthal, O. Sartor, L. G. Gomella, M.
Amin, J. Purdy, J. M. Michalski, M. Garzotto, N. Pervez, A. G. Balogh, G.
Rodrigues, L. Souhami, M. N. Reaume, S. G. Williams, R. Hannan, E. M. Horwitz,
A. Raben, R. Paulus, W. U. Shipley
10:21 AM
Ian Tannock, MD, PhD (Discussion of Abstract(s) 5000-LBA5002)
Princess Margaret Cancer Centre, University of Toronto
Clinical Trial Design and Chemotherapy Use in Prostate Cancer: Correcting Old
Mistakes, Making New Ones
10:33 AM
10:45 AM
Characterization of neuroendocrine prostate cancer (NEPC) in patients with
metastatic castration resistant prostate cancer (mCRPC) resistant to
abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the
SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
(Abstract 5003) E. J. Small, J. Huang, J. Youngren, A. Sokolov, R. R. Aggarwal,
G. Thomas, L. D. True, L. Zhang, A. Foye, J. J. Alumkal, C. J. Ryan, M. Rettig,
C. P. Evans, M. E. Gleave, R. Baertsch, J. Stuart, R. E. Reiter, P. Lara Jr., K. N.
Chi, T. M. Beer
185
SUNDAY
Daniel Costin Danila, MD—Co-Chair
SUNDAY
10:57 AM
Defining a molecular subclass of treatment resistant prostate cancer.
(Abstract 5004) H. Beltran, D. Prandi, J. Mosquera, E. Giannopoulou, L. Puca, C.
Marotz, D. M. Nanus, S. T. Tagawa, O. Elemento, E. M. Van Allen, A. Sboner, L. A.
Garraway, M. A. Rubin, F. Demichelis
11:09 AM
Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from
a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa)
versus LHRHa. (Abstract 5005) E. Efstathiou, W. Li, M. Gormley, R. McMullin,
D. S. Ricci, J. W. Davis, E. M. Li Ning Tapia, P. Troncoso, M. A. Titus, A. Hoang, S.
Wen, A. J. Zurita, N. Tran, W. Peng, T. Kheoh, A. Molina, C. Logothetis
11:12 AM
Scott Tomlins, MD, PhD (Discussion of Abstract(s) 5003–5005)
University of Michigan
Genomics as Classifiers and Predictors for Prostate Cancer: Implications for the Field
11:33 AM
11:45 AM
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as
salvage treatment for biological relapse (BR) after radical prostatectomy
(RP): Results of the GETUG-AFU 16 phase III randomized
trial—NCT00423475. (Abstract 5006) C. Carrie, A. Hasbini, G. De Laroche, M.
Habibian, P. Richaud, S. Guérif, I. Latorzeff, S. Supiot, M. Bosset, J. L. Lagrange,
V. Beckendorf, F. Lesaunier, B. Dubray, J. P. Wagner, T. N’Guyen, J. Suchaud, G.
Crehange, N. Barbier, A. Ruffion, S. Dussart
11:57 AM
TROG 03.06 and VCOG PR 01– 03: The “timing of androgen deprivation
therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative
randomised phase III trial. (Abstract 5007) G. M. Duchesne, J. Bassett, C.
D’Este, M. Frydenberg, L. Ledwich, J. L. Millar, R. L. Milne, R. Smith, N. Spry,
M. R. Stockler, R. Syme, S. Turner, K. H. Tai, H. Woo, TROG & Cancer Council
Victoria
12:09 PM
Long-term consequences of intermittent and continuous androgen
deprivation in older patients with metastatic prostate cancer. (Abstract 5008)
D. L. Hershman, J. M. Unger, J. D. Wright, S. D. Ramsey, C. Till, C. M. Tangen,
W. E. Barlow, C. D. Blanke, I. M. Thompson Jr., M. Hussain
12:21 PM
Celestia S. Higano, MD, FACP (Discussion of Abstract(s) 5006 –5008)
University of Washington/Fred Hutchinson Cancer Research Center
Early Androgen Deprivation Therapy for Prostate Cancer: Finding the Optimal
Timing and Interval
12:33 PM
11:30 AM - 12:45 PM Poster Discussion Session
Location: E354b
Andrew S. Artz, MD, MS—Co-Chair
Rebecca Leah Olin, MD—Co-Chair
11:30 AM
Charalambos Andreadis, MD, MSCE (Discussion of Abstract(s) 7011–7013)
Incorporating Novel Agents into the Treatment of Chronic Lymphocytic Leukemia
11:42 AM
11:48 AM
Alexander E. Perl, MD (Discussion of Abstract(s) 7014 –7016)
Biologically Based Management of Acute Myeloid Leukemia
12:00 PM
186
12:06 PM
Mark G. Frattini, MD, PhD (Discussion of Abstract(s) 7017–7019)
An Evolving Understanding of the Biology of Leukemia
12:18 PM
12:24 PM
Vikas Gupta, MD, FRCP, FRCPath (Discussion of Abstract(s) 7020 –7022)
Princess Margaret Cancer Center
Biology and Management of Myeloproliferative Neoplasms
12:36 PM
Posters discussed in this session are on display in the Leukemia, Myelodysplasia, and Transplantation Poster Session. See page 147 for poster information. Networking with presenters and
discussants will take place right outside of the session room after the discussion.
Pediatric Oncology
Location: S504
Stephen Hunger, MD—Co-Chair
Children’s Hospital of Philadelphia
11:30 AM
Examining Late Effects and Overall Health of Pediatric Cancer Survivors
11:42 AM
11:48 AM
Alberto S. Pappo, MD (Discussion of Abstract(s) 10021–10023)
Rare Tumors: Imporving Outcomes in the Modern Era
12:00 PM
12:06 PM
Jeffrey Toretsky, MD (Discussion of Abstract(s) 10024 –10026)
Georgetown University Hospital
Transitioning Ewing Sarcoma Research from the Bench to the Bedside: A Long
Strange Trip
12:18 PM
12:24 PM
Stephen Hunger, MD (Discussion of Abstract(s) 10027–10029)
Children’s Hospital of Philadelphia
Exploring the Childhood Leukemia Frontier
12:36 PM
SUNDAY
To Be Determined—Co-Chair
Posters discussed in this session are on display in the Pediatric Oncology Poster Session. See
page 163 for poster information. Networking with presenters and discussants will take place
Tumor Biology
Location: S406
Robert Bachoo, MD, PhD—Co-Chair
Victoria Louise Seewaldt, MD—Co-Chair
187
11:30 AM
Wolfgang Michael Korn, MD (Discussion of Abstract(s) 11010 –11011)
Next-Generation Sequencing: Making Sense of Genomic Complexity
11:42 AM
11:48 AM
Lawrence H. Schwartz, MD (Discussion of Abstract(s) 11012–11014)
New York-Presbyterian/Columbia University Medical Center
New Strategies for Molecular Imaging
12:00 PM
12:06 PM
Andrew B. Nixon, PhD (Discussion of Abstract(s) 11015–11017)
The Promises and Pitfalls of Molecular Diagnostics
12:18 PM
12:24 PM
Susan M. Domchek, MD (Discussion of Abstract(s) 11018 –11020)
Perelman School of Medicine at the University of Pennsylvania
Actionable Targets: Finding the Needle in the Haystack
12:36 PM
Posters discussed in this session are on display in the Tumor Biology Poster Session. See page
174 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion.
11:30 AM - 12:45 PM Education Session
SUNDAY
Beyond the Concept: The Patient-Centered Medical Home in Oncology
Location: S404
Ray D. Page, DO, PhD—Chair
The Center for Cancer and Blood Disorders
Beyond the Concept: The Patient-Centered Medical Home in Oncology
John David Sprandio, MD
Consultants in Medical Oncology and Hematology
Impact of Patient-Centered Oncology Care: A PCORI-Funded Study
Lee Nisley Newcomer, MD
United Health Group
United Healthcare Bundling Demonstration Project
COME HOME Project Data: What It Really Shows
Enrolling Patients in Early-Phase Clinical Trials: An Ethical Dilemma
Location: E450
Steven Joffe, MD, MPH—Chair
Enrolling Patients with Cancer in Early-Phase Clinical Trials: The Ethical Perspective
188
Stuart M. Lichtman, MD
The Role of Geriatric Oncology and Palliative Care in Clinical Trials
Carlos H. Barrios, MD
Latin American Cooperative Oncology Group
The Conduct of Clinical Trials Globally: Challenges and Opportunities
Genetic Testing in 2015: Who Owns the Data, How Do You Return Results, and
Other Clinical Dilemmas
Location: S100a
Wendy Kohlmann, MS—Chair
Huntsman Cancer Institute at the University of Utah
Role of the Genetic Counselor in Testing and Returning Results
William Foulkes, MBBS, PhD
Segal Cancer Center, Lady Davis Institute, Jewish General Hospital
Who Owns the Data: The Patient, the Doctor, or the Company?
SUNDAY
Mark E. Robson, MD
The Ethics of Germline Genetic Testing, Incidental Findings, and Sharing Results
Locally Advanced Rectal Cancer: Time for Change?
Location: E Hall D1
Martin R. Weiser, MD—Chair
Is Chemotherapy, Radiation, and Surgery Necessary in Everyone?
Zhen Zhang, MD, PhD
Fudan University, Shanghai Cancer Center
Radiation: Short or Long Course?
Deborah Schrag, MD, MPH
Total Neoadjuvant Therapy: What Is the Rationale and Data?
The Value Proposition in Oncology: Different Approaches to Understanding
Value in Cancer Care
Location: S102
189
Beverly E. Canin
Breast Cancer Options, Inc.
Patient Priorities on Value in Treatment Choices
Lowell E. Schnipper, MD—Chair
ASCO’s Value Initiative: A Case-Based Approach
Neal J. Meropol, MD
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case
Western Reserve University
Case Considerations: Valuing Clinician Priorities
Jennifer Malin, MD, PhD
Anthem, Inc.
Case Considerations: Value from the Payer Perspective
Updates in the Multimodality Management of Stage III Lung Cancer
Location: S100bc
SUNDAY
Nasser H. Hanna, MD
Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is
New?
Walter John Curran, MD—Chair
Winship Cancer Institute of Emory University
Radiation Therapy for Stage III Lung Cancer: What Is the Role of Proton Therapy?
David Jablons, MD
Surgical Management of Stage III Non-Small Cell Lung Cancer: New Techniques and Data
11:30 AM - 12:45 PM Meet the Professor Session
Translating Melanoma Immunology into Practice—Ticketed Session
Location: E451a
Jeffrey S. Weber, MD, PhD
11:30 AM - 12:45 PM Clinical Problems in Oncology Session
Optimal Treatment Strategies of the Geriatric Patient with Head and Neck
Cancer—Ticketed Session
Location: E451b
190
Beatriz Korc-Grodzicki, MD, PhD—Chair
Risk Assessment and Treatment Considerations in the Elderly Patient with Head and Neck
Cancer
Konstantinos N. Syrigos, MD, MBBS, PhD
Athens School of Medicine
Systemic Treatment Options/Alterations for the Geriatric Patient with Head and Neck Cancer
Kevin J. Harrington, MBBS, PhD
Institute of Cancer Research and The Royal Marsden Hospital
Radiotherapy Integration into Multimodality Therapy: Strategies to Minimize Toxicities in the
Geriatric Patient
11:30 AM - 1:00 PM Clinical Science Symposium
Predicting Response in Triple-Negative and HER2-Positive Breast Cancer:
Unlocking Pieces to Solve the Puzzles
Location: E Hall D2
Cornelia Liedtke, MD—Co-Chair
University of Schleswig-Holstein Campus Luebeck
11:30 AM
Meta-analysis of breast cancer expression data using published gene
signatures to reveal key cellular processes implicated in chemosensitivity
and resistance. (Abstract 509) D. G. Stover, L. M. Selfors, J. L. Coloff, J. S.
Brugge, E. P. Winer
11:42 AM
Prognostic significance of tumor-infiltrating CD8ⴙ and FOXP3ⴙ
lymphocytes in residual tumors and alterations in these parameters after
neoadjuvant chemotherapy in triple-negative breast cancer. (Abstract 510) M.
Miyashita, H. Sasano, K. Tamaki, H. Hirakawa, G. Watanabe, H. Tada, A. Suzuki,
T. Ishida, C. Ishioka, N. Ohuchi
11:54 AM
Aleix Prat, MD, PhD (Discussion of Abstract(s) 509 –510)
Vall d’Hebron Instituto de Oncologica
Challenges in Response and Outcome Prediction in Triple-Negative Breast Cancer
12:06 PM
Correlation of PIK3CA mutation with pathological complete response in
primary HER2-positive breast cancer: Combined analysis of 967 patients
from three prospective clinical trials. (Abstract 511) S. Loibl, I. Majewski, V.
Guarneri, V. Nekljudova, E. M. Holmes, E. Bria, C. Denkert, H. Eidtmann, C.
Sotiriou, S. Loi, F. Andre, M. Untch, P. F. Conte, M. J. Piccart-Gebhart, G. Von
Minckwitz, J. Baselga
12:18 PM
Predictive biomarkers of everolimus efficacy in HER2ⴙ advanced breast
cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.
(Abstract 512) D. J. Slamon, S. A. Hurvitz, D. Chen, F. Andre, L. Tseng, G. H.
Jerusalem, S. Wilks, R. O’Regan, C. Isaacs, M. Toi, H. A. Burris III, W. He, M.
Riester, D. Robinson, T. Taran, L. Gianni
12:42 PM
1:00 PM - 4:00 PM Plenary Session
Plenary Session Including the Science of Oncology Award and Lecture
Location: N Hall B1 (Simulcast Location: E Hall D1)
191
SUNDAY
Alexandra Thomas, MD, FACP—Co-Chair
University of Iowa
Alan P. Venook, MD—Co-Chair
1:00 PM
Presentation of the 2015 Science of Oncology Award
James Patrick Allison, PhD—Science of Oncology Award Lecturer
Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities,
and Prospects for a Cure
SUNDAY
1:35 PM
Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or
combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients
(pts) with advanced melanoma (MEL) (CheckMate 067). (Abstract LBA1) J. D.
Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J. Grob, C. L. Cowey,
C. D. Lao, D. Schadendorf, P. Ferrucci, M. Smylie, R. Dummer, A. G. Hill, J. B.
Haanen, M. Maio, G. A. McArthur, A. Yang, L. Rollin, C. E. Horak, J. M. Larkin,
F. S. Hodi
1:50 PM
Michael B. Atkins, MD (Discussion of Abstract(s) LBA 1)
2:05 PM
Reduction in late mortality among 5-year survivors of childhood cancer: A
report from the Childhood Cancer Survivor Study (CCSS). (Abstract LBA2)
G. T. Armstrong, Y. Yasui, Y. Chen, W. M. Leisenring, T. M. Gibson, A. Mertens,
M. Stovall, M. M. Hudson, K. C. Oeffinger, S. Bhatia, K. R. Krull, P. C. Nathan, J. P.
Neglia, D. M. Green, L. L. Robison
2:20 PM
Michael Paul Link, MD (Discussion of Abstract(s) LBA2)
2:35 PM
Elective versus therapeutic neck dissection in the clinically node negative
early oral cancer: A randomised control trial (RCT). (Abstract LBA3) A.
D’Cruz, M. Dandekar, R. Vaish, S. Arya, G. Pantvaidya, P. Chaturvedi, D. Chaukar,
P. S. Pai, A. Deshmukh, S. Kane, D. Nair, S. V. Nair, A. Patil, R. W. Hawaldar, M.
Dhopeshwarkar, J. Agarwal
2:50 PM
Hisham Mehanna, PhD, MD, (Discussion of Abstract(s) LBA3)
Institute of Head and Neck Studies and Education, University of Birmingham
3:05 PM
NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation
therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain
metastases. (Abstract LBA4) P. D. Brown, A. L. Asher, K. V. Ballman, E. Farace,
J. H. Cerhan, S. Anderson, X. W. Carrero, F. G. Barker II, R. L. Deming, S. Burri,
C. Menard, C. Chung, V. W. Stieber, B. E. Pollock, E. Galanis, J. C. Buckner, K. A.
Jaeckle
3:20 PM
Andrew B. Lassman, MD (Discussion of Abstract(s) LBA4)
Department of Neurology and Herbert Irving Comprehensive Cancer Center,
3:35 PM
Leonard B. Saltz, MD
Discussion
Post-Plenary Discussion I: Melanoma/Skin Cancers
Location: S100bc
Svetomir Markovic, MD, PhD—Chair
Mayo Clinic
192
Jedd D. Wolchok, MD, PhD
Michael B. Atkins, MD
Caroline Robert, MD, PhD
Gustave Roussy
Post-Plenary Discussion II: Survivorship
Location: S100a
Lisa Diller, MD—Chair
Gregory T. Armstrong, MD, MSCE
Michael Paul Link, MD, FASCO
SUNDAY
Patricia A. Ganz, MD
University of California, Los Angeles
Location: E354b
Amit Balkrishna Agarwal, MD, PhD—Chair
University of Arizona
4:30 PM
Mehdi Hamadani, MD (Discussion of Abstract(s) 8518 – 8520)
Medical College of Wisconsin
Moving the Needle: Potential Effects of Novel Drug Combinations on Care in
Lymphoma
4:42 PM
4:48 PM
Michelle A. Fanale, MD (Discussion of Abstract(s) 8521– 8522)
Moving Beyond CHOP in Front-line Management of Mature T-Cell Lymphoma
5:00 PM
5:06 PM
Antonio Palumbo, MD (Discussion of Abstract(s) 8523– 8524)
A. O. U. San Giovanni Battista di Torino - Ospedale Molinette
Continuous versus Fixed-Duration Front-line Therapy in Multiple Myeloma
5:18 PM
5:24 PM
Jatin J. Shah, MD (Discussion of Abstract(s) 8525– 8528)
Role of Proteasome and Histone Deacetylase Inhibition in Myeloma Therapy
5:36 PM
Posters discussed in this session are on display in the Lymphoma and Plasma Cell Disorders
Poster Session. See page 155 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion.
193
Sarcoma
Location: S404
Brian Andrew Van Tine, MD, PhD—Co-Chair
Washington University in St. Louis
Breelyn A. Wilky, MD—Co-Chair
University of Miami Miller School of Medicine
SUNDAY
4:30 PM
Discovery and Application of Targets in Clinical Research and Patient Care
4:42 PM
4:48 PM
Stefan Sleijfer, MD, PhD (Discussion of Abstract(s) 10511–10513)
Erasmus MC
Optimal Surrogate Markers for Patient Outcomes in Sarcoma
5:00 PM
5:06 PM
Rashmi Chugh, MD (Discussion of Abstract(s) 10514 –10516)
University of Michigain Health System
Early Clinical Trials for Refractory Soft Tissue Sarcoma Patients
5:18 PM
5:24 PM
To Be Determined (Discussion of Abstract(s) 10517–10519)
Potential Value of Circulating Tumor DNA
5:36 PM
Posters discussed in this session are on display in the Sarcoma Poster Session. See page 168
for poster information. Networking with presenters and discussants will take place right outside
of the session room after the discussion.
Emerging Topics in Immunotherapy and Cellular Therapy
Location: S504
Stephan A. Grupp, MD, PhD—Chair
The Children’s Hospital of Philadelphia
Immunotherapy for Childhood Leukemia
Crystal Mackall, MD
Immunotherapy for Solid Tumors
Ian Pollack, MD
Pittsburgh Children’s Hospital
Immunotherapy for Central Nervous System Tumors
ICD-10: History, Implementation, and Opportunities
Location: S102
194
Risë Marie Cleland—Chair
Washington State Medical Oncology Society
Historical Perspective
Stuart Staggs
McKesson Specialty Health
Practical Implementation: Before and after October 1, 2015
Sue Bowman, MJ, RHIA, CCS, FAHIMA
American Health Information Management Association
What Opportunities Does ICD-10 Provide?
Overcoming Drug Resistance in Targeted Therapy of Cancer
Mothaffar F. Rimawi, MD—Chair
Baylor College of Medicine
Resistance to Anti-HER2 Therapies in Breast Cancer
SUNDAY
Christine Marie Lovly, MD, PhD
Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Josep Tabernero, MD, PhD
Vall d’Hebron University Hospital
Resistance to Targeted Therapies in Gastrointestinal Cancers
Targeted Molecular Therapy in Melanoma
Location: S406
Ryan J. Sullivan, MD
Massachusetts General Hospital Cancer Center and Harvard Medical School
Targeting the Wild-Type Patient
Reinhard Dummer, MD
University Hospital Zurich
Targeting Patients with the BRAF Mutation: Is Combination Therapy the New Standard?
Alan Haruo Bryce, MD—Chair
Mayo Clinic, Scottsdale, AZ
Genomic Approaches in the Discovery of Novel Targets for Melanoma
195
Clinical and Translational Research in Older Patients with Cancer—Ticketed
Session
Location: E451a
Harvey Jay Cohen, MD
Lodovico Balducci, MD
Controversies in Management of High-Grade Glioma—Ticketed Session
Location: E451b
Roger Stupp, MD—Chair
University Hospital Zurich and University of Zurich
Medical Management of Newly Diagnosed Glioblastoma: Back to the Future
SUNDAY
Andrew B. Lassman, MD
Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia
University Medical Center
Anaplastic (WHO Grade III Gliomas): Should Practice-Changing Data Change Clinical
Practice?
Nicholas A. Butowski, MD
Recurrent High-Grade Glioma: One Patient, Many Options
4:30 PM - 6:00 PM Clinical Science Symposium
Immunotherapy in Lung Cancer: A Paradigm Shift
Location: E Hall D1
Geoffrey R. Oxnard, MD—Co-Chair
Nathan A. Pennell, MD, PhD—Co-Chair
Cleveland Clinic
4:30 PM
A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed
death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or
metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). (Abstract
8009) D. R. Spigel, K. L. Reckamp, N. A. Rizvi, E. Poddubskaya, H. J. West, W. E.
Eberhardt, P. Baas, S. J. Antonia, A. Pluzanski, E. E. Vokes, E. Holgado, D. M.
Waterhouse, N. Ready, J. F. Gainor, O. R. Aren, L. Horn, L. Paz-Ares, C. Baudelet,
B. J. Lestini, J. R. Brahmer
4:42 PM
Efficacy, safety and predictive biomarker results from a randomized phase II
study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).
(Abstract 8010) A. I. Spira, K. Park, J. Mazières, J. F. Vansteenkiste, A. Rittmeyer,
M. Ballinger, D. Waterkamp, M. Kowanetz, A. Mokatrin, L. Fehrenbacher
196
4:54 PM
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as
second-line therapy for advanced non-small cell lung cancer (NSCLC):
KEYNOTE-021 cohort D. (Abstract 8011) A. Patnaik, M. A. Socinski, M. A.
Gubens, L. Gandhi, J. Stevenson, R. D. Bachman, J. Bourque, J. Yang Ge, E. Im,
S. M. Gadgeel
5:06 PM
Marina Chiara Garassino, MD (Discussion of Abstract(s) 8009 – 8011)
Fondazione IRCCS Istituto Nazionale Dei Tumori
Changes in the Standard of Care for Non–Small Cell Lung Cancer
5:18 PM
Clinical correlation and frequency of programmed death ligand-1 (PD-L1)
expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer
(NSCLC). (Abstract 8012) J. F. Gainor, L. V. Sequist, A. T. Shaw, C. G. Azzoli, Z.
Piotrowska, T. Huynh, L. Fulton, K. Schultz, A. N. Hata, J. A. Engelman, M.
Mino-Kenudson
5:30 PM
Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE (Discussion of Abstract(s)
8012)
Aberdeen Royal Infirmary
Biomarkers for Immune Checkpoint Inhibitors
5:42 PM
SUNDAY
To Lump or To Split: Molecular, Anatomic, and Etiologic Subtyping of
Noncolorectal Gastrointestinal Malignancies and Potential Therapeutic
Implications
Location: E Hall D2
Ghassan K. Abou-Alfa, MD—Co-Chair
Andrew H. Ko, MD—Co-Chair
4:30 PM
Comprehensive genomic profiling of biliary tract cancers to reveal tumorspecific differences and frequency of clinically relevant genomic alterations.
(Abstract 4009) J. S. Ross, K. Wang, M. M. Javle, D. V. Catenacci, R. T. Shroff,
S. M. Ali, J. A. Elvin, J. Chmielecki, R. Yelensky, D. Lipson, V. A. Miller, P. J.
Stephens, F. Meric-Bernstam
4:42 PM
Melanie B. Thomas, MD (Discussion of Abstract(s) 4009)
Gibbs Cancer Center and Research Institute
Tumor-Specific Differences of Biliary Tract Cancers
4:54 PM
Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal
carcinoma: Preliminary results from KEYNOTE-028. (Abstract 4010) T. Doi,
S. A. Piha-Paul, S. I. Jalal, H. Mai-Dang, S. Yuan, M. Koshiji, I. Csiki, J. Bennouna
5:06 PM
Charles S. Fuchs, MD, MPH (Discussion of Abstract(s) 4010)
Potential Practice Effects of Gastric and Esophageal Cancer Subtyping
5:18 PM
Hepatitis B- and C-associated hepatocellular carcinoma in a large U.S.
cancer center: Do clinicopathologic features or patient outcomes differ by
the potentially causative viruses? (Abstract 4011) M. I. Uemura, A. O. Kaseb,
R. Abdel-Wahab, K. P. Raghav, G. Botrus, E. Hawk, R. A. Wolff, J. Morris, M.
Hassan
5:30 PM
Ghassan K. Abou-Alfa, MD (Discussion of Abstract(s) 4011)
Similarities and Differences in Hepatocellular Carcinoma: Etiology and Other
Factors
5:42 PM
197
Post-Plenary Discussion III: Head and Neck Cancer
Location: S100bc
Quynh-Thu Le, MD—Chair
Anil D’Cruz, MBBS, MS, FRCS
Tata Memorial Hospital
Hisham Mehanna, PhD, MD
Institute of Head and Neck Studies and Education, University of Birmingham
Robert L. Ferris, MD, PhD
Post-Plenary Discussion IV: Central Nervous System Tumors
Location: S100a
SUNDAY
Andrew B. Lassman, MD
Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia
University Medical Center
Paul D. Brown, MD
Minesh P. Mehta, MD
University of Maryland Medical Systems
Patrick Y. Wen, MD
198
Monday, June 1, 2015
Highlights of the Day Session II Including Partners in Progress Award
Location: E Hall D1
John Vernon Cox, DO, MBA, FACP—Chair
7:30 AM
Presentation of the 2015 Partners in Progress Award
Mary Lou Smith, JD, MBA—Partners in Progress Award Recipient
Research Advocacy Network
7:40 AM
Eileen Mary O’Reilly, MD
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
Kettering Cancer Center
8:00 AM
Robert Dreicer, MD, MS
University of Virginia School of Medicine
8:20 AM
8:40 AM
Edward B. Garon, MD
David Geffen School of Medicine at University of California, Los
Angeles/Translational Research in Oncology-US Network
Antibody-Drug Conjugates: New Horizons to Maximize Efficacy and Minimize
Toxicity
Location: S406
MONDAY
Beverly A. Teicher, PhD—Chair
Overview of Antibody-Drug Conjugates in Solid Tumors: History and Mechanism of Action
Francisco J. Esteva, MD, PhD
NYU Langone Medical Center
Integration of Antibody-Drug Conjugates in Clinical Practice
Kathy Miller, MD
Novel Antibody-Drug Conjugates and Rational Combination
Burnout in Oncology Health Care Providers: Identifying Silent Despair and
Maintaining Purpose
Location: S404
199
Anthony Back, MD—Chair
Seattle Cancer Care Alliance
What Is Burnout?
Tait D. Shanafelt, MD
Mayo Clinic
Fixing Burnout: Mind-Body Therapies for Health Care Providers
Cynda H. Rushton, PhD, RN, FAAN
Johns Hopkins University School of Nursing
Oncology Registered Nurse Burnout and Strategies to Improve Effectiveness
Integrating New Approaches in Complicated Bladder Cancer
Location: E Hall D2
Dan Theodorescu, MD, PhD
Detection and Monitoring of Bladder Cancer: Impact of the Genomic Revolution
Andrea Borghese Apolo, MD
Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Challenges in
Applying the Data
Nicholas J. Vogelzang, MD—Chair
Carolina Urologic Research Center, The US Oncology Network
Practical Considerations in the Treatment of the Frail Patient with Bladder Cancer
MONDAY
Progress and Challenges in Chronic Lymphocytic Leukemia
Stephan Stilgenbauer, MD
University Hospital Ulm
Upfront Approach: Focus on Identifying and Managing High-Risk Chronic Lymphocytic
Leukemia
Richard R. Furman, MD
Weill Cornell Medical College, New York Presbyterian Hospital
Incorporating Novel Therapies in the Management of Relapsed/Refractory Chronic
Lymphocytic Leukemia
Clive Zent, MD—Chair
University of Rochester
Management of Complications of Chronic Lymphocytic Leukemia
200
Quality Measurement in Health Care: Tools to Improve Care
Location: S100a
Helen Burstin, MD, MPH—Chair
National Quality Forum
How to Evaluate Quality in Health Care
Craig Earle, MD, MSc
Institute for Clinical Evaluative Sciences
The Current Quality Measure Landscape in Oncology
Lawrence N. Shulman, MD
Quality Improvement in Action
Rare Tumors of the Central Nervous System: More Similar than Different
Location: E450
Jaishri O’Neill Blakeley, MD—Chair
Johns Hopkins University School of Medicine
Rare Diseases Informing Neuro-oncology Clinical Practice: What We Are Learning from the
Tumors of Neurogenetic Syndromes?
Mark R. Gilbert, MD
Center for Cancer Research, National Cancer Institute
Challenges in Ependymoma Management: Recurrent Disease and Adult Patients
Matthias Preusser, MD
Medical University of Vienna
Management of Atypical and Anaplastic Meningioma: Implications for Secondary Malignancies
and Sporadic and Syndromic Tumors
Choosing the Best Initial Therapy for Advanced Lung Cancer—Ticketed
Session
Location: E451a
Ramaswamy Govindan, MD
Washington University School of Medicine
201
MONDAY
Scott Randall Plotkin, MD, PhD
Neurofibromatosis Type 2: A Model for Integrating Genetics and Functional Endpoints for
Multiple Nervous System Tumors
Using Adaptive Therapy to Treat Cancer—Ticketed Session
Location: E451b
To Be Determined
New Evidence on the Role of Surgery and PET Scans after Primary
Chemoradiotherapy
Location: S100bc
Robert I. Haddad, MD—Chair
MONDAY
8:00 AM
PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT)
comparing PETCT guided active surveillance with planned neck dissection
(ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with
head and neck squamous cell cancer (HNSCC) treated with primary radical
chemoradiotherapy (CRT). (Abstract 6009) H. M. Mehanna, W. L. Wong, C. C.
McConkey, J. K. Rahman, M. Robinson, A. G. Hartley, C. Nutting, N. Powell, H.
Al-Booz, E. Junor, C. Hulme, A. F. Smith, P. Hall, J. Dunn
8:12 AM
Richard F. Wahl, MD (Discussion of Abstract(s) 6009)
The Role of PET in the Surgical Management of Head and Neck Cancer
8:24 AM
Is PET-CT guided management for patients with locally advanced head and
neck squamous cell cancer (HNSCC) cost-effective? Results from a UK
non-inferiority phase III randomized trial. (Abstract 6010) A. F. Smith, P. Hall,
C. Hulme, J. Dunn, J. K. Rahman, C. C. McConkey, H. Mehanna
8:36 AM
John N. Waldron, MD, FRCPC (Discussion of Abstract(s) 6010)
Establishing the Value of PET
8:48 AM
Establishing quality indicators for neck dissection: Correlating the number
of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501– 0234.
(Abstract 6011) V. Divi, J. Harris, P. M. Harari, J. S. Cooper, J. B. McHugh, D.
Bell, E. M. Sturgis, A. Cmelak, M. Suntharalingam, D. Raben, H. E. Kim, S.
Spencer, G. E. Laramore, A. Trotti, R. L. Foote, C. J. Schultz, W. L. Thorstad, Q.
Zhang, Q. Le, F. C. Holsinger
9:00 AM
Brian Nussenbaum, MD (Discussion of Abstract(s) 6011)
Determining the Necessary Number of Nodes
9:12 AM
Location: N Hall B1
Tufia C. Haddad, MD—Co-Chair
Mayo Clinic
Priya Rastogi, MD—Co-Chair
University of Pittsburgh Medical Center
202
8:00 AM
Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole
(A) versus tamoxifen (tam) in postmenopausal patients with DCIS
undergoing lumpectomy plus radiotherapy. (Abstract LBA500) R. G.
Margolese, R. S. Cecchini, T. B. Julian, P. A. Ganz, J. P. Costantino, L. Vallow,
K. S. Albain, P. W. Whitworth, M. E. Cianfrocca, A. Brufsky, H. M. Gross, G. S.
Soori, J. O. Hopkins, L. Fehrenbacher, K. Sturtz, T. F. Wozniak, T. E. Seay, E. P.
Mamounas, N. Wolmark
8:12 AM
Phase III trial evaluating the addition of bevacizumab to letrozole as first-line
endocrine therapy for treatment of hormone-receptor positive advanced
breast cancer: CALGB 40503 (Alliance). (Abstract 501) M. N. Dickler, W. T.
Barry, C. T. Cirrincione, M. J. Ellis, M. Moynahan, F. Innocenti, A. Hurria, H. S.
Rugo, D. Lake, O. M. Hahn, B. P. Schneider, D. Tripathy, E. P. Winer, C. A. Hudis
8:24 AM
PALOMA3: A double-blind, phase III trial of fulvestrant with or without
palbociclib in pre- and post-menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior
endocrine therapy. (Abstract LBA502) N. C. Turner, J. Ro, F. Andre, S. Loi, S.
Verma, H. Iwata, N. Harbeck, S. Loibl, C. H. Bartlett, K. Zhang, C. Giorgetti, S.
Randolph, M. Koehler, M. Cristofanilli
8:36 AM
Joseph A. Sparano, MD (Discussion of Abstract(s) LBA500-LBA502)
Montefiore Medical Center
Novel Approaches to Hormone Receptor–Positive Disease
8:48 AM
9:00 AM
Phase III trial of bisphosphonates as adjuvant therapy in primary breast
cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG
Oncology study S0307. (Abstract 503) J. Gralow, W. E. Barlow, A. H. Paterson,
D. Lew, A. Stopeck, D. F. Hayes, D. L. Hershman, M. Schubert, M. J. Clemons,
C. H. Van Poznak, E. C. Dees, J. N. Ingle, C. I. Falkson, A. D. Elias, M. J. Messino,
J. H. Margolis, S. R. Dakhil, H. K. Chew, R. B. Livingston, G. N. Hortobagyi
9:12 AM
Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal
patients of the ABCSG-18 trial. (Abstract 504) M. Gnant, G. Pfeiler, P. C.
Dubsky, M. Hubalek, R. Greil, R. Jakesz, V. Wette, M. Balic, F. Haslbauer, E.
Melbinger-Zeinitzer, V. Bjelic Radisic, J. C. Bergh, F. Fitzal, D. Egle, B. Mlineritsch,
G. G. Steger, S. Talbot, D. J. Warner, C. Fesl, C. F. Singer, ABCSG
9:24 AM
Robert E. Coleman, MBBS, MD, FRCP (Discussion of Abstract(s) 503–504)
University of Sheffield, Weston Park Hospital
Optimizing Adjuvant Therapy with Bone-Modifying Agents
9:36 AM
9:48 AM
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of
neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).
(Abstract 505) L. Gianni, T. Pienkowski, Y. Im, L. Tseng, M. Liu, A. Lluch, E.
Staroslawska, J. de la Haba-Rodriguez, S. Im, J. L. Pedrini, B. Poirier, P. Morandi,
V. Semiglazov, V. Srimuninnimit, G. V. Bianchi, V. McNally, H. Douthwaite, G.
Ross, P. Valagussa
10:00 AM
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy
in HER2-positive hormone-receptor-positive early breast cancer: WSGADAPT HER2ⴙ/HRⴙ phase II trial. (Abstract 506) N. Harbeck, O. Gluz, M.
Christgen, M. W. Braun, S. Kummel, J. Potenberg, B. Aktas, C. Schumacher, H.
Forstbauer, D. Augustin, S. Kraemer, M. Just, J. Tio, A. Kleine-Tebbe, C. Liedtke,
R. E. Kates, D. Hofmann, R. Wuerstlein, H. H. Kreipe, U. Nitz, West German Study
Group ADAPT HER2⫹/HR⫹ Investigators
10:12 AM
Phase III, randomized study of trastuzumab emtansine (T-DM1) ⴞ
pertuzumab (P) vs trastuzumab ⴙ taxane (HT) for first-line treatment of
HER2-positive MBC: Primary results from the MARIANNE study. (Abstract
507) P. A. Ellis, C. H. Barrios, W. Eiermann, M. Toi, Y. Im, P. F. Conte, M. Martin,
T. Pienkowski, X. B. Pivot, H. A. Burris III, A. Strasak, M. Patre, E. A. Perez
203
MONDAY
10:24 AM
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive
early breast cancer: Primary analysis at 2 years of a phase 3, randomized,
placebo-controlled trial (ExteNET). (Abstract 508) A. Chan, S. Delaloge, F.
Holmes, B. Moy, H. Iwata, V. J. Harvey, N. J. Robert, T. Silovski, E. Gokmen, G.
Von Minckwitz, B. Ejlertsen, S. K. Chia, J. Mansi, C. H. Barrios, M. Gnant, A.
Wong, R. Bryce, B. Yao, M. Martin
10:36 AM
Shanu Modi, MD (Discussion of Abstract(s) 505–508)
HER2-Positive Breast Cancer: Beyond Trastuzumab
10:48 AM
Gynecologic Cancer
Location: E354b
John K. Chan, MD—Co-Chair
Rebecca Sophie Kristeleit, MD, PhD—Co-Chair
MONDAY
8:00 AM
A randomized phase II study of paclitaxel/carboplatin/bevacizumab,
paclitaxel/carboplatin/temsirolimus, and
ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage
III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. (Abstract
5500) C. Aghajanian, V. L. Filiaci, D. S. Dizon, J. Carlson, M. A. Powell, A. A.
Secord, K. S. Tewari, D. Bender, D. M. O’Malley, A. Stuckey, J. Rotmensch, D. A.
Levine, H. A. Lankes, K. N. Moore
8:12 AM
Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for
women with high-risk endometrial cancer: Toxicity and quality-of-life results
of the randomized PORTEC-3 trial. (Abstract 5501) C. L. Creutzberg, S. M. de
Boer, H. Putter, M. Powell, L. R. Mileshkin, D. Katsaros, P. Bessette, C. HaieMeder, J. A. Ledermann, P. B. Ottevanger, P. Khaw, A. Colombo, A. W. Fyles, M.
Baron, H. W. Nijman, R. A. Nout, V. T. Smit, K. Verhoeven-Adema, R. F.
Kruitwagen, H. C. Kitchener
8:24 AM
Randomized phase II trial of carboplatin-paclitaxel (CP) compared to
carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or
recurrent endometrial cancer: The MITO END-2 trial. (Abstract 5502) D.
Lorusso, G. Ferrandina, N. Colombo, S. Pignata, V. Salutari, G. Maltese, C.
Pisano, M. Lapresa, A. Savarese, P. Tagliaferri, R. Sorio, S. Cinieri, E. Breda, R.
Sabbatini, S. Lepori, C. Conte, S. C. Cecere, F. Raspagliesi, G. Scambia
8:36 AM
Rebecca Sophie Kristeleit, MD, PhD (Discussion of Abstract(s) 5500 –5502)
Endometrial Cancer: Catching up on Recent Data
8:48 AM
9:00 AM
Impact of trebananib plus weekly paclitaxel on overall survival (OS) in
patients (pts) with recurrent ovarian cancer and ascites: Results from the
phase III TRINOVA-1 study. (Abstract 5503) B. J. Monk, A. Poveda, I. Vergote,
F. Raspagliesi, K. Fujiwara, D. Bae, A. Oaknin, I. Ray-Coquard, D. M. Provencher,
B. Y. Karlan, C. Lhommé, G. Richardson, D. Gallardo Rincon, R. L. Coleman, A.
Brize, K. Zhang, F. D. Vogl, B. A. Bach, A. M. Oza
204
Efficacy and safety of chemotherapy (CT) ⴞ pertuzumab (P) for platinumresistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE
double-blind placebo-controlled randomized phase III trial. (Abstract 5504) C.
Kurzeder, I. Bover, F. Marmé, J. Rau, P. Pautier, N. Colombo, D. Lorusso, P.
Ottevanger, M. Bjurberg, C. Marth, P. Barretina-Ginesta, I. Vergote, A. Floquet, J.
Del Campo, S. Mahner, L. Bastiere-Truchot, L. Mitchell, S. Polleis, A. Du Bois, A.
Gonzalez-Martin
9:24 AM
Retrospective analysis of candidate predictive tumor biomarkers (BMs) for
efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel
(CP) ⴞ bevacizumab (BEV) for epithelial ovarian cancer (EOC). (Abstract
5505) M. J. Birrer, Y. Choi, M. F. Brady, R. S. Mannel, R. A. Burger, W. WEI, A.
Husain, C. Bais, NRG Oncology/Gynecologic Oncology Group
9:36 AM
Don S. Dizon, MD (Discussion of Abstract(s) 5503–5505)
Added Value or Splitting Hairs? Adding Targeted Therapy to the Mix
9:48 AM
10:00 AM
An international, biomarker-directed, randomized, phase II trial of AZD1775
plus paclitaxel and carboplatin (P/C) for the treatment of women with
platinum-sensitive, TP53-mutant ovarian cancer. (Abstract 5506) A. M. Oza,
J. I. Weberpals, D. M. Provencher, E. Grischke, M. Hall, D. Uyar, M. D. EstevezDiz, F. Marmé, A. Kuzmin, P. Rosenberg, R. M. Wenham, J. Qiu, M. A. Lee, J. Liu,
S. Rose, K. N. Moore
10:12 AM
A phase I study of continuous veliparib in combination with IV
carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly
diagnosed patients with previously untreated epithelial ovarian, fallopian
tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology
Group study. (Abstract 5507) K. M. Bell-McGuinn, W. E. Brady, R. J. Schilder,
P. M. Fracasso, K. N. Moore, J. L. Walker, L. R. Duska, C. A. Mathews, A. Chen,
S. P. Shepherd, V. L. Giranda, C. Aghajanian
10:24 AM
Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer
patients likely to respond to rucaparib using tumor genetic analysis.
(Abstract 5508) I. A. McNeish, A. M. Oza, R. L. Coleman, C. L. Scott, G. E.
Konecny, A. Tinker, D. M. O’Malley, J. Brenton, R. S. Kristeleit, K. Bell-McGuinn, A.
Oaknin, A. Leary, K. Lin, M. Raponi, H. Giordano, S. Goble, L. Rolfe, R. Yelensky,
A. R. Allen, E. M. Swisher
10:36 AM
Elise C. Kohn, MD (Discussion of Abstract(s) 5506 –5508)
A Wee Bit of DNA Repair Inhibition
10:48 AM
MONDAY
9:12 AM
Location: S102
Shari Beth Goldfarb, MD—Co-Chair
Karen L. Smith, MD—Co-Chair
Washington Cancer Institute, MedStar Washington Hospital Center
8:00 AM
Phase III trials of anamorelin in patients with advanced non-small cell lung
cancer (NSCLC) and cachexia (ROMANA 1 and 2). (Abstract 9500) J. S. Temel,
D. C. Currow, K. Fearon, Y. Yan, J. Friend, A. P. Abernethy
205
MONDAY
8:12 AM
CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs.
longer interval dosing of zoledronic acid in metastatic cancer. (Abstract
9501) A. L. Himelstein, R. Qin, P. J. Novotny, D. K. Seisler, J. L. Khatcheressian,
J. D. Roberts, S. S. Grubbs, T. O’Connor, D. Weckstein, C. L. Loprinzi, C. L.
Shapiro
8:24 AM
Olanzapine versus fosaprepitant for the prevention of nausea and vomiting
in patients receiving concurrent chemoradiation treatment. (Abstract 9502)
R. M. Navari, C. K. Nagy
8:36 AM
Jamie H. Von Roenn, MD (Discussion of Abstract(s) 9500 –9502)
Evidenced-Based Symptom Management: Worth the Weight
8:48 AM
9:00 AM
Chemotherapy-related cognitive impairment (CRCI), and neurotransmitter
signaling, longevity, and inflammation pathways in 366 breast cancer (BC)
patients and 366 age-matched cancer-free controls: A prospective,
nationwide, longitudinal URCC NCORP study. (Abstract 9503) M. C. Janelsins,
S. Yao, K. M. Mustian, L. J. Peppone, C. E. Heckler, B. Esparaz, J. K. Giguere, R.
Irwin, B. Neilan, T. Ahles, C. B. Ambrosone, G. R. Morrow
9:12 AM
EXCAP exercise effects on cognitive impairment and inflammation: A URCC
NCORP RCT in 479 cancer patients. (Abstract 9504) K. M. Mustian, M. C.
Janelsins, L. J. Peppone, C. S. Kamen, J. J. Guido, C. E. Heckler
9:24 AM
Cognition: Something to Think About
9:36 AM
9:48 AM
Randomized trial of exercise on quality of life and fatigue in women
diagnosed with ovarian cancer: The Women’s Activity and Lifestyle Study in
Connecticut (WALC). (Abstract 9505) Y. Zhou, L. Gottlieb, B. Cartmel, F. Li,
E. A. Ercolano, M. Harrigan, R. McCorkle, J. A. Ligibel, V. E. Von Gruenigen, R.
Gogoi, P. E. Schwartz, H. A. Risch, M. L. Irwin
10:00 AM
Results of the exercise and nutrition to enhance recovery and good health
for you (ENERGY) trial: A behavioral weight loss intervention in overweight
or obese breast cancer survivors. (Abstract 9506) C. L. Rock, S. Flatt, T. Byers,
G. A. Colditz, W. Demark-Wahnefried, P. A. Ganz, K. Y. Wolin, A. D. Elias, H.
Krontiras, J. Liu, M. Naughton, B. Pakiz, B. A. Parker, R. L. Sedjo, H. Wyatt,
Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY)
Trial Group
10:12 AM
The impact of physical activity on fatigue and quality of life in lung cancer
patients: A randomised controlled trial (RCT). (Abstract 9507) J. L. Vardy, M.
Bell, H. van der Ploeg, J. Turner, M. Kabourakis, L. Spencer, C. R. Lewis, R. Hui,
P. L. Blinman, S. J. Clarke, M. J. Boyer, H. M. Dhillon
10:24 AM
Impact of the LIVESTRONG at the YMCA Program on physical activity,
fitness, and quality of life in cancer survivors. (Abstract 9508) M. L. Irwin, B.
Cartmel, M. Harrigan, T. B. Sanft, C. Wong, M. Hughes, N. Hootsmans, B.
Winterhalter, L. Shockro, K. O’Connor, S. M. Tolaney, E. L. Mayer, R. L. Yung,
R. A. Freedman, J. A. Ligibel
10:36 AM
Lee Jones, PhD (Discussion of Abstract(s) 9505–9507)
Fit for Life
10:48 AM
206
Pediatric Oncology II
Location: S504
Lisa Diller, MD—Co-Chair
Dana-Farber Cancer Institute and Harvard Medical School
8:00 AM
Augmentation of therapy for favorable-histology Wilms tumor with combined
loss of heterozygosity of chromosomes 1p and 16q: A report from the
Children’s Oncology Group studies AREN0532 and AREN0533. (Abstract
10009) D. B. Dix, C. V. Fernandez, Y. Chi, J. R. Anderson, E. A. Mullen, J. I. Geller,
E. J. Gratias, G. Khanna, J. A. Kalapurakal, E. J. Perlman, N. Seibel, P. F. Ehrlich,
M. H. Malogolowkin, K. W. Gow, T. E. Hamilton, P. E. Grundy, J. Dome
8:12 AM
Outcome and prognostic factors in stage III favorable histology Wilms tumor
(FHWT): A report from the Children’s Oncology Group (COG) study
AREN0532. (Abstract 10010) C. V. Fernandez, E. A. Mullen, P. F. Ehrlich, J. A.
Kalapurakal, G. Khanna, Y. Chi, E. Perlman, A. Paulino, T. E. Hamilton, K. W.
Gow, F. A. Ferrer, Z. Tochner, Q. An, F. A. Hoffer, J. Withycombe, R. C.
Shamberger, J. I. Geller, J. R. Anderson, P. E. Grundy, J. S. Dome, AREN0532
Study Committee
8:24 AM
Omission of lung radiation in patients with stage IV favorable histology
Wilms tumor (FHWT) showing complete lung nodule response after
chemotherapy: A report from Children’s Oncology Group study AREN0533.
(Abstract 10011) D. B. Dix, E. J. Gratias, N. Seibel, J. R. Anderson, E. A. Mullen,
J. I. Geller, G. Khanna, J. A. Kalapurakal, E. J. Perlman, P. F. Ehrlich, M. H.
Malogolowkin, P. E. Grundy, J. S. Dome
8:36 AM
Daniel M. Green, MD (Discussion of Abstract(s) 10009 –10011)
Impact of Improved Risk Stratification in Wilms Tumor
8:48 AM
9:00 AM
Risk-based treatment for synovial sarcoma in patients under 30 years of age:
Children’s Oncology Group study ARST0332. (Abstract 10012) R.
Venkatramani, J. R. Anderson, L. Million, C. M. Coffin, B. McCarville, R. Randall,
D. Parham, S. C. Kao, A. A. Hayes-Jordan, S. L. Wolden, S. A. Terezakis, J. O.
Black, F. Laurie, R. A. Speights, S. Skapek, D. S. Hawkins, S. L. Spunt
9:12 AM
Long-term risks for chronic medical conditions and premature mortality in
survivors of pediatric soft tissue sarcoma: A report from the Childhood
Cancer Survivor Study (CCSS). (Abstract 10013) E. L. Mueller, R. J.
Hutchinson, P. Goodman, W. M. Leisenring, C. A. Sklar, M. M. Hudson, K. K. Ness,
G. T. Armstrong, L. L. Robison, M. Stovall, K. C. Oeffinger, P. C. Nathan
9:24 AM
Association of recurrent or progressive p of form types II and III
pleuropulmonary blastoma (PPB) with poor outcome: A report from the
international PPB registry. (Abstract 10014) K. P. Schultz, G. M. Williams, D.
Stewart, P. S. Rosenberg, L. A. Doros, L. P. Dehner, D. A. Hill, Y. H. Messinger
9:36 AM
Steven G. DuBois, MD (Discussion of Abstract(s) 10012–10013)
Rare Pediatric Solid Tumors: From Infancy to Survivorship
9:48 AM
10:00 AM
Early results from Children’s Oncology Group (COG) ARST08P1: Pilot
studies of cixutumumab or temozolomide with intensive multiagent
chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).
(Abstract 10015) S. Malempati, B. Weigel, J. R. Anderson, D. Parham, L. A. Teot,
D. A. Rodeberg, T. I. Yock, B. L. Shulkin, D. S. Hawkins
207
MONDAY
Noah Federman, MD—Co-Chair
10:12 AM
Banked EBV-specific T-cells from HLA-partially matched normal donors to
induce durable remissions rituximab refractory EBVⴙ B-cell lymphomas
post hematopoietic and organ allografts. (Abstract 10016) S. Prockop, E.
Doubrovina, K. Baroudy, F. Boulad, R. Khalaf, E. B. Papadopoulos, C. S. Sauter,
V. Szenes, S. Suser, G. Wasilewski, J. Ruggiero, R. J. O’Reilly
10:24 AM
A feasibility and phase II study of the hu14.18-IL2 immunocytokine in
combination with GM-CSF and isotretinoin in patients with recurrent or
refractory neuroblastoma: A Children’s Oncology Group study. (Abstract
10017) S. Shusterman, W. B. London, J. A. Hank, M. T. Parisi, B. L. Shulkin, S.
Servaes, A. Naranjo, H. Shimada, J. Gan, S. Gillies, J. M. Maris, J. R. Park, P. M.
Sondel
10:36 AM
Crystal Mackall, MD (Discussion of Abstract(s) 10014 –10017)
Antibody and Cellular Therapy in Pediatric Oncology: Mechanisms and Future
Directions
10:48 AM
Location: S Hall A
Abstracts 3509 –3520 will be session during the Gastrointestinal (Colorectal) Cancer Poster Discussion Session. See page 254 for session information.
MONDAY
Board 1
Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced
colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized
clinical trials (RCTs). (Abstract 3509) J. F. Seligmann, D. Fisher, F. Elliott, S.
Richman, R. Butler, J. Cheadle, R. A. Adams, P. Quirke, T. Maughan, M. T.
Seymour, G. W. Middleton
Board 2
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial
treatment for metastatic colorectal cancer (TRIBE study): Updated survival
results and final molecular subgroups analyses. (Abstract 3510) F. Loupakis,
C. Cremolini, C. Antoniotti, S. Lonardi, M. Ronzoni, A. Zaniboni, G. Tonini, L.
Salvatore, S. Chiara, C. Carlomagno, C. Banzi, F. Negri, L. Marcucci, C. Barone,
G. Fontanini, N. Borrelli, M. Giordano, E. Macerola, L. Boni, A. Falcone
Board 3
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab
in patients with BRAF-mutated metastatic colorectal cancer and advanced
cancers. (Abstract 3511) D. S. Hong, V. K. Morris II, B. E. El Osta, S. Fu, M. J.
Overman, S. A. Piha-Paul, V. Subbiah, B. K. Kee, A. M. Tsimberidou, R. Zinner,
D. R. Fogelman, J. Bellido, I. Shureiqi, F. Meric-Bernstam, S. Kopetz
Board 4
Randomized phase III study of adjuvant chemotherapy with S-1 versus
capecitabine (cape) in patients with stage III colon cancer (CC): Results of
Japan Clinical Oncology Group study (JCOG0910). (Abstract 3512) T.
Hamaguchi, Y. Shimada, J. Mizusawa, Y. Kinugasa, Y. Kanemitsu, M. Ohue, S.
Fujii, N. Takiguchi, T. Yatsuoka, Y. Takii, H. Ojima, H. Masuko, Y. Kubo, H.
Mishima, T. Yamaguchi, H. Bandou, T. Sato, T. Kato, K. Nakamura, H. Fukuda,
JCOG Colorectal Cancer Study Group
Board 5
Cochrane systematic review and meta-analysis of adjuvant therapy for stage
II colon cancer. (Abstract 3513) B. M. Meyers, H. O. Al-Shamsi, A. T. Figueredo
Board 6
Toxicity and quality of life data from SCOT: An international phase III
randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatinbased adjuvant chemotherapy. (Abstract 3514) T. Iveson, R. Kerr, M. P.
Saunders, A. M. Waterston, N. H. Hollander, L. C. Medley, J. Tabernero, C.
Wilson, R. Ellis, S. Essapen, A. M. Haydon, A. S. Dhadda, R. Hughes, S. Falk, S.
Abdel-Raouf, B. Glimelius, K. Allan, W. Barlow, A. Briggs, J. Paul
208
Board 7
A randomized phase III trial comparing S-1 versus UFT as adjuvant
chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). (Abstract
3515) A. Murata, K. Yoshida, K. Maeda, K. Ikejiri, Y. Munemoto, K. Sasaki, C.
Matsuda, M. Kotake, T. Suenaga, H. Matsuda, H. Baba, C. Hamada, E. Oki, Y.
Emi, S. Saji, Y. Maehara
Board 8
S0713: A phase II study of cetuximab (CET) added to induction
chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by
neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer
(LARC). (Abstract 3516) C. G. Leichman, S. L. McDonough, S. R. Smalley, K. G.
Billingsley, H. Lenz, M. A. Beldner, A. F. Hezel, M. R. Velasco, K. A. Guthrie, C. D.
Blanke, H. S. Hochster
Board 9
Safety and tolerability of veliparib combined with capecitabine plus
radiotherapy in patients with locally advanced rectal cancer (LARC): Final
results of a phase Ib study. (Abstract 3517) M. Michael, M. F. Mulcahy, D. A.
Deming, H. Vaghefi, G. S. Jameson, A. DeLuca, H. Xiong, W. Munasinghe, M. W.
Dudley, P. Komarnitsky, K. D. Holen, B. G. Czito
Board 10
Compliance to chemoradiation (CRT) using mitomycin (MMC) or cisplatin
(CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in
squamous cell carcinoma of the anus (SCCA) according to radiotherapy (RT)
dose, overall treatment time (OTT) and chemotherapy (CT) and their impact
on long-term outcome: Results of ACT II. (Abstract 3518) R. Glynne-Jones,
H. M. Meadows, A. Lopes, R. A. Adams, D. Sebag-Montefiore
Board 11
Comprehensive multiplatform biomarker analysis of 212 anal squamous cell
carcinomas. (Abstract 3519) P. M. Boland, J. Wang, D. Arguello, S. Z. Millis, Z.
Gatalica, S. K. Reddy, J. E. Meyer, T. R. Halfdanarson
Board 12
Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I,
dose-expansion study in patients (pts) with metastatic squamous cell
carcinoma (mSCC) of the anus. (Abstract 3520) J. C. Bendell, C. Eng, K. N.
Moore, H. A. Burris III, F. Meric-Bernstam, S. F. Jones, S. A. Piha-Paul, J. R.
Infante, V. Subbiah, T. M. Bauer, L. Golden, J. Lin, R. Martinez, S. Wijayawardana,
A. K. Lin, D. S. Hong
Board 13
Role of race and socioeconomic status in overall and cancer-specific
survival of anal cancer patients. (Abstract 3521) J. Belmonte, T. H. Taylor,
J. Carmichael, J. A. Zell
Board 14
Comprehensive genomic profiling of anal squamous cell carcinoma to reveal
frequency of clinically relevant genomic alterations in the PI3K/mTOR
pathway. (Abstract 3522) E. M. Sanford, S. M. Ali, J. A. Elvin, G. M. Frampton, J.
Sun, N. A. Palma, J. Chmielecki, R. Yelensky, D. Lipson, V. A. Miller, P. J.
Stephens, J. S. Ross
Board 15
Programmed cell death-Ligand 1 (PD-L1) expression and outcome in patients
with squamous cell cancer of anal canal (SCCAC). (Abstract 3523) S. Gujja,
S. K. Williamson, A. Batra, A. M. Saeed, K. Lai, B. J. Fogel, J. D. James, E. R.
Siegel, R. Govindarajan
Board 16
Sequential liver and lung resection for colorectal cancer metastases: In
which patients should surgery be proposed? (Abstract 3524) M. Rajakannu, P.
Magdeleinat, E. Vibert, P. F. Innominato, O. Ciacio, G. Pittau, M. Gelli, A. Sa
Cunha, D. Cherqui, F. Levi, D. Castaing, J. F. Morere, R. Adam
Board 17
Impact of UGT1A1 genotype on prognosis in Japanese advanced colorectal
cancer patients treated by irinotecan-based regimens. (Abstract 3525) W.
Ichikawa, K. Uehara, K. Minamimura, C. Tanaka, Y. Takii, H. Miyauchi, S.
Sadahiro, K. Shinozaki, K. Fukumoto, T. Otsuji, T. Kambara, S. Morita, Y. Ando, Y.
Okutani, M. Sugihara, T. Sugiyama, Y. Ohashi, Y. Sakata
Board 18
Masitinib plus FOLFIRI for second line treatment of metastatic colorectal
cancer: An open label phase Ib/II trial. (Abstract 3526) J. Taieb, C. Borg, T.
Lecomte, C. Lepère, T. Chatellier, D. M. Smith, P. Dubreuil, C. Mansfield, A.
Moussy, O. Hermine
209
MONDAY
MONDAY
Board 19
A phase II study of NK012, a polymeric micelle formulation of SN-38, in
colorectal cancer patients who had received prior oxaliplatin-based regimen.
(Abstract 3527) A. Tsuji, T. Hamaguchi, K. Yamaguchi, K. Takeda, H. Uetake, T.
Esaki, K. Amagai, N. Sugimoto, H. Baba, M. Kimura, Y. Matsumura, Y. Nambu
Board 20
Can we use radiofrequency ablation for liver metastases from colorectal
cancer over 25 mm initially but downsized by systemic chemotherapy?
(Abstract 3528) L. Benhaim, F. Peschaud, M. El hajjam, R. Malafosse, J. Sellier,
C. Julie, A. Beauchet, P. Rougier, B. Nordlinger
Board 21
Long-term follow-up of bone marrow micrometastases in colon cancer
patients. (Abstract 3529) C. T. Viehl, U. Guller, M. Ramser, S. Dell-Kuster, B.
Weixler, G. Sauter, L. Terracciano, R. Rosenthal, D. Oertli, M. Zuber
Board 22
Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab)
LY3022856/IMC-3C5 (3C5). (Abstract 3530) W. M. Saif, J. A. Knost, E. G.
Chiorean, S. Kambhampati, D. Yu, B. Pytowski, A. Qin, J. S. Kauh, B. H. O’Neil
Board 23
Relationship between metformin use and recurrence and survival in patients
(pts) with resected stage III colon cancer (CC) receiving adjuvant
chemotherapy: Results from NCCTG N0147 (Alliance). (Abstract 3531) P.
Singh, Q. Shi, N. R. Foster, A. Grothey, S. Nair, E. Chan, A. F. Shields, R. M.
Goldberg, S. Gill, M. S. Kahlenberg, F. A. Sinicrope, D. J. Sargent, S. R. Alberts
Board 24
DPYD c.1905ⴙ1G>A and c.2846A>T and UGT1A1*28 allelic variants as
predictors of toxicity: Pharmacogenetic translational analysis from the phase
III TRIBE study in metastatic colorectal cancer. (Abstract 3532) M. Del Re, C.
Cremolini, F. Loupakis, F. Marmorino, V. Citi, M. Palombi, F. Bergamo, M.
Schirripa, D. Rossini, E. Cortesi, G. Tomasello, R. Spadi, A. Buonadonna, D.
Amoroso, S. Vitello, S. Di Donato, C. Granetto, M. D’Amico, R. Danesi, A. Falcone
Board 25
Dual targeting of vascular endothelial growth factor-A (VEGF-A) and
angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer
(mCRC): Results of the VENGEANCE study. (Abstract 3533) J. Mooi, G.
Chong, S. Brown, R. Wong, T. J. Price, E. Skrinos, N. C. Tebbutt
Board 27
Tumor response outcomes in first-line treatment of wild-type (WT) RAS
metastatic colorectal carcinoma (mCRC) following modified FOLFOX6
(mFOLFOX6) ⴙ either panitumumab (pmab) or bevacizumab (bev). (Abstract
3535) F. Rivera, M. Karthaus, J. R. Hecht, G. Fasola, J. Canon, R. Koukakis, J.
Terwey, L. S. Schwartzberg
Board 28
Expression of amphiregulin (AREG) and response to first-line panitumumab
(pmab) ⴙ FOLFIRI in metastatic colorectal cancer (mCRC). (Abstract 3536) C.
Kohne, R. D. Hofheinz, L. Mineur, H. Letocha, R. Greil, J. Thaler, B. Twomey, K. S.
Oliner, M. Boedigheimer, J. Terwey, M. Karthaus
Board 29
A phase II, randomized, double-blinded, placebo-controlled study of
simtuzumab or placebo in combination with FOLFIRI for the second line
treatment of metastatic KRAS mutant colorectal adenocarcinoma. (Abstract
3537) J. R. Hecht, J. C. Bendell, D. Vyushkov, K. Bencardino, U. N. Verma, Y.
Yang, D. L. Thai
Board 30
Population-based assessment of surrogate endpoints (SE) in stage I-III colon
(CCa) and rectal cancers (RCa). (Abstract 3538) R. M. Lee-Ying, C. Speers, G.
Gresham, Y. J. McConnell, W. Y. Cheung, H. F. Kennecke
Board 31
Risk factors for interval advanced colorectal neoplasia after screening
colonoscopy. (Abstract 3539) L. W. Musselwhite, C. M. Thomas, D. H. Abbott,
E. R. Hauser, L. K. Wagner, S. F. Morris, D. G. Weiss, D. A. Lieberman, D. T.
Provenzale
Board 32
A phase Ib study of AUY922 and cetuximab in patients with KRAS wild-type
(WT) metastatic colorectal cancer (mCRC). (Abstract 3540) S. Subramaniam,
G. E. Goodman, B. Boatman, A. W. Smith, D. Iriarte, P. J. Gold
Board 33
PRODIGE 20: Bevacizumab ⴙ chemotherapy (BEV-CT) versus chemotherapy
alone (CT) in elderly patients (pts) with untreated metastatic colorectal
cancer (mCRC)—A randomized phase II trial. (Abstract 3541) T. Aparicio, O.
210
Board 34
A prospective, multi-center study of individualized, pharmacokinetically
(PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer
(mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing
regimens. (Abstract 3542) V. Kunzmann, K. Link, M. C. Miller, S. Holdenrieder, T.
Bertsch, L. Mueller, Y. Ko, O. J. Stoetzer, I. Suttmann, J. Braess, U. Jaehde, M.
Roessler, B. Moritz, S. Kraff, A. Fritsch, S. J. Salamone, M. Wilhelm
Board 35
The PRIME trial: Quality-adjusted survival in patients with RAS wild-type
(WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with
panitumumab plus FOLFOX versus FOLFOX alone. (Abstract 3543) J. Wang,
J. Dong, G. Hechmati, A. Rong, G. Maglinte, B. L. Barber, J. Douillard
Board 36
An investigator initiated multicenter phase I/II study of TAS-102 with
bevacizumab for metastatic colorectal cancer refractory to standard
therapies (C-TASK FORCE). (Abstract 3544) Y. Kuboki, T. Nishina, E. Shinozaki,
K. Yamazaki, K. Shitara, W. Okamoto, T. Kajiwara, T. Matsumoto, T. Tsushima, N.
Mochizuki, M. Fukutani, M. Nakamoto, H. Hasegawa, A. Sugama, S. Nomura, A.
Sato, A. Ohtsu, T. Yoshino
Board 37
Association between c-Met expression, miR-31–3p expression and
progression free survival in the New EPOC study. (Abstract 3545) S. A. Pugh,
J. A. Bridgewater, K. Moutasim, G. Thomas, P. Laurent-Puig, R. Thiébaut, F.
Liebaert, A. H. Mirnezami, M. Lopez, T. Mellows, S. Falk, M. Finch-Jones, J. W.
Valle, M. Rees, J. Hornbuckle, L. Stanton, O. J. Garden, D. Cunningham, T.
Maughan, J. N. Primrose
Board 38
Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody
drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.
(Abstract 3546) A. Starodub, A. J. Ocean, W. A. Messersmith, V. J. Picozzi, M. J.
Guarino, A. Bardia, S. S. Thomas, J. Berlin, M. A. Shah, P. P. Maliakal, W. A.
Wegener, R. M. Sharkey, F. Wilhelm, D. M. Goldenberg
Board 39
Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab
benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients
(pts) from the PICCOLO trial. (Abstract 3547) P. Laurent-Puig, S. Paget-Bailly,
D. Vernerey, C. Vazart, V. Decaulne, K. Fontaine, F. Rousseau, F. Elliott, P.
Quirke, S. Richman, J. Seligman, M. T. Seymour, F. Bonnetain, F. Liebaert, R.
Thiébaut
Board 40
C-reactive protein and interleukin-6 as markers of systemic inflammatory
response and as prognostic factors for metastatic colorectal cancer. Data
from the randomized phase III NORDIC-VII study. (Abstract 3548) M. Thomsen,
C. Kersten, H. Sorbye, E. Skovlund, T. Ikdahl, J. S. Johansen, P. Pfeiffer, B.
Glimelius, K. Tveit, T. Guren
Board 41
Epidermal growth factor receptor mutations may confer resistance or
cross-resistance to cetuximab and panitumumab and can be detected in
circulating tumor DNA. (Abstract 3549) M. Binder, F. Braig, A. Schieferdecker,
A. Schulte, A. Stein, T. Grob, M. Kriegs, E. Engel, U. J. Vanhoefer, S. Loges, K.
Riecken, B. Fehse, C. Bokemeyer
Board 42
PIK3CA mutations in colorectal and endometrial cancer with double somatic
mismatch repair mutations compared to Lynch syndrome. (Abstract 3550) S.
Shiovitz, E. Turner, M. Beightol, A. Jacobson, T. Gooley, S. J. Salipante, S.
Haraldsdottir, J. F. Tait, W. M. Grady, E. H. Lin, A. De La Chapelle, D. E. Cohn,
P. J. Goodfellow, M. Arnold, H. Hampel, C. C. Pritchard
Board 43
A simplified nomogram to predict long-term survival after conversion
chemotherapy followed by hepatectomy for initially unresectable colorectal
liver metastases. (Abstract 3551) K. Imai, M. Allard, C. Castro Benitez, E. Vibert,
A. Sa Cunha, D. Cherqui, D. Castaing, H. Baba, R. Adam
Board 44
Variations in genes regulating tumor-associated macrophages (TAMs) to
predict outcome of bevacizumab (bev)-based treatment in patients with
211
MONDAY
Bouche Sr., E. Francois, E. Maillard, S. Kirscher, J. Taïeb, P. Etienne, R. Faroux,
F. Khemissa, F. El Hajbi, C. Locher, Y. Rinaldi, T. Lecomte, S. Lavau-Denes, M.
Baconnier, A. Oden-Gangloff, D. Genet, E. Paillaud, F. Retornaz, L. Bedenne
metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.
(Abstract 3552) Y. Sunakawa, S. Stintzing, V. Heinemann, C. Cremolini, A.
Falcone, S. Cao, D. Yang, W. Zhang, S. Yamauchi, Y. Ning, S. Stremitzer, S.
Matsusaka, A. Parekh, S. Graver, A. Mendez, S. Okazaki, R. Elkhoueiry, S. J.
Scherer, F. Loupakis, H. Lenz
MONDAY
Board 45
Comprehensive genomic profiling of clinically advanced colorectal
carcinoma to reveal frequent opportunities for targeted therapies. (Abstract
3553) J. S. Ross, K. Wang, D. Khaira, A. Johnson, J. Chmielecki, S. M. Ali, J. A.
Elvin, J. Vergilio, R. Yelensky, D. Lipson, V. A. Miller, P. J. Stephens
Board 46
Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts)
treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and
TRIBE cohorts. (Abstract 3554) A. Parekh, Y. Ning, S. Stintzing, F. Loupakis, W.
Zhang, D. Yang, Y. Sunakawa, S. Stremitzer, S. Matsusaka, S. Okazaki, R.
Elkhoueiry, A. Mendez, A. Barzi, M. Schirripa, V. Heinemann, H. Lenz
Board 47
Calculators for overall survival (OS) and progression-free survival (PFS) in
metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD
patients. (Abstract 3555) K. M. Sjoquist, C. Bokemeyer, L. A. Renfro, J. Simes,
N. C. Tebbutt, S. J. Clarke, R. Adams, C. J. Punt, E. Van Cutsem, J. Douillard,
J. R. Hecht, V. Heinemann, I. Sougklakos, E. Diaz-Rubio, R. Porschen, J. P.
Meyers, W. I. Gonsalves, D. J. Sargent, A. De Gramont, J. R. Zalcberg, Fondation
Aide et Récherce en Cancerologie Digestive (ARCAD) Group
Board 48
Predicting individualized post-operative survival for colorectal cancer using
a new mobile application derived from the National Cancer Database.
(Abstract 3556) E. M. Gabriel, P. Thirunavukarasu, E. Al-Sukhni, K. Attwood, S. J.
Nurkin
Board 49
Impact of primary tumor stage on survival following resection of
metachronous liver and/or lung metastases in colorectal cancer. (Abstract
3557) H. Wong, V. Boolell, S. Kosmider, K. M. Field, R. Wong, J. D. Shapiro, P.
Cooray, I. Hayes, I. Faragher, M. Steel, P. Gibbs
Board 50
Molecular subtypes and outcomes in regorafenib-treated patients with
metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.
(Abstract 3558) M. Teufel, S. Schwenke, H. Seidel, G. Beckmann, J. Reischl, R.
Vonk, H. Lenz, J. Tabernero, S. Siena, A. Grothey, E. Van Cutsem, M. Jeffers, S.
Wilhelm, A. Wagner, D. Laurent, S. Kobina, M. D. Rutstein, P. Wirapati, J.
Guinney, S. Tejpar
Board 51
Two-stage hepatectomy for extensive colorectal liver metastases: How to
predict the failure to complete both sequential procedures? (Abstract 3559)
K. Imai, C. Castro Benitez, M. Allard, E. Vibert, A. Sa Cunha, D. Cherqui, D.
Castaing, H. Baba, R. Adam
Board 52
Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL)
in patients with metastatic colorectal cancer (mCRC) in the phase III
CONCUR trial. (Abstract 3560) J. Chang, C. Ngai, D. Odom, C. Radder, C.
Kappeler, R. Xu, S. Qin, T. Kim, J. Li
Board 53
Moving foward and beyond the standard through a non-operative
management in rectal cancer? Our watch and wait approach experience in
Co-Recto. (Abstract 3561) I. S. Iseas, M. Carballido, M. Coraglio, F. Leiro, A.
Dieguez, M. Eleta, R. Bianchi, C. Bertoncini, G. A. Mendez, M. E. Barugel, E. L.
Roca
Board 54
Effect of genetic variation on overall survival in a clinical trial of metastatic
colorectal cancer (mCRC). (Abstract 3562) H. Lenz, F. Schumacher, F.
Loupakis, C. Cremolini, Y. Ning, S. Stremitzer, Y. Sunakawa, S. Matsusaka, S.
Okazaki, W. Zhang, A. Falcone
Board 55
Improvement in long-term survival in patients with metastatic colorectal
cancer (CRC) after liver resection with modern chemotherapy and hepatic
arterial infusion (HAI). (Abstract 3563) N. E. Kemeny, J. F. Chou, T. M. Boucher,
M. Capanu, R. P. DeMatteo, W. R. Jarnagin, T. P. Kingham, P. J. Allen, Y. Fong, A.
Cercek, M. I. D’Angelica
212
Board 56
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive
care in patients with metastatic colorectal cancer: Geographic subgroups.
(Abstract 3564) A. Ohtsu, T. Yoshino, M. M. Wahba, F. M. Benedetti, R. J. Mayer,
E. Van Cutsem, RECOURSE Study Group
Board 57
Using mutational load in next generation sequencing (NGS) to identify
mismatch repair (MMR) deficiency in colorectal cancer (CRC). (Abstract
3565) F. Battaglin, Z. K. Stadler, A. Cercek, R. D. Yaeger, N. H. Segal, A. M.
Varghese, N. E. Kemeny, M. R. Weiser, J. Garcia-Aguilar, J. Shia, M. F. Berger,
J. F. Hechtman, M. E. Arcila, D. B. Solit, L. Saltz
Board 58
Genomic analysis of colitis-associated cancers. (Abstract 3566) R. D. Yaeger,
V. A. Miller, J. R. Kelsen, K. Wang, Y. He, E. M. Sanford, S. Balasubramanian,
L. H. Tang, D. P. Kelsen
Board 59
FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidineaflibercept as first-line therapy in patients with metastatic colorectal cancer:
A GERCOR single-arm phase II study (VELVET). (Abstract 3567) B. Chibaudel,
T. Andre, J. Bachet, D. Auby, J. Desramé, G. Deplanque, C. Lecaille, C. Louvet, C.
Tournigand, V. Lebrun-Ly, J. Dauba, G. Lledo, M. Garcia, N. Baba Hamed, M.
Wagner, M. Attia, A. Meurisse, A. Tijeras-Raballand, F. Bonnetain, A. De Gramont,
GERCOR
Board 60
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts)
with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC):
Primary endpoint and subgroup analysis of the CEBIFOX trial. (Abstract
3568) S. Kasper, J. Meiler, H. Knipp, T. Hoehler, P. Reimer, T. Steinmetz, W.
Berger, G. Linden, S. Ting, P. Markus, A. Paul, A. Dechene, B. Schumacher, K.
Kosbade, K. Worm, K. W. Schmid, T. Herold, M. H. Schuler, T. Trarbach
Board 61
Phase I study of preoperative chemoradiation with temozolomide and
capecitabine in patients with locally advanced rectal cancer. (Abstract 3569)
Y. Hong, S. Park, J. Kim, K. Kim, J. Lee, J. Park, C. Yu, T. Kim
Board 62
S-1 as adjuvant chemotherapy for stage III colon cancer: Updated outcomes
of ACTS-CC trial. (Abstract 3570) Y. Kinugasa, M. Ishiguro, E. Nakatani, T. Endo,
H. Shinozaki, Y. Takii, Y. Takahashi, H. Mochizuki, K. Kotake, S. Kameoka, K.
Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, K. Sugihara, ACTSCC Study Group
Board 63
Immunohistochemistry to initiate a complex screening cascade in the
detection of Lynch syndrome. (Abstract 3571) G. O’Kane, T. P. McVeigh, D.
Keegan, D. Flannery, K. O’Connor, M. P. Farrell, C. Shields, B. Meighan, P.
McCormick, D. C. Winter, N. Mulligan, C. Muldoon, R. Geraghty, A. J. Green, M. J.
Kennedy, K. Sheahan, D. J. Gallagher
Board 64
Cost-effectiveness for extended RAS/RAF testing in metastatic colorectal
cancer. (Abstract 3572) M. R. Al-hajeili, F. Elkhider, M. Tiba
Board 65
Molecular classification of the invasive front in colorectal cancer. (Abstract
3573) D. McArt, P. Dunne, E. Kay, A. O’Grady, H. Barrett, K. Arthur, D. Longley,
P. W. Hamilton, D. J. Waugh, M. Lawler, P. G. Johnston, M. Salto-Tellez, S. Van
Schaeybroeck
Board 66
Zonal differences in PD-1 expression in centre of tumour versus periphery in
microsatellite stable and unstable colorectal cancer. (Abstract 3574) G.
O’Kane, M. Lynch, S. Hooper, J. Aird, C. Muldoon, N. Mulligan, C. Loscher, D. J.
Gallagher
Board 67
A phase III, randomized, double-blind, placebo-controlled trial to evaluate the
efficacy and safety of pregabalin in the prevention and reduction of
oxaliplatin-induced painful neuropathy (PreOx). (Abstract 3575) D. C. de
Andrade, M. J. Teixeira, R. Galhardoni, K. A. Ferreira, P. B. Malieno, N. Scisci,
R. P. Riechelmann, W. G. Teixeira, D. F. Saragiotto, V. A. Silva, I. Raicher, I. de
Castro, D. Parravano, J. T. Fukushima, J. Lefaucheur, D. Bouhassira, R. S.
Macarenco, E. S. de Mello, P. M. Hoff, PreOx Workgroup
Board 68
Placebo-controlled, double-blinded multi-center phase III trial of
XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer. (Abstract
213
MONDAY
3576) S. Lim, T. Kim, S. Han, H. Kang, I. Hwang, J. Lee, M. Lee, H. Kim, S. Kim, J.
Park, S. Park, Y. Park, H. Lim, J. Ham, S. Byeon, W. Kang
MONDAY
Board 69
A randomized controlled trial to evaluate laparoscopic versus open with
Japanese D3 dissection for stage II,III colorectal cancer (CRC): First efficacy
results from Japan Clinical Oncology Group Study JCOG0404. (Abstract
3577) T. Akagi, M. Inomata, H. Katayama, J. Mizusawa, T. Yamaguchi, T. Masaki,
Y. Fukunaga, K. Murata, M. Okajima, Y. Munakata, T. Sato, H. Bandou, M. Yasui,
M. Sekimoto, M. Watanabe, K. Sugihara, F. Konishi, T. Etoh, Y. Shimada, S.
Kitano
Board 70
Effect of Sym004 on acquired resistance to cetuximab in colorectal cancer
(CRC) in a novel mouse avatar model. (Abstract 3578) D. B. Vangala, S. T.
Liffers, M. Pohl, C. Teschendorf, A. Tannapfel, W. H. Schmiegel, S. Hahn
Board 72
Long-term outcome after R1 resection for colorectal liver metastases: Is a
cure possible? (Abstract 3579) I. Hosokawa, O. Ciacio, G. Pittau, M. Gelli, M.
Allard, M. Sebagh, P. F. Innominato, D. Cherqui, A. Sa Cunha, E. Vibert, F. Levi,
J. F. Morere, D. Castaing, R. Adam
Board 73
Continuing single-agent capecitabin as maintenance therapy after induction
of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer.
(Abstract 3580) R. Xu, Y. Li, H. Luo, W. Wang, Z. Wang, X. Yuan, F. Wang, D.
Zhang, D. Ma, D. Lin, J. Jia, X. Hu, J. Peng
Board 74
Baseline carcinoembryonic antigen (CEA) serum levels to predict
bevacizumab-based treatment response in patients with KRAS exon wildtype metastatic colorectal cancer (mCRC) receiving 1st-line therapy with
FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).
(Abstract 3581) M. Michl, L. Fischer von Weikersthal, T. Decker, A. Kiani, U.
Vehling-Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmueller, C. Kahl, G. Seipelt,
F. Kullmann, M. Stauch, W. Scheithauer, J. Hielscher, M. Scholz, D. P. Modest, S.
Stintzing, T. Kirchner, A. Jung, V. Heinemann
Board 75
A phase III multicenter trial comparing two different sequences of
second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs.
FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic
colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab.
(Abstract 3582) S. Cascinu, G. Rosati, G. Nasti, S. Lonardi, A. Zaniboni, P.
Marchetti, M. Aglietta, D. Bilancia, R. V. Iaffaioli, V. Zagonel, M. Giordano, D. C.
Corsi, F. Ferraú, R. Labianca, M. Ronzoni, I. C. Floriani
Board 76
HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt
advanced colorectal cancer (aCRC). (Abstract 3583) J. F. Seligmann, F. Elliott,
B. Jacobs, A. J. Hatch, A. Sibley, S. Richman, C. Jiang, J. Barrett, K. Owzar, P.
Quirke, H. Hurwitz, M. T. Seymour, A. B. Nixon
Board 77
DYPD genotyping to predict toxicity in patients with stage III colon cancer
treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8
phase III trial. (Abstract 3584) V. Boige, M. Vincent, P. Alexandre, J.
Stoehlmacher, S. Tejpar, S. Landolfi, K. Le Malicot, R. Greil, P. A. Cuyle, M. K.
Yilmaz, R. Faroux, A. Matzdorff, R. Salazar, E. Sanches, L. Mineur, C. Lepage, J.
Taïeb, P. Laurent-Puig
Board 78
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in
patients previously treated with oxaliplatin-based adjuvant therapy: A
combined analysis of data from FIRE-3 and CALGB 80405. (Abstract 3585) V.
Heinemann, D. Niedzwiecki, R. V. Pearline, A. Grothey, H. S. Hochster, R. M.
Goldberg, F. Innocenti, R. J. Mayer, R. L. Schilsky, C. D. Blanke, M. M. Bertagnolli,
A. P. Venook, S. Stinzing, B. H. O’Neil
Board 79
Final results from ASPECCT: Randomized phase 3 non-inferiority study of
panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type
(WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (Abstract 3586) T. J.
Price, M. Peeters, T. Kim, J. Li, S. Cascinu, P. Ruff, A. V. Suresh, A. L. Thomas, S.
Tjulandin, K. Zhang, R. Sidhu, S. Murugappan
214
Board 80
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in
chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer
(mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT. (Abstract
3587) M. Peeters, T. J. Price, T. Kim, J. Li, S. Cascinu, P. Ruff, A. V. Suresh, A. L.
Thomas, S. Tjulandin, K. Zhang, R. Sidhu, S. Murugappan
Board 81
A single arm phase II study of neoadjuvant transarterial regional therapy
(TACE) using preloaded Irinotecan Beads in patients with resectable
colorectal liver metastases (CRLM). (Abstract 3588) R. P. Jones, H. Z. Malik,
S. W. Fenwick, T. Gruenberger, S. Stremitzer, M. Rees, G. Plant, J. Figueras, M.
Albiol, R. Adam, S. Awad, M. Terlizzo, E. O’Grady, G. J. Poston
Board 82
Treatment until progression: Data of the “on-treatment” population of the
FIRE-3 (AIO KRK-0306) study. (Abstract 3589) S. Stintzing, L. Fischer von
Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S. Al-Batran, T. Heintges, C.
Lerchenmueller, C. Kahl, G. Seipelt, F. Kullmann, M. Stauch, C. Hielscher, S. Held,
D. P. Modest, M. H. Moehler, W. Scheithauer, A. Jung, T. Kirchner, V. Heinemann
Board 83
Influence of molecular alterations on site-specific (ss) time to recurrence
(TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial
N0147). (Abstract 3590) R. E. Wilcox, Q. Shi, F. A. Sinicrope, D. J. Sargent, N. R.
Foster, J. P. Meyers, R. M. Goldberg, S. Nair, A. F. Shields, E. Chan, S. Gill, M. S.
Kahlenberg, S. R. Alberts
Board 84
Patients’ and physicians’ risk-benefit trade-off preferences for metastatic
colorectacl cancer treatments. (Abstract 3591) J. M. Gonzalez, R. Morlock, S.
Ogale, N. Sommer, J. Posner, A. Grothey
Board 85
Phase II trial of preoperative radiation with concurrent capecitabine,
oxaliplatin, and bevacizumab followed by surgery and postoperative 5fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients
with locally advanced rectal cancer: 5-year clinical outcomes of a trial of the
ECOG-ACRIN Cancer Research Group (E3204). (Abstract 3592) J. C. Landry,
Y. Feng, R. S. Prabhu, S. J. Cohen, C. A. Staley, R. M. Whittington, E. R.
Sigurdson, H. S. Nimeiri, U. N. Verma, A. B. Benson III
Board 86
Time-dependent patterns of recurrence and death in resected colon cancer
(CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT
database containing oxaliplatin. (Abstract 3593) L. A. Renfro, M. A. Shah, C. J.
Allegra, T. Andre, A. De Gramont, F. A. Sinicrope, H. Schmoll, D. G. Haller, S. R.
Alberts, G. Yothers, D. J. Sargent
Board 87
Monitoring minimal residual disease (MRD) by KRAS mutation burden in
urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC)
patients with resectable liver metastases. (Abstract 3594) C. T. Vibat, V.
Melnikova, M. Minarik, B. Belsanova, S. Hancock, L. Hassaine, E. Samuelsz, T. T.
Lu, M. G. Erlander, L. Benesova
Board 88
TAS-102 vs placebo (PBO) in patients (pts) >65 years (y) with metastatic
colorectal cancer (mCRC): An age-based analysis of the RECOURSE trial.
(Abstract 3595) E. Van Cutsem, F. M. Benedetti, H. Mizuguchi, R. J. Mayer, A.
Ohtsu, RECOURSE Study Group
Board 89
Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal
cancer. (Abstract 3596) B. F. El-Rayes, C. A. Staley, R. Diaz, P. S. Sullivan, W. L.
Shaib, J. C. Landry
Board 90
Therapeutic biomarker differences between MSI-H and MSS colorectal
cancers. (Abstract 3597) Z. Gatalica, N. Vijayvergia, S. Vranic, J. Xiu, S. K.
Reddy, C. L. Snyder, H. T. Lynch, W. S. El-Deiry
Board 91
Measuring the impact of Next Generation Sequencing (NGS) technique
implementation in metastatic colorectal cancer (mCRC) drug development
program. (Abstract 3598) C. Ortiz, G. Argilés, E. Élez, J. Matito, L. Mendizabal, D.
Lo Giacco, F. M. Mancuso, E. Sanz-Garcia, T. Macarulla, M. Alsina, J. Capdevila,
T. Saurı́, A. Azaro, C. Cruz, C. Hierro, S. Ramon y Cajal, P. Nuciforo, J. Rodón, J.
Tabernero, A. Vivancos
215
MONDAY
MONDAY
Board 92
A genome-wide association study (GWAS) of overall survival (OS) in 609
metastatic colorectal cancer (mCRC) patients treated with chemotherapy and
biologics in CALGB 80405. (Abstract 3599) F. Innocenti, K. Owzar, C. Jiang, A.
Sibley, D. Niedzwiecki, H. Lenz, M. M. Bertagnolli, P. N. Friedman, Y. Furukawa,
M. Kubo, M. J. Ratain, C. D. Blanke, A. P. Venook, H. L. McLeod
Board 93
Modified FOLFIRI (Irinotecan 150 mg/m2) compared to FOLFIRI (Irinotecan
180 mg/m2) in Korean patients with gastrointestinal cancer. (Abstract 3600)
K. Kim, T. Kim, Y. Hong, S. Kim, S. Park, B. Nam, K. Lee, J. Kim, I. Chung, Y. Park
Board 94
Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment
in refractory metastatic colorectal cancer patients. (Abstract 3601) V. K.
Morris, M. Morelli, F. Janku, M. J. Overman, B. K. Kee, D. R. Fogelman, E. Vilar
Sanchez, I. Shureiqi, C. R. Garrett, K. P. Raghav, C. Eng, S. Manuel, R. A. Wolff,
H. Eltoukhy, R. B. Lanman, A. Talasaz, S. Kopetz
Board 95
Outcome evolution of matched molecular targeted agents (MTAs) in
metastatic colorectal cancer (CRC) patients (pts): VHIO experience. (Abstract
3602) G. Argilés, E. Élez, C. Ortiz, E. Sanz-Garcia, T. Macarulla, M. Alsina, J.
Capdevila, A. Azaro, C. Cruz, C. Hierro, M. Vilaro, D. Moreno, R. Dienstmann, S.
Landolfi, P. Nuciforo, A. Vivancos, J. Rodón, J. Tabernero
Board 96
Retrospective study of patients (pts) who were managed with Watch and
Wait strategy (W&W) after neoadjuvant chemoradiation (NCRT) for Locally
Advanced Rectal Cancer (LARC). (Abstract 3603) S. Vatandoust, Y. Lam, A. C.
Roy, D. Wattchow, P. Hollington, C. S. Karapetis
Board 97
Predictors of clonal evolution in metastatic colorectal cancer patients.
(Abstract 3604) M. Morelli, M. J. Overman, B. K. Kee, E. Vilar Sanchez, V. K.
Morris II, D. R. Fogelman, F. Janku, C. R. Garrett, I. Shureiqi, K. P. Raghav, C.
Eng, S. Manuel, R. A. Wolff, H. Eltoukhy, R. B. Lanman, A. Talasaz, S. Kopetz
Board 98
Prognostic and predictive value of tumour budding in stage II colorectal
carcinoma. (Abstract 3605) B. Mitrovic, K. Handley, N. Assarzadegan, H. H. Li
Chang, H. Dawson, A. Grin, G. Hutchins, L. Magill, P. Quirke, R. Riddell, R. G.
Gray, R. Kirsch, QUASAR Collaborative Group
Board 99
Risk of colorectal cancer after diagnosis of prostate cancer: A populationbased study. (Abstract 3606) D. N. Desautels, Z. Nugent, A. Demers, S.
Mahmud, P. Czaykowski, H. Singh
Board 100
A phase II study of 5-fluorouracil (5-FU), ziv-aflibercept, and radiation for the
preoperative and adjuvant treatment of patients (pts) with stage II/III rectal
cancer. (Abstract 3607) P. Acs, D. S. Thompson, M. B. Hemphill, D. Wenk, J. C.
Bendell, A. S. Kennedy
Board 101
Prospective evaluation of a 409-gene next generation sequencing platform to
facilitate genotype-matched clinical trial enrollment. (Abstract 3608) S.
Kopetz, B. Litzenburger, W. Kinyua, B. Sajan, V. Subbiah, R. Zinner, J. J. Wheler,
D. S. Hong, A. M. Tsimberidou, M. J. Overman, L. C. Pagliaro, N. L. Busaidy , S. N.
Westin, B. S. Glisson, J. Heymach, F. Meric-Bernstam, K. R. Shaw, J. Lee, R.
Broaddus
Board 102
A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC)
with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative
radiotherapy (SCPRT) then immediate surgery in operable rectal cancer
(ORC): COPERNICUS (NCT01263171). (Abstract 3609) S. Gollins, D. SebagMontefiore, R. Adams, M. P. Saunders, R. Grieve, N. Scott, G. Brown, P. Quirke, L.
Butlin, R. Ray, G. Griffiths, C. Hurt
Board 103
Characterization of the immune microenvironment of synchronous primary
tumor and liver colorectal metastases. (Abstract 3610) M. Van Den Eynde, B.
Mlecnik, J. H. Machiels, D. Debetancourt, G. Bindea, A. Jouret-Mourin, C.
Sempoux, J. Carrasco, J. Gigot, C. Hubert, Y. Humblet, N. Haicheur, F. Marliot, F.
Pages, J. Galon
Board 104
Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type
microsatellite instable (MSI-H) colorectal cancer (CRC) and association of
216
Board 105
Proteomic signatures of colorectal cancer to identify distinct and
reproducible subgroups and to reflect prognosis. (Abstract 3612) M. S. Lee,
C. Clarke, Z. Jiang, G. C. Manyam, F. Tian, Y. Lu, J. Morris, B. M. Broom, D.
Menter, E. Vilar Sanchez, I. Shureiqi, K. P. Raghav, C. Eng, G. J. Chang, I. Simon,
R. Bernards, G. B. Mills, M. J. Overman, D. M. Maru, S. Kopetz
Board 106
Genetic variants of kinases suppressors of Ras (KSR) to predict tumor
response to first-line cetuximab in patients with mCRC: Prospective analysis
in the FIRE 3 trial. (Abstract 3613) L. Benhaim, W. Zhang, T. Wakatsuki, A.
Gerger, D. Yang, D. Paez, Y. Ning, R. E. El-Khoueiry, F. Loupakis, P. O. Bohanes,
S. Stintzing, V. Heinemann, H. Lenz
Board 107
Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with
FOLFOX/bevacizumab in the first-line treatment of advanced colorectal
cancer. (Abstract 3614) A. Loaiza-Bonilla, M. H. O’Hara, M. Redlinger, N.
Damjanov, U. R. Teitelbaum, I. Vasilevskaya, M. A. Rosen, D. F. Heitjan, R. K.
Amaravadi, P. J. O’Dwyer
Board 108
Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase
inhibitor, in patients with advanced colorectal cancer. (Abstract 3615) D. J.
Jonker, S. A. Laurie, G. M. Cote, K. Flaherty, C. S. Fuchs, R. Chugh, D. C. Smith,
W. J. Edenfield, P. R. Conkling, J. W. Mier, R. A. Goodwin, E. L. Kwak, T. A.
Abrams, R. Goel, J. M. Cleary, W. Li, Y. Li, J. Jemison, M. Hitron, C. Li
Board 109
A phase Ib study of BBI608 in combination with FOLFIRI with and without
bevacizumab in patients (pts) with advanced colorectal cancer (CRC).
(Abstract 3616) J. M. Hubbard, D. J. Jonker, B. H. O’Neil, T. R. Halfdanarson, A.
Grothey, Y. Li, L. Borodyansky, C. Li
Board 110
A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with
panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal
cancer (mCRC) following progression on anti-EGFR therapy. (Abstract 3617)
K. K. Ciombor, W. J. Edenfield, J. M. Hubbard, P. J. O’Dwyer, C. Becerra, T.
Larson, A. I. Spira, A. Grothey, D. Manoharan, W. Li, Y. Li, L. Borodyansky, C. Li,
T. S. Bekaii-Saab
Board 111
Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in
2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research
Network GI05–102. (Abstract 3618) E. G. Chiorean, J. Picus, T. Breen, R. H.
Ansari, W. A. Harb, M. Burns, A. J. Spittler, P. J. Loehrer Sr.
Board 112
Programmed death-ligand 1 (PD-L1) expression in small bowel
adenocarcinomas (SBA). (Abstract 3619) K. Pedersen, T. C. Smyrk, S.
Harrington, R. R. McWilliams
Board 113a
A phase III study of the impact of a physical activity program on disease-free
survival in patients with high-risk stage II or stage III colon cancer: A
randomized controlled trial (NCIC CTG CO.21). (Abstract TPS3620) C. M.
Booth, J. L. Vardy, C. J. O’Callaghan, S. Gill, D. J. Jonker, C. Friedenreich, R. M.
Meyer, M. D. Brundage, R. Wong, H. M. Dhillon, P. O’Brien, B. Baylock, N. S.
Chua, S. Lipichuk, M. S. Sanatani, S. Begbie, T. Bonaventura, M. E. Burge, D. Tu,
K. S. Courneya
Board 113b
Genotype-directed phase II study of irinotecan dosing in metastatic
colorectal cancer (mCRC) patients receiving FOLFIRI ⴙ bevacizumab: The
GENIC study. (Abstract TPS3621) G. R. Williams, F. Innocenti, W. A. Wood, J. N.
Patel, G. B. Sherrill, B. H. O’Neil, J. C. Boles, E. M. Basch, H. K. Sanoff
Board 114a
Treatment strategies in colorectal cancer patients with initially unresectable
liver-only metastases: The randomized phase III CAIRO5 study of the Dutch
Colorectal Cancer Group. (Abstract TPS3622) J. Huiskens, T. M. van Gulik,
K. P. van Lienden, M. R. Engelbrecht, G. A. Meijer, N. C. van Grieken, J. Schriek,
A. Keijser, L. Mol, I. Q. Molenaar, C. Verhoef, K. P. de Jong, C. H. Dejong, G.
Kazemier, T. Ruers, J. de Wilt, H. van Tinteren, C. J. Punt
217
MONDAY
wnt pathway corepressor TLE-3. (Abstract 3611) N. Vijayvergia, J. Innocent,
A. K. Bhatia, R. Shameem, J. Xiu, Z. Gatalica, S. Grivennikov, W. S. El-Deiry
MONDAY
Board 114b
Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r)
metastatic colorectal cancer (mCRC). (Abstract TPS3623) D. R. Fogelman,
M. D. Kochenderfer, G. B. Saylors, F. S. Braiteh, J. J. Nemunaitis, A. L. Cohn, P.
O’Neill, L. Zhou, J. C. Switzky, A. Assad, J. C. Bendell
Board 115a
FOLFOXIRI with or without bevacizumab as first-line treatment for
unresectable liver-only metastatic colorectal cancer patients with RAS
mutation-type. (Abstract TPS3624) Y. Deng, H. Hu, G. Liu, Y. Cai, J. Zhang, M.
Huang, L. Wang, L. Ping, J. Wang
Board 115b
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus
best supportive care (BSC) versus placebo plus BSC in patients with
colorectal cancer (CRC) refractory to standard therapies. (Abstract TPS3625)
H. Lenz, J. Tabernero, T. Yoshino, Z. Oum’Hamed, S. Vlassak, M. Sassi, E. Van
Cutsem
Board 116a
Induction mFOLFOX6 with or without aflibercept followed by chemoradiation
(CRT) and surgery in high risk rectal cancer: Phase II randomized,
multicenter, openlabel trial—The GEMCAD RIA study. (Abstract TPS3626) C.
Fernandez-Martos, V. Alonso, I. Busquier, J. Capdevila, A. C. Gracian, J. Gallego
Plazas, I. Guasch, L. Layos, F. Losa, J. Maurel, M. Martin-Richard, M. Martinez
Villacampa, B. Massuti, C. Montagut Viladot, M. Nogue, C. Pericay, M. Safont, N.
Salas, A. Salud Salvia, R. Vera
Board 116b
SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine
and Sulindac): A randomized, double-blind, placebo-controlled phase III
clinical trial. (Abstract TPS3627) J. A. Zell, J. M. Unger, G. L. Anderson, E. D.
Cook, R. S. Krouse, M. P. Lance, L. M. Minasian, L. Ford, P. Brown
Board 117a
Multi-center, randomized, controlled, open-label effectiveness study of
primary tumor resection or not in asymptomatic colorectal cancer with
unresectable metastatic disease. (Abstract TPS3628) G. Chen, R. Zhang, Y. Li,
J. Lin, L. Kong, Z. Wang, P. Ding, D. Wan, Z. Pan, Y. Deng, H. Wang, J. Peng, M.
Qiu, C. Wang, J. Zhang, W. Li, Y. Yuan, W. Wang
Board 117b
Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and
capecitabine for locally advanced rectal cancer. (Abstract TPS3629) A. Wang,
H. K. Sanoff, A. J. McRee, B. H. O’Neil, B. F. Calvo, M. G. Hennessy, C. Murphy,
M. T. Tynan, A. W. Blackstock, E. G. Garmey, J. E. Tepper
Board 118a
The CAIRO4 study: The role of surgery of the primary tumour with few or
absent symptoms in patients with synchronous unresectable metastases of
colorectal cancer—A randomized phase III study of the Dutch Colorectal
Cancer Group (DCCG). (Abstract TPS3630) J. ’t Lam - Boer, L. Mol, C. Verhoef,
M. K. Yilmaz, T. de Haan, C. J. Punt, J. de Wilt, M. Koopman
Board 118b
The ORCHESTRA trial: A phase III trial of adding tumor debulking to
systemic therapy versus systemic therapy alone in (mCRC) multi-organ
metastatic colorectal cancer. (Abstract TPS3631) E. C. Gootjes, T. E. Buffart,
M. Tol, J. Burger, D. J. Grunhagen, E. P. van der Stok, M. R. Meijerink, A. J. Ten
Tije, E. V. Meerten, P. M. van de Ven, J. Nuyttens, C. J. Haasbeek, C. Verhoef,
H. M. Verheul
Board 119a
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET
inhibitor crizotinib in RAS MT and RAS WT (with aberrant c-MET) metastatic
colorectal cancer (mCRC) patients. (Abstract TPS3632) S. Van Schaeybroeck,
C. D. Rolfo, E. Élez, S. Kelly, J. Houlden, L. Collins, S. Love, T. Andre, M. Lawler,
F. Di Nicolantonio, M. Grayson, V. C. Popovici, A. Bardelli, P. Laurent-Puig, M.
Salto-Tellez, T. Maughan, J. Tabernero, M. Peeters, R. H. Wilson, M. R. Middleton
Board 119b
Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a
first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as
the 3rd or 4th line treatment in metastatic colorectal cancer (mCRC).
(Abstract TPS3633) X. Liu, D. R. Adib, H. Barak, R. M. Goldberg, S. Yazji
Board 120a
Phase III study of regorafenib versus placebo as maintenance therapy in RAS
wild type metastatic colorectal cancer (RAVELLO trial). (Abstract TPS3634)
E. Martinelli, T. Troiani, F. Venturini, A. Cervantes, J. Douillard, A. Falcone, G.
218
Folprecht, C. Kohne, J. Taieb, J. Tabernero, C. Cardone, V. Sforza, G. Martini, S.
Napolitano, A. Capuano, F. Auricchio, F. Ciardiello
Board 120b
A phase 3 open-label, randomized, multicenter study of imprime PGG in
combination with cetuximab in patients with KRAS wild type metastatic
colorectal cancer. (Abstract TPS3635) R. D. Huhn, J. Lowe, M. M. Grady, C. C.
Taitt, A. H. Braun
Location: S Hall A
Board 121
METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients
with metastatic HER2-negative (HER2-) and MET-positive (METⴙ)
adenocarcinoma of the stomach or gastroesophageal junction (GEC).
(Abstract 4012) M. A. Shah, Y. Bang, F. Lordick, J. Tabernero, M. Chen, S. P.
Hack, S. Phan, D. S. Shames, D. Cunningham
Board 122
FOLFOX alone or combined to rilotumumab or panitumumab as first-line
treatment in patients (pts) with advanced gastroesophageal adenocarcinoma
(AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20
MEGA). (Abstract 4013) D. Malka, F. Castan, E. Francois, O. Bouche Sr., J.
Bennouna, F. Ghiringhelli, C. De La Fouchardiere, C. Borg, E. Samalin, J. Bachet,
J. Raoul, F. Cvitkovic, L. Miglianico, L. Bengrine-Lefevre, L. Dahan, C. Lecaille, T.
Aparicio, H. Perrier, S. Gourgou, J. Taïeb, Unicancer, Fédération Francophone de
Cancérologie Digestive (FFCD), Association des Gastro-Entérologues Oncologues
(AGEO)
Board 123
A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel
(P) in previously treated patients with advanced gastric cancer (AGC) with
Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene
amplification (amp): SHINE study. (Abstract 4014) Y. Bang, E. Van Cutsem, W.
Mansoor, R. D. Petty, Y. Chao, D. Cunningham, D. Ferry, D. Landers, P.
Stockman, N. R. Smith, C. Geh, E. Kilgour
Board 124
Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized
phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).
(Abstract 4015) J. A. Ajani, M. Abramov, V. Bondar, I. Bondarenko, Y. V. Shparyk,
V. Gorbunova, H. Anatoliy, Y. Vinnyk, M. Alsina, S. Lazarev, J. Feliu, A. Elme, V.
Esko, G. Rosati, K. C. Abdalla, U. N. Verma, F. M. Benedetti, T. Aoyama, H.
Mizuguchi, L. Makris, DIGEST Study Group
Board 125
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel
(FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally
advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data
from the phase II part of the FLOT4 phase III study of the AIO. (Abstract 4016)
C. Pauligk, A. Tannapfel, J. Meiler, K. B. Luley, H. Kopp, N. Homann, R. D.
Hofheinz, H. Schmalenberg, S. Probst, G. Haag, M. Egger, D. M. Behringer, J.
Stoehlmacher, N. Prasnikar, A. Block, J. Trojan, M. Koenigsmann, W. Schmiegel,
E. Jäger, S. Al-Batran
Board 126
A phase III study of laparoscopy-assisted versus open distal gastrectomy
with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912):
Analysis of the safety and short-term clinical outcomes. (Abstract 4017) M.
Takagi, H. Katai, J. Mizusawa, K. Nakamura, T. Yoshikawa, M. Terashima, S. Ito,
S. Teshima, K. Koeda, T. Sano, N. Fukushima, T. Yasuda, Y. Asao, Y. Fujiwara, M.
Sasako, Japan Clinical Oncology Group
Board 127
A randomized, double-blind, placebo-controlled phase III study of S-1 in
patients with sorafenib-refractory advanced hepatocellular carcinoma
219
MONDAY
Abstracts 4012– 4023 will be discussed during the Gastrointestinal (Noncolorectal) Cancer
(S-CUBE). (Abstract 4018) M. Kudo, M. Moriguchi, K. Numata, H. Hidaka, H.
Tanaka, M. Ikeda, S. Kawazoe, S. Ohkawa, Y. Sato, T. Okusaka
MONDAY
Board 128
The protective effect of hormonal intake on risk of hepatocellular carcinoma
in the United States. (Abstract 4019) G. Botrus, A. S. Shalaby, A. O. Kaseb, R.
Lenzi, R. Abdel-Wahab, R. A. Wolff, M. Hassan
Board 129
Multi-institutional phase II study of high dose, hypofractionated proton beam
therapy (HF-PBT) for unresectable primary liver cancers: Long term
outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).
(Abstract 4020) T. S. Hong, J. Y. Wo, B. Y. Yeap, E. Ben-Josef, E. I. McDonnell,
L. C. Drapek, L. S. Blaszkowsky, E. L. Kwak, J. W. Clark, L. Goyal, D. P. Ryan,
M. M. Javle, J. A. Wolfgang, R. Arellano, J. T. Mullen, C. Ferrone, K. Tanabe, T. F.
DeLaney, C. H. Crane, A. X. Zhu
Board 130
Quantification of tumor stroma as a biomarker in pancreatic
adenocarcinoma. (Abstract 4021) R. J. Torphy, K. E. Volmar, R. Naim, S. R.
Cader, J. S. Johansen, M. A. Hollingsworth, E. A. Collisson, J. Yeh
Board 131
Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and
serum CA19 –9 in unresectable pancreatic cancer (PC) patients. (Abstract
4022) J. S. Johansen, C. T. Vibat, S. Hancock, I. M. Chen, L. Hassaine, E.
Samuelsz, E. A. Collisson, B. V. Jensen, T. T. Lu, V. Melnikova, M. G. Erlander
Board 132
Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma.
(Abstract 4023) J. K. Lennerz, A. Stenzinger
Board 133
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed
by docetaxel plus capecitabine (TX) in patients with unresectable gastric
adenocarcinoma: The TCOG T3211 trial. (Abstract 4024) M. Chen, J. Lin, C.
Hsiao, Y. Shan, Y. Chen, L. Chen, T. Liu, C. Li, Y. Chao
Board 134
Risk of death due to heart disease after radiotherapy for esophageal cancer:
A SEER study. (Abstract 4025) J. E. Frandsen, D. Boothe, D. K. Gaffney, B.
Wilson, S. Lloyd
Board 135
Phase I/II study of a combination of capecitabine, cisplatin, and
intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer
with peritoneal metastasis. (Abstract 4026) H. Cho, M. Ryu, C. Yoo, B. Ryoo, S.
Park, K. Kim, B. Kim, M. Yoo, J. Yook, Y. Kang
Board 136
Masitinib plus irinotecan for second line treatment of esophagogastric
adenocarcinoma: An open label phase Ib/II trial. (Abstract 4027) A. Zaanan, J.
Bennouna, S. Hiret, J. Douillard, O. Bouche Sr., D. Tougeron, T. Lecomte, C.
Lepère, C. Mansfield, A. Moussy, P. Dubreuil, O. Hermine, J. Taieb
Board 137
Prognostic factor analysis of overall survival (OS) in gastric cancer from two
phase III studies of second-line ramucirumab (RAM) (REGARD and
RAINBOW) using pooled individual patient (pt) data. (Abstract 4028) C. S.
Fuchs, K. Muro, J. Tomasek, E. Van Cutsem, J. Y. Cho, S. Oh, H. Safran, G.
Bodoky, I. Chau, Y. Shimada, F. Dumitru, S. Al-Batran, R. Passalacqua, A. Ohtsu,
M. Emig, D. Ferry, K. Chandrawansa, Y. Hsu, A. Sashegyi, H. Wilke
Board 138
Candidate biomarker analyses in gastric or gastro-esophageal junction
carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo
(PL). (Abstract 4029) C. S. Fuchs, J. Tabernero, J. Tomasek, I. Chau, B. Melichar,
H. Safran, M. A. Tehfe, F. Dumitru, E. Topuzov, L. Schlittler, A. A. Udrea, W.
Campbell, S. Brincat, M. Emig, S. A. Melemed, R. R. Hozak, D. Ferry, W. Caldwell,
J. A. Ajani
Board 139
Phase I study of GS-5745 alone and in combination with chemotherapy in
patients with advanced solid tumors. (Abstract 4030) J. C. Bendell, A.
Starodub, M. A. Shah, S. Sharma, Z. A. Wainberg, D. L. Thai
Board 140
Adaptive immune resistance in gastro-esophageal cancer: Correlating
tumoral/stromal PDL1 expression with CD8ⴙ cell count. (Abstract 4031) R. J.
Kelly, E. Thompson, M. Zahurak, T. Cornish, N. Cuka, E. Abdelfatah, J. M. Taube,
S. Yang, M. Duncan, N. Ahuja, A. Murphy, R. A. Anders
220
Board 141
Laparoscopic D2 distal gastrectomy versus conventional open surgery for
advanced gastric cancer: The safety analysis from a multicenter prospective
randomized controlled trial in China (CLASS-01 Trial). (Abstract 4032) Y. Hu,
C. Huang, Y. Sun, X. Su, Z. Li, Y. Xue, J. Hu, X. He, K. Tao, G. Zhao, J. Suo, H.
Wei, W. Hu, M. Ying, X. Du, P. Chen, G. Li, Chinese Laparoscopic Gastrointestinal
Surgery Study (CLASS) Group
Board 142
Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric
cancer: PaFLO, a randomized phase II study from the AIO
(Arbeitsgemeinschaft Internistische Onkologie). (Abstract 4033) P. C.
Thuss-Patience, S. Al-Batran, J. T. Siveke, N. Homann, P. Malfertheiner, D.
Glaeser, A. Stein, I. Tamm, S. Daum, J. Potenberg, A. Florschütz, A. Vogel, K.
Ridwelski, M. Ritgen, M. Geissler, H. Schmalenberg, P. Schlattmann, M. Lorenz, K.
Breithaupt, U. Pichlmeier
Board 143
MET as a prognostic biomarker of survival in a large cohort of patients with
gastroesophageal cancer (GEC). (Abstract 4034) D. V. Catenacci, R. Tang,
K. S. Oliner, A. Ang, R. D. Loberg, E. O’Day, P. Xu, L. Henderson, A. Ruzzo, F.
Graziano
Board 144
Randomized phase II study of recombinant human endostatin combined with
definitive chemoradiotherapy in locally advanced esophageal squamous cell
carcinoma. (Abstract 4035) J. Lv, T. Li, X. Deng, F. Li, Y. Song, C. Li, J. Wang
Board 145
Estrogen receptor beta (ER␤) gene polymorphisms as a predictor of overall
survival in patients with gastric cancer (GC) from Japan and Los Angeles
County (LAC). (Abstract 4036) A. Parekh, Y. Sunakawa, S. Cao, S. Matsusaka,
D. Yang, W. Zhang, T. Wakatsuki, Y. Ning, S. Stremitzer, A. Mendez, S. Okazaki,
R. Elkhoueiry, S. Iqbal, A. Barzi, M. Azuma, M. Watanabe, W. Koizumi, A. H. Wu,
H. Lenz
Board 146
A phase I dose-escalating and safety study of AZD8931 in combination with
oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. (Abstract 4037) A. L. Thomas, M. M. Eatock, N.
Coupe, N. McGregor, S. Love, C. Ciria, L. Collins, C. McDowell, M. R. Middleton
Board 147
Multicenter phase 2: Capecitabine (CAP) ⴙ oxaliplatin (OX) ⴙ bevacizumab
(BEV) ⴙ trastuzumab (TRAS) for patients (pts) with metastatic
esophagogastric cancer (MEGCA). (Abstract 4038) P. C. Enzinger, T. A.
Abrams, J. A. Chan, N. J. McCleary, H. Zheng, E. L. Kwak, M. Yurgelun, L. S.
Blaszkowsky, J. M. Cleary, B. M. Wolpin, J. A. Meyerhardt, E. Regan, C. Graham,
K. Straw, C. S. Fuchs, R. J. Kelly
Board 148
Prognostic impact of Forkhead box-F1 (FOXF1) polymorphisms on the
clinical outcome in gastric cancer patients. (Abstract 4039) S. Matsusaka,
A. H. Wu, S. Cao, N. Mizunuma, K. Chin, W. Zhang, D. Yang, Y. Ning, S.
Stremitzer, Y. Sunakawa, S. Okazaki, A. Parekh, R. E. El-Khoueiry, A. Mendez, H.
Lenz
Board 149
The role of panitumumab in combination with ECX in perioperative
chemotherapy of unselected patients with locally advanced
gastroesophageal adenocarcinomas: Randomized phase II study of the
German Cancer Society. (Abstract 4040) M. H. Moehler, F. Lordick, A. L.
Mihaljevic, S. Kanzler, T. Hoehler, P. C. Thuss-Patience, S. P. Moenig, V.
Kunzmann, S. Schroll, H. Meyer, A. Sandermann, C. Schumacher, H. Wilke, A.
Tannapfel, M. Stahl
Board 150
Analysis of patients with esophageal cancer following trimodality therapy:
Pathological complete remission (PathCR) versus non-PathCR. (Abstract
4041) M. A. Blum, L. Xiao, A. M. Correa, R. Wadhwa, E. Elimova, H. D. Skinner, R.
Komaki, J. H. Lee, M. S. Bhutani, B. Weston, Z. X. Liao, D. C. Rice, S. Swisher,
W. L. Hofstetter, J. A. Ajani
Board 151
Prognostic significance of tumor infiltrating immune cells and PD-L1
expression in gastric carcinoma in Chinese patients. (Abstract 4042) R. Geng,
C. Dai, A. Wong, M. Qing, J. Hu, Y. Sun, A. W. Lo, J. Li
221
MONDAY
MONDAY
Board 152
Clinical characteristics and treatment outcomes of patients with metastatic,
MET-amplified esophagogastric cancers. (Abstract 4043) E. L. Kwak, J. K.
Lennerz, J. Szymonifka, R. B. Corcoran, J. W. Clark, A. L. Russo, D. R. Borger,
L. S. Blaszkowsky, L. E. Dias, J. E. Faris, J. E. Murphy, P. Fidias, I. T. Lennes,
C. G. Azzoli, J. F. Gainor, J. T. Mullen, G. Y. Lauwers, D. P. Ryan, A. J. Iafrate,
T. S. Hong
Board 153
A phase II single-arm pilot study of second-line icotinib treatment in
advanced esophageal cancer with EGFR over-expression or amplification.
(Abstract 4044) J. Huang, Q. Fan, P. Lu, J. Ying, C. Ma, W. Liu, J. Liu, Y. Liu, F.
Tan, Y. Sun
Board 154
Patterns of local-regional relapse after complete response by definitive
chemoradiotherapy for stage II/III (non–T4) esophageal squamous cell
carcinoma. (Abstract 4045) K. Sudo, K. Kato, H. Kuwabara, Y. Sasaki, N.
Takahashi, H. Shoji, S. Iwasa, Y. Honma, N. T. Okita, A. Takashima, T.
Hamaguchi, Y. Yamada, N. Boku
Board 155
Multicenter retrospective analysis for elderly patients with advanced gastric
cancer (AGC) received first-line chemotherapy in clinical practice. (Abstract
4046) K. Kunieda, A. Makiyama, M. Noguchi, T. Kajiwara, T. Tamura, K. Takeda,
Y. Tsuji, K. Minashi, T. Moriwaki, N. Sugimoto, M. Nagase, Y. Negoro, T. Tsuda, H.
Shimodaira, N. Okano, D. Sakai, K. Yanagihara, N. Boku, I. Hyodo, T. Esaki
Board 156
A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1
antibody, in Japanese patients with advanced gastric cancer. (Abstract 4047)
Y. Yamada, T. Nishina, S. Iwasa, K. Shitara, K. Muro, T. Esaki, S. Hironaka, K.
Yamaguchi, N. Machida, T. Satoh, A. von Heydebreck, H. Achiwa, T. Doi
Board 158
Evaluation of tumor MET protein expression, MET gene amplification, and
HER2 expression in Chinese patients with advanced gastric or
gastroesophageal junction (G/GEJ) cancer. (Abstract 4048) R. Xu, M. Qiu, Y.
Zhou, D. Wang, D. Zhang, F. Wang, Y. Li, J. Huang, H. Zhou, E. Tang, Z. Du, F.
Zhang
Board 159
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and
oxaliplatin) in previously untreated patients with advanced gastric cancer.
(Abstract 4049) M. Lee, S. Kim, J. Lee, S. Park, Y. Park, H. Lim, W. Kang, J. Park
Board 160
Quantitative measurement of HER2 levels by multiplexed mass spectrometry
to predict survival in gastric cancer patients treated with trastuzumab.
(Abstract 4050) C. Ock, E. An, D. Oh, T. Kim, K. Lee, S. Han, S. Im, W. Liao, F.
Cecchi, A. Blackler, S. P. Thyparambil, W. A. Hoos, W. Kim, J. Burrows, T. A.
Hembrough, Y. Bang
Board 161
First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin
(XELOX) in elderly patients with advanced gastric cancer (AGC): results from
the first interim analysis. (Abstract 4051) I. Hwang, H. Lee, J. Ji, J. Kang, S.
Lee, S. Kim, J. Lee, S. Park, W. Kang
Board 162
Comparison of open esophagectomy with minimally invasive
esophagectomy: An observational nationwide study in Japan. (Abstract
4052) H. Takeuchi, H. Miyata, S. Ozawa, H. Udagawa, H. Osugi, H. Matsubara, Y.
Kitagawa
Board 163
Phase II study of FOLFOX plus regorafenib (REGO) in patients with
unresectable or metastatic esophagogastric (EG) cancer. (Abstract 4053)
Y. Y. Janjigian, G. Y. Ku, J. F. Chou, M. Capanu, M. Siebel, S. B. Chalasani, M. S.
Boyar, Z. Goldberg, A. M. Desai, D. P. Kelsen, T. Imtiaz, D. H. Ilson
Board 164
Changing chemotherapy (C) with concurrent radiation (RT) followed by
surgery after sub-optimal FDG-PET response to induction chemotherapy
improves outcomes in locally advanced (LA) esophageal adenocarcinoma
(EA). (Abstract 4054) A. Kriplani, Y. Y. Janjigian, D. P. Kelsen, V. W. Rusch, M. S.
Bains, N. P. Rizk, J. F. Chou, M. Capanu, A. J. Wu, K. A. Goodman, D. H. Ilson,
G. Y. Ku
Board 165
Clinical outcomes following neoadjuvant nab-paclitaxel and cisplatin
chemotherapy for locally advanced esophageal squamous cell carcinoma.
222
Board 166
Comprehensive characterization of PDL-1 and CTLA-4 in gastric cancer.
(Abstract 4056) H. A. Schloesser, U. Drebber, M. Thelen, M. Kloth, S. Rothschild,
M. Garcia-Marquez, S. Zoghi, A. Urbanski, H. Alakus, A. Schauss, S. Theurich, U.
Warnecke-Eberz, D. L. Stippel, A. H. Hölscher, T. Zander, S. P. Moenig, M. S. von
Bergwelt-Baildon
Board 167
Phase II study of everolimus as a salvage treatment after failure of
fluoropyrimidine and platinum in patients with metastatic gastric cancer
positive for pS6Ser240/4 expression. (Abstract 4057) J. Park, M. Ryu, Y. Park, S.
Hong, B. Ryoo, S. Park, C. Yoo, Y. Kang
Board 168
The prognostic impact of extracapsular lymph node involvement after
neoadjuvant therapy and esophagectomy . (Abstract 4058) S. M. Lagarde, M.
Navidi, J. Sultan, H. W. Van Laarhoven, S. S. Gisbertz, S. L. Meijer, A. Immanuel,
M. Griffin, M. I. van Berge Henegouwen
Board 169
Comparison of HER2 gene amplification (AMP) in primary esophageal and
gastroesophageal junction adenocarcinomas (EAC) and their metastatic
regional lymph nodes (MLNs). (Abstract 4059) H. H. Yoon, Q. Shi, W. R. Sukov,
C. A. Sattler, A. E. Wiktor, R. B. Diasio, T. Wu, R. B. Jenkins, F. A. Sinicrope
Board 170
A serum microRNA biomarker panel for detection of gastric cancer. (Abstract
4060) J. So, R. Zou, L. Zhou, H. Too, F. Zhu, Y. Teo, C. T. Yap, S. Y. Rha, K.
Kono, J. Yoong, K. Yeoh, W. Yong
Board 171
NeoFLOT II: Multicenter phase II study with short time neoadjuvant
chemotherapy (stNACT) with 5-FU, FA, oxaliplatin, and docetaxel in rectable
adenocarcinoma of the gastresophageal junction and gastric
adenocarcinoma (T3, T4, and/or LNⴙ) with high R0 resection rate over 91.5%.
(Abstract 4061) K. Ridwelski, T. Heina, J. Fahlke, H. Kroening, W. Asperger, C.
Kahl, U. Halm, P. Stuebs, C. Meissner, R. Otto, K. Zierau, M. Krueger
Board 172
Prognostic value of tumor infiltrating lymphocytes in Epstein-Barr virusassociated gastric cancer. (Abstract 4062) S. Yoon, S. Lee, Y. Chae, B. Kang,
J. Kim, A. Seo, H. Bae, W. Yu, H. Chung, O. Kwon, S. Jeon, H. Lee
Board 173
Knocking on molecular alterations in advanced gastric cancer (AGC).
(Abstract 4063) F. Racca, C. Hierro, D. Moreno, M. Vilaro, S. Landolfi, A.
Vivancos, J. Jimenez, T. Macarulla, J. Capdevila, E. Élez, G. Argilés, T. Saurı́, C.
Cruz, A. Azaro, S. Castro, P. Nuciforo, J. Rodón, J. Tabernero, M. Alsina
Board 174
Accuracy of EUS-FNA for distant regional lymph nodes in the initial staging
of esophageal cancer (EC). (Abstract 4064) Y. Shimodaira, E. Elimova, H.
Shiozaki, R. Wadhwa, N. Charalampakis, V. Planjery, M. A. Blum, Q. Nguyen,
H. D. Skinner, R. Slack, D. M. Maru, W. L. Hofstetter, B. Weston, M. S. Bhutani,
J. H. Lee, J. A. Ajani
Board 175
A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with
FOLFOX for the treatment of patients (pts) with previously untreated
metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE)
junction, or stomach. (Abstract 4065) S. Pant, M. R. Patel, C. Kurkjian, M. B.
Hemphill, M. C. Flores, D. S. Thompson, J. C. Bendell
Board 176
The prognostic value of a modified tumor regression grade after neoadjuvant
chemoradiotherapy and resection of esophageal carcinoma. (Abstract 4066)
M. C. Anderegg, S. M. Lagarde, W. A. Borstlap, S. S. Gisbertz, S. L. Meijer, M.
Hulshof, J. Bergman, O. R. Busch, H. W. Van Laarhoven, M. I. van Berge
Henegouwen
Board 177
Signet ring cell (SRC) histology of localized gastric adenocarcinoma (LGAC)
to predict response to preoperative chemoradiation. (Abstract 4067) N.
Charalampakis, G. M. Nogueras-Gonzalez, E. Elimova, R. Wadhwa, H. Shiozaki,
Y. Shimodaira, M. A. Blum, J. E. Rogers, J. Garris, A. Matamoros Jr., T. L.
Sagebiel, P. Das, J. Estrella, B. D. Badgwell, J. A. Ajani
223
MONDAY
(Abstract 4055) F. Yun, J. Y. Hua Sr., Z. X. Min, C. Q. Xun, H. Z. Yu, G. Lei, Y. H.
Yuan, L. j. Shi, C. P. Chen, Z. Qiang, W. Mao
MONDAY
Board 178
Association of high tumor infiltrating cytotoxic T cells with absence of lymph
node involvement in resected colorectal and gastric cancer: Implications for
immunosurveillance. (Abstract 4068) T. Dai, S. S. Kim, P. Thakkar, Y. Liu, B.
He, N. C. Panarelli, M. A. Shah
Board 179
Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with
paclitaxel in advanced gastric and gastroesophageal junction (GEJ)
adenocarcinoma. (Abstract 4069) C. Becerra, J. Stephenson Jr., D. J. Jonker,
A. L. Cohn, T. R. Asmis, T. S. Bekaii-Saab, P. R. Conkling, L. E. Garbo, H. Lenz,
D. A. Richards, A. I. Spira, S. Mikhail, R. A. Goodwin, H. H. Yoon, S. Hume, M.
Hitron, C. Li
Board 181
Randomized phase II crossover trial exploring the clinical benefit from
targeting EGFR or VEGF with combination chemotherapy in patients with
non-resectable biliary tract cancer. (Abstract 4071) L. H. Jensen, E. Fernebro,
J. Ploen, J. Eberhard, J. Lindebjerg, A. K. Jakobsen
Board 182
Pazopanib (P) and trametinib (T) in advanced cholangiocarcinoma (CC): A
phase Ib study. (Abstract 4072) R. T. Shroff, A. O’Connor, D. Gallagher, M.
Zahurak, G. L. Rosner, C. Ohaji, S. Sartorius-Mergenthaler, R. Zinner, N. S. Azad
Board 183
A phase II clinical trial on combined axitinib and transarterial
chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results
and evaluation of clinical predictor for response. (Abstract 4073) S. L. Chan,
W. Yeo, F. Mo, L. Li, K. Lee, A. W. Chan, E. P. Hui, P. B. Lai, T. Mok, A. T. Chan,
S. Yu
Board 184
Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and
Asian patients with advanced hepatocellular carcinoma (HCC): Pooled
analysis of two randomized phase II trials. (Abstract 4074) T. Meyer, D. H.
Palmer, Y. Chao, C. Choi, A. Deptala, L. Fartoux, Y. Feng, J. S. Graham, J. Hocke,
T. Kim, D. Lin, Y. Ma, M. Peck-Radosavljevic, P. J. Ross, B. Ryoo, A. Wenz, C.
Yen, A. Loembe, A. Cheng
Board 185
Proposal of a new staging system for intrahepatic cholangiocarcinoma:
Analysis of surgical patients from a nationwide survey of Liver Cancer Study
Group of Japan. (Abstract 4075) Y. Sakamoto, N. Kokudo, Y. Matsuyama, M.
Sakamoto, M. Kadoya, S. Kaneko, Y. Ku, M. Kudo, T. Takayama, O. Nakashima,
The Liver Cancer Study Group of Japan
Board 186
Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with
advanced hepatocellular carcinoma: A randomized phase II trial. (Abstract
4076) M. Ikeda, S. Shimizu, T. Sato, M. Morimoto, Y. Inaba, Y. Kojima, A.
Hagihara, M. Kudo, S. Nakamori, S. Kaneko, R. Sugimoto, T. Tahara, T. Ohmura,
K. Yasui, K. Sato, H. Ishii, J. Furuse, T. Okusaka
Board 187
Ramucirumab (RAM) as second-line treatment in patients (pts) with
advanced hepatocellular carcinoma following first-line therapy with
sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH
study. (Abstract 4077) I. Chau, M. Peck-Radosavljevic, C. Borg, P. Malfertheiner,
J. Seitz, J. Park, B. Ryoo, C. Yen, M. Kudo, R. T. Poon, D. Pastorelli, J. Blanc, H.
Chung, A. D. Baron, T. Okusaka, Z. L. Cui, A. C. Girvan, P. Abada, L. Yang, A. X.
Zhu
Board 188
Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with
advanced biliary cancers (ABC): final results of a multicenter phase II study.
(Abstract 4078) R. V. Iyer, A. Groman, W. Ma, U. Malhotra, D. Iancu, C. Grande,
T. S. Bekaii-Saab
Board 189
Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk
prediction of hepatocellular carcinoma in compensated cirrhosis. (Abstract
4079) X. Verhelst, D. Vanderschaeghe, L. Castera, A. Geerts, N. Goutte, C.
Francoz, F. Durand, N. Callewaert, H. Van Vlieberghe
Board 190
A multicenter cohort study on transarterial chemoembolization with or
without sorafenib for intermediate-stage hepatocellular carcinoma:
Reconsidering combination-therapy trial design. (Abstract 4080) Y. Zhao, H.
224
Board 191
A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in
combination with either trans catheter arterial chemoembolization (TACE) or
radiofrequency ablation (RFA) in patients with hepatocellular carcinoma
(HCC). (Abstract 4081) A. G. Duffy, O. V. Makarova-Rusher, S. P. Kerkar, D. E.
Kleiner, S. Fioravanti, M. Walker, S. Carey, W. D. Figg, S. M. Steinberg, V.
Anderson, N. Abi-Jaoudeh, E. Levi, B. J. Wood, T. F. Greten
Board 192
Panitumumab in combination with gemcitabine/cisplatin (GemCis) for
patients with advanced kRAS WT biliary tract cancer: A randomized phase II
trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract
4082) A. Vogel, S. Kasper, W. Weichert, M. Bitzer, A. Block, H. Riess, H. SchulzeBergkamen, M. H. Moehler, K. E. Merx, V. Endris, E. Schnoy, J. T. Siveke, P.
Michl, D. Waldschmidt, J. Kuhlmann, M. Geissler, C. Kahl, S. Kubicka
Board 193
A phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular
carcinoma (HCC). (Abstract 4083) A. G. Duffy, C. Ma, S. V. Ulahannan, O. V.
Makarova-Rusher, S. Fioravanti, M. Walker, B. Turkbey, J. Trepel, L. Cao, S. M.
Steinberg, W. D. Figg, T. F. Greten
Board 194
Objective response by mRECIST to predict survival in hepatocellular
carcinoma: A multivariate, time-dependent analysis from the phase III
BRISK-PS study. (Abstract 4084) J. M. Llovet, J. Park, F. Torres, T. Decaens, E.
Boucher, J. Raoul, M. Kudo, C. Chang, V. Boige, E. Assenat, Y. Kang, H. Lim, I.
Walters, R. Lencioni
Board 195
Changes in plasma biomarkers over time in patients (pts) with advanced
biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial.
(Abstract 4085) A. C. Backen, M. G. McNamara, A. Lopes, H. Wasan, D. H.
Palmer, M. Duggan, D. Cunningham, A. Anthoney, P. Corrie, S. Madhusudan, A.
Maraveyas, P. J. Ross, J. S. Waters, W. P. Steward, C. Rees, S. Beare, J. A.
Bridgewater, C. Dive, J. W. Valle
Board 196
Molecular characterization of 350 hepatocellular carcinomas to identify
biomarker aberrations with potential novel therapeutic options. (Abstract
4086) C. Ang, J. T. Miura, T. C. Gamblin, S. Z. Millis, J. Xiu, Z. Gatalica, S. K.
Reddy, N. S. Yee
Board 197
The influence of tumor-infiltrating lymphocytes (TILs) and their prognostic
value in cholangiocarcinoma. (Abstract 4087) Y. Suleiman, D. Coppola, T.
Juan, J. K. Lee, H. H. Soliman, M. P. Malafa, R. D. Kim
Board 198
A phase II trial of bevacizumab and erlotinib as second line therapy for
advanced hepatocellular carcinoma. (Abstract 4088) A. O. Kaseb, H. O.
Al-Shamsi, J. Morris, M. Iwasaki, L. Xiao, R. Abdel-Wahab, K. P. Raghav, M.
Hassan, H. M. Hassabo, R. A. Wolff
Board 199
Prognostic score in high-grade gastrointestinal neuroendocrine tumours
(GI-NETs). (Abstract 4089) A. Lamarca, J. Barriuso, M. G. McNamara, R. Hubner,
J. W. Valle
Board 200
Association of progression-free survival with overall survival (OS) in patients
(pts) with neuroendocrine tumor (NET) treated with somatostatin analogs.
(Abstract 4090) M. Ter-Minassian, N. V. Brooks, L. K. Brais, J. A. Chan, D. C.
Christiani, X. Lin, S. Gabriel, J. Dinet, M. H. Kulke
Board 201
Everolimus in patients with advanced, progressive pancreatic
neuroendocrine tumors: Overall survival results from the phase III RADIANT3 study after adjusting for crossover bias. (Abstract 4091) M. E. Pavel, C.
Lombard-Bohas, E. Van Cutsem, D. H. Lam, T. Kunz, U. Brandt, J. Capdevila, E.
De Vries, P. Tomassetti, T. J. Hobday, R. F. Pommier, J. C. Yao
Board 203
Phase Ib study of pasireotide (P), everolimus (E), and selective internal
radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic
metastases. (Abstract 4092) B. F. El-Rayes, W. L. Shaib, R. S. Williams, Z. Chen,
P. Ganji, E. Brutcher, H. S. Kim
225
MONDAY
Li, W. Bai, J. Liu, W. Lv, S. Guan, X. Qin, W. Wang, W. Ren, W. Mu, W. Guo, S.
Gu, Y. Ma, Z. Yin, Y. Wang, J. Xia, R. Duran, D. Fan, G. Han
MONDAY
Board 204
Novel score to predict outcome in resected pancreatic neuroendocrine
tumors (pNET). (Abstract 4093) A. Viudez, D. A. Laheru, A. Stark, N. S. Azad,
C. L. Wolfgang, S. Baylin, J. G. Herman, Z. Maleki, A. De Jesus-Acosta
Board 205
Study of the therapeutic management of gastric carcinoid tumors from data
of the French national cohort of neuroendocrine tumors: CARGAS study.
(Abstract 4094) S. Manfredi, B. Leconte, T. Uguen, S. le Sourd, C. Cernon, J.
Morcet, F. Laine, E. Baudin, G. Cadiot
Board 206
Characteristics, prognosis and treatments of 294 patients with poorly
differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort.
(Abstract 4095) T. Walter, D. Tougeron, E. Baudin, K. Le Malicot, T. Lecomte, J.
Guigay, O. Hentic, S. Manfredi, I. Bonnet, R. Guimbaud, R. Coriat, P. Rougier, C.
Desauw, A. Thirot-Bidault, L. Dahan, G. Roquin, T. Aparicio, C. Lombard-Bohas,
C. Lepage, G. Cadiot
Board 207
Multicenter prospective phase II trial of bevacizumab (bev) for progressive
pancreatic neuroendocrine tumor (PNET). (Abstract 4096) T. J. Hobday, J. Yin,
A. Pettinger, J. R. Strosberg, D. L. Reidy, H. X. Chen, C. Erlichman
Board 208
Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End
Results (SEER) database review of demographics and survival in 187,991
cases. (Abstract 4097) M. A. Lewis, J. C. Yao
Board 209
Bronchial neuroendocrine neoplasms: A Surveillance Epidemiology and End
Results (SEER) database review of treatment outcomes. (Abstract 4098) M. A.
Lewis, J. C. Yao
Board 210
Identification of response predictors to capecitabine/temozolomide in
metastatic pancreatic neuroendocrine tumors. (Abstract 4099) J. R. Strosberg,
M. Cives, M. Brelsford, M. Black, A. Meeker, M. Ghayouri
Board 211
A phase II study of axitinib in advanced carcinoid tumors: Preliminary
results. (Abstract 4100) M. Cives, J. R. Strosberg, T. Campos, T. Weber, M.
Nickerson, C. E. Atreya, A. P. Venook, R. K. Kelley, T. Valone, D. Coppola, E. K.
Bergsland
Board 212
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in
post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative
Oncology Group T1206 study. (Abstract 4101) L. Chen, L. Jeng, C. Hsiao, C.
Wu, W. Lee, T. Wang, P. Lee, C. Chen, I. Chen, K. Lee, C. Hsieh, W. Hwang, M.
Yang, Y. Yang, D. Lin, M. Chen, P. Chen, Taiwan Cooperative Oncology Group
Board 213
Phase II studies of BEZ235 in patients with advanced pancreatic
neuroendocrine tumors (pNET). (Abstract 4102) R. Salazar, C. Verslype, E.
Baudin, S. K. Libutti, J. C. Yao, R. Buzzoni, L. Antonuzzo, R. Hubner, R. Garcı́aCarbonero, A. B. Custodio, E. M. Wolin, S. Turri, D. Dey, P. Aimone, J. Sulovski, N.
Mukherjee, F. Herbst, N. Fazio
Board 214
Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome
(CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of
the ELECT study. (Abstract 4103) A. Vinik, E. M. Wolin, H. Audry, E. GomezPanzani, G. A. Fisher, ELECT Study Group
Board 215
Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A
subgroup analysis from the CLARINET study. (Abstract 4104) A. Dasari, A. T.
Phan, M. E. Caplin, M. E. Pavel, J. B. Cwikla, M. Raderer, E. Sedlackova, G.
Cadiot, E. M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, E. GomezPanzani, P. B. Ruszniewski, CLARINET Study Group
Board 216
Low objective response and high toxicity to single-agent mitotane in patients
with metastatic adrenocortical carcinoma (ACC): A 25 year experience at
MSKCC. (Abstract 4105) B. Y. Lung, E. Valentino, S. R. Gerst, B. R. Untch, S.
Katz, V. E. Strong, N. P. Raj, K. Olino, L. Saltz, D. L. Reidy
Board 217
Clinical diagnostic utility of a blood-based multi-transcriptome assay for
gastroenteropancreatic disease. (Abstract 4106) I. M. Modlin, D. Alaimo, S.
Callahan, H. Aslanian, C. Lepensky, N. S. Teixeira, L. Bodei, I. Drozdov, M. S. Kidd
226
Board 218
Recurrence following surgical resection of gastroenteropancreatic
neuroendocrine tumors (NETs): An analysis from the NCCN oncology
outcomes database. (Abstract 4107) K. Van Loon, L. Zhang, J. M. Creasman,
M. A. Choti, J. C. Yao, M. H. Kulke, E. K. Nakakura, M. Bloomston, A. B. Benson
III, M. H. Shah, J. R. Strosberg, C. C. Zornosa, S. Bobiak, E. K. Bergsland
Board 219
Ramucirumab (RAM) as second-line treatment in patients (pts) with
advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by
Child-Pugh (CP) score. (Abstract 4108) A. X. Zhu, A. D. Baron, P. Malfertheiner,
M. Kudo, S. Kawazoe, D. Pezet, F. Weissinger, G. Brandi, C. Barone, T. Okusaka,
Y. Wada, J. Park, B. Ryoo, J. Y. Cho, H. C. Chung, C. Li, C. Yen, K. Lee, L. Yang,
I. Chau
Board 220
A phase I/II study of bavituximab and sorafenib in advanced hepatocellular
carcinoma (HCC). (Abstract 4109) A. C. Yopp, A. G. Singal, Y. E. Arriaga, U. N.
Verma, J. Shan, N. L. Kallinteris, M. S. Beg, J. C. Mansour, H. Zhu
Board 221
Prospective identification of potentially actionable molecular alterations in
cancers of unknown primary. (Abstract 4110) A. M. Varghese, D. M. Hyman, A.
Zehir, E. Vakiani, D. S. Klimstra, M. Ladanyi, M. F. Berger, D. B. Solit, L. Saltz
Board 222
Long-term outcomes of cytoreduction and HIPEC for malignant peritoneal
mesothelioma. (Abstract 4111) G. E. Bates, M. D. Kluger, Z. Jin, J. A. Chabot, J.
Leinwand, T. Bressler, M. Rae, R. N. Taub, A. C. Borczuk, M. Hesdorffer
Board 223
Importance of tumor grade in stage III mucinous appendiceal carcinoma: An
analysis of the SEER Database. (Abstract 4112) O. Fukui, K. W. Carpenter, Y.
Han, M. Salvino, J. C. Salo, E. S. Kim, J. S. Hill
Board 224
Prognostic impact of different FDG-PET uptake according to histology in
advanced gastric cancer. (Abstract 4113) H. Chon, A. Cho, C. Kim, S. Heo,
H. C. Chung, S. Noh, M. Yun, S. Y. Rha
Board 225
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of
necuparanib combined with nab-paclitaxel and gemcitabine in patients with
metastatic pancreatic cancer: Phase 1 results. (Abstract 4114) E. M. O’Reilly,
D. Mahalingam, J. M. Roach, B. C. Schultes, M. E. Rosano, P. J. Miller, J. Wolf, K.
Flaherty, D. P. Ryan
Board 226
A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel
for resectable pancreas cancer: The AGITG GAP study. (Abstract 4115) A.
Barbour, N. O’Rourke, M. D. Chandrasegaram, Y. Chua, J. Kench, J. S. Samra, N.
Pavlakis, K. S. Haghighi, S. Yip, J. Fawcett, M. Donoghoe, K. Walker, M. E. Burge,
S. Gananadha, M. Harris, M. Aghmesheh, W. L. Joubert, V. Gebski, J. Simes, D.
Goldstein
Board 227
Randomized phase II study of S-1 and concurrent radiotherapy with versus
without induction chemotherapy of gemcitabine for locally advanced
pancreatic cancer (JCOG1106). (Abstract 4116) A. Fukutomi, J. Mizusawa, H.
Katayama, S. Nakamura, Y. Ito, N. Hiraoka, T. Ioka, M. Ueno, M. Ikeda, K.
Sugimori, K. Shimizu, T. Okusaka, M. Ozaka, H. Yanagimoto, S. Nakamori, T.
Azuma, A. Hosokawa, N. Sata, T. Mine, J. Furuse, Japan Clinical Oncology Group
(JCOG)
Board 228
A phase II/III randomized study to compare the efficacy and safety of
rigosertib plus gemcitabine versus gemcitabine alone in patients with
previously untreated metastatic pancreatic cancer. (Abstract 4117) A. J. Scott,
B. H. O’Neil, W. Ma, S. J. Cohen, D. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho,
P. Rubin, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. A. Philip, J.
Boles, R. T. Maguire, F. Wilhelm, M. Maniar, C. Gomes, W. A. Messersmith
Board 229
A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) &
gemcitabine (GEM) ⴙ/- paclitaxel protein bound particles (nab-paclitaxel) in
pts with pancreatic cancer. (Abstract 4118) M. Hidalgo, P. Cooray, M. B.
Jameson, A. Carrato, F. Parnis, M. Jeffery, P. S. Grimison, R. J. Stagg, A. M.
Kapoun, J. Dupont, N. C. Tebbutt
Board 231
SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY
142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs.
227
MONDAY
mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.
(Abstract 4119) V. M. Chung, S. L. McDonough, P. A. Philip, D. B. Cardin, A.
Wang-Gillam, L. Hui, A. M. Lowy, K. Guthrie, C. D. Blanke, H. S. Hochster
MONDAY
Board 232
Effectiveness and tolerability of maintenance capecitabine administrated to
patients with metastatic pancreatic cancer treated with first line
FOLFIRINOX. (Abstract 4120) J. Reure, P. Follana, J. Gal, L. Evesque, G.
Cavaglione, A. Saint, E. Francois
Board 233
A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GMCSF and gemcitabine as adjuvant therapy for patients with resected
pancreatic adenocarcinoma. (Abstract 4121) D. H. Palmer, S. Dueland, J. W.
Valle, T. Otterhaug, J. A. Eriksen, H. Muller, B. Iversen, R. M. Miller
Board 234
DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a
second-line systemic therapy for patients with advanced and/or metastatic
adenocarcinoma of the pancreas—Final results. (Abstract 4122) T. J. Ettrich,
L. Perkhofer, V. Kaechele, A. W. Berger, M. Guethle, R. Muche, G. von Wichert,
T. M. Gress, P. Michl, M. Geissler, H. F. Hebart, P. Buechner-Steudel, T.
Seufferlein
Board 235
Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
after failure of folfirinox: Results of an AGEO multicenter prospective cohort.
(Abstract 4123) A. Portal, S. Pernot, C. Arbaud, D. Tougeron, A. Thirot-Bidault, C.
De La Fouchardiere, P. Hammel, T. Lecomte, J. Dreanic, R. Coriat, J. Bachet, O.
Dubreuil, L. Marthey, L. Dahan, J. Legoux, C. Locher, C. Lepère, P. Rougier, F.
Bonnetain, J. Taieb
Board 236
Multiplatform molecular profiling of pancreatic adenocarcinomas to identify
BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications.
(Abstract 4124) S. Z. Millis, B. L. Abbott, E. H. Baker, R. Bender, J. Swensen, Z.
Gatalica, S. K. Reddy, A. Rosemurgy, D. A. Iannitti
Board 237
A retrospective single institution review of 90 pancreatic adenosquamous
cancer (PASC) patients (pts). (Abstract 4125) J. B. Goldstein, G. M. NoguerasGonzalez, M. M. Javle, M. H. Katz, G. R. Varadhachary, D. R. Fogelman, M. J.
Overman, R. A. Wolff, R. T. Shroff
Board 238
A quantitative analysis of funding for pancreatic cancer research. (Abstract
4126) A. E. Hendifar, X. Zhang, R. Aizenberg, M. McCurrach, P. Morin, R. Tuli, L.
Matrisian, L. Davies
Board 239
Discovery of new potentially actionable mutations in pancreatic ductal
adenocarcinoma by next generation sequencing. (Abstract 4127) M. Di Marco,
S. Durante, S. Vecchiarelli, E. Grassi, A. Palloni, V. Indio, A. Astolfi, R. Panzacchi,
D. Santini, R. Casadei, C. Ricci, G. Taffurelli, G. Ercolani, N. Pagano, L. Calculli, C.
Serra, F. Minni, A. Pinna, M. A. Pantaleo, G. Biasco
Board 240
Dendritic cells generated with PDL-1 checkpoint blockade for treatment of
advanced pancreatic cancer. (Abstract 4128) J. Nesselhut, D. Marx, N. Cillien,
H. Lange, G. Regalo, M. Herrmann, T. Hupfeld, R. Y. Chang, T. Nesselhut
Board 241
Targeting Sema3D in pancreatic cancer: A novel therapeutic strategy.
(Abstract 4129) A. Murphy, J. Kleponis, A. Rucki, E. M. Jaffee, L. Zheng, K. Foley
Board 243a
A randomized, double-blind, placebo-controlled phase III study of cisplatin
plus a fluoropyrimidine with or without ramucirumab as first-line therapy in
patients with metastatic gastric or gastroesophogeal junction (GEJ)
adenocarcinoma (RAINFALL, NCT02314117). (Abstract TPS4131) C. S. Fuchs,
J. Tabernero, S. Al-Batran, I. Chau, D. H. Ilson, E. Van Cutsem, D. Ferry, M. Emig,
A. S. Melemed, V. Vanvoorden, Y. Hsu, Y. Xu, A. Sashegyi, M. Das, M. A. Shah
Board 243b
Perioperative chemotherapy and cytoreductive surgery with versus without
HIPEC in gastric cancer with limited peritoneal metastases: A randomized
phase III study (GASTRIPEC). (Abstract TPS4132) B. Rau, M. Loeffler, H. Rau,
U. Sulkowski, J. Kuhlmann, A. Weimann, T. Keck, M. Angele, S. A. Topp, A.
Koenigsrainer, E. Kuhnt, A. Kretzschmar, W. Knoefel, P. C. Thuss-Patience
228
Board 244a
Perioperative chemotherapy vs. adjuvant chemotherapy for potentially
resectable gastric cancer: A randomized and multicenter phase III study in
locally advanced gastric cancer with D2 dissection. (Abstract TPS4133) Q.
Zhao, Y. Li, C. Lian, B. Li, W. Li, Z. Huo, Z. Wang, Y. Wang, Y. Tian, S. Xie, S. Li
Board 244b
The Nationwide Cancer Genome Screening Projects for Gastrointestinal
Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of
actionable cancer genome alterations in advanced colorectal and noncolorectal gastrointestinal cancer (GI Screen 2013– 01-CRC and 2015– 01-Non
CRC). (Abstract TPS4134) K. Shitara, I. Miki, T. Sudo, S. Fujii, T. Kuwata, W.
Okamoto, T. Denda, T. Kajiwara, S. Yuki, T. E. Nakajima, A. Takashima, K.
Kawasaki, T. Tamura, T. Esaki, T. Yamanaka, A. Ochiai, T. Doi, A. Ohtsu, T. Hotta,
T. Yoshino
Board 245a
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for
recurrent or metastatic gastric or gastroesophageal junction (GEJ)
adenocarcinoma. (Abstract TPS4135) C. S. Fuchs, A. E. Denker, J. Tabernero,
E. Van Cutsem, A. Ohtsu, B. Lam, M. Koshiji, Y. Bang
Board 245b
A randomized phase III study of neoadjuvant chemotherapy with
docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and
adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric
cancer (PRODIGY). (Abstract TPS4136) Y. Kang, J. Yook, M. Ryu, J. Lee, Y.
Park, I. Chung, M. Jung, Y. Kim, M. Kim, S. Oh, S. Kim, J. Kim, H. Song, S. Ryu, S.
Roh, M. Kook, K. Shim, G. Kim, S. Noh
Board 246a
A randomized phase III study of adjuvant capecitabine vs observation in
curatively resected stage IB (by AJCC 6th edition) gastric cancer
(CATALYSIS; KCSG ST14 – 05). (Abstract TPS4137) M. Ryu, J. Y. Cho, D. Zang,
W. Lee, K. Lee, D. Shin, B. Nam, S. Lee, H. Lee, J. Kim, I. Hwang, J. Baek, C. Yoo,
Y. Kang
Board 246b
A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel)
versus IV paclitaxel in patients with metastatic or recurrent gastric cancer
after failure of first-line chemotherapy (DREAM). (Abstract TPS4138) S. Oh,
M. Ryu, S. Park, B. Ryoo, J. Kim, I. Chung, Y. Park, S. Rha, M. Kang, J. Y. Cho, S.
Kang, Y. Hong, B. Nam, Y. Jo, K. Yoon, Y. Kang
Board 247a
The BRIGHTER trial: A phase III randomized double-blind study of BBI608 ⴙ
weekly paclitaxel versus placebo (PBO) ⴙ weekly paclitaxel in patients (pts)
with pretreated advanced gastric and gastro-esophageal junction (GEJ)
adenocarcinoma. (Abstract TPS4139) M. A. Shah, K. Muro, K. Shitara, N. C.
Tebbutt, Y. Bang, F. Lordick, L. Borodyansky, C. Li
Board 247b
Adjuvant chemotherapy with gemcitabine and cisplatin compared to
observation after curative intent resection of cholangiocarcinoma and
muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized,
multidisciplinary, multinational phase III trial. (Abstract TPS4140) A. Stein, D.
Arnold, W. O. Bechstein, J. A. Bridgewater, D. Goldstein, L. H. Jensen, S. Kasper,
H. Klümpen, V. Kunzmann, U. Lindig, A. W. Lohse, B. Nashan, J. N. Primrose, R.
Markus, J. A. Shannon, M. Sinn, W. Karl-Heinz, H. Wege
Board 248a
Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS)
compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent
biliary tract cancer (KHBO1401-MITSUBA). (Abstract TPS4141) T. Ioka, M.
Kanai, S. Kobayashi, D. Sakai, A. Kitasato, H. Yamaue, H. Hayashi, N. Chayahara,
M. Takahashi, T. Yamada, E. Hatano, T. Goto, J. Fujimoto, M. Murakami, K.
Kamei, K. Yoshimura, KHBO1401-MITSUBA Study Group
Board 248b
SWOG S1310: Randomized phase II trial of single agent MEK inhibitor
trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary
cancer. (Abstract TPS4142) R. D. Kim, S. McDonough, A. B. El-Khoueiry, T. S.
Bekaii-Saab, K. Guthrie, H. S. Hochster
Board 249a
Randomized phase III study of etoposide plus cisplatin versus irinotecan
plus cisplatin in advanced neuroendocrine carcinoma of the digestive
system: A Japan Clinical Oncology Group study (JCOG1213). (Abstract
TPS4143) C. Morizane, N. Machida, Y. Honma, T. Okusaka, N. Boku, K. Kato, J.
229
MONDAY
Mizusawa, H. Katayama, N. Hiraoka, H. Taniguchi, M. Ikeda, Y. Shibuya, A.
Hosokawa, N. Mizuno, T. Sano, M. Tsuda, O. Yokosuka, Y. Kitagawa, M. Sasako,
J. Furuse, Japan Clinical Oncology Group (JCOG)
MONDAY
Board 250a
A randomized phase II trial of epigenetic therapy following adjuvant
treatment in patients with resected pancreatic cancer and high risk for
recurrence. (Abstract TPS4144) K. A. Reiss, N. Ahuja, S. Baylin, L. A. Mauro, S.
Linden, S. White, D. A. Laheru, J. M. Herman, C. L. Wolfgang, M. J. Weiss, J. L.
Cameron, M. Makary, N. S. Azad
Board 250b
A randomized study of temozolomide or temozolomide and capecitabine in
patients with advanced pancreatic neuroendocrine tumors: A trial of the
ECOG-ACRIN Cancer Research Group (E2211). (Abstract TPS4145) P. L.
Kunz, P. J. Catalano, H. S. Nimeiri, G. A. Fisher, T. A. Longacre, I. Schrijver, D. L.
Reidy, J. R. Strosberg, P. J. O’Dwyer, A. B. Benson III
Board 251a
JANUS 2: A phase III study of survival, tumor response, and symptom
response with ruxolitinib plus capecitabine or placebo plus capecitabine in
patients with advanced or metastatic pancreatic cancer (mPC) who failed or
were intolerant to first-line chemotherapy. (Abstract TPS4146) E. M. O’Reilly,
C. Walker, J. Clark, K. J. Brill, F. W. Dawkins, J. C. Bendell
Board 251b
JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus
capecitabine in patients with advanced or metastatic pancreatic cancer
(mPC) after failure or intolerance of first-line chemotherapy. (Abstract
TPS4147) H. Hurwitz, W. M. Garrett, J. Clark, K. J. Brill, F. W. Dawkins, M.
Hidalgo, E. Van Cutsem
Board 252a
Randomized phase II study of the safety, efficacy, and immune response of
GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or
without nivolumab in patients with previously treated metastatic pancreatic
adenocarcinoma (STELLAR). (Abstract TPS4148) D. T. Le, T. S. Crocenzi, J. N.
Uram, E. R. Lutz, D. A. Laheru, E. A. Sugar, R. H. Vonderheide, G. A. Fisher, A. H.
Ko, A. L. Murphy, K. McDougall, S. Ferber, D. G. Brockstedt, E. M. Jaffee
Board 252b
POLO: A randomized phase III trial of olaparib tablets in patients with
metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (g
BRCA m) who have not progressed following first-line chemotherapy.
(Abstract TPS4149) H. L. Kindler, G. Y. Locker, H. Mann, T. Golan
Board 253a
ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors–An
explorative randomized phase II trial. (Abstract TPS4150) M. Haas, S. H.
Boeck, D. Waldschmidt, A. Reinacher-Schick, J. Freiberg-Richter, T. Seufferlein,
S. Kanzler, R. Mahlberg, J. T. Siveke, V. Heinemann
Board 253b
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine
and S-1 versus surgery-first for resectable pancreatic carcer
(Prep-02/JSAP05). (Abstract TPS4151) M. Unno, F. Motoi, T. Kosuge, H. Ueno,
H. Yamaue, S. Satoi, M. Sho, G. Honda, I. Matsumoto, K. Wada, J. Furuse, T.
Furukawa, K. Ishida, K. Takase, Y. Matsuyama, K. Nakagawa, Y. Katayose
Board 254a
Randomized multicenter phase II/III study with adjuvant gemcitabine versus
neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The
NEPAFOX trial. (Abstract TPS4152) W. Hozaeel, C. Pauligk, N. Homann, K.
Luley, T. W. Kraus, J. Trojan, W. O. Bechstein, K. Grimm, B. Heise, W. Schmiegel,
D. Pink, S. Al-Batran
Board 254b
nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant
treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).
(Abstract TPS4153) M. A. Tempero, D. B. Cardin, A. Biankin, D. Goldstein, M.
Moore, E. M. O’Reilly, P. A. Philip, H. Riess, T. Macarulla, L. Yung, M. Li, B. Lu
230
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic
Cancers
Location: S Hall A
Board 255
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in
combination with etoposide and platinum (EP) in patients (pts) with
untreated extensive-stage small-cell lung cancer (ED-SCLC). (Abstract 7508)
M. Pietanza, A. I. Spira, R. M. Jotte, S. M. Gadgeel, A. C. Mita, L. L. Hart, W. L.
Gluck, A. C. Chiang, S. V. Liu, A. M. Kapoun, L. Xu, D. Hill, J. Dupont, D. R. Spigel,
L. Zhou
Board 256
Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as
second-line therapy in small cell lung cancer (SCLC). (Abstract 7509) M.
Forster, E. Calvo, M. Olmedo Garcia, M. Lopez Criado, V. Moreno, A. Soto-Matos,
E. Holgado, N. F. Brown, M. Flynn, V. Boni, E. Guerra Alia, S. A. Szyldergemajn
Board 257
Pazopanib (P) or placebo in completely resected stage I NSCLC patients:
Survival results of the phase II trial IFCT-0703. (Abstract 7510) B. Besse, J.
Mazières, L. Ribassin-Majed, F. Barlesi, J. Bennouna, R. Gervais, L. Moreau, H.
Berard, D. Debieuvre, O. Molinier, D. Moro-Sibilot, P. J. Souquet, J. Pignon Sr., E.
Amour, A. Celebic, F. Morin, B. Milleron, G. Zalcman, J. Soria, French Cooperative
Board 258
ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A
phase II trial from the University of Chicago Phase II Consortium. (Abstract
7511) S. B. Maron, T. Karrison, R. Kanteti, K. A. Rao, D. R. Gandara, M.
Koczywas, R. Salgia, H. L. Kindler
Board 259
A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus
cisplatin with concurrent thoracic radiotherapy for locally advanced nonsmall cell lung cancer (LA-NSCLC): WJOG 5008L. (Abstract 7512) T. Seto, T.
Sasaki, T. Yamanaka, N. Kunitake, J. Shimizu, T. Kodaira, M. Nishio, T. Kozuka, T.
Takahashi, H. Harada, N. Yoshimura, S. Tsutsumi, H. Kitajima, M. Kataoka, K.
Nakagawa, Y. Nishimura, Y. Nakanishi
Board 260
Survival following stereotactic body radiation therapy or conventionally
fractionated radiation for definitive non-operative treatment of stage I
non-small cell lung cancer: A review of the National Cancer Data Base.
(Abstract 7513) C. G. Robinson, A. Patel, J. D. Bradley, T. A. DeWees, S.
Rehman, M. C. Roach, D. Morgensztern, T. Crabtree, V. Puri
Board 261
Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer
(NSCLC): Analysis of the National Cancer Database. (Abstract 7514) M.
Behera, C. E. Steuer, F. Fernandez, Y. Liu, C. Fu, T. W. Gillespie, K. A. Higgins,
N. F. Saba, R. N. Pillai, S. Force, S. Pakkala, D. M. Shin, T. K. Owonikoko, C. P.
Belani, W. J. Curran Jr., F. R. Khuri, S. S. Ramalingam
Board 262
Programmed cell death 1 (PD-1) and its ligand (PD-L1) expression in thymic
epithelial tumors (TETs): Impact on the treatment efficacy and alteration in
expression after chemotherapy (C). (Abstract 7515) Y. Katsuya, H. Horinouchi,
T. Asao, S. Kitahara, K. Sunami, Y. Seki, Y. Goto, S. Kanda, Y. Fujiwara, H.
Nokihara, N. Yamamoto, K. Tsuta, S. Watanabe, Y. Ohe
Board 263
Defining the immunologic phenotype of thymic epithelial tumors. (Abstract
7516) J. Naidoo, K. Steele, C. S. Sima, J. Yuan, P. B. Robbins, A. L. Moreira, M.
Pietanza, J. D. Wolchok, G. J. Riely, N. A. Rizvi
Board 264
Evaluating causes of screen failure (SF) in non-small cell lung cancer
(NSCLC) clinical trials requiring specific biomarker (BioM) results for
enrollment. (Abstract 7517) D. J. Nameth, J. W. Goldman, B. R. Wolf, D. J.
231
MONDAY
Abstracts 7508 –7519 will be discussed during the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Discussion Session. See page 255 for session
information.
Wong, B. A. Ledezma, M. A. Mendenhall, O. Oshodi, S. R. Carrasco, C. R. Adame,
P. A. Abarca, M. Han, W. Sago, M. L. Spiegel, J. M. Horton, D. D. Pan, D. Gaut, C.
Diamant, S. M. Rosales, E. B. Garon
MONDAY
Board 265
Prospective molecular analysis of small cell lung cancer (SCLC) using next
generation sequencing (NGS). (Abstract 7518) M. Pietanza, H. H. Won, N.
Rekhtman, L. Wang, W. D. Travis, L. M. Krug, A. M. Varghese, P. K. Paik, G. J.
Riely, M. F. Zakowski, M. Ladanyi, M. F. Berger, M. G. Kris, C. M. Rudin
Board 266
Genomic profiling of large-cell neuroendocrine carcinoma of the lung.
(Abstract 7519) T. Miyoshi, S. Umemura, Y. Matsumura, S. Mimaki, S. Tada, G.
Ishii, S. Matsumoto, K. Yoh, S. Niho, H. Ohmatsu, K. Aokage, T. Hishida, J.
Yoshida, K. Nagai, K. Goto, M. Tsuboi, K. Tsuchihara
Board 267
Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer.
(Abstract 7520) D. Morgensztern, S. N. Waqar, A. Patel, S. Devarakonda, S. H.
Waqar, F. Gao, C. G. Robinson, J. D. Bradley, M. Q. Baggstrom, R. Govindan, V.
Puri
Board 268
Prognostic effect of single versus multiple somatic mutations in non-small
cell lung cancer (NSCLC). (Abstract 7521) K. Jao, P. Tomasini, S. Kamel-Reid,
M. S. Tsao, G. J. Korpanty, C. Mascaux, G. Liu, N. B. Leighl, R. Feld, P. A.
Bradbury, M. Ennis, F. A. Shepherd
Board 269
Validation of a cell cycle progression score for 5-year mortality risk in
patients with stage I non-small cell lung cancer. (Abstract 7522) T. Eguchi, K.
Kyuichi, B. Evans, C. S. Sima, T. Davis, S. A. Hamilton, K. Yager, K. A. Kolquist,
J. T. Jones, A. Hartman, P. S. Adusumili
Board 270
The effect of platinum based adjuvant chemotherapy on survival in the
surgically resected lung adenocarcinoma according to the expression of
EGFR mutation specific antibody and c-MET. (Abstract 7523) I. Kim, J. Lee, S.
Kim, H. An, S. Chun, E. Jeon, S. Hong, T. Kim, K. Lee, S. Sung, J. Park, Y. Kim, J.
Kim, J. Kang
Board 271
Therapeutic Interventional Mapping System (TIMS): A novel strategy for the
selection of tri-targeted therapy combinations for non-small cell lung cancer
(NSCLC). (Abstract 7524) J. Mendelsohn, V. Lazar, E. Rubin, Y. Pawitan, C.
Bresson, J. Soria, A. Eggermont, F. Wunder, J. Scoazec, W. K. Hong, J. Blay, R. L.
Schilsky, R. Kurzrock
Board 272
Prognostic value of cytokine profile on survival in non-small cell lung cancer
patients treated with radiotherapy. (Abstract 7525) S. Wang, J. Chen, R. Ten
Haken, P. Stanton, F. Kong
Board 273
Final overall survival (OS) analysis of a multicenter phase II study of
concurrent high-dose (72Gy) three-dimensional conformal radiotherapy
(3D-RT) without elective nodal irradiation with chemotherapy using cisplatin
(CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung
cancer (NSCLC). (Abstract 7526) H. Horinouchi, I. Sekine, M. Sumi, T. Soejima,
M. Satouchi, H. Nagakura, H. Isobe, N. Nishiyama, M. Harada, N. Ishizuka, T.
Tamura, Y. Ohe
Board 274
Incomplete non-small-cell lung cancer (NSCLC) resections in the National
Cancer Data Base (NCDB): Predictors, prognosis and value of adjuvant
therapy. (Abstract 7527) R. U. Osarogiagbon, C. Lin, M. Smeltzer, A. Jemal
Board 275
Phase II trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin
in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
(Abstract 7528) S. Wang, W. Ou, N. Li, S. Zhang, Q. Liu, P. Xu, C. Yuan, B. Wang
Board 276
Phase I study of bi-weekly nab—paclitaxel and carboplatin with concurrent
thoracic radiotherapy for locally advanced non-small cell lung cancer.
(Abstract 7529) Y. Hasegawa, D. Miura, T. Ota, J. Yokouchi
Board 277
Genomic heterogeneity of lung cancers and its potential clinical
implications. (Abstract 7530) J. Zhang, Y. Liu, D. R. Gomez, J. Fujimoto, C.
Behrens, A. M. Correa, C. Gumbs, X. Mao, S. Seth, X. Song, J. Heymach, J. Lee,
S. Swisher, W. N. William Jr., W. K. Hong, Y. Gao, I. I. Wistuba, A. Futreal
232
Board 278
The impact of a Bim deletion polymorphism on the survival of patients with
completely resected non-small cell lung cancer. (Abstract 7531) J. Atsumi, K.
Shimizu, K. Kaira, T. Nagashima, Y. Ohtaki, K. Obayashi, S. Kakegawa, O.
Kawashima, M. Kamiyoshihara, M. Sugano, I. Takeyoshi
Board 279
Prognostic value of miRNAs in resected lung adenocarcinomas. (Abstract
7532) S. Gallach, E. Jantus-Lewintre, S. Calabuig-Fariñas, A. Blasco, R. Guijarro,
M. Martorell, C. Camps
Board 280
“The burden upon me”: The complexity of healthcare utilization among
Medicare patients undergoing curative lung cancer treatment. (Abstract
7533) C. J. Presley, P. R. Soulos, J. B. Yu, C. P. Gross
Board 281
Effects of obesity and smoking on survival in non-small cell lung cancer.
(Abstract 7534) D. M. Hansra, T. Koru-Sengul, W. Zhao, F. Miao, S. L.
Tannenbaum, A. P. Monedero, D. J. Lee, J. Antunez de Mayolo, J. Hurley, M. M.
Byrne
Board 282
Association between the EGFR or KRAS mutation status and the FDG-PET
findings in surgically resected lung adenocarcinoma. (Abstract 7535) K.
Takamochi, K. Mogushi, K. Imashimizu, M. Fukui, S. Oh, M. Itoh, Y. Hayashizaki,
K. Suzuki, H. Kawaji
Board 283
Comparison of concurrent use of carboplatin-Paclitaxel versus cisplatinetoposide with thoracic radiation for stage III NSCLC patients: A systematic
review. (Abstract 7536) C. E. Steuer, M. Behera, K. A. Higgins, N. F. Saba, D. M.
Shin, S. Pakkala, R. N. Pillai, T. K. Owonikoko, W. J. Curran Jr., C. P. Belani, F. R.
Khuri, S. S. Ramalingam
Board 284
Pulmonary sarcomatoid carcinoma: An analysis of the National Cancer
Database. (Abstract 7537) C. E. Steuer, M. Behera, Y. Liu, C. Fu, T. W. Gillespie,
N. F. Saba, D. M. Shin, R. N. Pillai, S. Pakkala, T. K. Owonikoko, F. R. Khuri, S. S.
Ramalingam
Board 285
Association between radiation dose and outcomes with postoperative
radiotherapy for N0-N1 non-small-cell-lung cancer. (Abstract 7538) E. H.
Wang, C. D. Corso, H. S. Park, A. B. Chen, A. W. Kim, L. D. Wilson, R. H. Decker,
J. B. Yu
Board 286
Common and rare EGFR mutations (EGFR m) in the RADIANT trial: Final
follow-up with 5 year data. (Abstract 7539) F. A. Shepherd, W. E. Eberhardt,
N. K. Altorki, M. E. O’Brien, J. Wang, J. Wu, S. Gill, K. Iwata, F. C. Richardson,
J. D. Horan, M. A. Foley, K. Kelly
Board 287
Final follow-up (f/u) results from RADIANT: A randomized double blind phase
3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor
resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH)
non-small cell lung cancer (NSCLC). (Abstract 7540) M. E. O’Brien, K. Kelly,
N. K. Altorki, W. E. Eberhardt, D. R. Spigel, L. Crino, C. Tsai, J. Kim, E. Cho, P. C.
Hoffman, S. Keshavjee, S. Orlov, P. Serwatowski, J. Wang, M. A. Foley, J. D.
Horan, F. A. Shepherd
Board 288
A phase II study of concurrent chemoradiotherapy with cisplatin and oral
S-1, followed by surgery for locally advanced non-small cell lung cancer.
(Abstract 7541) T. Tsuchiya, Y. Nakamura, N. Hayashi, K. Matsumoto, T.
Miyazaki, K. Tabata, J. Fukuoka, N. Yamasaki, T. Nagayasu
Board 289
Retrospective analysis between PD-L1 expression and prognosis for stage III
non-small cell lung cancer patients who received concurrent
chemoradiotherapy. (Abstract 7542) T. Tokito, K. Azuma, H. Ishii, K. Yamada, T.
Hoshino
Board 290
Correlation between high-resolution computed tomography findings and
IASLC/ATS/ERS classification of small lung adenocarcinomas in Japanese
patients. (Abstract 7543) Y. Kudo, J. Matsubayashi, Y. Shimada, S. Akata, Y.
Kato, M. Kakihana, N. Kajiwara, T. Ohira, T. Nagao, N. Ikeda
233
MONDAY
MONDAY
Board 291
Comprehensive analysis of driver mutations in Chinese squamous cell lung
carcinomas by targeted next-generation sequencing. (Abstract 7544) S. Yang,
D. Tao, D. Wu, N. Zhang, L. Wang, Y. Liu, X. Han, Y. Shi
Board 292
Prognostic significance of a diagnosis of multiple lung cancers. (Abstract
7545) J. Naidoo, K. Woo, C. S. Sima, D. J. Finley, W. D. Travis, V. W. Rusch, M. G.
Kris, M. G. Zauderer
Board 293
Patterns and effectiveness of surveillance after curative intent surgery in
stage I-IIIA non-small cell lung cancer. (Abstract 7546) C. A. Ciunci, E. C.
Paulson, N. Mitra, C. M. Veenstra, J. Yang, C. J. Langer, A. J. Epstein, A. Vachani
Board 294
Prognostic role of expression levels of FABP3 and AKR1B10 genes in
adenocarcinoma stage I patients. (Abstract 7547) V. Ludovini, A. Siggillino, F.
Bianconi, L. Pistola, R. Chiari, G. Metro, F. R. Tofanetti, J. Vannucci, S. Treggiari,
G. Bellezza, A. Sidoni, F. Puma, L. Crino
Board 295
Utility of 18F-FDG PET and CT to assess response to neoadjuvant
chemotherapy. (Abstract 7548) J. E. Chaft, J. Naidoo, M. Dunphy, K. Woo, C. S.
Sima, R. J. Downey, W. D. Travis, M. G. Kris
Board 296
Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with
non squamous lung cancer patient characteristics and outcomes. (Abstract
7549) T. K. Owonikoko, M. Nelson, S. Y. Park, S. Kim, C. E. Steuer, M. Behera, Z.
Chen, E. Han, M. Kumar, V. Ernani, N. F. Saba, F. R. Khuri, S. S. Ramalingam,
M. R. Rossi
Board 298
Conditional survival estimates for lung cancer histologic subtypes in the U.S.
(2004 –2008). (Abstract 7550) K. Mosalpuria, Y. Xing, C. Hu, V. R. Bhatt, A. Ganti
Board 299
PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small
cell lung cancer. (Abstract 7551) T. K. Owonikoko, J. Kowalski, S. Kim, B.
Dwivedi, Z. Chen, M. Behera, W. Mayfield, R. C. Hermann, L. Chen, F. R. Khuri,
S. S. Ramalingam, G. Sica
Board 300
A phase II feasibility study of preoperative chemotherapy with bevacizumab
for resectable stage II/IIIA non-squamous non-small cell lung cancer.
(Abstract 7552) Y. Miyata, Y. Tsutani, K. Suzuki, K. Takamochi, F. Tanaka, H.
Nakayama, Y. Yamashita, M. Tsuboi, M. Oda, M. Okada
Board 301
Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for
locally advanced non-squamous non-small cell lung cancer (NSCLC).
(Abstract 7553) R. Mehra, A. Turaka, J. E. Meyer, B. L. Egleston, T. Tanvetyanon,
M. C. Pinder, T. J. Dilling, C. C. Williams, J. E. Gray, K. Shirai, R. K. Alpaugh, D.
Riordan, N. Somaiah, P. C. Shah, W. J. Scott, G. R. Simon, H. Borghaei
Board 302
Clinicopathological characteristics of squamous cell carcinoma of the lung
with programmed cell death ligand 1 (PD-L1) protein expression. (Abstract
7554) T. Huynh, A. Chi, V. Morales Oyarvide, J. F. Gainor, A. N. Hata, M. Lanuti,
E. J. Mark, J. A. Engelman, M. Mino-Kenudson
Board 303
Clinicopathological and molecular parameters of lung adenocarcinomas
(ADC) associated with programmed cell death ligand 1 (PD-L1) protein
expression. (Abstract 7555) T. Huynh, V. Morales Oyarvide, H. Uruga, E.
Bozkurtlar, J. F. Gainor, A. N. Hata, E. J. Mark, M. Lanuti, J. A. Engelman, M.
Mino-Kenudson
Board 304
Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for progressive and
pre-treated malignant pleural mesothelioma. (Abstract 7556) K. R. Aigner, E.
Selak, A. Sendler
Board 305
Treatment-free interval (TFI) after first-line therapy as a prognostic and
predictive factor in malignant pleural mesothelioma (MPM): Findings from
the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC)
versus placebo plus BIC. (Abstract 7557) V. Gregorc, D. Ghio, C. Sallemi, A.
Bulotta, G. Rossoni, M. G. Viganò, F. Fontana, S. Colombi, A. Lambiase, C.
Bordignon
Board 306
Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in
previously treated patients with malignant pleural mesothelioma (MPM)
234
Board 307
Phase I study of intra-pleural administration of GL-ONC1, an oncolytic
vaccinia virus, in patients with malignant pleural effusion. (Abstract 7559)
L. M. Krug, M. G. Zauderer, P. S. Adusumili, E. McGee, K. Sepkowitz, M. Klang,
Y. A. Yu, P. Scigalla, V. W. Rusch
Board 308
The association of T cells with survival in mesothelioma. (Abstract 7560) S. J.
Chee, M. Lopez, T. Mellows, A. Alzetani, G. Thomas, C. H. Ottensmeier
Board 309
Activity and safety of trabectedin in patients with sarcomatoid / biphasic
malignant pleural mesothelioma (MPM). (Abstract 7561) D. L. Cortinovis, L. H.
Hollander, I. C. Floriani, F. Grosso, A. Marinello, G. L. Ceresoli, I. Pacchetti, P. A.
Zucali, M. D’Incalci, S. Canova, M. I. Abbate, F. Ugo, S. Vukcaj, P. Bidoli
Board 310
MicroRNA prognostic signature in malignant pleural mesothelioma.
(Abstract 7562) F. Grossi, A. Truini, E. Nadal, C. Genova, E. Rijavec, G. Barletta,
F. Biello, S. Coco, M. Dal Bello, I. Vanni, A. Alama, D. G. Beer
Board 311
High throughput therapeutic screening of malignant pleural mesothelioma
(MPM) to identify correlation of sensitivity to FGFR inhibitors with BAP1
inactivation. (Abstract 7563) C. Alifrangis, J. Quispel Janssen, J. Badhai, F. Iorio,
L. Schunselaar, K. Kolluri, P. Baas, M. Garnett, U. McDermott
Board 312
Confirmation of high prevalence of BAP1 inactivation in mesothelioma.
(Abstract 7564) A. Cercek, M. G. Zauderer, A. Rimner, V. W. Rusch, P. S.
Adusumili, G. M. Nash, J. Hmeljak, M. Ladanyi, L. M. Krug
Board 313
Mesothelin-targeted immunotherapy CRS-207 in combination with standard
of care chemotherapy as treatment for malignant pleural mesothelioma
(MPM). (Abstract 7565) R. Hassan, S. J. Antonia, E. W. Alley, H. L. Kindler, T.
Jahan, J. J. Grous, S. Honarmand, K. McDougall, C. C. Whiting, N. Nair, E.
Lemmens, A. L. Murphy, A. Thomas, D. G. Brockstedt
Board 314
Immune escape correlates with an inflamed phenotype in malignant
mesothelioma. (Abstract 7566) A. Khattri, Z. Zuo, A. N. Husain, H. L. Kindler,
T. Y. Seiwert
Board 315
Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs)
as predictive response marker for CXCR4 antagonist LY2510924 in
combination with carboplatin-etoposide in extensive– disease small cell lung
cancer (ED-SCLC). (Abstract 7567) R. Salgia, R. W. Weaver, M. McCleod, J. R.
Stille, S. B. Yan, S. Roberson, O. Hamid, J. Polzer, A. Flynt, E. Raddad, D. R.
Spigel
Board 316
Prophylactic cranial irradiation (PCI) and consolidation thoracic radiotherapy
(TRT) for extensive stage small cell lung cancer (ES-SCLC): A systematic
review and meta-analysis. (Abstract 7568) Y. Soon, W. Koh, C. Leong, I. W.
Tham
Board 317
Loss of somatostatin receptor 2 expression and lung cancer growth.
(Abstract 7569) J. Lehman, M. Hoeksema, H. Chen, C. Shi, R. Eisenberg, P. P.
Massion
Board 318
New ARCHITECT plasma pro-gastrin-releasing peptide assay and lung
cancer: Implications for diagnosis, follow-up, and prognosis. (Abstract 7570)
B. Nisman, H. Nechushtan, H. Biran, N. Peled, H. Gantz-Sorotsky, V. Doviner, M.
Perelman, J. Bar, B. Uziely, T. Peretz-Yablonski
Board 319
Survival impact of switching to different topoisomerase I or II inhibitorsbased regimens (topo-I or topo-II) in extensive-disease small cell lung cancer
(ED-SCLC): supplemental analysis from JCOG0509. (Abstract 7571) S.
Nomura, S. Umemura, K. Yoh, T. Shinozaki, T. Shibata, K. Nakamura, M.
Satouchi, Y. Ohe, H. Fukuda
Board 320
Phase II study of topotecan and cisplatin with sequential radiotherapy in
elderly small cell lung cancer patients (Okayama Lung Cancer Study Group;
OLCSG 0102). (Abstract 7572) T. Kubo, S. Harita, T. Okada, H. Kamei, S.
235
MONDAY
enrolled in the NGR015 phase 3 trial. (Abstract 7558) A. Bulotta, V. Gregorc,
M. G. Viganò, G. Rossoni, F. Fontana, C. Ammannati, S. Colombi, A. Lambiase, C.
Bordignon
Hosokawa, T. Maeda, T. Kozuki, K. Fujiwara, K. Hotta, N. Takigawa, M. Tanimoto,
K. Kiura
MONDAY
Board 321
Detection of circulating tumor cells in the peripheral blood of patients with
small cell lung cancer (SCLC) using both the CellSearch platform and
immunofluorescence: Correlation with clinicopathological features.
(Abstract 7573) I. Messaritakis, D. Stoltidis, E. Politaki, S. Apostolaki, E.
Dermitzaki, M. Sfakianaki, A. Kotsakis, S. Agelaki, L. Vamvakas, K. Kalbakis, E.
Lagoudaki, D. Mavroudis, V. Georgoulias, I. Souglakos
Board 322
Distribution and clinical significance of CTLA4, PD-1 and PD-L1 in peripheral
blood of patients with small-cell lung cancer. (Abstract 7574) Y. Cheng, H. Li,
Y. Liu, L. Ma, X. Liu, J. Liu, S. Zhang
Board 323
Clinical correlation of genomic mutations in small cell lung cancer. (Abstract
7575) A. Dowlati, P. Fu, M. Lipka, G. Wildey
Board 324
Identification of RICTOR amplification as a recurrent and potentially
actionable alteration in small cell lung cancer patients. (Abstract 7576) S.
Dabir, G. Wildey, K. McColl, P. Fu, Y. Feng, A. Dowlati
Board 325
Conditional survival estimates for small cell lung cancer receiving
prophylactic cranial irradiation in the U.S. (1988 –1997). (Abstract 7577) Y.
Xing, K. Mosalpuria, C. Hu, V. R. Bhatt, A. Ganti
Board 326
Small cell lung cancer: Why has it become an orphan disease? (Abstract
7578) S. M. Malik, E. Korn, A. Thomas
Board 327
Impact of accurate staging with 18F-FDG-PET and brain MRI on clinical
benefit of prophylactic cranial irradiation (PCI) in patients with limited stage
(LS) small cell lung cancer (SCLC). (Abstract 7579) M. Choi, Y. Lee, S. Moon, J.
Han, H. Kim, J. Lee
Board 328
Phase II trial of single agent amrubicin (A) in patients (pts) with previously
treated advanced thymic malignancies (TM). (Abstract 7580) H. A. Wakelee,
S. K. Padda, M. Burns, A. J. Spittler, J. Riess, M. San Pedro-Salcedo, K.
Ramchandran, M. A. Gubens, J. W. Neal, P. J. Loehrer Sr.
Board 329
Somatostatin analogs as mainteinance therapy in heavily pretreated thymic
epithelial tumors. (Abstract 7581) G. Palmieri, M. Ottaviano, L. Nappi, P.
Rescigno, M. Marino, L. Montella, M. Micillo, G. Palumbo, S. Del Vecchio, V.
Damiano
Board 330
Effectiveness of somatostatin analogs plus prednisone in aggressive
histotype and advanced stage of thymic epithelial tumors. (Abstract 7582) M.
Ottaviano, V. Damiano, L. Nappi, P. Rescigno, L. Montella, M. Marino, S. Del
Vecchio, I. Tucci, C. Von Arx, G. Palmieri
Board 331a
ALCHEMIST: a clinical trial platform to bring genomic discovery and
molecularly targeted therapies to early-stage lung cancer. (Abstract
TPS7583) D. E. Gerber, G. R. Oxnard, S. J. Mandrekar, S. E. Dahlberg, S. M.
Malik, M. M. Mooney, J. S. Abrams, P. A. Janne, T. Li, S. S. Ramalingam, E. E.
Vokes, R. Govindan
Board 331b
Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR
mutations (EVENT trial). (Abstract TPS7584) C. Inal, B. Piperdi, S. M. Keller, B.
Halmos, M. Stoopler, S. A. Limaye, B. P. Levy, B. J. Schneider, M. Kim, J. Sides,
R. Perez-Soler, H. Cheng
Board 332a
NCI 9448: Phase I study of trametinib in combination with chemoradiation for
KRAS-mutant non-small cell lung cancer. (Abstract TPS7585) S. H. Lin, I. Mok,
D. Leos, M. G. Pasia, P. F. Thall, H. Y. Lin, M. X. Welliver, M. A. Villalona-Calero,
J. C. Yao, F. Meric-Bernstam, R. Komaki, H. X. Chen, G. R. Blumenschein Jr.
Board 332b
Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose
interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma
(MPM). (Abstract TPS7586) M. Doherty, N. B. Leighl, R. Feld, P. A. Bradbury, L.
Wang, J. Nie, P. Yen, M. Pniak, L. T. Nguyen, M. O. Butler, M. de Perrot
236
Location: S Hall A
Board 335
First-in-human phase I study of EGF816, a third generation, mutant-selective
EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer
(NSCLC) harboring T790M. (Abstract 8013) D. S. Tan, T. Seto, N. B. Leighl, G. J.
Riely, L. V. Sequist, E. Felip, J. Wolf, J. C. Yang, I. Matushansky, X. Yu, S. H.
Schmitz, X. Cui, D. Kim
Board 336
ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with
NSCLC harboring EGFR activating mutations: Preliminary results of first-inhuman phase I study in Japan. (Abstract 8014) Y. Goto, H. Nokihara, H.
Murakami, T. Shimizu, T. Seto, A. P. Krivoshik, A. T. Keating, K. Uegaki, K.
Takeda, K. Komatsu, S. Morita, M. Fukuoka, K. Nakagawa
Board 337
Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.
(Abstract 8015) Z. Piotrowska, D. B. Costa, M. Huberman, G. R. Oxnard, J. F.
Gainor, R. S. Heist, A. Muzikansky, A. T. Shaw, M. J. Niederst, L. Fulton, J. A.
Engelman, L. V. Sequist
Board 338
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for
the treatment of non-small cell lung cancer (NSCLC) with brain metastasis
(BM): Preclinical evidence and clinical cases. (Abstract 8016) D. Kim, J. C.
Yang, K. Chen, Z. Cheng, L. Yin, P. D. Martin, Z. Yang, H. Jiang, M. Ahn
Board 339
A phase I study of twice weekly pulse dose and daily low dose erlotinib as
initial treatment for patients (pts) with EGFR-mutant lung cancers. (Abstract
8017) H. A. Yu, C. S. Sima, D. Reales, S. Jordan, C. M. Rudin, M. G. Kris, F.
Michor, W. Pao, G. J. Riely
Board 340
Clinical activity and safety of PF-06463922 from a dose escalation study in
patients with advanced ALKⴙ or ROS1ⴙ NSCLC. (Abstract 8018) A. T. Shaw,
T. M. Bauer, E. Felip, B. Besse, L. P. James, J. S. Clancy, G. Mugundu, J. Martini,
A. Abbattista, B. J. Solomon
Board 341
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an
ALKⴙ non-small-cell lung cancer (NSCLC) U.S./Canadian population who
had progressed on crizotinib (NP28761). (Abstract 8019) L. Gandhi, A. Shaw,
S. M. Gadgeel, G. Riely, J. Cetnar, H. J. West, D. R. Camidge, M. A. Socinski, A.
Chiappori, T. Mekhail, B. H. Chao, H. Borghaei, K. A. Gold, A. H. Zeaiter, W.
Bordogna, B. Balas, O. Puig, V. Henschel, S. I. Ou, NP28761 Study Investigators
Board 342
Detection of frequent MET Exon 14 skipping events in pulmonary
sarcomatoid carcinoma and response to targeted inhibition. (Abstract 8020)
X. Liu, Y. Jia, Y. Shen, J. Chen, M. Mansukhani, H. Cheng, S. Koul, A. C. Borczuk,
B. Halmos
Board 343
Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma
patients with mutations that cause MET exon 14 skipping. (Abstract 8021)
P. K. Paik, A. E. Drilon, H. A. Yu, L. M. Krug, N. Rekhtman, L. Borsu, M. S.
Ginsberg, M. F. Berger, M. Ladanyi, C. M. Rudin
Board 344
Clinical and molecular characteristics of NF1 mutant lung cancer. (Abstract
8022) A. J. Redig, S. L. Mach, M. Capelletti, C. Fontes, Y. Shi, P. Chalasani, S. E.
Dahlberg, P. A. Janne
Board 345
Assessing the performance of Watson for oncology, a decision support
system, using actual contemporary clinical cases. (Abstract 8023) M. G. Kris,
A. Gucalp, A. S. Epstein, A. D. Seidman, J. Fu, J. Keesing, A. Caroline, M.
Megerian, T. Eggebraaten, R. DeLima, M. Setnes, M. G. Zauderer
Board 346
Electronic medical record as a research tool: Virtual clinical trial comparing
pemetrexed and gemcitabine, both given with cisplatin, in patients with lung
237
MONDAY
Abstracts 8013– 8024 will be discussed during the Lung Cancer—Non-Small Cell Metastatic
adenocarcinomas. (Abstract 8024) A. Grigorenko, P. May, N. Kastango, H. T.
Thaler, I. Wagner, A. Caroline, M. G. Kris, M. G. Zauderer
MONDAY
Board 347
First-line monotherapy with nivolumab (NIVO; anti-programmed death-1
[PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and
correlation of outcomes with PD-1 ligand (PD-L1) expression. (Abstract 8025)
S. N. Gettinger, M. D. Hellmann, F. A. Shepherd, S. J. Antonia, J. R. Brahmer,
L. Q. Chow, J. W. Goldman, R. A. Juergens, H. Borghaei, N. Ready, D. E. Gerber,
F. E. Nathan, Y. Shen, C. Harbison, N. A. Rizvi
Board 348
Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro;
MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell
lung cancer (NSCLC): Updated data from KEYNOTE-001. (Abstract 8026)
N. A. Rizvi, E. B. Garon, N. Leighl, M. D. Hellmann, A. Patnaik, L. Gandhi, J. P.
Eder, R. A. Rangwala, G. Lubiniecki, J. Zhang, K. Emancipator, C. M. Roach, R.
Rutledge, R. Hui, M. Ahn, L. Horn, E. Felip, E. Carcereny Costa
Board 349
Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients
with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung
cancer (NSCLC). (Abstract 8027) M. Nishio, T. Hida, K. Nakagawa, H. Sakai, N.
Nogami, S. Atagi, T. Takahashi, H. Nokihara, H. Saka, M. Takenoyama, S. Fujita,
H. Tanaka, K. Takeda, M. Satouchi, H. Isobe, M. Maemondo, K. Goto, T.
Hirashima, K. Minato, T. Tamura
Board 350
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (antiPDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).
(Abstract 8028) D. R. Spigel, J. E. Chaft, S. N. Gettinger, B. H. Chao, L. Y. Dirix,
P. Schmid, L. Q. Chow, C. Chappey, M. Kowanetz, A. Sandler, R. P. Funke, N. A.
Rizvi
Board 351
Clinical activity, safety and predictive biomarkers of the engineered antibody
MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from
a phase Ia study. (Abstract 8029) L. Horn, D. R. Spigel, S. N. Gettinger, S. J.
Antonia, M. S. Gordon, R. S. Herbst, L. V. Sequist, C. Chappey, M. Kowanetz, A.
Sandler, J. Soria
Board 352
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinumbased doublet chemotherapy in patients with advanced non-small cell lung
cancer (NSCLC). (Abstract 8030) S. V. Liu, J. D. Powderly II, D. R. Camidge, N.
Ready, R. S. Heist, F. S. Hodi, G. Giaccone, B. Liu, J. Wallin, R. P. Funke, D.
Waterkamp, S. N. Gettinger
Board 353
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy
(PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC):
KEYNOTE-021 Cohorts A and C. (Abstract 8031) V. Papadimitrakopoulou, A.
Patnaik, H. Borghaei, J. Stevenson, L. Gandhi, M. A. Gubens, J. C. Yang, L. V.
Sequist, J. Yang Ge, J. Bourque, R. D. Bachman, E. Im, S. M. Gadgeel
Board 354
Safety and clinical activity of MEDI4736, an anti-programmed cell deathligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer
(NSCLC). (Abstract 8032) N. A. Rizvi, J. R. Brahmer, S. I. Ou, N. H. Segal, S.
Khleif, W. Hwu, M. Gutierrez, P. Schoffski, O. Hamid, J. Weiss, J. Lutzky, M. Maio,
J. J. Nemunaitis, D. Jaeger, A. S. Balmanoukian, M. Rebelatto, K. Steele, X. Li,
J. A. Blake-Haskins, S. J. Antonia
Board 355
Development of a PD-L1 companion diagnostic assay for treatment with
MEDI4736 in NSCLC and SCCHN patients. (Abstract 8033) M. Rebelatto, A.
Mistry, C. Sabalos, J. Walker, A. Midha, K. Steele, P. B. Robbins, X. Li, L. Shi, J. A.
Blake-Haskins, R. A. Ibrahim, L. Richman
Board 356
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC
patients: A phase 1b, open-label expansion trial in patients progressing after
platinum-based chemotherapy. (Abstract 8034) J. L. Gulley, D. Spigel, K. Kelly,
J. C. Chandler, A. Rajan, R. Hassan, D. J. Wong, J. Leach, W. J. Edenfield, D.
Wang, N. Vrindavanam, G. J. Weiss, J. S. Gurtler, H. J. Grote, A. von Heydebreck,
K. M. Chin, N. Iannotti
238
Board 357
Activity and safety of pembrolizumab in patients with metastatic non-small
cell lung cancer with untreated brain metastases. (Abstract 8035) S. B.
Goldberg, S. N. Gettinger, A. Mahajan, R. S. Herbst, A. C. Chiang, A. J. Tsiouris,
A. Vortmeyer, L. Jilaveanu, S. Speaker, M. Madura, E. Rowen, H. Gerrish, E.
Knapp-Perry, X. Yao, V. Chiang, H. M. Kluger
Board 358
Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine.
(Abstract 8036) G. Bepler, W. Chen, S. Patrick, S. H. Astrow, C. Stephens, D. R.
Gandara, R. Rosell, J. Ramirez, G. V. Scagliotti, S. Busso, M. Volante, S. Novello
Board 359
Pre-treatment 5-methyltetrahydrofolate levels and response to pemetrexed in
stage IV adenocarcinoma of the lung. (Abstract 8037) S. J. Bagley, C. J.
Langer, C. Aggarwal, T. L. Evans, E. W. Alley, R. B. Cohen, S. Zhang, L. Werner,
I. A. Blair, A. S. Whitehead, A. Vachani
Board 360
Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients
with advanced NSCLC. (Abstract 8038) S. S. Ramalingam, N. Blais, J. Mazières,
M. Reck, C. Jones, E. Juhasz, L. Urban, S. Orlov, F. Barlesi, E. A. Kio, U. Keilholz,
J. Qian, Q. Qin, M. Dunbar, H. Xiong, R. K. Mittapalli, P. Ansell, M. D. McKee, V. L.
Giranda, V. Gorbunova
Board 361
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin
versus docetaxel and cisplatin in patients with untreated advanced nonsmall-cell lung cancer. (Abstract 8039) J. He, Y. Shi, J. Chang, M. Wang, B.
Han, X. Liu, G. Chen, C. Zhou, J. Liu, H. Pan, C. Huang, S. Zhang, J. Feng, X. Lin,
J. Wang, J. Huang, F. Li, S. Qin, Z. Wang, L. Wang
Board 362
SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL)
vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced
non-small cell lung cancer (NSCLC) and impaired performance status (PS 2)
as selected by serum proteomics. (Abstract 8040) P. Lara, J. Moon, P. J.
Hesketh, M. W. Redman, S. K. Williamson, F. R. Hirsch, P. C. Mack, D. R.
Gandara
Board 364
A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin
followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in
East Asian patients (pts) with locally advanced or metastatic nonsquamous
non-small cell lung cancer (nSqNSCLC): Final survival results. (Abstract
8041) J. C. Yang, V. Srimuninnimit, M. Ahn, C. Lin, S. Kim, C. Tsai, T. Mok, M.
Orlando, T. Puri, X. Wang, K. Park
Board 365
Intercalating and maintenance use of gefitinib plus chemotherapy versus
chemotherapy alone in selected advanced NSCLC(ISCAN,CTONG-1102): A
multicentre, open-label, randomised, phase 3 study. (Abstract 8042) S. Lu, H.
Jian, W. Li, M. Z. Yong, J. Huang, J. Feng, Y. Song, B. Gao, H. Zhu, M. Tao, C.
Bai, M. Shenglin, H. Pan, S. Qin, D. Hua
Board 366
Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after
induction therapy with P/platinum for metastatic lung adenocarcinoma
(MLADC) harboring no sensitizing epidermal growth factor receptor mutation
(sEGFRm): A phase II multicenter randomized open-label study (GENIUS
trial). (Abstract 8043) C. Tsai, C. Lai, C. Chiu, T. Hsia, C. Chen, G. Chang, J.
Shih, C. Ho, Y. Chen, J. C. Yang
Board 367
Pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl)
in patients (pts) with advanced, EGFR wild-type (wt) Non-Small Cell Lung
Cancer (NSCLC): A randomized phase II trial. (Abstract 8044) T. Li, B. Piperdi,
W. V. Walsh, M. Kim, L. A. Beckett, H. Wen, K. Zhou, R. A. Gucalp, M. Haigentz
Jr., V. G. Bathini, S. Gajavelli, M. Sreedhara, P. Lara Jr., D. R. Gandara, R.
Perez-Soler
Board 368
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM),
pemetrexed (PEM) & carboplatin (CARBO) in pts with 1st line non-squamous
NSCLC. (Abstract 8045) D. Kotasek, B. G. Hughes, B. Markman, M. Millward, E.
Holgado, M. B. Jameson, D. L. Harris, R. J. Stagg, A. M. Kapoun, J. Dupont, M. J.
McKeage
239
MONDAY
MONDAY
Board 369
A phase Ib study of selumetinib in patients (pts) with previously untreated
metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard
chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. (Abstract
8046) G. A. Nicholas, J. R. Goffin, S. A. Laurie, A. G. Robinson, G. D. Goss, M. N.
Reaume, M. Mates, P. Wheatley-Price, P. M. Ellis, R. A. Juergens, A. T. Tomiak,
R. W. Gregg, B. L. Melosky, D. Tu, H. Ritter, L. Seymour, P. A. Bradbury
Board 370
A phase Ib study of abemaciclib in combination with multiple single agents in
stage IV NSCLC. (Abstract 8047) E. S. Kim, K. Kelly, J. W. Goldman, P. Garrido
Lopez, S. I. Jalal, D. Mahadevan, M. Gutierrez, M. Provencio Pulla, E. S. Schaefer,
M. F. Shaheen, E. L. Johnston, N. Cai, W. J. John, L. Paz-Ares
Board 371
Individual patients data analysis (IPD) of three randomized studies
comparing erlotinib (E) with chemotherapy (CT) in patients with advanced
wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung
cancer (NSCLC). (Abstract 8048) V. Torri, M. Ando, E. Rulli, I. C. Floriani, T.
Kawaguchi, S. Isa, V. Gregorc, S. Novello, S. Barni, M. Cinquini, S. Marsoni, G.
Farina, M. C. Garassino
Board 372
Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced
squamous cell non-small cell lung cancer (SqNSCLC) failing first line
platinum based doublet chemotherapy stratified by VeriStrat Good vs
VeriStrat Poor: The European Thoracic Oncology Platform (ETOP)
EMPHASIS trial. (Abstract 8049) S. Peters, E. F. Smit, U. Dafni, S. Ponce Aix, B.
Massuti, O. Gautschi, L. Coate, A. López Martı́n, R. van Heemst, T. Berghmans, P.
Meldgaard, M. Cobo Dols, J. G. Noguera, I. C. Floriani, M. Kassapian, Y.
Chittazhathu Kurian Kuruvilla, A. Gasca-Ruchti, C. Zielinski, V. Gregorc, R. A.
Stahel, EMPHASIS Collaborative Group
Board 374
Open-label, randomized study of individualized, pharmacokinetically (PK)guided dosing of paclitaxel combined with carboplatin in advanced nonsmall cell lung cancer (NSCLC) patient. (Abstract 8051) M. Joerger, J. Von
Pawel, S. Kraff, J. R. Fischer, W. Eberhardt, T. C. Gauler, L. Mueller, N. Reinmuth,
M. Reck, M. Kimmich, F. Mayer, H. Kopp, D. M. Behringer, Y. Ko, M. Frueh, R. A.
Hilger, M. Roessler, B. Moritz, U. Jaehde
Board 375
Paclitaxel (PTX) dose individualization by exposure optimization in Chinese
patients with advanced non small-cell lung cancer (NSCLC) receiving
first-line paclitaxel-carboplatin (PC) chemotherapy. (Abstract 8052) J. Zhang,
H. Qi, C. Zhou, H. Ni, Y. Li
Board 376
Exposure-response relationship for ramucirumab (RAM) from the
randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC
plus RAM) in second-line treatment of metastatic non-small cell lung cancer
(NSCLC). (Abstract 8053) E. F. Smit, M. Perol, M. Reck, F. Cappuzzo, P. Bidoli,
R. B. Cohen, L. Gao, C. Ernest II, P. Lee, A. Zimmermann, D. Ferry, J. Treat, A. S.
Melemed, E. B. Garon
Board 377
Docetaxel ⴙ ramucirumab (DR) versus docetaxel ⴙ placebo (D) as secondline treatment for advanced non-small cell lung cancer (NSCLC): A
randomized, phase II, double-blind, multicenter trial in Japan. (Abstract 8054)
Y. Hosomi, K. Yoh, K. Kasahara, K. Yamada, T. Takahashi, K. Tanaka, T. Hida, H.
Yoshioka, T. Kato, K. Takeda, M. Nishio, H. Sakai, M. Maemondo, M.
Takenoyama, H. Nokihara, M. Tatsumi, T. Nakamura, S. Enatsu, T. Tamura, K.
Nakagawa
Board 378
Exploratory analysis of safety by histology and efficacy in a nonsquamous
NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab
(RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV
non-small-cell lung cancer (NSCLC). (Abstract 8055) L. Paz-Ares, M. Perol, T.
Ciuleanu, R. D. Kowalyszyn, M. Reck, C. R. Lewanski, K. N. Syrigos, O. Arrieta, K.
Prabhash, K. Park, J. Pikiel, T. Göksel, P. S. Lee, A. Zimmerman, J. Treat, D.
Ferry, A. S. Melemed, G. Cuyun Carter, E. Alexandris, E. B. Garon
Board 379
Bevacizumab beyond disease progression after first-line treatment with
bevacizumab plus chemotherapy in advanced nonsquamous non–small cell
lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.
240
Board 380
Efficacy and safety of BCD-021, bevacizumab biosimilar candidate,
compared to Avastin: Results of international multicenter randomized double
blind phase III study in patients with advanced non-squamous NSCLC.
(Abstract 8057) O. Filon, S. Orlov, O. Burdaeva, M. V. Kopp, B. Kotiv, S.
Alekseev, A. Pecheniy, D. Stroyakovskiy, O. Gladkov, A. Khorinko, M. Matrosova,
R. Galiulin, P. Skopin, G. Mukhametsina, S. Odarchenko, S. Kulik, J. Kulyaba, G.
Adamchuk, Y. Vinnyk, S. Tjulandin
Board 381
Comparative efficacy of ceritinib and crizotinib in previously treated
crizotinib-naïve anaplastic lymphoma kinase-positive (ALKⴙ) advanced or
metastatic non-small cell lung cancer (NSCLC): An adjusted indirect
comparison. (Abstract 8058) D. S. Tan, A. Araujo, J. Zhang, J. E. Signorovitch, Z.
Zhou, X. Cai, G. Liu
Board 382
ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in
adult patients (pts) with ALK-rearranged (ALKⴙ) non-small cell lung cancer
(NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
(Abstract 8059) T. Mok, D. Spigel, E. Felip, F. deMarinis, M. Ahn, H. J. Groen,
H. A. Wakelee, T. Hida, L. Crino, M. Nishio, G. V. Scagliotti, F. Branle, C.
Emeremni, M. Quadrigli, J. Zhang, A. T. Shaw
Board 383
ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in
ALKi-naïve adult patients (pts) with ALK-rearranged (ALKⴙ) non-small cell
lung cancer (NSCLC). (Abstract 8060) E. Felip, S. Orlov, K. Park, C. Yu, C. Tsai,
M. Nishio, M. Cobo Dols, M. J. McKeage, W. Su, T. Mok, G. V. Scagliotti, D. Spigel,
F. Branle, C. Emeremni, M. Quadrigli, A. T. Shaw
Board 384
A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in
ALK-rearranged non-small cell lung cancer (ALK ⴙ NSCLC) patients (pts):
Updates on progression free survival (PFS) and safety results from AF001JP. (Abstract 8061) Y. Ohe, M. Nishio, K. Kiura, T. Seto, K. Nakagawa, M.
Maemondo, A. Inoue, T. Hida, H. Yoshioka, M. Harada, N. Nogami, H. Murakami,
K. Takeuchi, T. Shimada, H. Kuriki, T. Tanaka, T. Tamura
Board 385
Safety and efficacy of brigatinib (AP26113) in advanced malignancies,
including ALKⴙ non–small cell lung cancer (NSCLC). (Abstract 8062) D. R.
Camidge, L. Bazhenova, R. Salgia, C. J. Langer, K. A. Gold, R. Rosell, A. T. Shaw,
G. J. Weiss, N. I. Narasimhan, D. J. Dorer, V. M. Rivera, T. P. Clackson, M. G.
Conlan, D. Kerstein, F. G. Haluska, S. N. Gettinger
Board 386
Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in
advanced solid tumors including crizotinib-resistant ALK positive non-small
cell lung cancer. (Abstract 8063) H. Arkenau, J. C. Sachdev, M. M. Mita, R.
Dziadziuszko, C. Lin, J. Yang, J. R. Infante, S. P. Anthony, M. Voskoboynik, W. Su,
J. De Castro, R. B. Natale, Z. Zhang, L. Hughes, D. Bobilev, G. J. Weiss
Board 387
A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung
cancers. (Abstract 8064) G. J. Riely, H. A. Yu, D. Stephens, M. Pietanza, S.
Smith-Marrone, J. J. Fiore, M. Goldstein, C. S. Sima, M. G. Kris, M. S. Ginsberg
Board 388
Crizotinib in patients with advanced ROS1-rearranged non-small cell lung
cancer (NSCLC). Preliminary results of the ACSé phase II trial. (Abstract
8065) D. Moro-Sibilot, L. Faivre, G. Zalcman, M. Pérol, F. Barlesi, J. Otto, I.
Monnet, A. B. Cortot, M. Wislez, H. Lena, J. Mazières, X. Durando, S. Lantuejoul, I.
Rouquette, A. McLeer Florin, G. Ferretti, N. Hoog Labouret, F. Nowak, M. Jimenez,
G. Vassal
Board 389
ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and
predicitve impact and genetic variability. (Abstract 8066) M. Scheffler, A. M.
Schultheis, C. Teixido, S. Y. Michels, D. Morales-Espinosa, S. Viteri, S.
Merkelbach-Bruse, R. Fischer, J. Fassunke, M. Sebastian, M. H. Serke, W.
Randerath, U. Gerigk, Y. Ko, S. Krüger, R. Schnell, A. Rothe, R. Rosell, R. Büttner,
J. Wolf, NGM ROS1 Group
241
MONDAY
(Abstract 8056) M. Takeda, T. Seto, H. Hayashi, M. Okada, K. Azuma, S.
Sugawara, H. Daga, T. Hirashima, K. Yonesaka, Y. Urata, H. Murakami, H. Saito,
A. Kubo, T. Sawa, E. Miyahara, N. Nogami, T. Yamanaka, Y. Nakanishi, K.
Nakagawa, I. Okamoto, West Japan Oncology Group
MONDAY
Board 390
Defining the spectrum and “overlap” of HER2 aberrations in lung cancers:
Associations of HER2 protein overexpression, HER2 amplification, and HER2
mutation. (Abstract 8067) B. T. Li, D. S. Ross, J. E. Chaft, M. Hsu, S. Kako, D. L.
Aisner, M. G. Kris, M. Varella-Garcia, M. E. Arcila
Board 391
Outcomes with chemotherapies and molecular characteristics of HER2mutant lung cancers. (Abstract 8068) J. Eng, B. T. Li, M. Hsu, J. E. Chaft, M. E.
Arcila, M. G. Kris
Board 392
EGFR mutation pattern in African American population in a communitybased academic center. (Abstract 8069) H. Cheng, C. Inal, Y. Yang, R. A.
Gucalp, M. Haigentz Jr., S. H. Packer, C. Zhu, K. Wilson, R. Perez-Soler
Board 393
EGFR mutations in Latinos from the United States and Latin America.
(Abstract 8070) A. Lopez-Chavez, M. Evbuomwan, L. Xi, G. Chun, T. Vidaurre, O.
Arrieta, G. Oblitas III, A. B. Oton, A. R. Calvo, A. Rajan, P. Amarapurkar, M.
Raffeld, S. M. Steinberg, L. Arze-Aimaretti, G. Giaccone
Board 394
Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic
NSCLC treated with EGFR-TKIs. (Abstract 8071) J. J. Lin, S. Cardarella, C. A.
Lydon, S. E. Dahlberg, D. M. Jackman, P. A. Janne, B. E. Johnson
Board 395
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E)
and of clinical factors in advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor mutations (EGFR mut) based on
meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
(Abstract 8072) C. Lee, L. C. Davies, Y. Wu, T. Mitsudomi, A. Inoue, R. Rosell, C.
Zhou, K. Nakagawa, S. Throngprasert, M. Fukuoka, R. J. Gralla, V. Gebski, T.
Mok, J. C. Yang
Board 397
Influence of dose adjustment on afatinib safety and efficacy in patients (pts)
with advanced EGFR mutation-positive (EGFRmⴙ) non-small cell lung
cancer (NSCLC). (Abstract 8073) J. C. Yang, M. Ahn, N. J. Dickgreber, B.
Halmos, V. Hirsh, M. J. Hochmair, B. P. Levy, F. De Marinis, T. Mok, K. O’Byrne, I.
Okamoto, M. H. Schuler, M. Sebastian, R. N. Shah, E. Tan, N. Yamamoto, A.
Marten, D. Massey, S. Wind, D. P. Carbone
Board 398
Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant nonsmall cell lung carcinoma (NSCLC): A retrospective analysis. (Abstract 8074)
B. L. Lampson, A. Santos, P. A. Janne, G. R. Oxnard
Board 399
Single institution experience with 75 mg dose of erlotinib in Latin American
patients with mutated metastatic non-small cell lung cancer. (Abstract 8075)
O. R. Aren, R. Silva, H. Cerda, J. M. Arancibia, C. Rojas, M. Reyes, R. A. Ascui, P.
Banchero, M. E. Burotto Pichun
Board 400
A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess
biopsy feasibility and acquired resistance at disease progression. (Abstract
8076) A. J. Redig, M. Taibi, G. R. Oxnard, D. Boucher, M. S. Rabin, J. Marcoux II,
L. Gandhi, M. Huberman, D. Rangachari, J. V. Lucca, L. K. Morse, M. Andan, B. E.
Johnson, D. B. Costa, P. A. Janne, D. M. Jackman
Board 401
Clinical implications of repeat tumor biopsy (RTB) in patients (pts) with
advanced lung cancer (LC): The Cleveland Clinic (CC) experience. (Abstract
8077) E. S. Agwa, F. Almeida, A. Haddad, B. R. Bastos, R. Lee, X. Jia, P. Ma
Board 402
Dynamic serial monitoring of EGFR mutations in plasma DNA samples in
EGFR mutant NSCLC patients treated with EGFR TKI. (Abstract 8078) M. Ahn,
J. Lee, S. Lim, M. Lee, H. Kim, S. Byeon, J. Ham, B. Yali, W. Xiumin, H. Lee, J.
Sun, J. Ahn, E. Cho, Y. Min, D. Kim, K. Park, X. Qing, M. Mao
Board 403
Early prediction of response to tyrosine kinase inhibitors by quantification of
EGFR mutations in plasma of non-small cell lung cancer patients. (Abstract
8079) A. Marchetti, J. F. Palma, L. Felicioni, T. M. De Pas, R. Chiari, M. Del
Grammastro, G. Filice, V. Ludovini, A. A. Brandes, A. Chella, F. Malorgio, F.
Guglielmi, M. De Tursi, A. Santoro, L. Crino, F. Buttitta
Board 404
Association of plasma EGFR T790M ctDNA status with clinical outcome in
advanced NSCLC patients with acquired EGFR-TKI resistance. (Abstract
242
Board 405
Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to
predict radiographic progression and response in patients with metastatic
lung adenocarcinoma. (Abstract 8081) H. Husain, K. Kosco, C. T. Vibat, V.
Melnikova, M. G. Erlander, E. E. Cohen, S. M. Lippman, R. Kurzrock
Board 406
EML4-ALK rearrangement in blood platelets and outcome to crizotinib in
non-small-cell lung cancer patients. (Abstract 8082) N. Karachaliou, R. A.
Nilsson, J. Berenguer, A. Gimenez Capitan, P. Schellen, C. Teixido, J. L. Kuiper, E.
Drees, M. Grabowska, M. van Keulen, J. M. Tannous, D. Heideman, E.
Thunnissen, A. C. Dingemans, S. Viteri Ramirez, B. A. Tannous, A. Drozdowskyj,
E. F. Smit, T. Wurdinger, R. Rosell
Board 407
Phase I dose escalation study of ASP8273, a mutant-selective irreversible
EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. (Abstract
8083) H. A. Yu, G. R. Oxnard, A. I. Spira, L. Horn, J. Weiss, Y. Feng, H. J. West, G.
Giaccone, T. L. Evans, R. J. Kelly, T. Fleege, S. Poondru, F. Jie, K. Aoyama, M. A.
Foley, D. Whitcomb, A. T. Keating, A. P. Krivoshik
Board 408
Updated safety and efficacy results from phase I/II study of HM61713 in
patients (pts) with EGFR mutation positive non-small cell lung cancer
(NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). (Abstract
8084) K. Park, J. Lee, K. Lee, J. Kim, Y. Min, J. Y. Cho, J. Han, B. Kim, D. Lee, J.
Kang, E. Cho, I. Jang, J. Jung, H. Kim, H. Sin, J. Son, J. Woo, D. Kim
Board 409
A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in
Korean patients with advanced or metastatic lung adenocarcinoma who have
acquired resistance to epidermal growth factor receptor tyrosine kinase
inhibitors. (Abstract 8085) J. Han, J. Lee, K. Lee, S. Kim, Y. Min, E. Cho, Y. Lee,
S. Lee, H. Kim, G. Lee, B. Nam, J. Kim, J. Jung
Board 410
A phase Ib/II study of afatinib in combination with nimotuzumab in non-small
cell lung cancer patients with acquired resistance to gefitinib or erlotinib.
(Abstract 8086) M. Ahn, J. Lee, J. Sun, B. Ku, J. Koh, S. Lim, M. Lee, H. Kim, J.
Ahn, K. Park
Board 411
Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients
(pts) with EGFR-mutant NSCLC with epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer
Consortium Phase II Trial (NCI 9303). (Abstract 8087) K. L. Reckamp, P. C.
Mack, N. Ruel, P. H. Frankel, B. J. Gitlitz, T. Li, M. Koczywas, S. M. Gadgeel, M. C.
Cristea, C. P. Belani, E. M. Newman, D. R. Gandara, P. Lara Jr.
Board 412
Genetic variability and clinical presentation of patients with non-small cell
lung cancer (NSCLC) harboring MET-amplifications. (Abstract 8088) A. Eisert,
M. Scheffler, S. Y. Michels, A. M. Schultheis, R. Frank, K. Koenig, S. MerkelbachBruse, R. Fischer, M. H. Serke, Y. Ko, U. Gerigk, T. Geist, L. C. Heukamp, R.
Büttner, J. Wolf
Board 413
Response to tyrosine kinase inhibtors in non-small-cell lung cancer with
concomitant c-MET overexpression and driver genes. (Abstract 8089) N. Lou,
J. Yang, X. Zhang, Q. Zhou, H. Chen, Z. Wang, J. Su, Z. Xie, B. Jiang, Z. Chen, X.
Bai, Y. Wu
Board 414
Crizotinib in advanced non-small-cell lung cancer with de novo c-Met
overexpression. (Abstract 8090) A. N. Li, J. Yang, X. Zhang, Y. Wu
Board 415
Targeting c-Met overexpression for overcoming acquired resistance to EGFR
TKIs in NSCLC. (Abstract 8091) L. Gou, Y. Wu, J. Yang, X. Zhang
Board 416
Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated
patients (pts) with metastatic NSCLC. (Abstract 8092) A. A. Tarhini, I. Rafique,
P. Tran, W. E. Gooding, L. C. Villaruz, T. F. Burns, D. Friedland, G. R. Tarabay,
A. D. Laman, D. R. Mehta, M. G. Sulecki, D. P. Petro, M. S. Georgiadis, K. M.
Kane, S. M. Peracha, K. K. Rajasenan, A. Megaludis, L. Dai, M. A. Socinski
243
MONDAY
8080) D. Zheng, X. Ye, M. Zhang, Y. Sun, J. Wang, J. Ni, H. Zhang, L. Zhang, J.
Luo, J. Zhang, L. Tang, B. Su, G. Chen, G. Zhu, Y. Gu, J. Xu
Nationwide genomic screening network for the development of novel
targeted therapies in advanced non-small cell lung cancer (LC-SCRUMJapan). (Abstract 8093) S. Matsumoto, K. Yoh, T. Seto, T. Yokoyama, H.
Murakami, E. Iwama, S. Sugawara, Y. Ohe, K. Takeda, M. Nishio, M. Satouchi, M.
Shingyoji, D. Harada, T. Okuyama, N. Okamoto, T. Kohno, K. Tsuta, G. Ishii, K.
Tsuchihara, K. Goto
Board 418
Migration to next-generation sequencing and the identification of RET and
ROS1 rearrangements plus PTEN and MET protein expression in tumor
specimens from patients with lung adenocarcinomas: Lung Cancer Mutation
Consortium (LCMC 2.0). (Abstract 8094) M. G. Kris, B. E. Johnson, D. J.
Kwiatkowski, I. I. Wistuba, L. D. Berry, E. B. Haura, M. A. Socinski, S. S.
Ramalingam, B. S. Glisson, S. N. Waqar, G. A. Otterson, J. H. Schiller, E. B.
Garon, J. P. Cetnar, K. A. Politi, J. R. Brahmer, L. V. Sequist, C. M. Lovly, K.
Kugler, P. A. Bunn Jr.
Board 419
Clinical implementation of anchored multiplex PCR with targeted nextgeneration sequencing for detection of ALK, ROS1, RET and NTRK1 fusions
in non-small cell lung carcinoma. (Abstract 8095) A. F. Farago, Z. Zheng, A.
Muzikansky, J. F. Gainor, A. J. Iafrate, J. A. Engelman, L. P. Le, A. T. Shaw
Board 420
Feasibility of next-generation sequencing (NGS) for squamous non-small cell
lung cancer (NSCLC): Implications for the NCI LungMAP study. (Abstract
8096) A. G. Sacher, L. M. Sholl, S. L. Mach, B. E. Johnson, P. S. Hammerman,
P. A. Janne, G. R. Oxnard
Board 422
KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).
(Abstract 8097) R. Frank, M. Scheffler, S. Y. Michels, A. Eisert, R. Fischer, K.
Koenig, S. Merkelbach-Bruse, M. H. Serke, Y. Ko, U. Gerigk, T. Geist, L. C.
Heukamp, R. Büttner, J. Wolf
Board 423
Clinical and molecular characteristics of non-small cell lung cancer in
patients harboring CTNNB1 mutations. (Abstract 8098) L. Gogl, M. Scheffler, I.
Michaela, S. Y. Michels, R. Fischer, M. H. Serke, U. Gerigk, C. Womper, S. Krüger,
B. Kaminsky, W. Schulte, G. Höffken, S. Merkelbach-Bruse, R. Büttner, J. Wolf
Board 424
Maximum severity score (MSS) of baseline patient-reported Lung Cancer
Symptom Scale (LCSS) as a prognostic and predictive factor for overall
survival (OS) in the Phase III SQUIRE study. (Abstract 8099) M. Reck, R. J.
Gralla, P. Bonomi, M. A. Socinski, V. Soldatenkova, J. Shahidi, P. Peterson, J.
Brown, C. K. Obasaju, N. Thatcher
Board 425
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with
advanced squamous cell carcinoma (SCC) of the lung following first-line
platinum-based chemotherapy: Patient-reported outcome (PRO) data from
the LUX-Lung 8 Phase III global trial. (Abstract 8100) S. M. Gadgeel, M. Cobo
Dols, E. Felip, J. Soria, K. Lee, S. Lu, V. Georgoulias, A. Fulop, E. Goker, K. N.
Syrigos, A. Morabito, H. Coskun, S. Z. Guclu, W. Li, S. Popat, A. Ardizzoni, J.
Lungershausen, B. Wang, V. K. Chand, G. D. Goss, LUX-Lung 8 Investigators
Board 426
Impact of crizotinib on patient-reported general health status compared with
chemotherapy in patients with no prior systemic treatment for advanced
non-squamous ALK-positive non-small cell lung cancer (NSCLC). (Abstract
8101) E. Felip, F. H. Blackhall, T. Mok, F. Cappuzzo, K. D. Wilner, A. Reisman, S.
Iyer, B. J. Solomon
Board 427a
A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI,
versus gefitinib or erlotinib in treatment-naïve patients with advanced
non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. (Abstract
TPS8102) S. S. Ramalingam, Y. Rukazenkov, K. Thomas, J. Soria
Board 427b
KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based
chemotherapy as first-line therapy for patients with metastatic non-small cell
lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).
(Abstract TPS8103) J. R. Brahmer, E. S. Kim, J. Zhang, M. M. Smith, R. A.
Rangwala, M. E. O’Brien
MONDAY
Board 417
244
Board 428a
A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or
in combination with Tremelimumab (T), versus standard of care (SOC) in
patients (pts) with advanced non-small cell lung cancer (NSCLC) who have
received at least two prior systemic treatment regimens (ARCTIC). (Abstract
TPS8104) D. Planchard, M. Shtivelband, K. Shi, R. Ibrahim, M. Ballas, J. Soria
Board 428b
Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum
doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive
advanced non-small cell lung cancer (NSCLC). (Abstract TPS8105) T. Mok, Y.
Wu, P. A. Watson, J. Zhang, R. A. Rangwala, G. Lopes
Board 429a
A phase 3 randomized trial of veliparib (ABT-888) plus carboplatin and
paclitaxel versus investigator’s choice of standard chemotherapy in
previously untreated patients with metastatic/advanced non-squamous
(NSq) non-small cell lung cancer (NSCLC). (Abstract TPS8106) M. D. McKee,
M. Pedersen, A. DeLuca, Q. Qin, J. Qian, J. Irving, P. Ansell, T. Leahy, C. Caskey,
V. L. Giranda
Board 429b
Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in
patients with previously untreated advanced/metastatic squamous (Sq)
non-small cell lung cancer (NSCLC): A randomized phase 3 trial. (Abstract
TPS8107) M. D. McKee, I. Bondarenko, S. Z. Guclu, V. Gorbunova, L. Urban, P.
Clingan, K. Leśniewski-Kmak, J. Mazières, S. S. Ramalingam, M. Pedersen, A.
DeLuca, C. Nickner, Q. Qin, V. L. Giranda
Board 430a
TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686)
or erlotinib as first-line treatment for EGFR-mutant non-small cell lung
cancer (NSCLC). (Abstract TPS8108) D. R. Camidge, J. Wolf, J. B. Litten, L. A.
Higashi, J. D. Isaacson, T. Mok
Board 430b
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic
chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer
(NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
(Abstract TPS8109) J. C. Yang, S. Popat, P. Georgiou, E. Miyamoto, J. D.
Isaacson, H. A. Wakelee
Board 431a
IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with
EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with
non-squamous advanced stage NSCLC. (Abstract TPS8110) J. Mazières, F.
Barlesi, O. Molinier, I. Monnet, C. Audigier-Valette, B. Besse, A. Toffart, P. Renault,
P. Masson, B. Mennecier, S. Moreau Fraboulet, S. Hiret, V. Westeel, P. Dumont,
A. B. Cortot, E. Pichon, M. Lebitasy, F. Morin, G. Zalcman, French Cooperative
Board 431b
Addition of apatorsen, an inhibitor of Hsp27, to first-line
gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of
the Cedar study. (Abstract TPS8111) P. Schmid, D. Muthukumar, F. H. Blackhall,
J. F. Lester, S. Khan, M. Illsley, J. Adams, A. Garcia-Alonso, C. MacDonald-Smith,
S. M. Lee, C. Jacobs, G. W. Middleton, C. James, K. Mousa, S. Sarker, L. Lim
ASCO/Society of Nuclear Medicine and Molecular Imaging (SNMMI) Joint
Session: Targeted Radionuclide Therapy
Location: S404
Hossein Jadvar, MD, PhD, MPH, MBA—Co-Chair
University of Southern California Positron Emission Tomography Center
Targeted Radionuclide Therapy in Prostate Cancer
245
MONDAY
Richard L. Wahl, MD
Targeted Radionuclide Therapy in Lymphoma
Alexander James Baird McEwan, MBBS
Cross Cancer Institute
Targeted Radionuclide Therapy in Neuroendocrine Tumors
Beyond Second-Line Treatment in Non-Small Cell Lung Cancer and Small Cell
Lung Cancer: What to Do When the Data End?
Location: E Hall D2
Gregory J. Riely, MD, PhD
Current Treatments, Upcoming Clinical Trials, and Use of Molecular Profiling in Second Line
and Beyond
Renato Martins, MD, MPH
The Value of Therapy Beyond Second-Line Treatment in Non-Small Cell Lung Cancer and
Small Cell Lung Cancer
Craig H. Reynolds, MD—Chair
Ocala Oncology Center
Moderator: Presenting Both Sides and the Ethics of Therapy versus Best Supportive Care
MONDAY
Controversial Topics in HPV-Related Head and Neck Cancer—Ticketed
Session
Location: E451a
Eric Michael Genden, MD
Anthony Cmelak, MD
Multidisciplinary Approach to Low-Grade Glioma—Ticketed Session
Location: E451b
Brigitta G. Baumert, MD, PhD, MBA
University of Bonn Medical Centre
Jan C. Buckner, MD
Mayo Clinic
246
A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing
Results Together
Location: S100bc
Eric Andrew Collisson, MD—Co-Chair
Brian M. Wolpin, MD, MPH—Co-Chair
Tumor relevant germline findings in targeted tumor sequencing using
matched normal DNA of 1,570 unselected cases. (Abstract 1509) K. A.
Schrader, D. T. Cheng, J. Vijai, M. Prasad, M. Walsh, A. Zehir, T. Thomas, R.
Benayed, Z. K. Stadler, A. Ashraf, M. E. Arcila, D. B. Solit, D. M. Hyman, L. Zhang,
D. Klimstra, M. Ladanyi, K. Offit, M. F. Berger, M. E. Robson
9:57 AM
Robert R. McWilliams, MD (Discussion of Abstract(s) 1509)
Mayo Clinic
Interpreting Germ-Line and Somatic Mutations Together in Tumor Sequencing
10:09 AM
Prevalence of incidental actionable germline mutations in 1,000 advanced
cancer patients on a prospective somatic genomic profiling program.
(Abstract 1510) F. Meric-Bernstam, L. Brusco, M. S. Daniels, L. C. Strong, K. R.
Shaw, K. H. Lu, Y. Qi, H. Lara-Guerra, J. K. Litton, H. Zhao, A. K. Eterovic, B. Arun,
M. Routbort, F. Janku, M. A. Davies, S. Kopetz, J. Mendelsohn, G. B. Mills, K.
Chen
10:21 AM
Stacy W. Gray, MD (Discussion of Abstract(s) 1510)
Incidental Germ-Line Findings: What Do the Physician and Patient Want and Need
to Know?
10:33 AM
Characteristics of high risk breast cancer patients with mutations identified
by multiplex panel testing. (Abstract 1511) K. N. Maxwell, B. Wenz, B.
Wubbenhorst, K. P. D’Andrea, B. Garman, B. Weathers, N. Goodman, C.
Colameco, J. M. Long, J. Powers, J. Stopfer, A. R. Bradbury, A. DeMichele, S. M.
Domchek, K. L. Nathanson
10:45 AM
Allison W. Kurian, MD, MSc (Discussion of Abstract(s) 1511)
Germ-Line Mutations in High-Risk Breast Cancer: Beyond BRCA 1/2
10:57 AM
MONDAY
9:45 AM
New Diagnostics: When Actionable Is Objectionable
Location: E Hall D1
Miguel Angel Villalona-Calero, MD—Chair
9:45 AM
Alan P. Venook, MD
Case Presentation
9:50 AM
Successful implementation of a novel trial model: The Signature program.
(Abstract 106) J. A. Peguero, J. A. Knost, T. M. Bauer, M. H. Taylor, F. S. Braiteh,
J. P. Eder, H. Safran, B. H. O’Neil, A. S. Alva, L. Nadauld, P. Joshi, F. Miranda, R.
Sidhu, J. Ero, E. D. Slosberg, C. Lebedinsky, B. Kang, S. Parasuraman, S. A.
Piha-Paul
247
10:05 AM
Richard L. Schilsky, MD, FASCO (Discussion of Abstract(s) 106)
Is Your Patient’s Tumor Signature Legible?
10:20 AM
Circulating tumor cells (CTC) and pathological complete response (pCR) as
independent prognostic factors in inflammatory breast cancer (IBC) in a
pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of
neoadjuvant chemotherapy combined with bevacizumab. (Abstract 108) J.
Pierga, F. Bidard, A. Autret, T. Petit, F. Andre, F. Dalenc, C. Levy, J. Ferrero, G.
Romieu, J. Bonneterre, F. Lerebours, T. D. Bachelot, P. Kerbrat, E. CharafeJaufret, J. Lemonnier, P. Viens
10:35 AM
Prospective evaluation of circulating tumor DNA sequencing in
pancreatobiliary carcinomas. (Abstract 107) E. A. Collisson, O. Zill, C. Greene,
J. Leng, L. Siew, M. A. Vu, R. K. Kelley, A. H. Ko, C. E. Atreya, K. Van Loon, T. G.
Bivona, M. A. Tempero, D. Sebisanovic, P. N. Munster, A. Talasaz
10:50 AM
Geoffrey R. Oxnard, MD (Discussion of Abstract(s) 107–108)
Replacing Tumor Biopsies with Liquid Biopsies: Close but Not Quite
11:05 AM
Genitourinary (Nonprostate) Cancer
Ana M. Molina, MD—Co-Chair
Guru Sonpavde, MD—Co-Chair
MONDAY
9:45 AM
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma
(mRCC): Association of biomarkers with clinical outcomes. (Abstract 4500)
T. K. Choueiri, M. N. Fishman, B. Escudier, D. F. McDermott, H. M. Kluger, W. M.
Stadler, J. L. Perez-Gracia, D. G. McNeel, B. D. Curti, M. R. Harrison, E. R.
Plimack, L. J. Appleman, L. Fong, C. G. Drake, T. C. Young, S. D. Chasalow, P.
Ross-Macdonald, J. S. Simon, D. Walker, M. Sznol
9:57 AM
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival
data in urothelial bladder cancer (UBC). (Abstract 4501) D. P. Petrylak, T.
Powles, J. Bellmunt, F. S. Braiteh, Y. Loriot, C. Cruz Zambrano, H. A. Burris III,
J. W. Kim, S. Teng, J. Bruey, P. Hegde, O. O. Abidoye, N. J. Vogelzang
10:09 AM
Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results
and biomarker analysis from KEYNOTE-012. (Abstract 4502) E. R. Plimack, J.
Bellmunt, S. Gupta, R. Berger, R. B. Montgomery, K. Heath, J. Juco, K.
Emancipator, K. Pathiraja, J. K. Lunceford, R. F. Perini, P. H. O’Donnell
10:21 AM
Noah M. Hahn, MD (Discussion of Abstract(s) 4500 – 4502)
The Johns Hopkins Medical Institutions
Immune Therapy in Genitourinary Cancers: The Beginning of the End or the End of
the Beginning?
10:33 AM
10:45 AM
First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen
or placebo in patients with advanced bladder cancer: The International
Borealis-1 trial. (Abstract 4503) J. Bellmunt, B. J. Eigl, E. Senkus-Konefka, Y.
Loriot, P. Twardowski, D. E. Castellano, N. Blais, S. S. Sridhar, C. N. Sternberg, M.
Retz, B. A. Blumenstein, C. Jacobs, P. S. Stewart, D. P. Petrylak
248
Eribulin in advanced urothelial cancer (AUC) patients (pts): A California
Cancer Consortium trial—NCI/CTEP 7435. (Abstract 4504) D. I. Quinn, N. Ruel,
P. Twardowski, S. G. Groshen, T. B. Dorff, S. K. Pal, W. M. Stadler, A. Aparicio, P.
Lara Jr., E. M. Newman
11:09 AM
A phase II/III, double-blind, randomized trial comparing maintenance
lapatinib versus placebo after first line chemotherapy in HER1/2 positive
metastatic bladder cancer patients. (Abstract 4505) T. Powles, R. A. Huddart,
T. Elliott, R. Jones, S. A. Hussain, S. J. Crabb, C. Ackerman, S. Jagdev, J. D.
Chester, S. Hilman, M. Beresford, A. Macdonald, S. Sundar, J. A. Frew, A.
Stockdale, S. Sarker, D. Berney, S. Chowdhury
11:21 AM
Maria De Santis, MD (Discussion of Abstract(s) 4503– 4505)
University of Warwick
Moving Beyond Platinum for Bladder Cancer
11:33 AM
11:45 AM
Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE),
and LENⴙEVE in patients (pts) with metastatic renal cell carcinoma (mRCC).
(Abstract 4506) R. Motzer, T. Hutson, H. Glen, D. Michaelson, A. M. Molina, T.
Eisen, J. Jassem, J. Zolnierek, P. Maroto, B. Mellado, B. Melichar, J. Tomasek, H.
Kim, K. Wood, C. Dutcus, J. M. Larkin
11:57 AM
Final clinical results of a randomized phase II international trial of everolimus
vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma
(ASPEN). (Abstract 4507) A. J. Armstrong, S. Broderick, T. Eisen, W. M. Stadler,
R. J. Jones, J. A. Garcia, U. N. Vaishampayan, J. Picus, R. E. Hawkins, J. D.
Hainsworth, C. K. Kollmannsberger, T. F. Logan, I. Puzanov, L. M. Pickering, C. W.
Ryan, A. Protheroe, C. M. Lusk, S. Oberg, S. Halabi, D. J. George
12:09 PM
Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for
unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.
(Abstract 4508) N. B. Haas, J. Manola, K. Flaherty, R. G. Uzzo, M. B. Atkins, J. P.
Dutcher, C. G. Wood, C. J. Kane, M. A. Jewett, B. Coomes, S. F. Matin, T. Kuzel,
W. J. Sexton, Y. Wong, T. K. Choueiri, R. Pili, I. Puzanov, M. Kohli, W. M. Stadler,
R. S. DiPaola, ECOG/ACRIN 2805 Authors Group
12:21 PM
Cora N. Sternberg, MD, FACP (Discussion of Abstract(s) 4506 – 4508)
San Camillo Forlanini Hospital
Improving Outcomes with Pathway-Directed Therapy
12:33 PM
MONDAY
10:57 AM
Lymphoma
Location: E450
Grzegorz S. Nowakowski, MD—Co-Chair
Mayo Clinic
Owen A. O’Connor, MD, PhD—Co-Chair
9:45 AM
Phase IIa study of single-agent MOR208 in patients with relapsed or
refractory B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 8500) W. Jurczak,
P. L. Zinzani, A. Goy, M. Provencio, Z. Nagy, T. Robak, K. J. Maddocks, C. Buske,
R. Korolkiewicz, M. Winderlich, K. A. Blum
249
MONDAY
9:57 AM
Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202,
and ibrutinib in relapsed B-cell malignancies. (Abstract 8501) N. H. Fowler,
L. J. Nastoupil, M. A. Lunning, J. Vose, T. Siddiqi, C. Flowers, J. B. Cohen, M. T.
Schreeder, M. Miguel, S. Blumel, B. Phye, W. H. Tse, E. K. Pauli, K. Cutter, P.
Sportelli, H. P. Miskin, M. S. Weiss, S. V. Vakkalanka, S. Viswanadha, S. M.
O’Brien
10:09 AM
GADOLIN: Primary results from a phase III study of obinutuzumab plus
bendamustine compared with bendamustine alone in patients with rituximabrefractory indolent non-Hodgkin lymphoma. (Abstract LBA8502) L. H. Sehn,
N. S. Chua, J. Mayer, G. S. Dueck, M. Trnı̀ný, K. Bouabdallah, N. H. Fowler, V.
Delwail, O. W. Press, G. A. Salles, J. G. Gribben, A. Lennard, P. J. Lugtenburg, N.
Franklin, E. Wassner Fritsch, G. Fingerle-Rowson, B. D. Cheson
10:21 AM
Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug
conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma
(FL): Durable responses at lower dose level. (Abstract 8503) R. H. Advani, I.
Flinn, J. P. Sharman, C. S. Magid Diefenbach, K. S. Kolibaba, O. W. Press, L. H.
Sehn, A. I. Chen, G. A. Salles, H. Tilly, B. D. Cheson, S. E. Assouline, M. H.
Dreyling, A. Hagenbeek, P. L. Zinzani, C. Jones, Y. Chu, J. Hirata, M. Wenger, F.
Morschhauser
10:33 AM
Grzegorz S. Nowakowski, MD (Discussion of Abstract(s) 8500 – 8503)
Mayo Clinic
What Does Drug Conjugation Add to the Unconjugated Antibody?
10:45 AM
10:57 AM
Evaluation of complete response rate at 30 months (CR30) as a surrogate for
progression-free survival (PFS) in first-line follicular lymphoma (FL) studies:
Results from the prospectively specified Follicular Lymphoma Analysis of
Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of
3,837 patients (pts). (Abstract 8504) D. J. Sargent, Q. Shi, S. De Bedout, C.
Flowers, N. H. Fowler, T. Fu, A. Hagenbeek, M. Herold, E. Hoster, J. Huang, E.
Kimby, M. Ladetto, F. Morschhauser, T. Nielsen, K. Takeshita, N. Valente, U.
Vitolo, E. Zucca, G. A. Salles, the FLASH (Follicular Lymphoma Analysis of
Surrogacy Hypothesis) group
11:09 AM
Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin
lymphoma: A phase II trial. (Abstract 8505) J. S. Abramson, J. E. Arnason, A. S.
LaCasce, R. Redd, J. A. Barnes, L. Sokol, R. Joyce, D. Avigan, D. S. Neuberg, T.
Takvorian, E. P. Hochberg, C. M. Bello
11:21 AM
Updated results of a phase II trial of brentuximab vedotin combined with
R-CHOP in frontline treatment of patients (pts) with high-intermediate/highrisk diffuse large B-cell lymphoma (DLBCL). (Abstract 8506) N. L. Bartlett,
C. M. Farber, C. A. Yasenchak, S. M. Ansell, R. H. Advani, M. H. Knapp, L. Fayad,
K. S. Kolibaba, D. Patel-Donnelly, M. Seetharam, H. A. Yimer, T. J. Manley, J. M.
Burke, B. Holkova, L. Budde, A. S. Halwani
11:33 AM
Owen A. O’Connor, MD, PhD (Discussion of Abstract(s) 8504 – 8506)
Explaining Why CD30-Negative Disease Responds to CD30-Targeted Therapy
11:45 AM
11:57 AM
Allogeneic or autologous transplantation as first-line therapy for younger
patients with peripheral T-cell lymphoma: Results of the interim analysis of
the AATT trial. (Abstract 8507) N. Schmitz, M. Nickelsen, B. Altmann, M. Ziepert,
K. Bouabdallah, C. Gisselbrecht, S. Maury, G. Cartron, E. Gyan, A. Jaccard, L.
Sanhes, P. Gaulard, A. Rosenwald, L. Truemper, B. Glass, P. Reimer, W. Herr, M.
Wilhelm, O. Tournilhac
12:09 PM
Francine M. Foss, MD (Discussion of Abstract(s) 8507)
Yale Cancer Center
The Potential Role of Allogeneic Stem Cell Transplantation in Peripheral T-Cell
Lymphoma
12:21 PM
250
11:30 AM - 12:45 PM Special Session
ASCO/American Cancer Society Award and Lecture
Location: S102
Presentation of the 2015 ASCO/American Cancer Society Award
Ernest Hawk, MD, MPH—Award Lecturer
Cancer Prevention as Our First Best Hope: Action in Prevention Research and Cancer Control
Cervical Cancer from Diagnosis to Survivorship
Location: E354b
Linda R. Mileshkin, MBBS, MD, MBioeth
Chemoradiotherapy in the Outback Era: Pitfalls and Potentials
Helen Mackay, MD—Chair
Princess Margaret Cancer Centre, University Health Network
Recurrent and Metastatic Cervical Cancer: Facing the Challenge of Developing New Therapies
in an Under-resourced Patient Population
Lari B. Wenzel, PhD
University of California, Irvine
Quality of Life after Treatment for Patients with Cervical Cancer
Controversies in Neoadjuvant Therapy for Breast Cancer: Surgery, Radiation,
and Therapeutic Trials
Location: N Hall B1
Angela DeMichele, MD, MSCE—Chair
Are We Using the Right Endpoints for Neoadjuvant Chemotherapy?
Julia R. White, MD
NRG Oncology and The Ohio State University
Postmastectomy Radiation Therapy after Neoadjuvant Chemotherapy: Who Needs It?
Tari A. King, MD
Axillary Management after Neoadjuvant Chemotherapy
251
MONDAY
New Therapies for Histologies Other than Adenocarcinoma
Location: E Hall D2
Paul K. Paik, MD
Updates in Therapy for Squamous Histology of Non-Small Cell Lung Cancer
David E. Gerber, MD—Chair
Updates in Therapy and Clinical Trials for Other Histologies (Including Neuroendocrine and
Large Cell)
Afshin Dowlati, MD
Case Western Reserve University
Updates in Therapy and Clinical Trials in Small Cell Lung Cancer
Nutritional Support in Gastrointestinal Malignancies
Location: E Hall D1
Vincent J. Picozzi, MD—Chair
Virginia Mason Medical Center
Nutritional Deficiency in Gastrointestinal Malignancy: Degree, Direction, and Data
Maria Q. B. Petzel, RD, CSO
Nutritional Support for Gastrointestinal Malignancy: Weighing the Options for Intervention
Egidio Del Fabbro, MD
Virginia Commonwealth University
Overcoming Cancer Cachexia: Existing Data and Investigational Approaches
MONDAY
Optimizing Treatment Modalities for Cancers of the Oral Cavity
Location: S100bc
Stephen Yenzen Lai, MD, PhD—Chair
Surgical Techniques, Functional Reconstruction, Sentinal Node Mapping
Allen M. Chen, MD
Adjuvant and Definitive Radiotherapy Techniques and Outcomes in Oral Cavity Cancers
252
Kumar Prabhash, MD, DM
Tata Memorial Centre
Preoperative Chemotherapy, Metronomic Scheduling, and Interventions for Premalignant
Lesions
Precision Medicine through Molecular Profiling: Are We There Yet?
Location: S406
Sameek Roychowdhury, MD, PhD—Chair
Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine
Michael F. Berger, PhD
Enterprise-Level Molecular Testing at Academic Institutions: Advantages of Doing It Yourself
versus Outsourcing
Martine J. Piccart-Gebhart, MD, PhD
Jules Bordet Institute
Clinical Trials of Precision Medicine through Molecular Profiling
Translating Survivorship Research into Health Surveillance Guidelines
Location: S504
MONDAY
Saro Armenian, DO, MPH—Chair
City of Hope National Medical Center
Surveillance for Subsequent Neoplasms
Leontien C. M. Kremer, MD, PhD
Emma Children’s Hospital and Academic Medical Center
Surveillance for Cardiotoxicity
Charles A. Sklar, MD
Surveillance for Gonadal Failure and Thyroid Disease
Trends, Anecdotes, and Predictions: Oncology Practices Today
Location: S404
Anupama Kurup Acheson, MD
Providence Oncology and Hematology Care Clinic
ASCO National Oncology Census Design and Results
253
Michael P. Kosty, MD, FACP—Chair
Scripps Research Institute
Describing the Oncology Workforce and Potential Interventions
Eric Daniel Tetzlaff, MHS, PA-C
Fox Chase Cancer Center
Challenges Facing Midlevel Oncology Providers: Integration into Clinical Practices
GIST: Imatinib and Beyond—Ticketed Session
Location: E451a
Suzanne George, MD
Dana-Farber/Brigham and Women’s Cancer Center
How to Create a Successful Survivorship Program—Ticketed Session
Location: E451b
Maria Alma Rodriguez, MD
ASCO Annual Business Meeting (ASCO Members Only)
Location: S100a
MONDAY
Location: E Hall D1
Bert H. O’Neil, MD—Co-Chair
Indiana University Health University Hospital
Thomas John Semrad, MD, MAS—Co-Chair
University of California, Davis
1:15 PM
Chloe Evelyn Atreya, MD, PhD (Discussion of Abstract(s) 3509 –3511)
Understanding the Role of BRAF in Colorectal Cancer
1:27 PM
1:33 PM
Gunnar Folprecht, MD (Discussion of Abstract(s) 3512–3514)
University Hospital Carl Gustav Carus
Improving Adjuvant Therapy for Colon Cancer
1:45 PM
254
1:51 PM
Cathy Eng, MD (Discussion of Abstract(s) 3515–3517)
“New” Drugs in Localized Rectal Cancer
2:03 PM
2:09 PM
Andrew Wang, MD (Discussion of Abstract(s) 3518 –3520)
Recent Progress in Anal Cancer Research
2:21 PM
Posters discussed in this session are on display in the Gastrointestinal (Colorectal) Cancer
Poster Session. See page 208 for poster information. Networking with presenters and discussants will take place right outside of the session room after the discussion.
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic
Cancers
Location: E Hall D2
Tom John, MBBS, PhD, FRACP—Co-Chair
Olivia Newton-John Cancer and Wellness Centre
1:15 PM
Leena Gandhi, MD, PhD (Discussion of Abstract(s) 7508 –7511)
Targeted Therapies in Unselected Populations
1:27 PM
1:33 PM
Benjamin Movsas, MD, PhD (Discussion of Abstract(s) 7512–7514)
Henry Ford Health System
Combined Modality Therapy for Non-Small Cell Lung Cancer
1:45 PM
1:51 PM
Giuseppe Giaccone, MD, PhD (Discussion of Abstract(s) 7515–7517)
Lombardi Comprehensive Cancer Center, Georgetown University
Biomarkers in Trial Design: Promise and Peril
2:03 PM
2:09 PM
Ramaswamy Govindan, MD (Discussion of Abstract(s) 7518 –7519)
Molecular Similarity of Neuroendocrine Cancers
2:21 PM
MONDAY
Feng Ming Kong, MD, PhD—Co-Chair
GRU Cancer Center and Medical College of Georgia
Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Session. See page 231 for poster information.
Networking with presenters and discussants will take place right outside of the session room
after the discussion.
ASCO Book Club: The End of Your Life Book Club by Will Schwalbe
Location: S102
Teresa Gilewski, MD—Chair
255
Will Schwalbe
Author
The End of Your Life Book Club
Challenging Issues in Metastatic Disease
Location: N Hall B1
Fabrice Andre, MD, PhD—Chair
The Use of Molecular Profiling in Metastatic Breast Cancer
Maxine S. Jochelson, MD
Advanced Imaging for Metastatic Disease: How and When
Joseph Kamel Salama, MD
Ablation of Oligometastases by Radiation or Surgery: Good Idea?
Shared Learning to Improve Cancer Outcomes in Adolescents and Young
Adults: Pediatric versus Adult Approaches
Location: S504
A. Lindsay Frazier, MD, ScM—Chair
Germ Cell Tumors in Adolescents and Young Adults: Coordinating Research across the Age
Barrier
MONDAY
Wendy Stock, MD
Leukemia and Lymphoma in Adolescent and Young Adults with Cancer: Improving Outcomes
through Research and Collaboration
Robert G. Maki, MD, PhD
Choice of Treatment of Sarcomas for the Adolescent and Young Adult Population: Adult versus
Pediatric Regimens
Translating Knowledge into Therapeutic Progress in Myelodysplastic
Syndromes
Location: E450
Olatoyosi Odenike, MD—Chair
Frontline Therapy in Myelodysplastic Syndrome: A Risk-Stratified Approach
256
Francesco Onida, MD
University of Milan
Transplant in Patients with Myelodysplastic Syndrome: Timing and Eligibility
Eric Padron, MD
Diagnosis and Management of MDS/MPN Overlap Syndromes
Understanding the Targets in Immunotherapy
Location: E354b
Jeffrey S. Weber, MD, PhD
Understanding the Concept of Antitumor Immunity
James Patrick Allison, PhD—Chair
Harnessing T-Cell Costimulation and Coinhibition for Clinical Benefit
Leisha A. Emens, MD, PhD
Where Are We with Cancer Vaccines?
Adjuvant Therapy for Corpus-Confined Endometrial Cancer: Who Do We
Treat?—Ticketed Session
Location: E451b
MONDAY
Carien L. Creutzberg, MD, PhD
Leiden University Medical Center
Gini F. Fleming, MD
University of Chicago Medical Center
Biliary Tract Cancer: Understanding What We Know and What We Don’t
Know—Ticketed Session
Location: E451a
Juan W. Valle, MD
Institute of Cancer Studies, University of Manchester, The Christie Hospital
Andrew X. Zhu, MD, PhD
257
Location: S406
Lawrence Fong, MD—Co-Chair
Zihai Li, MD, PhD—Co-Chair
Medical University of South Carolina
MONDAY
1:15 PM
Atypical patterns of response in patients (pts) with metastatic melanoma
treated with pembrolizumab (MK-3475) in KEYNOTE-001. (Abstract 3000) J. D.
Wolchok, O. Hamid, A. Ribas, C. Robert, R. Kefford, W. Hwu, J. S. Weber, A. M.
Joshua, T. C. Gangadhar, R. S. Dronca, A. Daud, A. Patnaik, R. W. Joseph, H. M.
Zarour, X. Li, D. Xue, S. Ebbinghaus, S. P. Kang, A. M. Perrone, F. S. Hodi
1:27 PM
Association of response to programmed death receptor 1 (PD-1) blockade
with pembrolizumab (MK-3475) with an interferon-inflammatory immune
gene signature. (Abstract 3001) A. Ribas, C. Robert, F. S. Hodi, J. D. Wolchok,
A. M. Joshua, W. Hwu, J. S. Weber, H. M. Zarour, R. Kefford, A. Loboda, A.
Albright, S. P. Kang, S. Ebbinghaus, J. Yearley, E. Murphy, M. Nebozhyn, J. K.
Lunceford, T. McClanahan, M. Ayers, A. Daud
1:39 PM
Density of immunogenic antigens and presence or absence of the T cellinflamed tumor microenvironment in metastatic melanoma. (Abstract 3002)
T. Gajewski, Y. Zha, K. Hernandez, Y. Li, R. Bao, P. Alexieff, J. Andrade, J. J.
Luke, S. Spranger
1:51 PM
Jonathan S. Cebon, MBBS, FRACP, PhD (Discussion of Abstract(s)
3000 –3002)
Ludwig Institute for Cancer Research, Austin Hospital
The Role of the Microenvironment in Response Prediction
2:03 PM
2:15 PM
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib)
and/or MEK (trametinib) inhibitors in advanced melanoma. (Abstract 3003) A.
Ribas, M. Butler, J. Lutzky, D. P. Lawrence, C. Robert, W. Miller, G. P. Linette,
P. A. Ascierto, T. Kuzel, A. P. Algazi, M. A. Postow, P. D. Nathan, B. D. Curti, P. B.
Robbins, X. Li, J. A. Blake-Haskins, M. S. Gordon
2:27 PM
A phase I study of PF-05082566 (anti-4 –1BB) ⴙ rituximab in patients with
CD20ⴙ NHL. (Abstract 3004) A. K. Gopal, N. L. Bartlett, R. Levy, R. Houot, S. D.
Smith, N. H. Segal, A. D. Thall, G. Mugundu, B. Huang, C. Davis, H. E. Kohrt
2:39 PM
Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with
advanced/metastatic solid tumors. (Abstract 3005) C. A. Gomez-Roca, P. A.
Cassier, A. Italiano, M. Cannarile, C. Ries, A. Brillouet, C. Mueller, A. Jegg, G.
Meneses-Lorente, M. Baehner, K. Abiraj, D. Loirat, M. Toulmonde, S. P. D’Angelo,
K. Weber, M. Campone, D. Ruettinger, J. Blay, J. Delord, C. Le Tourneau
2:51 PM
Zihai Li, MD, PhD (Discussion of Abstract(s) 3003–3005)
Medical University of South Carolina
Broadening the Approach to Immunotherapy
3:03 PM
3:15 PM
Immunotherapy with CD19-specific chimeric antigen receptor
(CAR)-modified T cells of defined subset composition. (Abstract 3006) C. J.
Turtle, C. Berger, D. Sommermeyer, T. Budiarto, L. Hanafi, K. Melville, B. Pender,
N. Steevens, C. Chaney, S. Heimfeld, S. Cherian, B. L. Wood, L. Soma, X. Chen,
M. Jensen, S. R. Riddell, D. G. Maloney
3:27 PM
Safety and antitumor activity of chimeric antigen receptor modified T cells in
patients with chemotherapy refractory metastatic pancreatic cancer.
(Abstract 3007) G. L. Beatty, M. H. O’Hara, A. M. Nelson, M. McGarvey, D. A.
Torigian, S. F. Lacey, J. J. Melenhorst, B. Levine, G. Plesa, C. H. June
258
3:39 PM
Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma:
Results from a phase I clinical trial. (Abstract 3008) N. M. Ahmed, V. S.
Brawley, O. Diouf, A. Ghazi, J. Yi, H. Liu, C. M. Rooney, G. Dotti, A. P. Gee, R.
Grossman, Y. Kew, D. S. Baskin, A. Ashoori, J. Zhang, J. Hicks, S. Powell, W.
Wels, M. K. Brenner, H. E. Heslop, S. M. Gottschalk
3:51 PM
Engineering the Effector
4:03 PM
Location: S100bc
1:15 PM
Phase III randomized trial of standard fractionation radiotherapy (SFX) with
concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy
(AFX) with panitumumab (PMab) in patients (pts) with locoregionally
advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC
Clinical Trials Group HN.6 trial. (Abstract 6000) L. L. Siu, J. N. Waldron, B. E.
Chen, E. Winquist, J. R. Wright, A. Nabid, J. H. Hay, J. Ringash, G. Liu, A.
Johnson, G. Shenouda, M. Chasen, A. Pearce, J. B. Butler, S. Breen, E. X. Chen,
T. J. Childs, A. Montenegro, B. O’Sullivan, W. R. Parulekar
1:27 PM
Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel,
cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in
previously untreated, locally advanced head and neck squamous cell
carcinoma (LAHNSCC). (Abstract 6001) E. Massarelli, R. I. Haddad, J. Lee, H. Y.
Lin, A. S. Garden, G. R. Blumenschein Jr., W. N. William Jr., R. B. Tishler, B. S.
Glisson, K. A. Gold, F. M. Johnson, G. Rabinowits, L. E. Ginsberg, M. D. Williams,
J. Myers, M. S. Kies, V. Papadimitrakopoulou
1:39 PM
Long-term results of GORTEC 2000 – 01: A multicentric randomized phase III
trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or
without docetaxel, for larynx preservation. (Abstract 6002) G. Janoray, Y.
Pointreau, P. Garaud, S. Chapet, M. Alfonsi, C. Sire, C. Tuchais, G. Calais
1:51 PM
The effect of age on outcome in prospective, phase III NRG Oncology/RTOG
trials of radiotherapy (XRT) ⴙ/- chemotherapy in locally advanced (LA) head
and neck cancer (HNC). (Abstract 6003) J. A. Kish, Q. Zhang, C. J. Langer, F.
Nguyen-Tan, D. I. Rosenthal, R. S. Weber, M. A. List, S. J. Wong, A. S. Garden,
J. S. Cooper, A. Trotti, J. A. Bonner, C. U. Jones, S. S. Yom, J. M. Michalski, C. J.
Schultz, J. A. Ridge, G. Shenouda, Q. Le
2:03 PM
Lisa F. Licitra, MD (Discussion of Abstract(s) 6000 – 6003)
Fondazione IRCCS Istituto Nazionale Tumori
Management of Locally Advanced Disease: An Update
2:15 PM
2:27 PM
A prospective phase II trail of de-intensified chemoradiotherapy for low-risk
HPV-associated oropharyngeal squamous cell carcinoma. (Abstract 6004)
B. S. Chera, R. J. Amdur, J. E. Tepper, R. L. Green, B. F. Qaqish, D. N. Hayes,
M. C. Weissler, J. Weiss, T. Hackman, A. M. Zanation, S. Patel, J. Zevallos, J. E.
Grilley-Olson, W. K. Funkhouser Jr., N. C. Sheets, W. M. Mendenhall
2:39 PM
Prognostic implication of persistent HPV16 DNA detection in oral rinses for
HPV-positive oropharyngeal carcinoma. (Abstract 6005) E. M. Rettig, A.
Wentz, M. R. Posner, N. D. Gross, R. I. Haddad, M. L. Gillison, H. Quon, A. G.
Sikora, W. Stott, J. H. Lorch, C. G. Gourin, B. Miles, J. Richmon, K. Misiukiewicz,
C. H. Chung, C. Fakhry, G. D’Souza
259
MONDAY
Vassiliki Papadimitrakopoulou, MD—Chair
2:51 PM
Mutational patterns of HPVⴙ and HPV- squamous cell carcinomas of the
head and neck (SCCHN) and their interference with outcome after adjuvant
chemoradiation: A multicenter biomarker study of the German Cancer
Consortium Radiation Oncology Group. (Abstract 6006) I. Tinhofer, V. Budach,
A. Linge, F. Lohaus, E. Gkika, M. Stuschke, P. Balermpas, C. Rödel, M. Avlar, A.
Grosu, A. Abdollahi, J. Debus, C. Belka, S. Pigorsch, S. E. Combs, D. Mönnich, D.
Zips, W. Weichert, M. Krause, M. Baumann, DKTK-ROG
3:03 PM
Serial early post-IMRT undetectable plasma EBV DNA to predict outcomes in
non-metastatic nasopharyngeal cancer. (Abstract 6007) V. H. Lee, D. L.
Kwong, T. Leung, C. Choi, S. C. Ng, K. Lam, C. Sze, C. Tong, P. P. Ho, W. W.
Chan, L. Wong, D. K. Leung, A. S. Chan, F. Chan, K. Lau
3:15 PM
Barbara Burtness, MD (Discussion of Abstract(s) 6004 – 6007)
HPV and Epstein–Barr Virus-Related Head and Neck Cancer: Deintensification
and Surveillance
3:27 PM
3:39 PM
Antitumor activity and safety of pembrolizumab in patients (pts) with
advanced squamous cell carcinoma of the head and neck (SCCHN):
Preliminary results from KEYNOTE-012 expansion cohort. (Abstract
LBA6008) T. Y. Seiwert, R. I. Haddad, S. Gupta, R. Mehra, M. Tahara, R. Berger,
S. Lee, B. Burtness, D. T. Le, K. Heath, A. Blum, M. Dolled-Filhart, K. Emancipator,
K. Pathiraja, J. D. Cheng, L. Q. Chow
3:51 PM
Julie E. Bauman, MD, MPH (Discussion of Abstract(s) LBA6008)
Immunotherapy for Head and Neck Cancer
4:03 PM
Location: S Hall A
Abstracts 1512–1523 will be discussed during the Cancer Prevention, Genetics, and Epidemiology Poster Discussion Session. See page 298 for session information.
MONDAY
Board 335
Identification of ERCC2 as novel susceptibility gene for hereditary breast and
ovarian cancer. (Abstract 1512) P. Wimberger, A. Benet-Pages, S. Schubert, R.
Janavicius, J. D. Kuhlmann, A. Tzschach, K. Kast, A. Meindl, E. Holinski-Feder, S.
Emmert, E. Schrock, A. Rump
Board 336
Clinical impact of multi-gene panel testing for hereditary breast and ovarian
cancer risk assessment. (Abstract 1513) L. W. Ellisen, A. W. Kurian, A. J.
Desmond, M. Mills, S. E. Lincoln, K. M. Shannon, M. Gabree, N. M. Tung, J. M.
Ford
Board 337
Assessment of the clinical presentation of patients with at least two
deleterious mutations on multi-gene panel testing. (Abstract 1514) J. N.
Weitzel, K. R. Blazer, B. Nehoray, J. Kidd, T. P. Slavin Jr., I. Solomon, M. NiellSwiller, C. Rybak, J. Saam
Board 338
Outcomes of clinical testing for 50,000 patients utilizing a panel of 25 genes
associated with increased risk for breast, ovarian, colorectal, endometrial,
gastric, pancreatic, melanoma, and prostate cancers. (Abstract 1515) E. T.
Rosenthal, H. McCoy, J. Kidd, B. Evans, K. Brown, J. Saam, S. Manly, R. J.
Wenstrup
Board 339
Sarcoma: A Lynch syndrome (LS)-associated malignancy? (Abstract 1516)
J. M. Kaczmar, J. Everett, K. Ruth, E. M. Stoffel, J. Stoll, S. Kupfer, H. Hampel,
Z. K. Stadler, P. Gaddam, C. Rybak, T. P. Slavin Jr., J. P. Terdiman, A. Blanco,
M. J. Hall
260
Board 340
A comparison of ascertainment of Lynch syndrome in colorectal cancer
patients via reflex testing vs. hereditary guideline-based testing. (Abstract
1517) S. Samimi, R. M. Lee-Ying, D. Schaeffer, R. Wolber, D. J. Renouf, W. Y.
Cheung, K. A. Schrader, G. Mitchell, H. J. Lim
Board 341
Usefulness of the patient self-administered cancer family history
questionnaire in identification of gynecological cancer patients suspected of
Lynch syndrome: KCOG-G1302 study. (Abstract 1518) R. Nishikawa, K. Oseto,
H. Nishikawa, A. Arakawa, K. Kai, K. Nasu, M. Morii-Kashima, H. Tsubamoto, K.
Ito, N. Furukawa
Board 342
Recreational activity and sedentary behavior in relation to lung cancer
incidence and mortality in the Women’s Health Initiative. (Abstract 1519) A.
Wang, F. Qin, H. Hedlin, M. Desai, R. T. Chlebowski, S. L. Gomez, C. Eaton, K.
Johnson, L. Qi, J. Wactawski-Wende, C. Womack, H. A. Wakelee, M. L. Stefanick
Board 343
Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive
protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched casecontrol study nested in the prostate, lung, colorectal and ovarian (PLCO)
cancer screening study. (Abstract 1520) P. J. Goodwin, M. Tammemagi, V.
Stambolic, R. J. Dowling, C. Williams, M. Moore, A. Lohmann, F. A. Shepherd
Board 345
Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL)
in the United States (US): Analysis of the National Cancer Data Base (NCDB).
(Abstract 1521) A. J. Olszewski, J. Fallah, J. J. Castillo
Board 346
Family history of breast cancer in Hodgkin disease and future risk for breast
cancer. (Abstract 1522) S. V. Colonna, K. Curtin, W. Kohlmann, J. A. Wright, S.
Tavtigian, J. D. Schiffman
Board 347
Hereditary implications of somatic tumor testing. (Abstract 1523) P. Funchain,
D. Sohal, A. A. Khorana, J. Abraham, N. A. Pennell, B. I. Rini, R. Dreicer, B. J.
Bolwell, C. Eng
Board 348
Clinical outcomes based on multigene profiling in metastatic breast cancer
patients. (Abstract 1524) R. K. Basho, D. D. Gagliato, N. T. Ueno, R. H. Alvarez,
C. Wathoo, H. Chen, C. Wei, A. A. Sahin, S. Roy-Chowdhuri, S. L. Moulder, M.
Chavez-Mac Gregor, J. K. Litton, V. Valero, R. Luthra, K. R. Shaw, J. Mendelsohn,
G. B. Mills, D. Tripathy, F. Meric-Bernstam
Board 349
Whole exome sequencing to identify potentially causative gene variants in
hereditary gastric cancer. (Abstract 1525) Y. Huang, K. Tan, H. Yap, S. G. Ow,
H. Yang, J. So, S. Lee
Board 350
Amplification of CRKL in human cancer: A rare event associated with
potential sensitivity to targeted therapy. (Abstract 1526) K. Wang, A. Johnson,
I. Garrido-Laguna, J. Chmielecki, R. Yelensky, D. Lipson, J. A. Elvin, J. Vergilio,
S. M. Ali, V. A. Miller, P. J. Stephens, J. S. Ross
Board 351
Germline testing in hereditary cancer genes subsequent to the identification
of mutations in tumor specimens. (Abstract 1527) V. Speare, J. S. Dolinsky, H.
Laduca, C. Horton, L. Panos, C. Mason, E. Dalton, E. Chao
Board 352
Comparison of genotyping performance in DNA extracted from matched
FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic
analyses. (Abstract 1528) D. L. Hertz, K. M. Kidwell, J. N. Thibert, C. L. Gersch,
M. M. Regan, T. C. Skaar, N. L. Henry, D. Hayes, C. Van Poznak, J. M. Rae
Board 353
Personalized Genomic Analyses for Cancer Mutation Discovery and
Interpretation. (Abstract 1529) V. Anagnostou, S. Jones, K. Lytle, S. Parpart-Li,
M. Nesselbush, V. Adleff, D. Riley, M. Shukla, B. Chesnick, M. Kadan, E. Papp, K.
Galens, D. M. Murphy, T. Zhang, L. Kann, M. Sausen, S. Angiuoli, L. A. Diaz Jr.,
V. E. Velculescu
Board 354
The landscape for genetic eligibility to basket clinical trials. (Abstract 1530)
T. C. Knepper, C. M. Walko, G. C. Bell, E. Padron, J. K. Teer, H. L. McLeod
Board 355
Patient-reported outcomes associated with population-based Jewish genetic
testing for BRCA1 and BRCA2. (Abstract 1531) K. A. Metcalfe, A. Poll, M.
Llacuachaqui, S. Virani, S. Nanda, P. Sun, S. Narod
261
MONDAY
MONDAY
Board 356
Somatic mutation profiling of advanced breast and ovarian cancers
according to germline BRCA1/2 mutation status. (Abstract 1532) N.
Stjepanovic, M. K. Wilson, A. M. Oza, B. Clarke, H. K. Berman, E. Amir, H.
Mackay, P. Shaw, M. O. Butler, A. Mulligan, A. Milea, L. Ahmed, A. Volenik, L.
Wang, T. J. Pugh, T. Stockley, R. H. Kim, L. L. Siu, S. Kamel-Reid, P. L. Bedard
Board 357
Multi-gene panel testing in an unselected endometrial cancer cohort.
(Abstract 1533) K. L. Ring, A. S. Bruegl, B. Allen, E. P. Elkin, N. Singh, A.
Hartman, R. Broaddus
Board 358
Evaluation of rapid whole-body magnetic resonance as screening strategy
for early cancer detection in 57 Brazilian Li-Fraumeni syndrome patients.
(Abstract 1534) D. Paixao, M. D. Guimaraes, A. F. Nobrega, D. Malkin, R.
Chojniak, M. W. Achatz
Board 359
Comprehensive genomic profiling of advanced stage esophageal squamous
cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC). (Abstract
1535) A. Johnson, S. M. Ali, R. Yelensky, J. Chmielecki, J. A. Elvin, D. Lipson,
V. A. Miller, P. J. Stephens, J. S. Ross, K. Wang
Board 360
Is there a role for multi-gene screening panels in patients who previously
underwent noninformative genetic testing? (Abstract 1536) M. K. Frey, S. H.
Kim, J. Martineau, R. Yee Bassett, S. V. Blank
Board 361
Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve?
(Abstract 1537) K. Phillips, I. M. Collins, R. L. Milne, R. Fisher, C. Stern, G.
Kannemeyer, C. Smith, M. Friedlander, S. McLachlan, M. Hickey, J. L. Hopper,
kConFab Investigators
Board 362
Predictors of BRCA mutation in male breast cancer. (Abstract 1538) C. Ardic,
A. M. Gutierrez-Barrera, N. Elsayegh, J. Song, J. Profato, J. K. Litton, S. H.
Giordano, D. Tripathy, B. Arun
Board 363
Solid tumor profiling via next-generation sequencing to identify tumorspecific actionable variants. (Abstract 1539) S. E. Patterson, C. S. Potter, G. A.
Stafford, X. Y. Woo, V. Spotlow, T. Mitchell, R. Liu, G. Ananda, G. J. Tsongalis,
S. M. Mockus
Board 364
Germline variation in NFE2L2, CUL3, KEAP1 and risk of head and neck
squamous cell carcinoma (HNSCC). (Abstract 1540) S. Sheth, J. L. Weissfeld,
M. Romkes, R. L. Ferris, J. R. Grandis, J. E. Bauman, B. Diergaarde
Board 365
Genetic testing decisions of breast cancer patients: Results from the
iCanCare study. (Abstract 1541) R. Jagsi, A. W. Kurian, K. A. Griffith, A. S.
Hamilton, K. C. Ward, S. T. Hawley, M. Morrow, S. J. Katz
Board 366
Assessment of functional impact of germline BRCA1/2 variants located in
noncoding regions in families with breast-ovarian cancer predisposition.
(Abstract 1542) E. Santana dos Santos, M. Gendrot, S. Caputo, A. Briaux, M.
Breault, L. Castera, D. Vaur, S. Krieger, C. Houdayer, I. Bieche, D. StoppaLyonnet, F. Lallemand, E. Rouleau
Board 367
Transgenerational genomic effect of chemotherapy exposure in testicular
cancer survivors. (Abstract 1543) E. M. Van Allen, G. Kryukov, C. Bielski, K.
Samocha, M. Fromer, S. Seepo, C. Gentry, B. Neale, C. Sweeney, L. A. Garraway,
M. Taplin
Board 368
Somatic mutations in Luminal HER2 negative tumors from young breast
cancer patients. (Abstract 1544) G. Encinas, M. D. Estevez-Diz, E. C. Lyra, M. H.
Katayama, F. S. Pasini, S. Maistro, V. Sabelnykova, P. Boutros, M. Brentani, R.
Basso, A. R. Chaves De Gouvea, R. Chammas, J. G. Sampaio Goes, M. A. Koike
Folgueira
Board 369
Patient interest and willingness-to-pay (WTP) out-of-pocket (OOP) for
comprehensive tumor genetic profiling (CGP). (Abstract 1545) J. Innocent, E.
Handorf, J. M. Matro, Y. Wong, Y. Chertock, M. B. Daly, M. J. Hall
Board 370
Evaluation of family history in newly diagnosed children with cancer.
(Abstract 1546) K. Garfield, W. Kohlmann, C. C. Mason, J. D. Schiffman
262
Board 371
Missense variants in Lynch Syndrome genes in endometrial cancer patients
characterized by The Cancer Genome Atlas (TCGA) project. (Abstract 1547)
C. S. Walsh, B. Karlan, D. Hazelett
Board 372
Rare germline TP53 variants in lung adenocarcinoma. (Abstract 1548) E. M.
Parry, D. L. Gable, S. E. Stanley, M. Y. Armanios
Board 373
Women with breast and uterine cancer in relation to genetic mutation risk: A
case-control analysis. (Abstract 1549) M. R. Milam, M. Stany, S. Li, K. Fulk, E.
Chao, H. Laduca
Board 374
The impact of a molecular tumor board on treatment decisions for 35
patients: The Dartmouth experience. (Abstract 1550) L. J. Tafe, I. P. Gorlov,
F. B. Blumental de Abreu, J. A. Lefferts, X. Liu, J. R. Pettus, K. J. Bloch, J. D.
Marotti, V. A. Memoli, A. A. Suriawinata, J. D. Peterson, G. J. Tsongalis, B. M.
Holderness, C. R. Morgan, T. W. Miller, M. D. Chamberlin
Board 375
Polymorphisms in the estrogen pathway, estrogen receptor alpha gene
(ESR1), daily cycling estrogen and mammographic density. (Abstract 1551)
F. N. Fjeldheim, H. Frydenberg, V. G. Flote, A. McTiernan, P. T. Ellison, E. S.
Barrett, G. Jasienska, K. W. Makar, G. Ursin, E. A. Wist, I. Thune
Board 376
Genetic testing for hereditary breast cancer: The decision to decline.
(Abstract 1552) B. White, K. Showers, C. S. Menendez, L. Amacker-North, K. W.
Carpenter, S. Lenarcic, L. McNeely, C. Harwood, B. Dellinger, R. L. White Jr.
Board 377
Identification of tropomyosin kinase receptor (TRK) mutations in cancer.
(Abstract 1553) N. Nanda, T. Fennell, J. A. Low
Board 378
Next-generation sequencing as an informing phenotype: A TP53 example.
(Abstract 1554) R. O Shea, M. P. Farrell, R. Clarke, B. Eileen, D. J. Gallagher
Board 379
The influence of BRCA variants of uncertain significance in cancer risk
management decision-making. (Abstract 1555) J. Chern, S. S. Lee, M. K. Frey,
R. Bassett, J. Martineau, S. Blank
Board 380
First one thousand families: Our multidisciplinary experience in the heredofamilial cancer unit from a Spanish University Hospital. (Abstract 1556) I.
Marquez Rodas, S. Luque Molina, M. Sanz, M. Peligros, C. Flores Sanchez, C.
Mata, M. Die Trill, S. Lizarraga, P. Rincon, O. Bueno, S. Lopez-Tarruella, Y. Jerez
Gilarranz, A. J. Muñoz Martin, A. Calvo, C. Lopez, P. Menchen, J. Pajares, C.
Gonzalez Asanza, J. Solera, M. Martin
Board 381
DNA repair landscape of discordant sibling pairs from hereditary breast
cancer families. (Abstract 1557) Y. Ji, T. Rounds, J. Dragon, J. Bond, S. Wallace,
J. Sweasy, M. Wood
Board 382
Intratumoral heterogeneity of cancer driver genomic alterations across
several tumor types. (Abstract 1558) K. Wang, A. Johnson, D. Khaira, J. Sun, B.
Katzman, T. Brennan, C. McMahon, K. Gowen, S. Balasubramanian, S. M. Ali,
J. A. Elvin, D. Lipson, V. A. Miller, P. J. Stephens, J. S. Ross, R. Yelensky
Board 383
Feasibility of using memantine in smoking cessation among cancer
survivors. (Abstract 1559) J. Spangler, K. E. Weaver, D. Case, G. Lesser, G. V.
Burton, I. A. Dy, C. Dul, P. Reddy, J. L. Wade III, B. Esparaz, E. G. Shaw
Board 384
Hormonal and lifestyle factors as modifiers of risk of breast cancer (BC) in
BRCA1 and BRCA2 carriers (C). (Abstract 1560) A. Torres, T. Ramón y Cajal,
G. Llort, D. Fisas, C. Yague, C. López, M. León, M. Pollán
Board 385
Physical activity, hormone replacement therapy and breast cancer risk: A
meta-analysis of prospective studies. (Abstract 1561) C. Pizot, M. Boniol, P.
Mullie, A. Koechlin, P. Boyle, P. Autier
Board 386
Impact of prior knowledge of mutation status on tumor stage in BRCA1/2
mutation carriers with newly diagnosed breast cancer. (Abstract 1562) C.
Yam, J. Stopfer, A. Brandt, J. Powers, J. M. Long, K. N. Maxwell, A. R. Bradbury,
K. L. Nathanson, S. M. Domchek
263
MONDAY
MONDAY
Board 387
Development and external validation of a melanoma risk prediction model
using self-assessed risk factors. (Abstract 1563) K. Vuong, A. E. Cust, B. K.
Armstrong, K. McGeechan
Board 388
Aspirin and risks of non-colorectal second primary cancer in patients with
prior colorectal cancer. (Abstract 1564) Y. Lee, C. Teng, J. Liu, T. Chiou, P.
Chen, C. Tzeng, C. Liu
Board 389
Cancer screening in France: Reaching a plateau? New edition of an iterative
nationwide survey. (Abstract 1565) J. Viguier, J. F. Morere, C. Touboul, F.
Eisinger, S. Couraud, L. Greillier, A. B. Cortot, J. Blay, C. Lhomel, X. B. Pivot
Board 390
The influence of inflammation on mammographic breast density in women at
increased risk of breast cancer. (Abstract 1566) S. S. Ambrale, T. Rounds, B. L.
Sussman, M. Rincon, D. Kontos, B. M. Keller, Y. Ji, B. Sprague, M. Wood
Board 391
Impact of a risk model based on routine lab results on colorectal cancer
screening in average risk population. (Abstract 1567) S. B. Boursi, R. Mamtani,
K. Haynes, Y. Yang
Board 392
Trends in CRC screening by average-risk Medicare enrollees over age 75:
2002–2010. (Abstract 1568) C. L. Bennett, J. Bian, D. Fisher
Board 393
Prediction models for primary melanoma: an independent external validation
study in an Australian population. (Abstract 1569) K. Vuong, A. E. Cust, B. K.
Armstrong, K. McGeechan
Board 394
Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.
(Abstract 1570) S. Couraud, A. B. Cortot, C. Touboul, X. B. Pivot, F. Eisinger, J. F.
Morere, J. Viguier, J. Blay, C. Lhomel, L. Greillier
Board 395
Omentin as a potential biomarker related to exercise and cancer risk.
(Abstract 1571) M. Onstad, K. Basen-Engquist, R. Schmandt, S. C. Mok, C. Au
Yeung, S. Scruggs, K. H. Lu
Board 396
Effect of green tea catechins in prostate cancer chemoprevention. (Abstract
1572) N. B. Kumar, J. Pow-Sang, K. Egan, P. E. Spiess, S. I. Dickinson, R. Salup,
M. Helal, J. McLarty, C. R. Williams, F. J. Schreiber III, H. Parnes, S. Sebti, A. Kazi,
L. Kang, G. P. Quinn, T. Smith, B. Yue, G. Chornokur, T. Crocker, M. J. Schell
Board 397
Do patients with longstanding IBD have higher cancer risk compared to the
general population? Results from the IBSEN study. (Abstract 1573) M.
Cvancarova, O. Hovde, M. Wanderaas, B. Moum
Board 398
Association between geriatric assessment findings and clinical depression
in 1092 older patients with cancer: The ELCAPA Cohort study. (Abstract
1574) C. Tournigand, F. Canoui-Poitrine, N. Reinald, M. Laurent, E. Guery, P.
Caillet, J. David, J. Lagrange, S. Bastuji-Garin, C. Lemogne, E. Paillaud
Board 400
Comparison of breast cancer risk in women with and without systemic lupus
erythematosus in a Medicare population. (Abstract 1576) W. Khaliq, R.
Qayyum, J. Clough, D. Vaidya, D. M. Becker
Board 401
Factors associated with early mortality in metastatic breast cancer (MBC) in
a population based cohort. (Abstract 1577) I. V. Luis, N. U. Lin, N. L. Keating, J.
Lii, W. T. Barry, E. P. Winer, R. A. Freedman
Board 402
Breast cancer in male AYA. (Abstract 1578) R. Bawa, D. C. Flaherty, C. Sadler,
M. Goldfarb
Board 403
Treatment intensity differences in screen-detected and community-detected
early stage breast cancer (ESBC). (Abstract 1579) K. J. Elder, S. Cooke, D.
Machalek, A. Rose, A. Mou, J. P. Collins, C. Nickson, A. Park, B. Mann
Board 404
Association of body mass index with survival outcome in three breast cancer
subtypes. (Abstract 1580) T. Fujii, T. Kogawa, C. Wei, T. M. Fouad, K. Harano, Y.
Park, B. Lim, D. Tripathy, N. T. Ueno, J. K. Litton
Board 405
Incidence, prevalence, and risk factors of malignancy in lung transplant
recipients. (Abstract 1581) V. K. Singh, V. D. Villgran, L. Beesley, A. Petraglia,
K. M. Kane, C. Gries, M. George
264
Board 406
Novel algorithms to predict the occurrence of in-hospital venous
thromboembolism in cancer patients: Machine learning classifiers developed
from the 2012 national inpatient sample. (Abstract 1582) S. L. James, K. Mody,
J. J. Shatzel
Board 407
Male breast cancer as a second primary cancer (SPC): Increased risk
following hematologic malignancies. (Abstract 1583) D. E. Farr, A. Thomas,
S. L. Sugg, W. J. Gradishar, S. A. Khan, M. C. Schroeder
Board 408
Pre-diabetes and breast cancer outcomes: Abrogating the confounding
effect of anti-diabetic therapy. (Abstract 1584) V. Kaur, A. M. Safar, E. R.
Siegel, J. Fariba, S. Medarametla, T. Kieber-Emmons, K. M. Behjatolah
Board 409
“Fight fat with fat”: The impact of brown adipose tissue (BAT) on breast
cancer prognosis–A retrospective analysis. (Abstract 1585) O. E. Silva, S. M.
Warsch, A. E. Torres, A. Gomez Arteaga, G. Westin, R. Dawar, Q. R. Sparrow,
D. M. Hansra, K. Hernandez, M. Torroella, P. Doshi, A. N. Serafini, M. E. Lippman
Board 410
Development of CNS metastasis and subsequent survival in patients with
inflammatory breast cancer. (Abstract 1586) J. T. French, K. R. Hess, D. D. Liu,
K. P. Raghav, G. N. Hortobagyi, B. Arun, V. Valero, N. T. Ueno, R. H. Alvarez,
W. A. Woodward, B. G. Debeb, S. L. Moulder, B. Lim, D. Tripathy, N. K. Ibrahim
Board 411
Prevalence of malnutrition in PS 0 –1 cancer patients: Results of the
NutriCancer2 one-day national survey in 2,197 cancer patients. (Abstract
1587) J. Durand, X. Hebuterne, B. Raynard, J. Lacau Saint Guily, F. Goldwasser
Board 412
The long-term use of calcium channel blockers and the risk of breast cancer.
(Abstract 1588) S. V. Soldera, N. Bouganim, J. Asselah, H. Yin, R. Maroun, L.
Azoulay
Board 413
Overall survival in solid tumor patients with abnormal renal function or renal
insufficiency. (Abstract 1589) V. Launay-Vacher, N. Janus, I. L. Ray-Coquard, P.
Beuzeboc, J. Thariat, G. Deray
Board 414
Determinants for no definitive therapy for early-stage non-small cell lung
cancer in U.S. population. (Abstract 1590) Y. Chen, A. Y. Chang, C. Chen, Y.
Chiu, Y. Feng, S. Lin, Y. Sheu, Y. Lin
Board 416
Effect of current smoking on risk of triple negative breast cancer. (Abstract
1592) D. Prabhakar, L. Harris, C. L. Thompson
Location: S Hall A
Abstracts 2012–2023 will be discussed during the Central Nervous System Tumors Poster Discussion Session. See page 298 for session information.
Board 1
Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II
trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with
recurrent glioblastoma (BTTC-1102). (Abstract 2012) V. K. Puduvalli, J. Wu, Y.
Yuan, T. S. Armstrong, M. D. Groves, J. J. Raizer, P. Giglio, H. Colman, D. M.
Peereboom, T. Walbert, N. G. Avgeropoulos, F. M. Iwamoto, M. C. Chamberlain,
N. Paleologos, K. L. Fink, R. Merrell, W. A. Yung, M. R. Gilbert
Board 2
Randomized, placebo-controlled, phase II study of dasatinib with standard
chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877
(Alliance). (Abstract 2013) N. N. Laack, E. Galanis, S. Anderson, C. Leinweber,
J. C. Buckner, C. Giannini, F. J. Geoffroy, D. R. Johnson, G. J. Lesser, K. A.
Jaeckle, J. N. Sarkaria
Board 3
A phase II study of galunisertib monotherapy or galunisertib plus lomustine
compared to lomustine monotherapy in recurrent glioblastoma. (Abstract
2014) A. A. Brandes, A. F. Carpentier, S. Kesari, J. Sepulveda, H. Wheeler, O. L.
265
MONDAY
Chinot, L. Cher, J. P. Steinbach, P. Specenier, A. Cleverly, C. Smith, I.
Gueorguieva, S. C. Guba, D. Desaiah, M. M. Lahn, W. Wick
MONDAY
Board 4
Onartuzumab plus bevacizumab versus placebo plus bevacizumab in
recurrent glioblastoma (GBM): HGF and MGMT biomarker data. (Abstract
2015) T. F. Cloughesy, G. Finocchiaro, C. Belda, L. Recht, A. A. Brandes, E.
Pineda, T. Mikkelsen, O. L. Chinot, C. Balana, D. R. Macdonald, M. Westphal, K.
Hopkins, M. Weller, B. Liu, J. Bruey, W. Verret
Board 5
Phase I study of ABT-414 mono- or combination therapy with temozolomide
(TMZ) in recurrent glioblastoma (GBM). (Abstract 2016) H. K. Gan, K. P.
Papadopoulos, L. Fichtel, A. B. Lassman, R. Merrell, M. J. Van Den Bent, P.
Kumthekar, A. M. Scott, M. Pedersen, E. J. Gomez, J. S. Fischer, W. Ames, H.
Xiong, H. Lee, W. Munasinghe, L. Roberts-Rapp, P. Ansell, K. D. Holen, R. Lai,
D. A. Reardon
Board 6
Defining the cutoff value of MGMT gene promoter methylation and its
predictive capacity. (Abstract 2017) A. Rocca, G. Brigliadori, D. Calistri, F. Foca,
M. Dall’Agata, C. Rengucci, S. Cerasoli, M. Faedi
Board 7
Impact of bevacizumab added to temozolomide-chemoradiation on time to
health-related quality of life deterioration in unresectable glioblastoma:
Results of a phase II randomized clinical trial. (Abstract 2018) F. Bonnetain,
T. S. Dabakuyo, A. Pozet, L. Feuvret, L. Taillandier, D. Frappaz, H. Taillia, R.
Schott, J. Honnorat, M. Fabbro, I. Tennevet, F. Ghiringhelli, C. Campello, D.
Castera, M. Frenay, C. Dalban, J. Skrzypski, O. L. Chinot, B. Chauffert, A. Anota
Board 8
Outcome of neurofibromatosis type 1 patients treated with first line
vinblastine for optic pathway gliomas: A Canadian multicenter study.
(Abstract 2019) A. Lassaletta, K. Scheinemann, S. M. Zelcer, J. Hukin, B. Wilson,
N. Jabado, A. Carret, L. Lafay Cousin, V. Larouche, C. Hawkins, G. R. Pond, K.
Poskitt, E. Barlev, D. Keene, D. Johnston, U. K. Bartels, U. Tabori, E. Bouffet
Board 9
A multi-institutional prospective observational study of stereotactic
radiosurgery (SRS) for patients with multiple brain metastases (BMs):
Updated results of the JLGK0901 Study—Long-term results of irradiationrelated complications and neurocognitive function (NCF). (Abstract 2020) M.
Yamamoto, T. Serizawa, Y. Higuchi, Y. Sato, J. Kawagishi, K. Yamanaka, T.
Shuto, A. Akabane, H. Jokura, S. Yomo, O. Nagano, H. Aoyama
Board 10
Results of a randomized, global, multi-center study of whole-brain radiation
therapy (WBRT) plus veliparib or placebo in patients (pts) with brain
metastases (BM) from non-small cell lung cancer (NSCLC). (Abstract 2021) P.
Chabot, J. Ryu, V. Gorbunova, C. Belda, D. Ball, E. A. Kio, M. Mehta, K. Papp, Q.
Qin, J. Qian, K. D. Holen, V. L. Giranda, J. H. Suh
Board 11
A phase II study of temozolomide in the treatment of adult patients with
supratentorial low-grade glioma. (Abstract 2022) M. T. Wahl, J. Aicardi, D. A.
Haas-Kogan, N. A. Butowski, J. L. Clarke, M. Prados, J. J. Phillips, M. S. Berger,
S. M. Chang
Board 12
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant
glioma. (Abstract 2023) K. C. Shih, M. R. Patel, N. A. Butowski, J. A. Bacha, D.
Brown, A. Steino, R. S. Schwartz, S. Kanekal, L. Lopez, S. F. Jones, H. A. Burris III
Board 13
ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using
FMISO PET and MRI. (Abstract 2024) E. R. Gerstner, Z. Zhang, J. R. Fink, M.
Muzi, L. Hanna, E. Greco, A. Mintz, L. Kostakoglu, E. A. Eikman, M. Prah, K. M.
Schmainda, G. A. Sorensen, D. Barboriak, D. A. Mankoff
Board 14
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with
recurrent glioblastoma. (Abstract 2025) X. Cai, V. Chandra, Y. Ou, K. E.
Emblem, A. Muzikansky, J. Evans, J. Kalpathy-Cramer, J. Dietrich, A. S. Chi, P. Y.
Wen, B. R. Rosen, T. Batchelor, E. R. Gerstner
Board 15
Characteristics and outcomes of breast cancer patients with leptomeningeal
metastasis at Memorial Sloan Kettering Cancer Center (MSKCC). (Abstract
2026) A. Morikawa, L. Jordan, R. Rozner, S. Patil, A. A. Boire, E. Pentsova, A. D.
Seidman
266
Board 16
Histopathological markers at craniotomy and outcome in breast cancer brain
metastases. (Abstract 2027) M. J. McKee, D. G. Trembath, A. M. Deal, K. Keith,
B. R. Midkiff, N. Nikolaishvilli-Feinberg, A. Garrett, K. L. Blackwell, J. P. Leone,
R. L. Hamilton, A. Brufsky, A. Morikawa, E. Brogi, A. D. Seidman, M. G. Ewend,
S. J. Moschos, C. K. Anders
Board 17
Determining viability of using APNG status as a prognostic marker in
patients with glioblastoma multiforme. (Abstract 2028) R. H. Dahlrot, S.
Hellwege, S. Fosmark, K. L. Jensen, J. Lohse, H. Derand, J. Hjelmborg, S.
Hansen, B. W. Kristensen
Board 18
A phase I trial of intravenous liposomal irinotecan in patients with recurrent
high-grade gliomas. (Abstract 2029) J. L. Clarke, A. M. Molinaro, A. A. DeSilva,
J. E. Rabbitt, D. C. Drummond, S. M. Chang, N. A. Butowski, M. Prados
Board 19
Differential molecular expression profile according to glioblastoma (GB)
location. (Abstract 2030) E. Denicolai, E. Tabouret, C. Colin, P. Metellus, I.
Nanni, C. Boucard, A. Tchoghandjian, N. Baeza-Kallee, F. Fina, O. L. Chinot, D.
Figarella-Branger
Board 20
Use of a novel radio-sensitizer for treatment of GBM. (Abstract 2031) J. L.
Gainer, J. Sheehan, J. M. Larner, D. R. Jones
Board 21
Long-term survival in patients with primary CNS lymphoma: Results from the
G-PCNSL-SG1 trial. (Abstract 2032) P. Roth, P. Martus, E. Thiel, A. Korfel, M.
Weller, G-PCNSL-SG1 study group
Board 22
Timed-sequential therapy with mibefradil and temozolomide in patients with
recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium
study. (Abstract 2033) M. Holdhoff, X. Ye, L. B. Nabors, A. S. Desai, T.
Mikkelsen, G. Lesser, W. L. Read, F. S. Lieberman, J. Supko, J. D. Fisher, S.
Desideri, S. A. Grossman, D. Schiff, ABTC Investigators
Board 23
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
(Abstract 2034) A. Ghiaseddin, D. A. Reardon, W. Massey, A. Mannerino, E. S.
Lipp, J. E. Herndon II, F. McSherry, A. Desjardins, D. M. Randazzo, G. Vlahovic,
H. S. Friedman, K. B. Peters
Board 24
Patterns of response and relapse of primary central nervous system
lymphomas (PCNSL) following first line of high-dose methotrexate-based
chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized
phase II trial. (Abstract 2035) E. Tabouret, C. Houillier, N. Martin-Duverneuil, M.
Blonski, C. Soussain, H. Ghesquieres, R. Houot, V. Delwail, P. Soubeyran, R.
Gressin, E. Gyan, O. L. Chinot, L. Taillandier, M. Tanguy, A. M. Omuro, K. HoangXuan
Board 25
Comparative impact of treatment on clinical benefit in patients with
glioblastoma (GBM) enrolled in the phase II trial of ICT-107. (Abstract 2036)
T. S. Armstrong, P. Y. Wen, D. A. Reardon, S. Phuphanich, R. Aiken, J. C.
Landolfi, W. T. Curry, J. Zhu, M. J. Glantz, D. M. Peereboom, J. Markert, R. V.
LaRocca, D. O’Rourke, K. L. Fink, L. J. Kim, M. L. Gruber, G. J. Lesser, E. Pan, S.
Kesari, J. Yu
Board 26
Correlation of dynamic 18FET-PET with IDH 1 mutation for prediction of
outcome in anaplastic astrocytoma WHO° III independently from tumor
vascularisation. (Abstract 2037) B. Suchorska, N. L. Jansen, T. Kraus, A. Giese,
P. Bartenstein, J. Tonn
Board 27
Prognostic model of lower grade gliomas. (Abstract 2038) K. Aoki, H. Suzuki,
H. Nakamura, K. Motomura, M. Mizoguchi, T. Abe, Y. Muragaki, T. Wakabayashi,
S. Ogawa, A. Natsume
Board 28
Phase I study of vorinostat combined with isotretinoin and temozolomide in
adults with recurrent malignant gliomas. (Abstract 2039) M. Penas-Prado,
K. R. Hess, V. A. Levin, J. F. De Groot, H. Colman, M. D. Groves, C. A. Conrad,
M. E. Loghin, K. Hunter, M. R. Gilbert, W. A. Yung, V. K. Puduvalli
267
MONDAY
MONDAY
Board 29
The impact of the time to start radiotherapy (TRT) on overall survival in newly
diagnosed glioblastoma. (Abstract 2040) V. Montes Santos, M. Coelho
Mesquita, M. D. Estevez-Diz, G. N. Marta, O. Feher
Board 30
Does extent of resection matter in recurrent glioblastoma? Lessons from the
DIRECTOR trial. (Abstract 2041) B. Suchorska, M. Weller, G. Tabatabai, C.
Senft, P. Hau, M. Sabel, U. Herrlinger, R. Ketter, U. S. Schlegel, C. Marosi, G.
Reifenberger, W. Wick, J. Tonn, H. Wirsching
Board 31
Effectiveness of transcranial magnetic stimulation in neurooncological
patients. (Abstract 2042) D. P. Atmachidi, A. I. Shikhlyarova, E. E. Rostorguev,
T. P. Protasova, E. P. Korobeynikova
Board 32
Mutational analysis of matched initial and recurrent TP53 WT primary GBM.
(Abstract 2043) D. M. Ashley, A. Muscat, J. Yin, E. Algar, K. Drummond, M.
Khasraw, K. M. Field, N. Wong, M. Rosenthal, K. L. McDonald
Board 33
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of
oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
(Abstract 2044) U. N. Lassen, M. Mau-Soerensen, A. L. Kung, P. Y. Wen, E. Q.
Lee, S. R. Plotkin, A. Muhic, T. Rashal, T. Williams, D. McCauley, J. Ellis, J. SaintMartin, R. Carlson, R. Frenkel, S. Shacham, M. R. Mirza, M. Kauffman, A. B. Lassman
Board 35
IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome
upfront Pignatti criteria and molecular profile in a retrospective analysis of a
single-centre cohort from Spain. (Abstract 2046) O. Etxaniz, C. Carrato, I. de
Aguirre, C. Queralt, A. Munoz, J. Ramirez, R. Rosell, S. Villà, R. Diaz, A. Estival, P.
Teixidor, A. Indacochea, S. Ahlal, L. V. Martinez, C. Balana
Board 36
Time to response (TTR) and early tumor shrinkage (ETS) in recurrent
glioblastoma patients treated with bevacizumab: an exploratory analysis of
the prospective randomized AVAREG (ML25739) phase II study. (Abstract
2047) E. Franceschi, G. Finocchiaro, V. Zagonel, M. Reni, A. Fabi, C. Caserta, M.
Clavarezza, E. Maiello, G. Carteni, G. Rosti, R. Agati, A. Tosoni, A. Paccapelo, E.
Proietti, A. A. Brandes
Board 37
The role of salvage radiation in recurrent glioblastoma after bevacizumab
failure. (Abstract 2048) N. Sarmey, S. T. Chao, E. S. Murphy, J. S. Yu, D. M.
Peereboom, G. Stevens, J. H. Suh, M. S. Ahluwalia
Board 38
Graded prognostic assessment index for colorectal cancer with brain
metastases. (Abstract 2049) V. Karivedu, V. Alva Venur, I. Kim, S. T. Chao, J. H.
Suh, D. Sohal, A. A. Khorana, X. Jia, M. S. Ahluwalia
Board 39
Phase II trial of dovitinib in recurrent glioblastoma. (Abstract 2050) M. S.
Ahluwalia, N. Papadantonakis, V. Alva Venur, C. Schilero, D. M. Peereboom, G.
Stevens, S. Rosenfeld, M. A. Vogelbaum, P. Elson, A. B. Nixon, K. McCrae
Board 40
Incidence of pseudo-progression in low-grade gliomas treated with
radiotherapy. (Abstract 2051) S. E. van West, H. G. de Bruin, B. van de Langerijt,
A. T. Swaak-Kragten, M. J. Van Den Bent, W. Taal
Board 41
Delineation of MGMT promoter hypermethylation as a predictive biomarker
for the A071102 clinical trial of veliparib combined with temozolomide (TMZ)
using patient-derived xenograft (PDX) GBM models. (Abstract 2052) J. N.
Sarkaria, S. Gupta, S. H. Kizilbash, B. Carlson, A. Mladek, K. Bakken, M. A.
Schroeder, P. A. Decker, E. P. Sulman, J. Eckel-Passow, G. Kitange, R. B. Jenkins
Board 42
The role of temozolomide (TMZ) in the management of anaplastic
astrocytoma (AA): A comparison of survival in the era prior to and following
TMZ. (Abstract 2053) I. Abuali, R. E. Strowd, Y. Lu, X. Ye, S. A. Grossman
Board 43
GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of
Neuro-Oncology): Analysis of factors influencing survival in glioblastoma
patients receiving the nitrosourea fotemustine at first relapse following
Stupp regimen. (Abstract 2054) R. Ruda, G. Lombardi, S. Scoccianti, M. Fabrini,
M. Santoni, A. Pace, A. Silvani, A. Marinelli, I. Lolli, M. Balducci, M. Arcicasa, M.
Salvati, A. Sponghini, S. Vallarelli, M. Caroli, F. Imbesi, D. Bilancia, M. Faedi, S.
Cascinu, R. Soffietti
268
Board 44
Phase II trial of bevacizumab in patients with surgery and radiation refractory
progressive meningioma. (Abstract 2055) S. A. Grimm, P. Kumthekar, M. C.
Chamberlain, D. Schiff, P. Y. Wen, F. M. Iwamoto, D. A. Reardon, B. Purow, J. J.
Raizer
Board 45
Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower
grade gliomas? (Abstract 2056) M. Eoli, V. Cuccarini, R. Paterra, M. Farinotti, L.
Cuppini, A. Erbetta, F. DI Meco, G. Filippini, G. Finocchiaro, M. Bruzzone
Board 46
Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in
Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay
(Abstract 2057) A. M. Omuro, A. Zehir, D. T. Cheng, M. F. Berger, D. M. Hyman,
D. B. Solit, J. Baselga, M. Ladanyi, M. E. Arcila, M. Hameed, P. Sabbatini, L. M.
DeAngelis, P. H. Gutin, M. Rosenblum, I. K. Mellinghoff, V. Tabar, T. A. Chan, S.
Briggs, J. T. Huse, C. W. Brennan
Board 47
Tumor profiling on 1245 gliomas and paired tumor study on 19 high grade
gliomas. (Abstract 2058) J. Xiu, D. Spetzler, R. Bender, A. Ghazalpour, Z.
Gatalica, S. K. Reddy, D. E. Piccioni, J. L. Hu, M. J. Glantz, S. Kesari
Board 48
Tumor infiltrating lymphocytes associated with brain metastasis in breast
cancer. (Abstract 2059) N. O. Williams, C. L. Thompson, S. Parsai, V. Varadan,
K. Miskimen, J. Barnholtz-Sloan, P. Silverman, S. Vinayak, L. R. Rogers, A. E.
Sloan, L. Harris, H. L. Gilmore
Board 49
Tumor profiles of brain metastases from NSCLC, breast cancer, and
melanoma. (Abstract 2060) S. Kesari, J. Xiu, J. L. Hu, M. E. Salacz, D. E.
Piccioni, S. K. Reddy
Board 50
A phase I trial everolimus and sorafenib in patients with recurrent high-grade
gliomas: Brain Tumor Treatment Collaborative trial 09 – 01. (Abstract 2061)
J. J. Raizer, S. A. Grimm, M. Penas-Prado, I. Tremont-Lukats, W. A. Yung, N. G.
Avgeropoulos, T. Walbert, M. E. Loghin, M. R. Gilbert
Board 51
Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT)
with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed
glioblastoma (GBM). (Abstract 2062) A. A. Thomas, K. Beal, K. A. McNeill, T. J.
Kaley, L. M. DeAngelis, I. K. Mellinghoff, E. L. Diamond, T. A. Chan, R. J. Young, J.
Arevalo Perez, Y. Yamada, B. D. Anderson, M. Lamson, B. Burch, R. A. Karmali,
A. M. Omuro
Board 52
Decision support needs analysis in newly diagnosed malignant glioma.
(Abstract 2063) L. K. Ronan, C. E. Fadul, H. Wishart
Board 53
Clinical outcome of adult brainstem glioma treated with concurrent
chemoradiotherapy: An institutional experience. (Abstract 2064) H.
Kunhiparambath, S. Gupta, S. Mallick, M. Annamalai, D. Sharma, P. K. Julka, G. K.
Rath
Board 54
A phase II study of the combination of BKM120 (buparlisib) and bevacizumab
in patients with relapsed/refractory glioblastoma multiforme (GBM).
(Abstract 2065) K. C. Shih, S. A. Chowdhary, K. P. Becker, J. M. Baehring, W. H.
Liggett, H. A. Burris III, J. D. Hainsworth
Board 55
The effect of regadenoson-induced transient disruption of the blood brain
barrier on temozolomide delivery to rat brain parenchyma. (Abstract 2066) S.
Jackson, N. Anders, A. Mangraviti, T. Wanjiku, H. Brem, B. Tyler, M. A. Rudek,
S. A. Grossman
Board 56
Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV)
for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
(Abstract 2067) A. Desjardins, K. B. Peters, G. Vlahovic, D. Randazzo, S. Boulton,
W. C. Massey, E. S. Lipp, J. E. Herndon II, P. Healy, E. Miller, R. A. Karmali, H. S.
Friedman
Board 57
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent
glioblastoma (GBM): Optimal dose determination. (Abstract 2068) A.
Desjardins, J. H. Sampson, K. B. Peters, G. Vlahovic, D. Randazzo, S. Threatt,
269
MONDAY
J. E. Herndon II, S. Boulton, D. Lally-Goss, F. McSherry, E. S. Lipp, A. H.
Friedman, H. S. Friedman, D. D. Bigner, M. Gromeier
MONDAY
Board 58
Targeting dopamine receptor 2 (DRD2) signaling in combination with
temozolomide chemotherapy as a novel therapeutic concept in
glioblastomas. (Abstract 2069) T. A. Johannessen, A. Grudic, H. Zhu, H. Saed,
J. Varughese, N. Yang, T. Sundstrom, B. Janji, J. Wang, M. Lund-Johansen, R.
Bjerkvig, L. Prestegarden
Board 59
A phase 1b/2 study of the combination of the IDO pathway inhibitor
indoximod and temozolomide for adult patients with
temozolomide-refractory primary malignant brain tumors: Safety analysis
and preliminary efficacy of the phase 1b component. (Abstract 2070) H.
Colman, F. Mott, A. I. Spira, T. S. Johnson, Y. Zakharia, N. N. Vahanian, C. J. Link,
E. P. Kennedy, R. F. Sadek, D. Munn, O. Rixe
Board 60
Identification of glioblastoma patients who stand to benefit from PARP
inhibitor therapy. (Abstract 2071) K. L. McDonald, M. Khasraw, D. M. Ashley
Board 62
Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells
(CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors.
(Abstract 2072) X. Lin, M. Fleisher, A. M. Omuro, L. Shagabayeva, E. Pentsova
Board 63
IDH1 mutation status and outcome in clinical trials for recurrent
glioblastoma. (Abstract 2073) J. J. Mandel, D. Cachia, D. D. Liu, K. D. Aldape, G.
Fuller, J. F. De Groot
Board 64
Analysis of BRAF alterations and molecular profiling in glioblastoma and
astrocytoma . (Abstract 2074) N. Faiq, J. Chmielecki, M. Goldberg, P. Stephens,
R. Kurzrock, S. Kesari, D. E. Piccioni
Board 65
Targeting PTBP1 as a therapeutic strategy to reverse lineage-specific
splicing of ANXA7 and ensuing EGFR activation in glioblastoma. (Abstract
2075) M. Bredel, R. Ferrarese, N. K. Thudi, V. K. Puliyappadamba, E. Bug, H.
Trummell, J. Anderson, C. D. Willey, E. S. Yang, W. Beck, J. A. Bonner, M. Carro
Board 66a
A phase I study of TPI 287 concurrent with fractionated stereotactic
radiotherapy (FSRT) in treatment of brain metastases from advanced breast
and non-small cell lung cancer (NSCLC). (Abstract TPS2076) S. Sahebjam,
N. D. Tran, H. H. Soliman, J. Arrington, T. Tanvetyanon, S. K. Raj, D. Chen, J.
Cooksey, M. Hayes, M. E. Montejo, P. A. Forsyth, N. G. Rao, G. Farmer, P. A.
Johnstone
Board 66b
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in
patients with glioblastoma (GBM). (Abstract TPS2077) D. A. Reardon, J.
Dietrich, T. J. Kaley, H. K. Gan, G. P. Dunn, T. F. Cloughesy, M. Lim, J. L. Clarke,
A. J. Park, L. S. Pan, D. W. Lai, J. J. Karakunnel, P. B. Robbins, R. Narwal, R. R.
Venhaus
Board 67a
An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the
treatment of glioblastoma multiforme. (Abstract TPS2078) J. D. Lickliter, D. B.
Wilson, H. Hendrickson, N. Raghunand, S. Khor, O. Longacre, E. C. Unger
Board 67b
CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III
study of adjuvant prophylactic anticoagulation in patients with glioblastoma
WHO IV. (Abstract TPS2079) S. A. Kuhn, C. Marosi, I. Pabinger, L. Bullinger, R.
Goldbrunner, A. A. Khorana, M. S. Ahluwalia, F. R. Rickles, G. H. Lyman, P.
Vajkoczy
Board 68a
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
(Abstract TPS2080) E. Q. Lee, A. Muzikansky, E. R. Gerstner, J. G. Kuhn, D. A.
Reardon, L. Nayak, A. D. Norden, L. M. Doherty, J. Rifenburg, D. C. LaFrankie, J.
Pulverenti, T. Vardam-Kaur, D. Stokes, K. H. Smith, C. S. McCluskey, S. C. Gaffey,
T. Batchelor, D. G. Duda, R. K. Jain, P. Y. Wen
Board 68b
A phase I study of convection-enhanced delivery of nanoliposomal
irinotecan using real-time imaging in patients with recurrent high grade
glioma. (Abstract TPS2081) N. A. Butowski, S. Han, J. W. Taylor, M. K. Aghi, M.
Prados, S. M. Chang, J. L. Clarke, K. Bankiewicz, D. C. Drummond, J. Fitzgerald
270
Location: S Hall A
Board 182
Association of p53-ness with chemo-resistance in urothelial cancers treated
with neoadjuvant gemcitabine plus cisplatin. (Abstract 4512) R. Seiler, W.
Choi, L. L. Lam, N. Erho, C. Buerki, E. Davicioni, G. N. Thalmann, D. J. McConkey,
P. C. Black
Board 183
Whole exome sequencing reveals chemotherapy-driven evolution of
platinum-resistant metastatic urothelial cancer. (Abstract 4513) B. Faltas, H.
Beltran, D. Prandi, K. Eng, C. Pauli, B. D. Robinson, J. Mosquera, D. M. Nanus,
S. T. Tagawa, O. Elemento, F. Demichelis, M. A. Rubin
Board 184
Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant
chemotherapy (NAC) for bladder cancer. (Abstract 4514) Y. Wong, R.
Dunbrack Jr., T. Brennan, M. D. Andrake, Y. Zhou, I. Serebriiskii, E. Dulaimi, J. H.
Hoffman-Censits, M. Bilusic, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. Chen,
C. D. Lallas, E. J. Trabulsi, R. Yelensky, V. A. Miller, E. Golemis, E. A. Ross, E. R.
Plimack
Board 185
Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with
gemcitabine and cisplatin in advanced or metastatic chemo-refractory
urothelial cancer (UC). (Abstract 4515) M. N. Fishman, D. A. Vaena, P. Singh, J.
Picus, U. N. Vaishampayan, J. Slaton, J. F. Mahoney, S. S. Agarwala, C. J.
Rosser, D. Landau, J. Hajdenberg, P. J. Van Veldhuizen, R. A. Parikh, S. Alter, L.
Hernandez, P. Rhode, H. C. Wong
Board 186
Expanded cohort results from CheckMate 016: A phase I study of nivolumab
in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
(Abstract 4516) H. J. Hammers, E. R. Plimack, J. R. Infante, B. I. Rini, D. F.
McDermott, M. Ernstoff, M. H. Voss, P. Sharma, S. K. Pal, A. R. Razak, C. K.
Kollmannsberger, D. Y. Heng, J. L. Spratlin, Y. Shen, P. Gagnier, A. Amin
Board 187
Impact of gemcitabine ⴙ cisplatin ⴙ ipilimumab on circulating immune cells
in patients (pts) with metastatic urothelial cancer (mUC). (Abstract 4586)
M. D. Galsky, N. M. Hahn, C. Albany, M. T. Fleming, A. Starodub, P. Twardowski,
R. J. Hauke, G. Sonpavde, M. Merad, S. Gnjatic, N. Bhardwaj, U. ChippadaVenkata, W. K. Oh, S. Kim-Schulze
Board 188
RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in
patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract 4518) R.
Motzer, A. Alyasova, D. Ye, A. Karpenko, H. Li, B. Y. Alekseev, L. Xie, G. P.
Kurteva, R. D. Kowalyszyn, Y. Neron, T. Cosgriff, L. Collins, T. Brechenmacher, S.
Segal, L. M. Morgan, L. Yang
Board 189
Activating genomic mutations in the mTOR pathway predict responses to
everolimus and temsirolimus in patients with metastatic renal cell carcinoma
(mRCC): Results from a large multi-institutional cohort. (Abstract 4519) A. P.
Fay, D. J. Kwiatkowski, K. P. Gray, A. Thorner, B. I. Rini, N. Agarwal, T. H. Ho, J.
Song, P. M. Barrios, L. Albiges, E. M. Van Allen, K. M. Krajewski, C. Porta, S. K.
Pal, J. Bellmunt, D. F. McDermott, D. Y. Heng, S. Signoretti, T. K. Choueiri
Board 190
Comprehensive genomic profiling of 443 patients with advanced renal cell
carcinoma (RCC) reveals clinically relevant genomic alterations and aids in
classification of rare subtypes. (Abstract 4520) S. K. Pal, S. M. Ali, Z.
Chalmers, J. A. Karam, J. A. Elvin, J. Chmielecki, R. Yelensky, E. M. Van Allen, D.
Lipson, K. Wang, A. P. Fay, V. A. Miller, P. Stephens, J. S. Ross, T. K. Choueiri
Board 191
Distinct MET alterations induce a common phenotype and define a METdriven subset of papillary RCC: Results from the Cancer Genome Atlas
(TCGA) Kidney Renal Papillary (KIRP) Working Group. (Abstract 4521) L.
271
MONDAY
Abstracts 4512– 4523 will be discussed during the Genitourinary (Nonprostate) Cancer Poster
Discussion Session. See page 299 for session information.
Albiges, B. Murray, A. Brooks, A. Cherniack, A. Berger, C. J. Creighton, C.
Ricketts, D. P. Bottaro, R. Srinivasan, L. S. Schmidt, M. Meyerson, P. Spellman,
W. M. Linehan, T. K. Choueiri, The Cancer Genome Atlas (TCGA) Kidney Renal
Papillary (KIRP) working group
MONDAY
Board 192
A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear
cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary
features. (Abstract 4522) M. H. Voss, Y. Chen, J. Chaim, D. T. Coskey, K. Woo,
A. Redzematovic, P. Wang, W. Lee, S. Patil, A. M. Molina, J. Hsieh, R. Motzer,
D. R. Feldman
Board 193
SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197)
and tivantinib in combination with erlotinib in patients (Pts) with papillary
renal cell carcinoma (pRCC). (Abstract 4523) P. Twardowski, M. Plets, E. R.
Plimack, N. Agarwal, C. M. Tangen, N. J. Vogelzang, I. M. Thompson Jr., P. Lara
Jr.
Board 194
Adjuvant chemotherapy for residual disease after neoadjuvant
chemotherapy for muscle invasive urothelial cancer (MIUC). (Abstract 4524)
L. C. Harshman, L. Werner, Y. Wong, E. Y. Yu, A. S. Alva, S. J. Crabb, T. Powles,
J. E. Rosenberg, J. Baniel, U. N. Vaishampayan, D. R. Berthold, S. Ladoire, S. A.
Hussain, M. I. Milowsky, N. Agarwal, A. Necchi, S. K. Pal, F. Recine, J. Bellmunt,
M. D. Galsky, RISC Investigators
Board 195
JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or
metastatic transitional-cell carcinoma (mTCC), who progressed before 12
months after cisplatin-based chemotherapy—A Spanish Oncologic
Genitourinary Group (SOGUG) study. (Abstract 4525) J. Arranz Arija, X. Garcia
del Muro, B. Perez-Valderrama, S. Vazquez-Estevez, N. Sala, M. Juan Fita, N.
Laı́nez, E. Noguerón, A. Font, M. Sáez, P. Maroto, E. Gallardo Diaz, M. J. MéndezVidal, M. Lopez Criado, A. Pinto, M. Lázaro Quintela, A. Gonzalez del Alba, R.
Luque, M. Lopez Brea, I. Duran
Board 196
Comprehensive genomic profiling of 295 cases of clinically advanced
urothelial carcinoma of the urinary bladder to reveal frequency of clinically
relevant genomic alterations. (Abstract 4526) M. J. Hawryluk, K. Wang, S. M.
Ali, H. Fisher, B. Mian, T. Nazeer, J. A. Elvin, J. Chmielecki, R. Yelensky, D.
Lipson, V. A. Miller, P. J. Stephens, J. S. Ross
Board 197
Effectiveness of adjuvant chemotherapy (AC) versus observation in patients
with > pT3 and/or pNⴙ bladder cancer (BCa). (Abstract 4517) M. D. Galsky, K.
Stensland, E. L. Moshier, J. Sfakianos, R. B. McBride, C. Tsao, M. F. Casey, S. J.
Hall, P. Boffetta, W. K. Oh, J. P. Wisnivesky
Board 198
Externally validated improved 5-factor prognostic model in patients (pts)
receiving salvage systemic therapy for advanced urothelial carcinoma (UC).
(Abstract 4527) G. Sonpavde, G. R. Pond, J. E. Rosenberg, D. F. Bajorin, A. M.
Regazzi, S. A. Mullane, G. Niegisch, P. Albers, A. Necchi, G. di Lorenzo, R.
Fougeray, Y. Ko, A. Rozzi, K. Matsumoto, J. Lee, H. Kitamura, H. Kume, M. I.
Milowsky, T. K. Choueiri, J. Bellmunt
Board 199
Molecular characterization of bladder cancer in smokers versus
non-smokers. (Abstract 4528) M. Joshi, S. Z. Millis, D. L. Lamm, S. K. Reddy,
S. L. Holder, N. J. Vogelzang, J. J. Drabick
Board 200
Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with
advanced urothelial carcinoma (UC): Preliminary analysis of a randomized
placebo controlled phase II trial (MAJA trial)—SOGUG 2011– 02. (Abstract
4529) J. Bellmunt, B. Perez Valderrama, A. Font, J. Virizuela, M. Climent, S.
Hernando Polo, B. Mellado, N. Laı́nez, A. Gonzalez del Alba, J. Arranz, J. Villa
Guzman, M. LLorente, D. E. Castellano, E. Gallardo, X. Garcia del Muro, U. Anido,
M. Domenech, J. Puente, J. Perez Gracia, J. Garcı́a-Donas
Board 201
Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in
cisplatin-treated bladder cancer patients. (Abstract 4530) C. W. Zhou, S. A.
Mullane, L. Werner, M. Taplin, A. P. Fay, T. K. Choueiri, D. Y. Takeda, M. Bowden,
J. Bellmunt
272
Board 203
The basal subtype to predict clinical benefit from neoadjuvant
chemotherapy: Final results from a phase II clinical trial of DDMVAC ⴙ
bevacizumab. (Abstract 4531) A. O. Siefker-Radtke, W. Choi, S. Porten, Y. Shen,
A. M. Kamat, S. F. Matin, R. E. Millikan, C. P. Dinney, B. Czerniak, D. J. McConkey
Board 204
Association of somatic mutations in DNA damage repair (DDR) genes with
efficacy of platinum-based chemotherapy in advanced urothelial carcinoma.
(Abstract 4532) R. M. Bambury, E. Jordan, E. C. Zabor, N. Bouvier, H. AlAhmadie, M. E. Boyd, S. A. Mullane, E. K. Cha, I. Ostrovnaya, D. M. Hyman, B. H.
Bochner, M. E. Arcila, D. B. Solit, D. F. Bajorin, J. Bellmunt, M. F. Berger, G. Iyer,
J. E. Rosenberg
Board 206
Germ cell cancer and multiple relapses: Toxicity and survival. (Abstract
4533) J. Lauritsen, M. G. Gundgaard Kier, M. S. Mortensen, M. Bandak, R. Gupta,
N. V. Holm, M. Agerbaek, G. Daugaard
Board 207
Wilms’ tumor gene 1 (WT1) aberrations in testicular germ cell tumors
(TGCTs). (Abstract 4534) L. Boublikova, V. Bakardjieva-Mihaylova, K. Skvarova
Kramarzova, D. Kuzilkova, T. Buchler, P. Dusek, M. Grega, B. Rosova, Z.
Vernerova, P. Klezl, R. Zachoval, M. Pesl, M. Krolupper, M. Kubecova, V.
Stahalova, M. Babjuk, J. Abrahamova, R. Kodet, J. Trka
Board 208
Impact of response to induction chemotherapy (CT) and prior paclitaxel
(TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT)
for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid
Tumors Working Party study. (Abstract 4535) A. Necchi, R. Miceli, M. Bregni, K.
Oechsle, E. Kanfer, C. Massard, A. Flechon, D. Laszlo, F. Arpaci, P. Wuchter,
M. M. Crysandt, A. Unal, A. Nagler, A. Wahlin, M. Michieli, K. Pflueger, M.
Ringhoffer, M. Badoglio, P. Pedrazzoli, F. Lanza, EBMT-Solid Tumors Working
Party
Board 209
Prognostic significance of thromboembolic events in chemotherapy-treated
germ cell tumors. (Abstract 4536) E. Gonzalez-Billalabeitia, J. Guma, D. E.
Castellano, M. Luengo, J. Aparicio, A. Sanchez Munoz, B. Mellado, A. Saenz,
C. M. Valverde, A. Fernandez, M. Margeli, I. Duran, S. Fernandez Arrojo, J. Sastre,
S. Ros, J. P. Maroto Rey, A. Carmona Bayonas, F. Ayala, D. Hervas, J. R. GermaLluch, Spanish Germ-Cell Cancer Group (Grupo Germinal) and the Spanish
Oncology Genitourinary Group (SOGUG)
Board 210
Clinical outcomes of late relapse in stage I seminoma. (Abstract 4537) A.
Hosni, P. R. Warde, P. L. Bedard, M. A. Jewett, R. J. Hamilton, M. J. Moore, R.
Huang, M. O’Malley, J. Sweet, P. W. Chung
Board 211
Perioperative morbidity and mortality with bleomycin in primary mediastinal
non seminomatous germ cell tumor (PMNSGCT). (Abstract 4538) P.
Ranganath, K. Kesler, J. Dentel, L. H. Einhorn
Board 212
A retrospective analysis of patients with metastatic germ cell tumor (GCT)
treated at Indiana University (IU) from 2000 to 2012. (Abstract 4539) K. Ku, S.
Ibrahim, N. Adra, S. Althouse, N. H. Hanna, L. H. Einhorn, C. Albany
Board 213
Bleomycin-induced pulmonary changes on restaging CT scans: Frequency
and correlation with fibrosis markers. (Abstract 4540) N. Westerink, S.
Lubberts, M. W. den Hollander, A. Bongaerts, R. Wolf, R. Altena, J. Nuver, S.
Oosting, E. De Vries, A. M. Walenkamp, C. Meijer, J. A. Gietema
Board 214
Early changes in renal function and late cardiovascular disease risk in
testicular cancer survivors with 25 years follow-up. (Abstract 4541) S.
Lubberts, J. A. Kampman, H. Boer, C. Meijer, G. J. Navis, J. A. Gietema
Board 215
Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal
cell cancer (mRCC): A California Cancer Consortium clinical trial. (Abstract
4542) T. B. Dorff, J. Longmate, S. K. Pal, W. M. Stadler, M. N. Fishman, U. N.
Vaishampayan, A. R. Rao, J. Hu, D. I. Quinn, P. Lara Jr.
Board 216
HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a
phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC),
CRLX101, in combination with bevacizumab (bev). (Abstract 4543) S. M.
Keefe, J. H. Hoffman-Censits, R. Mamtani, M. Walicki, J. Robinson, A. Smith, O.
273
MONDAY
Gunnarsson, A. Piscitelli, M. Hennessey, L. Jayaraman, A. B. Nixon, S. Eliasof,
R. B. Cohen, D. J. Vaughn, E. G. Garmey, N. B. Haas
MONDAY
Board 217
Cardiovascular toxicity following anti-angiogenic therapy in persons over
age 65 with advanced renal cell carcinoma. (Abstract 4544) S. Jang, C. Zheng,
H. Tsai, A. z. Fu, A. Barac, M. B. Atkins, A. N. Freeman, L. M. Minasian, A. L.
Potosky
Board 218
Overall survival analysis from a randomized phase II study of axitinib with or
without dose titration for first-line metastatic renal cell carcinoma. (Abstract
4545) B. I. Rini, Y. Tomita, B. Melichar, T. Ueda, V. Grünwald, M. N. Fishman, H.
Uemura, M. Oya, A. H. Bair, G. Andrews, D. Pavlov, E. Jonasch
Board 219
Analysis of real world treatment compliance in a cohort of 2,395 patients with
metastatic renal cell carcinoma (mRCC). (Abstract 4546) J. Margolis, N.
Princic, J. Doan, G. Lenhart, R. Motzer
Board 220
Randomized phase II study of sunitinib ⴙ CXCR4 inhibitor LY2510924 versus
sunitinib alone in first-line treatment of patients with metastatic renal cell
carcinoma. (Abstract 4547) J. D. Hainsworth, J. R. Mace, J. A. Reeves, E. J.
Crane, O. Hamid, J. R. Stille, A. Flynt, J. Polzer, A. Milner, S. Roberson, E.
Arrowsmith
Board 221
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in
metastatic renal cell carcinoma. (Abstract 4548) M. Diekstra, J. J. Swen, E.
Boven, D. E. Castellano, H. Gelderblom, R. H. Mathijssen, C. Rodriguez-Antona, J.
Garcı́a-Donas, B. I. Rini, H. Guchelaar
Board 222
Randomized phase II study of two different doses of AVE0005 (VEGF Trap,
aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An
ECOG-ACRIN study [E4805]. (Abstract 4549) R. Pili, J. Manola, M. A. Carducci,
J. P. Dutcher, L. J. Appleman, D. L. Groteluschen, R. S. DiPaola
Board 223
Pancreatic metastases from renal cell carcinoma: Prognostic relevance and
outcome in patients treated with targeted agents. (Abstract 4550) P. Grassi,
L. S. Doucet, P. Giglione, V. Gruenwald, B. Melichar, L. Galli, U. De Giorgi, A.
Guida, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, A. Necchi, L. Derosa, H.
Studentova, M. Pacifici, F. G. De Braud, C. Porta, B. J. Escudier, G. Procopio
Board 224
Early tumor shrinkage (eTS) as a predictive and prognostic factor in
metastatic renal cell carcinoma (mRCC). (Abstract 4551) V. Gruenwald, X. Lin,
D. Kalanovic, R. Simantov
Board 225
Novel chromosome copy number changes to predict clinical response to
sunitinib in patients with advanced renal cell carcinoma. (Abstract 4552) C.
Lee, R. Motzer, A. Hoetker, O. Akin, A. M. Molina, T. M. Gold, S. Patil, B.
Gowrishankar, J. Houldsworth
Board 227
Updated survival results from a randomized, dose-ranging phase II study of
nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). (Abstract 4553)
E. R. Plimack, H. J. Hammers, B. I. Rini, D. F. McDermott, B. Redman, T. Kuzel,
M. R. Harrison, U. N. Vaishampayan, H. A. Drabkin, S. George, T. F. Logan, K. A.
Margolin, L. Xu, I. Waxman, R. Motzer
Board 228
Final overall survival analysis for the RECORD-3 study of first-line
everolimus followed by sunitinib versus first-line sunitinib followed by
everolimus in metastatic RCC (mRCC). (Abstract 4554) J. J. Knox, C. H.
Barrios, T. Kim, T. Cosgriff, V. Srimuninnimit, K. B. Pittman, R. Sabbatini, S. Y.
Rha, T. W. Flaig, R. D. Page, J. T. Beck, F. Cheung, S. Yadav, P. M. Patel, L.
Geoffrois, E. Schiff, J. Niolat, N. Berkowitz, M. Voi, R. Motzer
Board 229
Phase II study of individualized sunitinib as first-line therapy for metastatic
renal cell cancer (mRCC). (Abstract 4555) G. A. Bjarnason, J. J. Knox, C. K.
Kollmannsberger, D. Soulieres, D. S. Ernst, C. M. Canil, E. Winquist, P. Zalewski,
S. J. Hotte, S. A. North, D. Y. Heng, R. J. Macfarlane, P. M. Venner, I. Tannock, A.
Kapoor, B. J. Eigl, A. R. Hansen, P. Czaykowski, B. Boyd, N. S. Basappa
274
Board 230
Molecular analysis of sarcomatoid renal cell carcinoma (sRCC). (Abstract
4556) T. H. Ho, S. Z. Millis, D. Bryant, Z. Gatalica, S. K. Reddy, M. L. Stanton, E. P.
Castle, R. W. Joseph, N. J. Vogelzang
Board 231
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma:
Final results of a phase III trial (901) and efficacy results of a 2nd line
tivozanib extension study (902). (Abstract 4557) T. Hutson, D. Nosov, P.
Tomczak, I. Bondarenko, O. N. Lipatov, C. N. Sternberg, M. N. Needle, T. Eisen
Board 232
Characteristics of metastatic renal cell carcinoma (mRCC) patients treated
with delayed targeted therapy: results from the International mRCC
Consortium (IMDC). (Abstract 4558) H. Li, T. K. Choueiri, C. Wells, N. Agarwal,
F. Donskov, J. Lee, R. J. Broom, T. Yuasa, B. I. Rini, S. K. Pal, L. Wood, D. S.
Ernst, C. K. Kollmannsberger, U. N. Vaishampayan, S. Y. Rha, G. A. Bjarnason,
J. J. Knox, S. Saleem, B. Beuselinck, D. Y. Heng
Board 233
A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients
(pts) with metastatic renal cell carcinoma (mRCC) progressing on prior
vascular endothelial growth factor (VEGF) therapies. (Abstract 4559) R. R.
McKay, L. Werner, L. C. Harshman, J. Bellmunt, C. Sweeney, J. E. Rosenberg, E.
VanAllen, M. K. Walsh, U. N. Vaishampayan, D. F. McDermott, T. K. Choueiri
Board 234
Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell
Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. (Abstract
4560) G. de Velasco, A. P. Fay, A. Culhane, A. A. Hakimi, M. H. Voss, N. M.
Tannir, P. Tamboli, L. J. Appleman, J. Bellmunt, K. Rathmell, L. K. Albiges, J.
Hsieh, D. Y. Heng, S. Signoretti, T. K. Choueiri
Board 235
Metastatic chromophobe renal cell carcinoma treated with target therapies: A
Renal Cross Chanel Group (RCCG) study. (Abstract 4561) E. Colomba, L.
Albiges, G. Le Teuff, T. Eisen, G. Stewart, K. Fife, A. Srinivasan Jr., J. M. Larkin, A.
Biondo, L. M. Pickering, H. J. Boyle, L. Derosa, C. Ralph, C. Saldana, J. Bernhard,
P. Barthelemy, F. Recine, B. Escudier, Renal Cross Chanel Group (RCCG)
Board 236
Clinical effect of TKI dose-escalation after disease progression in patients
with metastatic renal cell carcinoma. (Abstract 4562) M. C. Ornstein, P. Elson,
J. A. Garcia, T. D. Gilligan, L. S. Wood, K. D. Allman, A. Martin, B. I. Rini
Board 237
Clinical impact of loss of H3K36me3 expression in patients with clear cell
renal cell carcinoma. (Abstract 4563) A. Swaika, T. H. Ho, P. Kapur, D. Serie, J.
Eckel-Passow, J. Brugarolas, A. S. Parker, R. W. Joseph
Board 238
Precision medicine approach in kidney cancer: A pan renal cell carcinoma
(RCC) study across three cancer genome atlas (TCGA) datasets for clinically
relevant target identification. (Abstract 4564) B. Murray, L. Albiges, E. M. Van
Allen, A. Cherniack, A. P. Fay, M. Meyerson, T. K. Choueiri
Board 239
Extension of overall survival (OS) beyond objective responses (OR) in
patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high
dose interleukin-2 (HD IL-2). (Abstract 4565) D. D. Stenehjem, M. Toole, J.
Merriman, K. Parikh, S. Daignault, S. Scarlett, P. Esper, K. Skinner, A. Udager,
S. K. Tantravahi, A. M. Straubhar, A. M. Agarwal, J. Van Atta, K. F. Grossmann,
W. E. Samlowski, B. G. Redman, N. Agarwal, A. S. Alva
Board 240
Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine
kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor
treatment in patients with metastatic clear cell renal cell carcinoma
(mccRCC). (Abstract 4566) R. Nadal, A. Amin, D. M. Geynisman, M. H. Voss, M.
Weinstock, J. Doyle, Z. Zhang, A. Viudez, E. R. Plimack, D. F. McDermott, R.
Motzer, B. I. Rini, H. J. Hammers
Board 241
The DART Study: Part 1 results from the dalantercept plus axitinib dose
escalation and expansion cohorts in patients with advanced renal cell
carcinoma (RCC). (Abstract 4567) M. H. Voss, E. R. Plimack, B. I. Rini, M. B.
Atkins, R. Alter, R. S. Bhatt, J. T. Beck, M. Mutyaba, K. M. Pappas, D. Wilson, X.
Zhang, M. L. Sherman, S. S. Pandya
Board 242
Impact of salvage surgery and radiotherapy on overall survival in patients
with recurrent primary urethral cancer. (Abstract 4568) G. Gakis, T. M.
275
MONDAY
Morgan, S. Daneshmand, K. A. Keegan, R. H. Clayman, J. Mischinger, H. B. Zaid,
J. Hrbacek, B. Ali-El-Dein, S. Galland, K. Olugbade Jr., M. Rink, H. Fristche, M.
Burger, S. Chang, M. Babjuk, G. N. Thalmann, A. Stenzl, J. A. Efstathiou
MONDAY
Board 243
Multi-institutional validation of the predictive value of Ki-67 in patients with
high-grade urothelial carcinoma of the upper urinary tract. (Abstract 4569) L.
Krabbe, A. Bagrodia, A. Haddad, P. Kapur, D. Khalil, L. S. Hynan, C. G. Wood,
J. A. Karam, A. Z. Weizer, J. D. Raman, M. Remzi, N. Rioux-Leclercq, A. Haitel, M.
Roscigno, C. Bolenz, K. Bensalah, A. I. Sagalowsky, S. F. Shariat, Y. Lotan, V.
Margulis
Board 244a
Design of an open label, randomized, phase II study of paclitaxel and
panitumumab compared to paclitaxel alone in patients with relapsed or
refractory urothelial cancer. (Abstract TPS4570) A. Necchi, L. Mariani, P.
Giannatempo, D. Raggi, G. Calareso, F. Crippa, E. Togliardi, R. Salvioni, F. G. De
Braud
Board 244b
KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475)
versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic
urothelial cancer. (Abstract TPS4571) J. Bellmunt, G. Sonpavde, R. De Wit, T. K.
Choueiri, A. O. Siefker-Radtke, E. R. Plimack, N. M. Lewis, H. Brown, Y. Mai, C. K.
Gause, D. R. Kaufman, D. F. Bajorin
Board 245a
KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line
therapy for patients (pts) with unresectable or metastatic urothelial cancer
ineligible for cisplatin-based therapy. (Abstract TPS4572) D. F. Bajorin, E. R.
Plimack, A. O. Siefker-Radtke, T. K. Choueiri, R. De Wit, G. Sonpavde, A. Gipson,
H. Brown, Y. Mai, L. Pang, R. F. Perini, J. Bellmunt
Board 245b
A multicenter randomized phase II trial comparing nab-paclitaxel to
paclitaxel in patients with advanced urothelial cancer progressing on or after
a platinum containing regimen: NCIC Clinical Trials Group BL 12
(NCT02033993). (Abstract TPS4573) S. S. Sridhar, N. Blais, S. A. North, B. Tran,
K. N. Chi, J. W. Robinson, M. N. Reaume, G. Liu, G. T. McDonald, K. Ding, W. R.
Parulekar
Board 246a
Phase II randomised placebo controlled neoadjuvant chemotherapy study of
nintedanib with gemcitabine and cisplatin in locally advanced muscle
invasive bladder cancer. (Abstract TPS4574) S. A. Hussain, R. Jackson, A.
Shields, L. Dickinson, P. Cornford, R. J. Jones, J. F. Lester, J. D. Chester, A. J.
Birtle, T. Powles, S. J. Crabb, D. Mazhar, R. A. Huddart, A. Protheroe, F. Azam, N.
Vasudev, M. Butt, N. D. James
Board 246b
A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in
patients with urothelial carcinoma (UC) and inactivating alterations of
acetyltransferase genes. (Abstract TPS4575) N. M. Hahn, J. Picus, R. M.
Bambury, S. K. Pal, L. L. Hart, P. Grivas, M. I. Milowsky, A. S. Alva, G. Sonpavde,
A. Mortazavi, J. Bellmunt, E. A. Guancial, S. Gupta, R. C. Chao, M. A. Collier,
J. Christensen, I. Chen, J. E. Rosenberg
Board 247a
A phase I/II multi-center study of intravesical nanoparticle albumin-bound
rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive
bladder cancer. (Abstract TPS4576) J. M. McKiernan, D. Lascano, J. Ahn, R.
Ghandour, J. S. Pak, A. RoyChoudhury, S. Chang, G. J. DeCastro, N. Desai
Board 247b
The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427
(Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory
metastatic urothelial cancer. (Abstract TPS4577) T. K. Choueiri, N. M. Hahn,
A. S. Alva, R. C. Lauer, R. Dreicer, J. Picus, R. Pili, A. V. Balar, G. Sonpavde, J. H.
Hoffman-Censits, E. A. Guancial, R. Alter, M. M. Regan, C. Jacobs, P. S. Stewart,
S. K. Pal, J. E. Rosenberg
Board 248a
CheckMate 214: A phase III, randomized, open-label study of nivolumab
combined with ipilimumab versus sunitinib monotherapy in patients with
previously untreated metastatic renal cell carcinoma. (Abstract TPS4578)
H. J. Hammers, E. R. Plimack, C. Sternberg, D. F. McDermott, J. M. Larkin, A.
Ravaud, B. I. Rini, P. Sharma, P. Bhagavatheeswaran, P. Gagnier, R. Motzer
276
Board 248b
Randomized phase 2 study to assess the safety and efficacy of CRLX101 in
combination with bevacizumab in patients (pts.) with metastatic renal cell
carcinoma (RCC) versus standard of care (SOC). (Abstract TPS4579) M. H.
Voss, A. Coates, E. G. Garmey, N. B. Haas, T. Hutson, S. M. Keefe, R. Motzer, A.
Piscitelli, N. J. Vogelzang, R. A. Figlin
Board 249a
A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the
safety and efficacy of RX-0201 in combination with everolimus to treat
subjects with advanced renal cell carcinoma. (Abstract TPS4580) C. Peterson,
E. Benaim
Board 249b
A randomized, open label, multicenter phase 2 study to evaluate the efficacy
of sorafenib in patients (pts) with advanced Renal Cell Carcinoma (RCC) after
a radical resection of the metastases. (Abstract TPS4581) E. Verzoni, P.
Grassi, R. Montone, C. Maggi, F. Cognetti, M. Milella, A. Bearz, C. Ortega, F.
Morelli, V. E. Chiuri, A. Necchi, F. G. De Braud, G. Procopio
Board 250a
Patient identification and eligibility insights in the synchronous metastatic
RCC population: An update from the ongoing ADAPT* phase 3 study
experience. (Abstract TPS4582) R. A. Figlin, C. G. Wood
Board 250b
The DART Study: A phase 2 randomized double-blind study of dalantercept
plus axitinib versus placebo plus axitinib in advanced clear cell renal cell
carcinoma (RCC). (Abstract TPS4583) M. H. Voss, E. R. Plimack, B. I. Rini, M. B.
Atkins, R. Alter, R. S. Bhatt, J. T. Beck, M. Mutyaba, K. M. Pappas, D. Wilson, X.
Zhang, M. L. Sherman, S. S. Pandya
Board 251a
Phase II study of pazopanib and weekly paclitaxel in metastatic or locally
advanced squamous penile carcinoma patients previously treated with
cisplatin-based chemotherapy: PAZOPEN study. (Abstract TPS4584) M.
Climent, J. Puente, S. Vazquez-Estevez, M. J. Méndez-Vidal, E. GonzalezBillalabeitia, N. Laı́nez, J. P. Maroto Rey, J. Rodriguez-Moreno, X. Garcia del Muro
Board 251b
ATR-101 phase 1 clinical study for adrenocortical carcinoma. (Abstract
TPS4585) A. Naing, S. Fu, M. A. Habra, R. Chugh, E. Kebebew, J. Russell, D.
Welshans, M. Fassnacht, M. Kroiss, M. Goebeler, M. Ijzerman, M. R. Plaunt, P.
Mohideen, M. Phillips, D. C. Smith
Location: S Hall A
Abstracts 6512– 6523 will be discussed during the Health Services Research and Quality of
Care Poster Discussion Session. See page 299 for session information.
Board 69
Development of cost and quality composites for the 2012 ASCO Choosing
Wisely measures: Methods and evidence. (Abstract 6512) M. K. Simon, A.
Milstein, K. L. Kreizenbeck, C. R. Fedorenko, S. D. Ramsey
Board 70
Trends in antineoplastic receipt after Medicare payment reform: Implications
for future oncology payment design. (Abstract 6513) H. M. Parsons, S.
Schmidt, A. J. Davidoff, L. L. Tenner, B. A. Virnig
Board 71
A randomized controlled trial (RCT) to improve enrollment to cancer clinical
trials. (Abstract 6514) C. Parker, J. L. Millar, D. M. Dilts, M. Jefford, R. Wolfe,
R. D. Snyder
Board 72
Psychosocial outcomes of the electronic self-report assessment for cancer-II
randomized trial. (Abstract 6515) D. L. Berry, F. Hong, B. Halpenny
Board 73
Patient-reported care coordination and outcomes of colorectal cancer
surgery. (Abstract 6516) S. T. Hawley, S. E. Regenbogen, C. M. Veenstra, A. M.
Morris
277
MONDAY
MONDAY
Board 74
Family perspectives on aggressive cancer care near the end of life. (Abstract
6517) A. A. Wright, N. L. Keating, J. Ayanian, E. A. Chrischilles, K. L. Kahn, C.
Ritchie, C. Earle, M. B. Landrum
Board 75
Use of online communication and social media by newly diagnosed breast
cancer patients: Results from the iCanCare Study. (Abstract 6518) S. T.
Hawley, N. K. Janz, L. P. Wallner, S. J. Katz
Board 76
Email communication practices and preferences among patients and
providers in a large comprehensive cancer center. (Abstract 6519) N. Cook, A.
Dobriyal, M. Maganti, M. Sheinis, A. C. Wei, J. Ringash, M. K. Krzyzanowska
Board 77
Disease-specific hashtags for online communication about cancer care.
(Abstract 6520) M. S. Katz, A. Utengen, P. F. Anderson, M. A. Thompson, M.
Fisch, C. Johnston, D. J. Attai, L. Aase, R. S. Miller, T. Lee, D. S. Dizon
Board 78
Machine-learning prediction of cancer survival: A prospective study
examining the impact of combining clinical and genomic data. (Abstract
6521) D. M. Ashley, S. Gupta, T. Tran, L. Wei, P. K. Lorgelly, D. M. Thomas, S. B.
Fox, S. Venkatesh
Board 79
Predicting low accrual in the Clinical Trials Cooperative Group Program’s
phase II/III oncology trials. (Abstract 6522) C. S. Bennette, S. D. Ramsey, C. L.
McDermott, J. J. Carlson, A. Basu, D. L. Veenstra
Board 80
Colonoscopy versus less invasive approaches for colorectal cancer (CRC)
screening (Scr): A strategic perspective. (Abstract 6523) A. Barzi, H. Lenz, D. I.
Quinn, S. Sadeghi
Board 81
Developing a CAncer genomics Digital Educational Tool to assess the
knowledge and expectations of patients with advanced solid tumors
(CADET). (Abstract 6524) H. H. Loong, A. Spreafico, N. Cook, K. K. Chan, G. D.
Krishna, H. Chow, C. Yu, S. Kang, P. S. Blanchette, P. L. Bedard, A. R. Razak,
L. L. Siu
Board 82
Utilization of palliative chemotherapy for advanced bladder cancer: Patterns
of care in routine clinical practice. (Abstract 6525) A. G. Robinson, X. Wei,
W. J. Mackillop, C. M. Booth
Board 83
Is online patient information at NCI cancer centers too complex for broad
general readership? (Abstract 6526) S. Rosenberg, D. Francis, C. Hullett, Z. S.
Morris, J. Brower, M. Fisher, B. M. Anderson, M. F. Bassetti, R. J. Kimple
Board 84
A discrete choice experiment to examine the preferences of patients with
cancer and their willingness to pay for different types of health care
appointments. (Abstract 6527) S. Wong, R. Norman, T. L. Dunning, D. M.
Ashley, M. Khasraw, P. K. Lorgelly
Board 85
Impact of age on the associations between genomic testing in breast cancer
(BrCA) and chemotherapy (chemo) use and costs. (Abstract 6528) Y. Wong,
A. J. Epstein, N. Mitra, A. Vachani, S. Hin, L. Yang, A. Smith-McLallen, K.
Armstrong, P. W. Groeneveld
Board 86
The influence of hospital and surgeon factors on the prevalence of axillary
evaluation in ductal carcinoma in situ. (Abstract 6529) E. J. Coromilas, J. D.
Wright, Y. Huang, S. M. Feldman, A. I. Neugut, L. Chen, D. L. Hershman
Board 87
Improving veteran access to lung cancer care (IVaLuCancerCare): A quality
improvement project at the Louis Stokes Cleveland VA Medical Center
(LSVAMC). (Abstract 6530) R. Manochakian, J. Smith, S. Mervar, D. Fox, K.
Woods, M. Driscol, D. Whittlesey, A. Ludin, F. Jacono, B. Jesberger, N. Alvarado,
J. Robke, S. Berman, J. Dimick, S. Curry, M. Barnum, M. Vallette, A. Howard, J. A.
Bokar, L. M. Arfons
Board 88
Cancer pain management practices and their impact on quality of life for
Asian cancer patients. (Abstract 6531) Y. C. Kim, H. Moon, J. S. Ahn, M. M. P.
Calimag, T. C. Chao, K. Y. Ho, L. M. Tho, Z. J. Xia, and L. Ward
278
Board 89
State variation in Medicare Part D and choice of initial endocrine therapy for
breast cancer. (Abstract 6532) L. E. Pezzin, J. A. Charlson, E. McGinley, P.
Laud, J. M. Neuner, A. Nattinger
Board 90
Analysis of home care coordination activities in oncology: A mixed methods
study. (Abstract 6533) F. Yatim, G. Moutel, P. Cristofalo, M. Ferrua, M. Di Palma,
E. Minvielle
Board 91
Patients with advanced non-small cell lung cancer (NSCLC): Are research
biopsies a barrier to participation in clinical trials? (Abstract 6534) C. H. Lim,
M. Sung, N. Z. Nouriany, M. Sawczak, T. Paul, N. Perera-Low, R. Feld, G. Liu,
F. A. Shepherd, N. B. Leighl
Board 92
Validation of a clinical trial accrual predictive model. (Abstract 6535) W. R.
Tate, L. D. Cranmer III
Board 93
Emergency diagnosis of lung cancer: An international problem. (Abstract
6536) T. Newsom-Davis, R. Berardi, N. Cassidy, L. Coate, A. Figueiredo, G.
Gamerith, G. Giblin, M. Jakopović, C. Van Der Leest, D. Pouessel, M. Tiseo, A.
Toffart, C. Hughes
Board 94
Healthcare resource utilization and cost considerations in patients with soft
tissue sarcoma treated with chemotherapy. (Abstract 6537) C. M. Kozma, T. L.
Slaton, R. S. McKenzie
Board 95
Disparity by insurance status and race in receipt of aggressive and advanced
treatments for high risk prostate cancer/PCa. (Abstract 6538) B. R. Baker, R.
Basak, J. J. Mohiuddin, R. C. Chen
Board 96
Impact of health insurance transitions on cancer survivors and those with no
cancer history. (Abstract 6539) K. S. Virgo, C. Lin, A. J. Davidoff, HEROIC
workgroup
Board 97
Comprehensive genomic profiling of rare tumors in a dedicated community
clinic. (Abstract 6540) W. J. Edenfield
Board 98
Precision oncology: molecular testing and targeted treatment beyond
indication. (Abstract 6541) J. J. Carlson, B. Ely, R. N. Hansen, G. H. Lyman
Board 99
Social-ecological perspectives on breast cancer care seeking patterns in
Karnataka, India. (Abstract 6542) A. S. Shet, S. Krishnan, S. M. Travasso, G.
Raju, S. Meleth, S. Kumar
Board 100
Medical Oncologists’ and Surgeons’ approaches to communication of breast
cancer recurrence risk. (Abstract 6543) A. Sabolch, B. Zikmund-Fisher, N. K.
Janz, S. T. Hawley, K. A. Griffith, R. Jagsi
Board 101
A systematic approach to smoking cessation in Ontario’s Regional Cancer
Programs. (Abstract 6544) W. K. Evans, R. Presutti, M. Haque, R. Truscott, M.
Bassier-Paltoo, A. Peter, L. Rabeneck
Board 102
The impact of chemotherapy on hospitalizations and emergency care in older
adults with advanced cancer. (Abstract 6545) E. B. Elkin, C. O’Neill, C. L.
Atoria, E. M. O’Reilly, P. Bach
Board 103
Wealth, health expenditure, and cancer: A national perspective. (Abstract
6546) J. Chahoud, A. G. Rieber, A. Semaan
Board 104
How TNM stage affects surveillance intensity after treatment for breast
cancer. (Abstract 6547) D. Wu, E. S. Allam, K. S. Virgo, L. Chen, J. A.
Margenthaler, F. E. Johnson
Board 105
Racial differences in 20-year cardiovascular outcomes among childhood and
young adult cancer survivors. (Abstract 6548) A. M. Berkman, L. Jones, A.
Crocker, A. M. Brewster, S. G. Lakoski
Board 106
Factors associated with the large disparities in BRCA testing among high
risk Black women. (Abstract 6549) T. Pal, D. Cragun, D. Bonner, L. P.
Camperlengo, E. Robinson, S. T. Vadaparampil
279
MONDAY
MONDAY
Board 107
Perceptions of clinical trial participation in African American cancer patients.
(Abstract 6550) D. M. Geynisman, L. Fleisher, S. B. Bass, A. Washington, A.
Nicholson, L. Maurer
Board 108
Racial disparities in attrition among oncology clinical trial participants.
(Abstract 6551) L. Chen, B. J. Eigl, J. Grant, W. Y. Cheung
Board 109
Evaluation of hematology/oncology patient and physician expectations for
integrative oncology in an ethnically diverse population. (Abstract 6552)
D. M. Hansra, J. Ramdial, F. Farooq, J. Antunez de Mayolo, E. Ahn, A. Mehta
Board 110
Genomic landscape of primary breast cancer in black vs. white women and
association with tumor recurrence. (Abstract 6553) T. Keenan, B. Moy, E. A.
Mroz, K. Ross, A. Niemierko, J. W. Rocco, S. J. Isakoff, L. W. Ellisen, A. Bardia
Board 111
Treatment and characteristics of stage II colon cancer patients residing in
CDC Specialized Registry areas. (Abstract 6554) M. E. O’Neil, C. Eheman, F.
Babcock, C. Morris, V. Chen, T. Styles
Board 112
The impact of the National Breast and Cervical Cancer Early Detection
Program (NBCCEDP) in reducing outcome disparities based on race.
(Abstract 6555) M. A. Fiala, T. M. Wildes
Board 113
Religious beliefs and stage at diagnosis in a biracial sample of newly
diagnosed colon cancer patients. (Abstract 6556) B. N. Polite, T. M. Cipriano,
F. J. Hlubocky, P. Jean-Pierre, K. Brewer, Y. Cheng, G. H. Rauscher, G. Fitchett
Board 114
Impact of racial residential segregation (RRS) on stage at diagnosis and
survival after diffuse large B-cell lymphoma (DLBCL). (Abstract 6557) L. J.
Nastoupil, C. Flowers, D. Lichtensztajn, S. L. Gomez, J. Williams, C. A. Clarke,
T. H. Keegan
Board 115
Effect of demographic factors and histology on stage IV non-small cell lung
cancer (NSCLC): A National Cancer Database review. (Abstract 6558) B.
Slostad, J. Gries, A. Ganti, P. T. Silberstein
Board 116
Patient navigation as a model to increase minority participation in cancer
clinical trials. (Abstract 6559) M. Fouad, A. Acemgil, S. Bae, A. Forero, M.
Martin, G. R. Oates, E. E. Partridge, S. M. Vickers
Board 117
Endocrine therapy adherence, side effects, and risk perception among
racially diverse breast cancer patients. (Abstract 6560) S. B. Wheeler, C. C.
Murphy, K. E. Reeder-Hayes, J. Earp, L. A. Carey, A. Olshan
Board 118
Disparities in hospice use among patients with cancer in the Deep South.
(Abstract 6561) B. E. Jackson, G. B. Rocque, E. A. Kvale, K. Kenzik, A. Acemgil,
R. A. Taylor, M. Martin, W. Demark-Wahnefried, N. Lisovicz, Y. Li, K. Meneses, M.
Fouad, E. Partridge, M. Pisu
Board 119
Utility of surveillance following curative intent resection of metastases.
(Abstract 6562) R. M. Lee-Ying, D. J. Renouf, H. J. Lim, H. F. Kennecke, S. Gill,
C. Speers, W. Y. Cheung
Board 120
Trends in use of PET imaging in surveillance of lung and colorectal cancer.
(Abstract 6563) C. M. Veenstra, A. Vachani, A. J. Epstein, C. A. Ciunci, H. M.
Zafar, E. C. Paulson
Board 121
Young adult cancer survivors’ expectations of physicians for follow-up and
general health care: Implications for health services delivery. (Abstract 6564)
P. Camateros, Y. Wang, W. Y. Cheung
Board 122
Effect of improving guideline-based prophylactic growth factor (pGCSF) use
with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small
cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer
Institute (TCI) Quality Improvement (QI) Project. (Abstract 6565) L. M.
Goodman, M. Moeller, C. K. Dalby, A. Azzouqa, A. E. Guthrie, M. A. Earl, V.
Velcheti, M. A. Shapiro, N. A. Pennell, J. Stevenson
Board 123
Utility of pre-operative PET/CT staging in sentinel lymph node-positive
melanoma. (Abstract 6566) B. Scheier, C. D. Lao, K. M. Kidwell, B. G. Redman
280
Board 124
Developing oncology goals and objectives for medical students: A national
Delphi process. (Abstract 6567) V. C. Tam, P. A. Gfeller-Ingledew, S. R. Berry,
S. Verma, M. E. Giuliani
Board 125
Quality of life EQ-5D results from the AETHERA trial: A phase III study of
brentuximab vedotin consolidation following autologous stem cell transplant
for HL. (Abstract 6568) S. D. Ramsey, A. Nademanee, T. Masszi, J. Holowiecki,
M. Abidi, A. I. Chen, P. J. Stiff, S. Viviani, Y. Zhu, V. Bonthapally, E. Thomas, N. N.
Hunder, J. A. Walewski
Board 126
Evaluation of a pharmacist-driven oral chemotherapy adherence program.
(Abstract 6569) I. C. Zhao, J. Lai, B. Seiki, M. Wilson, L. A. Brennan, T. Li, T. Wun
Board 128
Impact of enhanced reimbursement on provider participation a cancer care
quality program and adherence to cancer treatment pathways in a
commercial health plan. (Abstract 6571) J. Malin, A. NGUYEN, S. E. Ban, V.
Willey, R. Quimbo, J. Barron, P. Inches, B. Spevak, M. Fisch
Board 129
Avoiding overtreatment in rectal cancer when the benefit of adjuvant
chemotherapy is unclear. (Abstract 6572) J. M. Loree, H. F. Kennecke, H. J.
Lim, D. J. Renouf, M. M. Vickers, C. Speers, W. Y. Cheung
Board 130
Can oncology readmissions be reduced? The Cleveland Clinic experience.
(Abstract 6573) A. J. Montero, J. Stevenson, A. E. Guthrie, C. Best, L. M.
Goodman, A. Parala, R. Lagman, B. J. Bolwell, M. E. Kalaycio, A. A. Khorana
Board 131
How well do surrogate endpoints and overall survival endpoints in clinical
trials predict real-world survival? (Abstract 6574) J. Shafrin, R. Brookmeyer, D.
Peneva, J. Park, J. Zhang, R. A. Figlin, D. N. Lakdawalla
Board 132
Time to treatment (TTT) and breast cancer survival in the United States.
(Abstract 6575) R. J. Bleicher, K. Ruth, E. R. Sigurdson, J. R. Beck, E. A. Ross, Y.
Wong, S. A. Patel, M. Boraas, E. I. Chang, N. S. Topham, B. L. Egleston
Board 133
Are conflict of interest (COI) slides displayed long enough to comprehend?
(Abstract 6576) J. A. Talcott, A. D’Silva, J. Shulman, D. Lucido
Board 134
An analysis of corrective action plans to address slow accruing NCI-held IND
early phase trials. (Abstract 6577) H. A. Massett, E. Godwin, L. Rubinstein, P.
Ivy, K. DiPiazza, J. Zwiebel, S. Friedman, A. Denicoff, G. E. Mishkin, J. Abrams
Board 135
Prevalence and prognostic impact of prior cancer in locally advanced lung
cancer. (Abstract 6578) D. E. Gerber, A. L. Laccetti, L. Xuan, E. Halm, S. Pruitt
Board 136
Outcomes and predictors of life sustaining treatments in patients with
metastatic cancer. (Abstract 6579) K. Loh, M. Shieh, A. J. Kansagra, P.
Lindenauer, P. Pekow, M. Stefan, T. Lagu
Board 137
Determinants of early mortality in 37,568 colon cancer patients participating
in 25 clinical trials of the ACCENT database. (Abstract 6580) W. Y. Cheung,
L. A. Renfro, G. Yothers, R. G. Gray, D. G. Haller, C. Twelves, T. Andre, E. Van
Cutsem, L. Saltz, A. Grothey, R. Labianca, S. R. Alberts, H. Schmoll, K. Guthrie, A.
De Gramont, C. J. Allegra, D. J. Sargent, ACCENT Collaborative Group
Board 138
Hospital treatment patterns and survival for metastatic colorectal cancer.
(Abstract 6581) R. W. Krell, S. E. Regenbogen, M. Banerjee, S. L. Wong
Board 139
Association between Oncologic Drugs Advisory Committee (ODAC)
members’ financial conflicts of interest (FCOIs) and recommendations for
drug approval by the U.S. Food and Drug Administration (FDA). (Abstract
6582) A. Tibau Martorell, A. Ocana, B. Seruga, A. J. Templeton, A. Barnadas, E.
Amir
Board 140
Frequency and predictors of hospitalization during chemotherapy: a
systematic review. (Abstract 6583) R. M. Prince, M. K. Krzyzanowska, E. G.
Atenafu
Board 141
Choosing wisely: Treatment recommendations from 36 Michigan Oncology
Clinical Treatment Pathways practices. (Abstract 6584) A. H. Seung, L. M.
Hamel, P. J. Stella, J. F. Klamerus, D. W. Blayney
281
MONDAY
MONDAY
Board 142
Prospective clinical study of precision oncology in solid tumors. (Abstract
6585) D. Sohal, B. I. Rini, A. A. Khorana, R. Dreicer, J. Abraham, G. Procop, Y.
Saunthararajah, N. A. Pennell, J. Stevenson, R. J. Pelley, B. N. Estfan, D. R.
Shepard, P. Funchain, D. J. Adelstein, B. J. Bolwell
Board 143
Breast cancer progression and workplace productivity. (Abstract 6586) W.
Yin, R. Horblyuk, J. J. Perkins, S. Sison, G. Smith, J. Thornton Snider, Y. Wu, T. J.
Philipson
Board 144
Uncontrolled chronic conditions prior to cancer diagnosis in older adults as
a predictor of unplanned hospitalizations during cancer care: A Medicare
claims analysis. (Abstract 6587) N. A. VanderWalde, T. Li, C. Kaplan, E. Kaplan,
L. Stevens, J. Webster, B. L. McAneny, T. Waters
Board 145
Potentially inappropriate medication use in elderly breast cancer patients.
(Abstract 6588) M. S. Karuturi, H. M. Holmes, X. Lei, M. L. Johnson, S. H.
Giordano
Board 146
Creating a national collaborative strategy to enhance trial accrual in NCI’s
National Clinical Trials Network (NCTN) in the era of precision medicine.
(Abstract 6589) A. Denicoff, H. A. Massett, G. E. Mishkin, R. Bangs, J. Berlin,
M. B. Bischoff, F. DeSanto, A. Duli, L. E. Horvath, M. S. Katz, R. Lambersky, B. S.
Mann, W. J. McCaskill-Stevens, N. Seibel, S. H. Stine, W. Williams, M. M. Mooney,
J. S. Abrams
Board 147
Does paid sick leave affect the unmeasured costs of colorectal cancer
treatment? (Abstract 6590) C. M. Veenstra, S. E. Regenbogen, S. T. Hawley,
J. J. Griggs, A. M. Morris
Board 148
Impact of maternal death from female cancers on child mortality. (Abstract
6591) R. Mailhot Vega, O. Balogun, S. Formenti
Board 149
Nationwide utilization of cardiac imaging in patients undergoing cardiotoxic
chemotherapy. (Abstract 6592) M. A. Dinan, Y. Li, S. D. Reed, W. Y. Cheung
Board 150
A prospective evaluation of radiotherapy (RT) related skin reactions in a
multi-racial/ethnic population of women with newly diagnosed breast cancer
(BC). (Abstract 6593) J. J. Urbanic, D. Case, L. Baez-Diaz, D. R. Brown, J.
Strasser, G. Enevold, M. Naughton, K. E. Weaver, K. Baglan, D. Bryant, C.
Langefeld, T. E. Lad, L. Lee, G. Rine, A. E. Curtis, C. D. Koprowski, W. V.
Tomlinson, G. J. Lesser, E. G. Shaw, J. J. Hu
Board 151
PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian
rectal cancer consortium. (Abstract 6594) D. Bosse, J. Mercer, S. Raissouni, K.
Dennis, R. A. Goodwin, M. Jiang, E. D. Powell, A. Kumar, R. M. Lee-Ying, J. A.
Price Hiller, D. Y. Heng, P. A. Tang, A. MacLean, W. Y. Cheung, M. M. Vickers
Board 152
Conflicts of interest in pharmaceutical sponsored economic studies of
breast cancer therapies: An empirical study. (Abstract 6595) J. D. Lane, M. W.
Friedberg, C. L. Bennett
Board 153
Cancer mortality and published research output: Is there any relationship?
(Abstract 6596) F. Patafio, S. C. Brooks, X. Wei, Y. Peng, J. Biagi, C. M. Booth
Board 154
Trends in the costs and utilization of targeted cancer therapies for the
privately insured non-elderly: 2001–2011. (Abstract 6597) F. Smieliauskas,
Y. T. Shih, D. M. Geynisman, R. J. Kelly, T. J. Smith
Board 155
Target wise and pound foolish: A simple technique to evaluate the trade-off
between economic burden and clinical benefit of monoclonal antibodies.
(Abstract 6598) M. C. Brennan, T. J. Brown, K. M. Koller, M. K. Vasekar, P. H.
Cygan, J. M. Sivik, M. J. Glantz
Board 156
Serum tumor marker utilization in patients with advanced solid tumors.
(Abstract 6599) M. K. Accordino, J. D. Wright, S. Vasan, A. I. Neugut, A. I. Tergas,
D. L. Hershman
Board 157
Assessing financial toxicity in insured patients with multiple myeloma.
(Abstract 6600) S. F. Huntington, B. M. Weiss, D. T. Vogl, A. D. Cohen, A. L.
Garfall, J. A. Doshi, E. A. Stadtmauer
282
Board 158
Impact of site of service on chemotherapy costs: Influence of geographic
location and diagnosis. (Abstract 6601) M. A. Kolodziej, B. Cullum, K. Hastings,
M. Sipala, A. Supraner, C. Dubois, H. Paz, I. Klein
Board 159
Quantifying the relative value of drug therapy options in HER2ⴙ, ER-/PRbreast cancer. (Abstract 6602) J. Whang, A. R. Steinkellner, J. M. Borne, E. N.
Piana, W. Wong, R. E. Aubert, N. C. Selby
Board 160
Real-world treatment patterns, healthcare resource utilization (HRU), and
costs of initial line of therapy (LOT1) in multiple myeloma (MM). (Abstract
6603) S. D. Byfield, T. Bancroft, E. Ma, V. Bonthapally, A. H. Teitelbaum
Board 161
H-TArget model: Early technology assessment for ext generation sequencing
in oncology. (Abstract 6604) V. Retel, M. A. Joore, B. Ramaekers, M. M. van den
Heuvel, M. S. Van Der Heijden, W. van Harten
Board 162
Economic evaluation for the United States (US) of gemcitabine (GEM),
nab-paclitaxel plus gemcitabine (NAB-PⴙGEM), and FOLFIRINOX as first-line
treatment for metastatic pancreatic cancer (MPC). (Abstract 6605) M.
Gharaibeh, A. McBride, J. Bootman, L. D. Cranmer III, I. Abraham
Board 163
Price migration of oncology drugs launched in the United States between
2010 and 2015. (Abstract 6606) A. Bastian, J. Li, A. Asabere
Board 164
Patient-reported symptoms and Canadian Health Utility scores in esophageal
cancer patients. (Abstract 6607) M. Doherty, Y. Leung, H. Naik, D. Patel, L. Eng,
Q. Q. Kong, C. Brown, O. Espin-Garcia, A. Vennettilli, D. J. Renouf, O. O. Faluyi,
J. J. Knox, H. Mackay, R. Wong, D. Cella, G. E. Darling, D. Howell, N. Mittmann,
W. Xu, G. Liu
Board 165
Financial hardship associated with cancer in the United States. (Abstract
6608) K. R. Yabroff, E. Dowling, G. Guy, M. Banegas, T. S. McNeel, A. J. Davidoff,
N. Chawla, D. B. Hartigan, X. Han, E. E. Kent, C. Li, K. S. Virgo, J. Rodriguez, J. de
Moor, Z. Zheng, A. Jemal, D. U. Ekwueme
Board 166
Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance
(M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).
(Abstract 6609) M. A. Shapiro, J. Stevenson, E. Van Wagoner, K. Glass, C. W.
Cummings, N. A. Pennell, P. C. Ma, V. Velcheti, B. R. Bastos, B. J. Bolwell, A.
Haddad
Board 167
Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive
advanced breast cancer (ABC). (Abstract 6610) Q. A. Le, Y. Bae
Board 168
A network meta-analysis-based cost-effectiveness analysis of systematic
therapies in advanced pancreatic cancer. (Abstract 6611) K. K. Chan, Y. Ko, K.
Shah, K. Lien, H. Lam, D. Coyle
Board 169
Costs and resource utilization associated with skeletal related events in
Medicare patients with prostate cancer metastatic to bones. (Abstract 6612)
J. A. McDougall, B. Goulart, A. Bansal, S. D. Sullivan, J. S. McCune, A. Karnopp,
C. R. Fedorenko, A. Valdarrama, S. D. Ramsey
Board 170
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
(Abstract 6613) D. A. Goldstein, B. B. Ahmad, Q. Chen, T. Ayer, D. H. Howard, J.
Lipscomb, B. F. El-Rayes, C. Flowers
Board 171
Stage specific health utility index scores of Canadian cancer patients.
(Abstract 6614) H. Naik, D. Howell, J. Su, X. Qiu, C. Brown, A. Vennettilli, M. Irwin,
V. Pat, H. Solomon, T. Wang, H. Hon, L. Eng, M. Mahler, H. Thai, V. Ho, W. Xu, S.
Seung, N. Mittmann, G. Liu
Board 172
Disclosure of industry payments to oncologists: Early open payments data.
(Abstract 6615) D. C. Marshall, M. E. Jackson, J. A. Hattangadi
Board 173
Improving the value of PSA prostate cancer screening with “smarter”
strategies and increased use of active surveillance. (Abstract 6616) J. A.
Roth, R. Gulati, J. L. Gore, M. R. Cooperberg, R. D. Etzioni
283
MONDAY
Board 174
Hepatitis B virus screening before adjuvant chemotherapy in patients with
early stage breast cancer: A cost-effectiveness analysis. (Abstract 6617) W.
Wong, L. K. Hicks, H. Tu, M. Krahn, K. I. Pritchard, J. J. Feld, K. K. Chan
Board 175
Grading financial toxicity based upon its impact on health-related quality of
life (HRQol). (Abstract 6618) J. A. De Souza, K. Wroblewski, B. J. Yap, J.
O’Connor, B. Brockstein, M. T. Pho, M. J. Ratain, C. Daugherty, D. Cella
Board 176
Medical expenditures and productivity loss among colorectal, breast, and
prostate cancer survivors in the US. (Abstract 6619) Z. Zheng, A. Jemal, G.
Guy, X. Han, M. Banegas, C. Li, D. U. Ekwueme, K. R. Yabroff
Board 177
Contribution of cancer care to total spending among high-cost Medicare
beneficiaries. (Abstract 6620) M. Kim, B. M. Alexander, L. Burke, A. Jha
Board 178
A framework to assess the cost effectiveness of predictive biomarkers in
oncology: Test Incremental Cost Effectiveness Ratio (TICER). (Abstract 6621)
A. Safonov, W. Shi, J. Platt, B. Aktas, T. Kurita, L. Pusztai, C. Hatzis
Board 179
Cost-sharing and financial burden for Medicare patients with newly
diagnosed cancer. (Abstract 6622) A. Narang, L. Nicholas
Board 180
Out-of-pocket cost trends for Medicare patients with newly diagnosed
cancer. (Abstract 6623) A. Narang, L. Nicholas
Board 181a
Patients’ competence in oral cancer therapies. (Abstract TPS6624) C. Riese,
A. Beylich, M. Welslau, J. Benser, U. Borges Jr., W. Baumann
Board 181b
Health and economic outcomes of two different follow up strategies in
effectively cured advanced head and neck cancer patients. (Abstract
TPS6625) L. F. Licitra, F. Favales, E. Sesenna, G. Spriano, M. Ansarin, M.
Benazzo, P. Nicolai, R. Corvò, C. Grandi, G. Grando, M. Squadrelli, C. Marchetti,
F. Ionna, C. Simon, A. Richetti, L. Presutti, M. Meregaglia, L. Mariani, C. Rognoni,
P. Bossi
Location: S Hall A
Abstracts 9009 –9020 will be discussed during the Melanoma/Skin Cancers Poster Discussion
MONDAY
Board 252
Safety and activity of pembrolizumab in melanoma patients with untreated
brain metastases. (Abstract 9009) H. M. Kluger, S. B. Goldberg, M. Sznol, J.
Tsiouris, A. Vortmeyer, L. Jilaveanu, A. L. Ralabate, A. L. Rivera, M. M. Burke,
U. P. Hegbe, J. V. Cohen, X. Yao, S. Speaker, M. Madura, E. Knapp-Perry, A.
Mahajan, V. Chiang
Board 253
The use of pembrolizumab for the treatment of metastatic uveal melanoma.
(Abstract 9010) L. A. Kottschade, R. R. McWilliams, S. Markovic, M. S. Block, J.
Villasboas Bisneto, A. Q. Pham, R. S. Dronca
Board 254
Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic
melanoma. (Abstract 9011) Z. Eroglu, D. W. Kim, D. B. Johnson, A. P. Algazi,
R. R. Munhoz, E. Liniker, B. Kong, N. Khurana, B. Chmielowski, J. A. Sosman,
R. A. Scolyer, M. S. Carlino, M. A. Postow, W. Hwu, G. V. Long, A. Ribas
Board 255
Deep profiling of tumor immune microenvironment (TME) with fluorescence
activated cell sorting (FACS) in advanced melanoma. (Abstract 9012) K. Loo,
K. K. Tsai, M. Rosenblum, N. Khurana, J. Hwang, R. Sanchez, M. Broz, M.
Krummel, P. Tumeh, A. P. Algazi, A. Daud
Board 256
Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in
metastatic melanoma (MM). (Abstract 9013) R. S. Dronca, S. Markovic, L. A.
Kottschade, R. R. McWilliams, M. S. Block, W. K. Nevala, M. A. Thompson, H.
Dong
284
Board 257
Effect of melanoma intrinsic ␤-catenin signaling on immune exclusion and
resistance to immunotherapies. (Abstract 9014) S. Spranger, Y. Zha, T.
Gajewski
Board 258
Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from
plasma as a diagnostic and therapeutic biomarker in pts with BRAF V600
mutant melanoma. (Abstract 9015) M. Schreuer, G. Meersseman, Y. Jansen, T.
Seremet, I. Chevolet, A. Bott, S. Wilgenhof, G. Maertens, B. Neyns
Board 259
Circulating melanoma cells and recurrence in stage III melanoma patients.
(Abstract 9016) A. Lucci, C. S. Hall, M. Karhade, B. A. Laubacher, J. B. Bauldry,
R. E. Royal, J. Upshaw, C. L. Roland, M. I. Ross
Board 260
Plasma-based monitoring of BRAF mutations during therapy for malignant
melanoma (MM) using combined exosomal RNA and cell-free DNA analysis.
(Abstract 9017) R. J. Sullivan, V. J. O’Neill, K. Brinkmann, D. Enderle, T. Koestler,
A. Spiel, J. Emenegger, M. Noerholm, J. Skog, C. Berking, K. Flaherty
Board 261
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma
(MEL): A pooled analysis. (Abstract 9018) J. S. Weber, S. J. Antonia, S. L.
Topalian, D. Schadendorf, J. M. Larkin, M. Sznol, H. Y. Liu, I. Waxman, C. Robert
Board 262
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune
disorders. (Abstract 9019) D. B. Johnson, N. I. Khushalani, I. Puzanov, T.
Mudigonda, H. Kaufman, J. A. Sosman, J. M. Mehnert, J. Clark
Board 263
Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM)
with cobimetinib (COBI) in BRAF-mutant melanoma. (Abstract 9020) A. C.
Pavlick, A. Ribas, R. Gonzalez, O. Hamid, T. Gajewski, A. Daud, I. Puzanov, J. J.
Hsu, N. W. Choong, G. A. McArthur
Board 264
Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma
receiving vemurafenib (V) and cobimetinib (C). (Abstract 9021) B. Dréno, K.
Bartley, P. A. Ascierto, V. Atkinson, G. Liszkay, M. Maio, M. Mandalà, L. V.
Demidov, D. Stroyakovskiy, L. Thomas, L. De La Cruz-Merino, C. Dutriaux, C.
Garbe, I. Chang, S. P. Hack, J. M. Larkin, G. A. McArthur, A. Ribas
Board 265
Determination of locally advanced basal cell carcinoma (BCC) in the first 285
patients enrolled in the RegiSONIC disease registry study. (Abstract 9022)
S. S. Yoo, J. Y. Tang, G. S. Rogers, T. Olencki, M. E. Lacouture, R. R.
Kudchadkar, J. Guillen, Y. Mun, K. L. Dawson, A. Sekulic
Board 266
The RegiSONIC disease registry: Preliminary effectiveness and safety in the
first 66 newly diagnosed locally advanced basal cell carcinoma (BCC)
patients treated with vismodegib. (Abstract 9023) M. E. Lacouture, J. Y. Tang,
G. S. Rogers, T. Olencki, R. R. Kudchadkar, S. S. Yoo, J. Guillen, Y. Mun, K. L.
Dawson, A. Sekulic
Board 267
Impact of treatment breaks on vismodegib patient outcomes: Exploratory
analysis of the STEVIE study. (Abstract 9024) R. Dummer, N. Basset-Seguin, J.
Hansson, J. Grob, R. Kunstfeld, B. Dréno, L. Mortier, P. A. Ascierto, L. F. Licitra, C.
Dutriaux, T. Jouary, N. Meyer, B. Guillot, K. Fife, D. S. Ernst, S. Williams, A. G.
Fittipaldo, I. Xynos, A. Hauschild
Board 268
De novo versus nevus-associated melanomas: Differences in associations
with prognostic indicators and survival. (Abstract 9025) R. M. Cymerman, K.
Wang, E. C. Murzaku, L. A. Penn, I. Osman, Y. Shao, D. Polsky
Board 269
PD1/PDL-1 and VEGF expression in lymph node microenvironment and
relation with tumor burden and survival in cutaneous melanomas. (Abstract
9026) V. L. Vazquez, C. Viana, C. Scapulatempo, S. V. Serrano, C. Alessi
Board 270
Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with
treatment-naïve advanced melanoma (MEL): Results of a phase III study
(CheckMate 066). (Abstract 9027) G. V. Long, V. Atkinson, P. A. Ascierto, C.
Robert, J. C. Hassel, P. Rutkowski, K. J. Savage, F. Taylor, C. Coon, I. Gilloteau,
H. Dastani, I. Waxman, A. P. Abernethy
285
MONDAY
Nivolumab in resected and unresectable melanoma: Immune-related adverse
events and association with survival outcomes. (Abstract 9028) M. L.
Freeman-Keller, J. S. Weber
Board 272
Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI
alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced
melanoma (MEL): Results of a phase II study (CheckMate 069). (Abstract
9029) A. P. Abernethy, M. A. Postow, J. A. Chesney, K. F. Grossmann, F. Taylor,
C. Coon, I. Gilloteau, H. Dastani, P. Gagnier, C. Robert
Board 273
Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21)
oncolytic virus immunotherapy in patients with advanced melanoma.
(Abstract 9030) R. I. Andtbacka, B. D. Curti, H. Kaufman, G. A. Daniels, J. J.
Nemunaitis, L. E. Spitler, S. Hallmeyer, J. Lutzky, S. M. Schultz, E. D. Whitman, K.
Zhou, R. Karpathy, J. I. Weisberg, M. Grose, D. Shafren
Board 274
Clinical characteristics predictive of response to pembrolizumab in
advanced melanoma. (Abstract 9031) K. K. Tsai, K. Loo, N. Khurana, A. P.
Algazi, J. Hwang, R. Sanchez, M. Krummel, M. Rosenblum, P. Tumeh, A. Daud
Board 275
A single-arm, open-label, phase II study to evaluate the safety of vemurafenib
(VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic
melanoma (MM). (Abstract 9032) A. Amin, D. H. Lawson, A. K. Salama, H. B.
Koon, T. H. Guthrie, S. S. Thomas, S. O’Day, M. F. Shaheen, B. Zhang, S. Francis,
F. S. Hodi
Board 276
Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR)
in BRAF-mutated melanoma patients (pts) treated in the coBRIM study.
(Abstract 9033) L. De La Cruz-Merino, L. Di Guardo, J. Grob, A. Venosa, J. M.
Larkin, G. A. McArthur, A. Ribas, S. Eng, J. J. Hsu, G. Barteselli, N. W. Choong, B.
Dréno
Board 277
Prognostic relevance of baseline neutrophils and derived neutrophil to
lymphocyte ratio for ipilimumab-treated advanced melanoma patients.
(Abstract 9034) P. Ferrucci, D. Giannarelli, S. Gandini, E. Cocorocchio, M. Del
Vecchio, V. Picasso, J. Pigozzo, A. Di Giacomo, E. Simeone, V. Chiarion-Sileni, P.
Queirolo, M. Maio, P. A. Ascierto, C. Martinoli
Board 278
An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells
in vivo, in fully resected melanoma patients. (Abstract 9035) P. M. Patel, C.
Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, D. Hannaman, M. Cunnell, R.
Metheringham, V. Brentville, I. Daniels, L. Machado, L. G. Durrant
Board 279
Updated overall survival (OS) results for BRF113220, a phase I–II study of
dabrafenib alone versus combined dabrafenib and trametinib in patients with
BRAF V600 metastatic melanoma (MM). (Abstract 9036) A. Daud, J. S. Weber,
J. A. Sosman, K. Kim, R. Gonzalez, O. Hamid, J. R. Infante, J. S. Cebon, L. M.
Schuchter, G. V. Long, A. P. Algazi, R. R. Kudchadkar, I. Puzanov, D. P.
Lawrence, R. Kefford, A. S. Kline, H. L. Del Buono, P. Sun, D. O. McDowell, K.
Flaherty
Board 280
Prognostic value of BRAFV600 mutations in American Joint Committee on
Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort
prospective cohort. (Abstract 9037) P. Saiag, P. Aegerter, C. Lebbe, P.
Wolkenstein, N. Dupin, V. Descamps, S. Aractingi, M. Battistella, Z. HeliasRodzewicz, S. Mourah, J. Emile, MelanCohort Group
Board 281
XPC, XPF, TP53 and GSTP1 polymorphisms in prognosis of cutaneous
melanoma patients. (Abstract 9038) C. S. Lima, G. V. Gomez, C. Oliveira, G. J.
Lourenco, J. A. Rinck Jr., A. M. Moraes
Board 282
A global genomic and small molecule inhibitor interrogation of KIT mutant
melanoma to reveal underlying biology and novel molecular targets.
(Abstract 9039) J. Oba, W. Wang, A. K. Eterovic, C. C. Stephan, J. Roszik, C. R.
Kale, C. L. Haymaker, M. Routbort, L. E. Haydu, C. Bernatchez, M. A. Davies, A. J.
Lazar, E. A. Grimm, S. E. Woodman
Board 283
Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of
pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory
MONDAY
Board 271
286
Board 284
Melanoma-specific MHC-II expression to predict response to ␣-PD-1 therapy.
(Abstract 9041) J. M. Balko, D. B. Johnson, M. V. Estrada, V. Sanchez, M.
Sanders, M. C. Kelley, C. M. Lovly, J. A. Sosman
Board 285
Multiplatform biomarker analysis on non-sun exposed mucosal melanoma.
(Abstract 9042) A. H. Bryce, D. Arguello, S. Z. Millis, R. Bender, S. K. Reddy, Z.
Gatalica, R. Gonzalez
Board 286
Analysis of CTLA4 expression on T regulatory cells in patients with
advanced stage melanoma in the setting of high dose IL-2 (HDIL-2). (Abstract
9043) M. L. Diller, C. E. Eysmans, D. H. Lawson, K. A. Delman, R. R. Kudchadkar,
M. Ford
Board 287
Association of PD-L1 expression in melanoma with response and prognosis
to ipilimumab. (Abstract 9044) C. Brueggemann, B. Weide, S. M. Goldinger, A.
Konrad, M. Erdmann, D. Schadendorf, R. S. Croner, L. Kraehenbuehl, K. C.
Kaehler, C. Hafner, W. Leisgang, F. Kiesewetter, R. Dummer, G. Schuler, M.
Stürzl, L. Heinzerling
Board 288
Evaluation of the impact of infliximab use for the treatment of ipilimumab
related diarrhoea on the outcome of patients with advanced melanoma.
(Abstract 9045) E. Arriola, M. J. Wheater, A. Warrier, I. Karydis, C. H. Ottensmeier
Board 289
Safety of infusing ipilimumab (ipi) over 30 minutes (min). (Abstract 9046) P.
Momtaz, V. Park, K. Panageas, J. D. Guillen, M. A. Postow, M. K. Callahan, J. D.
Wolchok, P. B. Chapman
Board 290
Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma
harboring gene mutations. (Abstract 9047) X. Wang, L. L. Mao, L. Si, Z. Chi, C.
Cui, X. N. Sheng, B. LIAN, B. Tang, X. Yan, J. Guo
Board 291
Evaluation of genetic heterogeneity in paired lymph node metastases from
melanoma patients using next-generation sequencing (NGS) approaches.
(Abstract 9048) G. Palmieri, A. Cossu, C. Caraco, P. A. Ascierto, N. Mozzillo, G.
Botti, A. Lissia, S. Canzanella, M. Sini, A. Manca, M. Colombino, M. Casula
Board 292
Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation
of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. (Abstract 9049) Y.
Kong, L. Si, Y. q. Li, X. w. Wu, X. W. Xu, J. Dai, H. Tang, M. Ma, Z. Chi, X. N.
Sheng, C. Cui, J. Guo
Board 293
Association of immune-related thyroid disorders with pembrolizumab
(pembro, MK-3475) in patients (pts) with advanced melanoma treated in
KEYNOTE-001. (Abstract 9050) C. Robert, A. M. Joshua, R. Kefford, R. W.
Joseph, J. D. Wolchok, F. S. Hodi, O. Hamid, J. S. Weber, T. C. Gangadhar, R. S.
Dronca, A. Patnaik, H. M. Zarour, W. Hwu, P. Hersey, A. Daud, M. Giannotti, X. Li,
S. Ebbinghaus, S. P. Kang, A. Ribas
Board 294
Utility of PET/CT for surveillance of asymptomatic patients with resected
stage III or IV melanoma. (Abstract 9051) R. A. Leon-Ferre, L. A. Kottschade,
V. J. Lowe, S. Markovic
Board 295
Identification of a predictive signature based on immunohistochemical (IHC),
RNA-seq and epigenetic profiling of melanoma metastases for response to
ipilimumab-based immunotherapy. (Abstract 9052) T. Seremet, A. Koch, S.
Wilgenhof, M. Schreuer, Y. Jansen, D. Lienard, V. Del Marmol, K. Thielemans, N.
Van Baren, P. Coulie, T. De Meyer, W. Van Criekinge, B. Neyns
Board 296
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with
vemurafenib in patients with BRAF-V600E mutation positive advanced
melanoma. (Abstract 9053) J. Clark, M. S. Ernstoff, M. M. Milhem, C. D. Lao,
D. H. Lawson, L. E. Flaherty, T. L. Luna, S. Aung
Board 297
Triple wild type melanoma profiling in the Caris Molecular Intelligence
registry. (Abstract 9054) K. Homicsko, K. Russell, A. Voss, O. Michielin
287
MONDAY
(IPI-R) metastatic melanoma (MEL). (Abstract 9040) D. Schadendorf, R.
Dummer, A. Hauschild, C. Robert, O. Hamid, A. Daud, A. J. van den Eertwegh,
L. D. Cranmer III, S. O’Day, I. Puzanov, J. Schachter, C. U. Blank, A. K. Salama, C.
Loquai, J. M. Mehnert, Y. Wang, S. Ebbinghaus, S. P. Kang, W. Zhou, A. Ribas
MONDAY
Board 298
Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients
that progressed on ipilimumab (IPI). (Abstract 9055) J. S. Weber, G. T. Gibney,
B. Yu, P. Cheng, A. J. Martinez, J. Kroeger, J. Freed, A. Richards, X. Zhao, M. J.
Schell
Board 299
A phase I study of vemurafenib and decitabine in metastatic melanoma.
(Abstract 9056) S. D. Phadke, E. S. Engelman, R. A. Leon-Ferre, L. I. Abushahin,
S. C. Mott, Y. Zakharia, M. M. Milhem
Board 300
Demographics, tumor characteristics, and clinical outcomes associated with
somatic mutations in 201 cancer-related genes in advanced melanoma
patients (pts). (Abstract 9057) M. A. Davies, A. Joon, R. L. Bassett Jr., J. Roszik,
A. Siroy, L. E. Haydu, K. Chen, F. Stingo, V. Baladandayuthapani, K. R. Shaw, F.
Meric-Bernstam, M. T. Tetzlaff, J. E. Gershenwald, S. E. Woodman, A. J. Lazar
Board 301
Trends in demographics, incidence, and survival in children, adolescents
and young adults (AYA) with melanoma: A Surveillance, Epidemiology and
End Results (SEER) population-based analysis. (Abstract 9058) D. K. Mitsis,
A. Groman, L. M. Beaupin, K. E. Salerno, V. Francescutti, J. J. Skitzki, J. M. Kane
III, N. I. Khushalani
Board 302
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab
in patients with metastatic melanoma who have progressed on anti-PD-1
therapy. (Abstract 9059) P. Prithviraj, G. A. McArthur, V. Atkinson, P. Parente,
M. C. Andrews, S. Parakh, J. S. Cebon, O. Klein
Board 303
Adoptive Cell Therapy for metastatic melanoma: A UK centre experience.
(Abstract 9060) M. R. Pillai, R. Guest, N. Kirillova, S. Chow, P. Lorigan, R. E.
Hawkins
Board 304
The expression quantitative trait loci (eQTLs) and their association with
melanoma clinical outcomes. (Abstract 9061) M. Vogelsang, C. N. Martinez, A.
Romanchuk, C. Hecht, O. Richardson, R. L. Shapiro, R. S. Berman, I. Osman, T.
Kirchhoff
Board 305
One-year overall survival (OS) and biomarker correlates from a phase II study
of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with
unresectable stage III or IV metastatic melanoma (MM). (Abstract 9062) R.
Jamal, L. Van Kempen, P. Thebault, K. Belanger, J. E. Friedmann, J. M. Ayoub, E.
Cocolakis, S. Kazemi, J. Dionne, C. Lambert, H. Le, C. Grange, J. Cailhier, A.
Spatz, R. Lapointe, W. H. Miller Jr.
Board 306
Survival, safety, and response patterns in a phase 1b multicenter trial of
talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously
untreated, unresected stage IIIB-IV melanoma. (Abstract 9063) I. Puzanov,
M. M. Milhem, R. I. Andtbacka, D. R. Minor, O. Hamid, A. Li, J. Chou, H. Kaufman
Board 307
Identification of potentially actionable mutations in RTKs in melanoma
detected by next generation sequencing (NGS). (Abstract 9064) J. Kemnade,
J. Roszik, A. Joon, F. Stingo, V. Baladandayuthapani, A. J. Lazar, S. E. Woodman,
M. A. Davies
Board 308
The effect of ipilimumab on natural killer cells identifies the subset of
advanced melanoma patients with clinical response. (Abstract 9065) I. E.
Pires Da Silva, A. Gallois, K. P. Lui, R. L. Shapiro, A. C. Pavlick, N. Bhardwaj, I.
Osman
Board 309
Continued evaluation of a 31-gene expression profile test (GEP) for
prediction of distant metastasis (DM) in cutaneous melanoma (CM). (Abstract
9066) D. H. Lawson, R. W. Cook, C. Johnson, M. C. Russell, R. N. Amaria, J.
Wilkinson, P. Gerami, D. Maetzold, L. Ferris, K. M. Oelschlager, A. Greisinger, R.
Gonzalez, T. C. Windham, B. Middlebrook, K. A. Delman, S. Lyle
Board 310
Long-term results of ultrasound (US)-guided fine needle aspiration cytology
(FNAC) in conjunction with sentinel node biopsy (SNB) to support step-wise
approach in melanoma. (Abstract 9067) A. C. Van Akkooi, P. Siegel, A.
Schoengen, J. Roewert-Huber, A. M. Eggermont, C. A. Voit
288
Board 311
Phase II trial of trametinib in combination with the AKT inhibitor GSK
2141795 in BRAF wild-type melanoma. (Abstract 9068) A. P. Algazi, A. H.
Muthukumar, K. O’Brien, A. Lencioni, K. K. Tsai, M. Kadafour, P. B. Chapman, A.
Daud
Board 312
Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long
term disease control in metastatic melanoma. (Abstract 9069) L. Gaba, I.
Victoria, E. Pineda, A. Fernandez, F. Aya, A. Prat, A. Arance
Board 313
Immunologic profile of melanoma brain metastases (MBM) in patients (pts)
with prolonged survival. (Abstract 9070) K. P. Lui, I. E. Silva, S. A. Weiss, S. W.
Han, F. Darvishian, A. C. Pavlick, J. Golfinos, D. Moogk, M. Krogsgaard, I. Osman
Board 314
A novel algorithm applicable to cancer next-generation sequencing panels to
predict total tumor mutation load and correlation with clinical outcomes in
melanoma. (Abstract 9071) J. Roszik, A. Joon, A. Siroy, L. E. Haydu, F. Stingo, V.
Baladandayuthapani, P. Hwu, M. T. Tetzlaff, J. A. Wargo, J. Q. Chen, L. G.
Radvanyi, C. Bernatchez, J. E. Gershenwald, A. J. Lazar, M. A. Davies, S. E.
Woodman
Board 315
Low vemurafenib plasma exposure as a short-term predictive parameter of
progression disease in metastatic BRAFV600mut melanoma. (Abstract 9072)
L. Goldwirt, I. Chami, J. Feugeas, F. Brunet-Possenti, C. Pagès, C. Allayous, B.
Baroudjian, I. Madelaine, H. Sauvageon, S. Mourah, C. Lebbe
Board 316
Patterns of response to anti-PD1 treatment: Comparison of three radiological
response criteria and effect on overall survival (OS) in metastatic melanoma
patients (MM). (Abstract 9073) M. Kibiro, L. Khoja, D. Hogg, M. O. Butler, U.
Metser, E. G. Atenafu, A. M. Joshua
Board 317
Tumor size and clinical outcomes in melanoma patients (MEL pts) treated
with talimogene laherparepvec (T-VEC). (Abstract 9074) H. Kaufman, T.
Amatruda, J. J. Nemunaitis, J. A. Chesney, K. A. Delman, L. E. Spitler, F. A.
Collichio, M. I. Ross, Y. Zhang, M. Shilkrut, R. I. Andtbacka
Board 318
Investigation of intrapatient heterogeneity in the tumor infiltrating T cell
repertoire in patients with metastatic melanoma treated with pembrolizumab.
(Abstract 9075) R. R. Munhoz, T. Merghoub, R. O. Emerson, M. K. Callahan, J. D.
Wolchok, M. A. Postow
Board 319
Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination
with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant
melanoma. (Abstract 9076) A. Diab, A. Martin, L. Simpson, A. P. Algazi, P.
Chawla, D. W. Kim, S. Santra, V. Patel, N. Jadhav, D. Abhyankar, M. A. Davies,
S. C. Buch, K. Kim, A. Daud
Board 320
Next generation sequencing of solid tumor and circulating tumor DNA
(ctDNA) in metastatic melanoma. (Abstract 9077) E. L. Carpenter, S. S. Yee, D.
Soucier, J. J. Morrissette, W. Xu, S. R. Harmon, N. Salathia, Y. Zhao, J. Waters, J.
Fan, L. M. Schuchter, R. K. Amaravadi, G. C. Karakousis, T. C. Gangadhar
Board 321
Factors associated with worse outcome for patients with AJCC stage IIC
relative to stage IIIA melanoma. (Abstract 9078) C. C. Kim, J. S. Najita, S. Y.
Tan, S. Varada, L. X. Tong, H. Dunbar, M. Lee, V. J. Seery, E. I. Buchbinder, N. E.
Tawa Jr., J. Fuller, R. A. Frankenthaler, D. F. McDermott, S. J. Lee, M. B. Atkins
Board 322a
A randomized phase II study of ipilimumab induction in patients with
melanoma brain metastases receiving stereotactic radiosurgery. (Abstract
TPS9079) A. W. Silk, Y. Cao, D. Gomez-Hassan, B. G. Redman, J. Hayman,
J. Heth, C. D. Lao
Board 322b
A multi-center phase II open-label study (CheckMate 204) to evaluate safety
and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI)
followed by NIVO monotherapy in patients (pts) with melanoma (MEL)
metastatic to the brain. (Abstract TPS9080) K. A. Margolin, H. A. Tawbi, M. S.
Ernstoff, F. S. Hodi, D. F. McDermott, R. Edwards, A. Avila, M. B. Atkins
Board 323a
A multicenter, open–label trial of talimogene laherparepvec (T-VEC) plus
pembrolizumab vs pembrolizumab monotherapy in previously untreated,
289
MONDAY
unresected, stage IIIB-IV melanoma. (Abstract TPS9081) A. Ribas, I. Puzanov,
T. Gajewski, G. V. Long, R. Dummer, J. M. Kirkwood, A. VanderWalde, J. S.
Cebon, G. A. McArthur, C. K. Gause, L. Chen, D. R. Kaufman, J. Chou, R. I.
Andtbacka, F. S. Hodi
MONDAY
Board 323b
Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells
loaded with irradiated autologous tumor cells (DC-TC) in granulocytemacrophage colony stimulating factor (GM-CSF) in patients with metastatic
melanoma (INTUS trial). (Abstract TPS9082) R. O. Dillman, M. E. Bayer, J. A.
Langford, C. Y. Hseih, T. J. Wyatt, G. Liang, D. J. Carbonyell, A. N. Cornforth
Board 324a
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of
nivolumab (NIVO) safety in European patients (pts) with advanced melanoma
(MEL) who have progressed after ipilimumab therapy (IPI). (Abstract
TPS9083) D. Schadendorf, P. A. Ascierto, E. Espinosa, J. B. Haanen, F. Hermann,
P. D. Nathan
Board 324b
Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects
with skin cancer. (Abstract TPS9084) D. M. Miller, M. Yamada, M. Lowe, C.
Rowe, D. Wood, K. Byrnes-Blake, T. Prow, L. Spelman
Board 325a
SWOG S1404: A phase III randomized trial comparing high dose interferon to
pembrolizumab in patients with high risk resected melanoma. (Abstract
TPS9085) K. F. Grossmann, M. Othus, A. A. Tarhini, S. P. Patel, J. M. Kirkwood, J.
Moon, V. K. Sondak, A. Ribas
Board 325b
A phase II, open-label, multicenter trial to investigate the clinical activity and
safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell
carcinoma. (Abstract TPS9086) H. Kaufman, O. Hamid, S. P. D’Angelo, G. Yuan,
K. M. Chin, S. Bhatia, J. Cuillerot, P. Nghiem
Board 326a
Randomized phase II study comparing the MET inhibitor cabozantinib to
temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201.
(Abstract TPS9087) J. J. Luke, J. B. Allred, L. E. Horvath, B. R. Bastos, C.
Erlichman, G. K. Schwartz
Board 326b
Phase 2 study of cobimetinib in combination with vemurafenib in active
melanoma brain metastases (coBRIM-B). (Abstract TPS9088) M. K. Yee, Y.
Lin, V. C. Gorantla, L. H. Butterfield, H. M. Kluger, P. B. Chapman, T. C.
Gangadhar, M. M. Milhem, A. C. Pavlick, R. K. Amaravadi, L. M. Schuchter, A. A.
Tarhini, J. M. Kirkwood, H. A. Tawbi
Board 327a
A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients
with advanced melanoma. (Abstract TPS9089) E. McWhirter, O. Hamid, B.
Chmielowski, R. D. Carvajal, D. A. Jaffray, B. Driscoll, T. Shek, I. Yeung, H. Keller,
T. D. McKee, T. E. Pearce, S. Kroll, A. M. Joshua
Board 327b
A randomized, phase III study of fotemustine versus the combination of
fotemustine and ipilimumab or the combination of ipilimumab and nivolumab
in patients with metastatic melanoma with brain metastasis: the NIBIT-M2
trial. (Abstract TPS9090) A. Di Giacomo, D. Annesi, P. A. Ascierto, L. Calabrò, V.
Chiarion-Sileni, R. Danielli, M. Del Vecchio, V. Ferraresi, P. Ferrucci, E. Fonsatti,
M. Guida, D. Giannarelli, M. Guidoboni, M. Mandalà, P. Quaglino, P. Queirolo, C.
Maccalli, G. Parmiani, M. Maio
Board 328a
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk
resectable stage III and IV melanoma. (Abstract TPS9091) J. A. Wargo, R. N.
Amaria, M. I. Ross, R. P. Saw, J. E. Gershenwald, P. Hwu, S. P. Patel, I. C. Glitza,
A. Diab, R. Kefford, R. A. Scolyer, H. Rizos, J. F. Thompson, K. Shannon, A.
Spillane, M. S. Carlino, A. Guminski, L. Simpson, M. A. Davies, G. V. Long
Board 328b
A pilot study of neoadjuvant cetuximab in locally advanced squamous cell
carcinomas of skin (SCCS). (Abstract TPS9092) K. R. Spencer, A. D. Kaveney,
J. Goydos, S. Kim, V. P. Koshenkov, S. Goyal, A. J. Khan, E. M. Castrorao, A. W.
Silk, H. Kaufman, L. Huzzy, M. L. Ruppert, S. Ganesan, J. M. Mehnert
Board 329a
SWOG S1320: A randomized phase II trial of intermittent versus continuous
dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.
290
(Abstract TPS9093) A. P. Algazi, M. Othus, A. Daud, J. M. Mehnert, C. D. Lao,
R. R. Kudchadkar, K. F. Grossmann, R. Lo, J. Moon, J. M. Kirkwood, A. Ribas
Board 329b
Phase 2, multicenter, randomized, open-label trial assessing efficacy and
safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus
surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL).
(Abstract TPS9094) R. I. Andtbacka, M. Chastain, A. Li, M. Shilkrut, M. I. Ross
Location: E Hall D1
3:00 PM
Syma Iqbal, MD (Discussion of Abstract(s) 4012– 4015)
University of Southern California/Norris Comprehensive Cancer Center
Gastroesophageal Cancers: Finding the Right Targets
3:12 PM
3:18 PM
David H. Ilson, MD, PhD (Discussion of Abstract(s) 4016 – 4017)
Resectable Gastric and Esophageal Cancer: Increasing the Likelihood of Cure
3:30 PM
3:36 PM
Robin Kate Kelley, MD (Discussion of Abstract(s) 4018 – 4020)
Hepatobiliary Cancers: Looking through the Prism
3:48 PM
3:54 PM
Emil Lou, MD, PhD (Discussion of Abstract(s) 4021– 4023)
Outside of the Proverbial Box: Molecular and Cellular Heterogeneity in Pancreatic
Cancer
4:06 PM
Posters discussed in this session are on display in the Gastrointestinal (Noncolorectal) Cancer
Poster Session. See page 219 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion.
Location: E Hall D2
Jhanelle Elaine Gray, MD—Co-Chair
Jonathan Riess, MD, MS—Co-Chair
3:00 PM
Heather A. Wakelee, MD (Discussion of Abstract(s) 8013– 8015)
Stanford Cancer Institute/Stanford University School of Medicine
New Insights in Epidermal Growth Factor Receptor Inhibition
3:12 PM
291
MONDAY
Milind M. Javle, MD—Chair
3:18 PM
Jean-Charles Soria, MD, PhD (Discussion of Abstract(s) 8016 – 8019)
Gustave-Roussy Cancer Campus
Breaking Barriers: Tyrosine Kinase Inhibitors for Management of Lung Cancers
with Central Nervous System Penetration
3:30 PM
3:36 PM
Christine Marie Lovly, MD, PhD (Discussion of Abstract(s) 8020 – 8022)
Skipping Toward a New Target
3:48 PM
3:54 AM
David Michael Jackman, MD (Discussion of Abstract(s) 8023– 8024)
Can Computers Do It Better?
4:06 PM
Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Metastatic
The Challenges of Pain Management
Location: S102
Toby Christopher Campbell, MD
University of Wisconsin Carbone Cancer Center
Nonopioid Pain Medicines and Adjunctive Alternatives
Eduardo Bruera, MD
Opioid Pain Medicines and Regulatory Issues
Judith A. Paice, PhD, RN—Chair
Northwestern University
Screening and Managing Misuse and Abuse
MONDAY
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies
Ranjana H. Advani, MD—Co-Chair
Stanford School of Medicine
Alexander M. Lesokhin, MD—Co-Chair
3:00 PM
292
Stephen Maxted Ansell, MD
Mayo Clinic
Chimeric Antigen Receptor T-Cell Technology 101
3:12 PM
Phase I trial of 19 –28z chimeric antigen receptor modified T cells (19 –28z
CAR-T) post-high dose therapy and autologous stem cell transplant (HDTASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin
lymphoma (B-NHL). (Abstract 8515) C. S. Sauter, I. Riviere, Y. Bernal, X. Wang,
T. Purdon, S. Yoo, C. H. Moskowitz, S. Giralt, M. J. Matasar, K. J. Curran, J. H.
Park, M. Sadelain, R. J. Brentjens
3:24 PM
Phase IIa trial of chimeric antigen receptor modified T cells directed against
CD19 (CTL019) in patients with relapsed or refractory CD19ⴙ lymphomas.
(Abstract 8516) S. J. Schuster, J. Svoboda, S. Nasta, D. L. Porter, A. Mato, G. D.
Shah, D. J. Landsburg, E. A. Chong, S. F. Lacey, J. J. Melenhorst, A. Chew, J.
Hasskarl, N. N. Shah, M. A. Wasik, K. Marcucci, Z. Zheng, B. Levine, C. H. June
3:36 PM
Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified
autologous T cells (CTL019) in advanced multiple myeloma. (Abstract 8517)
A. L. Garfall, M. V. Maus, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, Z. Zheng,
D. T. Vogl, A. D. Cohen, B. M. Weiss, K. Dengel, N. D. Kerr, W. Hwang, B. Levine,
C. H. June, E. A. Stadtmauer
3:48 PM
Madhav V. Dhodapkar, MBBS (Discussion of Abstract(s) 8515– 8517)
Yale University
A Clinical Perspective on Chimeric Antigen Receptor T-Cell Research
4:00 PM
David Avigan, MD
The Future of Chimeric Antigen Receptor T-Cell Research
4:12 PM
Intersection of the Mutanome and the Immunome
Location: E354b
Kunle Odunsi, MD, PhD—Co-Chair
3:00 PM
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with
previously treated, recurrent or refractory ovarian cancer: A phase Ib,
open-label expansion trial. (Abstract 5509) M. L. Disis, M. R. Patel, S. Pant,
J. R. Infante, A. Lockhart, K. Kelly, J. T. Beck, M. S. Gordon, G. J. Weiss, S. Ejadi,
M. H. Taylor, A. von Heydebreck, K. M. Chin, J. Cuillerot, J. L. Gulley
3:12 PM
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1
positive advanced ovarian cancer: Interim results from a phase Ib study.
(Abstract 5510) A. Varga, S. A. Piha-Paul, P. A. Ott, J. M. Mehnert, D. BertonRigaud, E. A. Johnson, J. D. Cheng, S. Yuan, E. H. Rubin, D. E. Matei
3:24 PM
Adil Daud, MD (Discussion of Abstract(s) 5509 –5510)
Paddling Along with PD-L1 Research
3:36 PM
Association of POLE-mutated and MSI endometrial cancers with an elevated
number of tumor-infiltrating and peritumoral lymphocytes and higher
expression of PD-L1. (Abstract 5511) B. E. Howitt, L. M. Sholl, L. Ritterhouse,
J. C. Watkins, S. J. Rodig, K. Strickland, A. D. D’Andrea, U. Matulonis, P.
Konstantinopoulos
3:48 PM
Tumor infiltrating and peritumoral T cells and expression of PD-L1 in
BRCA1/2-mutated high grade serous ovarian cancers. (Abstract 5512) K.
Strickland, B. E. Howitt, S. J. Rodig, L. Ritterhouse, A. D. D’Andrea, U. Matulonis,
P. Konstantinopoulos
293
MONDAY
David R. Spriggs, MD—Co-Chair
4:00 PM
Alexandra Snyder Charen, MD (Discussion of Abstract(s) 5511–5512)
Defining Neoantigens
4:12 PM
Location: N Hall B1
Steven J. Isakoff, MD, PhD—Co-Chair
Pamela N. Munster, MD—Co-Chair
MONDAY
3:00 PM
TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by
ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast
cancer (TNBC). (Abstract 1000) D. A. Yardley, L. D. Bosserman, M. R. Keaton,
M. A. Ackerman, S. A. Goble, D. Shipley, E. Salloum, W. N. Harwin, B. R. Daniel,
J. D. Hainsworth, H. A. Burris III
3:12 PM
Phase III trial of etirinotecan pegol (EP) versus treatment of physician’s
choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose
disease has progressed following anthracycline (A), taxane (T) and
capecitabine (C): The BEACON study. (Abstract 1001) E. A. Perez, A. Awada,
J. O’Shaughnessy, H. S. Rugo, C. Twelves, S. Im, C. Zhao, U. Hoch, A. L. Hannah,
J. Cortes
3:24 PM
Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for
receptor-negative early breast cancer (BC). (Abstract 1002) M. Colleoni, K. P.
Gray, S. I. Gelber, I. Lang, B. J. Thurlimann, L. Gianni, E. A. Abdi, K. N. Price, R. D.
Gelber, G. Viale, A. S. Coates, A. Goldhirsch, International Breast Cancer Study
Group
3:36 PM
Harold J. Burstein, MD, PhD (Discussion of Abstract(s) 1000 –1002)
Chemotherapy for Breast Cancer: The Long and Winding Road
3:48 PM
4:00 PM
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor
(AR) inhibitor, in advanced ARⴙ triple-negative breast cancer (TNBC).
(Abstract 1003) T. A. Traina, K. Miller, D. A. Yardley, J. O’Shaughnessy, J. Cortes,
A. Awada, C. M. Kelly, M. E. Trudeau, P. Schmid, L. Gianni, L. Garcı́a-Estevez, R.
Nanda, F. O. Ademuyiwa, S. Chan, J. L. Steinberg, M. E. Blaney, I. C. Tudor, H.
Uppal, A. C. Peterson, C. A. Hudis
4:12 PM
Prediction of pathological complete response (pCR) by Homologous
Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant
chemotherapy in patients with TNBC: Results from GeparSixto. (Abstract
1004) G. Von Minckwitz, K. Timms, M. Untch, E. P. Elkin, P. A. Fasching, A.
Schneeweiss, C. Salat, M. Rezai, J. Blohmer, D. Zahm, C. Jackisch, B. Gerber, P.
Klare, S. Kümmel, H. Eidtmann, S. Paepke, J. E. Reid, V. Nekljudova, A. Hartman,
S. Loibl
4:24 PM
Prevalence and predictors of androgen receptor (AR) and programmed
death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple
negative breast cancer (TNBC). (Abstract 1005) N. M. Tung, J. E. Garber, V.
Torous, M. R. Hacker, G. J. Freeman, S. J. Rodig, E. Poles, B. M. Alexander, L. J.
Lee, L. C. Collins, S. J. Schnitt
294
4:36 PM
Pamela N. Munster, MD (Discussion of Abstract(s) 1003–1005)
High Hopes for Exploitation of the Heterogeneity of Triple-Negative Breast Cancer
4:48 PM
5:00 PM
The survival benefit offered by the surgical management of low-grade ductal
carcinoma in situ of the breast. (Abstract 1006) Y. Sagara, W. T. Barry, M. A.
Mallory, S. M. Wong, F. Aydogan, S. DeSantis, M. Golshan
5:12 PM
Impact of neoadjuvant therapy on breast conservation rates in triple-negative
and HER2-positive breast cancer: Combined results of CALGB 40603 and
40601 (Alliance). (Abstract 1007) M. Golshan, C. T. Cirrincione, L. A. Carey,
W. M. Sikov, D. A. Berry, H. J. Burstein, B. Overmoyer, N. L. Henry, G. Somlo,
E. R. Port, E. P. Winer, C. A. Hudis, D. W. Ollila
5:24 PM
Relationship of omission of adjuvant radiotherapy to outcomes of
locoregional control and disease-free survival in patients with or without
pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on
3481 patients from the Gepar-trials. (Abstract 1008) D. Krug, B. Lederer, J.
Debus, J. Blohmer, S. D. Costa, H. Eidtmann, C. Hanusch, J. Hilfrich, J. B. Huober,
C. Jackisch, S. Kümmel, S. Paepke, A. Schneeweiss, M. Untch, G. Von Minckwitz,
S. Loibl
5:36 PM
Monica Morrow, MD (Discussion of Abstract(s) 1006 –1008)
Tailoring Local Therapy: You Can’t Always Get What You What, But You Should
Get What You Need
5:48 PM
Sarcoma
Location: S504
Sebastian Bauer, MD—Co-Chair
Universitaetsklinikum Essen-Innere Medizin-Essen
3:00 PM
GeDDiS: A prospective randomised controlled phase III trial of gemcitabine
and docetaxel compared with doxorubicin as first-line treatment in
previously untreated advanced unresectable or metastatic soft tissue
sarcomas (EudraCT 2009 – 014907-29). (Abstract 10500) B. M. Seddon, J.
Whelan, S. J. Strauss, M. G. Leahy, P. J. Woll, F. Cowie, C. A. Rothermundt, Z.
Wood, S. Forsyth, I. Khan, S. Nash, P. Patterson, S. Beare
3:12 PM
A randomized phase Ib/II study evaluating the safety and efficacy of
olaratumab (IMC-3G3), a human anti-platelet-derived growth factor ␣
(PDGFR␣) monoclonal antibody, with or without doxorubicin (Dox), in
advanced soft tissue sarcoma (STS). (Abstract 10501) W. D. Tap, R. L. Jones,
B. Chmielowski, A. D. Elias, D. Adkins, B. A. Van Tine, M. Agulnik, M. M. Cooney,
M. B. Livingston, G. K. Pennock, A. Qin, A. Shahir, R. L. Ilaria Jr., I. Conti, J.
Cosaert, G. K. Schwartz
3:24 PM
Laurence H. Baker, DO (Discussion of Abstract(s) 10500 –10501)
Front-Line Therapies for Soft-Tissue Sarcomas: Advancing the Standard of Care
3:36 PM
295
MONDAY
Vicki Leigh Keedy, MD, MSCI—Co-Chair
Vanderbilt University Medical Center
MONDAY
3:48 PM
Randomized, open-label, multicenter, phase III study of eribulin versus
dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic
sarcoma (ADI). (Abstract LBA10502) P. Schöffski, R. G. Maki, A. Italiano, H.
Gelderblom, G. Grignani, V. P. Camargo, S. Bauer, S. Y. Rha, S. P. Chawla, J.
Blay, P. Hohenberger, D. R. D’Adamo, B. Wang, B. Chmielowski, A. Le Cesne,
G. D. Demetri, S. Patel
4:00 PM
A randomized phase III study of trabectedin (T) or dacarbazine (D) for the
treatment of patients (pts) with advanced liposarcoma (LPS) or
leiomyosarcoma (LMS). (Abstract 10503) G. D. Demetri, M. von Mehren, R. L.
Jones, M. L. Hensley, S. Schuetze, A. P. Staddon, M. M. Milhem, A. D. Elias, K. N.
Ganjoo, H. A. Tawbi, B. A. Van Tine, A. I. Spira, A. P. Dean, N. Z. Khokhar, Y. C.
Park, R. E. Knoblauch, T. V. Parekh, R. G. Maki, S. Patel
4:12 PM
Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of
soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo
(PL) controlled phase II trial. (Abstract 10504) O. Mir, T. Brodowicz, J. Wallet, A.
Italiano, A. Le Cesne, J. Blay, T. Ryckewaert, F. Bertucci, S. Piperno-Neumann, F.
Ploner, M. Toulmonde, J. Domont, E. Saada, C. Delcambre, N. Isambert, S. C.
Delaine, S. Taieb, E. Lindner, B. Lieg-Atzwanger, N. Penel
4:24 PM
Ian Robert Judson, MD (Discussion of Abstract(s) LBA10502–10504)
The Institute of Cancer Research
Potential New Treatments for Patients with Soft-Tissue Sarcoma
4:36 PM
4:48 PM
Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The
second planned analysis of the randomized SSGXVIII/AIO trial. (Abstract
10505) H. Joensuu, M. Eriksson, K. Sundby Hall, A. Reichardt, G. Ramadori, P.
Hohenberger, S. Al-Batran, M. Schlemmer, S. Bauer, D. Pink, J. Duyster, B. E.
Nilsson, O. R. Monge, R. Kallio, P. Bono, J. Junnila, E. Wardelmann, T. Alvegard,
P. Reichardt
5:00 PM
Final results of the multicenter randomized phase II PAZOGIST trial
evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs
BSC alone in resistant unresectable metastatic and/or locally advanced
gastrointestinal stromal tumors (GIST). (Abstract 10506) J. Blay, M. Molimard,
C. Cropet, J. Domont, M. Toulmonde, E. Bompas, P. A. Cassier, I. L.
Ray-Coquard, M. Rios, A. Adenis, A. Italiano, A. Le Cesne, O. Bouche Sr., O. Mir,
F. Duffaud, F. Bertucci, N. Isambert, A. Belleville, J. Gautier, D. Pérol
5:12 PM
A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with
imatinib in patients with advanced gastrointestinal stromal tumor (GIST).
(Abstract 10507) P. Chi, L. Qin, S. P. D’Angelo, M. A. Dickson, M. M. Gounder, M.
Keohan, A. N. Shoushtari, M. M. Condy, T. Konen, A. Fruauff, R. P. DeMatteo, S.
Singer, S. Hwang, C. R. Antonescu, W. D. Tap
5:24 PM
Robert G. Maki, MD, PhD (Discussion of Abstract(s) 10505–10507)
Gastrointestinal Stromal Tumor: Attempting to Improve the Adjuvant and
Refractory Treatment Landscape
5:36 PM
Tumor Biology
Location: E450
Michael J. Birrer, MD, PhD—Co-Chair
Harvard Medical School Massachusetts General Hospital
David Potter, MD, PhD—Co-Chair
296
3:00 PM
Identifying somatic oncogenic mutations in leukocytes that infiltrate primary
breast cancers. (Abstract 11000) E. A. Comen, M. Kleppe, Y. H. Wen, F.
Rapaport, Z. Granot, N. D. Socci, A. Viale, D. You, R. Benezra, B. Weigelt, E.
Brogi, M. F. Berger, J. Reis-Filho, R. L. Levine, L. Norton, L. Bastian, M. Keller
3:12 PM
White adipose tissue inflammation and breast cancer progression. (Abstract
11001) N. M. Iyengar, P. G. Morris, X. K. Zhou, H. Wang, A. Gucalp, D. D. Giri,
M. D. Harbus, J. Park, S. S. Park, M. Morrow, C. A. Hudis, A. Dannenberg
3:24 PM
Association of inactivation of STK11/LKB1 with a suppressive immune
microenvironment in lung adenocarcinoma (LUAC). (Abstract 11002) F.
Skoulidis, W. Denning, L. Diao, P. Tong, Y. H. Fan, V. Papadimitrakopoulou, J.
Izzo, C. Behrens, H. Kadara, E. R. Parra Cuentas, J. Rodriguez, J. Wang, D. L.
Gibbons, L. A. Byers, I. I. Wistuba, J. Heymach
3:36 PM
Victoria Louise Seewaldt, MD (Discussion of Abstract(s) 11000 –11002)
The Role of the Microenvironment in Therapeutic Targeting
3:48 PM
4:00 PM
Discordance between HER2-phenotype on circulating tumor cells and
primary tumor in women with advanced breast cancer. (Abstract 11003) A.
Schramm, T. W. Friedl, F. Schochter, J. B. Huober, L. M. Wiesmueller, B. K. Rack,
M. Alunni-Fabbroni, P. A. Fasching, F. Taran, A. D. Hartkopf, A. Schneeweiss, V.
Mueller, B. Aktas, K. Pantel, N. Krawczyk, W. Janni, T. N. Fehm
4:12 PM
Detection rate of actionable mutations in diverse cancers using a biopsy-free
(blood) circulating tumor DNA assay. (Abstract 11004) R. Kurzrock, M. C.
Schwaederle, H. Husain, R. B. Schwab, R. J. Nagy, R. B. Lanman, A. Talasaz
4:24 PM
Protein expression by genetic mutations identified in gene panels (hotspots)
and efficacy of targeted treatments. (Abstract 11005) S. C. Benz, S.
Rabizadeh, J. Z. Sanborn, C. J. Vaske, G. A. Palmer, P. Soon-Shiong
4:36 PM
Biomarkers and Circulating Tumor Cells: Promise and Controversies
4:48 PM
5:00 PM
Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small
interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with
advanced solid tumors. (Abstract 11006) A. W. Tolcher, K. P. Papadopoulos, A.
Patnaik, D. W. Rasco, D. Martinez, D. L. Wood, B. Fielman, M. Sharma, L. A.
Janisch, B. D. Brown, P. Bhargava, M. J. Ratain
5:12 PM
Comprehensive genomic profiling (CGP) of advanced cancers to identify
MET exon 14 alterations that confer sensitivity to MET inhibitors. (Abstract
11007) G. M. Frampton, S. M. Ali, M. Rosenzweig, J. W. Goldman, C. B. Lee, J.
Weiss, J. A. Bufill, R. Salgia, M. Jahanzeb, K. Konduri, P. M. Forde, D. Morosini,
J. S. Ross, S. I. Ou, R. Yelensky, V. A. Miller, P. J. Stephens
5:24 PM
Altering the tumor microenvironment: A phase II study of copper depletion
using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at
high risk for recurrence. (Abstract 11008) E. N. Nackos, N. Kornhauser, M. M.
Ward, T. Cigler, A. Moore, E. Andreopoulou, N. Chan, V. Fitzpatrick, S. E.
Schneider, A. Wiener, J. D. Warren, A. Rubinchik, A. Willis, S. Lee, M. E. Lane, V.
Mittal, L. T. Vahdat
5:36 PM
Mark M. Moasser, MD (Discussion of Abstract(s) 11006 –11008)
Myc, Met, and Metal: Linking Therapy to Biology
5:48 PM
297
MONDAY
Location: S102
James M. Foran, MD—Co-Chair
Mayo Clinic
Joshua David Schiffman, MD—Co-Chair
University of Utah
4:45 PM
Susan M. Domchek, MD (Discussion of Abstract(s) 1512–1515)
University of Pennsylvania Perelman School of Medicine
Putting Germline Mutations into Context
4:57 PM
5:03 PM
Matthew B. Yurgelun, MD (Discussion of Abstract(s) 1516 –1518)
Identifying Lynch Syndrome
5:15 PM
5:21 PM
Jonathan Riess, MD, MS (Discussion of Abstract(s) 1519 –1520)
Emerging Risk Factors for Lung Cancer
5:33 PM
5:39 PM
Christopher Flowers, MD (Discussion of Abstract(s) 1521–1522)
Winship Cancer Institute of Emory University
Lymphoma Epidemiology and Survivorship
5:51 PM
Posters discussed in this session are on display in the Cancer Prevention, Genetics, and Epidemiology Poster Session. See page 260 for poster information. Networking with presenters and
discussants will take place right outside of the session rooms after the discussion.
MONDAY
Location: S100a
Phioanh Leia Nghiemphu, MD—Co-Chair
Christina L. Tsien, MD—Co-Chair
4:45 PM
Erik P. Sulman, MD, PhD (Discussion of Abstract(s) 2012–2014)
Key Phase II Trials for Glioblastoma
4:57 PM
5:03 PM
Ingo K. Mellinghoff, MD (Discussion of Abstract(s) 2015–2017)
EGFR and MGMT: Present or Passé?
5:15 PM
5:21 PM
Tobias Walbert, MD, PhD (Discussion of Abstract(s) 2018 –2019)
Henry Ford Hospital
Improving Quality of Life for Patients with Central Nervous System Tumors
5:33 PM
298
5:39 PM
Manmeet Singh Ahluwalia, MD (Discussion of Abstract(s) 2020 –2021)
Cleveland Clinic
Novel Approaches to Brain Metastases
5:51 PM
Posters discussed in this session are on display in the Central Nervous System Tumors Poster
Session. See page 265 for poster information. Networking with presenters and discussants will
take place right outside of the session rooms after the discussion.
Peter H. O’Donnell, MD—Co-Chair
4:45 PM
Matthew I. Milowsky, MD (Discussion of Abstract(s) 4512– 4514)
UNC Chapel Hill Lineberger Comprehensive Cancer Center
Novel Research on Prediction of Chemotherapy Resistance
4:57 PM
5:03 PM
Lawrence Fong, MD (Discussion of Abstract(s) 4515, 4516, 4586)
Combination Immunotherapy in Genitourinary Tumors
5:15 PM
5:21 PM
Bernard J. Escudier, MD (Discussion of Abstract(s) 4518 – 4519)
Targets and Targeted Therapy in Kidney Cancer
5:33 PM
5:39 PM
Daniel J. George, MD (Discussion of Abstract(s) 4520 – 4523)
Duke Cancer Institute
The Optimal Targets in Papillary Renal Cell Carcinoma
5:51 PM
Posters discussed in this session are on display in the Genitourinary (Nonprostate) Cancer
Location: S404
George J. Chang, MD, MS—Co-Chair
Monika K. Krzyzanowska, MD, MPH, FRCPC—Co-Chair
4:45 PM
Christine Marie Veenstra, MD (Discussion of Abstract(s) 6512– 6514)
Shaping Cancer Care through Policy
299
MONDAY
Phillip Lee Palmbos, MD, PhD—Co-Chair
University of Michigain Health System
4:57 PM
5:03 PM
Jennifer Elston Lafata, PhD (Discussion of Abstract(s) 6515– 6517)
Virginia Commonwealth University
Talking to Those Who Know Best: Patient- and Family-Reported Outcomes
5:15 PM
5:21 PM
David L. Graham, MD (Discussion of Abstract(s) 6518 – 6520)
Levine Cancer Institute-Cornelius
Twitter, Social Media, and Email as Cancer Communication Tools
5:33 PM
5:39 PM
Rebecca A. Miksad, MD, MPH (Discussion of Abstract(s) 6521– 6523)
Data-Driven Strategies for Change in Cancer Care
5:51 PM
Posters discussed in this session are on display in the Health Services Research and Quality of
Care Poster Session. See page 277 for poster information. Networking with presenters and discussants will take place right outside of the session rooms after the discussion.
Location: S100bc
Alain Patrick Algazi, MD—Co-Chair
Roxana Stefania Dronca, MD—Co-Chair
Mayo Clinic
MONDAY
4:45 PM
Richard Kefford, MB, BS, PhD (Discussion of Abstract(s) 9009 –9011)
Crown Princess Mary Cancer Centre
Anti-PD-1 Therapy in Special Clinical Cohorts
4:57 PM
5:03 PM
Antoni Ribas, MD, PhD (Discussion of Abstract(s) 9012–9014)
David Geffen School of Medicine at UCLA
Biomarkers for PD1 Inhibition
5:15 PM
5:21 PM
Mohammed Kashani-Sabet, MD (Discussion of Abstract(s) 9015–9017)
California Pacific Medical Center Research Institute
Usefulness of Liquid Biopsies
5:33 PM
5:39 PM
Georgina V. Long, PhD, MBBS, FRACP (Discussion of Abstract(s)
9018 –9019)
Melanoma Institute Australia and The University of Sydney
Checkpoint Inhibitor-Associated Toxicity
5:51 PM
Posters discussed in this session are on display in the Melanoma/Skin Cancers Poster Session.
See page 284 for poster information. Networking with presenters and discussants will take place
right outside of the session rooms after the discussion.
300
Progress in Myeloproliferative Neoplasms: Biology to Bedside
Location: E354b
Alison Moliterno, MD—Chair
Johns Hopkins University
Risk Stratification in Ph-Negative Myeloproliferative Neoplasms
Jean-Jacques Kiladjian, MD, PhD
Hôpital Saint-Louis and Paris Diderot University
Current Therapies and Their Indications for Ph-Negative Myeloproliferative Neoplasms
Michael W. N. Deininger, MD, PhD
University of Utah Huntsman Cancer Institute
Identify and Manage Advanced or Progressive Chronic Myeloid Leukemia
The ABCs of Cancer Immunotherapy
Location: S406
F. Stephen Hodi, MD
How to Interpret Antitumor Response in Immunotherapy
Drew M. Pardoll, MD, PhD—Chair
The Johns Hopkins University School of Medicine
Immunotherapy Overview: Mechanisms and Modalities
Michael Andrew Postow, MD
Managing Immunotherapy-Related Side Effects
MONDAY
Treatment of Colorectal Cancer Peritoneal Carcinomatosis: The Role of
Surgery, Systemic, and Heated Intraperitoneal Chemotherapy
Location: E Hall D1
David P. Ryan, MD—Chair
The Role of Systemic Chemotherapy
Andrea Cercek, MD
The Role of Intraperitoneal Chemotherapy
James C. Cusack, MD
The Role of Debulking Surgery
301
Tuesday, June 2, 2015
Highlights of the Day Session III
Location: E Hall D1
Apar Kishor Ganti, MD—Chair
University of Nebraska Medical Center
7:30 AM
Eric P. Winer, MD
Breast Cancer
7:50 AM
Ian D. Davis, MBBS, PhD, FRACP, FAChPM
Monash University Eastern Health Clinical School
8:05 AM
Peter Albers, MD
Duesseldorf University
8:20 AM
Kunle Odunsi, MD, PhD
Gynecologic Cancer
8:35 AM
Quynh-Thu Le, MD
8:50 AM
Jonathan C. Trent, MD, PhD
Sylvester Comprehensive Cancer Center, University of Miami
Sarcoma
9:05 AM
Mark M. Moasser, MD
Tumor Biology
Adjuvant Treatment of Soft Tissue Sarcoma: What, When, and Why
Location: S504
H. Thomas Temple, MD
Nova Southeastern University
Optimization of Surgical Resection for Soft Tissue Sarcoma
Paolo Giovanni Casali, MD—Chair
Fondazione IRCCS Istituto Nazionale dei Tumori
Is There a Role for Adjuvant Chemotherapy for Resected Soft-Tissue Sarcoma?
Brian O’Sullivan, MD
Princess Margaret Hospital
What Are the Indications for Adjuvant Radiation for Resected Soft-Tissue Sarcomas?
TUESDAY
Integrative Cancer Prevention: Nutrition, Supplements, and Lifestyle
Location: S102
302
Michelle Harvie, PhD
Nightingale and Genesis Prevention Centre, Wythenshawe Hospital
Can Correct Diet and Exercise Choices Prevent Cancer?
Heather Greenlee, ND, PhD
Clinical Practice Guidelines on the Use of Integrative Therapies During Breast Cancer
Treatment
Donald I. Abrams, MD—Chair
San Francisco General Hospital
Lifestyle Modification and Dietary Supplements in Secondary Prevention
New Targets and Therapies for Triple-Negative Breast Cancer
Location: E450
Brian D. Lehmann, PhD
Illuminating the Biology of Triple-Negative Breast Cancer
Mary L. Disis, MD
Immunology and Triple-Negative Disease
Antoinette R. Tan, MD—Chair
Levine Cancer Institute/Carolinas Healthcare System
Novel Therapies for Triple-Negative Breast Cancer
Personalized Therapy for Multiple Myeloma in a Value-Oriented Environment
Location: E354b
Marı́a-Victoria Mateos, MD, PhD
University Hospital of Salamanca-IBSAL
Smoldering Multiple Myeloma: When to Observe and When to Treat?
Saad Zafar Usmani, MD—Chair
Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?
TUESDAY
Philippe Moreau, MD
CHU de Nantes, Hotel Dieu—HME
Multiple Myeloma: How to Sequence Therapy?
303
Targeting Cancer Metabolism
Location: S100bc
W. Marston Linehan, MD—Chair
Lessons from IDH: Understanding Basic Metabolic Pathways and Translation to Clinical Trials
Jeff Rathmell, PhD
Duke University
Metabolic Reprogramming of the Immune Response in the Tumor Microenvironment
Robert Bachoo, MD, PhD
Identification of New Metabolic Targets from Metabolic Tracer Studies in Patients
Location: S404
Manmeet Singh Ahluwalia, MD—Co-Chair
Cleveland Clinic
Lakshmi Nayak, MD—Co-Chair
TUESDAY
8:00 AM
Tumor treating fields (TTFields): A novel treatment modality added to
standard chemo- and radiotherapy in newly diagnosed glioblastoma—First
report of the full dataset of the EF14 randomized phase III trial. (Abstract
2000) R. Stupp, S. Taillibert, A. Kanner, S. Kesari, S. A. Toms, G. H. Barnett, K. L.
Fink, A. Silvani, F. S. Lieberman, J. Zhu, L. P. Taylor, J. Honnorat, A. Hottinger, T.
Chen, D. D. Tran, C. Kim, H. W. Hirte, M. E. Hegi, Y. Palti, Z. Ram
8:12 AM
Long-term analysis of the NOA-04 randomized phase III trial of sequential
radiochemotherapy of anaplastic glioma with PCV or temozolomide.
(Abstract 2001) W. Wick, P. Roth, B. Wiestler, C. Hartmann, P. Hau, M.
Nakamura, F. Stockhammer, M. Sabel, S. Koeppen, R. Ketter, P. Vajkoczy, I.
Eyupoglus, S. Kaendler, R. Kalff, N. Galldiks, F. Schmidt-Graf, A. von Deimling, M.
Platten, G. Reifenberger, M. Weller
8:24 AM
Results of NRG oncology/RTOG 9813: A phase III randomized study of
radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea
(NU) therapy for anaplastic astrocytoma (AA). (Abstract 2002) S. M. Chang, P.
Zhang, J. G. Cairncross, M. R. Gilbert, J. Bahary, C. Dolinskas, K. D. Aldape, A.
Chakravarti, D. Schiff, K. A. Jaeckle, P. D. Brown, G. Barger, M. Werner-Wasik,
H. A. Shih, D. Brachman, M. Penas-Prado, H. Robins, K. Belanger, C. J. Schultz,
M. P. Mehta
8:36 AM
Martin J. Van Den Bent, MD (Discussion of Abstract(s) 2000 –2002)
Daniel den Hoed Cancer Center
Radiation, Chemotherapy, or More for Newly Diagnosed, High-Grade Gliomas
8:48 AM
304
9:00 AM
Continuing or ceasing bevacizumab at disease progression: Results from
the CABARET study, a prospective randomized phase II trial in patients with
recurrent glioblastoma. (Abstract 2003) E. J. Hovey, K. M. Field, M. Rosenthal,
A. K. Nowak, L. Cher, H. Wheeler, E. Barnes, P. Phal, A. Livingstone, K. Sawkins,
J. Simes, COGNO CABARET Investigators
9:12 AM
NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of
bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM).
(Abstract 2004) E. Galanis, S. Anderson, P. Anastasiadis, D. D. Tran, S. A.
Jeyapalan, D. M. Anderson, T. J. Kaufmann, C. Giannini, J. C. Buckner, D. Schiff
9:24 AM
A randomized phase II trial of standard dose bevacizumab versus low dose
bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
(Abstract 2005) S. S. Weathers, S. X. Han, D. D. Liu, C. A. Conrad, M. R. Gilbert,
M. E. Loghin, B. J. O’Brien, M. Penas-Prado, V. K. Puduvalli, I. Tremont-Lukats,
W. A. Yung, J. F. De Groot
9:36 AM
Timothy F. Cloughesy, MD (Discussion of Abstract(s) 2003–2005)
Bevacizumab for Glioblastoma: Selection, Dose, and Schedule
9:48 AM
10:00 AM
Radiotherapy in relation to temozolomide: Subgroup analysis of molecular
markers of the randomized phase III study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033–26033) in patients with a
high risk low-grade glioma. (Abstract 2006) B. G. Baumert, M. E. Hegi, W. P.
Mason, G. Ryan, K. Hoang-Xuan, J. E. Bromberg, M. J. Van Den Bent, M. Ben
Hassel, C. Marosi, A. A. Brandes, J. Rees, A. von Deimling, C. Hartmann, J. M.
Kros, D. A. Lacombe, T. Gorlia, D. Capper, S. Kurscheid, R. Stupp
10:12 AM
Molecular classification of diffuse cerebral gliomas using genome- and
transcriptome-wide profiling. (Abstract 2007) M. Weller, R. Weber, E. Willscher,
V. Riehmer, B. Hentschel, M. Kreuz, J. Felsberg, U. Beyer, H. Loeffler-Wirth, K.
Kaulich, D. Gramatzki, M. Westphal, G. Schackert, M. Simon, J. Tonn, T. Pietsch,
M. Loeffler, A. von Deimling, H. Binder, G. Reifenberger, German Glioma Network
10:24 AM
The landscape and clonal architecture in lower grade glioma. (Abstract 2008)
H. Suzuki, K. Aoki, K. Chiba, Y. Sato, Y. Shiozawa, Y. Shiraishi, T. Shimamura, A.
Niida, K. Motomura, F. Ohka, H. Nakamura, M. Mizoguchi, T. Abe, Y. Muragaki, R.
Watanabe, I. Ito, T. Wakabayashi, S. Ogawa, A. Natsume
10:36 AM Howard Alan Fine, MD (Discussion of Abstract(s) 2006 –2008)
Weill Cornell Medical Center
Molecular Determinants in the Management of Gliomas
10:48 AM
Therapeutics
Location: S100a
TUESDAY
Emiliano Calvo, MD, PhD—Co-Chair
START Madrid, Centro Integral Oncológico Clara Campal
Timothy Anthony Yap, MD, PhD—Co-Chair
305
TUESDAY
8:00 AM
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I
trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA
mutant breast and gynecological cancers. (Abstract 2500) U. Banerji, E. J.
Dean, J. A. Perez-Fidalgo, G. Batist, P. L. Bedard, B. You, S. N. Westin, P. Kabos,
B. Davies, P. Elvin, P. Lawrence, J. W. Yates, H. Ambrose, P. Rugman, A. Foxley,
S. Salim, E. Casson, J. P. Lindemann, J. H. Schellens
8:12 AM
First-in-human, phase I, dose-escalation study of selective PI3K␣ isoform
inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
(Abstract 2501) D. Juric, J. S. De Bono, P. LoRusso, J. J. Nemunaitis, E. I. Heath,
E. L. Kwak, T. Macarulla, E. Geuna, M. de Miguel Luken, C. Patel, K. Kuida, S.
Sankoh, F. Zohren, Y. Shou, J. Tabernero
8:24 AM
Filip Janku, MD, PhD (Discussion of Abstract(s) 2500 –2501)
PI3K Pathway as a Target: Early-Phase Data
8:36 AM
8:48 AM
Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced
refractory renal cell carcinomas (RRCC). (Abstract 2503) J. A. Thompson, R.
Motzer, A. M. Molina, T. K. Choueiri, E. I. Heath, C. K. Kollmannsberger, B. G.
Redman, R. S. Sangha, D. S. Ernst, R. Pili, A. Butturini, A. Wiseman, F. Trave, B.
Anand, Y. Huang, L. M. Reyno
9:00 AM
Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38
antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase
I/II clinical experience. (Abstract 2504) M. J. Guarino, A. Starodub, G. A.
Masters, R. S. Heist, W. A. Messersmith, A. Bardia, A. J. Ocean, S. S. Thomas,
P. P. Maliakal, W. A. Wegener, R. M. Sharkey, F. Wilhelm, D. M. Goldenberg
9:12 AM
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in
controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory
or relapsing after irinotecan-containing chemotherapies: Initial results of a
phase I/II study. (Abstract 2505) E. Dotan, A. Starodub, J. Berlin, C. H. Lieu, M. J.
Guarino, J. Marshall, J. R. Hecht, S. J. Cohen, W. A. Messersmith, P. P. Maliakal,
W. A. Wegener, R. M. Sharkey, D. M. Goldenberg
9:24 AM
Anthony W. Tolcher, MD (Discussion of Abstract(s) 2503–2505)
START
Antibody-Drug Conjugates: To Join or Not to Join?
9:36 AM
9:48 AM
Dose escalation stage of a first-in-class phase I study of the novel oral ERK
1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid
tumors. (Abstract 2506) J. R. Infante, F. Janku, A. W. Tolcher, M. R. Patel, R. J.
Sullivan, K. Flaherty, R. D. Carvajal, A. M. Varghese, D. J. Wong, M. Sznol, J. A.
Sosman, A. Wang-Gillam, H. A. Burris III, A. Ribas, S. P. Patel, D. J. Welsch, S.
Saha
10:00 AM
Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with
p53 mutated ovarian cancer refractory or resistant (<3 months) to standard
first line therapy. (Abstract 2507) S. Leijen, R. van Geel, G. S. Sonke, D. de
Jong, E. H. Rosenberg, S. Marchetti, D. Pluim, E. D. van Werkhoven, S. Rose,
M. A. Lee, J. H. Beijnen, J. H. Schellens
10:12 AM
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified
tumours. (Abstract 2508) E. C. Smyth, N. C. Turner, C. Peckitt, A. Pearson, G.
Brown, S. Chua, A. Gillbanks, S. R. Johnston, N. Tarazona, R. Cutts, E. Kilgour, C.
Rooney, N. R. Smith, K. A. Sumpter, M. A. Ajaz, A. L. Thomas, D. Watkins, I. Chau,
S. Popat, D. Cunningham
10:24 AM
Ryan Bruce Corcoran, MD, PhD (Discussion of Abstract(s) 2506 –2508)
Promising Novel Targets and Agents
10:36 AM
306
Latest Advances in Systemic Therapy for Bone Sarcomas
Location: S504
Robert S. Benjamin, MD
Chemotherapy for Adults with Bone Sarcomas
Paul A. Meyers, MD
Chemotherapy for Children with Bone Sarcomas
Jonathan C. Trent, MD, PhD—Chair
Sylvester Comprehensive Cancer Center, University of Miami
Novel Aproaches to the Treatment of Chondrosarcoma and Nonosteosarcoma of Bone
Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on
the Right Track?
Location: E450
Andrew H. Ko, MD
Current and Emerging Cytotoxic and Targeted Therapeutics: An Expanding Landscape
Tanios S. Bekaii-Saab, MD—Chair
The Ohio State University Comprehensive Cancer Center
The Emerging Role of Immunotherapeutic Approaches in Pancreas Cancer: The Future Is Now
Neal J. Meropol, MD
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case
Western Reserve University
Of Nab-, Nano-, and Other Emerging Therapies in Pancreas Cancer: Do They Provide Good
Value?
Moving Survivorship Care Forward: Lessons from Quality Measures
Location: S100bc
TUESDAY
Charles L. Shapiro, MD
Mount Sinai School of Medicine
Survivorship Quality Measures
Deborah Mayer, RN, PhD
Integration of Survivorship Care Plans into Electronic Health Records
307
Mary S. McCabe, RN, MA—Chair
Using Quality Measures to Guide Improvements in Survivorship Care
Optimizing Treatment of HER2-Positive Breast Cancer
Location: E Hall D1
Stephen K. L. Chia, MD—Chair
BC Cancer Agency
Neoadjuvant and Adjuvant Therapy for HER2-Positive Disease
Sunil Verma, MD, MSEd, FRCP(C)
Sunnybrook Odette Cancer Centre
Targeted Therapies for Metastatic HER2-Positive Disease
Michelle E. Melisko, MD
Management of Brain Metastases in HER2-Positive Breast Cancer
Universal Screening for BRCA1/2 Mutations: Good Idea or Bad Idea?
Location: S102
Allison W. Kurian, MD, MSc—Chair
Moderator
Elizabeth M. Swisher, MD
University of Washington School of Medicine
The Pros of Universal Genetic Testing
Mark E. Robson, MD
The Cons of Universal Genetic Testing
TUESDAY
Molecular Drivers and Genomic Biomarkers in Genitourinary Cancers
Location: S406
Petros Grivas, MD, PhD—Co-Chair
Cleveland Clinic
Gopa Iyer, MD—Co-Chair
308
9:45 AM
Identification of efficacy biomarkers in a large metastatic renal cell
carcinoma (mRCC) cohort through next generation sequencing (NGS):
Results from RECORD-3. (Abstract 4509) J. Hsieh, D. Chen, P. Wang, Y. Chen,
A. Redzematovic, M. Marker, P. Patel, M. Chevinsky, U. Bhanot, P. Pinciroli, N.
Bouvier, K. H. Huberman, M. F. Berger, N. D. Socci, E. Cheng, W. Lee, J. J. Knox,
M. H. Voss, M. Voi, R. Motzer
9:57 AM
Walter Michael Stadler, MD (Discussion of Abstract(s) 4509)
Molecular Predictors of Response in Renal Cell Cancer
10:09 AM
Association of genomic alterations with cisplatin resistance (cisR) in
advanced germ cell tumors (aGCT). (Abstract 4510) D. R. Feldman, A.
Bagrodia, B. Lee, W. Lee, H. Al-Ahmadie, E. K. Cha, J. Sfakianos, G. Iyer, E. C.
Zabor, I. Ostrovnaya, J. Eng, M. E. Arcila, R. S. Chaganti, N. Schultz, V. E. Reuter,
M. S. Bains, J. Sheinfeld, B. S. Carver, G. J. Bosl, D. B. Solit
10:21 AM
Carsten Bokemeyer, MD (Discussion of Abstract(s) 4510)
University Medical Center Hamburg-Eppendorf
Using Sequencing as a New Risk Stratifier for Germ Cell Tumors
10:33 AM
Molecular drivers of the non-T cell-inflamed tumor microenvironment in
urothelial bladder cancer. (Abstract 4511) R. F. Sweis, S. Spranger, T. Gajewski
10:45 AM
William Y. Kim, MD (Discussion of Abstract(s) 4511)
UNC Lineberger Comprehensive Cancer Center
Genomics and Inflammation in Genitourinary Tumors
10:57 AM
Myeloma
Location: E354b
Thomas G. Martin III, MD—Co-Chair
Saad Zafar Usmani, MD—Co-Chair
ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide
(Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts)
with relapsed/refractory multiple myeloma (RRMM). (Abstract 8508) S. Lonial,
M. A. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Spicka, A. Walter-Croneck,
P. Moreau, M. Mateos, H. Magen-Nativ, A. Belch, D. E. Reece, M. Beksac, M.
Taniwaki, C. Röllig, A. K. Singhal, J. Katz, E. W. Bleickardt, V. Poulart, P. G.
Richardson, ELOQUENT-2 Investigators
9:57 AM
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone
(Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from
the phase III study ENDEAVOR. (Abstract 8509) M. A. Dimopoulos, P. Moreau,
A. Palumbo, D. E. Joshua, L. Pour, R. Hajek, T. Facon, H. Ludwig, A. Oriol, H.
Goldschmidt, L. Rosinol, J. Straub, A. Suvorov, C. Araujo, T. Pika, G. Gaidano, K.
Weisel, V. Goranova-Marinova, H. H. Gillenwater, W. J. Chng
TUESDAY
9:45 AM
10:09 AM Jeffrey Lee Wolf, MD (Discussion of Abstract(s) 8508 – 8509)
Using Big Data to Guide Therapeutic Decisions for Early-Relapsed Multiple
Myeloma
10:21 AM
309
10:33 AM
Phase II MMRC trial of extended treatment with carfilzomib (CFZ),
lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell
transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
(Abstract 8510) T. M. Zimmerman, K. A. Griffith, J. Jasielec, C. A. Rosenbaum, K.
McDonnell, J. Waite-Marin, J. G. Berdeja, N. S. Raje, D. E. Reece, R. Vij, M.
Alonge, S. Rosebeck, S. Gurbuxani, M. Faham, K. A. Kong, J. Levy, A. J.
Jakubowiak
10:45 AM
Results from two phase III studies of bortezomib (BTZ) consolidation vs
observation (OBS) post-transplant in patients (pts) with newly diagnosed
multiple myeloma (NDMM). (Abstract 8511) C. Straka, M. Vogel, J. Müller, M.
Kropff, B. Metzner, C. Langer, H. Sayer, W. Jung, H. A. Dürk, H. Wandt, F.
Bassermann, M. Gramatzki, W. Rösler, S. Knop, H. Wolf, W. Brugger, M. M.
Engelhardt, T. Fischer, H. Einsele
10:57 AM
Saad Zafar Usmani, MD (Discussion of Abstract(s) 8510 – 8511)
Optimal Management of Newly Diagnosed Transplant-Eligible Multiple Myeloma
11:09 AM
11:21 AM
Phase II study of daratumumab (DARA) monotherapy in patients with > 3
lines of prior therapy or double refractory multiple myeloma (MM):
54767414MMY2002 (Sirius). (Abstract LBA8512) S. Lonial, B. M. Weiss, S. Z.
Usmani, S. Singhal, A. Chari, N. J. Bahlis, A. Belch, A. Y. Krishnan, R. A. Vescio,
M. Mateos, A. Mazumder, R. Z. Orlowski, H. J. Sutherland, J. Blade, E. C. Scott, H.
Feng, I. Khan, C. M. Uhlar, T. Ahmadi, P. M. Voorhees
11:33 AM
A phase I/II study of the combination of panobinostat (PAN) and carfilzomib
(CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma
(MM). (Abstract 8513) J. G. Berdeja, T. K. Gregory, J. Matous, L. L. Hart, R.
Owera, J. R. Mace, J. H. Essell, I. Flinn, E. A. Faber
11:45 AM
Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in
patients with AL amyloidosis and persistent organ dysfunction. (Abstract
8514) M. A. Gertz, H. J. Landau, R. Comenzo, D. C. Seldin, B. M. Weiss, J. A.
Zonder, J. Walling, G. Kinney, M. Koller, M. Liedtke
11:57 AM
Suzanne Lentzsch, MD, PhD (Discussion of Abstract(s) LBA8512– 8514)
New Drug Classes in Plasma Cell Disorders
12:09 PM
Immunotherapy for Genitourinary Tumors: Are We Ready for Prime Time?
Location: S406
Susan F. Slovin, MD, PhD, FACP—Chair
Immunotherapeutic Approaches in Prostate Cancer, Combinations, and Clinical Integration
TUESDAY
Piyush K. Agarwal, MD
Evolving Immunotherapy Strategies in Urothelial Carcinoma
David F. McDermott, MD
Emerging Role for Novel Immunotherapy Agents in Renal Cell Carcinoma: From Bench to
Bedside
310
Managing Side Effects of Endocrine Therapy in Men and Women
Location: S100bc
Catherine H. Van Poznak, MD
Don’t Break the Bones
Leslie R. Schover, PhD
Sexual Healing in Men with Cancer
Shari Beth Goldfarb, MD—Chair
Don’t Lose That Loving Feeling: Sexual Health in Women with Cancer
The Many Faces of Neuroendocrine Cancers
Location: E450
David Klimstra, MD
Pathologist Perspective
Rogerio Lilenbaum, MD
Yale University School of Medicine
Lung Cancer
Himisha Beltran, MD
New York-Presbyterian Hospital
Prostate Cancer
Emily K. Bergsland, MD—Chair
Pancreatic Cancer
Well-Differentiated and Dedifferentiated Liposarcoma: New Challenges and
New Directions
TUESDAY
Location: S504
Samuel Singer, MD—Chair
Dissecting the Molecular Biology of Liposarcoma for Therapeutic Interventions and Novel
Surgical Approaches
Andrew Koff, PhD
Understanding the Biology of CDK4 Targeting: A Biomarker-Driven Approach to Patient
Selection
311
Gary K. Schwartz, MD
MDM2 Targeting in Liposarcoma: Where Are We Going and Will Toxicites Impede Drug
Development in Liposarcoma?
TUESDAY
312
Attendee Resource Center
Streamline Your Meeting
FIND A
COLLEAGUE
Connect with other
attendees through
the Message
& Networking
Center. Limited
to professional
attendees.
ABSTRACTS AND
EDUCATIONAL
ARTICLES
Download abstracts
and articles from the
Educational Book, a
peer-reviewed and
PubMed-indexed
publication.
ASCO DAILY NEWS
Read expert
perspectives on
controversial
topics and session
highlights as well
as live coverage of
sessions.
Accessible through your desktop and mobile
device, the Attendee Resource Center is
your single point of access to the planning
and networking tools needed to optimize your
Meeting experience.
PLAN YOUR
MEETING
Browse and search
sessions to create a
customized schedule
with the iPlanner.
This publication is supported by
Additional support has been provided by
Support for this program is funded through

Annual Meeting Program

Transcription

Similar documents

Kriteria Kepentingan Umum dalam Peraturan Pengadaan Tanah

Act 13

Electronic Access Control

Preservazione fertilità carcinoma mammario

scelta dell`intervento

Untitled - Istituto Nazionale dei Tumori

extreme gigantomastia

CATALOGO AGGIORNATO nov. 2014-1

Program and relations abstracts

Diapositiva 1 - Università del Salento

annual meeting program

Detailed Schedule - Monday, April 7

I nuovi farmaci per l`epatite cronica HCV

I brevetti nelle biotecnologie

Program - Biophysical Society

Now - Hospital Kuala Krai

Program List

pensiero innovativo nei materiali avanzati petrolchimico e industriale

Corso tecniche avanzate di videosorveglianza

GIORNALE ITALIANO DI MEDICINA RIABILITATIVA

+8 - HCM Kinzel

is available - AP